,createDate,id,therapyDescriptions,therapyName,updateDate
0,2014-07-29T18:29:52Z,1215,[], LY3023414 + Letrozole ,2014-07-29T18:29:52Z
0,2014-08-01T00:52:20Z,1332,"[{'description': 'Sandostatin Lar Depot (octreotide acetate) mimics the activity of somatostatin, inhibiting growth hormone, glucagon, and insulin, decreasing LH response to gonadotropin-releasing hormone, decreasing splanchnic blood flow, and inhibiting the release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]", octreotide acetate  ,2014-10-24T00:14:03Z
0,2017-05-19T19:20:20Z,5707,"[{'description': 'Limited information is currently available on PF-06688992 (May, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]", PF-06688992,2017-05-19T19:20:42Z
0,2015-12-11T14:36:24Z,3281,"[{'description': '(–)BI97D6 is a pan-BCL2 family inhibitor, which inhibits BCL-2, MCL1, BCL-XL, and BFL1, resulting in increased tumor cell apoptosis (PMID: 26045609).', 'references': [{'id': 4092, 'pubMedId': 26045609, 'title': 'Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26045609'}]}]",(–)BI97D6,2015-12-11T14:36:24Z
0,2015-12-18T20:35:02Z,3304,"[{'description': '10058-F4 binds to MYC and inhibits the interaction between MYC and MAX, potentially resulting in decreased growth of MYC-expressing tumor cells (PMID: 25143136, PMID: 17876039).', 'references': [{'id': 4130, 'pubMedId': 25143136, 'title': 'Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25143136'}, {'id': 4131, 'pubMedId': 17876039, 'title': 'Improved low molecular weight Myc-Max inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17876039'}]}]",10058-F4,2015-12-18T20:38:21Z
0,2015-07-23T17:09:21Z,2953,"[{'description': '11C12 is a monoclonal antibody against EphA5, which may result in inhibition of cell proliferation and induce senescence (PMID: 25623065). ', 'references': [{'id': 3290, 'pubMedId': 25623065, 'title': 'Receptor tyrosine kinase EphA5 is a functional molecular target in human lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25623065'}]}]",11C12,2015-07-23T17:09:21Z
0,2016-07-29T14:16:11Z,4507,[],11C12 + Radiotherapy,2016-07-29T14:16:11Z
0,2014-09-11T01:22:52Z,1425,"[{'description': '131I-MIBG is a radioconjugate comprised of radiolabeled norepinephrine, which can be used to image or eliminate tumor cells (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",131I-MIBG,2015-04-10T16:17:59Z
0,2014-09-11T01:24:22Z,1426,[],131I-MIBG + Irinotecan + Vincristine,2014-09-11T01:24:22Z
0,2014-09-11T01:25:16Z,1427,[],131I-MIBG + Vorinostat,2014-09-11T01:25:16Z
0,2017-05-30T15:50:01Z,5804,"[{'description': '131I-MIP-1095 is a small molecule inhibitor of FOLH1 (prostate specific membrane antigen, PSMA) radiolabeled with iodine 131, which may result in antitumor efficacy (PMID: 24577951).', 'references': [{'id': 9013, 'pubMedId': 24577951, 'title': 'Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24577951'}]}]",131I-MIP-1095,2017-05-30T15:51:34Z
0,2016-05-16T10:10:20Z,4122,"[{'description': '17-demethoxy-reblastatin is a second generation HSP90 inhibitor, which may lead to decreased proliferation and increased apoptosis of tumor cells (PMID: 26323360).', 'references': []}]",17-Demethoxy-reblastatin,2016-05-19T19:56:03Z
0,2014-08-01T06:47:11Z,1341,[],2-Methoxyestradiol ,2014-08-01T06:47:11Z
0,2017-06-23T18:35:21Z,5926,"[{'description': '20G7-D9 is a monoclonal antibody that targets AXL, potentially resulting in decreased growth and metastasis of AXL-expressing tumors (PMID: 24240689, PMID: 27923843).', 'references': [{'id': 9209, 'pubMedId': 24240689, 'title': 'Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24240689'}]}]",20G7-D9,2017-06-23T18:38:23Z
0,2014-06-09T15:47:35Z,1071,"[{'description': '212Pb-TCMC-Trastuzumab, a combination of trastuzumab, the chelating agent TCMC, and lead Pb 212, targets and destroys HER2 positive cells through cytotoxic radiation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",212Pb-TCMC-Trastuzumab,2015-11-19T16:57:52Z
0,2014-09-25T16:25:11Z,1540,[],212Pb-TCMC-Trastuzumab + Trastuzumab ,2014-09-25T16:25:11Z
0,2016-10-12T20:40:19Z,4821,"[{'description': '23814 is a monoclonal antibody that binds to the Notch1 ligand-binding domain and inhibits ligand-mediated signaling, potentially resulting in decreased tumor growth (PMID: 25995436).', 'references': [{'id': 6764, 'pubMedId': 25995436, 'title': '23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25995436'}]}]",23814,2016-10-12T20:40:19Z
0,2016-10-13T15:08:46Z,4824,[],23814 + Tivozanib,2016-10-13T15:08:46Z
0,2014-05-14T14:52:46Z,974,"[{'description': '2B3-101 is a glutathione pegylated liposomal doxorubicin hydrochloride formulation (NCI Drug Dictionary).  ', 'references': []}]",2B3-101,
0,2014-07-30T17:20:17Z,1274,[],2B3-101 + Trastuzumab,2014-07-30T17:20:17Z
0,2015-01-15T14:57:32Z,1942,"[{'description': '2G8 is a monoclonal antibody that targets murine TGFBR2, potentially resulting in decreased tumor cell proliferation (PMID: 25060520).', 'references': [{'id': 1706, 'pubMedId': 25060520, 'title': 'Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25060520'}]}]",2g8,2017-07-26T17:28:34Z
0,2017-05-10T18:56:57Z,5658,"[{'description': '3144 is a Pan-RAS inhibitor, which binds to KRAS, NRAS, and HRAS proteins and decreases RAS-mediated signaling, and may reduce growth of RAS-dependent tumors (PMID: 28235199).', 'references': [{'id': 8866, 'pubMedId': 28235199, 'title': 'Multivalent Small-Molecule Pan-RAS Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28235199'}]}]",3144,2017-05-10T18:56:57Z
0,2016-05-26T15:33:42Z,4136,"[{'description': '4SC-202 is a class I histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cells (PMID: 26773495).', 'references': [{'id': 5685, 'pubMedId': 26773495, 'title': '4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26773495'}]}]",4SC-202,2017-03-16T15:04:31Z
0,2016-05-26T15:42:41Z,4137,"[{'description': '4SC-205 inhibits human kinesin-related motor protein Eg5, which may lead to cell cycle arrest and apoptosis in tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",4SC-205,2016-05-26T15:42:41Z
0,2016-03-21T00:08:51Z,3788,"[{'description': '5-Fluoro-2-deoxycytidine is a fluorinated pyrimidine analogue that is metabolized to 5-fluorouracil (5-FU) intercellularly, which is cytotoxic (PMID: 17899082).', 'references': [{'id': 4939, 'pubMedId': 17899082, 'title': ""Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU)."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17899082'}]}]",5-Fluoro-2-deoxycytidine,2016-03-21T00:08:51Z
0,2015-05-01T14:50:05Z,2620,"[{'description': '6MHP vaccine is a peptide vaccine containing 6 melanoma helper peptides as epitopes, which may stimulate TH1-biased immune response against tumor cells expressing these antigens (PMID: 25126421).', 'references': [{'id': 2636, 'pubMedId': 25126421, 'title': 'A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25126421'}]}]",6MHP vaccine,2015-05-19T13:41:49Z
0,2017-02-20T19:25:13Z,5339,"[{'description': '79-6 is a small molecule that binds and inhibits BCL6, potentially resulting in increased death of BCL6-expressing tumor cells (PMID: 20385364).', 'references': [{'id': 7892, 'pubMedId': 20385364, 'title': 'A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20385364'}]}]",79-6,2017-06-16T15:50:28Z
0,2017-05-12T15:24:07Z,5669,"[{'description': '7RH is a small molecule inhibitor of discoidin domain receptor 1 (DDR1) that induces apoptosis and inhibits proliferation in tumor cells (PMID: 27900042).', 'references': [{'id': 8886, 'pubMedId': 27900042, 'title': 'Antitumor activity of 7RH, a discoidin domain receptor 1 inhibitor, alone or in combination with dasatinib exhibits antitumor effects in nasopharyngeal carcinoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27900042'}]}]",7RH,2017-05-12T15:24:07Z
0,2017-05-12T16:02:56Z,5670,[],7RH + LY411575,2017-05-12T16:02:56Z
0,2015-02-23T01:45:08Z,2131,"[{'description': '81C6 is a monoclonal antibody against tenascin conjugated to iodine 131, which has utility in radioimmunotherapy targeting tenacin expressing cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",81C6,2015-02-23T01:45:08Z
0,2015-03-31T14:56:05Z,2485,"[{'description': '90Y basiliximab consists of an anti-IL-2 receptor antibody (basiliximab) conjugated to radioactive yttrium Y 90, which binds to IL-2R and prevents IL-2 binding, as well as delivering cytotoxic radiation to IL-2R expressing cells, thereby potentially decreasing T-cell activation and immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",90Y basiliximab,2015-03-31T14:56:05Z
0,2017-07-07T03:22:19Z,5976,"[{'description': '9F7-F11 is a non-ligand competitive antibody targeting ERBB3 (HER3) that has enhanced binding to ERBB3 (HER3) in the presence of its ligand NRG1, which reduces downstream signaling and may inhibit growth of NRG1-expressing tumors (PMID: 28507002).', 'references': [{'id': 9293, 'pubMedId': 28507002, 'title': 'Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28507002'}]}]",9F7-F11,2017-07-07T03:31:57Z
0,2015-04-24T02:09:14Z,2576,"[{'description': 'A-1155463 inhibits BCL-XL, resulting in apoptosis in BCL-XL dependent tumor cells (PMID: 25787766).', 'references': [{'id': 2473, 'pubMedId': 25787766, 'title': 'Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25787766'}]}]",A-1155463,2015-08-10T15:43:26Z
0,2017-05-11T18:07:45Z,5665,[],A-1155463 + BETd-246,2017-05-11T18:07:45Z
0,2015-12-11T17:26:05Z,3288,"[{'description': 'A-1155905 inhibits MCL1, resulting in increased apoptosis in MCL1-dependent tumor cells (PMID: 25590800).', 'references': [{'id': 4087, 'pubMedId': 25590800, 'title': 'Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25590800'}]}]",A-1155905,2015-12-11T17:26:05Z
0,2015-12-11T17:25:03Z,3286,"[{'description': 'A-1208746 inhibits MCL1, resulting in increased apoptosis in MCL1-dependent tumor cells (PMID: 25590800).', 'references': [{'id': 4087, 'pubMedId': 25590800, 'title': 'Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25590800'}]}]",A-1208746,2015-12-11T17:25:03Z
0,2015-12-10T21:02:12Z,3276,"[{'description': 'A-1210477 binds to and inhibits MCL1, resulting in increased apoptosis of MCL1-dependent tumor cells (PMID: 25590800).', 'references': [{'id': 4087, 'pubMedId': 25590800, 'title': 'Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25590800'}]}]",A-1210477,2015-12-10T21:02:12Z
0,2016-12-19T20:06:04Z,5110,[],A-1210477 + A-1331852,2016-12-19T20:06:04Z
0,2016-12-13T20:13:10Z,5091,[],A-1210477 + Cobimetinib,2016-12-13T20:13:10Z
0,2016-12-13T20:20:12Z,5093,[],A-1210477 + Cobimetinib + Vemurafenib,2016-12-13T20:20:12Z
0,2017-08-01T15:47:23Z,6068,[],A-1210477 + G-TPP,2017-08-01T15:47:23Z
0,2017-02-28T21:35:44Z,5394,[],A-1210477 + Lapatinib + WEHI-539,2017-02-28T21:35:44Z
0,2016-12-13T20:18:38Z,5092,[],A-1210477 + Vemurafenib,2016-12-13T20:18:38Z
0,2017-02-28T20:37:10Z,5392,[],A-1210477 + WEHI-539,2017-02-28T20:37:10Z
0,2015-12-11T17:25:35Z,3287,"[{'description': 'A-1248767 inhibits MCL1, resulting in increased apoptosis in MCL1-dependent tumor cells (PMID: 25590800).', 'references': [{'id': 4087, 'pubMedId': 25590800, 'title': 'Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25590800'}]}]",A-1248767,2015-12-11T17:25:35Z
0,2015-04-24T05:03:29Z,2578,"[{'description': 'A-1331852 inhibits BCL-XL, resulting in increased tumor cell apoptosis and decreased tumor growth (PMID: 25787766).', 'references': [{'id': 2473, 'pubMedId': 25787766, 'title': 'Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25787766'}]}]",A-1331852,2015-08-10T15:44:16Z
0,2016-12-20T14:51:25Z,5111,[],A-1331852 + BKM120,2016-12-20T14:51:25Z
0,2015-04-24T05:10:40Z,2579,[],A-1331852 + Docetaxel,2015-04-24T05:10:40Z
0,2016-12-19T20:04:14Z,5109,[],A-1331852 + Ipatasertib,2016-12-19T20:04:14Z
0,2017-06-13T19:02:15Z,5889,"[{'description': 'A-395 is an inhibitor of PRC2, which binds to the H3K27me3 site in EED, thereby inhibiting H3K27 methylation and PRC2 activation, and potentially resulting in inhibition of cell proliferation and tumor growth inhibition (PMID: 28135237). ', 'references': [{'id': 9122, 'pubMedId': 28135237, 'title': 'The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28135237'}]}]",A-395,2017-06-13T19:02:15Z
0,2015-03-20T19:00:43Z,2448,"[{'description': 'A-443654 is a pan-AKT inhibitor, which may inhibit proliferation and promote apoptosis in cancer cells (PMID: 19208828). ', 'references': [{'id': 2291, 'pubMedId': 19208828, 'title': 'Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19208828'}]}]",A-443654,2017-03-17T18:11:09Z
0,2017-03-15T15:09:12Z,5437,"[{'description': 'A-674563 is an inhibitor of AKT1, which may result in induction of apoptotic activity and inhibition of tumor growth (PMID: 26970307). ', 'references': []}]",A-674563,2017-03-15T15:09:12Z
0,2017-06-29T18:17:35Z,5945,"[{'description': 'A-770041 is an inhibitor of LCK, which may lead to increased sensitivity to chemotherapeutics, thereby resulting in increased apoptotic activity (PMID: 25236161).', 'references': [{'id': 9241, 'pubMedId': 25236161, 'title': 'A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25236161'}]}]",A-770041,2017-06-29T18:17:35Z
0,2017-06-29T18:29:10Z,5947,[],A-770041 + PRT062607,2017-06-29T18:29:10Z
0,2017-06-29T18:30:00Z,5948,[],A-770041 + R406,2017-06-29T18:30:00Z
0,2015-07-22T16:30:49Z,2945,"[{'description': 'A-966492 inhibits PARP-1 and PARP-2, potentially resulting in increased sensitivity of tumor cells to DNA damaging agents (PMID: 20337371).', 'references': [{'id': 3297, 'pubMedId': 20337371, 'title': 'Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20337371'}]}]",A-966492,2017-05-09T15:29:10Z
0,2017-01-03T18:13:26Z,5136,"[{'description': 'Resimmune (A-dmDT390-bisFv(UCHT1)) comprises the diphtheria toxin catalytic and translocation domains fused to antibody fragments that target the CD3-epsilon component of the T-cell receptor, potentially resulting in increased death of CD3-epsilon expressing tumor cells (PMID: 25795722)', 'references': [{'id': 7464, 'pubMedId': 25795722, 'title': 'Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25795722'}]}]",A-dmDT390-bisFv(UCHT1),2017-01-03T18:13:26Z
0,2017-01-03T18:14:49Z,5137,[],A-dmDT390-bisFv(UCHT1) + Pembrolizumab,2017-01-03T18:14:49Z
0,2016-02-01T19:51:07Z,3495,"[{'description': 'A3 is a mouse monoclonal antibody that targets human Erbb3 (Her3), resulting in decreased ligand binding and downstream signaling, which potentially leads to reduced tumor growth (PMID: 22213458, PMID: 22889873).', 'references': [{'id': 4501, 'pubMedId': 22213458, 'title': 'Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22213458'}, {'id': 4500, 'pubMedId': 22889873, 'title': 'The promise of anti-ErbB3 monoclonals as new cancer therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22889873'}]}]",A3,2016-02-01T19:51:07Z
0,2014-03-12T15:53:16Z,617,"[{'description': 'A66 inhibits PIK3CA, preventing the activation of the PI3K signaling pathway and potentially inhibiting tumor cell proliferation (PMID: 21668414).', 'references': [{'id': 223, 'pubMedId': 21668414, 'title': 'A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21668414'}]}]",A66,2015-07-29T18:35:26Z
0,2016-03-10T20:05:50Z,3707,[],A66 + AZD6482,2016-03-10T20:05:50Z
0,2016-03-10T20:06:15Z,3708,[],A66 + GSK2636771,2016-03-10T20:06:15Z
0,2015-06-01T18:41:48Z,2757,"[{'description': 'A83-01 is an inhibitor of TGFBR1, ACVR1B, and ACVR1C, which may block downstream signaling, proliferation, and migration in cancer cells (PMID: 16271073). ', 'references': [{'id': 2880, 'pubMedId': 16271073, 'title': 'The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16271073'}]}]",A83-01,2015-06-01T18:43:26Z
0,2016-06-19T23:36:11Z,4317,"[{'description': 'AB-16B5 is a monoclonal antibody bonds to and inhibits the activity of human clusterin (sCLU), resulting in inhibition pf tumor cell proliferation and metastasis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AB-16B5,2016-06-19T23:36:11Z
0,2016-09-09T16:10:44Z,4677,"[{'description': 'AB0023 is a monoclonal antibody that targets LOXL2 and may result in decreased production of growth factors and inhibition of fibroblast activation within a tumor environment (PMID: 20818376).\r\n', 'references': [{'id': 202, 'pubMedId': 20818376, 'title': 'Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20818376'}]}]",AB0023,2016-09-09T16:10:44Z
0,2016-05-11T15:04:43Z,4099,"[{'description': 'AB61 is a 7-deazapurine nucleoside that incorporates into DNA and RNA resulting in DNA/RNA damage thereby repressing protein translation, and is demonstrated to be specifically cytotoxic to cancer cells (PMID: 26819331). ', 'references': [{'id': 5498, 'pubMedId': 26819331, 'title': '7-(2-Thienyl)-7-Deazaadenosine (AB61), a New Potent Nucleoside Cytostatic with a Complex Mode of Action.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26819331'}]}]",AB61,2016-05-11T15:04:43Z
0,2015-07-09T19:28:56Z,2892,"[{'description': 'Abagovomab is a murine monoclonal antibody that targets MUC16 (CA125), which may result in enhanced immune response against MUC16-expressing tumor cells (PMID: 23478059).', 'references': [{'id': 3208, 'pubMedId': 23478059, 'title': 'Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23478059'}]}]",Abagovomab,2015-07-10T16:34:30Z
0,2014-03-12T15:53:16Z,618,[],Abarelix,
0,2016-04-29T18:00:54Z,4028,"[{'description': 'ABBV-075 (Mivebresib) is a bromodomain (BET) inhibitor, which may inhibit Ar and Myc downstream signalling to prevent growth and proliferation of tumor cells (AACR 107th Annual Meeting; April 16-20, 2016, Abstract 4694).', 'references': []}]",ABBV-075,2017-03-17T16:11:54Z
0,2017-06-23T04:59:13Z,5924,[],ABBV-075 + Azacitidine,2017-06-23T04:59:13Z
0,2017-06-23T05:00:00Z,5925,[],ABBV-075 + Bortezomib,2017-06-23T05:00:00Z
0,2017-06-23T04:57:48Z,5923,[],ABBV-075 + Venetoclax,2017-06-23T04:57:48Z
0,2016-03-25T18:07:37Z,3846,"[{'description': 'ABBV-085 is a monoclonal anti-tumor-associated antigen (TAA) antibody in conjugation with a cytotoxic agent, which may selectively kill TAA-positive cancer cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",ABBV-085,2016-03-25T18:07:37Z
0,2017-05-24T17:35:09Z,5766,"[{'description': 'Limited information is currently available on ABBV-181 (May, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",ABBV-181,2017-05-24T17:35:09Z
0,2015-07-14T01:08:14Z,2914,"[{'description': 'ABBV-221 is an antibody-drug conjugate consists of a monoclonal EGFR antibody and a cytotoxic molecule MMAE, which demonstrates anti-tumor activity against EGFR -expressing tumors (Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 2510-2510).', 'references': [{'id': 9794, 'pubMedId': None, 'title': 'Preliminary results from a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to express EGFR.', 'url': 'http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2510'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",ABBV-221,2017-08-28T13:38:24Z
0,2017-03-16T02:57:54Z,5446,"[{'description': 'Limited information is currently available on ABBV-368 (Mar, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",ABBV-368,2017-03-22T15:25:17Z
0,2017-03-16T02:59:17Z,5447,[],ABBV-368 + Nivolumab,2017-03-16T02:59:17Z
0,2014-08-05T07:14:09Z,1363,"[{'description': 'ABBV-399 is an antibody-drug conjugate comprising a MET-targeted antibody linked to MMAE, which delivers the cytotoxic agent to MET expressing tumor cells, resulting in cell death (PMID: 27573171).', 'references': [{'id': 7833, 'pubMedId': 27573171, 'title': 'ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27573171'}]}]",ABBV-399,2017-02-16T18:50:46Z
0,2014-08-05T07:29:09Z,1366,[],ABBV-399 + Bevacizumab,2014-08-05T07:29:09Z
0,2014-11-25T17:44:26Z,1743,[],ABBV-399 + Carboplatin,2014-11-25T17:44:26Z
0,2014-08-05T07:26:31Z,1365,[],ABBV-399 + Cetuximab,2014-08-05T07:26:31Z
0,2014-08-05T07:15:48Z,1364,[],ABBV-399 + Erlotinib,2014-08-05T07:15:48Z
0,2016-12-02T04:53:53Z,5050,"[{'description': 'Limited information is currently available on ABBV-428 (Dec, 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",ABBV-428,2016-12-02T04:53:53Z
0,2016-12-02T04:55:21Z,5051,[],ABBV-428 + Nivolumab,2016-12-02T04:55:21Z
0,2017-05-24T01:43:02Z,5756,"[{'description': 'Limited information is currently available on ABBV-621, a putative TRAIL receptor agonist (May, 2017).', 'references': []}]",ABBV-621,2017-05-24T01:43:02Z
0,2017-01-03T19:22:56Z,5142,"[{'description': 'Limited information is currently available on ABBV-927 (Jan 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",ABBV-927,2017-01-03T19:22:56Z
0,2017-01-03T19:24:44Z,5143,[],ABBV-927 + Nivolumab,2017-01-03T19:24:44Z
0,2015-12-18T19:50:56Z,3301,"[{'description': 'ABC294640 is a selective inhibitor of sphingokinase 2 (SK2), which results in decreased SK2 activity, leading to reduced cell signaling and tumor cell growth (PMID: 26271487).', 'references': [{'id': 4127, 'pubMedId': 26271487, 'title': 'Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26271487'}]}]",ABC294640,2015-12-18T19:50:56Z
0,2017-05-05T03:39:27Z,5617,[],ABC294640 + Gemcitabine,2017-05-05T03:39:27Z
0,2014-03-12T15:53:16Z,802,"[{'description': 'Verzenio (abemaciclib) is a dual CDK4/6 inhibitor, which inhibits Rb1 protein phosphorylation and may induce cell cycle arrest and prevent growth in cancer cells (PMID: 24919854). Verzenio (abemaciclib) is FDA approved as a monotherapy and in combination with Faslodex (fulvestrant) in patients with hormone receptor-positive and ERBB2 (HER2) receptor-negative breast cancer (FDA.gov). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 1786, 'pubMedId': 24919854, 'title': 'Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24919854'}]}]",Abemaciclib,2017-10-02T14:47:48Z
0,2015-03-03T02:01:08Z,2255,[],Abemaciclib + Anastrozole,2017-06-06T17:51:28Z
0,2014-12-24T16:25:14Z,1854,[],Abemaciclib + Anastrozole + Letrozole,2017-06-05T20:38:12Z
0,2017-04-07T19:00:41Z,5516,[],Abemaciclib + Anastrozole + Xentuzumab,2017-04-07T19:04:43Z
0,2014-10-30T16:02:35Z,1690,[],Abemaciclib + Clarithromycin,2017-06-05T20:34:14Z
0,2016-05-24T17:52:50Z,4127,[],Abemaciclib + Everolimus,2017-06-06T17:55:49Z
0,2015-03-03T02:03:10Z,2257,[],Abemaciclib + Exemestane,2017-06-06T17:52:25Z
0,2017-06-06T17:58:08Z,5859,[],Abemaciclib + Fulvestrant,2017-06-06T17:58:08Z
0,2017-04-07T19:02:21Z,5517,[],Abemaciclib + Fulvestrant + Xentuzumab,2017-04-07T19:02:21Z
0,2017-01-09T20:13:53Z,5176,[],Abemaciclib + Galunisertib,2017-01-09T20:13:53Z
0,2016-09-21T15:27:08Z,4731,[],Abemaciclib + Lapatinib,2016-09-21T15:27:08Z
0,2015-03-03T02:00:32Z,2254,[],Abemaciclib + Letrozole,2017-06-06T17:50:52Z
0,2017-04-07T18:51:09Z,5515,[],Abemaciclib + Letrozole + Xentuzumab,2017-04-07T18:51:09Z
0,2016-06-28T00:14:03Z,4387,[],Abemaciclib + Loperamide,2016-06-28T00:14:03Z
0,2017-01-09T20:11:16Z,5175,[],Abemaciclib + LY3023414,2017-01-09T20:12:41Z
0,2016-06-27T00:42:35Z,4373,[],Abemaciclib + LY3039478,2016-06-27T00:42:35Z
0,2016-06-05T21:54:19Z,4242,[],Abemaciclib + Pembrolizumab,2016-06-05T21:54:19Z
0,2016-06-02T21:49:20Z,4209,[],Abemaciclib + Ramucirumab,2016-06-02T21:49:20Z
0,2015-03-03T02:02:16Z,2256,[],Abemaciclib + Tamoxifen,2017-06-06T17:51:51Z
0,2016-12-01T03:27:08Z,5028,[],Abemaciclib + Temozolomide,2016-12-01T03:27:08Z
0,2016-05-24T17:53:21Z,4128,[],Abemaciclib + Torin2,2017-06-06T17:56:15Z
0,2015-03-03T02:05:05Z,2259,[],Abemaciclib + Trastuzumab,2017-06-06T17:52:52Z
0,2017-04-07T18:49:19Z,5514,[],Abemaciclib + Xentuzumab,2017-04-07T18:49:19Z
0,2014-06-16T12:27:17Z,1081,"[{'description': 'Abexinostat (PCI-24781) is an HDAC inhibitor, which induces tumor cell apoptosis and decreases tumor cell growth (PMID: 16731764, PMID: 25520806).', 'references': [{'id': 8242, 'pubMedId': 16731764, 'title': 'CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16731764'}, {'id': 8241, 'pubMedId': 25520806, 'title': 'PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25520806'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Abexinostat,2017-03-16T15:25:21Z
0,2016-01-10T19:11:42Z,3381,[],Abexinostat + Doxorubicin,2016-01-10T19:11:42Z
0,2014-12-18T16:58:15Z,1805,"[{'description': 'Zytiga (abiraterone) inhibits cytochrome P-450c17, resulting in decreased androgen synthesis (PMID: 25560485). Zytiga (abiraterone) is FDA approved for patients with metastatic castration-resistant prostate cancer (FDA.gov).', 'references': [{'id': 2398, 'pubMedId': 25560485, 'title': 'CYP17A1 inhibitors in castration-resistant prostate cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25560485'}]}]",Abiraterone,2016-10-13T16:57:16Z
0,2015-04-22T02:02:24Z,2553,[],Abiraterone + Alisertib + Prednisone,2015-04-22T02:02:24Z
0,2016-07-31T15:19:04Z,4510,[],Abiraterone + ARN-509 + Degarelix + Indomethacin + Prednisone,2016-07-31T15:19:04Z
0,2017-04-07T19:46:23Z,5523,[],Abiraterone + ARN-509 + Degarelix + Prednisone,2017-04-07T19:47:42Z
0,2016-09-27T00:02:22Z,4767,[],Abiraterone + ARN-509 + Docetaxel + Prednisone,2016-09-27T00:02:22Z
0,2017-05-22T20:03:12Z,5743,[],Abiraterone + ARN-509 + Gonadorelin + Prednisone,2017-05-22T20:05:59Z
0,2016-07-31T15:16:16Z,4509,[],Abiraterone + ARN-509 + Indomethacin + Prednisone,2016-07-31T15:16:16Z
0,2016-06-02T19:52:10Z,4206,[],Abiraterone + ARN-509 + Leuprolide,2016-06-02T19:52:10Z
0,2016-09-25T17:24:48Z,4758,[],Abiraterone + ARN-509 + Leuprolide + Prednisone,2016-09-25T17:24:48Z
0,2015-05-08T15:22:21Z,2649,[],Abiraterone + ARN-509 + Prednisone,2015-05-08T15:22:21Z
0,2015-04-07T03:22:13Z,2499,[],Abiraterone + BKM120 + Prednisone,2015-04-07T03:22:13Z
0,2016-09-25T17:30:18Z,4759,[],Abiraterone + Cabazitaxel + Carboplatin + Enzalutamide + Prednisone,2016-09-25T17:30:18Z
0,2016-09-29T17:33:01Z,4770,[],Abiraterone + cabozantinib,2016-09-29T17:33:01Z
0,2014-12-19T15:22:11Z,1818,[],Abiraterone + Dasatinib	,2014-12-19T15:22:11Z
0,2016-05-27T20:16:03Z,4182,[],Abiraterone + Denosumab + Enzalutamide + Prednisone,2016-05-27T20:18:55Z
0,2017-02-20T19:25:39Z,5340,[],Abiraterone + Dutasteride,2017-02-20T19:25:39Z
0,2017-07-28T17:57:47Z,6034,[],Abiraterone + GSK525762,2017-07-28T17:57:47Z
0,2017-03-15T15:31:22Z,5438,[],Abiraterone + Ipatasertib,2017-03-15T15:31:22Z
0,2015-09-14T00:07:41Z,3079,[],Abiraterone + Leuprolide + Prednisone,2015-09-14T00:07:41Z
0,2016-09-12T00:59:50Z,4678,[],Abiraterone + Methylprednisolone,2016-09-12T00:59:50Z
0,2015-04-28T22:39:15Z,2597,[],Abiraterone + Navitoclax,2017-08-01T16:02:42Z
0,2016-06-27T01:43:59Z,4377,[],Abiraterone + Niclosamide + Prednisone,2016-06-27T01:43:59Z
0,2015-05-29T14:13:43Z,2748,[],Abiraterone + Prednisone,2015-05-29T14:13:43Z
0,2017-01-19T05:57:40Z,5226,[],Abiraterone + Prednisone + Olaparib,2017-01-19T05:57:40Z
0,2017-06-20T19:23:58Z,5913,[],Abiraterone + Prednisone + Veliparib,2017-06-20T19:23:58Z
0,2014-12-19T15:21:18Z,1817,[],Abiraterone + Sunitinib,2014-12-19T15:21:18Z
0,2015-03-31T14:47:09Z,2484,"[{'description': 'Asciminib (ABL001) is an allosteric inhibitor of BCR-ABL that binds to a unique location outside the ATP binding site, resulting in decreased BCR-ABL kinase activity and reduced tumor growth (Blood Dec 2014, 124 (21) 398).', 'references': [{'id': 2361, 'pubMedId': None, 'title': 'ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia', 'url': 'http://www.bloodjournal.org/content/124/21/398.abstract?sso-checked=true'}]}]",ABL001,2017-03-28T19:25:27Z
0,2017-09-26T19:12:32Z,6243,"[{'description': 'ABP 980 is a Herceptin (trastuzumab) biosimilar that binds to Erbb2 (Her2), which results in anti-tumor immune response against Erbb2 (Her2)-positive tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 151PD; NCT01901146).', 'references': [{'id': 10002, 'pubMedId': None, 'title': 'Efficacy and safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early breast cancer', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]}]",ABP 980,2017-09-26T19:12:32Z
0,2014-03-12T15:53:16Z,619,"[{'description': 'Abraxane (nab-paclitaxel) is an albumin-stablized version of paclitaxel, which binds microtubules and prevents depolymerization, resulting in decreased cell motility and division (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Abraxane,2017-06-19T18:46:27Z
0,2014-07-28T13:03:03Z,1144,[],Abraxane + Avastin + Gemcitabine,2014-07-28T13:03:03Z
0,2015-01-16T15:10:39Z,1950,[],Abraxane + Azacitidine,2015-01-16T15:10:39Z
0,2014-09-18T20:08:26Z,1496,[],Abraxane + Bevacizumab + Erlotinib,2014-09-18T20:08:26Z
0,2015-01-16T15:34:35Z,1957,[],Abraxane + Carboplatin + Cetuximab,2015-01-16T15:34:35Z
0,2014-12-28T21:24:41Z,1859,[],Abraxane + Cisplatin + Carboplatin,2014-12-28T21:24:41Z
0,2015-01-16T15:33:20Z,1956,[],Abraxane + Cisplatin + Cetuximab,2015-01-16T15:33:20Z
0,2015-02-27T16:49:32Z,2204,[],Abraxane + Gemcitabine + Metformin,2015-02-27T16:49:32Z
0,2015-03-19T10:04:35Z,2429,[],Abraxane + Gemcitabine + Sorafenib + Vorinostat,2015-03-19T10:04:35Z
0,2015-04-03T14:41:25Z,2490,[],Abraxane + Nilotinib,2015-04-03T14:41:25Z
0,2015-04-03T13:53:41Z,2489,[],Abraxane + Nivolumab,2015-04-03T13:53:41Z
0,2015-02-11T13:44:21Z,2039,[],Abraxane + Ramucirumab,2015-02-11T13:44:21Z
0,2014-08-06T01:12:21Z,1380,[],Abraxane + Temozolomide + Bevacizumab,2014-08-06T01:12:21Z
0,2017-02-13T19:23:16Z,5319,[],ABT-263 + Alpelisib + CGM097 + Trametinib,2017-02-13T19:23:16Z
0,2017-02-13T19:01:06Z,5318,[],ABT-263 + Alpelisib + Dabrafenib + Erlotinib,2017-02-13T19:01:06Z
0,2017-02-13T18:47:23Z,5316,[],ABT-263 + Alpelisib + Erlotinib + Trametinib,2017-02-13T18:47:23Z
0,2017-02-13T18:55:34Z,5317,[],ABT-263 + CGM097 + Dabrafenib + PF-04217903,2017-02-13T18:55:34Z
0,2017-02-13T18:26:57Z,5315,[],ABT-263 + CGM097 + Trametinib,2017-02-13T18:26:57Z
0,2014-05-14T14:52:46Z,975,"[{'description': 'Ilorasertib (ABT-348) is an ATP-competitive multitargeted kinase inhibitor with activity towards Aurora kinases, and VEGFR, and PDGFR kinase families (PMID: 22935731).', 'references': [{'id': 70, 'pubMedId': 22935731, 'title': 'Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22935731'}]}]",ABT-348,2017-04-04T10:09:18Z
0,2014-05-14T14:52:46Z,976,"[{'description': 'ABT-414 is an antibody-drug conjugate that binds to EGFR and delivers the conjugated cytotoxin to EGFR overexpressing cells, thereby possibly inhibiting growth of EGFR-overexpressing tumor cells (Mol Cancer Ther November 2013 12:A250).', 'references': [{'id': 2351, 'pubMedId': None, 'title': 'Abstract A250: ABT-414: An anti-EGFR antibody-drug conjugate as a potential therapeutic for the treatment of patients with squamous cell tumors.', 'url': 'http://mct.aacrjournals.org/content/12/11_Supplement/A250.short?rss=1'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",ABT-414,2015-03-30T15:57:01Z
0,2016-06-22T18:22:32Z,4346,[],ABT-414 + Temozolomide + Radiotherapy,2016-06-22T19:42:22Z
0,2014-06-06T17:02:46Z,1063,"[{'description': 'ABT-700 (h224G11) is a monoclonal antibody that targets and inhibits c-MET (PMID: 23134362).', 'references': [{'id': 330, 'pubMedId': 23134362, 'title': 'Characterization of therapeutic antibodies and related products.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23134362'}]}]",ABT-700,2015-04-30T13:18:21Z
0,2014-12-09T11:14:01Z,1772,"[{'description': 'ABT-737 is a BH3 mimetic, which targets Bcl2, Bcl-xl, and Bcl-w to induce apoptosis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",ABT-737,2015-12-10T19:17:42Z
0,2016-02-20T01:18:09Z,3586,[],ABT-737 + Anti-CD19 CAR T cells,2016-02-20T01:18:09Z
0,2017-01-12T18:32:37Z,5191,[],ABT-737 + AZD8055 + Trametinib,2017-01-12T18:32:37Z
0,2017-02-28T16:42:45Z,5381,[],ABT-737 + BEZ235,2017-02-28T16:42:45Z
0,2017-01-12T18:37:55Z,5192,[],ABT-737 + BEZ235 + Trametinib,2017-01-12T18:37:55Z
0,2016-04-09T13:40:28Z,3919,[],ABT-737 + Cisplatin,2016-04-09T13:40:28Z
0,2016-04-09T13:39:30Z,3918,[],ABT-737 + Doxorubicin,2016-04-09T13:39:38Z
0,2016-04-09T13:43:18Z,3920,[],ABT-737 + Gemcitabine,2016-04-09T13:43:18Z
0,2017-01-12T18:48:04Z,5193,[],ABT-737 + MK2206 + Trametinib,2017-01-12T18:48:04Z
0,2017-02-28T19:25:39Z,5388,[],ABT-737 + MLN0128,2017-02-28T19:25:39Z
0,2017-01-11T18:57:00Z,5187,[],ABT-737 + Perifosine,2017-01-11T18:57:00Z
0,2016-05-26T23:04:56Z,4151,"[{'description': 'ABT-751 is an anti-mitotic agent that binds to tubulin and exhibits anti-cancer activity in preclinical models (PMID: 19398903, PMID: 23670235). ', 'references': [{'id': 5698, 'pubMedId': 19398903, 'title': 'ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19398903'}, {'id': 5697, 'pubMedId': 23670235, 'title': 'Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670235'}]}]",ABT-751,2016-05-26T23:04:56Z
0,2016-05-26T23:09:50Z,4152,[],ABT-751 + Bevacizumab + Capecitabine + Irinotecan,2016-05-26T23:09:50Z
0,2016-11-02T18:47:20Z,4909,[],ABT-751 + Fenretinide,2016-11-02T18:47:20Z
0,2016-05-26T14:09:45Z,4133,"[{'description': 'ABT-767 binds to and inhibits the nuclear enzymes poly(ADP-ribose) polymerase (PARP) 1 and 2, therefore prevents DNA damage repair and leads to apoptosis (PMID: 28247011).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 8850, 'pubMedId': 28247011, 'title': 'Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28247011'}]}]",ABT-767,2017-05-09T15:30:02Z
0,2016-06-06T19:00:22Z,4256,"[{'description': 'ABT-806 is a monoclonal antibody that binds to the epitope of EGFR vIII and amplified EGFR, but not wild-type EGFR, and may result in anti-tumor activity (PMID: 25731184). ', 'references': []}]",ABT-806,2016-06-06T19:00:22Z
0,2015-02-24T18:59:56Z,2151,"[{'description': 'ABTL0812 is a lipid analog that inhibits mTOR and DHFR, potentially resulting in decreased tumor cell proliferation and increased tumor cell death (Cancer Res April 15, 2012 72:922).', 'references': [{'id': 1984, 'pubMedId': None, 'title': 'Abstract 922: ABTL0812: A new drug class with oral antitumor action inhibiting mTOR activity and DHFR expression', 'url': 'http://cancerres.aacrjournals.org/content/72/8_Supplement/922.short'}]}]",ABTL0812,2015-04-03T00:16:39Z
0,2015-07-14T00:33:15Z,2909,"[{'description': 'AC0010MA is a third generation EGFR inhibitor, which inhibits mutant forms of EGFR while sparing wild-type EGFR, potentially resulting in increased tumor cell death (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AC0010MA,2015-07-14T00:33:15Z
0,2014-05-14T14:52:46Z,977,"[{'description': 'AC480 is an inhibitor of EGFR and ERBB2 (HER2), which may prevent downstream signaling and inhibit the proliferation of tumor cells that overexpress these receptors (PMID: 17062696).', 'references': [{'id': 2309, 'pubMedId': 17062696, 'title': 'Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17062696'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AC480,2015-07-20T01:05:26Z
0,2015-06-18T18:18:19Z,2845,"[{'description': 'AC708 is a small molecule inhibitor of CSF1R, which leads to reduced CSF1R activation and a decrease in tumor associated macrophages (Cancer Res April 15, 2013 73; 903).', 'references': [{'id': 3082, 'pubMedId': None, 'title': 'Abstract 903: AC708 is a potent and selective inhibitor of CSF1R and reduces tumor associated macrophage infiltration in a breast tumor model.', 'url': 'http://cancerres.aacrjournals.org/content/73/8_Supplement/903.short'}]}]",AC708,2015-06-18T18:18:19Z
0,2014-10-02T18:15:15Z,1605,"[{'description': 'Acalabrutinib (ACP-196) inhibits BTK, preventing activation of the B-cell antigen receptor pathway and leading to growth inhibition of BTK expressing B-cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Acalabrutinib,2017-06-19T18:07:21Z
0,2017-03-22T20:34:14Z,5466,[],Acalabrutinib + ACP-319,2017-06-19T18:09:27Z
0,2016-04-22T15:29:00Z,3996,[],Acalabrutinib + Bendamustine + Rituximab,2017-06-19T18:09:02Z
0,2016-01-29T14:52:36Z,3477,[],Acalabrutinib + Obinutuzumab,2017-06-19T18:08:20Z
0,2017-09-11T15:35:43Z,6188,[],Acalabrutinib + Vistusertib,2017-09-11T15:35:43Z
0,2016-04-15T16:41:29Z,3939,[],Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron,2016-04-15T16:41:29Z
0,2015-12-04T01:19:20Z,3265,"[{'description': 'ACP-319 is an inhibitor of PI3K delta, which may block the proliferation of tumor cells (Eur J of Cancer, Dec 2016, 69;1, S39-S40).', 'references': [{'id': 8797, 'pubMedId': None, 'title': 'The novel BTK and PI3K-delta inhibitors acalabrutinib (ACP-196) and ACP-319 show activity in pre-clinical B-cell lymphoma models', 'url': 'http://www.ejcancer.com/article/S0959-8049(16)32699-5/abstract'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",ACP-319,2017-05-03T15:18:53Z
0,2014-10-02T20:01:41Z,1613,"[{'description': 'Ricolinostat (ACY-1215) is a selective inhibitor of HDAC6, which may decrease tumor cell viability and reduce tumor growth, alone or in combination with other agents (PMID: 22262760, PMID: 27926524).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 8244, 'pubMedId': 27926524, 'title': 'Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27926524'}, {'id': 8243, 'pubMedId': 22262760, 'title': 'Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22262760'}]}]",ACY-1215,2017-03-16T16:16:18Z
0,2017-01-24T20:10:59Z,5251,[],ACY-1215 + Bortezomib + Dexamethasone,2017-01-24T20:10:59Z
0,2016-08-07T15:55:13Z,4526,[],ACY-1215 + Cisplatin + Gemcitabine,2016-08-07T15:55:13Z
0,2016-11-02T16:46:25Z,4907,[],ACY-1215 + Dexamethasone + lenalidomide,2016-11-02T16:46:25Z
0,2016-06-10T20:55:20Z,4272,[],ACY-1215 + Ibrutinib,2016-06-10T20:55:20Z
0,2016-06-10T20:55:52Z,4273,[],ACY-1215 + Idelalisib ,2016-06-10T20:55:52Z
0,2015-12-21T00:53:43Z,3313,[],ACY-1215 + nab-paclitaxel,2015-12-21T00:53:43Z
0,2016-01-29T03:12:01Z,3469,[],ACY-1215 + Paclitaxel,2016-01-29T03:12:01Z
0,2014-10-02T20:03:33Z,1614,[],ACY-1215 + Pomalidomide + Dexamethasone,2014-10-02T20:03:33Z
0,2015-12-20T23:02:24Z,3312,[],ACY-241 + Ipilimumab + Nivolumab,2015-12-20T23:02:24Z
0,2017-02-15T20:30:17Z,5327,[],ACY-241 + Paclitaxel,2017-02-15T20:30:17Z
0,2016-05-26T17:33:25Z,4144,"[{'description': 'ACY-957 is a small molecule inhibitor of HDAC1/2, which may result in increased H3K27ac, increased DNA damage, and impairment of DNA repair (PMID: 25605023). ', 'references': [{'id': 5689, 'pubMedId': 25605023, 'title': 'HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605023'}]}]",ACY-957,2016-05-26T17:33:25Z
0,2016-06-01T15:20:42Z,4187,[],ACY-957 + Doxorubicin,2016-06-01T15:20:42Z
0,2016-05-26T18:17:57Z,4147,[],ACY-957 + DZNeP,2016-05-26T18:17:57Z
0,2016-05-26T18:19:01Z,4148,[],ACY-957 + GSK126,2016-05-26T18:19:01Z
0,2017-02-20T01:39:40Z,5336,[],Ad-CEA + Bevacizumab + FOLFOX,2017-03-21T18:44:50Z
0,2017-02-20T01:37:45Z,5335,"[{'description': 'Ad-CEA is a cancer vaccine expressing carcinoembryonic antigen (CEA), which may result in an improved anti-tumor immune response (PMID: 15906358, PMID: 17053815).', 'references': [{'id': 8300, 'pubMedId': 15906358, 'title': 'Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15906358'}, {'id': 8301, 'pubMedId': 17053815, 'title': 'CD4+CD25+ regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17053815'}]}]",Ad-CEA vaccine,2017-03-21T18:40:11Z
0,2016-12-13T04:32:49Z,5083,[],Ad-MAGEA3,2016-12-13T04:32:49Z
0,2016-06-06T14:22:06Z,4250,"[{'description': 'Ad-RTS-IL-12 plus AL is a replication incompetent adenovirus that initiates interleukin-12 (IL-12) production upon veledimex induction, which may stimulate anti-tumor immunity (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Ad-RTS-IL-12 plus AL,2016-06-06T14:22:06Z
0,2014-05-14T14:52:46Z,978,"[{'description': 'INGN-225 (Ad.p53-DC vaccine) is an adenoviral-p53 dendritic cell vaccine, which potentially induces a cytotoxic immune response against tumor cells over expressing Tp53 (PMID: 20420527).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 3929, 'pubMedId': 20420527, 'title': 'INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20420527'}]}]",Ad.p53-DC vaccine,2015-11-17T14:48:31Z
0,2017-10-02T17:56:53Z,6283,"[{'description': 'Ad5-yCD/mutTKSR39rep-hIL12 is an oncolytic adenovirus engineered to express the cytokine interleukin-12 (IL-12) gene and two suicide fusion genes, which induces both tumor cell lysis and anti-tumor immune response (PMID: 26767191).', 'references': [{'id': 10032, 'pubMedId': 26767191, 'title': 'Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26767191'}]}]",Ad5-yCD/mutTKSR39rep-hIL12 ,2017-10-02T17:56:53Z
0,2014-05-14T14:52:46Z,979,"[{'description': 'Advexin (Ad5CMV-p53) is a replication-defective adenoviral-CMV vector that encodes a wild-type Tp53 gene, which induces tumor cells to produce wild-type Tp53 to block cell cycle progression (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Ad5CMV-p53 gene,2017-06-06T13:42:00Z
0,2017-06-12T16:20:31Z,5879,[],Ad5CMV-p53 gene + Capecitabine,2017-06-12T16:20:31Z
0,2017-06-06T13:39:59Z,5854,[],Ad5CMV-p53 gene + unspecified PD-1 antibody,2017-06-06T13:39:59Z
0,2017-06-21T17:08:52Z,5915,"[{'description': 'AD80 inhibits several kinases including RET and S6K, which may result in decreased tumor growth (PMID: 22678283, PMID:     28249155).', 'references': [{'id': 9183, 'pubMedId': 22678283, 'title': 'Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22678283'}, {'id': 9185, 'pubMedId': 28249155, 'title': 'Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28249155'}]}]",AD80,2017-06-21T18:49:20Z
0,2017-05-19T14:51:44Z,5689,"[{'description': 'ADCT-502 is an antibody-drug conjugate comprising a ERBB2 (HER2) targeted antibody linked to a pyrrolobenzodiazepine dimer, which delivers the drug to ERBB2 (HER2)-expressing tumor cells, potentially resulting in decreased tumor growth (Eur J Cancer, 2016, Vol. 69, Supp 1, S28).', 'references': [{'id': 8939, 'pubMedId': None, 'title': '62 - ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody–drug conjugate (ADC) targeting low HER2-expressing solid cancers', 'url': 'http://www.sciencedirect.com/science/article/pii/S0959804916326624'}]}]",ADCT-502,2017-05-19T15:12:12Z
0,2016-10-11T15:19:16Z,4812,"[{'description': 'ADDA 5 is a non-competitive inhibitor of cytochrome c oxidase (CcO) that leads to growth inhibition in tumor cells (PMID: 27679486).', 'references': [{'id': 6750, 'pubMedId': 27679486, 'title': 'Identification of Small Molecule Inhibitors of Human Cytochrome c Oxidase That Target Chemoresistant Glioma Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27679486'}]}]",ADDA 5,2016-10-11T15:19:16Z
0,2016-11-04T18:57:51Z,4916,"[{'description': 'ADH-1 is a peptide that contains a cadherin cell adhesion recognition sequence thereby inhibiting N-Cadherin (CDH2), which may result in antitumor activity (PMID: 22280327).', 'references': [{'id': 6940, 'pubMedId': 22280327, 'title': 'Phase I clinical trial of Exherin (ADH-1) in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22280327'}]}]",ADH-1,2016-11-04T19:27:11Z
0,2016-11-13T22:15:15Z,4952,[],ADH-1 + Cisplatin + Gemcitabine,2016-11-13T22:15:15Z
0,2015-03-17T13:50:49Z,2424,"[{'description': 'ADI-PEG 20 is polyethylene glycol-conjugated arginine deiminase which degrades arginine, thereby depleting arginine and potentially inhibiting growth of arginine-dependent tumor cells (PMID: 22864522).', 'references': [{'id': 2245, 'pubMedId': 22864522, 'title': 'Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22864522'}]}]",ADI-PEG 20,2015-03-17T13:50:49Z
0,2016-07-17T23:27:39Z,4461,"[{'description': 'AdV-tk is an engineered adenoviral vector expressing the herpes simplex virus thymidine kinase that sensitizes tumor cells to therapy with acyclic guanosine analogues (PMID: 26843484).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}, {'id': 9166, 'pubMedId': 26843484, 'title': 'Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843484'}]}]",AdV-tk,2017-06-19T13:34:25Z
0,2016-07-17T23:28:58Z,4462,[],AdV-tk + Nivolumab,2017-06-19T13:34:45Z
0,2017-01-09T19:48:02Z,5172,[],AdV-tk + Valacyclovir,2017-06-19T13:35:06Z
0,2015-10-01T01:07:07Z,3090,"[{'description': 'Lovaxin C (ADXS11-001) is an attenuated Listeria monocytogenes expressing HPV 16 E7 which may induce cytotoxic immune response against tumor cells expressing HPV 16 E7 (PMID: 25483687).', 'references': [{'id': 3683, 'pubMedId': 25483687, 'title': 'ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25483687'}]}]",ADXS11-001,2015-10-01T01:07:07Z
0,2015-08-26T02:25:36Z,3050,"[{'description': 'ADXS31-142 consists of a live attenuated Listeria monocytogenes encoding prostate-specific antigen (PSA) and listeriolysin O (LLO) fusion protein which may have immunostimulatory and antitumor activities (PMID: 22644735).', 'references': [{'id': 3558, 'pubMedId': 22644735, 'title': 'Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22644735'}]}]",ADXS31-142 ,2015-08-26T02:25:36Z
0,2016-09-06T19:40:11Z,4654,"[{'description': 'ADXS31-164 consists of a live attenuated Listeria monocytogenes encoding Erbb2 (Her2) and listeriolysin O (LLO) fusion protein which may have immunostimulatory and antitumor activities (PMID: 20725099).', 'references': [{'id': 6565, 'pubMedId': 20725099, 'title': 'Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20725099'}]}]",ADXS31-164,2016-09-06T19:40:11Z
0,2014-03-12T15:53:16Z,621,"[{'description': 'Sotrastaurin (AEB071) is a pan-PKC inhibitor, which induces cell cycle arrest and apoptosis (PMID: 19491325).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 2279, 'pubMedId': 19491325, 'title': 'The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19491325'}]}]",AEB071,2017-05-01T18:00:57Z
0,2014-12-28T22:37:24Z,1861,[],AEB071 + BYL719,2014-12-28T22:37:24Z
0,2017-04-28T04:07:56Z,5587,[],AEB071 + CGM097,2017-04-28T04:07:56Z
0,2015-01-16T15:14:09Z,1951,[],AEB071 + Everolimus,2015-01-16T15:14:09Z
0,2015-03-03T16:26:07Z,2275,[],AEB071 + PD-0325901,2015-03-03T16:26:07Z
0,2014-03-12T15:53:16Z,622,"[{'description': 'AEE788 is a multi-kinase inhibitor with activity against EGFR and ERBB2 (HER2), which reduces kinase activity resulting in decreased tumor cell proliferation (PMID: 15256466)', 'references': [{'id': 1957, 'pubMedId': 15256466, 'title': 'AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15256466'}]}]",AEE788,2015-03-31T13:45:17Z
0,2015-12-18T20:15:55Z,3303,"[{'description': 'AEZS-131 is an inhibitor of both Erk1 and Erk2, which may result in cell cycle arrest and inhibit tumor growth (Cancer Res April 15, 2011 71; 3563).', 'references': [{'id': 4129, 'pubMedId': None, 'title': 'Abstract 3563: A highly selective Erk1/2 Inhibitor with in-vivo anti tumor potency', 'url': 'http://cancerres.aacrjournals.org/content/71/8_Supplement/3563.short'}]}]",AEZS-131,2015-12-18T20:15:55Z
0,2014-03-12T15:53:16Z,623,"[{'description': 'Gilotrif (afatinib) is a second-generation pan-Egfr inhibitor with activity against EGFR T790M and EGFR exon 19 and 21 deletions, and also inhibits ERBB2 (HER2), ERBB3 (HER3), ERBB4 (HER4) (PMID: 24435321, PMID: 25505694). Gilotrif (afatinib) is FDA approved for use in non-small cell lung cancer patients harboring EGFR exon 19 deletions and EGFR L858R mutations (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Afatinib,2015-07-23T16:38:58Z
0,2016-10-28T15:03:02Z,4873,[],Afatinib + Alectinib,2016-10-28T15:03:02Z
0,2017-10-12T15:12:46Z,6313,[],Afatinib + Capmatinib,2017-10-12T15:12:46Z
0,2015-03-20T14:03:32Z,2442,[],Afatinib + Carboplatin + Paclitaxel,2015-03-20T14:03:32Z
0,2016-06-01T19:45:54Z,4190,[],Afatinib + Cetuximab,2016-06-01T19:45:54Z
0,2016-09-26T17:20:42Z,4764,[],Afatinib + Cetuximab + Sirolimus,2016-09-26T17:20:42Z
0,2016-01-10T11:10:31Z,3378,[],Afatinib + Crizotinib,2016-01-10T11:10:31Z
0,2015-06-04T19:34:07Z,2801,[],Afatinib + Ganetespib,2015-06-04T19:34:21Z
0,2014-08-05T18:05:37Z,1374,[],Afatinib + Loperamide,2014-08-05T18:06:02Z
0,2017-02-25T04:00:42Z,5363,[],Afatinib + Necitumumab,2017-02-25T04:00:42Z
0,2016-05-03T12:37:13Z,4040,[],Afatinib + Nimotuzumab,2016-05-03T12:37:13Z
0,2015-03-20T13:50:09Z,2441,[],Afatinib + Paclitaxel,2015-03-20T13:50:09Z
0,2015-03-19T15:42:12Z,2435,[],Afatinib + Pembrolizumab,2015-03-19T15:42:12Z
0,2016-09-14T14:46:58Z,4711,[],Afatinib + Radiotherapy,2016-09-14T14:46:58Z
0,2016-07-19T18:16:01Z,4482,[],Afatinib + Trametinib,2016-07-19T18:16:01Z
0,2014-07-27T13:12:19Z,1106,[],Afatinib + Trastuzumab,2014-07-27T13:12:19Z
0,2017-01-27T19:28:28Z,5254,[],Afatinib + Vinorelbine,2017-01-27T19:28:28Z
0,2017-01-03T17:23:03Z,5132,"[{'description': 'Afimoxifene (4-hydroxy-tamoxifen) is a metabolite of tamoxifen, which binds to the estrogen receptor and acts as an antagonist in tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Afimoxifene,2017-01-04T19:56:43Z
0,2017-01-04T19:51:33Z,5158,[],Afimoxifene + XMU-MP-2,2017-01-04T19:51:33Z
0,2014-03-12T15:53:16Z,624,"[{'description': 'Zaltrap (aflibercept) is comprised of human IgG fused to the extracellular domains of VEGFR1 and VEGFR2, which binds VEGF to inhibit tumor angiogenesis and metastasis (NCI Drug Dictionary). Zaltrap (aflibercept) is FDA approved in patients with metastatic colorectal cancer (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Aflibercept,2015-05-27T17:02:03Z
0,2015-03-12T14:25:39Z,2368,[],Aflibercept + Capecitabine,2015-03-12T14:25:39Z
0,2017-01-24T14:57:06Z,5246,[],Aflibercept + Docetaxel,2017-01-24T14:57:06Z
0,2015-02-18T16:38:43Z,2095,[],Aflibercept + FOLFIRI,2015-02-18T16:38:43Z
0,2014-12-23T15:03:24Z,1841,[],Aflibercept + Leucovorin + Fluorouracil,2014-12-23T15:03:24Z
0,2015-03-12T14:00:54Z,2367,[],Aflibercept + mFOLFOX-6,2015-03-12T14:00:54Z
0,2014-10-02T15:08:39Z,1595,[],Aflibercept + MLN0128,2014-10-02T15:08:39Z
0,2015-03-12T14:28:48Z,2369,[],Aflibercept + Pembrolizumab,2015-03-12T14:28:48Z
0,2016-06-28T00:51:26Z,4389,"[{'description': 'AFM13 is a bispecific antibody against human CD30 and CD16A, which cross-links tumor cells and NK cells, resulting in anti-tumor immune response (PMID: 26231785).', 'references': [{'id': 6119, 'pubMedId': 26231785, 'title': 'AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26231785'}]}]",AFM13,2016-06-28T00:51:26Z
0,2016-06-28T00:52:40Z,4390,[],AFM13 + Pembrolizumab,2016-06-28T00:52:40Z
0,2017-06-06T14:30:41Z,5856,"[{'description': 'AFM24 is a bispecific antibody against EGFR and CD16A, which may result in an anti-tumor immune response, specifically, natural killer cells targeting tumor cells that express Egfr (J Clin Oncol 35, 2017 (suppl; abstr e14001)).', 'references': []}]",AFM24,2017-06-06T14:31:20Z
0,2014-03-12T15:53:16Z,625,"[{'description': 'Afuresertib (GSK2110183) is a pan-AKT, ATP-competitive inhibitor, which may result in inhibition of the PI3K/AKT signaling pathway and tumor cell proliferation, and induction of tumor cell apoptosis (PMID: 25075128).', 'references': [{'id': 8265, 'pubMedId': 25075128, 'title': 'The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25075128'}]}]",Afuresertib,2017-03-17T18:12:11Z
0,2014-12-23T14:26:19Z,1839,[],Afuresertib + Carfilzomib,2014-12-23T14:26:19Z
0,2015-11-13T20:13:42Z,3204,[],Afuresertib + Trametinib,2015-11-13T20:13:42Z
0,2014-09-18T19:37:39Z,1491,"[{'description': 'AG-120 (Ivosidenib) inhibits mutant IDH1, leading to increased differentiation and decreased proliferation in IDH1 positive tumors (PMID: 27245312).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 8938, 'pubMedId': 27245312, 'title': 'Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27245312'}]}]",AG-120,2017-09-14T14:21:33Z
0,2016-04-22T19:28:58Z,4002,[],AG-120 + Azacitidine,2016-04-22T19:28:58Z
0,2015-07-22T16:15:19Z,2943,"[{'description': 'AG-14361 inhibits PARP-1, resulting in decreased survival of DNA damage repair-deficient tumor cells and increased sensitivity to chemotherapeutics and radiation (PMID: 14709739, PMID: 14871963).', 'references': [{'id': 3294, 'pubMedId': 14871963, 'title': 'Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/14871963'}, {'id': 3293, 'pubMedId': 14709739, 'title': 'Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/14709739'}]}]",AG-14361,2015-07-22T16:15:19Z
0,2015-08-06T03:01:36Z,2995,"[{'description': 'AG-881 inhibits both mutant IDH1 and IDH2, thereby inhibiting cell proliferation in tumors expressing mutant IDH (PMID: 27292784).', 'references': [{'id': 9914, 'pubMedId': 27292784, 'title': 'The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27292784'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AG-881,2017-09-14T17:23:03Z
0,2015-04-24T00:52:25Z,2570,"[{'description': 'AG1295 inhibits the tyrosine kinase activity of PDGFRA, PDGFRB, KIT, and FLT3, which may inhibit growth and promote apoptosis in cancer cells (PMID: 11468194, PMID: 7954456).', 'references': [{'id': 1969, 'pubMedId': 7954456, 'title': 'Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/7954456'}, {'id': 2556, 'pubMedId': 11468194, 'title': 'A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11468194'}]}]",AG1295,2015-04-27T13:08:06Z
0,2015-02-23T21:38:20Z,2139,"[{'description': 'AG1296 is a tyrphostin which binds and inhibits PDGFR and c-KIT which may reduce proliferation and tumor growth (PMID: 7954456, PMID: 15150607).', 'references': [{'id': 1969, 'pubMedId': 7954456, 'title': 'Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/7954456'}, {'id': 1970, 'pubMedId': 15150607, 'title': 'Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15150607'}]}]",AG1296,2015-03-06T11:33:43Z
0,2017-05-19T15:43:44Z,5695,"[{'description': 'AGEN1884 is an antibody that targets CTLA-4, potentially resulting in increased anti-tumor immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AGEN1884,2017-09-25T18:20:20Z
0,2017-05-19T15:37:06Z,5693,"[{'description': 'AGEN2034 is an antibody that targets PD-1, resulting in enhanced anti-tumor immune response (AACR 2017, Abstract 3654).', 'references': [{'id': 8940, 'pubMedId': None, 'title': 'AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays and in a non-human primate pharmacodynamic (PD) model', 'url': 'http://www.abstractsonline.com/pp8/#!/4292/presentation/6300'}]}]",AGEN2034,2017-05-19T15:37:06Z
0,2015-04-24T00:07:14Z,2569,"[{'description': 'AGI-5198 inhibits IDH1 R132H and R132C mutants but not IDH1 wild-type, which may inhibit growth in cancer cells (PMID: 23558169).', 'references': [{'id': 2552, 'pubMedId': 23558169, 'title': 'An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558169'}]}]",AGI-5198,2015-04-24T00:18:50Z
0,2017-02-14T21:20:30Z,5326,[],AGI-5198 + Olaparib,2017-02-14T21:20:30Z
0,2016-04-05T18:55:16Z,3895,[],AGI-5198 + Radiotherapy,2016-04-05T18:55:16Z
0,2017-02-14T21:19:25Z,5325,[],AGI-5198 + Talazoparib,2017-06-12T16:03:47Z
0,2014-10-02T05:35:41Z,1585,"[{'description': 'AGI-6780 inhibits IDH2 R140Q mutant in cancer cells and induces cell differentiation (PMID: 23558173).', 'references': [{'id': 881, 'pubMedId': 23558173, 'title': 'Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558173'}]}]",AGI-6780,2014-10-15T03:37:08Z
0,2015-04-24T00:59:40Z,2571,"[{'description': 'AGL2043 inhibits the tyrosine kinase activity of PDGFRA, PDGFRB, KIT, and FLT3, which may inhibit growth and promote apoptosis in cancer (PMID: 12670652).', 'references': [{'id': 2557, 'pubMedId': 12670652, 'title': 'Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12670652'}]}]",AGL2043,2015-04-27T13:08:37Z
0,2016-05-05T18:08:36Z,4075,"[{'description': 'AGS-003 is an immunotherapy that comprises autologous dendritic cells transfected with patient tumor-derived RNA and CD40L RNA, which may result in induction of an anti-tumor immune response (PMID: 25901286).', 'references': [{'id': 5380, 'pubMedId': 25901286, 'title': 'Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25901286'}]}]",AGS-003,2016-05-05T18:09:56Z
0,2016-05-05T18:12:10Z,4076,[],AGS-003 + Sunitinib,2016-05-05T18:12:10Z
0,2016-06-03T00:28:16Z,4220,"[{'description': 'AGS-16C3F is a monoclonal antibody against ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3) linked to the cytotoxic drug monomethyl auristatin F (MMAF), which may result in apoptosis of ENPP3-expressing tumor cells (NCI Drug Dictionary).', 'references': []}]",AGS-16C3F,2016-06-03T18:42:05Z
0,2016-09-13T13:51:05Z,4697,"[{'description': 'AGS-1C4D4 is a human monoclonal antibody against prostate stem cell antigen (PSCA), which may result in anti-tumor activity (PMID: 22020316).', 'references': []}]",AGS-1C4D4 ,2016-09-13T13:51:05Z
0,2016-09-13T14:26:19Z,4699,"[{'description': 'AGS-PSCA is a human monoclonal antibody against prostate stem cell antigen, which may result in tumor growth inhibition by specifically blocking the growth of prostate cancer cells expressing PSCA (PMID: 22553195). ', 'references': [{'id': 6604, 'pubMedId': 22553195, 'title': 'A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22553195'}]}]",AGS-PSCA,2016-09-13T14:26:19Z
0,2015-06-19T13:58:15Z,2859,"[{'description': 'AI-10-49 is a small molecule inhibitor, which selectively inhibits the binding of the fusion protein, CBFbeta-SMMHC, to RUNX1, resulting in apoptotic cell death of leukemia cells (PMID: 25678665).', 'references': [{'id': 3100, 'pubMedId': 25678665, 'title': 'Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678665'}]}]",AI-10-49,2015-06-19T13:58:15Z
0,2017-07-27T19:33:56Z,6020,"[{'description': 'AIC-47 is a fatty acid derivative that suppresses BCR-ABL1 transcription, therefore results in apoptosis of tumor cells (PMID: 25644089).', 'references': [{'id': 9605, 'pubMedId': 25644089, 'title': 'Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25644089'}]}]",AIC-47,2017-07-27T19:33:56Z
0,2017-07-27T20:22:03Z,6021,[],AIC-47 + Imatinib,2017-07-27T20:22:03Z
0,2016-03-22T15:08:45Z,3801,"[{'description': 'AIM-100 is a small molecule inhibitor of Tnk2 (Ack1), which may lead to increased apoptosis and decreased proliferation of tumor cells (PMID: 22322295, PMID: 20623637).', 'references': [{'id': 4965, 'pubMedId': 22322295, 'title': 'Ack1 tyrosine kinase activation correlates with pancreatic cancer progression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22322295'}, {'id': 4966, 'pubMedId': 20623637, 'title': 'Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20623637'}]}]",AIM-100,2016-03-22T15:08:45Z
0,2015-03-10T15:19:44Z,2338,"[{'description': 'AJI-100 is a dual-AURKA/B, JAK2 inhibitor, which prevents cell growth and induces apoptosis (PMID: 24930769, PMID: 28077684).', 'references': [{'id': 2143, 'pubMedId': 24930769, 'title': 'Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24930769'}]}]",AJI-100,2017-04-04T12:09:44Z
0,2015-03-10T15:18:48Z,2337,"[{'description': 'AJI-214 is a dual-AURKA/B, JAK2 inhibitor, which prevents cell growth and induces apoptosis (PMID: 24930769, PMID: 28077684).', 'references': [{'id': 2143, 'pubMedId': 24930769, 'title': 'Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24930769'}]}]",AJI-214,2017-04-04T12:10:09Z
0,2017-05-23T19:33:23Z,5753,"[{'description': 'Limited information is currently available on AK-01 (May, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",AK-01,2017-05-23T19:33:23Z
0,2016-05-05T16:48:15Z,4073,"[{'description': 'AKI603 is a small molecule inhibitor of Aurora Kinase A, which may induce cell cycle arrest and inhibit cell proliferation and tumor growth (PMID: 24899685). ', 'references': [{'id': 5376, 'pubMedId': 24899685, 'title': 'A novel small molecule aurora kinase inhibitor attenuates breast tumor-initiating cells and overcomes drug resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24899685'}]}]",AKI603,2017-04-04T12:13:31Z
0,2016-05-05T18:01:47Z,4074,[],AKI603 + Epirubicin,2016-05-05T18:01:47Z
0,2017-04-26T17:46:51Z,5572,[],AKI603 + Imatinib,2017-04-26T17:46:51Z
0,2015-11-03T16:31:25Z,3170,"[{'description': 'AKN-028 inhibits wild-type and mutant forms of FLT3 and KIT, potentially resulting in decreased tumor cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AKN-028,2015-11-03T16:31:25Z
0,2014-05-14T14:52:46Z,980,"[{'description': 'Anlotinib (AL-3818) inhibits KDR (VEGFR2) and VEGFR3, thereby preventing angiogenesis and tumor cell growth (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AL-3818,2014-10-27T15:48:51Z
0,2014-08-06T14:34:15Z,1392,"[{'description': 'Alclometasone is a topical, synthetic corticosteroid used as a anti-inflammatory and antipruritic agent (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Alclometasone,2014-08-06T14:34:15Z
0,2014-07-28T17:11:51Z,1167,"[{'description': 'Aldesleukin may induce T cell-mediated tumor regression by activating the IL-2 receptor to enhance lymphocyte mitogenesis; enhance lymphocyte cytotoxicity; induce lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induce expression of interferon-gamma (NCI Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Aldesleukin,2014-07-28T17:11:51Z
0,2015-02-19T13:28:01Z,2098,[],Aldesleukin + Bevacizumab,2015-02-19T13:28:01Z
0,2016-01-14T14:08:05Z,3409,[],Aldesleukin + Cyclophosphamide + Fludarabine ,2016-01-14T14:08:05Z
0,2017-05-18T19:33:17Z,5683,[],Aldesleukin + Cyclophosphamide + Fludarabine + Mesna + Pembrolizumab,2017-05-18T19:33:17Z
0,2016-08-14T16:35:15Z,4562,[],Aldesleukin + Cyclophosphamide + Fludarabine + Pembrolizumab,2016-08-14T16:35:15Z
0,2017-05-22T14:13:27Z,5733,[],Aldesleukin + Cyclophosphamide + Ipilimumab,2017-05-22T14:17:47Z
0,2016-06-02T18:02:12Z,4193,[],Aldesleukin + Cyclophosphamide + Pembrolizumab,2016-06-02T18:02:12Z
0,2015-02-12T13:23:30Z,2058,[],Aldesleukin + GD2Bi-a ATC + Sargramostim ,2015-02-12T13:23:30Z
0,2014-10-02T19:32:14Z,1612,[],Aldesleukin + Ipilimumab,2014-10-02T19:32:14Z
0,2015-03-25T15:19:13Z,2459,[],Aldesleukin + Melphalan + Sargramostim,2015-03-25T15:19:13Z
0,2017-01-03T18:50:24Z,5139,[],Aldesleukin + Nivolumab,2017-01-03T18:50:24Z
0,2016-05-27T14:25:10Z,4165,[],Aldesleukin + Pembrolizumab,2016-05-27T14:25:10Z
0,2014-07-29T20:02:50Z,1229,[],Aldesleukin + Vemurafenib,2014-07-29T20:02:50Z
0,2014-07-28T22:02:34Z,1188,[],Aldesleukin + Vemurafenib + IFN A2b,2014-07-28T22:02:34Z
0,2014-09-11T03:34:44Z,1440,"[{'description': 'Aldoxorubicin is a derivative prodrug of doxorubicin that  is converted to free doxorubicin within the acidic environment within tumors. Once converted, doxorubicin intercalates DNA, inhibits DNA synthesis and induces apotosis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Aldoxorubicin,2015-04-07T00:19:07Z
0,2015-12-29T16:34:01Z,3347,[],Aldoxorubicin + Bendamustine + Bortezomib,2015-12-29T16:34:01Z
0,2016-01-21T22:03:02Z,3435,[],Aldoxorubicin + Cisplatin + Cyclophosphamide + Dexamethasone + Etoposide,2016-01-21T22:03:02Z
0,2015-04-23T02:16:01Z,2564,[],Aldoxorubicin + Cisplatin + Filgrastim + Methotrexate + Vinblastine,2015-04-23T02:16:01Z
0,2015-05-14T00:08:11Z,2668,[],Aldoxorubicin + Cisplatin + Methotrexate + Vincristine,2015-05-14T00:08:11Z
0,2015-07-31T15:03:09Z,2989,[],Aldoxorubicin + Cyclophosphamide + Veliparib,2015-07-31T15:03:09Z
0,2015-09-30T02:22:10Z,3087,[],Aldoxorubicin + Docetaxel + Estramustine + Ketoconazole,2015-09-30T02:22:10Z
0,2015-08-26T02:49:31Z,3052,[],Aldoxorubicin + Ganetespib,2015-08-26T02:49:31Z
0,2015-10-06T00:16:39Z,3101,[],Aldoxorubicin + MEDI4736 + Motolimod,2017-05-17T15:12:46Z
0,2016-01-10T21:19:11Z,3388,[],Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine,2016-01-10T21:19:11Z
0,2014-03-12T15:53:16Z,698,"[{'description': 'Alecensa (alectinib) is an inhibitor of RET and ALK, including ALK fusions and the gatekeeper mutation, L1196M (PMID: 21575866, PMID: 25349307). Alecensa (alectinib) is FDA-approved for use in patients with ALK-positive non-small cell lung cancer (FDA.gov).', 'references': [{'id': 1817, 'pubMedId': 21575866, 'title': 'CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21575866'}]}]",Alectinib,2017-04-03T11:19:13Z
0,2016-02-01T15:25:57Z,3490,[],Alectinib + Atezolizumab,2017-06-12T15:06:17Z
0,2017-07-06T20:02:38Z,5971,[],Alectinib + Cobimetinib,2017-07-06T20:02:38Z
0,2017-07-13T17:50:16Z,5989,[],Alectinib + Doxorubicin,2017-07-13T17:50:16Z
0,2014-08-01T01:06:41Z,1334,[],Alectinib + Erlotinib,2017-06-25T19:51:35Z
0,2014-07-29T15:45:13Z,1205,[],Alemtuzumab,2014-07-29T15:45:13Z
0,2015-03-06T00:08:00Z,2305,[],Alemtuzumab + Cyclosporine,2015-03-06T00:08:00Z
0,2014-03-12T15:53:16Z,626,"[{'description': 'Alisertib (MLN8237) binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation (PMID: 26999067).', 'references': [{'id': 8420, 'pubMedId': 26999067, 'title': 'An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26999067'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Alisertib,2017-04-04T12:25:24Z
0,2014-07-30T06:57:09Z,1239,[],Alisertib  + Esomeprazole,2014-07-30T06:57:09Z
0,2014-07-29T19:38:45Z,1226,[],Alisertib + Abraxane,2014-07-29T19:38:45Z
0,2016-02-19T19:53:54Z,3581,[],Alisertib + Bortezomib + Rituximab,2016-02-19T19:53:54Z
0,2016-06-17T18:58:51Z,4301,[],Alisertib + Brentuximab vedotin,2016-06-17T18:58:51Z
0,2017-01-13T15:48:47Z,5195,[],Alisertib + Cisplatin,2017-01-13T15:48:47Z
0,2017-01-30T20:15:38Z,5257,[],Alisertib + Cisplatin + Etoposide,2017-01-30T20:15:38Z
0,2014-10-29T00:00:50Z,1678,[],Alisertib + Docetaxel,2014-10-29T00:00:50Z
0,2016-08-30T20:09:11Z,4626,[],Alisertib + Eribulin,2016-08-30T20:09:11Z
0,2017-01-26T20:37:03Z,5253,[],Alisertib + Etoposide,2017-01-26T20:37:03Z
0,2016-08-14T16:02:26Z,4561,[],Alisertib + Fulvestrant,2016-08-14T16:02:26Z
0,2014-07-31T07:04:00Z,1289,[],Alisertib + Gemcitabine,2014-07-31T07:04:00Z
0,2015-05-07T02:50:53Z,2628,[],Alisertib + Irinotecan + Temozolomide,2015-05-07T02:50:53Z
0,2016-06-02T23:54:39Z,4214,[],Alisertib + MLN0128,2016-06-02T23:54:39Z
0,2017-05-25T18:44:46Z,5776,[],Alisertib + MP7,2017-05-25T18:44:46Z
0,2014-07-29T17:44:49Z,1212,[],Alisertib + Pazopanib,2014-07-29T17:44:49Z
0,2014-07-30T06:58:28Z,1240,[],Alisertib + Rifampin,2014-07-30T06:58:28Z
0,2014-10-29T00:34:20Z,1679,[],Alisertib + Taxol,2014-10-29T00:34:20Z
0,2016-06-17T18:49:08Z,4298,"[{'description': 'Limited information is currently available on ALKS 4230 (Jun 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",ALKS 4230,2016-06-17T18:49:08Z
0,2016-02-26T16:49:49Z,3628,[],Allopurinol,2016-02-26T16:49:49Z
0,2015-03-06T13:24:52Z,2311,[],Allopurinol + Cyclophosphamide + Fludarabine,2015-03-06T13:24:52Z
0,2017-06-12T15:41:40Z,5876,[],Allopurinol + Ibrutinib + Venetoclax,2017-06-12T15:41:40Z
0,2017-09-21T14:19:46Z,6225,"[{'description': 'ALM201 is a peptide therapy that is based on the human anti-angiogenic protein FKPB-L, which may decrease tumor cell migration and invasion and reduce formation of new vessels (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #383P).', 'references': [{'id': 9966, 'pubMedId': None, 'title': 'A phase I dose-escalation study of the novel peptide ALM201 in patients (pts) with advanced solid tumours', 'url': 'http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts'}]}]",ALM201,2017-09-21T14:19:46Z
0,2016-10-18T14:59:37Z,4851,[],Alpelisib + AZD1208,2016-10-18T14:59:37Z
0,2017-05-05T19:17:09Z,5627,[],Alpelisib + Cisplatin,2017-05-05T19:17:09Z
0,2017-06-26T17:27:29Z,5929,[],Alpelisib + Fulvestrant,2017-06-26T17:27:29Z
0,2016-08-03T18:45:41Z,4519,[],Alpelisib + GSK2334470,2016-08-03T18:45:41Z
0,2016-07-12T12:54:32Z,4441,[],Alpelisib + LSZ 102,2016-07-12T12:55:30Z
0,2017-01-05T20:56:52Z,5164,[],Alpelisib + Lucitanib,2017-01-05T20:56:52Z
0,2016-12-21T18:03:44Z,5119,[],Alpelisib + PLX4720,2016-12-21T18:03:44Z
0,2017-02-28T17:15:26Z,5383,[],Alpelisib + WEHI-539,2017-02-28T17:15:26Z
0,2014-07-28T21:58:49Z,1187,"[{'description': 'Roferon-A (alpha 2 Interferon) is a recombinant form of human interferon alfa-2a,  which binds to its receptor, activating anti-viral, anti-proliferative, anti-cancer, and immune modulating downstream effectors (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Alpha 2 Interferon,2017-06-19T21:07:53Z
0,2015-03-03T15:26:16Z,2273,"[{'description': 'ALRN-6924 binds to MDM2 and MDMX and prevents their interaction with p53, resulting in restoration of p53 activity and potentially leading to increased tumor cell death (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",ALRN-6924,2015-03-03T15:26:16Z
0,2016-09-25T14:44:32Z,4755,[],ALRN-6924 + Cytarabine,2016-09-25T14:44:32Z
0,2015-02-27T05:16:05Z,2187,"[{'description': 'ALT-801 is comprised of IL-2 fused to a T-cell receptor domain that targets p53, potentially enhancing immune response to p53-expressing tumor cells and resulting in increased tumor cell death (PMID: 21994418).', 'references': [{'id': 2040, 'pubMedId': 21994418, 'title': 'Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21994418'}]}]",ALT-801,2015-11-17T14:52:39Z
0,2015-02-27T11:00:53Z,2191,[],ALT-801 + Gemcitabine,2015-02-27T11:00:53Z
0,2015-08-27T04:01:06Z,3060,"[{'description': 'ALT-803 is a fusion protein consisting a mutant IL-15 and a soluble IL-15Ra Fc, which activates and converts memory CD8+ T cells to effector immune cells with antitumor activity (PMID: 24404427).', 'references': [{'id': 3562, 'pubMedId': 24404427, 'title': 'The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24404427'}]}]",ALT-803,2015-08-27T04:01:06Z
0,2017-01-20T05:27:37Z,5238,[],ALT-803 + BCG solution,2017-01-20T05:27:37Z
0,2017-02-11T22:42:28Z,5300,[],ALT-803 + Cyclophosphamide + Fludarabine phosphate,2017-02-14T17:19:30Z
0,2017-09-25T15:21:45Z,6239,[],ALT-803 + ETBX-011,2017-09-25T15:21:45Z
0,2015-10-05T17:00:47Z,3095,[],ALT-803 + Gemcitabine + nab-paclitaxel,2015-10-05T17:00:47Z
0,2015-08-27T04:02:00Z,3061,[],ALT-803 + Nivolumab,2015-08-27T04:02:00Z
0,2017-07-28T18:27:10Z,6037,[],ALT-803 + Pembrolizumab,2017-07-28T18:27:10Z
0,2016-04-15T15:49:55Z,3936,[],ALT-803 + Rituximab,2016-04-15T15:50:01Z
0,2014-10-16T21:20:38Z,1656,"[{'description': 'Altiratinib (DCC-2701) is an inhibitor of MET, VEGFR2, TIE2, and Trk that decreases endothelial cell survival and may inhibit cell proliferation and increase cell death in tumors expressing these factors (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Altiratinib,2015-05-11T19:25:59Z
0,2016-06-24T04:44:43Z,4353,[],Altiratinib + Bevacizumab,2016-06-24T04:44:43Z
0,2017-02-24T20:27:39Z,5361,[],Altiratinib + Dabrafenib,2017-02-24T20:27:39Z
0,2017-02-24T20:28:15Z,5362,[],Altiratinib + Trametinib,2017-02-24T20:28:15Z
0,2014-03-12T15:53:16Z,627,"[{'description': 'Alvespimycin is a small molecule inhibitor of HSP90, which potentially leads to decreased tumor growth (PMID: 15791458).', 'references': [{'id': 2910, 'pubMedId': 15791458, 'title': 'In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15791458'}]}]",Alvespimycin,2015-06-03T17:10:41Z
0,2016-03-11T02:38:52Z,3723,[],Alvespimycin + Vorinostat,2016-03-11T02:38:52Z
0,2014-03-12T15:53:16Z,628,"[{'description': 'Alvocidib (flavopiridol) is an inhibitor of CDK1, CDK2, CDK4, CDK6, CDK7, and CDK9, which may induce cell cycle arrest and apoptosis in cancer cells (PMID: 12165651, PMID: 8674031, PMID: 24470357). ', 'references': [{'id': 922, 'pubMedId': 12165651, 'title': 'The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12165651'}, {'id': 921, 'pubMedId': 8674031, 'title': 'Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/8674031'}]}]",Alvocidib,2015-05-27T18:45:26Z
0,2015-06-04T19:00:49Z,2800,[],Alvocidib + Aldoxorubicin,2015-06-04T19:00:49Z
0,2017-10-08T01:27:47Z,6300,[],Alvocidib + Cytarabine + Daunorubicin,2017-10-08T01:27:47Z
0,2016-09-02T17:28:26Z,4646,[],Alvocidib + Doxorubicin,2016-09-02T17:28:26Z
0,2016-04-19T19:26:52Z,3961,[],Alvocidib + Palbociclib,2016-04-19T19:26:52Z
0,2016-05-24T20:01:20Z,4131,[],Alvocidib + Sorafenib,2016-05-24T20:01:20Z
0,2015-12-10T17:57:28Z,3274,"[{'description': 'ALW-II-41-27 is a small molecule that inhibits EPHA2 and RET, leading to decreased tumor cell proliferation and viability (PMID: 24713656, PMID: 26046350).', 'references': [{'id': 4082, 'pubMedId': 24713656, 'title': 'Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24713656'}]}]",ALW-II-41-27,2017-04-03T11:20:26Z
0,2015-06-18T21:09:28Z,2852,"[{'description': 'ALX-0651 is a nanobody that targets CXCR4 and prevents SDF-1 (CXCL12) binding, potentially resulting in decreased cell migration (PMID: 23211868)', 'references': [{'id': 3089, 'pubMedId': 23211868, 'title': 'Halting metastasis through CXCR4 inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23211868'}]}]",ALX-0651,2015-06-25T21:05:30Z
0,2017-01-15T23:34:10Z,5211,"[{'description': 'Limited information is currently available on ALX148 (Jan, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",ALX148,2017-01-16T18:34:10Z
0,2017-01-15T23:35:48Z,5212,[],ALX148 + Atezolizumab,2017-01-15T23:35:48Z
0,2017-01-15T23:36:40Z,5213,[],ALX148 + Trastuzumab,2017-01-15T23:36:40Z
0,2016-08-16T17:35:24Z,4570,"[{'description': 'AM-0687 is an inhibitor of PI3K-delta, which demonstrates blockade of Akt phosphorylation (PMID: 27411843). ', 'references': [{'id': 6486, 'pubMedId': 27411843, 'title': 'Discovery and in Vivo Evaluation of the Potent and Selective PI3Kδ Inhibitors 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-5-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-1430).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27411843'}]}]",AM-0687,2016-08-16T17:35:24Z
0,2016-08-16T17:36:48Z,4571,"[{'description': 'AM-1430 is an inhibitor of PI3K-delta, which demonstrates blockade of Akt phosphorylation (PMID: 27411843). ', 'references': [{'id': 6486, 'pubMedId': 27411843, 'title': 'Discovery and in Vivo Evaluation of the Potent and Selective PI3Kδ Inhibitors 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-5-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-1430).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27411843'}]}]",AM-1430,2016-08-16T17:36:48Z
0,2015-05-01T15:04:34Z,2621,"[{'description': 'AM0010 is recombinant human interleukin-10 (IL-10) conjugated with polyethylene glycol (PEG), which may induce anti-tumor immune response (J Clin Oncol 34, 2016 (suppl; abstr 3082)).', 'references': [{'id': 9015, 'pubMedId': None, 'title': 'Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with pancreatic or colorectal cancer.', 'url': 'http://meetinglibrary.asco.org/record/125848/abstract'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AM0010 ,2017-05-30T17:30:35Z
0,2017-05-30T17:19:41Z,5810,[],AM0010 + Capecitabine,2017-05-30T17:19:41Z
0,2017-06-04T01:38:36Z,5849,[],AM0010 + mFOLFOX-6,2017-06-04T01:38:36Z
0,2016-01-25T17:19:51Z,3457,"[{'description': 'Ama-HEA125 is an inhibitor of POLR2A, comprising alpha-amanitin conjugated to the monoclonal antibody, HEA125, which may induce apoptosis and inhibit tumor growth (PMID: 25901683). ', 'references': [{'id': 4431, 'pubMedId': 25901683, 'title': 'TP53 loss creates therapeutic vulnerability in\xa0colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25901683'}]}]",Ama-HEA125,2016-01-25T17:19:51Z
0,2016-02-11T11:25:31Z,3513,"[{'description': 'Amatuximab is a chimeric anti-mesothelin monoclonal antibody being evaluated in clinical trials (PMID: 25502863).', 'references': [{'id': 4551, 'pubMedId': 25502863, 'title': 'Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25502863'}]}]",Amatuximab,2016-02-15T14:37:19Z
0,2017-09-22T19:12:55Z,6233,"[{'description': 'AMC303 is an allosteric inhibitor of CD44v6, the co-receptor of c-MET, RON, and VEGFR2, which may result in decreased cell invasion and migration, and tumor regression (Cancer Res 2017;77(13 Suppl):Abstract nr 4911).', 'references': []}]",AMC303,2017-09-22T19:12:55Z
0,2015-06-18T20:53:15Z,2851,"[{'description': 'AMD11070 is a CXCR4 antagonist that inhibits SDF-1 (CXCL12)-CXCR4- mediated cell migration, potentially resulting in decreased tumor cell metastasis (PMID: 23538388).\r\n', 'references': [{'id': 3088, 'pubMedId': 23538388, 'title': 'Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23538388'}]}]",AMD11070,2015-06-25T21:00:24Z
0,2014-09-11T15:51:30Z,1452,"[{'description': 'AMG 232 is a potent inhibitor of the MDM2-p53 interaction, and inhibits proliferation of tumor cells in a p53 dependent manner (PMID: 24456472).', 'references': [{'id': 698, 'pubMedId': 24456472, 'title': 'Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24456472'}]}]",AMG 232,2017-05-19T18:59:18Z
0,2016-09-01T15:38:08Z,4638,[],AMG 232 + Carboplatin,2016-09-01T15:38:08Z
0,2016-09-01T15:37:29Z,4637,[],AMG 232 + Cisplatin,2016-09-01T15:37:29Z
0,2017-09-11T14:47:50Z,6185,[],AMG 232 + Decitabine,2017-09-11T14:47:50Z
0,2016-09-01T15:36:54Z,4636,[],AMG 232 + Doxorubicin,2016-09-01T15:36:54Z
0,2016-09-01T16:41:25Z,4639,[],AMG 232 + Irinotecan,2016-09-01T16:41:25Z
0,2016-09-08T20:50:35Z,4671,[],AMG 232 + Radiotherapy,2016-09-08T20:50:35Z
0,2014-09-11T15:55:24Z,1454,[],AMG 232 + Trametinib,2014-09-11T15:55:24Z
0,2014-09-11T15:54:09Z,1453,[],AMG 232 + Trametinib + Dabrafenib,2014-09-11T15:54:09Z
0,2014-05-14T14:52:46Z,982,"[{'description': 'AMG 319 is a selective inhibitor of PI3K-delta, thus decreasing proliferation and inducing cell death (PMID: 25469863).', 'references': [{'id': 4910, 'pubMedId': 25469863, 'title': 'Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25469863'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AMG 319,2016-03-17T19:31:13Z
0,2014-06-06T17:06:23Z,1064,"[{'description': 'AMG 337 inhibits c-MET and may induce cell death in tumors overexpressing c-MET or expressing constitutively activated c-MET (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AMG 337,2014-10-29T23:51:11Z
0,2015-02-25T19:57:53Z,2163,"[{'description': 'AMG 458 inhibits wild-type and mutant forms of MET and has additional activity against MST1R (RON), resulting in decreased tumor growth (PMID: 20015007).', 'references': [{'id': 2015, 'pubMedId': 20015007, 'title': 'Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20015007'}]}]",AMG 458,2015-12-03T16:36:58Z
0,2017-09-29T15:24:13Z,6261,"[{'description': 'Limited information is currently available on AMG 596 (Sep 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",AMG 596,2017-09-29T15:24:13Z
0,2016-09-20T12:44:17Z,4724,"[{'description': 'AMG 780 is a humanized monoclonal antibody that binds to angiopoietin-1 (Ang1) and -2 (Ang2), therefore prevents angiogenesis, leading to anti-tumor effects (PMID: 27076631).', 'references': [{'id': 6651, 'pubMedId': 27076631, 'title': 'A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27076631'}]}]",AMG 780,2016-09-20T12:44:17Z
0,2014-05-14T14:52:46Z,983,"[{'description': 'AMG 900 selectively binds to and inhibits the activities of Aurora kinases A, B and C, which may result in inhibition of cellular division and proliferation in tumor cells that overexpress these kinases (PMID: 25367255).', 'references': [{'id': 8412, 'pubMedId': 25367255, 'title': 'AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25367255'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AMG 900,2017-04-04T10:39:26Z
0,2016-09-09T15:26:21Z,4676,[],AMG 900 + Ixabepilone,2016-09-09T15:27:56Z
0,2014-03-12T15:53:16Z,629,"[{'description': 'Rilotumumab is a humanized monoclonal antibody directed against HGF, which interferes with the interaction between HGF and c-Met to prevent c-Met activation (PMID: 19649990).', 'references': [{'id': 1307, 'pubMedId': 19649990, 'title': 'Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19649990'}]}]",AMG102,2017-07-20T18:13:23Z
0,2014-03-12T15:53:16Z,630,"[{'description': 'AMG 208 is a small molecule inhibitor of c-MET, which blocks c-MET activation, resulting in inhibition of downstream signaling and potentially resulting in decreased growth of c-MET expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AMG208,2015-02-25T15:36:33Z
0,2014-07-28T12:35:20Z,1138,[],AMG479 + Everolimus + Panitumumab,2014-07-28T12:35:20Z
0,2015-06-18T17:06:16Z,2842,"[{'description': 'AMG820 is a monoclonal antibody that binds CSF1R and prevents ligand binding, potentially resulting in decreased growth of CSF1-driven tumor cells (Cancer Res May 1, 2009 69; 2077).', 'references': [{'id': 3079, 'pubMedId': None, 'title': 'Abstract #2077: Antagonistic antibodies to c-fms block c-fms-mediated activities, reduce tumor-associated macrophages and decrease tumor growth in preclinical models', 'url': 'http://cancerres.aacrjournals.org/content/69/9_Supplement/2077.short'}]}]",AMG820,2015-06-18T17:06:16Z
0,2016-05-27T16:07:56Z,4170,[],AMG820 + Pembrolizumab,2016-05-27T16:07:56Z
0,2017-03-22T17:47:12Z,5463,"[{'description': 'AMI-408 inhibits PRMT1, potentially resulting in decreased tumor cell growth (PMID: 26766589).', 'references': [{'id': 8304, 'pubMedId': 26766589, 'title': 'Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26766589'}]}]",AMI-408,2017-03-22T17:47:12Z
0,2017-01-19T16:21:14Z,5229,[],Amlexanox + Selumetinib,2017-01-19T16:21:14Z
0,2015-12-28T19:09:16Z,3337,"[{'description': 'AMP-224 is a fusion protein comprised of the extracellular domain of PD-L2 and the Fc region of IgG1, which binds to the PD-1 receptor thereby potentially resulting in restoration of the T-cell mediated immune response (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AMP-224,2016-01-28T02:24:38Z
0,2015-07-23T01:23:14Z,2951,"[{'description': 'Amrubicin is a synthetic anthracycline, which intercalates into DNA resulting in growth inhibition and cell death (PMID: 21188110).', 'references': [{'id': 3308, 'pubMedId': 21188110, 'title': 'Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21188110'}]}]",Amrubicin,2015-10-14T20:10:11Z
0,2014-03-12T15:53:16Z,632,"[{'description': 'Amuvatinib (MP470) is a multi-kinase inhibitor, with activity against KIT, MET, AXL, RET, FLT3, and PDGFR-alpha, that also inhibits Rad51 induction, which may enhance the efficacy of chemotherapeutic agents (NCI Drug Dictionary, PMID: 17325667).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Amuvatinib,2017-04-03T11:29:33Z
0,2015-02-26T12:54:04Z,2165,[],Amuvatinib + Paclitaxel + Carboplatin,2015-02-26T12:54:04Z
0,2017-05-19T19:51:26Z,5711,"[{'description': 'AMG-564 is a tandem diabody that targets both CD33 and CD3, which may result in increased T-cell activation and death of CD33-expressing tumor cells (PMID: 27189165, PMID: 28157217).', 'references': [{'id': 8952, 'pubMedId': 28157217, 'title': 'Acute myeloid leukemia targets for bispecific antibodies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28157217'}, {'id': 8953, 'pubMedId': 27189165, 'title': 'Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27189165'}]}]",AMV-564,2017-05-30T14:20:06Z
0,2014-07-28T23:26:58Z,1192,[],Anakinra + Everolimus,2014-07-28T23:26:58Z
0,2014-03-12T15:53:16Z,633,"[{'description': 'Arimidex (anastrozole) is an aromatase inhibitor, which inhibits estrogen synthesis (NCI Drug Dictionary). Arimidex (anastrozole) is FDA approved for postmenopausal women with breast cancer (FDA.gov). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Anastrozole,2015-03-27T19:23:00Z
0,2015-01-05T15:00:09Z,1911,[],Anastrozole  + Fulvestrant,2015-01-05T15:00:09Z
0,2015-03-03T02:55:21Z,2268,[],Anastrozole + Everolimus,2015-03-03T02:55:21Z
0,2016-05-17T21:12:19Z,4123,[],Anastrozole + GDC-0941,2016-05-17T21:12:19Z
0,2014-12-24T16:23:32Z,1853,[],Anastrozole + Letrozole,2014-12-24T16:23:32Z
0,2016-06-01T18:36:32Z,4188,[],Anastrozole + MK2206,2016-06-01T18:36:32Z
0,2016-11-19T22:59:07Z,4974,[],Anastrozole + Palbociclib,2016-11-19T22:59:07Z
0,2017-10-17T17:35:43Z,6323,[],Anastrozole + Palbociclib + Pertuzumab + Trastuzumab,2017-10-17T17:35:43Z
0,2015-04-24T19:53:17Z,2591,[],Andriol,2015-04-24T19:53:17Z
0,2016-08-20T20:24:08Z,4593,"[{'description': 'Anetumab ravtansine is a monoclonal antibody against mesothelin in conjugation with maytansinoid DM4, which delivers maytansinoid DM4 to tumor cells over expressing mesothelin, resulting in tumor cell death (PMID: 24714131).', 'references': []}]",Anetumab ravtansine,2017-05-30T14:22:45Z
0,2016-08-29T13:00:33Z,4617,[],Anetumab ravtansine + Cisplatin + Pemetrexed,2016-08-29T13:00:33Z
0,2016-08-20T20:25:33Z,4594,[],Anetumab ravtansine + Itraconazole,2016-08-20T20:25:33Z
0,2016-02-20T01:02:01Z,3585,"[{'description': 'Anti-CD19 CAR T cells are T-cells that express a chimeric antigen receptor that targets the CD19 surface protein on B-lymphocytes, which results in anti-tumor activity in B-cell malignancies (PMID: 25999455, PMID: 26425336).', 'references': [{'id': 4640, 'pubMedId': 25999455, 'title': 'CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25999455'}]}]",Anti-CD19 CAR T,2017-08-08T16:25:43Z
0,2015-07-14T01:15:07Z,2915,"[{'description': 'Anti-EGFR CAR T are autologous T-cells that express a chimeric antigen receptor against EGFR, potentially enhancing immune response to EGFR-overexpressing tumors (PMID: 23633926).', 'references': [{'id': 3244, 'pubMedId': 23633926, 'title': 'Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23633926'}]}]",anti-EGFR CAR T,2017-07-26T17:50:50Z
0,2017-07-31T17:30:48Z,6061,"[{'description': 'Anti-KRAS G12V murine T-cell receptor (mTCR) cells are peripheral blood lymphocytes that have been transduced with a murine T-cell receptor that recognizes KRAS G12V, which may result in decreased growth of tumors harboring KRAS G12V (PMID: 26701267).', 'references': []}]",anti-KRAS G12V mTCR cells,2017-07-31T17:30:48Z
0,2017-08-03T19:08:28Z,6086,"[{'description': 'Anti-OX40 MoAb is a monoclonal antibody that binds to and activates OX40, resulting in activation of anti-tumor immunity (PMID: 22017441).', 'references': [{'id': 9678, 'pubMedId': 22017441, 'title': 'Science gone translational: the OX40 agonist story.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22017441'}]}]",anti-OX40 MoAb,2017-08-03T19:08:28Z
0,2014-12-23T15:48:21Z,1844,"[{'description': 'Thymoglobulin (anti-thymocyte globulin) is an immunoglobulin that binds to and destroys T-lymphocytes, which may aid in reduction of graft-vs-host disease when administered with stem cell transplantation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",anti-thymocyte globulin,2014-12-23T15:48:21Z
0,2016-07-01T19:47:25Z,4411,[],anti-thymocyte globulin + BKT140 + Cyclosporine + Methylprednisolone,2016-07-01T19:47:25Z
0,2014-05-14T14:52:46Z,984,"[{'description': ""Anti-VEGFR2 CAR CD8 lymphocytes consists of patient's own T-lymphocytes transduced with a recombinant retroviral vector encoding a chimeric T cell receptor specific for KDR (VEGFR2), expanded and reintroduced into the patient. The cells bind to and subsequently lyse VEGFR2-expressing cells (NCI Drug Dictionary)."", 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Anti-VEGFR2 CAR CD8 lymphocytes,2017-07-26T17:51:42Z
0,2014-05-14T14:52:46Z,985,"[{'description': 'Hocena (antroquinonol) is derived from the fungus, Antrodia camphorata, and has been reported to have antitumor effects against various cancer cells through inhibition of mTOR (PMID: 21185843).', 'references': [{'id': 168, 'pubMedId': 21185843, 'title': 'Antroquinonol inhibits NSCLC proliferation by altering PI3K/mTOR proteins and miRNA expression profiles.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21185843'}]}]",Antroquinonol,2014-11-14T03:32:03Z
0,2015-05-19T14:36:25Z,2706,"[{'description': 'AP 11014 is an antisense oligonucleotide that inhibits TGFB1 translation, which may result in decreased proliferation and migration of cancer cells (J Clin Oncol: July 2004 vol. 22 no. 14_suppl 3132).', 'references': [{'id': 2757, 'pubMedId': None, 'title': 'The TGF-beta1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: Preclinical studies', 'url': 'http://meeting.ascopubs.org/cgi/content/short/22/14_suppl/3132'}]}]",AP 11014,2016-03-24T15:22:34Z
0,2015-04-28T19:37:27Z,2593,"[{'description': 'AP23464 is a dual kinase inhibitor of Src and Abl, which is capable of inducing apoptosis and cell cycle arrest as well as inhibiting cellular proliferation (PMID: 15256422, PMID: 16492148). ', 'references': [{'id': 2591, 'pubMedId': 15256422, 'title': 'Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15256422'}]}]",AP23464,2015-04-28T20:15:27Z
0,2014-03-12T15:53:16Z,634,"[{'description': 'Alunbrig (brigatinib) is a multi-kinase inhibitor with selected activity against ALK and ROS1, and also demonstrates activity against FLT3, IGF1R and mutant EGFR, potentially resulting in decreased tumor growth (PMID: 27780853). Alunbrig (brigatinib) is FDA approved for use in patients with ALK-positive non-small cell lung cancer (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]}]",AP26113,2017-06-19T19:24:36Z
0,2016-04-21T19:42:08Z,3981,"[{'description': 'AP32788 is an inhibitor of oncogenic forms of EGFR and ERBB2, results in growth inhibition in mutatn EGFR or ERBB2-expressing cancer cells (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).', 'references': [{'id': 5195, 'pubMedId': None, 'title': 'AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=407e597a-33c8-4936-87f4-08ee4b23e8b9&cKey=34ee7ebf-07c6-40ea-825f-28fb5018ec92&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]}]",AP32788,2016-04-25T14:58:01Z
0,2014-05-14T14:52:46Z,986,"[{'description': 'Apatinib (YN968D1) is an inhibitor of receptor tyrosine kinases, including KDR (VEGFR2), RET, c-KIT, Src, and PDGFRa (NCI Drug Dictionary; PMID: 21443688). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 592, 'pubMedId': 21443688, 'title': 'YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21443688'}]}]",Apatinib,2017-04-03T11:32:40Z
0,2017-05-31T17:58:01Z,5826,"[{'description': 'APG-115, a derivative of SAR405838, inhibits MDM2 and its interaction with p53, thereby stabilizing and activating wild-type p53, which may result in antitumor activity (PMID: 28498808). ', 'references': [{'id': 9032, 'pubMedId': 28498808, 'title': 'Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28498808'}]}]",APG-115,2017-05-31T17:58:01Z
0,2017-05-24T02:01:20Z,5757,"[{'description': 'APG-1252 inhibits BCL2 and BCL-XL, potentially resulting in increased tumor cell apoptosis and decreased tumor growth (Eur J Cancer, 2014, Vol 50 , pp.109-10).', 'references': [{'id': 8970, 'pubMedId': None, 'title': '338 BM-1252 (APG-1252): a potent dual specific Bcl-2/Bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicity', 'url': 'http://www.sciencedirect.com/science/article/pii/S0959804914704642'}]}]",APG-1252,2017-05-24T02:01:53Z
0,2016-11-01T20:27:26Z,4900,"[{'description': 'Aphanin is a triterpenoid derived from the plant Amoora rohituka that inhibits proliferation and induces apoptosis in cancer cells through inhibition of mutant Kras, Stat3, Akt, and Myc signaling, and regulation of reactive oxygen species (PMID: 27333990).', 'references': [{'id': 6915, 'pubMedId': 27333990, 'title': 'Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27333990'}]}]",Aphanin,2016-11-01T20:27:26Z
0,2014-12-19T04:27:15Z,1810,"[{'description': 'Apigenin (APG) is a naturally occurring plant flavone that has shown to possess anti-inflammatory, antioxidant, anti-carcinogenic and properties and demonstrates cancer chemopreventive effects (PMID: 17143534). Apigenin (APG) has demonstrated has shown to induce apoptosis in cancer cells (PMID: 22084167).', 'references': [{'id': 1400, 'pubMedId': 17143534, 'title': 'Apigenin and cancer chemoprevention: progress, potential and promise (review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17143534'}, {'id': 1401, 'pubMedId': 22084167, 'title': 'Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22084167'}]}]",Apigenin,2014-12-19T04:27:15Z
0,2017-05-23T19:22:57Z,5751,"[{'description': 'APN401 is composed of autologous peripheral blood mononuclear cells in which Cbl-b has been silenced with siRNA, which potentially results in increased anti-tumor immune response upon infusion (J Clin Oncol 34, 2016 (suppl; abstr e14541)).', 'references': [{'id': 8967, 'pubMedId': None, 'title': 'Adoptive cellular immunotherapy with APN401, autologous Cbl-b-silenced peripheral blood mononuclear cells, in patients with solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/170952-176'}]}]",APN401,2017-05-23T19:22:57Z
0,2015-01-16T04:47:48Z,1946,"[{'description': 'APR-246 is an analogue of PRIMA-1, which modifies the core domain of mutant p53, resulting in restoration of wild-type p53 conformation and reactivation of normal p53 function, leading to increased cell cycle arrest and tumor cell death (PMID: 20498645).', 'references': [{'id': 8782, 'pubMedId': 20498645, 'title': 'Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20498645'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",APR-246,2017-05-02T13:14:57Z
0,2017-03-16T02:44:50Z,5445,[],APR-246 + Azacitidine,2017-03-16T02:44:50Z
0,2016-01-22T03:45:32Z,3444,[],APR-246 + Carboplatin,2016-01-22T03:45:55Z
0,2015-01-16T15:17:48Z,1952,[],APR-246 + Carboplatin + Doxorubicin,2015-01-16T15:17:48Z
0,2016-01-22T03:44:59Z,3443,[],APR-246 + Cisplatin,2016-01-22T03:44:59Z
0,2015-03-11T17:48:21Z,2355,"[{'description': 'Aprinocarsen (ISIS 3521) is an antisense inhibitor of protein kinase C alpha (PKC alpha), which may inhibit the growth of tumor cells (PMID: 7972137, PMID: 15701280).', 'references': [{'id': 2165, 'pubMedId': 15701280, 'title': 'Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15701280'}, {'id': 2164, 'pubMedId': 7972137, 'title': 'Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/7972137'}]}]",Aprinocarsen,2015-03-20T15:11:50Z
0,2016-08-29T16:13:40Z,4619,"[{'description': 'APS-2-79 is a small molecule that stabilizes the inactive conformation of Kinase Suppressor of Ras (KSR), resulting in decreased MAPK signaling, and potentially resulting in increased sensitivity to MAPK inhibitors in RAS mutant tumors (PMID: 27556948).', 'references': [{'id': 6534, 'pubMedId': 27556948, 'title': 'Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27556948'}]}]",APS-2-79,2016-08-29T16:13:40Z
0,2016-08-29T16:42:32Z,4621,[],APS-2-79 + Binimetinib,2016-08-29T16:42:32Z
0,2016-08-29T16:44:12Z,4623,[],APS-2-79 + PD-0325901,2016-08-29T16:44:12Z
0,2016-08-29T16:43:03Z,4622,[],APS-2-79 + Selumetinib,2016-08-29T16:43:36Z
0,2016-08-29T16:17:50Z,4620,[],APS-2-79 + Trametinib,2016-08-29T16:17:50Z
0,2016-02-11T20:10:49Z,3519,"[{'description': 'APTO-253 is a small molecule that induces expression of KLF4, resulting in decreased tumor cell proliferation (PMID: 26268924).', 'references': [{'id': 4557, 'pubMedId': 26268924, 'title': 'Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26268924'}]}]",APTO-253,2016-02-11T20:10:49Z
0,2016-03-25T16:50:11Z,3835,"[{'description': 'APX005M is a monoclonal antibody that targets and activates CD40, resulting in increased anti-tumor immunity and apoptosis of CD40-expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",APX005M,2016-03-31T19:58:32Z
0,2017-07-28T19:17:31Z,6048,[],APX005M + Gemcitabine + nab-paclitaxel,2017-07-28T19:17:31Z
0,2017-07-28T19:18:33Z,6049,[],APX005M + Gemcitabine + nab-paclitaxel + Nivolumab,2017-07-28T19:18:33Z
0,2017-05-04T01:39:36Z,5608,[],APX005M + Nivolumab,2017-05-04T01:39:36Z
0,2017-05-28T02:22:19Z,5797,[],APX005M + Paclitaxel + Carboplatin,2017-05-28T02:22:19Z
0,2016-03-25T16:51:07Z,3836,[],APX005M + Pembrolizumab,2016-03-25T16:51:07Z
0,2014-05-14T14:52:46Z,987,"[{'description': 'AR-42 is a histone deacetylase (HDAC) inhibitor, which may lead to increased apoptosis of tumor cells and decreased tumor growth (PMID: 23178755, PMID: 21778190).', 'references': [{'id': 205, 'pubMedId': 23178755, 'title': 'Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23178755'}]}]",AR-42,2017-03-16T16:58:43Z
0,2016-01-11T23:44:26Z,3400,[],AR-42 + Cisplatin,2016-01-11T23:44:26Z
0,2014-11-29T00:14:35Z,1751,[],AR-42 + Decitabine,2014-11-29T00:14:35Z
0,2016-06-17T18:53:41Z,4299,[],AR-42 + Dexamethasone + Pomalidomide,2016-06-17T18:53:41Z
0,2016-06-10T19:48:49Z,4267,[],AR-42 + Pazopanib,2016-06-10T19:48:49Z
0,2016-03-28T17:59:45Z,3850,"[{'description': 'AR-mTOR-26 is a selective inhibitor of mTOR, which leads to decreased signaling through mTORC1 and mTORC2, and may lead to decreased tumor growth (Cancer Res April 15, 2010 70; 4484).', 'references': [{'id': 5033, 'pubMedId': None, 'title': 'Abstract 4484: AR-mTOR-26 - A potent, selective mTORC 1/2 kinase inhibitor for the treatment of malignancy', 'url': 'http://cancerres.aacrjournals.org/content/70/8_Supplement/4484.short'}]}]",AR-mTOR-26,2016-03-28T18:00:13Z
0,2015-02-25T14:54:37Z,2157,"[{'description': 'ARGX-111 is a monoclonal antibody that binds to c-MET, resulting in inhibition of downstream signaling and decreased proliferation of c-MET expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",ARGX-111,2015-04-30T13:19:35Z
0,2015-01-16T05:30:48Z,1947,"[{'description': 'Apalutamide (ARN-509) binds to the androgen receptor (AR) and inhibits signaling, potentially resulting in decreased cell growth in AR-expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",ARN-509,2017-09-29T19:02:13Z
0,2015-01-16T05:35:15Z,1948,[],ARN-509 + Abiraterone,2015-01-16T05:35:15Z
0,2017-04-07T19:48:38Z,5524,[],ARN-509 + Degarelix,2017-04-07T19:48:38Z
0,2017-04-07T19:31:43Z,5521,[],ARN-509 + Docetaxel,2017-04-07T19:31:43Z
0,2015-03-05T16:41:20Z,2303,[],ARN-509 + Everolimus,2015-03-05T16:41:20Z
0,2016-10-30T20:46:16Z,4890,[],ARN-509 + JNJ-64041809,2016-10-30T20:46:16Z
0,2016-06-02T19:57:34Z,4207,[],ARN-509 + Leuprolide,2016-06-02T19:57:34Z
0,2016-10-16T20:33:56Z,4832,[],ARN-509 + Niraparib,2016-10-16T20:33:56Z
0,2015-07-10T15:40:03Z,2900,"[{'description': 'ARQ 087 is an ATP-competitive inhibitor of Fgfr 1-3, which prevents cell proliferation and angiogenesis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",ARQ 087,2015-07-10T15:40:03Z
0,2017-01-18T11:06:23Z,5224,"[{'description': 'ARQ 531 is an ATP-competitive BTK inhibitor with activity against wild-type BTK and BTK C481S and has been demonstrated to inhibit migration and viability of chronic lymphocytic leukemia cells (ASH, Blood 2016 128:3232).', 'references': [{'id': 7590, 'pubMedId': None, 'title': ""The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia"", 'url': 'http://www.bloodjournal.org/content/128/22/3232?sso-checked=true'}]}]",ARQ 531,2017-01-18T11:06:23Z
0,2016-06-20T16:42:39Z,4331,"[{'description': 'ARQ 751 is an inhibitor of AKT1, AKT2, and AKT3, which may result in inhibition of the AKT/PI3K/MTOR pathway, thereby leading to tumor growth inhibition (PMID: 26469692). ', 'references': [{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}, {'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",ARQ 751,2017-03-16T14:56:12Z
0,2014-03-12T15:53:16Z,635,"[{'description': 'ARQ092 is a pan-AKT inhibitor, resulting in inhibition of the PI3K/AKT signaling pathway and cell proliferation (PMID: 26469692).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 2274, 'pubMedId': None, 'title': 'Abstract A230: Discovery and characterization of ARQ 092, an ATP-independent, potent and selective inhibitor of AKT kinases.', 'url': ''}]}]",ARQ092,2017-03-17T18:14:17Z
0,2017-03-16T15:01:09Z,5455,[],ARQ092 + Paclitaxel,2017-03-16T15:01:09Z
0,2017-03-16T15:01:56Z,5456,[],ARQ092 + Trametinib,2017-03-16T15:01:56Z
0,2017-03-16T15:00:17Z,5454,[],ARQ092 + Trastuzumab,2017-03-16T15:00:17Z
0,2014-03-12T15:53:16Z,637,"[{'description': 'ARQ736 is a pan-RAF inhibitor with activity against BRAF V600E, BRAF wild-type, and c-RAF (PMID: 23617957).', 'references': [{'id': 1812, 'pubMedId': 23617957, 'title': 'B-Raf and the inhibitors: from bench to bedside.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23617957'}]}]",ARQ736,2015-02-06T10:49:27Z
0,2016-02-11T18:07:02Z,3516,"[{'description': 'ARQ761 is metabolized intracellularly by NQO1, generating reactive oxygen species, which leads to DNA damage and PARP1 hyperactivation and potentially results in increased death of NQO1-expressing tumor cells (PMID: 26602448).', 'references': [{'id': 4554, 'pubMedId': 26602448, 'title': 'Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26602448'}]}]",ARQ761,2016-02-11T18:36:51Z
0,2016-02-11T18:43:27Z,3517,[],ARQ761 + CB-839,2016-02-11T18:43:27Z
0,2015-02-06T11:33:52Z,2012,"[{'description': 'ARRY-300 is an analog of Binimetinib (MEK162) with activity against MEK1 and MEK2 (PMID: 24434059).', 'references': [{'id': 1813, 'pubMedId': 24434059, 'title': 'MEK1/2 inhibitors in the treatment of gynecologic malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24434059'}]}]",ARRY-300,2017-04-06T09:45:16Z
0,2014-09-30T20:02:49Z,1577,[],ARRY-380 + Capecitabine,2014-09-30T20:02:49Z
0,2015-12-29T15:22:38Z,3340,[],ARRY-380 + Capecitabine + Trastuzumab,2015-12-29T15:22:38Z
0,2017-02-20T00:11:10Z,5334,[],ARRY-380 + Palbociclib + Letrozole,2017-02-20T00:11:10Z
0,2014-09-26T02:42:31Z,1560,[],ARRY-380 + Trastuzumab,2014-09-26T02:42:31Z
0,2014-09-30T19:13:15Z,1573,[],ARRY-380 + Trastuzumab emtansine,2014-09-30T19:13:15Z
0,2015-06-18T16:58:21Z,2841,"[{'description': 'ARRY-382 is a small molecule inhibitor of CSF1R, which potentially leads to decreased growth of CSF1R over expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",ARRY-382,2015-06-18T16:58:21Z
0,2016-08-27T01:38:32Z,4608,[],ARRY-382 + Pembrolizumab,2016-08-27T01:38:32Z
0,2016-02-19T03:22:18Z,3553,"[{'description': 'ARS-853 selectively inhibits KRAS G12C, resulting in a decrease in activated KRAS G12C and potentially leading to reduced growth of KRAS G12C-expressing tumor cells (PMID: 26739882).', 'references': [{'id': 4628, 'pubMedId': 26739882, 'title': 'Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26739882'}]}]",ARS-853,2016-02-19T03:22:18Z
0,2014-03-12T15:53:16Z,640,"[{'description': 'Trisenox (arsenic trioxide) has multiple mechanisms of action, including inhibition of Gli1 and Gli2 transcription factors (PMID: 26891329). Trisenox (arsenic trioxide) is FDA approved for patients with acute promyelocytic leukemia with PML-RARA translocations (FDA.gov).', 'references': [{'id': 4675, 'pubMedId': 26891329, 'title': 'Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26891329'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Arsenic trioxide,2016-07-28T16:07:53Z
0,2017-07-05T14:40:38Z,5965,[],Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin,2017-07-05T14:40:38Z
0,2016-03-06T21:36:38Z,3685,[],Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin,2016-03-11T19:26:57Z
0,2016-03-21T00:58:34Z,3791,[],Arsenic trioxide + Itraconazole,2016-03-21T00:58:34Z
0,2016-05-12T20:31:42Z,4117,[],Arsenic trioxide + Posaconazole,2016-05-12T20:31:42Z
0,2016-03-06T21:44:45Z,3687,[],Arsenic trioxide + Tretinoin,2016-03-06T21:44:45Z
0,2015-07-29T19:08:18Z,2964,"[{'description': 'AS-252424 inhibits PI3KCG which may block activation of the PI3K signaling pathway and inhibit tumor cell proliferation (PMID: 16789742).', 'references': [{'id': 3349, 'pubMedId': 16789742, 'title': 'Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16789742'}]}]",AS-252424,2015-07-29T19:30:12Z
0,2016-09-13T15:16:41Z,4700,"[{'description': 'AS1409 is a fusion protein comprising BC1 and interleukin-12 (IL-12), which allows recognition of the extra-domain B(ED-B) fibronectin isoform present in tumor cells and directly delivers IL-12 to the tumor thereby stimulating an immunological response (PMID: 21447719).', 'references': [{'id': 6606, 'pubMedId': 21447719, 'title': 'A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21447719'}]}]",AS1409,2016-09-13T15:16:41Z
0,2016-01-06T18:23:43Z,3367,"[{'description': 'AS601245 is an ATP-competitive inhibitor of JNK1, 2, and 3, which may lead to decreased tumor cell proliferation (PMID: 22619672, PMID: 15210584).', 'references': [{'id': 4216, 'pubMedId': 22619672, 'title': 'AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22619672'}, {'id': 4217, 'pubMedId': 15210584, 'title': 'Inhibition of c-Jun N-terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15210584'}]}]",AS601245,2016-01-06T18:24:25Z
0,2015-04-09T20:14:18Z,2517,"[{'description': 'AS605240 is a selective inhibitor for PIK3CG, which may inhibit tumor growth and metastasis (PMID: 16127437, PMID: 20224967).\r\n', 'references': [{'id': 2436, 'pubMedId': 16127437, 'title': 'Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16127437'}, {'id': 2437, 'pubMedId': 20224967, 'title': 'Targeting PI3K in neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20224967'}]}]",AS605240,2016-03-17T18:05:55Z
0,2016-11-11T15:19:06Z,4937,[],AS605240 + Dexamethasone,2016-11-11T15:19:06Z
0,2016-03-17T18:12:46Z,3776,[],AS605240 + Methylprednisolone,2016-03-17T18:12:46Z
0,2016-11-11T15:16:56Z,4936,[],AS605240 + Prednisolone,2016-11-11T15:16:56Z
0,2014-03-12T15:53:16Z,642,"[{'description': 'Cenisertib (AS703569) is a pan-Aurora kinase inhibitor with additional activity against Flt3 to prevent cell proliferation (PMID: 19609559).', 'references': [{'id': 866, 'pubMedId': 19609559, 'title': 'Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19609559'}]}]",AS703569,2014-09-29T16:05:55Z
0,2017-04-19T15:04:17Z,5561,[],Asciminib + Dasatinib,2017-04-19T15:04:17Z
0,2017-04-19T15:06:32Z,5562,[],Asciminib + Imatinib,2017-04-19T15:06:32Z
0,2017-04-19T15:03:09Z,5560,[],Asciminib + Nilotinib,2017-04-19T15:03:09Z
0,2016-11-04T03:17:37Z,4914,"[{'description': 'ASG-5ME is an antibody-drug conjugate comprising an anti-SLC44A4 antibody linked to MMAE, which delivers the cytotoxic agent to SLC44A4-expressing tumor cells, potentially resulting in increased tumor cell death and decreased tumor growth (PMID: 27550944).', 'references': [{'id': 6935, 'pubMedId': 27550944, 'title': 'The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550944'}]}]",ASG-5ME,2016-11-04T03:17:37Z
0,2016-11-04T03:42:45Z,4915,[],ASG-5ME + Nab-paclitaxel,2016-11-04T03:42:45Z
0,2017-05-31T19:58:48Z,5827,"[{'description': 'ASN003 is a small molecule inhibitor of BRAF, PIK3CA, and PIK3CG, which may result in inhibition of cell proliferation and antitumor activity (J Clin Oncol 35, 2017 (suppl; abstr e14102)).', 'references': [{'id': 9034, 'pubMedId': None, 'title': 'ASN003, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors', 'url': 'http://abstracts.asco.org/199/AbstView_199_186123.html'}]}]",ASN003,2017-05-31T19:58:48Z
0,2015-06-01T18:26:17Z,2755,"[{'description': 'ASP015K is a JAK inhibitor with increased selectivity for JAK3 over JAK1 and JAK2 (PMID: 25704750).', 'references': [{'id': 2878, 'pubMedId': 25704750, 'title': 'A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25704750'}]}]",ASP015K,2015-06-01T18:26:17Z
0,2014-03-12T15:53:16Z,643,"[{'description': 'ASP3026 is a selective ALK inhibitor which may not be subject to resistance like crizotinib (PMID: 24091716).', 'references': [{'id': 11, 'pubMedId': 24091716, 'title': 'Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24091716'}]}]",ASP3026,2015-06-03T19:08:48Z
0,2015-04-10T02:44:48Z,2521,"[{'description': 'ASP3096 is a small molecule inhibitor of ALK, which potentially reduces growth of ALK-driven tumors (J Clin Oncol 32:5s, 2014 (suppl; abstr 2624).', 'references': [{'id': 2443, 'pubMedId': None, 'title': 'Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design.', 'url': 'http://meetinglibrary.asco.org/content/132526-144'}]}]",ASP3096,2015-04-10T02:44:48Z
0,2016-02-19T21:11:37Z,3584,"[{'description': 'ASP5878 is an inhibitor of FGFR1-4 that inhibits tumor cell proliferation (Mol Cancer Ther December 2015 14; A170).', 'references': [{'id': 4639, 'pubMedId': None, 'title': 'Preclinical antitumor activity of ASP5878, a novel inhibitor of FGFR1, 2, 3 and 4, in bladder cancer harboring FGFR3-fusion or -mutation', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/A170.short'}]}]",ASP5878,2016-02-19T21:11:37Z
0,2014-06-25T20:43:28Z,1082,"[{'description': 'ASP8273 is a third-generation EGFR inhibitor which binds mutant forms of EGFR, including T790M, thus preventing EGFR-mediated signaling and possibly inducing cell death and growth inhibition of EGFR-overexpressing tumor cells (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",ASP8273,2015-02-08T23:32:29Z
0,2015-02-27T16:52:17Z,2206,[],Asparaginase,2015-02-27T16:52:17Z
0,2015-03-11T14:40:21Z,2348,[],Asparaginase + Cyclophosphamide + Etoposide,2015-03-11T14:40:21Z
0,2015-03-13T15:03:32Z,2394,[],Asparaginase + Cytarabine,2015-03-13T15:03:32Z
0,2017-06-19T18:37:17Z,5912,"[{'description': 'Erwinaze (asparaginase Erwinia chrysanthemi) is an bacterial derived enzyme that converts L-asparagine to L-aspartate and ammonia, which decreases L-asparagine levels, potentially leading to reduced leukemic cell growth (PMID: 25098829, PMID: 26698391). Erwinaze (asparaginase Erwinia chrysanthemi) is FDA-approved for use in a chemotherapeutic regimen for acute lymphoblastic leukemia (FDA.gov).', 'references': [{'id': 9168, 'pubMedId': 25098829, 'title': 'Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25098829'}]}]",Asparaginase Erwinia chrysanthemi,2017-06-19T19:14:48Z
0,2017-07-27T18:16:27Z,6018,"[{'description': 'ASTX-660 is a SMAC mimetic that inhibits cIAP and XIAP, potentially resulting in tumor cell death (Cancer Res 2016;76(14 Suppl):Abstract nr 1287).', 'references': [{'id': 9603, 'pubMedId': None, 'title': 'The dual IAP antagonist, ASTX660, increases the anti-tumor activity of paclitaxel in preclinical models of triple-negative breast cancer in vivo', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1287'}]}]",ASTX-660,2017-09-25T19:08:36Z
0,2017-07-27T18:22:09Z,6019,[],ASTX-660 + Paclitaxel,2017-07-27T18:22:09Z
0,2014-12-04T23:00:19Z,1759,"[{'description': 'ASTX727 combines a cytidine deaminase inhibitor (E7727) and decitabine, a cytidine antimetabolite, so that the breakdown of decitabine is prevented, allowing lower dosing while increasing the bioavailability of decitabine. Decitabine is incorporated into DNA and inhibits DNA methyltransferase, causing arrest of DNA replication (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",ASTX727,2014-12-04T23:00:19Z
0,2014-03-12T15:53:16Z,644,"[{'description': 'AT-101 is a pan-BCL2 inhibitor that inhibits the anti-apoptotic proteins BCL2, BCL-XL, and MCL1, potentially resulting in increased tumor cell apoptosis and decreased cell proliferation (PMID: 26089640, PMID: 16611409).', 'references': [{'id': 4085, 'pubMedId': 16611409, 'title': '(-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16611409'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 4084, 'pubMedId': 26089640, 'title': 'Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26089640'}]}]",AT-101,2015-12-10T18:55:25Z
0,2016-05-02T17:08:26Z,4039,[],AT-101 + Bicalutamide,2016-05-02T17:08:26Z
0,2016-02-26T20:04:55Z,3644,"[{'description': 'AT-406 is a SMAC mimetic, which antagonizes Inhibitor of Apoptosis Protein (IAP) family proteins, resulting in increased tumor cell apoptosis and decreased tumor growth (PMID: 21443232).', 'references': [{'id': 4721, 'pubMedId': 21443232, 'title': 'A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21443232'}]}]",AT-406,2017-09-25T19:08:56Z
0,2017-09-08T16:09:03Z,6178,[],AT-406 + Avelumab,2017-09-08T16:09:03Z
0,2016-02-26T20:07:08Z,3645,[],AT-406 + Daunorubicin + Cytarabine,2016-02-26T20:07:08Z
0,2015-03-20T18:24:35Z,2447,"[{'description': 'AT7867 is an ATP-competitive inhibitor of AKT1, AKT2, AKT3, PKA, and P70S6K, which inhibits cell proliferation and tumor growth (PMID: 20423992).', 'references': [{'id': 2290, 'pubMedId': 20423992, 'title': 'AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20423992'}]}]",AT-7867,2017-05-08T16:13:37Z
0,2016-02-28T15:24:07Z,3653,"[{'description': 'AT13148 is a small molecule ATP-competitive inhibitor of AGC kinases including AKT1, AKT2, AKT3, p70S6K (RPS6KB1), PKA (PRKACA), ROCK1, ROCK2, RSK1, and SGK3, which results in decreased growth of tumor cells (PMID: 22781553, PMID: 25840982).', 'references': [{'id': 204, 'pubMedId': 22781553, 'title': 'AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22781553'}, {'id': 4738, 'pubMedId': 25840982, 'title': 'Rho kinase inhibitors block melanoma cell migration and inhibit metastasis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25840982'}]}]",AT13148,2016-03-04T19:19:30Z
0,2014-03-12T15:53:16Z,645,"[{'description': 'Onalespib (AT13387) inhibits Hsp90, which may result in decreased tumor growth (PMID: 22181674, PMID: 22714264).', 'references': [{'id': 2907, 'pubMedId': 22714264, 'title': 'The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22714264'}, {'id': 2906, 'pubMedId': 22181674, 'title': 'The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22181674'}]}]",AT13387,2015-06-03T16:52:05Z
0,2014-08-05T07:05:56Z,1362,[],AT13387 + Dabrafenib + Trametinib,2014-08-05T07:05:56Z
0,2015-05-20T20:10:51Z,2727,"[{'description': 'AT7519 is an ATP competitive inhibitor of CDK1, CDK2, CDK4, CDK5, CDK6, and CDK9, which may induce cell cycle arrest and apoptosis in cancer cells (PMID: 19174555).', 'references': [{'id': 2794, 'pubMedId': 19174555, 'title': 'Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19174555'}]}]",AT7519,2017-06-07T14:42:34Z
0,2014-03-12T15:53:16Z,646,"[{'description': 'AT9283 is a dual inhibitor of JAK 2 and 3 kinases, Aurora kinases A and B, and has activity against Abl T315I (PMID: 19143567).', 'references': [{'id': 864, 'pubMedId': 19143567, 'title': 'Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19143567'}]}]",AT9283,2017-04-04T12:26:12Z
0,2014-07-29T13:33:46Z,1201,"[{'description': 'Tecentriq (atezolizumab) is a monoclonal antibody that binds to PD-L1, preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (NCI Drug Dictionary). Tecentriq (atezolizumab) is FDA approved for use in patients with advanced urothelial carcinoma and non-small cell lung cancer (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Atezolizumab,2017-06-19T19:18:11Z
0,2016-07-17T21:58:41Z,4456,[],Atezolizumab + BCG solution,2016-07-17T21:58:41Z
0,2016-01-10T21:33:50Z,3390,[],Atezolizumab + Bendamustine + Obinutuzumab,2017-06-12T15:06:55Z
0,2016-08-21T01:50:13Z,4595,[],Atezolizumab + Bevacizumab,2017-06-12T14:59:42Z
0,2014-07-29T13:35:54Z,1202,[],Atezolizumab + Bevacizumab + Capecitabine,2017-06-12T15:09:57Z
0,2015-03-12T14:50:29Z,2370,[],Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel,2017-06-12T15:13:17Z
0,2016-07-26T19:46:11Z,4496,[],Atezolizumab + Bevacizumab + Doxil,2016-07-26T19:46:11Z
0,2017-09-29T19:15:55Z,6270,[],Atezolizumab + Bevacizumab + Exemestane,2017-09-29T19:15:55Z
0,2017-09-29T19:16:39Z,6271,[],Atezolizumab + Bevacizumab + Fulvestrant,2017-09-29T19:16:39Z
0,2017-09-29T19:18:58Z,6272,[],Atezolizumab + Bevacizumab + Tamoxifen,2017-09-29T19:18:58Z
0,2017-09-26T22:34:46Z,6252,[],Atezolizumab + Bevacizumab +Peg-interferon alfa-2a,2017-09-26T22:34:46Z
0,2017-06-29T16:47:13Z,5942,[],Atezolizumab + BKT140,2017-06-29T16:47:13Z
0,2017-10-09T15:31:37Z,6305,[],Atezolizumab + BTCT4465A,2017-10-09T15:31:37Z
0,2017-08-08T16:37:23Z,6094,[],Atezolizumab + Cabozantinib,2017-08-08T16:37:23Z
0,2017-07-07T18:41:21Z,5983,[],Atezolizumab + Carboplatin,2017-07-07T18:41:21Z
0,2016-05-27T14:22:36Z,4164,[],Atezolizumab + Carboplatin + Etoposide,2016-05-27T14:22:36Z
0,2017-04-12T19:03:53Z,5541,[],Atezolizumab + Carboplatin + Etoposide + Trilaciclib,2017-05-22T17:27:40Z
0,2016-07-14T15:41:39Z,4450,[],Atezolizumab + Carboplatin + Gemcitabine,2017-06-12T15:00:06Z
0,2016-04-15T18:14:57Z,3946,[],Atezolizumab + Carboplatin + nab-Paclitaxel,2017-06-12T15:04:29Z
0,2014-07-29T13:39:08Z,1203,[],Atezolizumab + Carboplatin + Paclitaxel,2017-06-12T15:10:25Z
0,2014-07-29T13:40:02Z,1204,[],Atezolizumab + Carboplatin + Pemetrexed,2017-06-12T15:10:51Z
0,2017-01-03T18:56:07Z,5140,[],Atezolizumab + Cisplatin + Gemcitabine,2017-01-03T18:56:07Z
0,2017-07-28T18:10:13Z,6036,[],Atezolizumab + Cisplatin + Pemetrexed,2017-07-28T18:10:28Z
0,2016-02-19T17:59:10Z,3575,[],Atezolizumab + CO1686,2017-06-12T15:05:54Z
0,2014-08-01T08:23:51Z,1343,[],Atezolizumab + Cobimetinib,2017-06-12T15:11:41Z
0,2017-07-06T19:51:44Z,5970,[],Atezolizumab + Cobimetinib + Eribulin,2017-07-06T19:51:44Z
0,2017-06-06T16:25:19Z,5858,[],Atezolizumab + CPI-444,2017-06-06T16:25:19Z
0,2017-01-20T04:29:04Z,5236,[],Atezolizumab + Daratumumab,2017-01-20T04:29:04Z
0,2016-06-02T19:05:13Z,4204,[],Atezolizumab + DEC-205-NY-ESO-1 fusion protein vaccine,2016-06-02T19:05:13Z
0,2016-07-26T19:45:39Z,4495,[],Atezolizumab + Doxil,2016-07-26T19:45:39Z
0,2017-01-20T04:04:22Z,5235,[],Atezolizumab + Entinostat + Bevacizumab,2017-01-20T04:04:22Z
0,2017-01-15T22:08:48Z,5204,[],Atezolizumab + Enzalutamide,2017-06-12T14:59:11Z
0,2015-05-08T01:43:54Z,2636,[],Atezolizumab + Epacadostat,2017-06-23T18:45:08Z
0,2017-08-08T19:32:57Z,6098,[],Atezolizumab + Eribulin,2017-08-08T19:32:57Z
0,2014-08-04T04:23:24Z,1352,[],Atezolizumab + Erlotinib,2017-06-12T15:12:04Z
0,2017-04-19T02:26:25Z,5558,[],Atezolizumab + FANG vaccine,2017-04-19T02:26:44Z
0,2017-09-29T19:13:26Z,6268,[],Atezolizumab + Fulvestrant,2017-09-29T19:13:26Z
0,2017-06-07T19:35:00Z,5863,[],Atezolizumab + GDC-0919,2017-06-07T19:35:00Z
0,2016-04-15T18:29:03Z,3947,[],Atezolizumab + Gemcitabine + nab-paclitaxel,2017-06-12T15:01:20Z
0,2017-09-26T22:36:38Z,6253,[],Atezolizumab + Interferon alfa-2b,2017-09-26T22:36:38Z
0,2017-09-29T19:14:08Z,6269,[],Atezolizumab + Ipatasertib,2017-09-29T19:14:08Z
0,2017-09-29T19:20:12Z,6273,[],Atezolizumab + Ipatasertib + Fulvestrant,2017-09-29T19:20:12Z
0,2017-09-26T22:24:48Z,6249,[],Atezolizumab + Ipilimumab,2017-09-26T22:24:48Z
0,2016-10-16T20:15:57Z,4830,[],Atezolizumab + KTE-C19,2016-10-16T20:15:57Z
0,2016-01-10T21:04:13Z,3387,[],Atezolizumab + lenalidomide + Obinutuzumab,2017-06-12T15:07:58Z
0,2017-09-29T19:33:32Z,6276,[],Atezolizumab + Linagliptin,2017-09-29T19:37:34Z
0,2017-03-16T04:26:14Z,5451,[],Atezolizumab + MOXR0916,2017-03-16T04:26:14Z
0,2016-06-10T20:22:47Z,4269,[],Atezolizumab + MTIG7192A ,2016-06-10T20:22:47Z
0,2015-08-26T01:58:35Z,3049,[],Atezolizumab + nab-paclitaxel,2017-06-12T15:14:23Z
0,2015-01-26T00:13:24Z,1975,[],Atezolizumab + Obinutuzumab,2017-06-12T15:12:41Z
0,2016-06-26T19:38:29Z,4362,[],Atezolizumab + Obinutuzumab + Polatuzumab Vedotin,2016-06-26T19:38:29Z
0,2017-05-04T01:26:36Z,5606,[],Atezolizumab + Paclitaxel,2017-05-04T01:26:36Z
0,2017-05-02T04:28:44Z,5600,[],Atezolizumab + Paclitaxel + Trastuzumab + Pertuzumab,2017-06-12T14:58:10Z
0,2017-09-26T22:26:51Z,6250,[],Atezolizumab + Peg-interferon alfa-2a,2017-09-26T22:34:13Z
0,2017-06-29T16:45:33Z,5941,[],Atezolizumab + PEGPH20,2017-06-29T16:45:33Z
0,2016-10-30T17:06:19Z,4881,[],Atezolizumab + Ra 223,2016-10-30T17:06:19Z
0,2016-01-14T14:34:02Z,3412,[],Atezolizumab + RO6958688 ,2017-06-12T15:07:23Z
0,2017-09-25T00:23:51Z,6235,[],Atezolizumab + RO7198457,2017-09-25T00:23:51Z
0,2016-09-12T20:23:26Z,4693,[],Atezolizumab + SGI-110,2016-09-12T20:23:26Z
0,2017-07-07T18:17:47Z,5982,[],Atezolizumab + SGI-110 + DEC-205-NY-ESO-1 fusion protein vaccine,2017-07-07T18:17:47Z
0,2017-05-07T20:15:21Z,5642,[],Atezolizumab + Sipuleucel-T,2017-05-07T20:15:21Z
0,2017-06-12T13:47:08Z,5872,[],Atezolizumab + Temozolomide,2017-06-12T13:47:08Z
0,2017-10-02T19:13:03Z,6286,[],Atezolizumab + TEN-010,2017-10-02T19:13:03Z
0,2015-12-03T15:03:45Z,3250,[],Atezolizumab + Trastuzumab,2017-06-12T15:08:58Z
0,2015-09-26T00:49:33Z,3086,[],Atezolizumab + Varlilumab,2017-06-12T15:09:22Z
0,2016-07-31T15:23:31Z,4511,[],Atezolizumab + Veliparib,2016-07-31T15:23:31Z
0,2014-07-29T18:33:49Z,1216,[],Atezolizumab + vemurafenib,2017-06-12T15:11:17Z
0,2016-10-13T18:17:46Z,4825,[],Atezolizumab + Vemurafenib + Cobimetinib,2016-10-13T18:17:46Z
0,2014-09-30T19:41:08Z,1576,[],Atorvastatin + Metformin,2014-09-30T19:41:08Z
0,2016-06-17T18:08:50Z,4296,"[{'description': 'ATR-101 is a selective inhibitor of Acyl-CoA Acyltransferase 1 that leads to apoptosis in adrenal and adrenal cancer cells (PMID: 26986192).', 'references': [{'id': 5962, 'pubMedId': 26986192, 'title': 'ATR-101, a Selective and Potent Inhibitor of Acyl-CoA Acyltransferase 1, Induces Apoptosis in H295R Adrenocortical Cells and in the Adrenal Cortex of Dogs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26986192'}]}]",ATR-101,2016-06-17T18:08:50Z
0,2015-04-29T17:38:35Z,2613,"[{'description': 'ATSP-7041 is a stapled peptide that inhibits MDM2 and MDM4 (MDMX), resulting in activation of p53 and decreased tumor growth (PMID: 23946421).', 'references': [{'id': 2611, 'pubMedId': 23946421, 'title': 'Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23946421'}]}]",ATSP-7041,2015-06-03T19:20:17Z
0,2017-06-01T14:14:05Z,5828,"[{'description': 'AU-011 is a photodynamic therapy comprised of human papilloma virus derived nanoparticles conjugated to infrared dye, IR700, which upon irradiation results in reactive oxygen species generation and thus, subsequent cell death (Cancer Res 2014;74(19 Suppl):Abstract nr 1770).', 'references': [{'id': 9036, 'pubMedId': None, 'title': 'Abstract 1770: Viral-based nanoparticles: a new therapeutic approach for anticancer therapy', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/1770'}]}]",AU-011,2017-06-01T14:14:05Z
0,2015-03-05T16:31:59Z,2300,[],Auranofin,2015-03-05T16:31:59Z
0,2015-03-05T16:32:16Z,2301,[],Auranofin + Sirolimus,2015-03-05T16:32:58Z
0,2017-01-19T17:12:40Z,5230,"[{'description': 'Aurora Kinase Inhibitor II (AI II) inhibits Aurora kinase A and B, which potentially results in reduced tumor cell proliferation and increased tumor cell death (PMID: 16337122, PMID: 26842935).', 'references': [{'id': 7603, 'pubMedId': 26842935, 'title': 'Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26842935'}, {'id': 7602, 'pubMedId': 16337122, 'title': 'SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16337122'}]}]",Aurora Kinase Inhibitor II,2017-04-04T12:29:58Z
0,2014-08-27T16:42:13Z,1403,"[{'description': 'Autologous TGF beta resistant HER2 EBV CTLs are EBV-specific autologous cytotoxic T lymphocytes that express a chimeric ERBB2 (HER2) antigen receptor as well as a dominant negative TGF-beta receptor, which target ERBB2 (HER2) expressing tumor cells, potentially resulting in increased CTL-mediated tumor cell death (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Autologous TGF beta resistant HER2 EBV CTLs,2017-07-20T17:18:20Z
0,2014-03-12T15:53:16Z,647,"[{'description': 'AUY922 inhibits HSP90, resulting in increased tumor cell apoptosis and decreased tumor cell angiogenesis and proliferation (PMID: 25955495, PMID: 18413753).\r\n', 'references': [{'id': 2915, 'pubMedId': 25955495, 'title': 'Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25955495'}, {'id': 2916, 'pubMedId': 18413753, 'title': 'NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413753'}]}]",AUY922,2015-06-03T17:39:30Z
0,2015-02-02T14:34:56Z,1996,[],AUY922 + Cetuximab,2015-02-02T14:34:56Z
0,2015-06-04T17:48:34Z,2799,[],AUY922 + Erlotinib,2015-06-04T17:48:34Z
0,2014-07-30T16:50:03Z,1270,[],AUY922 + Pemetrexed,2014-07-30T16:50:03Z
0,2015-06-12T01:47:24Z,2827,[],AUY922 + Sirolimus,2015-06-12T01:47:24Z
0,2015-06-12T01:52:54Z,2828,[],AUY922 + Torin 1,2015-06-12T01:52:54Z
0,2014-05-14T14:52:46Z,990,"[{'description': 'AV-412 binds and inhibits EGFR and ERBB2 (HER2), which may result in the inhibition of tumor growth and angiogenesis in EGFR/HER2-expressing tumors (PMID: 17888033).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 1110, 'pubMedId': 17888033, 'title': 'Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17888033'}]}]",AV-412,2015-03-24T14:41:12Z
0,2014-03-12T15:53:16Z,648,"[{'description': 'AV203 is a humanized monoclonal antibody which binds ERBB3 (HER3) preventing ligand binding and heterodimer formation, which may inhibit tumor growth (Cancer Res April 15, 2012 72; 2509).', 'references': [{'id': 3322, 'pubMedId': None, 'title': 'Abstract 2509: AV-203, a humanized ERBB3 inhibitory antibody inhibits ligand-dependent and ligand-independent ERBB3 signaling in vitro and in vivo', 'url': 'http://cancerres.aacrjournals.org/content/72/8_Supplement/2509'}]}]",AV203,2015-07-24T21:13:20Z
0,2015-04-17T19:27:39Z,2551,"[{'description': 'Avagacestat (BMS-708163) is a gamma secretase inhibitor, which blocks Notch cleavage and activation, and may inhibit angiogenesis and tumor growth (PMID: 24900185).', 'references': [{'id': 2514, 'pubMedId': 24900185, 'title': 'Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24900185'}]}]",Avagacestat,2015-04-27T12:40:48Z
0,2014-10-16T15:52:49Z,1654,[],Avastin + Cetuximab,2014-10-16T15:52:49Z
0,2014-09-09T15:24:59Z,1421,[],Avastin + Doxorubicin + Docetaxel,2014-09-09T15:24:59Z
0,2015-05-29T03:54:57Z,2741,"[{'description': 'AVE-1642 is a humanized antibody that targets IGF-1R, potentially resulting in decreased tumor cell proliferation (PMID: 20591650, PMID: 23104723).\r\n', 'references': [{'id': 2851, 'pubMedId': 20591650, 'title': 'Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20591650'}, {'id': 2852, 'pubMedId': 23104723, 'title': 'Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23104723'}]}]",AVE1642,2015-06-02T13:16:24Z
0,2015-10-21T02:16:03Z,3144,"[{'description': 'Bavencio (avelumab) is a monoclonal antibody binds to and blocks human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein signaling, resulting in immune regulation and antitumor immunity (PMID: 26014098). Bavencio (avelumab) is FDA-approved for use in patients with metastatic Merkel cell carcinoma and urothelial carcinoma (FDA.gov).', 'references': [{'id': 3775, 'pubMedId': 26014098, 'title': 'Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26014098'}]}]",Avelumab,2017-06-19T19:18:40Z
0,2015-10-21T02:18:02Z,3145,[],Avelumab + Axitinib,2015-10-21T02:18:02Z
0,2017-02-26T23:44:25Z,5372,[],Avelumab + Azacitidine,2017-02-26T23:44:25Z
0,2016-12-13T18:05:15Z,5088,[],Avelumab + Azacitidine + Utomilumab,2016-12-13T18:05:15Z
0,2016-12-13T18:06:11Z,5089,[],Avelumab + Bendamustine + Rituximab,2016-12-13T18:06:47Z
0,2016-12-02T04:59:35Z,5052,[],Avelumab + Cisplatin,2016-12-02T04:59:35Z
0,2017-09-25T14:54:22Z,6238,[],Avelumab + eFT508,2017-09-25T14:54:36Z
0,2017-04-19T13:37:40Z,5559,[],Avelumab + Entinostat,2017-04-19T13:37:40Z
0,2017-01-03T16:42:46Z,5131,[],Avelumab + NHS-IL12,2017-01-03T16:42:46Z
0,2017-07-28T19:06:56Z,6045,[],Avelumab + PF-04518600,2017-07-28T19:06:56Z
0,2017-07-28T19:06:26Z,6044,[],Avelumab + PF-04518600 + Utomilumab,2017-07-28T19:06:26Z
0,2016-12-13T18:04:11Z,5087,[],Avelumab + Rituximab + Utomilumab,2016-12-13T18:04:11Z
0,2017-03-16T02:24:58Z,5444,[],Avelumab + trabectedin,2017-03-16T02:24:58Z
0,2017-07-28T19:04:07Z,6043,[],Avelumab + Utomilumab,2017-07-28T19:04:07Z
0,2017-09-01T19:50:29Z,6153,[],Avelumab + VX15/2503,2017-09-01T19:50:29Z
0,2017-05-23T19:45:08Z,5755,"[{'description': 'AVID100 is an antibody-drug conjugate comprising an EGFR-targeted antibody linked to a cytotoxic drug, which potentially results in decreased growth of EGFR-expressing tumors (Eur J Cancer, Dec 2016, Vol 69, S147).', 'references': [{'id': 8969, 'pubMedId': None, 'title': 'Development of AVID100, a novel antibody–drug conjugate for the treatment of EGFR expressing solid tumors', 'url': 'http://www.ejcancer.com/article/S0959-8049%2816%2933037-4/abstract'}]}]",AVID100,2017-05-23T19:45:08Z
0,2015-07-14T01:25:24Z,2917,"[{'description': 'Avitinib is a selective inhibitor of mutant forms of EGFR, which may result in decreased growth of tumors harboring EGFR mutations (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Avitinib,2015-07-14T01:25:24Z
0,2014-06-09T13:50:42Z,1068,"[{'description': 'AVX901 is a virally based vaccine that infects cells and causes expression of a ERBB2 (HER2) ECD+TM protein that may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against ERBB2 (HER2)-expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AVX901,2017-07-20T16:55:43Z
0,2014-03-12T15:53:16Z,649,"[{'description': 'Inlyta (axitinib) inhibits the VEGFRs, PDGFR, and KIT, potentially resulting in decreased angiogenesis and reduced tumor growth (PMID: 16027439, PMID: 25709499). Inlyta (axitinib) is approved for renal cell carcinoma (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Axitinib,2016-02-08T01:25:17Z
0,2015-03-02T19:15:47Z,2246,[],Axitinib + Bevacizumab,2015-03-02T19:15:47Z
0,2016-06-05T21:31:26Z,4241,[],Axitinib + Bosutinib,2016-06-05T21:31:26Z
0,2014-08-04T03:47:01Z,1350,[],Axitinib + Crizotinib,2014-08-04T03:47:01Z
0,2014-11-01T10:35:29Z,1697,[],Axitinib + FOLFIRI,2014-11-01T10:35:29Z
0,2014-11-01T10:38:20Z,1698,[],Axitinib + FOLFOX,2014-11-01T10:38:20Z
0,2014-11-01T10:28:17Z,1696,[],Axitinib + Gemcitabine,2014-11-01T10:28:17Z
0,2017-06-02T14:47:17Z,5837,[],Axitinib + Nivolumab,2017-06-02T14:47:17Z
0,2015-01-23T12:11:08Z,1972,[],Axitinib + Paclitaxel + Carboplatin,2015-01-23T12:11:08Z
0,2015-04-06T20:12:47Z,2494,[],Axitinib + Pembrolizumab,2015-04-06T20:12:47Z
0,2017-04-07T19:38:37Z,5522,[],Axitinib + PF-04518600,2017-04-07T19:38:37Z
0,2016-11-11T18:17:53Z,4938,[],Axitinib + Radiotherapy,2016-11-11T18:17:53Z
0,2016-01-29T13:54:51Z,3474,[],Axitinib + Selenomethionine,2016-01-29T13:54:51Z
0,2015-05-29T04:30:44Z,2745,"[{'description': 'AXL1717 inhibits IGF-1R, potentially leading to decreased tumor growth (PMID: 21875414).', 'references': [{'id': 2850, 'pubMedId': 21875414, 'title': 'Insulin-like growth factor: current concepts and new developments in cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21875414'}]}]",AXL1717,2015-07-08T18:12:41Z
0,2015-05-14T17:27:08Z,2678,"[{'description': 'AZ-23 is a selective TRK inhibitor, which potentially inhibits growth of TRK-expressing tumors (PMID: 19509272).\r\n', 'references': [{'id': 2713, 'pubMedId': 19509272, 'title': 'Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19509272'}]}]",AZ-23,2015-05-14T17:27:08Z
0,2017-02-24T16:22:31Z,5359,"[{'description': 'AZ-TAK1 is an ATP-competitive inhibitor of TAK1, which may result in apoptotic activity and inhibition of cell growth in cancer cells (PMID: 22649101). ', 'references': []}]",AZ-TAK1,2017-02-24T16:22:31Z
0,2017-02-24T16:28:17Z,5360,[],AZ-TAK1 + Selumetinib,2017-02-24T16:28:17Z
0,2016-01-15T17:44:34Z,3418,"[{'description': 'AZ12489875-002 is a small molecule inhibitor of EphB4, which may result in decreased cell growth (PMID: 23844053).', 'references': [{'id': 4341, 'pubMedId': 23844053, 'title': 'The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23844053'}]}]",AZ12489875-002,2016-01-15T17:44:34Z
0,2017-03-23T18:13:49Z,5473,"[{'description': 'AZ1366 inhibits Tankyrase1/2 (TNKS1/2), resulting in decreased Wnt/Beta-catenin signaling and potentially leading to decreased tumor growth in combination with other agents (PMID: 27663586).', 'references': [{'id': 8317, 'pubMedId': 27663586, 'title': 'AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27663586'}]}]",AZ1366,2017-03-23T19:05:27Z
0,2015-12-23T17:45:10Z,3333,"[{'description': 'AZ191 is an ATP-competitive inhibitor, which targets the serine/threonine kinase activity of DYRK1B thereby inhibiting phosphorylation of CCND1 (PMID: 24134204).', 'references': [{'id': 4162, 'pubMedId': 24134204, 'title': 'A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr(286), not Thr(288).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24134204'}]}]",AZ191,2015-12-23T17:45:10Z
0,2015-07-02T14:42:44Z,2880,"[{'description': 'AZ20 is a small molecule inhibitor of ATR, which may inhibit tumor growth and induce cell death (Cancer Res April 15, 2012 72; 1823). ', 'references': [{'id': 3173, 'pubMedId': None, 'title': 'AZ20, a novel potent and selective inhibitor of ATR kinase with in vivo antitumour activity', 'url': 'http://cancerres.aacrjournals.org/content/72/8_Supplement/1823'}]}]",AZ20,2015-07-10T12:09:35Z
0,2017-03-07T20:50:00Z,5420,[],AZ20 + RVX2135,2017-03-07T20:50:00Z
0,2015-10-08T10:15:28Z,3117,"[{'description': 'AZ3146, inhibits phosphorylation of TTK (MPS1) to prevent spindle assembly checkpoint (PMID: 20624899).', 'references': [{'id': 3724, 'pubMedId': 20624899, 'title': 'Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20624899'}]}]",AZ3146,2015-10-08T10:15:28Z
0,2017-06-16T20:00:00Z,5901,"[{'description': 'AZ5104 is the active metabolite of Osimertinib, which inhibits wild-type and mutant EGFR and ERBB2 (HER2), potentially resulting in decreased tumor growth (PMID: 27439477, PMID: 28274957).', 'references': [{'id': 9161, 'pubMedId': 27439477, 'title': 'Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic-Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27439477'}]}]",AZ5104,2017-06-16T20:02:47Z
0,2015-07-23T18:21:20Z,2956,"[{'description': 'AZ12576089 (AZ6089) binds and inhibits FGFR1, 2, 3, and 4, and to a lesser extent CDK2, SRC, and LCK, which may result in the inhibition of FGFR mediated signal transduction pathways and inhibition of tumor cell proliferation (PMID: 22869148).', 'references': [{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]}]",AZ6089,2015-10-06T21:18:42Z
0,2014-07-25T10:00:04Z,1093,"[{'description': 'AZ628 is an irreversible pan-RAF inhibitor with activity against RAF1 and BRAF, including BRAF V600E, which leads to increased cell-cycle arrest and apoptosis of tumor cells (PMID: 18020980, PMID: 23288408).', 'references': [{'id': 473, 'pubMedId': 23288408, 'title': 'A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23288408'}]}]",AZ628,2017-06-07T15:40:33Z
0,2016-07-20T17:22:58Z,4487,[],AZ628 + CPI-455,2016-07-20T17:22:58Z
0,2016-10-05T19:44:23Z,4791,[],AZ628 + Selumetinib,2016-10-05T19:44:23Z
0,2016-10-05T20:35:28Z,4795,[],AZ628 + Trametinib,2016-10-05T20:35:28Z
0,2016-10-05T20:38:27Z,4796,[],AZ628 + VTX-11e,2016-10-05T20:38:27Z
0,2015-05-14T17:29:32Z,2679,"[{'description': 'AZ64 is a selective TRK inhibitor, which potentially leads to decreased growth of TRK-expressing tumors (PMID: 22623209).', 'references': [{'id': 2715, 'pubMedId': 22623209, 'title': 'AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22623209'}]}]",AZ64,2015-05-14T17:29:32Z
0,2016-01-13T13:38:38Z,3408,[],AZ64 + Irinotecan + Temozolomide,2016-01-13T13:38:38Z
0,2015-07-23T18:14:30Z,2955,"[{'description': 'AZ12908010 (AZ8010) binds and inhibits FGFR1, 2, and 3, which may result in the inhibition of FGFR mediated signal transduction pathways and inhibition of tumor cell proliferation (PMID: 22869148).', 'references': [{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]}]",AZ8010,2015-10-06T21:16:03Z
0,2015-06-04T10:08:21Z,2786,"[{'description': 'AZ960 is an ATP-competitive inhibitor of JAK2, which induces apoptosis and induces cell growth arrest (PMID: 21207414).', 'references': [{'id': 2944, 'pubMedId': 21207414, 'title': 'Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21207414'}]}]",AZ960,2015-06-08T18:33:01Z
0,2014-03-12T15:53:16Z,651,"[{'description': 'Vidaza (azacitidine) is a cytidine analog that is incorporated into DNA and inhibits DNA-methyltransferase. This leads to decreased DNA methylation, which may result the activation of silenced tumor suppressor genes (NCI Drug Dictionary).\r\n', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Azacitidine,2017-05-26T16:25:47Z
0,2017-04-12T18:29:54Z,5538,[],Azacitidine + BI 836858,2017-04-12T18:29:54Z
0,2014-07-28T13:16:42Z,1149,[],Azacitidine + CC-223,2014-07-28T13:16:42Z
0,2017-08-04T20:11:06Z,6093,[],Azacitidine + Decitabine + PF-06747143,2017-08-04T20:11:06Z
0,2017-06-12T16:47:12Z,5881,[],Azacitidine + Durvalumab + Romidepsin,2017-06-12T16:47:12Z
0,2016-04-22T19:29:34Z,4003,[],Azacitidine + Enasidenib,2017-06-23T19:01:17Z
0,2015-05-08T14:18:58Z,2645,[],Azacitidine + Entinostat,2015-05-08T14:18:58Z
0,2017-04-12T18:32:59Z,5539,[],Azacitidine + Entospletinib,2017-04-12T18:32:59Z
0,2015-04-22T02:56:09Z,2557,[],Azacitidine + Gemcitabine + vorinostat,2015-04-22T02:56:09Z
0,2017-08-21T17:12:40Z,6133,[],Azacitidine + Hu5F9-G4,2017-08-21T17:12:40Z
0,2016-02-26T17:05:48Z,3632,[],Azacitidine + Ibrutinib,2016-02-26T17:05:48Z
0,2017-03-27T13:45:43Z,5477,[],Azacitidine + INCB024360 + Pembrolizumab,2017-03-27T13:45:43Z
0,2016-05-27T18:45:06Z,4178,[],Azacitidine + MEDI4736,2016-05-27T18:45:06Z
0,2015-03-26T14:59:38Z,2471,[],Azacitidine + Midostaurin,2015-03-26T14:59:38Z
0,2017-09-05T15:55:53Z,6164,[],Azacitidine + MLN4924,2017-09-05T15:55:53Z
0,2015-11-09T00:25:55Z,3196,[],Azacitidine + Nivolumab,2015-11-09T00:25:55Z
0,2015-11-16T17:01:54Z,3214,[],Azacitidine + Panobinostat,2015-11-16T17:01:54Z
0,2015-04-06T20:22:47Z,2496,[],Azacitidine + Pembrolizumab,2015-04-06T20:22:47Z
0,2017-05-26T16:26:39Z,5782,[],Azacitidine + Pembrolizumab + Romidepsin,2017-05-26T16:26:39Z
0,2016-05-27T17:29:43Z,4177,[],Azacitidine + PF-04449913,2016-05-27T17:29:43Z
0,2016-07-18T00:07:07Z,4464,[],Azacitidine + Ponatinib,2016-07-18T00:07:07Z
0,2017-07-13T03:20:53Z,5987,[],Azacitidine + Pracinostat,2017-07-13T03:20:53Z
0,2015-03-06T16:08:01Z,2320,[],Azacitidine + Regorafenib,2015-03-06T16:08:01Z
0,2014-08-06T14:49:37Z,1396,[],Azacitidine + Romidepsin,2017-05-26T16:26:08Z
0,2015-03-02T14:52:50Z,2233,[],Azacitidine + Sirolimus,2015-03-02T14:52:50Z
0,2016-02-19T14:40:04Z,3557,"[{'description': 'AZD0156 is an inhibitor of ataxia telangiectasia mutated (ATM) kinase, which leads to defective DNA damage repair and apoptosis in tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AZD0156,2016-02-19T14:40:04Z
0,2016-02-19T14:41:00Z,3558,[],AZD0156 + Axitinib,2016-02-19T14:41:00Z
0,2015-04-13T18:31:35Z,2535,"[{'description': 'AZD0424 is a tyrosine kinase inhibitor of Abl and Src kinases, which may result in apoptosis and tumor growth inhibition (PMID: 25662515, PMID: 17704648). ', 'references': [{'id': 2477, 'pubMedId': 25662515, 'title': 'Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25662515'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AZD0424,2017-04-27T10:21:27Z
0,2015-11-23T22:27:59Z,3224,"[{'description': 'AZD1208 is a pan-PIM kinase inhibitor, which blocks PIM downstream signaling and leads to cell cycle arrest and apoptosis (PMID: 25505253).', 'references': [{'id': 3983, 'pubMedId': 25505253, 'title': 'PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25505253'}]}]",AZD1208,2015-12-11T20:47:45Z
0,2016-02-18T17:59:07Z,3550,[],AZD1208 + Ruxolitinib,2016-02-18T17:59:07Z
0,2014-03-12T15:53:16Z,652,"[{'description': 'AZD1480 is an ATP-competitive inhibitor of JAK1 and JAK2, which inhibits STAT3 signaling to prevent tumor growth (PMID: 22027691).', 'references': [{'id': 2932, 'pubMedId': 22027691, 'title': 'Therapeutic potential of AZD1480 for the treatment of human glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22027691'}]}]",AZD1480,2015-06-08T17:16:16Z
0,2016-03-07T20:26:15Z,3691,"[{'description': 'AZD1897 is an ATP-competitive inhibitor of PIM kinases 1, 2, and 3, which may result in decreased cell proliferation (PMID: 24975213).', 'references': [{'id': 4783, 'pubMedId': 24975213, 'title': 'PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24975213'}]}]",AZD1897,2016-03-07T20:26:15Z
0,2016-03-07T20:41:47Z,3692,[],AZD1897 + AZD5363,2016-03-07T20:41:47Z
0,2015-04-16T02:38:10Z,2542,"[{'description': 'AZD2461 inhibits PARP1 and PARP2, resulting in decreased tumor cell growth (PMID: 27550455).', 'references': [{'id': 2489, 'pubMedId': 23103855, 'title': 'Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23103855'}, {'id': 6793, 'pubMedId': 27550455, 'title': 'The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550455'}]}]",AZD2461,2017-05-09T16:14:50Z
0,2016-10-18T18:39:29Z,4852,[],AZD2461 + Temozolomide,2016-10-18T18:39:29Z
0,2016-02-18T14:11:20Z,3547,"[{'description': 'AZD2811 is nanoparticle formulation of Barasertib (AZD1152), which inhibits Aurora kinase B to induce cell cycle arrest and results in tumor regression (PMID: 26865565, PMID: 28292940).', 'references': [{'id': 4618, 'pubMedId': 26865565, 'title': 'Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26865565'}]}]",AZD2811,2017-04-04T13:19:51Z
0,2014-10-02T06:27:06Z,1586,"[{'description': 'AZD3463 is a dual inhibitor of IGF1R and ALK, including wild-type and mutant ALK, and has additional activity against ROS1 fusions, which decreases downstream signaling resulting in reduced tumor cell growth (PMID: 26786851, PMID: 26372962).', 'references': [{'id': 7594, 'pubMedId': 26786851, 'title': 'Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26786851'}, {'id': 882, 'pubMedId': None, 'title': '', 'url': 'http://cancerres.aacrjournals.org/content/73/8_Supplement/919.abstract'}]}]",AZD3463,2017-03-24T13:52:03Z
0,2017-07-13T18:24:48Z,5990,[],AZD3463 + Doxorubicin,2017-07-13T18:24:48Z
0,2015-06-11T19:22:16Z,2826,"[{'description': 'AZD3514 binds to androgen receptor (AR) and inhibits its nuclear translocation and activation, and also inhibits AR protein expression, resulting in decreased tumor cell proliferation (PMID: 23861347).', 'references': [{'id': 3022, 'pubMedId': 23861347, 'title': 'AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23861347'}]}]",AZD3514,2015-06-11T19:23:44Z
0,2015-07-14T00:57:16Z,2912,"[{'description': 'AZD3759 inhibits EGFR, potentially resulting in decreased growth of EGFR-expressing tumors (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AZD3759,2015-07-14T00:57:16Z
0,2014-03-12T15:53:16Z,653,"[{'description': 'AZD3965 inhibits monocarboxylate transporter 1 (MCT1), which disrupts lactate transport, potentially resulting in increased tumor cell death (PMID: 25281618).', 'references': [{'id': 4051, 'pubMedId': 25281618, 'title': 'Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25281618'}]}]",AZD3965,2015-12-07T15:11:45Z
0,2014-03-12T15:53:16Z,654,"[{'description': 'AZD4547 selectively binds and inhibits FGFR1, 2, and 3, which may result in the inhibition of FGFR-mediated signal transduction pathways and inhibition of tumor cell proliferation (PMID: 22369928).', 'references': [{'id': 1844, 'pubMedId': 22369928, 'title': 'AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22369928'}]}]",AZD4547,2015-10-21T19:49:23Z
0,2016-11-21T19:37:43Z,4983,[],AZD4547 + AZD8055,2016-11-21T19:37:43Z
0,2017-06-16T17:09:14Z,5898,[],AZD4547 + BKM120,2017-06-16T17:09:14Z
0,2016-06-22T17:40:54Z,4345,[],AZD4547 + Cisplatin + Gemcitabine,2016-06-22T17:40:54Z
0,2016-08-18T18:32:18Z,4585,[],AZD4547 + Gefitinib,2016-08-18T18:32:18Z
0,2017-07-31T20:01:16Z,6062,[],AZD4547 + Lapatinib,2017-07-31T20:01:16Z
0,2016-11-21T19:39:32Z,4985,[],AZD4547 + Sirolimus,2016-11-21T19:39:32Z
0,2016-07-19T18:05:26Z,4478,[],AZD4547 + Trametinib,2016-07-19T18:05:26Z
0,2016-11-21T19:38:44Z,4984,[],AZD4547 + Vistusertib,2017-06-09T15:03:46Z
0,2016-06-03T02:15:57Z,4223,"[{'description': 'Limited information is currently available on AZD4635 (Jun 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",AZD4635,2016-06-03T02:15:57Z
0,2016-06-23T14:38:01Z,4349,[],AZD4635 + MEDI4736,2016-06-23T14:38:01Z
0,2017-06-20T20:12:40Z,5914,"[{'description': 'AZD4785 is an antisense oligonucleotide targeting KRAS that results in the depletion of KRAS mRNA and protein, therefore leads to inhibition of tumor cell growth (PMID: 28615361).', 'references': [{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]}]",AZD4785,2017-09-22T14:44:13Z
0,2015-10-01T01:46:43Z,3092,"[{'description': 'AZD5069 binds to and inhibits CXCR2 signaling, resulting in reduced neutrophil chemotaxis (PMID: 25736418).', 'references': [{'id': 3685, 'pubMedId': 25736418, 'title': 'Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25736418'}]}]",AZD5069,2015-10-01T01:46:43Z
0,2015-10-05T23:55:57Z,3099,[],AZD5069 + MEDI4736,2015-10-05T23:55:57Z
0,2016-11-02T20:05:13Z,4910,"[{'description': 'AZD5153 is a selective BET inhibitor that binds to BRD4 bivalently, resulting in enhanced anti-tumor activity (PMID: 27573426).', 'references': [{'id': 6927, 'pubMedId': 27573426, 'title': 'AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27573426'}]}]",AZD5153,2016-11-02T20:06:06Z
0,2014-03-12T15:53:16Z,655,"[{'description': 'AZD5363 decreases PI3K/AKT/mTOR signaling by inhibition of AKT1, AKT2, and AKT3, resulting in decreased cell proliferation (PMID: 22294718).', 'references': [{'id': 693, 'pubMedId': 22294718, 'title': 'Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22294718'}]}]",AZD5363,2017-03-17T18:17:15Z
0,2016-07-20T17:47:15Z,4490,[],AZD5363 + Anastrozole,2016-07-20T17:47:15Z
0,2015-12-29T16:24:19Z,3346,[],AZD5363 + AZD4547,2015-12-29T16:24:19Z
0,2017-09-05T16:21:58Z,6166,[],AZD5363 + Docetaxel + Prednisone,2017-09-05T16:21:58Z
0,2016-07-14T19:16:10Z,4452,[],AZD5363 + Fulvestrant,2016-07-14T19:16:10Z
0,2015-10-21T00:12:31Z,3139,[],AZD5363 + Olaparib,2015-10-21T00:12:31Z
0,2015-02-27T11:53:39Z,2192,[],AZD5363 + Paclitaxel,2015-02-27T11:53:39Z
0,2016-07-20T17:45:49Z,4489,[],AZD5363 + Tamoxifen,2016-07-20T17:45:49Z
0,2015-05-20T20:14:33Z,2728,"[{'description': 'AZD5438 is an inhibitor of CDK1, CDK2, and CDK9, which may promote cell cycle arrest and induction of apoptosis in cancer cells (PMID: 19509270). ', 'references': [{'id': 2795, 'pubMedId': 19509270, 'title': 'AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19509270'}]}]",AZD5438,2015-05-20T20:14:33Z
0,2014-03-12T15:53:16Z,659,"[{'description': 'AZD6482 inhibits PIK3CB and PIK3CD, preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival (PMID: 24992874, PMID: 23674493).', 'references': [{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}]}]",AZD6482,2016-03-10T20:14:33Z
0,2016-05-03T17:17:26Z,4054,[],AZD6482 + Binimetinib,2016-05-03T17:17:26Z
0,2016-05-03T18:34:35Z,4059,[],AZD6482 + Binimetinib + BYL719,2016-05-03T18:34:35Z
0,2016-05-03T18:00:48Z,4058,[],AZD6482 + Binimetinib + LGX818,2016-05-03T18:00:48Z
0,2016-05-03T18:37:47Z,4063,[],AZD6482 + Binimetinib + LGX818 + BYL719,2016-05-03T18:37:47Z
0,2016-05-03T18:38:43Z,4064,[],AZD6482 + Binimetinib + LGX818 + NVP-AEW541,2016-05-03T18:38:43Z
0,2016-05-03T18:35:11Z,4060,[],AZD6482 + Binimetinib + NVP-AEW541,2016-05-03T18:35:11Z
0,2016-03-10T20:45:51Z,3714,[],AZD6482 + BYL719,2016-03-10T20:45:51Z
0,2016-05-03T17:09:51Z,4048,[],AZD6482 + LGX818,2016-05-03T17:09:51Z
0,2016-05-03T18:37:00Z,4062,[],AZD6482 + LGX818 + BYL719,2016-05-03T18:37:00Z
0,2016-05-03T18:35:56Z,4061,[],AZD6482 + LGX818 + NVP-AEW541,2016-05-03T18:35:56Z
0,2016-03-10T21:21:51Z,3718,[],AZD6482 + Niraparib,2016-03-10T21:21:51Z
0,2016-05-03T16:16:43Z,4044,[],AZD6482 + NVP-AEW541,2016-05-03T16:16:43Z
0,2016-03-10T21:23:14Z,3719,[],AZD6482 + Olaparib,2016-03-10T21:23:14Z
0,2016-03-10T21:24:46Z,3721,[],AZD6482 + Rucaparib,2016-03-10T21:24:46Z
0,2016-03-10T21:20:12Z,3717,[],AZD6482 + Talazoparib,2017-06-12T15:58:29Z
0,2016-03-10T21:23:48Z,3720,[],AZD6482 + Veliparib,2016-03-10T21:23:48Z
0,2015-07-02T16:45:42Z,2881,"[{'description': 'AZD6738 is an inhibitor of ATR, which may enhance the sensitivity of chemotherapeutic agents and inhibit tumor growth (Cancer Res April 15, 2013 73; 3343).\r\n', 'references': [{'id': 3174, 'pubMedId': None, 'title': 'The pre-clinical in vitro and in vivo activity of AZD6738: A potent and selective inhibitor of ATR kinase', 'url': 'http://cancerres.aacrjournals.org/content/73/8_Supplement/3343.short'}]}]",AZD6738,2015-07-10T12:09:55Z
0,2016-09-21T17:24:48Z,4737,[],AZD6738 + Carboplatin,2016-09-21T17:24:48Z
0,2016-03-30T17:40:58Z,3876,[],AZD6738 + Cisplatin,2016-03-30T17:40:58Z
0,2016-03-30T18:10:42Z,3877,[],AZD6738 + Ibrutinib,2016-03-30T18:10:42Z
0,2016-09-21T17:44:12Z,4738,[],AZD6738 + MEDI4736,2016-09-21T17:47:43Z
0,2016-09-21T17:49:20Z,4739,[],AZD6738 + Olaparib,2016-09-21T17:49:20Z
0,2017-04-20T19:52:33Z,5565,[],AZD6738 + Paclitaxel,2017-04-20T19:52:33Z
0,2017-02-21T16:34:48Z,5346,[],AZD6738 + Radiotherapy,2017-02-21T16:34:48Z
0,2015-05-11T19:53:49Z,2652,"[{'description': 'AZD6918 is a selective TRK receptor inhibitor, which potentially leads to increased tumor cell death (PMID: 25700942).', 'references': [{'id': 2683, 'pubMedId': 25700942, 'title': 'Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25700942'}]}]",AZD6918,2015-05-14T17:32:04Z
0,2015-05-14T17:37:17Z,2680,"[{'description': 'AZD7451 is a selective pan-TRK inhibitor, which may inhibit growth of TRK overexpressing tumor cells (PMID: 25054037).', 'references': [{'id': 792, 'pubMedId': 25054037, 'title': 'Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25054037'}]}]",AZD7451,2015-05-14T17:37:17Z
0,2014-03-12T15:53:16Z,656,"[{'description': 'AZD7762 is an ATP-competitive checkpoint kinase inhibitor which abrogates DNA damage-induced cell cycle checkpoints. AZD7762 demonstrates antitumor activity when administered in combination with DNA-damaging agents (PMID: 18790776).', 'references': [{'id': 1210, 'pubMedId': 18790776, 'title': 'AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18790776'}]}]",AZD7762,2014-12-01T07:30:13Z
0,2014-12-01T07:31:06Z,1755,[],AZD7762 + Cisplatin,2014-12-01T07:31:06Z
0,2015-01-20T10:29:14Z,1968,[],AZD7762 + Gemcitabine,2015-01-20T10:29:14Z
0,2016-05-03T17:13:37Z,4050,[],AZD7762 + Hydroxyurea + VE-821,2016-05-03T17:13:37Z
0,2016-06-02T16:38:13Z,4191,[],AZD7762 + Ixazomib,2016-06-02T16:38:13Z
0,2016-05-03T17:14:30Z,4051,[],AZD7762 + VE-821,2016-05-03T17:14:30Z
0,2016-05-03T17:54:11Z,4057,[],AZD7762 + VX-970,2016-05-03T17:54:11Z
0,2014-09-19T11:27:50Z,1519,"[{'description': 'AZD8055 is a PI3K/MTOR inhibitor that reduces downstream signaling, resulting in decreased tumor cell growth (PMID: 20028854)', 'references': [{'id': 2288, 'pubMedId': 20028854, 'title': 'AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028854'}, {'id': 780, 'pubMedId': 25156567, 'title': 'CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25156567'}]}]",AZD8055,2016-04-01T16:28:48Z
0,2016-11-29T19:52:39Z,5023,[],AZD8055 + Binimetinib,2016-11-29T19:52:39Z
0,2017-07-26T20:17:28Z,6008,[],AZD8055 + Cetuximab,2017-07-26T20:17:28Z
0,2015-08-13T01:18:20Z,3017,[],AZD8055 + MK-1775,2015-08-13T01:18:20Z
0,2016-11-17T19:52:37Z,4966,[],AZD8055 + MK2206,2016-11-17T19:52:37Z
0,2016-11-23T16:53:42Z,4994,[],AZD8055 + SCH772984,2016-11-23T16:53:42Z
0,2015-04-22T17:22:03Z,2561,[],AZD8055 + Selumetinib,2015-04-22T17:22:03Z
0,2014-05-14T14:52:46Z,992,"[{'description': 'AZD8186 selectively inhibits the activity of PI3Kbeta (PIK3CB) and delta (PIK3CD) in the PI3K/Akt/mTOR signaling pathway, which may result in decreased tumor cell proliferation (PMID: 25514658).', 'references': [{'id': 4117, 'pubMedId': 25514658, 'title': 'Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25514658'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AZD8186,2016-08-15T16:22:26Z
0,2016-11-22T18:29:54Z,4987,[],AZD8186 + BVD-523,2016-11-22T18:29:54Z
0,2016-03-16T14:14:52Z,3749,[],AZD8186 + BYL719,2016-03-16T14:14:52Z
0,2016-03-16T14:15:23Z,3750,[],AZD8186 + BYL719 + Enzalutamide,2016-03-16T14:15:23Z
0,2017-07-28T19:15:41Z,6046,[],AZD8186 + Docetaxel,2017-07-28T19:15:41Z
0,2016-03-16T14:16:50Z,3752,[],AZD8186 + Enzalutamide,2016-03-16T14:16:50Z
0,2016-11-22T17:48:00Z,4986,[],AZD8186 + SCH772984,2016-11-22T17:48:00Z
0,2017-06-09T15:33:50Z,5868,[],AZD8186 + Vistusertib,2017-06-09T15:33:50Z
0,2014-03-12T15:53:16Z,658,"[{'description': 'AZD8330 is a MEK1/2 inhibitor, which blocks signaling of the Ras/Raf/MEK/ERK pathway to prevent cell proliferation (PMID: 24434059).', 'references': [{'id': 1813, 'pubMedId': 24434059, 'title': 'MEK1/2 inhibitors in the treatment of gynecologic malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24434059'}]}]",AZD8330,2017-04-06T09:47:24Z
0,2015-02-06T11:39:09Z,2013,"[{'description': 'AZD8835 inhibits PIK3CA and PIK3CD, potentially resulting in decreased growth of PI3K-dependent tumors (PMID: 26839307).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 4106, 'pubMedId': None, 'title': 'High dose intermittent scheduling of AZD8835, a novel potent and selective inhibitor of PI3K? and PI3K?, identifies potential treatment strategies for PIK3CA-dependent cancers', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/2665.short'}, {'id': 4877, 'pubMedId': 26839307, 'title': 'Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26839307'}]}]",AZD8835,2016-05-31T16:12:15Z
0,2016-03-16T15:37:08Z,3753,[],AZD8835 + Fulvestrant,2016-03-16T15:37:08Z
0,2016-03-16T15:37:44Z,3754,[],AZD8835 + Fulvestrant + Palbociclib,2016-03-16T15:37:44Z
0,2016-03-16T15:38:06Z,3755,[],AZD8835 + Palbociclib,2016-03-16T15:38:06Z
0,2015-06-03T22:19:28Z,2782,"[{'description': 'ISIS-STAT3rx (AZD9150) is an antisense oligonucleotide that inhibits translation of STAT3, which is often activated by receptor tyrosine kinases including FGFR, thereby preventing cell proliferation (NCI Drug Dictionary, PMID: 23935373). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AZD9150 ,2016-06-29T15:22:19Z
0,2015-10-05T23:55:02Z,3098,[],AZD9150 + MEDI4736,2015-10-05T23:55:02Z
0,2016-09-18T15:19:56Z,4718,[],AZD9150 + Selumetinib,2016-09-18T15:19:56Z
0,2016-07-27T19:37:50Z,4502,[],AZD9291 + JNJ-61186372,2016-07-27T19:37:50Z
0,2015-02-28T11:17:45Z,2223,[],AZD9291 + MEDI4736,2015-02-28T11:17:45Z
0,2015-08-06T02:41:34Z,2994,[],AZD9291 + MLN0128,2015-08-06T02:41:34Z
0,2015-08-06T04:04:16Z,2997,"[{'description': 'AZD9496 is a selective degrader of estrogen receptor, which leads to growth inhibition of ER-positive tumors (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",AZD9496,2017-03-09T16:25:33Z
0,2016-06-17T03:23:54Z,4293,[],AZD9496 + AZD8835,2016-06-17T03:23:54Z
0,2016-06-17T03:24:57Z,4294,[],AZD9496 + Palbociclib,2016-06-17T03:24:57Z
0,2016-06-17T03:26:00Z,4295,[],AZD9496 + Vistusertib,2017-06-09T14:59:02Z
0,2015-07-20T15:46:46Z,2934,"[{'description': 'B-701 is a monoclonal antibody which binds FGFR3 to prevent phosphorylation and signaling, thereby possibly inhibiting proliferation and promoting apoptosis in cancer cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",B-701,2015-07-24T21:48:36Z
0,2017-05-05T03:00:49Z,5615,[],B-701 + Atezolizumab,2017-05-05T03:00:49Z
0,2016-10-16T20:18:58Z,4831,[],B-701 + Pembrolizumab,2016-10-16T20:18:58Z
0,2015-05-06T17:43:26Z,2622,"[{'description': 'B02 is a small molecule inhibitor of RAD51 with the potential to block homologous recombination repair thereby increasing the sensitivity of therapies that induce DNA damage (PMID: 25401086).', 'references': [{'id': 2655, 'pubMedId': 25401086, 'title': 'A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25401086'}]}]",B02,2017-09-25T19:05:39Z
0,2015-05-06T17:58:35Z,2623,[],B02 + Aldoxorubicin,2015-05-06T17:58:35Z
0,2016-11-29T17:38:35Z,5018,[],B02 + Veliparib,2016-11-29T17:38:35Z
0,2014-03-12T15:53:16Z,661,"[{'description': 'Bafetinib (NS-187) is a tyrosine kinase inhibitor with activity against Lyn, SRC kinase, DDR1/2, and BCR-ABL, but not the T315I mutation (PMID: 21154127, PMID: 19890374).', 'references': [{'id': 1816, 'pubMedId': 21154127, 'title': 'Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21154127'}]}]",Bafetinib,2015-12-07T16:01:54Z
0,2016-09-26T15:27:39Z,4763,"[{'description': 'Baicalein is a plant-derived small molecule that binds to Msh2 and mismatched DNA and inhibits the interaction between Msh2 and Chk1/Atm, resulting in increased double-strand breaks and cell death in mismatch repair-deficient tumor cells (PMID: 27262172), and induces DDIT4 expression, which leads to inhibition of mTORC1 activity (PMID: 25543165).', 'references': [{'id': 6673, 'pubMedId': 27262172, 'title': 'A Novel Chemotherapeutic Agent to Treat Tumors with DNA Mismatch Repair Deficiencies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27262172'}]}]",Baicalein,2017-07-25T19:56:36Z
0,2016-11-02T17:18:16Z,4908,"[{'description': 'BAL101553 is the prodrug of the microtubule inhibiting drug BAL27862, which may result in decreased growth and migration of tumor cells (PMID: 27540016).', 'references': [{'id': 6923, 'pubMedId': 27540016, 'title': 'The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27540016'}]}]",BAL101553,2016-11-02T17:18:16Z
0,2017-02-14T16:00:26Z,5323,[],Balsalazide + Parthenolide,2017-02-14T16:00:26Z
0,2014-03-12T15:53:16Z,662,"[{'description': 'Barasertib (AZD1152) is a selective Aurora B kinase inhibitor, which induces cell cycle arrest (PMID: 17495131).', 'references': [{'id': 2125, 'pubMedId': 17495131, 'title': 'AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17495131'}]}]",Barasertib,2017-04-04T13:17:10Z
0,2017-08-14T17:38:43Z,6112,[],Barasertib + Navitoclax,2017-08-14T17:38:43Z
0,2014-12-19T02:17:18Z,1809,"[{'description': 'Bardoxolone methyl (CDDO-Me) is a derivative of a synthetic triterpenoid, 2-cyano-3,12-dioxooleana- 1,9-dien-28-oic acid (CDDO), which targets KEAP1, leading to the activation of NRF2. CDDO-Me also binds to IKK? and inhibits NF-?B activation. CDDO-Me is developed for the treatment of inflammation and cancer (PMID: 25364233)', 'references': [{'id': 1396, 'pubMedId': 25364233, 'title': 'Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25364233'}]}]",Bardoxolone methyl,2014-12-19T02:17:18Z
0,2015-06-01T17:31:58Z,2751,"[{'description': 'Baricitinib (LY3009104) is an inhibitor of JAK1, JAK2, and TYK2 and is under investigation for treatment of RA and cancer (PMID: 20363976).', 'references': [{'id': 2874, 'pubMedId': 20363976, 'title': 'Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20363976'}]}]",Baricitinib,2015-06-04T10:04:05Z
0,2017-07-13T03:04:11Z,5985,"[{'description': 'Simulect (basiliximab) is an antibody that binds and inhibits IL-2, potentially resulting in reduced T-cell activation and decreased immune response (PMID: 16098072, PMID: 12476283).', 'references': [{'id': 9395, 'pubMedId': 16098072, 'title': 'Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16098072'}, {'id': 9394, 'pubMedId': 12476283, 'title': 'Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12476283'}]}]",Basiliximab,2017-07-13T03:04:11Z
0,2017-09-29T13:35:57Z,6258,[],Basiliximab + 90Y basiliximab + Carmustine + Cytarbine + Etoposide + Melphalan,2017-09-29T13:35:57Z
0,2016-02-17T22:03:02Z,3545,"[{'description': 'Tarvacin (bavituximab) is a monoclonal antibody that targets phosphatidylserine, which may induce an immune response targeting the tumor vasculature (PMID: 26550540).', 'references': [{'id': 4616, 'pubMedId': 26550540, 'title': 'Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26550540'}]}]",Bavituximab,2016-02-18T19:51:48Z
0,2016-03-06T21:30:49Z,3684,[],Bavituximab + Capecitabine,2016-03-06T21:30:49Z
0,2016-09-13T14:18:37Z,4698,[],Bavituximab + Docetaxel,2016-09-13T14:18:37Z
0,2017-01-03T18:43:01Z,5138,[],Bavituximab + Sorafenib,2017-01-03T18:43:01Z
0,2017-05-05T21:55:00Z,5634,[],Bavituximab + Temozolomide,2017-05-05T21:55:00Z
0,2017-03-07T18:04:56Z,5408,"[{'description': 'BAY 11-7082 is an inhibitor of kB kinase (IKK) 1 and 2, which may result in inhibition of NF kappa B pathway signaling leading to cell death (PMID: 23527154). ', 'references': [{'id': 8147, 'pubMedId': 23527154, 'title': 'The IKK inhibitor Bay 11-7082 induces cell death independent from inhibition of activation of NFκB transcription factors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23527154'}]}]",BAY 11-7082,2017-03-07T18:04:56Z
0,2017-03-07T18:07:14Z,5409,[],BAY 11-7082 + Erlotinib,2017-03-07T18:07:14Z
0,2017-05-09T18:24:27Z,5651,"[{'description': 'BAY 1129980 is an antibody-drug conjugate comprising an antibody targeting C4.4A (LYPD3) linked to a derivative of auristatin W, which delivers the microtubule-disrupting compound to C4.4A (LYPD3)-expressing tumor cells, resulting decreased cell viability (PMID: 28292941).', 'references': []}]",BAY 1129980,2017-05-09T18:30:59Z
0,2015-04-28T22:51:50Z,2598,"[{'description': 'BAY 1238097 inhibits BET, potentially leading to decreased tumor cell proliferation (AACR Annual Meeting 2015, Abstract 3524).', 'references': [{'id': 2597, 'pubMedId': None, 'title': 'BAY 1238097, a novel BET inhibitor with strong efficacy in hematological tumor models', 'url': 'http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=b4807182-6a38-470a-b895-86207d0fe55a&cKey=83e86e35-c100-4b31-9794-2db7bdbb4faf&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424'}]}]",BAY 1238097 ,2015-04-30T02:05:45Z
0,2016-04-21T20:32:52Z,3987,"[{'description': 'BAY 1436032 is an IDH1 inhibitor with selectivity over mutant forms of IDH1, which leads to anti-tumor effects in mutant IDH1-dependent cancer cells (AACR, Cancer Res: April 2016; Volume 57, Abstract #2645).', 'references': [{'id': 5199, 'pubMedId': None, 'title': 'BAY 1436032: A highly selective, potent and orally available inhibitor of mutant forms of IDH1', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=407e597a-33c8-4936-87f4-08ee4b23e8b9&cKey=7b015533-ade6-4611-8ab3-68f274bd3bac&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]}]",BAY 1436032,2017-10-16T18:28:12Z
0,2015-05-13T19:37:21Z,2665,"[{'description': 'BAY 61-3606 is a small molecule inhibitor of Spleen Tyrosine Kinase (SYK), which may suppress cell growth (PMID: 22237022). ', 'references': [{'id': 2704, 'pubMedId': 22237022, 'title': 'A novel retinoblastoma therapy from genomic and epigenetic analyses.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22237022'}]}]",BAY 61-3606,2015-10-21T20:36:58Z
0,2017-05-23T15:39:51Z,5746,"[{'description': 'BAY-826 is a tyrosine kinase inhibitor with selectivity towards Tek (Tie2). BAY-826 may enhance tumor response to other treatments in tumors with active angiogenesis (PMID: 27787897).', 'references': [{'id': 8963, 'pubMedId': 27787897, 'title': 'Novel TIE-2 inhibitor BAY-826 displays in\xa0vivo efficacy in experimental syngeneic murine glioma models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27787897'}]}]",BAY-826,2017-05-23T15:39:51Z
0,2015-07-01T17:46:43Z,2876,"[{'description': 'BAY-853474 inhibits MET, resulting in decreased proliferation of MET-dependent tumor cells (PMID: 24959084).', 'references': [{'id': 2627, 'pubMedId': 24959084, 'title': 'The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24959084'}]}]",BAY-853474,2015-07-01T17:46:43Z
0,2014-03-12T15:53:16Z,663,"[{'description': 'Roniciclib (BAY1000394) is a pan-CDK inhibitor that induces cell-cycle arrest and apoptosis, resulting in inhibition of tumor cell growth (PMID: 22821149).', 'references': [{'id': 2289, 'pubMedId': 22821149, 'title': 'BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22821149'}]}]",BAY1000394,2015-07-22T19:10:18Z
0,2014-03-12T15:53:16Z,666,"[{'description': 'BAY1082439 is an inhibitor of PIK3CA and B, which prevents PI3K/Akt/mTOR signaling to promote apoptosis and inhibit cell proliferation (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BAY1082439,2015-04-10T16:21:57Z
0,2016-02-29T20:42:39Z,3655,"[{'description': 'BAY11-7085 is an inhibitor of NF-kappaB, which may result in necrotic cell death (PMID: 17889719). ', 'references': [{'id': 4744, 'pubMedId': 17889719, 'title': 'Cytotoxicity of NF-kappaB inhibitors Bay 11-7085 and caffeic acid phenethyl ester to Ramos and other human B-lymphoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17889719'}]}]",BAY11-7085,2016-02-29T20:42:39Z
0,2014-05-14T14:52:46Z,994,"[{'description': 'BAY1125976 inhibits the activity of AKT1/2, which may result in reduced tumor cell proliferation and decreased growth of tumors with activated PI3K/AKT/mTOR signaling (PMID: 27699769).', 'references': [{'id': 2275, 'pubMedId': None, 'title': 'Abstract 3685: BAY 1125976, is a selective allosteric AKT1/2 inhibitor with high efficacy in AKT1-mutated cancers', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/3685'}, {'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BAY1125976,2016-10-12T17:50:38Z
0,2016-04-29T17:39:42Z,4027,"[{'description': 'BAY1143572 is a selective PTEFb/CDK9 inhibitor that inhibits proliferation and induces apoptosis in tumor cells (Cancer Res, August 1, 2015 75; DDT02-02). ', 'references': []}]",BAY1143572,2016-04-29T17:39:42Z
0,2016-01-25T09:57:13Z,3445,"[{'description': 'BAY1161909, an inhibitor of TTK (MPS1), inhibits the spindle assembly checkpoint to induce cell death (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BAY1161909,2016-05-24T16:06:24Z
0,2016-01-25T10:17:55Z,3448,[],BAY1161909 + Paclitaxel,2016-01-25T10:17:55Z
0,2015-07-20T14:59:40Z,2932,"[{'description': 'BAY1179470 is an FGFR2 monoclonal antibody, which causes receptor internalization and degradation, thereby possibly inhibiting proliferation and promoting apoptosis in cancer cells (NCI Drug Dictionary, Cancer Res October 1, 2014 74; DDT02-01).', 'references': [{'id': 3277, 'pubMedId': None, 'title': 'Abstract 4766: Pharmacodynamic and stratification biomarker for the anti-FGFR2 antibody (BAY1179470) and the FGFR2-ADC', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/4766.abstract'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BAY1179470,2015-10-21T20:39:00Z
0,2015-07-20T14:27:30Z,2931,"[{'description': 'BAY1187982 is an FGFR2 antibody conjugated to a toxin, which may promote apoptosis and inhibit tumor growth (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BAY1187982,2015-10-21T20:47:06Z
0,2016-01-25T09:58:30Z,3446,"[{'description': 'BAY1217389, an inhibitor of TTK (MPS1), inhibits the spindle assembly checkpoint to induce cell death (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BAY1217389,2016-05-24T16:42:12Z
0,2016-01-25T10:16:26Z,3447,[],BAY1217389 + Paclitaxel,2016-01-25T10:16:26Z
0,2017-05-19T16:39:28Z,5698,"[{'description': 'BAY1436032 inhibits IDH1, including mutant IDH1, resulting in decreased levels of (R)-2-hydroxyglutarate (R-2HG) and leading to reduced proliferation and increased differentiation of IDH1-mutant tumor cells (PMID: 28232670).', 'references': [{'id': 8943, 'pubMedId': 28232670, 'title': 'Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28232670'}]}]",BAY1436032,2017-10-16T18:27:35Z
0,2017-07-03T19:23:18Z,5962,"[{'description': 'BAY1895344 is a selective Atr inhibitor that inhibits proliferation of a variety of tumor cells (Proceedings of the AACR, Vol 58, Apr 2017, Abstract 983).', 'references': [{'id': 9262, 'pubMedId': None, 'title': 'ATR inhibitor BAY 1895344 in monotherapy and combination in preclinical tumor models', 'url': 'https://books.google.com/books?id=4UFUDgAAQBAJ&pg=PT918&lpg=PT918&dq=ATR+inhibitor+BAY+1895344+in+monotherapy+and+combination+in+preclinical+tumor+models&source=bl&ots=qSIo1S4wDW&sig=FG2REd6HnsC284nxW'}]}]",BAY1895344,2017-07-03T19:23:18Z
0,2015-12-21T01:08:03Z,3315,[],BAY80-6946 + Cisplatin + Gemcitabine,2015-12-21T01:08:03Z
0,2017-10-04T14:34:46Z,6295,[],BAY80-6946 + Ibrutinib,2017-10-04T14:34:46Z
0,2015-05-29T03:26:19Z,2737,"[{'description': 'Bazedoxifene is a selective estrogen receptor modulator, which improves bone health and lipid metabolism without adverse effects on breast and uterus (PMID: 15961563).', 'references': [{'id': 2848, 'pubMedId': 15961563, 'title': 'Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15961563'}]}]",Bazedoxifene,2016-05-31T16:34:21Z
0,2016-11-09T17:39:46Z,4931,[],Bazedoxifene + Gemcitabine,2016-11-09T17:39:46Z
0,2016-11-09T17:30:20Z,4930,[],Bazedoxifene + Paclitaxel,2016-11-09T17:30:20Z
0,2015-05-29T03:27:31Z,2738,[],Bazedoxifene + Palbociclib,2015-05-29T03:27:31Z
0,2017-02-02T19:53:20Z,5278,"[{'description': 'bb2121 is a chimeric antigen receptor T cell specific to B cell maturation antigen (BCMA), which could potentially result in decreased volume of BCMA expressing tumor cells (Journal for ImmunoTherapy of Cancer 2015 3(Suppl 2):P124).\r\n\r\n', 'references': [{'id': 7730, 'pubMedId': None, 'title': 'A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity', 'url': 'https://jitc.biomedcentral.com/articles/10.1186/2051-1426-3-S2-P124'}]}]",bb2121,2017-02-02T19:53:20Z
0,2015-01-16T04:13:45Z,1945,"[{'description': 'BBI503 is a kinase inhibitor that inhibits signaling pathways that regulate survival of cancer stem cells, resulting in decreased cancer cell growth (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BBI503,2015-01-16T04:13:45Z
0,2015-03-12T12:39:27Z,2361,[],BBI503 + Sorafenib,2015-03-12T12:39:27Z
0,2015-02-11T19:58:52Z,2057,"[{'description': 'BBI608 (Napabucasin) is a small molecule inhibitor of cancer “stemness” that reduces activated Stat3 signaling, which is often activated by FGFRs, thereby decreasing proliferation of cancer stem cells, and possibly resulting in decreased cancer metastasis (PMID: 25605917, PMID: 23935373).', 'references': [{'id': 1867, 'pubMedId': 25605917, 'title': 'Suppression of cancer relapse and metastasis by inhibiting cancer stemness.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605917'}]}]",BBI608,2016-07-01T23:55:41Z
0,2015-02-18T16:01:30Z,2093,[],BBI608 + Bevacizumab,2015-02-18T16:01:30Z
0,2015-02-18T15:51:53Z,2091,[],BBI608 + Capecitabine,2015-02-18T15:51:53Z
0,2015-02-18T15:51:29Z,2090,[],BBI608 + Cetuximab,2015-02-18T15:51:29Z
0,2015-05-07T03:07:26Z,2630,[],BBI608 + Gemcitabine + nab-paclitaxel,2015-05-07T03:07:26Z
0,2015-04-24T13:54:22Z,2586,[],BBI608 + Paclitaxel,2015-04-24T13:54:22Z
0,2015-02-18T15:52:29Z,2092,[],BBI608 + Panitumumab,2015-02-18T15:52:29Z
0,2015-02-18T16:01:54Z,2094,[],BBI608 + Regorafenib,2015-02-18T16:01:54Z
0,2015-03-12T12:40:01Z,2362,[],BBI608 + Sorafenib,2015-03-12T12:40:01Z
0,2017-09-11T16:18:06Z,6190,"[{'description': 'BC2059 binds to beta-catenin (CTNNB1) and interferes with binding to TBL1 and TBLR1, resulting in increased degradation of beta-catenin and potentially leading to increased apoptosis of tumor cells with activated canonical Wnt signaling (PMID: 28500235).', 'references': [{'id': 9885, 'pubMedId': 28500235, 'title': 'β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28500235'}]}]",BC2059,2017-09-11T16:18:06Z
0,2017-09-11T16:41:47Z,6191,[],BC2059 + Bortezomib,2017-09-11T16:41:47Z
0,2015-03-16T16:59:29Z,2410,"[{'description': 'BC21 inhibits the interaction of CTNNB1 with TCF7L2 to block Wnt signaling, which can prevent cell proliferation and induce apoptosis (PMID: 22224445).', 'references': [{'id': 2222, 'pubMedId': 22224445, 'title': 'Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22224445'}]}]",BC21,2015-03-16T16:59:29Z
0,2016-07-17T21:56:39Z,4455,"[{'description': 'TICE BCG solution (BCG solution) is an attenuated live culture of Bacillus Calmette Guerin that induces anti-tumor immunity in bladder cancer (PMID: 26000263). TICE BCG solution (BCG solution) is FDA approved for carcinoma in situ of the bladder (FDA.gov).', 'references': [{'id': 6315, 'pubMedId': 26000263, 'title': 'Immunotherapy for bladder cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26000263'}]}]",BCG solution,2017-09-27T20:32:57Z
0,2016-07-17T22:00:46Z,4457,[],BCG solution + Pembrolizumab,2016-07-17T22:00:46Z
0,2017-03-28T02:17:06Z,5478,"[{'description': 'BCG Tokyo-172 strain solution contains an attenuated live culture of  the BCG strain of Mycobacterium bovis, which induces an immune response in bladder cancer cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BCG Tokyo-172 Strain Solution,2017-07-31T18:43:57Z
0,2017-08-02T17:42:13Z,6073,"[{'description': 'BCI-121 is a small molecule that inhibits Smyd3 methyltransferase activity and downstream gene expression, therefore results in tumor cell death (PMID: 25728514).', 'references': [{'id': 9659, 'pubMedId': 25728514, 'title': 'A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25728514'}]}]",BCI-121,2017-09-25T19:11:11Z
0,2015-12-10T19:59:04Z,3275,"[{'description': 'BDA-366 is a small molecule selective inhibitor of BCL2 that targets the BH4 domain and induces pro-apoptotic activity, potentially resulting in increased tumor cell apoptosis (PMID: 26004684).\r\n', 'references': [{'id': 4086, 'pubMedId': 26004684, 'title': 'Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26004684'}]}]",BDA-366,2015-12-10T19:59:04Z
0,2016-08-31T14:57:42Z,4627,[],BDA-366 + Everolimus,2016-08-31T14:57:42Z
0,2015-05-19T17:38:09Z,2708,"[{'description': 'Lucanix (belagenpumatucel-L) is a TGFB2 allogeneic NSCLC cell vaccine, which may promote an immune response against NSCLC cells and thus, decrease cell proliferation (Molecular Therapy (2006) 13, S424).', 'references': [{'id': 2761, 'pubMedId': None, 'title': '1104. Phase II Study of Lucanix|[trade]| a Transforming Growth Factor |[beta]|2 (TGF-|[beta]|2) Antisense Gene Modified Allogeneic Tumor Cell Vaccine in Non Small Cell Lung Cancer (NSCLC)', 'url': 'http://www.nature.com/mt/journal/v13/n1s/full/mt20061245a.html'}]}]",belagenpumatucel-L,2017-07-20T17:07:51Z
0,2014-06-16T11:09:53Z,1078,"[{'description': 'Beleodaq (belinostat) is an HDAC inhibitor, which promotes tumor cell apoptosis, potentially leading to decreased tumor growth (PMID: 12939461, PMID: 16928830, PMID: 17935615). Beleodaq (belinostat) is FDA approved for patients with relapsed or refractory peripheral T-cell lymphoma (FDA.gov).', 'references': [{'id': 8246, 'pubMedId': 16928830, 'title': 'Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16928830'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 8248, 'pubMedId': 12939461, 'title': 'Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12939461'}, {'id': 8247, 'pubMedId': 17935615, 'title': 'The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17935615'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Belinostat,2017-03-16T17:14:21Z
0,2014-07-28T00:03:18Z,1123,[],Belinostat + Cisplatin + Etoposide,2014-07-28T00:03:18Z
0,2015-11-09T00:30:48Z,3197,[],Belinostat + MK-1775,2015-11-09T00:30:48Z
0,2016-10-13T18:39:25Z,4826,[],Belinostat + Volasertib,2016-10-13T18:39:25Z
0,2016-06-26T19:32:26Z,4361,[],Belinostat + Zidovudine,2016-06-26T19:32:26Z
0,2014-07-29T20:15:04Z,1231,"[{'description': 'Bendamustine is a mechlorethamine derivative that has alkylator and antimetabolite activities, but appears to function primarily to alkylate and crosslink macromolecules, leading to apoptosis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Bendamustine,2017-08-11T16:13:16Z
0,2016-04-07T19:46:25Z,3910,[],Bendamustine + Bortezomib + Ofatumumab,2016-04-07T19:46:25Z
0,2015-12-29T18:02:47Z,3349,[],Bendamustine + Bortezomib + pegylated liposomal-doxorubicin,2015-12-29T18:02:47Z
0,2016-06-16T03:13:04Z,4291,[],Bendamustine + Bortezomib + Rituximab,2016-06-16T03:13:04Z
0,2015-03-12T15:48:53Z,2378,[],Bendamustine + Cytarabine + Etoposide,2015-03-12T15:48:53Z
0,2015-03-10T15:17:30Z,2336,[],Bendamustine + Everolimus,2015-03-10T15:17:30Z
0,2016-02-26T18:51:56Z,3638,[],Bendamustine + GDC-0199 + Obinutuzumab,2016-02-26T18:51:56Z
0,2016-02-26T18:49:48Z,3637,[],Bendamustine + GDC-0199 + Rituximab,2016-02-26T18:49:48Z
0,2015-03-06T16:40:41Z,2324,[],Bendamustine + Idelalisib + Rituximab,2015-03-06T16:40:41Z
0,2017-09-29T14:24:59Z,6260,[],Bendamustine + INCB050465 + Obinutuzumab,2017-09-29T14:24:59Z
0,2016-06-11T18:33:30Z,4279,[],Bendamustine + MEDI4736 + Rituximab,2016-06-11T18:33:30Z
0,2017-09-05T18:48:42Z,6169,[],Bendamustine + MK2206 + Rituximab,2017-09-05T18:48:42Z
0,2017-01-18T19:24:43Z,5225,[],Bendamustine + Obinutuzumab,2017-01-18T19:24:43Z
0,2016-04-07T19:45:58Z,3909,[],Bendamustine + Ofatumumab,2016-04-07T19:45:58Z
0,2016-08-08T20:00:55Z,4548,[],Bendamustine + Olaparib,2016-08-08T20:00:55Z
0,2017-08-03T20:33:41Z,6088,[],Bendamustine + PF-06747143,2017-08-03T20:33:41Z
0,2015-03-06T16:32:55Z,2323,[],Bendamustine + Rituximab,2015-03-06T16:32:55Z
0,2017-01-03T20:14:27Z,5147,[],Bendamustine + Rituximab + TAK-659,2017-01-03T20:14:27Z
0,2017-08-03T15:37:29Z,6077,[],Bendamustine + Rituximab + Veliparib,2017-08-03T15:37:29Z
0,2017-01-03T20:13:42Z,5146,[],Bendamustine + TAK-659,2017-01-03T20:13:42Z
0,2017-08-03T15:36:27Z,6076,[],Bendamustine + Veliparib,2017-08-03T15:36:27Z
0,2017-05-02T19:36:25Z,5603,"[{'description': 'BETd-246 is a small molecule that induces degradation of Brd2, Brd3, and Brd4 proteins, leading to apoptosis of tumor cells (PMID: 28209615).', 'references': [{'id': 8792, 'pubMedId': 28209615, 'title': 'Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28209615'}]}]",BETd-246,2017-05-02T19:36:25Z
0,2017-05-11T18:05:40Z,5663,[],BETd-246 + BM-1197,2017-05-11T18:05:40Z
0,2017-05-11T18:06:37Z,5664,[],BETd-246 + Navitoclax,2017-08-01T15:59:14Z
0,2014-03-12T15:53:16Z,667,"[{'description': 'Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer (FDA.gov).\r\n', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Bevacizumab,2016-06-09T13:40:09Z
0,2014-07-30T15:54:23Z,1261,[],Bevacizumab + Abraxane,2014-07-30T15:54:23Z
0,2015-04-08T16:52:24Z,2511,[],Bevacizumab + Alpha 2 Interferon,2015-04-08T16:54:04Z
0,2016-12-28T02:42:46Z,5126,[],Bevacizumab + Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin,2016-12-28T02:42:46Z
0,2015-02-20T16:10:33Z,2122,[],Bevacizumab + Bortezomib + Temozolomide,2015-02-20T16:10:33Z
0,2017-01-03T19:40:03Z,5144,[],Bevacizumab + Brentuximab vedotin,2017-01-03T19:40:03Z
0,2015-02-18T16:51:24Z,2097,[],Bevacizumab + Capecitabine,2015-02-18T16:51:24Z
0,2015-02-18T16:43:10Z,2096,[],Bevacizumab + Capecitabine + Carboplatin,2015-02-18T16:43:10Z
0,2016-01-22T01:41:34Z,3441,[],Bevacizumab + Capecitabine + Oxaliplatin + Trastuzumab,2016-01-22T01:41:40Z
0,2016-08-12T14:32:51Z,4555,[],Bevacizumab + Capecitabine + Paclitaxel,2016-08-12T14:32:51Z
0,2015-02-13T15:51:38Z,2073,[],Bevacizumab + Capecitabine + Temozolomide,2015-02-13T15:51:38Z
0,2015-02-13T16:04:22Z,2074,[],Bevacizumab + Carboplatin,2015-02-13T16:04:22Z
0,2014-07-28T13:22:55Z,1152,[],Bevacizumab + Carboplatin + Paclitaxel,2017-06-09T15:22:17Z
0,2014-09-18T18:54:14Z,1487,[],Bevacizumab + Carboplatin + Paclitaxel + Hydroxychloroquine,2014-09-18T18:54:14Z
0,2015-02-19T15:12:55Z,2104,[],Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab,2015-02-19T15:12:55Z
0,2015-02-20T15:37:15Z,2121,[],Bevacizumab + Carboxyamidotriazole Orotate ,2015-02-20T15:37:15Z
0,2015-03-12T14:55:04Z,2371,[],Bevacizumab + Carmustine,2015-03-12T14:55:04Z
0,2016-08-15T19:23:15Z,4569,[],Bevacizumab + Cediranib,2016-08-15T19:23:15Z
0,2015-01-06T14:55:05Z,1923,[],Bevacizumab + Cetuximab + Irinotecan,2015-01-06T14:55:05Z
0,2017-02-01T21:08:44Z,5273,[],Bevacizumab + Cisplatin + Etoposide,2017-02-01T21:08:44Z
0,2015-04-08T19:23:35Z,2512,[],Bevacizumab + Cisplatin + Paclitaxel,2015-04-08T19:23:35Z
0,2017-05-05T05:26:06Z,5624,[],Bevacizumab + CVX-060,2017-05-05T05:26:06Z
0,2016-08-07T16:21:22Z,4528,[],Bevacizumab + Cyclophosphamide + Pembrolizumab,2016-08-07T16:21:22Z
0,2015-02-13T15:48:06Z,2072,[],Bevacizumab + Cyclophosphamide + Zoledronic acid,2017-06-19T18:22:15Z
0,2016-06-09T16:05:46Z,4264,[],Bevacizumab + Docetaxel,2016-06-09T16:05:46Z
0,2015-07-31T05:06:48Z,2988,[],Bevacizumab + Docetaxel + Fluorouracil + Epirubicin + Cyclophosphamide,2015-07-31T05:07:29Z
0,2014-09-18T18:45:18Z,1486,[],Bevacizumab + Doxorubicin + Cyclophosphamide + Paclitaxel ,2014-09-18T18:45:18Z
0,2017-04-25T18:32:40Z,5569,[],Bevacizumab + Doxorubicin + Everolimus,2017-04-25T18:32:40Z
0,2017-04-25T18:35:10Z,5570,[],Bevacizumab + Doxorubicin + Temsirolimus,2017-04-25T18:35:10Z
0,2016-10-16T21:05:22Z,4836,[],Bevacizumab + Emactuzumab + Paclitaxel,2016-10-16T21:05:22Z
0,2014-07-28T13:11:55Z,1146,[],Bevacizumab + Erlotinib,2014-07-28T13:11:55Z
0,2016-06-09T16:53:49Z,4265,[],Bevacizumab + Erlotinib + Gemcitabine,2016-06-09T16:53:49Z
0,2015-02-20T13:48:58Z,2116,[],Bevacizumab + Erlotinib + Temozolomide,2015-02-20T13:48:58Z
0,2015-02-24T09:12:53Z,2144,[],Bevacizumab + Evofosfamide,2017-05-26T14:39:21Z
0,2017-07-19T18:32:43Z,6001,[],Bevacizumab + Fluorouracil + Irinotecan + Oxaliplatin,2017-07-19T18:32:43Z
0,2014-10-02T15:51:24Z,1599,[],Bevacizumab + Fluorouracil + Leucovorin,2014-10-02T15:51:24Z
0,2015-02-19T14:57:47Z,2102,[],Bevacizumab + Fluorouracil + Oxaliplatin,2015-02-19T14:57:47Z
0,2015-02-27T02:51:23Z,2181,[],Bevacizumab + FOLFIRI,2015-02-27T02:51:23Z
0,2015-02-27T03:05:21Z,2183,[],Bevacizumab + FOLFIRINOX,2015-02-27T03:05:21Z
0,2015-02-19T15:26:45Z,2109,[],Bevacizumab + Fosbretabulin,2015-02-19T15:26:45Z
0,2014-09-18T13:29:20Z,1466,[],Bevacizumab + Gemcitabine + Docetaxel + Valproic Acid ,2014-09-18T13:29:20Z
0,2015-04-29T01:06:10Z,2600,[],Bevacizumab + INC280,2015-04-29T01:06:10Z
0,2015-02-19T16:06:14Z,2112,[],Bevacizumab + Irinotecan,2015-02-19T16:06:14Z
0,2014-07-27T22:07:34Z,1122,[],Bevacizumab + Ixabepilone,2014-07-27T22:07:34Z
0,2015-02-20T14:59:29Z,2118,[],Bevacizumab + Lomustine,2015-02-20T14:59:29Z
0,2015-02-26T13:22:52Z,2166,[],Bevacizumab + Marizomib,2015-02-26T13:22:52Z
0,2015-02-20T14:33:09Z,2117,[],Bevacizumab + MEDI4736,2015-02-20T14:33:09Z
0,2016-05-06T19:05:28Z,4086,[],Bevacizumab + MEDI4736 + Tremelimumab,2016-05-06T19:05:28Z
0,2016-05-11T13:29:31Z,4097,[],Bevacizumab + MEDI4736 + Tremelimumab + FOLFOX,2016-05-11T13:29:31Z
0,2016-07-27T01:08:54Z,4498,[],Bevacizumab + Nintedanib,2016-07-27T01:08:54Z
0,2016-06-06T17:46:26Z,4254,[],Bevacizumab + Niraparib,2016-06-06T17:46:26Z
0,2015-02-19T15:48:13Z,2111,[],Bevacizumab + Nivolumab,2015-02-19T15:48:13Z
0,2016-06-27T00:12:03Z,4366,[],Bevacizumab + Osimertinib,2016-06-27T00:12:03Z
0,2014-09-18T18:35:30Z,1484,[],Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil,2014-09-18T18:35:30Z
0,2015-02-20T16:49:08Z,2123,[],Bevacizumab + Paclitaxel,2015-02-20T16:49:08Z
0,2015-02-20T15:29:14Z,2119,[],Bevacizumab + Pembrolizumab,2015-02-20T15:29:14Z
0,2015-02-20T13:23:36Z,2114,[],Bevacizumab + Pemetrexed,2015-02-20T13:23:36Z
0,2015-02-20T15:33:47Z,2120,[],Bevacizumab + Plerixafor,2015-02-20T15:36:33Z
0,2017-04-11T19:20:52Z,5528,[],Bevacizumab + PRX177561,2017-04-11T19:20:52Z
0,2015-02-19T13:34:13Z,2099,[],Bevacizumab + Reolysin,2015-02-19T13:34:13Z
0,2016-11-29T20:54:41Z,5025,[],Bevacizumab + SL-701,2016-11-29T20:54:41Z
0,2016-08-03T13:52:15Z,4517,[],Bevacizumab + Sorafenib,2016-08-03T13:52:15Z
0,2016-04-09T00:19:23Z,3917,[],Bevacizumab + Sorafenib + Temsirolimus,2016-04-09T00:19:34Z
0,2014-10-28T18:55:47Z,1670,[],Bevacizumab + Telatinib,2014-10-28T18:56:03Z
0,2015-02-20T13:46:45Z,2115,[],Bevacizumab + Temozolomide,2015-02-20T13:46:45Z
0,2014-07-27T21:56:42Z,1121,[],Bevacizumab + Temsirolimus + Doxil,2014-07-27T21:56:42Z
0,2014-07-30T15:27:15Z,1254,[],Bevacizumab + Tivantinib,2014-07-30T15:27:15Z
0,2015-04-08T19:24:17Z,2513,[],Bevacizumab + Topotecan + Paclitaxel,2015-04-08T19:24:17Z
0,2014-07-30T13:20:19Z,1243,[],Bevacizumab + TRC105,2014-07-30T13:20:19Z
0,2016-03-06T21:02:04Z,3682,[],Bevacizumab + trifluridine/tipiracil hydrochloride,2017-06-19T19:43:14Z
0,2017-01-31T03:44:22Z,5260,[],Bevacizumab + TVB-2640,2017-01-31T03:44:22Z
0,2015-03-03T16:51:31Z,2277,[],Bevacizumab + VB-111,2015-03-03T16:51:31Z
0,2015-08-25T00:27:28Z,3047,[],Bevacizumab + Veliparib,2015-08-25T00:27:28Z
0,2017-01-09T20:30:04Z,5178,[],Bevacizumab + Vinblastine,2017-01-09T20:30:04Z
0,2015-02-19T15:37:46Z,2110,[],Bevacizumab + Vorinostat,2015-02-19T15:37:46Z
0,2015-02-24T03:31:57Z,2141,"[{'description': 'Mvasi (bevacizumab-awwb) is a biosimilar to the anti-VEGF antibody Avastin (bevacizumab), which binds to and inhibits VEGF, resulting in decreased tumor growth and angiogenesis (Ann Oncol (2014) 25 (suppl 4): iv163; Abstract 489P). Mvasi (bevacizumab-awwb) is FDA approved for patients with colorectal cancer, non-small cell lung carcinoma, glioblastoma, renal cell carcinoma, and cervical cancer (FDA.gov). ', 'references': [{'id': 1976, 'pubMedId': None, 'title': '489P: FUNCTIONAL SIMILARITY ASSESSMENT RESULTS COMPARING BEVACIZUMAB TO BIOSIMILAR CANDIDATE ABP 215', 'url': 'http://annonc.oxfordjournals.org/content/25/suppl_4/iv163.2.short'}]}]",Bevacizumab-awwb,2017-09-27T15:30:44Z
0,2017-09-27T16:51:03Z,6255,[],Bevacizumab-awwb + Carboplatin + Paclitaxel,2017-09-27T16:51:03Z
0,2017-07-13T03:13:27Z,5986,[],Bevicizumab + DSP-7888,2017-07-13T03:13:27Z
0,2015-10-30T12:49:29Z,3159,[],Bexarotene,2015-10-30T12:49:29Z
0,2014-03-12T15:53:16Z,672,"[{'description': 'BEZ235 inhibits PI3K kinase, mTOR kinase, and ATR, which may result in tumor cell apoptosis and growth inhibition of tumor cells (PMID: 18606717, PMID: 21552262).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 2281, 'pubMedId': 18606717, 'title': 'Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18606717'}]}]",BEZ235,2016-07-25T14:58:13Z
0,2016-11-10T19:46:41Z,4932,[],BEZ235 + Binimetinib,2016-11-10T19:46:41Z
0,2015-07-06T20:25:50Z,2885,[],BEZ235 + Docetaxel,2015-07-06T20:25:50Z
0,2016-03-17T13:44:18Z,3763,[],BEZ235 + Doxorubicin,2016-03-17T13:44:18Z
0,2014-07-31T19:14:14Z,1321,[],BEZ235 + Everolimus,2014-07-31T19:14:14Z
0,2017-01-05T17:43:02Z,5162,[],BEZ235 + PD-0325901,2017-01-05T17:43:02Z
0,2015-05-01T02:14:56Z,2619,[],BEZ235 + PD98509,2015-05-01T02:14:56Z
0,2016-04-14T19:37:39Z,3928,[],BEZ235 + Ruxolitinib,2016-04-14T19:37:39Z
0,2015-04-24T01:31:25Z,2574,[],BEZ235 + U0126,2015-04-24T01:31:25Z
0,2017-03-28T18:08:25Z,5491,[],BEZ235 + unspecified CTLA4 antibody + unspecified PD-1 antibody,2017-03-28T18:08:25Z
0,2016-03-17T17:23:41Z,3774,[],BEZ235 + Vemurafenib,2016-03-17T17:23:41Z
0,2017-02-28T15:55:55Z,5376,[],BEZ235 + Venetoclax,2017-02-28T15:55:55Z
0,2017-02-28T15:57:01Z,5377,[],BEZ235 + WEHI-539,2017-02-28T15:57:01Z
0,2016-04-29T17:09:06Z,4025,"[{'description': 'BGB-283 is a dual RAF kinase and EGFR inhibitor, which may lead to decreased tumor cell proliferation and reduced growth of tumors with activation of BRAF and/or EGFR (PMID: 26208524).', 'references': []}]",BGB-283,2016-05-11T14:32:49Z
0,2016-08-31T15:45:57Z,4628,[],BGB-283 + Cetuximab,2016-08-31T15:45:57Z
0,2015-07-22T16:47:45Z,2947,"[{'description': 'BGB-290 inhibits PARP-1 and PARP-2, potentially resulting in increased sensitivity to DNA damaging agents (AACR; 2015. Abstract nr 1651).', 'references': [{'id': 3299, 'pubMedId': None, 'title': 'BGB-290, a novel PARP inhibitor with unique brain penetration ability, demonstrated strong synergism with temozolomide in subcutaneous and intracranial xenograft models', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=1fa5c23e-9775-40a7-9008-02f75c55446d&cKey=46922991-5337-4928-a46c-5a7af33b209d&mKey={19573A54-AE8F-4E00-9C23-BD6D62268424}'}]}]",BGB-290,2017-05-09T18:27:24Z
0,2017-08-18T18:32:28Z,6124,[],BGB-290 + Temozolomide,2017-08-18T18:32:28Z
0,2015-04-17T02:18:49Z,2544,"[{'description': 'BGB-3111 inhibits Bruton Tyrosine Kinase (BTK), leading to decreased B-cell activation and reduced growth of BTK over-expressing B-cells (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BGB-3111,2015-08-10T15:42:58Z
0,2016-09-12T03:06:53Z,4682,[],BGB-3111 + Obinutuzumab,2016-09-12T03:06:53Z
0,2015-05-12T15:24:05Z,2660,"[{'description': 'BGB-324 is a small molecule inhibitor of Axl, which inhibits tumor growth and may overcome EMT-mediated acquired drug resistance (PMID: 20145120). ', 'references': [{'id': 5002, 'pubMedId': 20145120, 'title': 'R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20145120'}, {'id': 2690, 'pubMedId': None, 'title': 'Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/1747.short'}]}]",BGB-324,2017-07-04T12:02:49Z
0,2016-12-22T15:37:34Z,5124,[],BGB-324 + Ceritinib,2016-12-22T15:37:34Z
0,2016-03-23T14:40:14Z,3825,[],BGB-324 + Cetuximab,2016-03-23T14:40:14Z
0,2016-12-22T15:31:15Z,5123,[],BGB-324 + Crizotinib,2016-12-22T15:31:15Z
0,2017-07-06T21:00:07Z,5973,[],BGB-324 + Docetaxel,2017-07-06T21:00:07Z
0,2015-05-15T00:35:54Z,2684,[],BGB-324 + Erlotinib,2015-05-15T00:36:47Z
0,2017-05-11T20:14:14Z,5668,[],BGB-324 + Imatinib ,2017-05-11T20:14:14Z
0,2016-03-23T14:10:42Z,3823,[],BGB-324 + Metformin,2016-03-23T14:10:42Z
0,2017-01-12T16:30:42Z,5190,[],BGB-324 + Olaparib,2017-01-12T16:30:42Z
0,2017-07-04T12:03:52Z,5964,[],BGB-324 + Pembrolizumab,2017-07-04T12:03:52Z
0,2017-06-09T18:36:09Z,5871,"[{'description': 'BGB-A317 is a human monoclonal antibody that targets PD-1, thereby blocking the binding of PD-L1 and potentially resulting in activation of a T-cell immune response against tumor cells (NCI Drug Dictionary).', 'references': []}]",BGB-A317,2017-06-09T18:36:09Z
0,2017-06-12T17:16:38Z,5883,[],BGB-A317 + BGB-290,2017-06-12T17:16:38Z
0,2017-09-26T20:27:51Z,6245,"[{'description': 'BGB659 is a pan-RAF inhibitor that results in inhibition of MEK/ERK signaling generated by either RAF dimers or RAF monomers and thus, prevents cell proliferation (PMID: 26343582).', 'references': [{'id': 7141, 'pubMedId': 26343582, 'title': 'BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343582'}]}]",BGB659,2017-09-26T20:27:51Z
0,2015-12-02T16:25:24Z,3238,"[{'description': 'BGC 638 (CB300638) is a thymidylate synthase inhibitor that binds to Folr1 and is internalized via endocytosis, leading to decreased growth of Folr1-expressing cells (PMID: 16357184).', 'references': [{'id': 4010, 'pubMedId': 16357184, 'title': 'BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16357184'}]}]",BGC 638,2015-12-02T16:25:24Z
0,2015-12-01T21:24:25Z,3233,"[{'description': 'BGC 945 (ONX-0801) is a thymidylate synthase inhibitor that binds to Folr1 and is internalized via endocytosis, leading to decreased growth of Folr1-expressing cells (PMID: 16357184).', 'references': [{'id': 4010, 'pubMedId': 16357184, 'title': 'BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16357184'}]}]",BGC 945,2015-12-02T18:02:49Z
0,2014-03-12T15:53:16Z,674,"[{'description': 'BGJ398 is pan-FGFR inhibitor, which inhibits tumor angiogenesis and tumor cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BGJ398,2014-09-26T18:41:52Z
0,2017-05-04T20:21:09Z,5612,[],BGJ398 + BKM120,2017-05-04T20:21:09Z
0,2014-07-31T07:19:34Z,1293,[],BGJ398 + BYL719,2014-07-31T07:19:34Z
0,2014-08-01T02:10:33Z,1336,[],BGJ398 + Encorafenib,2017-06-14T18:53:34Z
0,2017-01-30T19:15:05Z,5255,[],BGJ398 + Fluorouracil,2017-01-30T19:15:05Z
0,2015-10-21T01:11:48Z,3142,[],BGJ398 + Fluorouracil + Irinotecan + Oxaliplatin,2015-10-21T01:11:48Z
0,2017-05-04T20:22:08Z,5613,[],BGJ398 + GDC-0941,2017-05-04T20:22:08Z
0,2015-03-04T17:35:25Z,2284,[],BGJ398 + Imatinib,2015-03-04T17:35:25Z
0,2017-01-30T19:24:57Z,5256,[],BGJ398 + Oxaliplatin,2017-01-30T19:24:57Z
0,2016-01-19T18:09:15Z,3423,[],BGJ398 + Trabectedin,2016-01-19T18:09:15Z
0,2016-07-19T18:07:35Z,4479,[],BGJ398 + Trametinib,2016-07-19T18:07:35Z
0,2015-04-15T18:13:55Z,2537,"[{'description': 'BGP-15 inhibits poly(ADP-ribose) polymerase (PARP), potentially resulting in decreased tumor cell growth (PMID: 11931842, PMID: 22661288).\r\n  ', 'references': [{'id': 2480, 'pubMedId': 11931842, 'title': 'BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11931842'}, {'id': 2481, 'pubMedId': 22661288, 'title': 'Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D3 analogs, in-vitro and in-vivo studies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22661288'}]}]",BGP-15,2017-05-09T18:29:38Z
0,2014-03-12T15:53:16Z,675,"[{'description': 'BGT226 is a dual inhibitor of class I PI3K kinases and mTOR, which inhibits cell proliferation (PMID: 21976531).', 'references': [{'id': 1000, 'pubMedId': 21976531, 'title': 'Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21976531'}]}]",BGT226,2016-04-01T16:30:33Z
0,2016-07-19T14:57:25Z,4475,"[{'description': 'BHA536 is a selective PKC alpha/beta inhibitor, which may result in decreased tumor cell proliferation (PMID: 21324920). ', 'references': [{'id': 3976, 'pubMedId': 21324920, 'title': 'Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21324920'}]}]",BHA536,2017-04-26T15:47:05Z
0,2017-05-30T19:06:45Z,5817,"[{'description': 'BI 1361849 (CV9202) is a cancer vaccine comprising six mRNAs for non-small cell lung cancer-associated antigens, which may result in increased immune response against tumor cells (PMID: 25288198).', 'references': [{'id': 9019, 'pubMedId': 25288198, 'title': 'Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25288198'}]}]",BI 1361849,2017-05-30T19:06:45Z
0,2017-05-30T19:09:25Z,5818,[],BI 1361849 + Durvalumab + Tremelimumab,2017-05-30T19:09:25Z
0,2017-05-19T15:10:53Z,5692,"[{'description': 'Limited information is currently available on BI 754091, a putative PD-1 antibody (May, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",BI 754091,2017-05-19T15:10:53Z
0,2017-05-30T16:04:01Z,5806,[],BI 754091 + BI 754111,2017-05-30T16:04:01Z
0,2017-09-29T15:55:30Z,6263,[],BI 754091 + BI 891065,2017-09-29T15:55:30Z
0,2017-05-19T15:09:46Z,5690,"[{'description': 'Limited information is currently available on BI 754111, a putative lymphocyte activating 3 (LAG3) antibody (May, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",BI 754111,2017-05-19T15:09:46Z
0,2016-06-11T18:01:34Z,4276,"[{'description': 'BI 836826 is a monoclonal antibody that binds to CD37, resulting in anti-tumor immune response and tumor cell death (PMID: 26271483).', 'references': [{'id': 5863, 'pubMedId': 26271483, 'title': 'Cytotoxicity of the CD37 antibody BI 836826 against chronic lymphocytic leukaemia cells in combination with chemotherapeutic agents or PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26271483'}]}]",BI 836826,2016-06-11T18:01:34Z
0,2016-06-11T18:03:08Z,4277,[],BI 836826 + Ibrutinib,2016-06-11T18:03:08Z
0,2016-06-28T01:39:03Z,4396,[],BI 836826 + Idelalisib ,2016-06-28T01:39:03Z
0,2017-04-12T18:27:21Z,5537,"[{'description': 'BI 836858 is a human antibody against CD33 that induces cytotoxic immune response against CD33-positive tumor cells (PMID: 27013443).', 'references': []}]",BI 836858,2017-04-12T18:27:21Z
0,2017-04-12T18:38:58Z,5540,[],BI 836858 + Decitabine,2017-04-12T18:38:58Z
0,2016-02-23T21:34:21Z,3599,"[{'description': 'BI 853520 is an inhibitor of PTK2 (FAK), which has demonstrated anti-tumor activity, including tumor growth inhibition and regression (Mol Cancer Ther November 2011 10; A249).', 'references': [{'id': 4672, 'pubMedId': None, 'title': 'BI 853520, a potent and highly selective inhibitor of protein tyrosine kinase 2 (focal adhesion kinase), shows efficacy in multiple xenograft models of human cancer.', 'url': 'http://mct.aacrjournals.org/content/10/11_Supplement/A249.short'}]}]",BI 853520,2016-02-23T21:34:21Z
0,2016-03-10T20:04:54Z,3706,"[{'description': 'BI 882370 is a Raf kinase inhibitor with potent activity against the inactive conformation of Braf and may result in tumor regression (PMID: 26916115). ', 'references': [{'id': 4823, 'pubMedId': 26916115, 'title': 'A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26916115'}]}]",BI 882370,2016-03-10T20:04:54Z
0,2016-03-10T20:32:32Z,3712,[],BI 882370 + Afatinib,2016-03-10T20:32:32Z
0,2016-03-10T20:31:36Z,3711,[],BI 882370 + Cetuximab,2016-03-10T20:31:36Z
0,2016-03-10T20:13:46Z,3709,[],BI 882370 + Trametinib,2016-03-10T20:13:46Z
0,2016-05-25T14:46:40Z,4132,"[{'description': 'BI 885578 is a dual inhibitor of insulin like growth factor-1 receptor (IGF1R) and insulin receptor (INSR) that blocks downstream signaling and leads to growth inhibition in tumor cells (PMID: 26438154).', 'references': []}]",BI 885578,2016-05-25T14:46:40Z
0,2017-09-29T15:48:16Z,6262,"[{'description': 'Limited information is currently available on BI 891065 (Sep, 2017). ', 'references': [{'id': 285, 'pubMedId': None, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed'}, {'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",BI 891065,2017-09-29T15:51:09Z
0,2017-06-12T17:56:06Z,5884,"[{'description': 'BI 894999 is a bromodomain (BET) inhibitor with selective activity against BRD2/3/4 and BRDT, which may result in G1 arrest and apoptosis, and inhibition of tumor growth (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B79).', 'references': [{'id': 9104, 'pubMedId': None, 'title': 'Abstract B79: BI 894999, a novel BET inhibitor: Treatment of hematological malignancies by repression of super-enhancer driven oncogenes', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/B79.short'}]}]",BI 894999,2017-06-12T17:56:06Z
0,2015-12-19T20:41:17Z,3308,"[{'description': 'BI-69A11 binds to and inhibits the activity of Akt1 in the ATP binding pocket leading to inhibition of Akt signaling in cancer cells (PMID: 19175524).', 'references': [{'id': 4138, 'pubMedId': 19175524, 'title': 'BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19175524'}]}]",BI-69A11,2015-12-19T20:41:17Z
0,2014-05-14T14:52:46Z,1059,"[{'description': 'BI-847325 is a dual pan-MEK/Aurora inhibitor, with specific activity against MEK 1 and 2, and Aurora kinases A, B, and C (PMID: 27496137).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 6751, 'pubMedId': 27496137, 'title': 'Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27496137'}]}]",BI-847325,2017-04-21T20:14:08Z
0,2014-03-12T15:53:16Z,676,"[{'description': 'BI 2536 inhibits Polo-like kinase 1 (Plk1), which disrupts mitosis and induces apoptosis in tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BI2536,2015-11-19T17:04:15Z
0,2015-11-18T22:16:24Z,3223,[],BI2536 + Metformin,2015-11-18T22:16:24Z
0,2017-03-08T18:10:05Z,5423,[],BI2536 + PD-0325901,2017-03-08T18:10:05Z
0,2017-03-08T18:07:09Z,5422,[],BI2536 + PLX4720,2017-03-08T18:07:09Z
0,2016-08-08T16:53:43Z,4537,"[{'description': 'BI8622 is a small molecule that inhibits the ubiquitin ligase HUWE1, which results in decreased transactivation of Myc target genes and potentially leads to decreased tumor cell growth (PMID: 25253726).', 'references': [{'id': 6447, 'pubMedId': 25253726, 'title': 'Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25253726'}]}]",BI8622,2016-08-08T16:53:43Z
0,2016-08-08T16:56:22Z,4538,"[{'description': 'BI8626 is a small molecule that inhibits the ubiquitin ligase HUWE1, which results in decreased transactivation of Myc target genes and potentially leads to decreased tumor cell growth (PMID: 25253726).', 'references': [{'id': 6447, 'pubMedId': 25253726, 'title': 'Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25253726'}]}]",BI8626,2016-08-08T16:56:22Z
0,2014-09-19T04:31:02Z,1507,"[{'description': 'Casodex (bicalutamide) is an androgen-receptor antagonist that binds androgen receptors and inhibits androgen binding (NCI Drug Dictionary). Casodex (bicalutamide) is approved, in combination with a luteinizing hormone-releasing hormone (LHRH) analog, for metastatic carcinoma of the prostate (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Bicalutamide,2015-02-27T17:13:33Z
0,2017-03-16T03:18:25Z,5450,[],Bicalutamide + Docetaxel + Flutamide + Goserelin + Leuprolide + Nilutamide,2017-03-21T20:25:31Z
0,2016-04-15T18:06:21Z,3945,[],Bicalutamide + Docetaxel + Leuprolide,2016-04-15T18:06:21Z
0,2016-04-19T16:24:18Z,3952,[],Bicalutamide + Everolimus,2016-04-19T16:24:18Z
0,2017-03-16T03:16:34Z,5449,[],Bicalutamide + Flutamide + Goserelin + Leuprolide + Nilutamide,2017-03-21T20:24:55Z
0,2017-05-22T19:53:06Z,5742,[],Bicalutamide + Gonadorelin,2017-05-22T19:53:06Z
0,2015-12-03T15:11:29Z,3252,[],Bicalutamide + Palbociclib,2015-12-03T15:11:29Z
0,2016-08-29T13:15:39Z,4618,[],Bicalutamide + Ra 223,2016-08-29T13:15:39Z
0,2015-06-03T17:30:40Z,2766,"[{'description': 'BIIB021 is a synthetic HSP90 inhibitor, which may lead to increased tumor cell death and decreased tumor growth (PMID: 19372565).\r\n', 'references': [{'id': 2914, 'pubMedId': 19372565, 'title': 'BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19372565'}]}]",BIIB021,2015-06-03T17:30:40Z
0,2014-03-12T15:53:16Z,679,"[{'description': 'BIIB022 is a monoclonal antibody that binds IGF-1R, preventing binding of IGF-1 and IGF-2, thereby resulting in decreased pathway activation and potentially leading to decreased tumor growth (PMID: 24458261).', 'references': [{'id': 2860, 'pubMedId': 24458261, 'title': 'A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24458261'}]}]",BIIB022,2015-06-02T13:14:56Z
0,2016-02-26T19:11:22Z,3640,"[{'description': 'BIND-014 is a docetaxel-containing nanoparticle targeted to prostate-specific membrane antigen (PSMA) that gradually releases docetaxel, resulting in tumor cell death (PMID: 26847057).', 'references': [{'id': 4716, 'pubMedId': 26847057, 'title': 'Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26847057'}]}]",BIND-014,2016-03-11T18:49:24Z
0,2014-03-12T15:53:16Z,807,"[{'description': 'Binimetinib (MEK162) inhibits MEK1 and MEK2 resulting in inhibition of growth factor-mediated signaling and decreased tumor cell proliferation (PMID: 23587417). ', 'references': [{'id': 1838, 'pubMedId': 23587417, 'title': 'MEK and the inhibitors: from bench to bedside.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23587417'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Binimetinib,2017-05-16T15:09:11Z
0,2017-03-01T19:53:08Z,5400,[],Binimetinib + BKM120,2017-03-01T19:53:08Z
0,2016-10-30T20:13:03Z,4886,[],Binimetinib + Cetuximab + LGX818,2016-10-30T20:13:03Z
0,2015-05-29T03:34:42Z,2740,[],Binimetinib + Docetaxel,2015-05-29T03:34:42Z
0,2014-07-25T18:26:07Z,1100,[],Binimetinib + Encorafenib,2017-06-14T18:56:01Z
0,2014-07-25T18:26:49Z,1101,[],Binimetinib + Encorafenib + Ribociclib,2017-06-14T18:52:30Z
0,2016-11-29T19:31:04Z,5022,[],Binimetinib + Everolimus,2016-11-29T19:31:04Z
0,2015-12-03T02:45:04Z,3247,[],Binimetinib + FOLFIRI,2015-12-03T02:45:04Z
0,2017-10-17T18:10:37Z,6326,[],Binimetinib + Ipilimumab + Nivolumab,2017-10-17T18:10:37Z
0,2017-10-17T18:10:00Z,6325,[],Binimetinib + Nivolumab,2017-10-17T18:10:00Z
0,2017-06-02T15:07:01Z,5838,[],Binimetinib + Palbociclib,2017-06-02T15:07:01Z
0,2017-04-23T19:50:06Z,5568,[],Binimetinib + Pembrolizumab,2017-04-23T19:50:06Z
0,2017-05-20T19:53:07Z,5730,[],Binimetinib + PLX3397,2017-05-20T19:53:07Z
0,2014-01-20T22:51:07Z,5,[],Binimetinib + Ribociclib,2017-05-15T18:01:18Z
0,2016-06-15T18:17:40Z,4288,"[{'description': 'BIRB-796 is an oral inhibitor of P38 MAPK that enhances cytotoxicity of other anti-tumor agents (PMID: 17173546).', 'references': []}]",BIRB-796,2016-06-15T18:17:40Z
0,2016-06-15T18:18:43Z,4289,[],BIRB-796 + Dasatinib,2016-06-15T18:18:43Z
0,2017-05-05T03:00:00Z,5614,[],BIRB-796 + Tozasertib,2017-05-05T03:00:00Z
0,2015-05-08T14:48:24Z,2647,"[{'description': 'TL32711 (Birinapant) is a a bivalent SMAC-mimetic compound, which binds to and inhibits Inhibitor of Apoptosis proteins (IAPs), leading to tumor cell death (PMID: 24563541)', 'references': [{'id': 2673, 'pubMedId': 24563541, 'title': 'Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24563541'}]}]",Birinapant  ,2017-09-25T19:09:13Z
0,2017-09-05T13:49:11Z,6160,[],Birinapant  + Pembrolizumab,2017-09-05T13:49:11Z
0,2016-11-14T16:38:21Z,4953,[],Birinapant + Radiotherapy,2016-11-14T16:38:21Z
0,2015-01-04T01:15:27Z,1897,[],Bisoprolol,2015-01-04T01:15:27Z
0,2015-06-23T19:34:47Z,2862,"[{'description': 'BIX-01294 is a small molecule inhibitor of EHMT2, which may result in inhibition of cellular proliferation and induction of apoptosis via caspase 8 and caspase 3 activation (PMID: 25685062). ', 'references': [{'id': 3117, 'pubMedId': 25685062, 'title': 'EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25685062'}]}]",BIX-01294,2015-08-10T15:48:22Z
0,2014-03-12T15:53:16Z,680,"[{'description': 'Buparlisib (BKM120) specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, and may result in apoptotic activity and inhibition of cell proliferation (PMID: 22188813).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 156, 'pubMedId': 22188813, 'title': 'Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22188813'}]}]",BKM120,2017-04-18T14:55:44Z
0,2014-08-05T07:41:46Z,1367,[],BKM120 + Abraxane,2014-08-05T07:41:46Z
0,2015-08-13T17:02:42Z,3019,[],BKM120 + AG490,2015-08-13T17:02:57Z
0,2014-07-28T18:59:56Z,1178,[],BKM120 + Bevacizumab,2014-10-15T13:55:04Z
0,2016-09-30T02:36:19Z,4772,[],BKM120 + BLZ945,2016-09-30T02:36:19Z
0,2016-10-24T19:38:22Z,4856,[],BKM120 + BMS-777607 ,2016-10-24T19:38:22Z
0,2014-09-25T15:21:12Z,1536,[],BKM120 + Capecitabine,2014-09-25T15:21:12Z
0,2014-09-25T15:24:13Z,1538,[],BKM120 + Capecitabine + Lapatinib,2014-09-25T15:24:13Z
0,2014-09-25T15:22:35Z,1537,[],BKM120 + Capecitabine + Trastuzumab,2014-09-25T15:22:35Z
0,2015-04-07T03:26:38Z,2501,[],BKM120 + Carboplatin,2015-04-07T03:26:38Z
0,2014-07-28T20:27:45Z,1183,[],BKM120 + Carboplatin + Paclitaxel,2014-07-28T20:27:45Z
0,2016-02-18T15:43:14Z,3548,[],BKM120 + Cetuximab,2016-02-18T15:43:14Z
0,2014-10-30T17:03:18Z,1691,[],BKM120 + Cisplatin,2014-10-30T17:03:18Z
0,2014-07-31T21:34:18Z,1330,[],BKM120 + Docetaxel,2014-07-31T21:34:18Z
0,2016-03-17T13:46:32Z,3764,[],BKM120 + Doxorubicin,2016-03-17T13:46:32Z
0,2014-07-31T18:29:05Z,1319,[],BKM120 + Erlotinib,2014-07-31T18:29:05Z
0,2014-10-07T20:38:48Z,1626,[],BKM120 + Etoposide + Cisplatin,2014-10-07T20:38:48Z
0,2014-07-31T17:31:52Z,1314,[],BKM120 + Everolimus,2014-09-25T17:19:58Z
0,2015-03-06T15:28:49Z,2315,[],BKM120 + Fulvestrant + LEE011,2015-03-06T15:28:49Z
0,2014-07-31T09:17:53Z,1304,[],BKM120 + Gemcitabine + Cisplatin,2014-07-31T09:17:53Z
0,2016-02-26T16:54:41Z,3630,[],BKM120 + Ibrutinib,2016-02-26T16:54:41Z
0,2015-03-26T12:49:13Z,2461,[],BKM120 + INC280,2015-03-26T12:49:13Z
0,2014-09-30T18:48:27Z,1570,[],BKM120 + Letrozole,2014-09-30T18:48:27Z
0,2017-07-27T15:49:07Z,6009,[],BKM120 + LJM716,2017-07-27T15:49:07Z
0,2015-04-07T03:25:52Z,2500,[],BKM120 + Lomustine,2015-04-07T03:25:52Z
0,2016-12-19T19:55:00Z,5105,[],BKM120 + Navitoclax,2017-08-01T16:04:28Z
0,2016-02-26T16:53:50Z,3629,[],BKM120 + Ofatumumab,2016-02-26T16:53:50Z
0,2015-02-26T15:21:11Z,2170,[],BKM120 + Olaparib,2015-02-26T15:21:11Z
0,2017-06-28T16:47:45Z,5935,[],BKM120 + Osimertinib,2017-06-28T16:47:45Z
0,2014-09-25T17:20:33Z,1545,[],BKM120 + Paclitaxel,2014-09-25T17:20:56Z
0,2015-01-29T16:45:54Z,1990,[],BKM120 + Panitumumab,2015-01-29T16:45:54Z
0,2017-02-07T19:48:02Z,5289,[],BKM120 + Panobinostat,2017-02-07T19:48:02Z
0,2014-07-27T18:27:41Z,1112,[],BKM120 + Pemetrexed + Carboplatin,2014-07-27T18:27:41Z
0,2017-07-27T16:08:46Z,6010,[],BKM120 + Pertuzumab,2017-07-27T16:08:46Z
0,2015-04-07T03:30:22Z,2502,[],BKM120 + Rituximab,2015-04-07T03:30:22Z
0,2016-09-06T19:13:14Z,4652,[],BKM120 + Selumetinib,2016-09-06T19:13:14Z
0,2014-09-25T18:13:11Z,1547,[],BKM120 + Sonidegib,2017-06-19T19:28:39Z
0,2016-07-19T01:36:06Z,4474,[],BKM120 + Temozolomide,2016-07-19T01:36:06Z
0,2015-01-25T01:26:23Z,1974,[],BKM120 + Trametinib,2015-01-25T01:26:23Z
0,2014-08-31T16:12:46Z,1417,[],BKM120 + Trastuzumab,2014-08-31T16:12:46Z
0,2014-08-31T16:28:52Z,1419,[],BKM120 + Trastuzumab + Lapatinib,2014-08-31T16:28:52Z
0,2014-08-31T16:26:54Z,1418,[],BKM120 + Trastuzumab + Pertuzumab,2014-08-31T16:26:54Z
0,2014-07-31T19:17:38Z,1322,[],BKM120 + Vemurafenib,2014-07-31T19:17:38Z
0,2016-12-19T20:01:26Z,5107,[],BKM120 + Venetoclax,2016-12-19T20:01:26Z
0,2017-02-28T17:14:23Z,5382,[],BKM120 + WEHI-539,2017-02-28T17:14:37Z
0,2015-06-18T20:36:30Z,2849,"[{'description': 'BKT140 is a selective CXCR4 antagonist, which may lead to decreased tumor growth (PMID: 21138752).', 'references': [{'id': 3086, 'pubMedId': 21138752, 'title': 'CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21138752'}]}]",BKT140,2015-06-25T20:59:34Z
0,2015-11-01T20:42:03Z,3168,[],BKT140 + Cytarabine,2015-11-01T20:42:03Z
0,2016-06-11T17:02:15Z,4275,[],BKT140 + Nelarabine,2016-06-11T17:02:15Z
0,2016-09-25T15:24:43Z,4757,[],BKT140 + Pembrolizumab,2016-09-25T15:24:43Z
0,2014-07-28T12:18:56Z,1137,[],Bleomycin,2014-07-28T12:18:56Z
0,2016-08-08T18:56:02Z,4546,[],Bleomycin + CBP501,2016-08-08T18:56:02Z
0,2017-02-09T15:49:07Z,5295,[],Bleomycin + Dacarbazine + Doxorubicin + Vinblastine + Nivolumab,2017-02-09T15:49:07Z
0,2014-12-31T03:42:56Z,1876,"[{'description': 'Blincyto (blinatumomab) is a bispecific antibody that binds both CD19 on B-cells and the CD3 complex on T-cells, therefore facilitates T-cell mediated killing of CD19-expressing tumor cells (PMID: 26337639). Blincyto (blinatumomab) is FDA approved for the treatment of B-cell precursor acute lymphoblastic leukemia (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 9652, 'pubMedId': 26337639, 'title': 'Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26337639'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Blinatumomab ,2017-08-01T20:19:46Z
0,2017-09-01T20:19:05Z,6155,[],Blinatumomab + Cytarabine + Dexamethasone + Methotrexate + Ponatinib,2017-09-01T20:19:05Z
0,2017-09-01T20:20:14Z,6156,[],Blinatumomab + Dexamethasone + Ponatinib,2017-09-01T20:20:14Z
0,2016-12-28T02:14:04Z,5125,[],Blinatumomab + Ibrutinib,2016-12-28T02:14:04Z
0,2016-08-28T20:19:08Z,4613,[],Blinatumomab + Ipilimumab + Nivolumab,2016-08-28T20:19:08Z
0,2017-06-02T15:20:04Z,5839,[],Blinatumomab + Pembrolizumab,2017-06-02T15:20:04Z
0,2015-07-21T17:16:31Z,2941,"[{'description': 'BLU-285 is a selective inhibitor of PDGFRA D842V and KIT exon 17 mutants, including KIT D816V, potentially resulting in decreased tumor growth (AACR; 2015. Abstract nr 791).', 'references': [{'id': 3289, 'pubMedId': None, 'title': 'BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants', 'url': 'http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424'}]}]",BLU-285,2016-09-30T15:37:42Z
0,2015-10-30T16:24:37Z,3165,"[{'description': 'BLU-554 binds to and inhibits FGFR4, potentially resulting in decreased proliferation of FGFR4-expressing tumor cells (European Journal of Cancer, Dec 2016, Vol 69, Suppl 1, S41).', 'references': [{'id': 8833, 'pubMedId': None, 'title': 'First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation', 'url': 'http://www.sciencedirect.com/science/article/pii/S0959804916327046?via%3Dihub'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BLU-554,2017-05-08T15:29:04Z
0,2017-04-12T17:32:41Z,5530,"[{'description': 'BLU-667 inhibits mutant RET and RET fusions, which may result in decreased tumor growth (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BLU-667,2017-04-12T17:32:41Z
0,2015-04-08T15:26:01Z,2509,"[{'description': 'BLU9931 is a selective FGFR4 inhibitor which inhibits activation and blocks cell proliferation and tumor growth (PMID: 25776529).', 'references': [{'id': 2415, 'pubMedId': 25776529, 'title': 'First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25776529'}]}]",BLU9931,2015-04-08T15:26:01Z
0,2015-06-18T17:57:14Z,2844,"[{'description': 'BLZ945 is a selective inhibitor of CSF1R, which potentially leads to a decrease in tumor associated macrophages (PMID: 24498562).', 'references': [{'id': 3081, 'pubMedId': 24498562, 'title': 'CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24498562'}]}]",BLZ945,2015-06-18T17:57:14Z
0,2016-09-30T03:05:17Z,4773,[],BLZ945 + Linsitinib,2016-09-30T03:05:17Z
0,2016-12-08T17:13:56Z,5071,[],BLZ945 + PDR001,2016-12-08T17:13:56Z
0,2015-12-11T14:49:31Z,3283,"[{'description': 'BM-1197 is a dual inhibitor of BCL2 and BCL-XL, which may result in increased apoptosis and decreased tumor growth (PMID: 24901320).', 'references': [{'id': 4093, 'pubMedId': 24901320, 'title': 'BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24901320'}]}]",BM-1197,2015-12-11T14:49:31Z
0,2014-03-12T15:53:16Z,683,"[{'description': 'BMS-536924 is an ATP-competitive inhibitor of IGF-1R and IR, which induces tumor cell apoptosis and decreases tumor growth (PMID: 25897243).', 'references': [{'id': 2856, 'pubMedId': 25897243, 'title': 'BMS-536924, an ATP-competitive IGF-1R/IR inhibitor, decreases viability and migration of temozolomide-resistant glioma cells in vitro and suppresses tumor growth in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25897243'}]}]",BMS-536924,2015-05-29T04:14:10Z
0,2015-06-11T18:38:09Z,2819,"[{'description': 'BMS-641988 is an androgen receptor (AR) antagonist, which inhibits AR  signaling, resulting in decreased tumor growth (PMID: 19654297).', 'references': [{'id': 3018, 'pubMedId': 19654297, 'title': 'Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19654297'}]}]",BMS-641988,2015-06-11T18:38:09Z
0,2014-03-12T15:53:16Z,685,"[{'description': 'BMS-690514 is a pan-EGFR/VEGFR inhibitor, which may result in increased tumor cell apoptosis, and decreased tumor cell proliferation and angiogenesis (PMID: 21531814, PMID: 17616683).', 'references': [{'id': 1826, 'pubMedId': 17616683, 'title': 'A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17616683'}, {'id': 1825, 'pubMedId': 21531814, 'title': 'Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21531814'}]}]",BMS-690514,2015-03-24T15:06:16Z
0,2014-03-12T15:53:16Z,686,"[{'description': 'BMS-754807 is a multi-kinase inhibitor with activity against IGF-1R, insulin receptor, MET, ALK, TRKA, and TRKB, potentially resulting in decreased tumor cell proliferation (PMID: 25748921).', 'references': [{'id': 2717, 'pubMedId': 25748921, 'title': 'A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25748921'}]}]",BMS-754807,2016-01-14T14:10:21Z
0,2016-04-27T14:55:32Z,4009,[],BMS-754807 + Dacomitinib,2016-04-27T14:55:32Z
0,2017-02-28T16:33:52Z,5379,[],BMS-754807 + Midostaurin,2017-02-28T16:33:52Z
0,2016-11-23T17:43:28Z,5007,[],BMS-754807 + SCH772984,2016-11-23T17:43:28Z
0,2014-03-12T15:53:16Z,687,"[{'description': 'BMS-777607 (ASLAN002) is a small molecule that inhibits c-MET, MST1R (RON), and AXL, resulting in decreased downstream pathway activation, potentially resulting in decreased tumor cell growth and metastasis (PMID: 20515943, PMID: 24233399, PMID: 26555154).', 'references': [{'id': 2000, 'pubMedId': 20515943, 'title': 'BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20515943'}]}]",BMS-777607,2017-03-16T13:58:31Z
0,2017-06-19T13:15:19Z,5902,"[{'description': 'BMS-813160 inhibits both CCR2 and CCR5, potentially modulates immune response (PMID: 21936726).', 'references': [{'id': 9165, 'pubMedId': 21936726, 'title': 'A dual CCR2/CCR5 chemokine antagonist, BMS-813160? Evaluation of WO2011046916.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21936726'}]}]",BMS-813160,2017-06-19T13:15:19Z
0,2017-06-19T13:20:31Z,5905,[],BMS-813160 + Fluorouracil + Irinotecan + Leucovorin,2017-06-19T13:20:31Z
0,2017-06-19T13:17:40Z,5904,[],BMS-813160 + Gemcitabine + nab-paclitaxel,2017-06-19T13:17:40Z
0,2017-06-19T13:16:27Z,5903,[],BMS-813160 + Nivolumab,2017-06-19T13:16:27Z
0,2015-03-17T01:29:56Z,2415,"[{'description': 'BMS-833923 (XL139) is a small molecule Smoothened (SMO) antagonist, which may inhibit downstream Hedgehog pathway signaling resulting in reduced tumor cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BMS-833923,2016-02-24T12:07:07Z
0,2015-07-24T02:12:03Z,2957,"[{'description': 'BMS-871 is a pan-NOTCH inhibitor, which may limit growth and survival of cancer cells (PMID: 25857941).', 'references': [{'id': 3324, 'pubMedId': 25857941, 'title': 'BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agent.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25857941'}]}]",BMS-871,2015-07-24T02:12:03Z
0,2015-04-17T17:11:52Z,2545,"[{'description': 'BMS-906024 is a pan-NOTCH inhibitor, which may limit growth and survival of cancer cells (Am Soc Hematology: December 6, 2014; Volume 124, Issue 21, Abstract #968).', 'references': [{'id': 2503, 'pubMedId': None, 'title': 'The Safety and Activity of BMS-906024, a Gamma Secretase Inhibitor (GSI) with Anti-Notch Activity, in Patients with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): Initial Results of a Phase 1 Trial', 'url': 'https://ash.confex.com/ash/2014/webprogram/Paper70285.html'}]}]",BMS-906024,2015-04-27T15:55:25Z
0,2015-06-03T21:29:37Z,2779,"[{'description': 'BMS-911543 is an ATP-competitive inhibitor of JAK2, which decreases cell proliferation (PMID: 22015772).', 'references': [{'id': 2934, 'pubMedId': 22015772, 'title': 'Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22015772'}]}]",BMS-911543,2015-06-08T17:19:31Z
0,2015-12-28T19:42:13Z,3339,"[{'description': 'BMS-936559 is a PD-1 human monoclonal antibody, which blocks the binding of PD-L1 resulting in a T-cell mediated immune response and possible tumor regression (PMID: 22658128). ', 'references': [{'id': 4175, 'pubMedId': 22658128, 'title': 'Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22658128'}]}]",BMS-936559,2016-01-28T02:25:30Z
0,2016-08-07T17:10:09Z,4534,"[{'description': 'BMS-986012 is a monoclonal antibody that binds to the ganglioside fucosyl-GM1, which may lead to anti-tumor immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BMS-986012,2016-08-07T17:10:09Z
0,2016-08-14T16:43:37Z,4564,[],BMS-986012 + Carboplatin + Etoposide,2016-08-14T16:43:37Z
0,2016-08-14T16:42:51Z,4563,[],BMS-986012 + Cisplatin + Etoposide,2016-08-14T16:42:51Z
0,2016-08-07T17:11:47Z,4535,[],BMS-986012 + Nivolumab,2016-08-07T17:11:47Z
0,2016-06-02T18:13:29Z,4196,"[{'description': 'BMS-986016 is a monoclonal antibody that binds to lymphocyte activation gene-3 (LAG-3), potentially resulting in induction of T-lymphocyte killing of tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BMS-986016,2016-06-03T18:28:58Z
0,2016-06-02T18:14:25Z,4197,[],BMS-986016 + Nivolumab,2016-06-02T18:14:25Z
0,2016-11-06T22:02:47Z,4923,"[{'description': 'BMS-986148 is a a monoclonal antibody against mesothelin in conjugation with an undisclosed cytotoxic drug, which may results in cytotoxic effects in of mesothelin-expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BMS-986148,2016-11-06T22:02:47Z
0,2016-11-06T22:03:44Z,4924,[],BMS-986148 + Nivolumab,2016-11-06T22:03:44Z
0,2016-02-19T14:45:50Z,3559,"[{'description': 'Limited information is currently available on BMS-986156 (Feb, 2016). ', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",BMS-986156,2016-02-25T16:59:09Z
0,2016-04-29T18:58:55Z,4030,"[{'description': 'Limited information is currently available on BMS-986178 (Apr, 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",BMS-986178,2016-04-29T18:58:55Z
0,2016-06-02T18:07:35Z,4194,"[{'description': 'Limited information is currently available on BMS-986179 (Jun, 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",BMS-986179,2016-06-02T18:07:35Z
0,2016-06-02T18:08:25Z,4195,[],BMS-986179 + Nivolumab,2016-06-02T18:08:25Z
0,2017-05-05T19:29:36Z,5628,"[{'description': 'Limited information is currently available on BMS-986183 (May 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",BMS-986183,2017-05-05T19:29:36Z
0,2017-05-05T19:30:52Z,5629,[],BMS-986183 + Nivolumab,2017-05-05T19:30:52Z
0,2016-02-19T15:16:32Z,3568,"[{'description': 'Limited information is currently available on BMS-986205 (Feb, 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",BMS-986205,2016-02-25T17:34:06Z
0,2016-02-19T15:17:18Z,3569,[],BMS-986205 + Nivolumab,2016-02-19T15:17:18Z
0,2016-10-30T20:19:09Z,4887,"[{'description': 'Limited information is currently available on BMS-986207 (Oct 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",BMS-986207 ,2016-10-30T20:19:09Z
0,2016-10-30T20:20:12Z,4888,[],BMS-986207 + Nivolumab,2016-10-30T20:20:12Z
0,2017-04-17T20:56:34Z,5551,"[{'description': 'Limited information is currently available on BMS-986218 (April, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",BMS-986218,2017-04-17T20:56:34Z
0,2017-04-17T20:57:40Z,5552,[],BMS-986218 + Nivolumab,2017-04-17T20:57:40Z
0,2017-08-21T17:36:02Z,6134,"[{'description': 'Limited information is currently available on BMS-986226 (Aug, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",BMS-986226,2017-08-21T17:36:02Z
0,2017-08-21T17:37:14Z,6135,[],BMS-986226 + Ipilimumab,2017-08-21T17:37:14Z
0,2017-08-21T17:38:47Z,6136,[],BMS-986226 + Nivolumab,2017-08-21T17:38:47Z
0,2015-12-02T20:04:45Z,3245,"[{'description': 'BMS753493 consists of folate linked to the anti-microtubule agent epothilone, which targets the drug to folate receptor-expressing cells, resulting in cell death (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BMS753493,2015-12-02T20:04:45Z
0,2015-06-10T09:41:06Z,2811,"[{'description': 'BMS986158 is BET inhibitor, which interferes with chromatin remodeling to prevent gene expression and tumor growth (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BMS986158,2015-06-10T09:41:06Z
0,2017-06-01T14:33:42Z,5829,"[{'description': 'BMX-001 is a human mitochondrial manganese superoxide dismutase (MnSOD) mimetic that clears reactive oxygen species upon cellular internalization, thereby potentially reducing the degree of chemotoxicity within healthy tissue (NCI Drug Dictionary). ', 'references': []}]",BMX-001,2017-06-01T14:33:42Z
0,2017-06-02T16:47:18Z,5840,[],BMX-001 + Cisplatin,2017-06-02T16:47:18Z
0,2017-06-02T16:51:17Z,5841,[],BMX-001 + Temozolomide,2017-06-02T16:51:17Z
0,2014-03-12T15:53:16Z,688,"[{'description': 'Velcade (bortezomib) inhibits cellular proteasome activity, thereby altering multiple signaling pathways and induces cytotoxicity and apoptosis. Velcade (bortezomib) also inactivates the NF-kB pathway in various cancers (PMID: 20530581). Velcade (bortezomib) is FDA approved for the treatment of relapsed and refractory mantle cell lymphoma and refractory multiple myeloma (FDA.gov).', 'references': [{'id': 1487, 'pubMedId': 20530581, 'title': 'PRDM1 is required for mantle cell lymphoma response to bortezomib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20530581'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Bortezomib,2016-09-01T20:58:27Z
0,2014-10-07T20:31:32Z,1625,[],Bortezomib + Carfilzomib + Clarithromycin,2014-10-07T20:31:32Z
0,2016-01-10T22:46:11Z,3394,[],Bortezomib + Cladribine + Rituximab,2016-01-10T22:46:11Z
0,2015-08-28T01:09:13Z,3063,[],Bortezomib + Clofarabine,2015-08-28T01:09:13Z
0,2017-03-17T01:58:15Z,5460,[],Bortezomib + Cyclophosphamide,2017-03-17T01:58:15Z
0,2016-11-13T22:08:30Z,4951,[],Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone,2016-11-13T22:08:30Z
0,2017-03-17T01:56:08Z,5459,[],Bortezomib + Cyclophosphamide + G-CSF,2017-03-17T01:56:08Z
0,2015-12-31T19:32:22Z,3358,[],Bortezomib + Cyclophosphamide + lenalidomide,2015-12-31T19:32:22Z
0,2016-01-21T21:53:13Z,3434,[],Bortezomib + Cyclosporine + Mycophenolate,2016-01-21T21:53:13Z
0,2016-12-14T21:09:49Z,5100,[],Bortezomib + Daratumumab + Dexamethasone,2016-12-14T21:09:49Z
0,2015-03-26T14:36:45Z,2470,[],Bortezomib + Dexamethasone,2015-03-26T14:36:45Z
0,2016-01-21T22:15:28Z,3437,[],Bortezomib + Dexamethasone + Dinaciclib,2016-01-21T22:15:28Z
0,2016-04-29T19:08:20Z,4031,[],Bortezomib + Dexamethasone + Elotuzumab + Panobinostat,2016-04-29T19:08:20Z
0,2016-01-21T22:13:16Z,3436,[],Bortezomib + Dexamethasone + GDC-0199	,2016-01-21T22:13:16Z
0,2015-12-29T15:43:08Z,3342,[],Bortezomib + Dexamethasone + lenalidomide,2015-12-29T15:43:08Z
0,2016-01-06T13:25:14Z,3362,[],Bortezomib + Dexamethasone + lenalidomide + Panobinostat,2016-01-06T13:25:14Z
0,2017-01-19T19:39:08Z,5231,[],Bortezomib + Dexamethasone + LGH447,2017-01-19T19:39:08Z
0,2016-07-27T02:14:03Z,4501,[],Bortezomib + Dexamethasone + Pomalidomide,2016-07-27T02:14:03Z
0,2017-09-05T14:46:33Z,6161,[],Bortezomib + Dexamethasone + radium Ra 223 dichloride,2017-09-05T14:46:33Z
0,2016-01-21T21:26:20Z,3432,[],Bortezomib + Dexamethasone + Reolysin,2016-01-21T21:26:20Z
0,2016-02-19T14:20:28Z,3556,[],Bortezomib + Dexamethasone + Ulocuplumab,2016-02-19T14:20:28Z
0,2016-06-04T22:04:39Z,4240,[],Bortezomib + Duvelisib,2017-05-15T18:37:27Z
0,2017-08-11T16:25:31Z,6105,[],Bortezomib + EDO-S101,2017-08-11T16:25:31Z
0,2016-08-07T16:58:32Z,4533,[],Bortezomib + Elotuzumab + Dexamethasone + lenalidomide,2016-08-07T16:58:32Z
0,2015-03-02T15:14:05Z,2234,[],Bortezomib + Everolimus,2015-03-02T15:14:05Z
0,2014-12-12T21:02:21Z,1778,[],bortezomib + fasudil,2014-12-12T21:02:21Z
0,2015-12-29T16:12:03Z,3345,[],Bortezomib + Filgrastim,2015-12-29T16:12:03Z
0,2015-03-05T14:44:45Z,2288,[],Bortezomib + Fludarabine + Melphalan,2015-03-05T14:44:45Z
0,2016-01-21T19:05:39Z,3427,[],Bortezomib + GO-203-2C,2016-01-21T19:05:39Z
0,2015-11-16T18:21:56Z,3220,[],Bortezomib + lenalidomide,2015-11-16T18:21:56Z
0,2016-09-01T20:51:48Z,4642,[],Bortezomib + Lenalidomide + PAT-SM6,2016-09-01T20:51:48Z
0,2016-09-06T20:23:31Z,4655,[],Bortezomib + Midostaurin + MEC,2016-09-06T20:23:31Z
0,2015-08-28T01:23:38Z,3064,[],Bortezomib + Oxaliplatin,2015-08-28T01:23:38Z
0,2016-03-22T18:29:18Z,3811,[],Bortezomib + Panobinostat,2016-03-22T18:29:18Z
0,2015-11-06T02:23:45Z,3184,[],Bortezomib + pegylated liposomal-doxorubicin,2015-11-06T02:23:45Z
0,2015-12-29T16:36:17Z,3348,[],Bortezomib + Plerixafor,2015-12-29T16:36:17Z
0,2015-11-08T22:04:30Z,3191,[],Bortezomib + Pravastatin,2015-11-08T22:04:30Z
0,2015-12-03T20:05:19Z,3262,[],Bortezomib + Ruxolitinib,2015-12-03T20:05:19Z
0,2017-08-03T16:18:26Z,6079,[],Bortezomib + SJB3-019A,2017-08-03T16:18:26Z
0,2015-01-16T15:26:54Z,1954,[],Bortezomib + Sonidegib,2017-06-19T19:30:10Z
0,2014-12-18T14:34:20Z,1793,[],Bortezomib + Sorafenib + Decitabine   ,2014-12-18T14:34:20Z
0,2015-03-12T13:55:33Z,2366,[],Bortezomib + Sorafenib + vorinostat,2015-03-12T13:55:33Z
0,2016-12-05T17:20:21Z,5062,[],Bortezomib + Tapalumab,2016-12-05T17:20:21Z
0,2015-08-27T00:48:27Z,3055,[],Bortezomib + Temozolomide,2015-08-27T00:48:27Z
0,2015-10-16T15:05:30Z,3134,[],Bortezomib + Temsirolimus + Topotecan,2015-10-16T15:05:30Z
0,2016-03-03T16:45:21Z,3671,[],Bortezomib + Torkinib,2017-07-07T18:43:33Z
0,2016-03-22T18:27:51Z,3810,[],Bortezomib + Vorinostat,2016-03-22T18:27:51Z
0,2014-03-12T15:53:16Z,690,"[{'description': 'Bosulif (bosutinib) inhibits SRC and ABL kinases, and has additional activity against other kinases including AXL, TNK2, BTK, resulting in decreased pathway activation and inhibition of tumor cell proliferation (PMID: 12543790, PMID: 19039322, PMID: 26555154). Bosulif (bosutinib) is FDA approved for use in patients with Ph+ chronic myelogenous leukemia (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 1917, 'pubMedId': 12543790, 'title': 'SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12543790'}]}]",Bosutinib,2016-12-22T15:05:21Z
0,2016-11-29T17:58:24Z,5021,[],Bosutinib + Cisplatin,2016-11-29T17:58:24Z
0,2016-11-29T17:57:16Z,5020,[],Bosutinib + Gemcitabine,2016-11-29T17:57:16Z
0,2015-11-09T01:40:53Z,3200,[],Bosutinib + inotuzumab ozogamicin,2015-11-09T01:40:53Z
0,2017-01-20T05:01:38Z,5237,[],Bosutinib + Pemetrexed,2017-01-20T05:01:38Z
0,2016-03-10T15:47:00Z,3703,"[{'description': 'BP-1-108 is a small molecule that inhibits STAT5, resulting in decreased downstream signaling and potentially leading to decreased growth of tumor cells with STAT5 activation (PMID: 22148584).', 'references': [{'id': 4812, 'pubMedId': 22148584, 'title': 'Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22148584'}]}]",BP-1-108,2016-03-10T15:47:00Z
0,2016-03-23T12:51:40Z,3822,"[{'description': 'Limited information is currently available on BPI-9016M, a putative MET/AXL inhibitor (Jul, 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",BPI-9016M,2016-07-20T13:16:57Z
0,2017-05-24T15:18:32Z,5759,"[{'description': 'BPM 31510 is a small molecule agent containing a formulation of co-enzyme Q10, thereby affecting metabolism via Warburg effect reversal and thus, potentially resulting in apoptotic activity of cancer cells (Cancer Res 2014;74(19 Suppl):Abstract nr 4321).', 'references': [{'id': 8974, 'pubMedId': None, 'title': 'Abstract 4321: Effect of pretreatment, dose and route of administration of BPM31510 (Coenyzme Q10 containing proprietary formulation) alone or in combination with gemcitabine improves survival in pancreatic cancer', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/4321.short'}]}]",BPM 31510,2017-06-02T17:04:02Z
0,2017-06-02T17:04:47Z,5842,[],BPM 31510 + Gemcitabine,2017-06-02T17:04:47Z
0,2016-10-06T13:27:12Z,4798,"[{'description': 'BPR1J373 is a derivative of 5-phenylthiazol-2-ylamine-pyriminide that inhibits multiple tyrosine kinases including KIT, FLT3, VEGFR1, 2, 3, PDGFR-alpha, PDGFR-beta, RET, and SRC, and may result in anti-tumor activity (PMID: 27512117). ', 'references': [{'id': 6711, 'pubMedId': 27512117, 'title': 'BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27512117'}]}]",BPR1J373,2017-04-03T11:34:57Z
0,2017-01-12T19:14:11Z,5194,"[{'description': 'BPTES is a small molecule that inhibits glutaminase, which results in decreased conversion of glutamine to glutamate, and potentially leads to decreased tumor cell growth (PMID: 21045145, PMID: 25915584).', 'references': [{'id': 7525, 'pubMedId': 21045145, 'title': 'Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21045145'}, {'id': 7526, 'pubMedId': 25915584, 'title': 'Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25915584'}]}]",BPTES,2017-01-12T19:14:51Z
0,2017-05-16T17:56:55Z,5677,[],BPTES + Olaparib,2017-05-16T17:56:55Z
0,2017-07-28T19:42:22Z,6053,"[{'description': 'BPX-501 comprises allogeneic T-cells transduced with a vector encoding inducible Casp9 that is linked to a drug binding domain, which enables induction of Casp9 with AP1903 if GVHD develops, resulting increased Casp9 expression and induction of T-cell death (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BPX-501,2017-07-28T19:42:22Z
0,2017-07-17T13:57:21Z,5995,"[{'description': 'BPX-601 are autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting human prostate stem cell antigen (PSCA) and the zeta chain of the T-cell receptor (TCRzeta), and a rimiducid-induced co-stimulatory molecule, which activates anti-tumor immune response (PMID: 27824842).', 'references': []}]",BPX-601,2017-07-17T13:57:21Z
0,2017-07-17T13:58:18Z,5996,[],BPX-601 + Rimiducid,2017-07-17T13:58:18Z
0,2017-07-14T17:25:37Z,5991,"[{'description': 'BPX-701 is an autologous T-cell therapy that targets HLA-A201, PRAME (preferentially-expressed antigen in melanoma), and contains a drug binding domain for caspase 9 initiation, thereby potentially inducing cell death (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BPX-701,2017-07-14T17:25:37Z
0,2017-07-14T17:46:36Z,5993,[],BPX-701 + Rimiducid,2017-07-14T17:46:36Z
0,2017-04-26T19:26:01Z,5574,"[{'description': 'BRD-7880 selectively inhibits Aurora kinase B and C, resulting in growth inhibition in tumor cells (PMID: 26928769).', 'references': [{'id': 8730, 'pubMedId': 26928769, 'title': 'High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26928769'}]}]",BRD-7880,2017-04-26T19:26:01Z
0,2014-11-29T20:15:48Z,1754,"[{'description': 'BRD4770 inhibits the histone methyltransferase EHMT2 (G9A), resulting in decreased H3K9 di- and trimethylation, decreased proliferation, cell cycle arrest, and cell senescence (PMID: 2536950).', 'references': [{'id': 1184, 'pubMedId': 2536950, 'title': 'Pharmacological studies of lappaconitine. Occurrence of analgesic effect without opioid receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/2536950'}]}]",BRD4770,2015-11-19T17:05:12Z
0,2015-03-31T15:22:05Z,2486,"[{'description': 'Brentuximab vedotin (SGN-35) is an antibody-drug conjugate comprised of a monoclonal antibody targeting CD30 linked to the tubulin-binding drug MMAE, which binds CD30-expressing cells and disrupts microtubule polymerization, potentially resulting in decreased tumor growth (PMID: 22684302).', 'references': [{'id': 2362, 'pubMedId': 22684302, 'title': 'Brentuximab vedotin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22684302'}]}]",Brentuximab vedotin,2017-06-19T19:23:25Z
0,2016-12-02T21:00:01Z,5055,[],Brentuximab vedotin + Bendamustine,2016-12-02T21:00:01Z
0,2016-05-27T15:02:55Z,4169,[],Brentuximab vedotin + Ceritinib,2016-05-27T15:02:55Z
0,2016-12-02T21:02:15Z,5056,[],Brentuximab vedotin + Dacarbazine,2016-12-02T21:02:15Z
0,2017-10-17T18:40:35Z,6328,[],Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine,2017-10-17T18:40:35Z
0,2016-06-17T18:56:11Z,4300,[],Brentuximab vedotin + Ibrutinib,2016-06-17T18:56:11Z
0,2015-04-03T12:14:45Z,2487,[],Brentuximab vedotin + Ipilimumab,2015-04-03T12:14:45Z
0,2015-12-03T20:46:34Z,3264,[],Brentuximab vedotin + Mocetinostat,2015-12-03T20:46:34Z
0,2015-12-03T20:38:41Z,3263,[],Brentuximab vedotin + Nivolumab,2015-12-03T20:38:41Z
0,2016-03-17T15:35:44Z,3770,[],Brentuximab vedotin + TGR-1202,2016-03-17T15:35:44Z
0,2014-05-14T14:52:46Z,996,"[{'description': 'Brivanib (BMS-540215) selectively binds and inhibits KDR (VEGFR2), while demonstrating moderate activity against VEGFR1 and FGFR1, which inhibits tumor angiogenesis, tumor cell growth, and induces tumor regression (PMID: 18829493, PMID: 16570908).', 'references': [{'id': 1857, 'pubMedId': 16570908, 'title': 'Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16570908'}, {'id': 1856, 'pubMedId': 18829493, 'title': 'Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829493'}]}]",Brivanib,2015-02-10T17:58:13Z
0,2014-03-12T15:53:16Z,839,"[{'description': 'Brontictuzumab (OMP-52M51) is a monoclonal antibody that binds Notch1 and prevents ligand interaction and pathway activation, which may inhibit angiogenesis and tumor growth (PMID: 23774673). ', 'references': [{'id': 2506, 'pubMedId': 23774673, 'title': 'Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23774673'}]}]",Brontictuzumab,2016-07-15T14:18:31Z
0,2017-01-31T04:15:18Z,5261,[],Brontictuzumab + Trifluridine,2017-01-31T04:15:18Z
0,2015-03-10T17:19:04Z,2344,"[{'description': 'Bryostatin 1 (NSC 339555) binds to PKC-alpha, PKC-delta, and PKC-epsilon, initially resulting in protein activation followed by subsequent membrane depletion and decreased activation of PKC (PMID: 17585335).', 'references': [{'id': 2151, 'pubMedId': 17585335, 'title': 'Targeting the protein kinase C family: are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17585335'}]}]",Bryostatin 1,2015-03-19T20:58:31Z
0,2016-02-17T16:44:55Z,3539,"[{'description': 'BSI-401 inhibits PARP-1 activity, resulting in decreased tumor cell growth and increased sensitivity to DNA damaging agents (PMID: 19808866).', 'references': [{'id': 4607, 'pubMedId': 19808866, 'title': 'Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19808866'}]}]",BSI-401,2016-02-17T16:44:55Z
0,2016-02-17T16:45:52Z,3540,[],BSI-401 + Oxaliplatin,2016-02-17T16:45:52Z
0,2017-10-09T15:30:17Z,6304,"[{'description': 'BTCT4465A is a bispecific antibody targeting CD20 and CD3, which results in killing of CD20-positive tumor cells (PMID: 25972002)', 'references': [{'id': 10091, 'pubMedId': 25972002, 'title': 'Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25972002'}]}]",BTCT4465A,2017-10-09T15:30:17Z
0,2017-10-18T15:30:39Z,6336,"[{'description': 'BTP-114 is a prodrug of cisplatin that has prolonged plasma circulation time and increased tumor distribution, which leads to improved anti-tumor activity (Cancer Res 2015;75(15 Suppl):Abstract nr 4484).', 'references': [{'id': 10140, 'pubMedId': None, 'title': 'BTP-114: An albumin binding cisplatin prodrug with improved and sustained tumor growth inhibition', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/4484'}]}]",BTP-114,2017-10-18T15:30:39Z
0,2014-12-29T04:26:38Z,1862,"[{'description': 'Bufalin is a cardiac glycoside that acts as a small molecule inhibitor of SRC-1 and SRC-3 and has potential anti-tumor activity (PMID: 24390736).', 'references': [{'id': 1489, 'pubMedId': 24390736, 'title': 'Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24390736'}]}]",Bufalin,2014-12-29T04:26:38Z
0,2015-04-08T02:07:57Z,2506,[],Bupropion,2015-04-08T02:07:57Z
0,2014-07-29T16:27:34Z,1206,"[{'description': 'Busulfex (busulfan) inhibits DNA replication and RNA transcription, likely through induction of DNA alkylation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Busulfan,2014-11-21T04:18:34Z
0,2015-11-09T02:20:32Z,3201,[],Busulfan + Clofarabine + Fludarabine,2015-11-09T02:20:32Z
0,2016-04-22T14:15:08Z,3992,[],Busulfan + Clofarabine + Gemcitabine,2016-04-22T14:15:08Z
0,2015-03-26T14:26:27Z,2469,[],Busulfan + Clofarabine + Thymoglobulin,2015-03-26T14:26:27Z
0,2015-03-06T15:06:21Z,2314,[],Busulfan + Cyclophosphamide + Etoposide,2015-03-06T15:06:21Z
0,2016-04-15T12:51:13Z,3932,[],Busulfan + Cyclophosphamide + Gemtuzumab ozogamicin,2016-04-15T12:51:13Z
0,2017-08-18T15:03:21Z,6116,[],Busulfan + Fludarabine,2017-08-18T15:03:21Z
0,2014-12-23T15:55:52Z,1846,[],Busulfan + Fludarabine + anti-thymocyte globulin,2014-12-23T15:55:52Z
0,2017-05-20T03:00:23Z,5724,[],Busulfan + Fludarabine phosphate + Cyclophosphamide,2017-05-20T03:00:23Z
0,2016-11-19T23:18:38Z,4976,[],Busulfan + Gemcitabine + Melphalan + Panobinostat,2016-11-19T23:18:38Z
0,2015-03-25T15:23:13Z,2460,[],Busulfan + Hu14.18K322A,2015-03-25T15:23:13Z
0,2015-04-22T02:56:57Z,2558,[],Busulfan + Melphalan,2015-04-22T02:56:57Z
0,2017-08-18T15:16:36Z,6122,[],Busulfan + Sorafenib + Fludarabine,2017-08-18T15:19:43Z
0,2016-11-23T15:42:40Z,4989,"[{'description': 'Buthionine sufoximine (BSO) is a GSH synthesis inhibitor, which results in increased reactive oxygen species, thereby possibly leading to apoptotic and/or cytotoxic activity (PMID: 17991446). ', 'references': [{'id': 7133, 'pubMedId': 17991446, 'title': 'Mechanisms of BSO (L-buthionine-S,R-sulfoximine)-induced cytotoxic effects in neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17991446'}]}]",Buthionine sufoximine,2016-11-23T15:42:40Z
0,2016-11-23T15:44:56Z,4990,[],Buthionine sufoximine + Sirolimus,2016-11-23T15:44:56Z
0,2014-05-14T14:52:46Z,997,"[{'description': 'BVD-523 (Ulixertinib) inhibits both ERK 1 and 2, thereby preventing the activation of ERK-mediated signal transduction pathways (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",BVD-523,2015-09-09T10:07:03Z
0,2015-12-03T03:29:20Z,3249,[],BVD-523 + Gemcitabine + nab-paclitaxel,2015-12-03T03:29:20Z
0,2016-02-29T20:45:09Z,3656,"[{'description': 'BX-320 is a small molecule inhibitor of PDPK1, which may block cell growth and induce apoptosis (PMID: 15772071).', 'references': [{'id': 4745, 'pubMedId': 15772071, 'title': 'Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15772071'}]}]",BX-320,2016-02-29T20:45:09Z
0,2016-01-28T21:33:07Z,3467,"[{'description': 'BX-795 is a small molecule inhibitor of PDPK1, as well as TBK and IKBKE, which may result in inhibition of cell growth (PMID: 23887393, PMID: 28455392).', 'references': [{'id': 4479, 'pubMedId': 23887393, 'title': 'PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23887393'}]}]",BX-795,2017-08-07T18:17:26Z
0,2016-02-29T20:46:07Z,3657,"[{'description': 'BX-912 is a small molecule inhibitor of PDPK1, which may result in cell growth inhibition and apoptotic activity (PMID: 15772071).', 'references': [{'id': 4745, 'pubMedId': 15772071, 'title': 'Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15772071'}]}]",BX-912,2016-02-29T20:46:07Z
0,2016-02-29T20:50:13Z,3660,[],BX-912 + BAY11-7085,2016-02-29T20:50:13Z
0,2016-02-29T20:47:10Z,3658,[],BX-912 + Bortezomib,2016-02-29T20:47:10Z
0,2016-02-29T20:48:00Z,3659,[],BX-912 + Etoposide,2016-02-29T20:48:00Z
0,2014-03-12T15:53:16Z,691,"[{'description': 'Alpelisib (BYL719) is a selective PIK3CA inhibitor that blocks activation of the PI3K signaling pathway and inhibits tumor growth (PMID: 23726034).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 236, 'pubMedId': 23726034, 'title': 'Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23726034'}]}]",BYL719,2016-06-22T14:49:00Z
0,2014-07-27T18:08:34Z,1109,[],BYL719 + AMG 479,2014-07-27T18:08:34Z
0,2014-09-25T15:15:47Z,1535,[],BYL719 + Capecitabine,2014-09-25T15:15:47Z
0,2014-12-23T14:06:41Z,1837,[],BYL719 + Cetuximab,2014-12-23T14:06:41Z
0,2016-03-16T14:16:17Z,3751,[],BYL719 + Enzalutamide,2016-03-16T14:16:17Z
0,2014-08-06T02:00:27Z,1384,[],BYL719 + Everolimus,2014-08-06T02:00:27Z
0,2014-08-06T02:04:34Z,1385,[],BYL719 + Everolimus + Exemestane,2014-08-06T02:04:34Z
0,2015-03-06T15:33:27Z,2318,[],BYL719 + Exemestane,2015-03-06T15:33:27Z
0,2015-03-06T15:29:38Z,2317,[],BYL719 + Fulvestrant + LEE011,2015-03-06T15:29:38Z
0,2014-12-30T14:14:18Z,1870,[],BYL719 + Gemcitabine + Abraxane,2014-12-30T14:14:18Z
0,2016-05-03T15:45:54Z,4042,[],BYL719 + GSK2636771,2016-05-03T15:45:54Z
0,2016-05-03T19:02:49Z,4065,[],BYL719 + GSK2636771 + LGX818,2016-05-03T19:02:49Z
0,2016-04-20T15:24:08Z,3969,[],BYL719 + LEE011,2016-04-20T15:24:08Z
0,2015-03-17T12:26:19Z,2419,[],BYL719 + LGH447,2015-03-17T12:26:19Z
0,2016-05-03T17:10:35Z,4049,[],BYL719 + LGX818,2016-05-03T17:12:10Z
0,2015-03-04T15:21:11Z,2283,[],BYL719 + LJM716,2015-03-04T15:21:11Z
0,2015-02-12T13:34:08Z,2059,[],BYL719 + LJM716 + Trastuzumab,2015-02-12T13:34:08Z
0,2014-07-31T14:11:08Z,1311,[],BYL719 + MEK162,2014-07-31T14:11:08Z
0,2015-04-07T03:43:47Z,2503,[],BYL719 + nab-paclitaxel,2015-04-07T03:43:47Z
0,2016-05-03T16:18:50Z,4047,[],BYL719 + NVP-AEW541,2016-05-03T16:18:50Z
0,2015-02-26T15:21:47Z,2171,[],BYL719 + Olaparib,2015-02-26T15:21:47Z
0,2014-08-06T01:09:28Z,1379,[],BYL719 + Paclitaxel,2014-08-06T01:09:28Z
0,2014-09-30T19:21:15Z,1575,[],BYL719 + Trastuzumab emtansine,2014-09-30T19:21:15Z
0,2014-12-29T18:59:28Z,1866,"[{'description': 'C-myb antisense oligonucleotide G4460 is a antisense oligonucleotide that targets MYB, potentially resulting in decreased proliferation and increased apoptosis in MYB overexpressing tumors (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",c-myb antisense oligonucleotide G4460,2014-12-29T18:59:28Z
0,2015-06-03T17:45:18Z,2767,"[{'description': 'C086 inhibits HSP90 and BCR-ABL, resulting in decreased proliferation of tumor cells, including imatinib-resistant cells (PMID: 25501124).', 'references': [{'id': 2917, 'pubMedId': 25501124, 'title': 'Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25501124'}]}]",C086,2015-06-03T17:45:18Z
0,2017-07-03T15:43:21Z,5961,"[{'description': 'C188-9 is a small molecule that binds to and inhibits Stat3 signaling, resulting in tumor cell death (PMID: 27027445).', 'references': []}]",C188-9,2017-07-03T15:43:21Z
0,2015-12-16T04:38:07Z,3294,"[{'description': 'C19 is a small molecule that activates MTS/LATS and AMPK, leading to increased degradation of TAZ and reduced downstream signaling, which potentially results in decreased proliferation and migration of tumor cells (PMID: 24694946).', 'references': [{'id': 4112, 'pubMedId': 24694946, 'title': 'Identification, mechanism of action, and antitumor activity of a small molecule inhibitor of hippo, TGF-β, and Wnt signaling pathways.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24694946'}]}]",C19,2015-12-16T04:38:07Z
0,2015-05-14T18:28:47Z,2681,"[{'description': 'C3742 is an inhibitor of Chk2, which may result in enhanced antitumor activity when combined with chemotherapeutic agents (PMID: 22312557). ', 'references': [{'id': 2723, 'pubMedId': 22312557, 'title': 'The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22312557'}]}]",C3742,2015-05-14T18:28:47Z
0,2016-02-25T15:21:14Z,3603,"[{'description': 'C6-ceramide is an activator of PP2A via binding directly to SET, which may result in tumor suppression (PMID: 24025258). ', 'references': [{'id': 4692, 'pubMedId': 24025258, 'title': 'Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24025258'}]}]",C6-ceramide,2016-02-25T15:21:14Z
0,2016-03-21T19:26:07Z,3797,"[{'description': 'C61 inhibits the substrate binding site of SYK, resulting in increased apoptosis of SYK-expressing tumor cells (PMID:  20151979).', 'references': [{'id': 4954, 'pubMedId': 20151979, 'title': 'Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20151979'}]}]",C61,2016-03-21T19:27:22Z
0,2016-07-19T19:36:53Z,4483,"[{'description': 'C646 is a small molecule inhibitor of EP300, which may result in increased apoptosis and decreased cell growth (PMID: 26603525).', 'references': [{'id': 6332, 'pubMedId': 26603525, 'title': 'Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26603525'}]}]",C646,2016-07-19T19:36:53Z
0,2016-10-12T18:51:25Z,4818,"[{'description': 'C75 inhibits fatty acid synthase (FASN), resulting in apoptosis in FASN over expressing cancer cells (PMID: 27106068).', 'references': [{'id': 6760, 'pubMedId': 27106068, 'title': 'Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27106068'}]}]",C75,2016-10-12T18:51:25Z
0,2017-06-12T18:43:52Z,5885,"[{'description': 'CA-170 is a small molecule inhibitor of PD-L1, PD-L2, and VSIR (VISTA), which potentially results in a T-cell mediated immune  response against tumor cells (NCI Drug Dictionary). ', 'references': []}]",CA-170,2017-06-12T18:43:52Z
0,2014-09-30T19:00:01Z,1571,"[{'description': 'Jevtana (cabazitaxel) inhibits microtubule depolymerization by binding to tubulin, resulting in cell cycle arrest and decreased tumor cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Cabazitaxel,2017-06-19T19:27:49Z
0,2016-03-25T17:37:35Z,3844,[],Cabazitaxel + Carboplatin,2016-03-25T17:37:35Z
0,2015-08-27T01:19:26Z,3056,[],Cabazitaxel + Enzalutamide,2015-08-27T01:19:26Z
0,2014-09-30T19:01:26Z,1572,[],Cabazitaxel + Lapatinib,2014-09-30T19:01:26Z
0,2014-05-14T14:52:46Z,998,"[{'description': 'Cometriq (Cabometyx, cabozantinib) inhibits several receptor tyrosine kinases, including VEGFR 1-3, FLT3, AXL, MET, RET, ROS, and c-KIT (PMID: 21613405, PMID: 21926191). Cometriq (cabozantinib) is FDA approved for medullary thyroid cancer and Cabometyx (cabozantinib) is FDA approved for renal cell carcinoma (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}]}]",cabozantinib,2017-04-03T11:43:09Z
0,2017-10-17T19:09:47Z,6330,[],Cabozantinib + Carfilzomib + Dexamethasone,2017-10-17T19:09:47Z
0,2016-12-07T20:15:17Z,5066,[],Cabozantinib + CT-707,2016-12-07T20:15:17Z
0,2015-02-12T16:44:51Z,2069,[],cabozantinib + Docetaxel,2015-02-12T16:44:51Z
0,2014-07-30T15:32:16Z,1255,[],Cabozantinib + Erlotinib,2014-07-30T15:32:16Z
0,2015-01-19T16:18:57Z,1965,[],cabozantinib + Fulvestrant,2015-01-19T16:18:57Z
0,2016-12-06T18:57:04Z,5064,[],Cabozantinib + Gefitinib,2016-12-06T18:57:04Z
0,2015-02-13T13:25:43Z,2070,[],Cabozantinib + Gemcitabine,2015-02-13T13:25:43Z
0,2015-02-12T15:58:13Z,2068,[],Cabozantinib + Ipilimumab + Nivolumab,2015-02-12T15:58:13Z
0,2017-03-07T18:20:55Z,5412,[],Cabozantinib + Navitoclax,2017-08-01T16:00:14Z
0,2015-02-12T15:52:58Z,2067,[],Cabozantinib + Nivolumab,2015-02-12T15:52:58Z
0,2014-07-30T06:06:10Z,1236,[],Cabozantinib + Sunitinib,2014-07-30T06:06:10Z
0,2017-03-28T18:07:26Z,5490,[],Cabozantinib + unspecified CTLA4 antibody + unspecified PD-1 antibody,2017-03-28T18:07:26Z
0,2014-07-30T06:05:16Z,1235,[],Cabozantinib + Vemurafenib,2014-07-30T06:05:16Z
0,2016-03-11T19:45:50Z,3729,[],Caffeine + Dextromethorphan + Midazolam + Warfarin,2016-03-11T19:45:50Z
0,2016-03-08T17:46:04Z,3695,"[{'description': 'Dovonex (calcipotriene) is a synthetic vitamin D derivative that inhibits proliferation in normal and cancer cells (PMID: 26224368).', 'references': [{'id': 4790, 'pubMedId': 26224368, 'title': 'Calcipotriol Targets LRP6 to Inhibit Wnt Signaling in Pancreatic Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26224368'}]}]",calcipotriene,2016-03-08T17:46:04Z
0,2015-07-08T15:51:23Z,2889,"[{'description': 'Rocaltrol (calcitriol) is a vitamin D3 analog that promotes cell-cycle arrest, which may result in decreased tumor cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",calcitriol,2015-07-08T15:51:40Z
0,2016-02-14T01:47:54Z,3528,"[{'description': 'Cambinol inhibits SIRT1/2, which may result in increased cell-cycle arrest and reduced tumor growth (PMID: 16618762, PMID:  23339189).', 'references': [{'id': 4581, 'pubMedId': 16618762, 'title': 'Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16618762'}, {'id': 521, 'pubMedId': 22703804, 'title': 'Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22703804'}]}]",Cambinol,2017-03-16T17:40:35Z
0,2016-02-14T01:50:55Z,3529,[],Cambinol + Doxorubicin,2016-02-14T01:50:55Z
0,2014-08-28T18:58:11Z,1406,[],Camptosar + Cisplatin,2014-08-28T18:58:11Z
0,2016-01-11T01:07:35Z,3397,"[{'description': 'Camptothecin is a natural product alkaloid topoisomerase I inhibitor from which irinotecan and topotecan are derived (PMID: 16990856)', 'references': [{'id': 4271, 'pubMedId': 16990856, 'title': 'Topoisomerase I inhibitors: camptothecins and beyond.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16990856'}]}]",Camptothecin,2016-01-11T01:07:35Z
0,2017-09-11T18:39:29Z,6193,[],Camptothecin + NU6027,2017-09-11T18:39:29Z
0,2016-05-10T18:14:42Z,4095,[],Camptothecin + Olaparib,2016-05-10T18:14:42Z
0,2015-02-23T16:47:50Z,2136,"[{'description': 'Canertinib (CI-1033) is a pan-ERBB inhibitor that inhibits EGFR, ERBB2 (HER2), ERBB3 (HER3), and ERBB4 (HER4) signaling, which may result in decreased tumor growth (PMID: 11706399, PMID: 17342332).', 'references': [{'id': 1961, 'pubMedId': 11706399, 'title': 'CI-1033, a pan-erbB tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11706399'}, {'id': 1962, 'pubMedId': 17342332, 'title': 'The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17342332'}]}]",Canertinib,2015-05-15T18:49:47Z
0,2015-05-07T19:15:48Z,2632,"[{'description': 'Cannabidiol is a cannabis derivative, which has been shown to interfere with proliferation, migration, and metastasis in cultured cells and xenograft models (PMID: 22506672).\r\n', 'references': [{'id': 2664, 'pubMedId': 22506672, 'title': 'Cannabidiol as potential anticancer drug.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22506672'}]}]",Cannabidiol,2015-05-07T19:15:48Z
0,2015-08-19T20:11:19Z,3037,[],Capcitabine + Cisplatin + Pertuzumab + Trastuzumab,2015-08-19T20:11:19Z
0,2014-07-25T21:39:31Z,1105,"[{'description': 'Xeloda (capecitabine) is an antimetabolite that when activated to 5-FU ultimately inhibits DNA synthesis and cell division (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Capecitabine,2014-08-12T15:19:18Z
0,2016-04-22T18:30:45Z,3999,[],Capecitabine + Cisplatin,2016-04-22T18:30:45Z
0,2017-07-28T19:22:11Z,6050,[],Capecitabine + Cisplatin + Pembrolizumab,2017-07-28T19:22:11Z
0,2016-11-13T21:12:45Z,4945,[],Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab,2016-11-13T21:12:45Z
0,2015-01-04T02:02:23Z,1899,[],Capecitabine + Cisplatin + Trastuzumab,2015-01-04T02:02:23Z
0,2014-09-26T02:26:59Z,1559,[],Capecitabine + Cyclophosphamide + Lapatinib + Trastuzumab,2014-09-26T02:26:59Z
0,2016-06-17T21:18:54Z,4309,[],Capecitabine + Docetaxel,2016-06-17T21:18:54Z
0,2016-06-02T18:56:05Z,4203,[],Capecitabine + Docetaxel + Gemcitabine,2016-06-02T18:56:05Z
0,2017-05-30T15:59:16Z,5805,[],Capecitabine + E7046,2017-05-30T15:59:16Z
0,2016-10-04T14:33:08Z,4776,[],Capecitabine + Epirubicin + Oxaliplatin + Pembrolizumab,2016-10-04T14:33:08Z
0,2014-10-07T19:33:37Z,1619,[],Capecitabine + Fluorouracil,2014-10-07T19:33:37Z
0,2015-01-04T00:54:11Z,1894,[],Capecitabine + Fluorouracil + Cisplatin + Trastuzumab,2015-01-04T00:54:11Z
0,2015-03-12T18:52:25Z,2383,[],Capecitabine + Fluorouracil + Gemcitabine ,2015-03-12T18:52:25Z
0,2017-05-26T17:35:36Z,5788,[],Capecitabine + Galunisertib,2017-05-26T17:35:36Z
0,2016-10-04T14:48:43Z,4779,[],Capecitabine + Lenvatinib,2016-10-04T14:48:43Z
0,2014-09-25T17:04:38Z,1543,[],Capecitabine + Neratinib,2014-09-25T17:04:38Z
0,2015-04-24T14:31:51Z,2589,[],Capecitabine + Nintedanib,2015-04-24T14:31:51Z
0,2014-10-02T15:19:15Z,1597,[],Capecitabine + Oxaliplatin,2014-10-02T15:19:15Z
0,2014-10-02T17:00:32Z,1601,[],Capecitabine + Oxaliplatin + Bevacizumab,2014-10-02T17:00:32Z
0,2017-04-17T20:36:26Z,5549,[],Capecitabine + Oxaliplatin + Pembrolizumab,2017-04-17T20:36:26Z
0,2015-01-16T15:53:12Z,1960,[],Capecitabine + Panitumumab,2015-01-16T15:53:12Z
0,2016-04-29T14:50:39Z,4022,[],Capecitabine + Pembrolizumab,2016-04-29T14:50:39Z
0,2016-06-22T01:44:48Z,4335,[],Capecitabine + TAS-114,2016-06-22T01:44:48Z
0,2014-08-29T09:27:10Z,1409,[],Capecitabine + Trastuzumab,2014-08-29T09:27:10Z
0,2017-04-12T20:41:54Z,5543,[],Capecitabine + Varlitinib,2017-04-12T20:41:54Z
0,2016-10-16T21:35:55Z,4838,[],Capecitabine + Veliparib,2016-10-16T21:35:55Z
0,2016-07-17T23:37:56Z,4463,[],Capecitabine + Veliparib + Temozolomide,2016-07-17T23:37:56Z
0,2014-06-06T17:07:34Z,1065,"[{'description': 'Capmatinib (INC280) inhibits c-MET and may induce cell death in tumors over expressing c-MET or expressing constitutively activated c-MET (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Capmatinib,2017-10-12T15:15:03Z
0,2014-08-01T02:13:06Z,1338,[],Capmatinib + Encorafenib,2017-10-12T15:14:05Z
0,2014-07-17T21:55:17Z,1092,"[{'description': 'Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Carboplatin,2015-03-20T18:10:58Z
0,2015-02-19T15:14:06Z,2105,[],Carboplatin +  Pembrolizumab + Pemetrexed ,2015-02-19T15:14:06Z
0,2016-05-27T14:56:49Z,4168,[],Carboplatin + Cetuximab + Cisplatin + Fluorouracil,2016-05-27T14:56:49Z
0,2015-01-29T14:13:32Z,1989,[],Carboplatin + Cetuximab + Paclitaxel,2015-01-29T14:13:32Z
0,2017-06-12T13:57:11Z,5873,[],Carboplatin + Cisplatin + Durvalumab + Paclitaxel,2017-06-12T13:57:11Z
0,2016-09-21T14:45:10Z,4728,[],Carboplatin + Cisplatin + Etoposide,2016-09-21T14:45:10Z
0,2017-09-11T13:55:38Z,6184,[],Carboplatin + Cisplatin + Etoposide + Pembrolizumab,2017-09-11T13:55:38Z
0,2016-09-12T17:55:01Z,4686,[],Carboplatin + Cisplatin + Gemcitabine,2016-09-12T17:55:01Z
0,2017-08-21T15:31:19Z,6132,[],Carboplatin + Cisplatin + Paclitaxel + Pemetrexed,2017-08-21T15:31:19Z
0,2016-08-29T12:40:57Z,4616,[],Carboplatin + Cisplatin + Pemetrexed,2016-08-29T12:40:57Z
0,2016-02-26T21:50:53Z,3650,[],Carboplatin + Custirsen + Gemcitabine,2016-02-26T21:51:34Z
0,2016-06-27T19:24:11Z,4386,[],Carboplatin + Demcizumab + Pemetrexed,2016-06-27T19:24:11Z
0,2016-06-17T19:53:15Z,4307,[],Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab,2016-06-17T19:53:15Z
0,2016-06-17T19:56:42Z,4308,[],Carboplatin + Dexamethasone + Idarubicin + Ifosfamide + Rituximab + Vincristine,2016-06-17T19:56:42Z
0,2016-12-05T15:16:54Z,5059,[],Carboplatin + Docetaxel + Gemcitabine + Itraconazole,2016-12-05T15:16:54Z
0,2015-10-08T02:38:48Z,3111,[],Carboplatin + Docetaxel + Sirolimus ,2015-10-08T02:38:48Z
0,2015-02-26T14:57:02Z,2168,[],Carboplatin + Doxil + Everolimus,2015-02-26T14:57:02Z
0,2015-01-16T15:19:03Z,1953,[],Carboplatin + Doxorubicin,2015-01-16T15:19:03Z
0,2016-04-22T18:21:06Z,3997,[],Carboplatin + Durvalumab + Paclitaxel,2017-06-12T13:56:08Z
0,2016-05-26T17:32:47Z,4143,[],Carboplatin + E7449,2016-05-26T17:32:47Z
0,2016-03-06T20:48:27Z,3681,[],Carboplatin + Enzalutamide + Paclitaxel,2016-03-06T20:48:27Z
0,2016-08-17T19:55:27Z,4581,[],Carboplatin + Erlotinib + Paclitaxel,2016-08-17T19:55:27Z
0,2014-12-17T14:37:28Z,1791,[],Carboplatin + Etoposide,2014-12-17T14:37:28Z
0,2015-03-11T15:21:16Z,2352,[],Carboplatin + Etoposide + Ifosfamide ,2015-03-11T15:21:16Z
0,2015-12-31T20:13:22Z,3360,[],Carboplatin + Etoposide + Ifosfamide + Rituximab,2015-12-31T20:13:22Z
0,2015-04-22T03:04:06Z,2559,[],Carboplatin + Etoposide + Melphalan + Vincristine,2015-04-22T03:04:06Z
0,2015-04-29T02:12:30Z,2604,[],Carboplatin + Etoposide + Pembrolizumab,2015-04-29T02:12:30Z
0,2014-09-25T17:15:23Z,1544,[],Carboplatin + Etoposide + Veliparib,2015-05-08T15:30:01Z
0,2017-06-23T04:16:39Z,5921,[],Carboplatin + ETP-46464,2017-06-23T04:16:39Z
0,2014-12-22T17:03:48Z,1832,[],Carboplatin + Fluorouracil	,2014-12-22T17:03:48Z
0,2015-02-13T15:22:30Z,2071,[],Carboplatin + Fluorouracil + Paclitaxel + Vandetanib,2015-02-13T15:22:30Z
0,2017-09-29T17:13:18Z,6265,[],Carboplatin + Galunisertib + Paclitaxel,2017-09-29T17:13:18Z
0,2016-12-16T19:05:01Z,5103,[],Carboplatin + Ganetespib + Paclitaxel + Radiotherapy,2016-12-16T19:17:43Z
0,2015-05-14T00:03:43Z,2667,[],Carboplatin + Gemcitabine,2015-05-14T00:03:48Z
0,2016-06-27T00:45:14Z,4375,[],Carboplatin + Gemcitabine + LY3039478,2016-06-27T00:45:14Z
0,2016-08-07T16:35:23Z,4529,[],Carboplatin + Gemcitabine + Pembrolizumab,2016-08-07T16:35:23Z
0,2017-05-22T17:24:32Z,5737,[],Carboplatin + Gemcitabine + Trilaciclib,2017-05-22T17:24:32Z
0,2015-12-21T01:53:19Z,3316,[],Carboplatin + Gemcitabine + VX-970,2015-12-21T01:53:19Z
0,2014-07-30T16:47:40Z,1267,[],Carboplatin + GSK1120212,2014-07-30T16:47:40Z
0,2016-03-22T19:29:42Z,3814,[],Carboplatin + GSK2830371,2016-03-22T19:29:42Z
0,2016-08-31T17:03:54Z,4632,[],Carboplatin + JQ1,2016-08-31T17:03:54Z
0,2015-04-24T14:18:24Z,2587,[],Carboplatin + Melphalan,2015-04-24T14:18:24Z
0,2015-02-27T16:43:03Z,2203,[],Carboplatin + Metformin + Pemetrexed,2015-02-27T16:43:03Z
0,2015-05-14T00:38:17Z,2669,[],Carboplatin + Methotrexate + Rituximab,2015-05-14T00:38:17Z
0,2015-05-08T01:18:57Z,2634,[],Carboplatin + nab-paclitaxel,2015-05-08T01:18:57Z
0,2015-04-29T00:27:09Z,2599,[],Carboplatin + nab-paclitaxel + Necitumumab,2015-04-29T00:27:09Z
0,2017-04-28T17:28:22Z,5591,[],Carboplatin + nab-paclitaxel + Pembrolizumab,2017-04-28T17:28:22Z
0,2017-07-10T20:14:23Z,5984,[],Carboplatin + Niraparib,2017-07-10T20:14:23Z
0,2017-09-01T20:37:06Z,6159,[],Carboplatin + Nivolumab + Pemetrexed,2017-09-01T20:37:06Z
0,2016-11-08T19:36:38Z,4928,[],Carboplatin + Nutlin-3,2016-11-08T19:36:38Z
0,2016-01-10T20:45:39Z,3386,[],Carboplatin + Paclitaxel + Panitumumab,2016-01-10T20:45:49Z
0,2017-07-28T02:43:18Z,6027,[],Carboplatin + Paclitaxel + PDR001,2017-07-28T02:43:18Z
0,2015-02-19T15:12:26Z,2103,[],Carboplatin + Paclitaxel + Pembrolizumab,2015-02-19T15:12:26Z
0,2016-12-02T05:10:19Z,5053,[],Carboplatin + Paclitaxel + Pemetrexed + Nivolumab + Veliparib,2016-12-02T05:10:19Z
0,2016-12-02T05:11:16Z,5054,[],Carboplatin + Paclitaxel + Pemetrexed + Veliparib,2016-12-02T05:11:16Z
0,2017-09-29T17:33:30Z,6266,[],Carboplatin + Paclitaxel + PTC596,2017-09-29T17:33:30Z
0,2015-05-08T12:54:56Z,2640,[],Carboplatin + Paclitaxel + Selinexor,2015-05-08T12:54:56Z
0,2017-10-18T14:48:36Z,6333,[],Carboplatin + Paclitaxel + Temsirolimus,2017-10-18T14:48:36Z
0,2015-02-27T14:58:31Z,2196,[],Carboplatin + Paclitaxel + Trametinib,2015-02-27T14:58:31Z
0,2017-10-17T16:19:39Z,6322,[],Carboplatin + Paclitaxel + TSR-042,2017-10-17T16:19:39Z
0,2017-02-02T15:16:22Z,5274,[],Carboplatin + Paclitaxel + Veliparib,2017-02-02T15:16:22Z
0,2016-09-21T15:51:08Z,4735,[],Carboplatin + Palbociclib,2016-09-21T15:51:08Z
0,2017-01-31T04:45:36Z,5265,[],Carboplatin + Pembrolizumab,2017-01-31T04:45:36Z
0,2014-10-02T17:05:52Z,1602,[],Carboplatin + Pemetrexed,2014-10-02T17:05:52Z
0,2016-06-04T16:20:17Z,4235,[],Carboplatin + Pertuzumab + Trastuzumab + Paclitaxel,2016-06-04T16:20:17Z
0,2016-10-17T17:26:15Z,4843,[],Carboplatin + STA-8666,2016-10-17T17:26:15Z
0,2017-02-20T20:46:02Z,5341,[],Carboplatin + Topotecan + Veliparib,2017-02-20T20:46:02Z
0,2016-10-27T18:12:43Z,4870,[],Carboplatin + Torkinib,2017-07-07T18:44:24Z
0,2016-08-14T16:58:00Z,4566,[],Carboplatin + Triciribine,2016-08-14T16:58:00Z
0,2016-06-06T16:40:02Z,4253,[],Carboplatin + VX-970,2016-06-06T16:40:02Z
0,2014-05-14T14:52:46Z,999,"[{'description': 'Carboxyamidotriazole orotate binds to and inhibits non-voltage-operated calcium channels and inhibits PI3 activity and vascular endothelial growth factor (VEGF) signaling (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Carboxyamidotriazole Orotate,2014-11-20T18:26:00Z
0,2014-10-27T13:36:39Z,1663,[],Carboxyamidotriazole Orotate + Paclitaxel,2014-10-27T13:36:39Z
0,2014-10-07T20:28:38Z,1624,"[{'description': 'Kyprolis (carfilzomib) binds to the 20S proteasome and inhibits its protein degradation activity, thereby leading to the accumulation of ubiquinated proteins, which may result in apoptosis and growth arrest in tumor cells (NCI Drug Dictionary). Kyprolis (carfilzomib), in combination with lenalidomide and dexamethasone, is FDA approved for multiple myeloma (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Carfilzomib,2017-06-19T19:36:10Z
0,2016-06-27T00:17:41Z,4367,[],Carfilzomib + Dexamethasone + lenalidomide + Panobinostat,2016-06-27T00:17:41Z
0,2017-10-03T16:23:19Z,6289,[],Carfilzomib + Dexamethasone + Panobinostat,2017-10-03T16:23:19Z
0,2015-03-26T13:23:39Z,2463,[],Carfilzomib + Dexamethasone + Reolysin,2017-10-03T16:22:21Z
0,2015-07-31T01:44:18Z,2985,[],Carfilzomib + Dexamethasone + Selinexor,2015-07-31T01:44:18Z
0,2017-01-31T23:29:19Z,5268,[],Carfilzomib + Dexamethasone + Venetoclax,2017-01-31T23:29:19Z
0,2017-07-27T18:14:45Z,6016,[],Carfilzomib + DT204,2017-07-27T18:14:45Z
0,2017-08-11T16:26:04Z,6106,[],Carfilzomib + EDO-S101,2017-08-11T16:26:04Z
0,2016-12-01T14:46:51Z,5033,[],Carfilzomib + Elotuzumab + Dexamethasone + lenalidomide,2016-12-01T14:46:51Z
0,2017-04-19T01:57:51Z,5555,[],Carfilzomib + Elotuzumab + Dexamethasone + Pomalidomide,2017-04-19T01:57:51Z
0,2015-12-11T14:45:26Z,3282,[],Carfilzomib + Ibrutinib,2015-12-11T14:45:26Z
0,2016-01-21T22:18:48Z,3438,[],Carfilzomib + Panobinostat,2016-01-21T22:18:48Z
0,2016-01-10T19:33:52Z,3384,[],Carfilzomib + Ricolinostat,2016-01-10T19:33:52Z
0,2015-03-11T15:19:21Z,2351,[],Carfilzomib + Rituximab,2015-03-11T15:19:21Z
0,2017-08-22T19:55:09Z,6143,[],Carfilzomib + Selinexor,2017-08-22T19:55:09Z
0,2017-06-16T18:08:28Z,5899,[],Carfilzomib + TG02,2017-06-16T18:08:28Z
0,2016-08-21T02:40:10Z,4598,[],Carfilzomib + TGR-1202,2016-08-21T02:40:10Z
0,2014-12-19T05:26:01Z,1811,[],Carmustine,2014-12-19T05:26:01Z
0,2015-12-31T19:56:21Z,3359,[],Carmustine + Cytarabine + Etoposide + Melphalan,2015-12-31T19:56:21Z
0,2015-04-22T02:26:51Z,2555,[],Carmustine + Filgrastim + Plerixafor + Temozolomide,2015-04-22T02:26:51Z
0,2016-02-25T15:23:07Z,3604,"[{'description': 'Carnosic acid is a polyphenol, which has been shown to activate PP2A thereby inducing apoptosis and inhibiting cell proliferation (PMID: 22453599).', 'references': [{'id': 4693, 'pubMedId': 22453599, 'title': 'Carnosic acid modulates Akt/IKK/NF-κB signaling by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in human prostate carcinoma PC-3 cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22453599'}]}]",Carnosic acid,2016-02-25T15:23:07Z
0,2014-07-30T13:19:13Z,1242,"[{'description': 'Carotuximab (TRC105) is a monoclonal antibody that binds to endoglin, a TGF beta-1 accessory receptor highly expressed on tumor vessel endothelial cells, blocking signaling essential for angiogenesis and potentially decreasing proliferation of tumor cells (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Carotuximab,2017-10-18T14:54:29Z
0,2017-10-18T14:51:41Z,6334,[],Carotuximab + Nivolumab,2017-10-18T14:55:01Z
0,2015-03-13T14:28:42Z,2389,[],Carotuximab + Sorafenib,2017-10-18T14:55:56Z
0,2017-07-17T18:17:46Z,5999,"[{'description': 'CART19 cells are allogeneic T lymphocytes engineered to express a chimeric antigen receptor consists of the CD3 zeta chain and the 4-1BB signaling domain, which may have immune modulating and anti-tumor activities (PMID: 21716851).', 'references': [{'id': 9451, 'pubMedId': 21716851, 'title': 'Chimeric Antigen Receptor Therapy for B-cell Malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21716851'}]}]",CART19 cells,2017-07-17T18:17:46Z
0,2015-01-04T02:09:27Z,1901,[],Carvedilol,2015-01-04T02:09:27Z
0,2017-09-19T17:01:00Z,6221,"[{'description': 'CB-103 is a small molecule inhibitor of NOTCH signaling via inhibition of the NOTCH transcriptional activation complex, which may result in antitumor efficacy (Cancer Res 2016;76(14 Suppl):Abstract nr 338).', 'references': [{'id': 9944, 'pubMedId': None, 'title': 'Abstract 338: A novel small molecule inhibitor of the Notch transcription activation complex', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/338'}]}]",CB-103,2017-09-19T17:01:00Z
0,2016-09-20T03:19:03Z,4721,"[{'description': 'CB-1158 is a human arginase inhibitor that restores arginine levels in T-cells, therefore promoting T-cell proliferation and anti-tumor immunity (Cancer Res 2016;76(14 Suppl):Abstract nr 552).', 'references': [{'id': 6662, 'pubMedId': None, 'title': 'Immuno-oncology agent CB-1158 is a potent and selective arginase inhibitor and causes an immune-mediated anti-tumor response', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/552'}]}]",CB-1158,2016-09-21T13:30:58Z
0,2016-09-20T03:21:14Z,4722,[],CB-1158 + Nivolumab,2016-09-20T03:21:14Z
0,2015-01-16T03:37:38Z,1944,"[{'description': 'CB-5083 binds to and inhibits p97, which prevents ubiquitin-mediated degradation of ER-associated proteins, resulting in ER-stress pathway activation, induction of apoptosis, and decreased tumor cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",CB-5083,2015-01-16T03:37:38Z
0,2016-07-31T18:58:30Z,4513,[],CB-5083 + Dexamethasone,2016-07-31T18:58:30Z
0,2014-10-28T16:06:14Z,1667,"[{'description': 'CB-839 binds to and inhibits glutaminase, preventing the conversion of glutamine to glutamate, which results in a decrease in cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",CB-839,2014-10-28T16:06:14Z
0,2017-02-03T03:03:45Z,5280,[],CB-839 + Everolimus,2017-02-03T03:03:45Z
0,2017-09-01T20:27:00Z,6158,[],CB-839 + Irinotecan + Panitumumab,2017-09-01T20:27:00Z
0,2016-06-10T21:00:44Z,4274,[],CB-839 + Nivolumab,2016-06-10T21:00:44Z
0,2017-05-16T17:51:54Z,5675,[],CB-839 + Olaparib,2017-05-16T17:51:54Z
0,2016-04-15T16:49:11Z,3940,"[{'description': 'CBL0137 is a Curaxin compound that binds to and inhibits the Facilitates Chromatin Transcription (FACT) complex, resulting in apoptosis in cancer cells (PMID: 25402820).', 'references': [{'id': 5164, 'pubMedId': 25402820, 'title': 'Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25402820'}]}]",CBL0137 ,2016-04-15T16:49:11Z
0,2016-04-15T16:59:12Z,3941,[],CBL0137 + Gemcitabine,2016-04-15T16:59:12Z
0,2016-08-08T18:47:05Z,4545,"[{'description': 'CBP501 is a peptide drug that inhibits the activity of several kinases responsible for phosphorylation of CDC25C, including MAPKAP-K2, C-Tak1, and CHK1, resulting in disruption of the G2 checkpoint and potentially leading to cell-cycle arrest and increased tumor cell death (PMID: 17237275).', 'references': [{'id': 6450, 'pubMedId': 17237275, 'title': 'Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17237275'}]}]",CBP501,2016-08-08T18:47:05Z
0,2016-08-08T18:57:46Z,4547,[],CBP501 + Cisplatin,2016-08-08T18:58:19Z
0,2017-09-11T15:08:10Z,6186,[],CBP501 + Cisplatin + Nivolumab,2017-09-11T15:08:10Z
0,2017-07-04T11:48:33Z,5963,"[{'description': 'Llimited information is currently available on CBT-101, a putative Met inhibitor (Jul 2017).', 'references': []}]",CBT-101,2017-07-04T11:48:33Z
0,2014-05-14T14:52:46Z,1000,"[{'description': 'CC-115 binds to and inhibits the activity of DNA-PK, raptor-mTOR, and rictor-mTOR, which may lead to reduced cell proliferation of cancer cells expressing DNA-PK and TOR (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",CC-115,2016-04-01T16:30:16Z
0,2016-07-17T22:17:29Z,4459,[],CC-115 + Enzalutamide,2016-07-17T22:17:29Z
0,2015-03-12T03:33:30Z,2358,"[{'description': 'CC-122 is an immunomodulatory drug analog that targets Cereblon and promotes degradation of several proteins, including Ikaros and Aiolos, leading to decreased B-cell proliferation and decreased tumor angiogenesis (Blood Dec 2014, 124 (21) 3500).', 'references': [{'id': 2168, 'pubMedId': None, 'title': 'CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma', 'url': 'http://www.bloodjournal.org/content/124/21/3500?sso-checked=true'}]}]",CC-122,2015-03-12T03:33:30Z
0,2015-03-12T15:38:03Z,2375,[],CC-122 + CC-223,2015-03-12T15:38:03Z
0,2015-03-12T15:38:29Z,2376,[],CC-122 + CC-292,2015-03-12T15:38:29Z
0,2016-08-27T03:02:35Z,4611,[],CC-122 + Nivolumab,2016-08-27T03:02:35Z
0,2014-03-12T15:53:16Z,693,"[{'description': 'CC-223 is a selective inhibitor of mTOR that induces apoptosis and growth inhibition in tumor cells (PMID: 25855786).', 'references': [{'id': 3513, 'pubMedId': 25855786, 'title': 'CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25855786'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",CC-223,2017-07-07T18:39:04Z
0,2015-03-12T15:39:01Z,2377,[],CC-223 + CC-292,2015-03-12T15:39:01Z
0,2015-03-12T03:41:04Z,2359,"[{'description': 'CC-292 (Spebrutinib) is a covalent inhibitor of Btk that decreases Btk kinase activity and activation of downstream signaling, resulting in reduced B-cell proliferation (PMID: 24518207).', 'references': [{'id': 2169, 'pubMedId': 24518207, 'title': ""A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24518207'}]}]",CC-292,2017-01-09T11:42:52Z
0,2016-01-06T18:41:10Z,3368,"[{'description': 'CC-401 is a small molecule that inhibits JNK1, 2, and 3, potentially resulting in decreased cell proliferation and increased sensitivity to chemotherapeutics (PMID: 26023085, PMID: 17202416).', 'references': [{'id': 4219, 'pubMedId': 17202416, 'title': 'A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17202416'}, {'id': 4218, 'pubMedId': 26023085, 'title': 'Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26023085'}]}]",CC-401,2016-01-06T18:41:10Z
0,2015-06-30T01:48:37Z,2874,"[{'description': 'CC-90003 inhibits ERK, which leads to decreased proliferation of ERK-dependent tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",CC-90003,2015-06-30T01:48:37Z
0,2016-03-28T18:11:15Z,3853,"[{'description': 'CC214-1 is an ATP-competitive mTOR inhibitor, which inhibits signaling through mTORC1 and mTORC2, potentially resulting in decreased tumor cell growth (PMID: 24030701).', 'references': [{'id': 5035, 'pubMedId': 24030701, 'title': 'The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24030701'}]}]",CC214-1,2016-03-28T18:11:15Z
0,2016-03-28T18:11:59Z,3854,"[{'description': 'CC214-2 is an ATP-competitive mTOR inhibitor, which inhibits signaling through mTORC1 and mTORC2, potentially resulting in decreased tumor cell growth (PMID: 24030701, PMID: 23414803).', 'references': [{'id': 5036, 'pubMedId': 23414803, 'title': 'Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23414803'}]}]",CC214-2,2016-03-28T18:11:59Z
0,2017-01-10T21:01:41Z,5186,"[{'description': 'CCG-203971 is a small molecule inhibitor that blocks the activity and nuclear localization of MRTF-A, thereby possibly resulting in mitigation of cell migration and metastasis, and decreased tumor growth (PMID: 27837031). ', 'references': [{'id': 7518, 'pubMedId': 27837031, 'title': 'Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27837031'}]}]",CCG-203971,2017-01-10T21:01:41Z
0,2017-06-05T19:19:54Z,5852,"[{'description': 'CCS1477 binds to and inhibits p300 (EP300) and CBP (CREBBP), potentially resulting in decreased tumor cell proliferation and inhibition of tumor growth (J Clin Oncol 35, 2017 (suppl; abstr 11590)).', 'references': [{'id': 9061, 'pubMedId': None, 'title': 'Characterisation of CCS1477: A novel small molecule inhibitor of p300/CBP for the treatment of castration resistant prostate cancer.', 'url': 'http://abstracts.asco.org/199/AbstView_199_189631.html'}]}]",CCS1477,2017-06-05T19:19:54Z
0,2016-03-15T15:22:23Z,3740,"[{'description': 'CCT007093 is a small molecule inhibitor of PPM1D, which induces phosphorylation of P38 and thereby may result in cell growth inhibition (PMID: 17700519). ', 'references': [{'id': 4861, 'pubMedId': 17700519, 'title': 'A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17700519'}]}]",CCT007093,2016-03-15T15:22:23Z
0,2016-03-22T17:39:28Z,3806,[],CCT007093 + Nutlin-3,2016-03-22T17:39:28Z
0,2016-03-22T18:06:43Z,3807,[],CCT007093 + Paclitaxel,2016-03-22T18:06:43Z
0,2015-03-16T15:13:09Z,2400,"[{'description': 'CCT031374 inhibits TCF/CTNNB1 dependent transcription thereby blocking Wnt signaling, which results in apoptosis (PMID: 20610623).', 'references': [{'id': 2213, 'pubMedId': 20610623, 'title': 'A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20610623'}]}]",CCT031374,2015-03-16T15:13:09Z
0,2015-03-16T14:48:00Z,2398,"[{'description': 'CCT036477 inhibits TCF/CTNNB1 dependent transcription thereby blocking Wnt signaling, which results in apoptosis (PMID: 20610623).', 'references': [{'id': 2213, 'pubMedId': 20610623, 'title': 'A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20610623'}]}]",CCT036477,2015-03-16T14:48:00Z
0,2015-03-16T15:11:17Z,2399,"[{'description': 'CCT070535 inhibits TCF/CTNNB1 dependent transcription thereby blocking Wnt signaling, which results in apoptosis (PMID: 20610623).', 'references': [{'id': 2213, 'pubMedId': 20610623, 'title': 'A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20610623'}]}]",CCT070535,2015-03-16T15:11:17Z
0,2014-09-11T10:04:41Z,1445,"[{'description': 'CCT128930 is an ATP-competitive inhibitor of AKT2 with a lesser affinity for PKA and RPS6KB2. CCT128930 has antitumor activity in cells with activated PI3K-AKT-mTOR pathway (PMID: 21191045).', 'references': [{'id': 692, 'pubMedId': 21191045, 'title': 'Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21191045'}]}]",CCT128930,2014-09-11T11:34:12Z
0,2015-03-08T21:41:44Z,2332,"[{'description': 'CCT129202 is a pan-Aurora A,B,C kinase inhibitor, which induces cell proliferation (PMID: 18089709).', 'references': [{'id': 2123, 'pubMedId': 18089709, 'title': 'Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18089709'}]}]",CCT129202,2017-04-04T10:45:56Z
0,2016-02-28T15:30:28Z,3654,"[{'description': 'CCT129254 is a small molecule ATP-competitive inhibitor of AKT and Rho kinases, which results in decreased tumor cell migration and metastasis (PMID: 25840982).', 'references': [{'id': 4738, 'pubMedId': 25840982, 'title': 'Rho kinase inhibitors block melanoma cell migration and inhibit metastasis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25840982'}]}]",CCT129254,2016-03-04T19:21:50Z
0,2014-10-08T15:50:07Z,1629,"[{'description': 'CCT137690 selectively inhibits aurora kinases (AURKA, AURKB, and AURKC) with nanomolar affinities (PMID: 20565112).', 'references': [{'id': 915, 'pubMedId': 20565112, 'title': 'Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20565112'}]}]",CCT137690,2015-03-08T21:44:49Z
0,2017-04-04T10:51:37Z,5502,"[{'description': '', 'references': []}]",CCT137690 + Radiotherapy,2017-04-04T10:51:37Z
0,2015-10-07T17:44:35Z,3105,"[{'description': 'CCT196969 is a paradox-breaking pan-RAF inhibitor, with additional activity against SRC and LCK, which potentially results in decreased growth of tumor cells, including cells resistant to BRAF inhibitors (PMID: 25500121).', 'references': [{'id': 3714, 'pubMedId': 25500121, 'title': 'Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25500121'}]}]",CCT196969,2015-10-07T17:44:35Z
0,2015-10-07T17:48:26Z,3106,"[{'description': 'CCT241161 is a paradox-breaking pan-RAF inhibitor, with additional activity against SRC and LCK, which potentially results in decreased growth of tumors, including those resistant to BRAF inhibitors (PMID: 25500121).', 'references': [{'id': 3714, 'pubMedId': 25500121, 'title': 'Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25500121'}]}]",CCT241161,2015-10-07T17:48:26Z
0,2015-04-10T17:49:19Z,2533,"[{'description': 'CCT241533 is an ATP-competitive inhibitor of CHK2, which enhances PARP inhibitor efficacy in cells lacking functional p53 (PMID:  19741151).', 'references': [{'id': 2452, 'pubMedId': 19741151, 'title': 'Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19741151'}]}]",CCT241533,2015-04-10T17:49:19Z
0,2016-09-09T04:23:33Z,4672,"[{'description': 'CCT244747 inhibits CHK1, potentially resulting in increased tumor cell death and increased sensitivity to other antitumor agents (PMID: 22929806, PMID: 27422809).', 'references': [{'id': 6591, 'pubMedId': 27422809, 'title': 'CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27422809'}, {'id': 6590, 'pubMedId': 22929806, 'title': 'CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22929806'}]}]",CCT244747,2016-09-09T04:23:33Z
0,2017-09-06T14:15:12Z,6172,[],CCT244747 + Gemcitabine,2017-09-06T14:15:12Z
0,2017-09-06T14:11:36Z,6171,[],CCT244747 + Irinotecan,2017-09-06T14:11:36Z
0,2016-09-09T04:24:33Z,4673,[],CCT244747 + Radiotherapy,2016-09-09T04:32:27Z
0,2016-09-09T04:33:04Z,4674,[],CCT244747 + Radiotherapy + Paclitaxel,2016-09-09T04:33:04Z
0,2015-10-08T10:23:21Z,3118,"[{'description': 'CCT251455 inhibits autophosphorylation of TTK (MPS1) to promote cell death (PMID: 26202014).', 'references': [{'id': 3711, 'pubMedId': 26202014, 'title': 'Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26202014'}]}]",CCT251455,2015-10-08T10:23:21Z
0,2014-07-29T19:58:26Z,1227,"[{'description': 'T cells that have been sensitized to vaccine tumor antigen(s) in vivo, then collected from the patient, costimulated with antibodies to the T-cell cell surface proteins CD3 and CD28 and expanded, then re-infused to the same patient (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",CD3/CD28 costimulated vaccine-primed autologous T-cells,2014-07-29T19:59:58Z
0,2014-10-08T14:19:45Z,1628,"[{'description': 'CD532 is a specific inhibitor of AURKA that simultaneously inhibits its kinase activity and also destabilizes its interaction with MYCN, leading to the loss of  Mycn protein (PMID: 25175806).', 'references': [{'id': 913, 'pubMedId': 25175806, 'title': 'Drugging MYCN through an allosteric transition in Aurora kinase A.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25175806'}]}]",CD532,2017-04-04T12:32:28Z
0,2017-05-25T15:00:36Z,5774,"[{'description': 'CDX-014 is a monoclonal antibody against the extracellular domain of T-cell immunoglobulin mucin-1 (TIM-1) in conjugation with the cytotoxin monomethyl auristatin E (MMAE), which may results in cytotoxicity specific to TIM-1 over-expressing tumor cells (PMID: 27671527).', 'references': [{'id': 8982, 'pubMedId': 27671527, 'title': 'Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27671527'}]}]",CDX-014,2017-05-25T15:00:36Z
0,2016-04-29T19:54:15Z,4037,"[{'description': 'CDX-0158 (KTN0158) is a humanized anti-cKIT antibody that inhibits KIT signaling, resulting in inhibition of cell proliferation (Mol Cancer Ther December 2015 14; C167 ).', 'references': [{'id': 5291, 'pubMedId': None, 'title': 'KTN0158, a humanized anti-KIT monoclonal antibody, demonstrates antitumor activity in dogs with mast cell tumors', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/C167.short?rss=1'}]}]",CDX-0158,2017-05-24T18:04:18Z
0,2015-08-12T00:12:04Z,3007,"[{'description': 'Mobista (CDX-301) is a recombinant Flt3 ligand that binds to and activates the Flt3 receptor, leading to proliferation of immune precursor cells (PMID: 25915810).', 'references': [{'id': 3427, 'pubMedId': 25915810, 'title': 'Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25915810'}]}]",CDX-301,2015-09-03T01:19:38Z
0,2016-06-22T01:54:37Z,4337,[],CDX-301 + poly ICLC ,2016-06-22T01:54:37Z
0,2015-02-11T18:36:46Z,2054,"[{'description': 'CDX-3379 (KTN3379) is a monoclonal antibody that targets ERBB3 (HER3) and prevents ligand binding, which may reduce downstream signaling associated with ERBB2 (HER2) dimerization, and potentially leads to decreased cell proliferation and differentiation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",CDX-3379,2017-05-24T18:05:19Z
0,2015-02-12T14:33:02Z,2062,[],CDX-3379 + Erlotinib,2017-05-24T18:06:28Z
0,2015-02-12T14:35:31Z,2064,[],CDX-3379 + Trastuzumab,2017-05-24T18:07:29Z
0,2015-02-12T14:33:47Z,2063,[],CDX-3379 + Vemurafenib,2017-05-24T18:06:52Z
0,2014-05-14T14:52:46Z,1001,"[{'description': 'Cediranib (AZD-2171) is an ATP-competitive inhibitor of all three vascular endothelial growth factor receptors (FLT1, KDR, and FLT4) and KIT, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth (PMID: 15899831, PMID: 24714778). ', 'references': [{'id': 1858, 'pubMedId': 15899831, 'title': 'AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15899831'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Cediranib,2016-04-25T16:45:28Z
0,2016-08-02T19:29:58Z,4514,[],Cediranib + Carboplatin,2016-08-02T19:29:58Z
0,2014-10-27T17:34:58Z,1664,[],Cediranib + Carboplatin + Paclitaxel,2014-10-27T17:34:58Z
0,2015-03-19T10:39:43Z,2432,[],Cediranib + Cisplatin + Pemetrexed,2015-03-19T10:39:43Z
0,2015-07-10T14:43:40Z,2895,[],Cediranib + Durvalumab,2017-05-25T19:43:01Z
0,2017-09-21T15:00:14Z,6227,[],Cediranib + Durvalumab + Olaparib,2017-09-21T15:00:14Z
0,2015-11-30T16:54:11Z,3229,[],Cediranib + Gefitinib,2015-11-30T16:54:11Z
0,2015-11-30T16:25:00Z,3228,[],Cediranib + Gemcitabine + Cisplatin,2015-11-30T16:25:00Z
0,2015-03-20T00:59:36Z,2437,[],Cediranib + Lenalidomide,2015-03-20T00:59:36Z
0,2016-08-02T20:08:38Z,4515,[],Cediranib + Lomustine,2016-08-02T20:08:38Z
0,2015-01-23T03:24:29Z,1971,[],Cediranib + Olaparib,2015-01-23T03:24:29Z
0,2016-03-10T13:27:48Z,3698,[],Cediranib + PLX4720,2016-03-10T13:27:48Z
0,2016-04-13T01:53:18Z,3922,[],Cediranib + Saracatinib,2016-04-13T01:53:32Z
0,2016-03-10T13:28:22Z,3699,[],Cediranib + Selumetinib + PLX4720,2016-03-10T13:28:22Z
0,2015-02-20T17:22:11Z,2124,"[{'description': 'Celebra (celecoxib) is a COX-2 inhibitor FDA approved as an anti-inflammatory agent and for colorectal polyp reduction (FDA.gov). Celebra (celecoxib) also promotes apoptosis of tumor cells (PMID: 17909047). ', 'references': [{'id': 1924, 'pubMedId': 17909047, 'title': 'Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17909047'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Celecoxib,2015-04-24T14:37:25Z
0,2015-10-21T01:48:27Z,3143,[],Celecoxib + Cyclophosphamide + Etoposide + Sirolimus,2015-10-21T01:48:27Z
0,2015-02-20T17:28:34Z,2125,[],Celecoxib + Erlotinib,2015-02-20T17:28:34Z
0,2016-01-21T21:31:46Z,3433,[],Celecoxib + Itraconazole + Tretinoin ,2016-01-21T21:31:46Z
0,2016-09-08T13:53:04Z,4667,[],Celecoxib + OBP-801,2016-09-08T13:53:04Z
0,2015-04-10T02:33:46Z,2519,"[{'description': 'CEP-28122 is a small molecule inhibitor of ALK, potentially resulting  in reduced growth of ALK-positive tumors (PMID: 22203728).', 'references': [{'id': 2441, 'pubMedId': 22203728, 'title': 'CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22203728'}]}]",CEP-28122,2015-04-10T02:33:46Z
0,2014-05-14T14:52:46Z,1002,"[{'description': 'RXDX-105 (CEP-32496) inhibits wild-type BRAF, BRAF V600E, c-RAF, ABL1 (and BCR-ABL), c-KIT, RET, PDGFR beta, and VEGFR2, potentially resulting in decreased tumor growth (PMID: 22319199).', 'references': [{'id': 203, 'pubMedId': 22319199, 'title': 'CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22319199'}]}]",CEP-32496,2017-04-21T14:09:00Z
0,2015-06-04T10:13:06Z,2787,"[{'description': 'CEP-33779 is a selective inhibitor of JAK2, which inhibits STAT3 signaling to prevent cell proliferation (PMID: 22334590).', 'references': [{'id': 2945, 'pubMedId': 22334590, 'title': 'Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22334590'}]}]",CEP-33779,2015-06-04T10:13:06Z
0,2015-02-24T15:47:44Z,2147,"[{'description': 'CEP-37440 is a dual kinase inhibitor, which binds to and inhibits ALK and FAK, resulting in decreased downstream signaling and reduced tumor growth (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",CEP-37440,2015-02-24T15:47:44Z
0,2016-02-17T15:39:19Z,3536,"[{'description': 'CEP-8983 inhibits PARP1 and PARP2, potentially resulting in decreased tumor cell viability and increased sensitivity to DNA damaging agents (PMID: 24439051, PMID: 23428903).', 'references': [{'id': 4605, 'pubMedId': 23428903, 'title': 'Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23428903'}, {'id': 4604, 'pubMedId': 24439051, 'title': 'Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24439051'}]}]",CEP-8983,2017-05-09T20:07:31Z
0,2016-02-17T15:49:01Z,3537,[],CEP-8983 + Cisplatin,2016-02-17T15:49:01Z
0,2015-04-15T18:19:12Z,2538,"[{'description': 'CEP-9722 inhibits PARP-1 and PARP-2, potentially resulting in decreased tumor growth and increased sensitivity to DNA damaging agents (PMID: 24880570, PMID: 24714082).', 'references': [{'id': 2482, 'pubMedId': 24880570, 'title': 'Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24880570'}, {'id': 2483, 'pubMedId': 24714082, 'title': 'Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24714082'}]}]",CEP-9722,2017-05-10T14:43:53Z
0,2017-05-10T14:45:41Z,5654,[],CEP-9722 + Temozolomide,2017-05-10T14:45:41Z
0,2015-04-10T17:31:06Z,2531,"[{'description': 'Cerdulatinib (PRT062070) is an inhibitor of JAK1/3 and SYK, which may result in decreased tumor growth (PMID: 25253883).', 'references': [{'id': 2450, 'pubMedId': 25253883, 'title': 'The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25253883'}]}]",Cerdulatinib,2015-10-21T20:37:19Z
0,2017-07-07T04:30:43Z,5979,[],Cerdulatinib + Venetoclax,2017-07-07T04:30:43Z
0,2014-03-12T15:53:16Z,789,"[{'description': 'Zykadia (ceritinib) inhibits ALK, including ALK mutations and fusions, and has additional activity against ROS1, potentially resulting in decreased tumor cell growth (PMID: 25322323, PMID: 26372962). Zykadia (ceritinib) is FDA approved for ALK-positive lung cancer (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Ceritinib,2017-10-13T15:14:36Z
0,2015-02-24T16:34:04Z,2148,[],Ceritinib + CGM097,2015-02-24T16:34:04Z
0,2015-10-07T18:57:37Z,3108,[],Ceritinib + Crizotinib,2015-10-07T18:57:37Z
0,2015-03-05T15:41:54Z,2295,[],Ceritinib + Everolimus,2015-03-05T15:41:54Z
0,2015-04-22T02:15:58Z,2554,[],Ceritinib + Gemcitabine,2015-04-22T02:15:58Z
0,2015-05-08T01:54:58Z,2638,[],Ceritinib + LEE011,2015-05-08T01:54:58Z
0,2015-04-23T02:25:18Z,2565,[],Ceritinib + Nivolumab,2015-04-23T02:25:18Z
0,2016-10-05T15:32:38Z,4786,[],Ceritinib + Selumetinib,2016-10-05T15:32:38Z
0,2017-10-09T15:02:20Z,6303,[],Ceritinib + Trametinib,2017-10-09T15:02:20Z
0,2014-03-12T15:53:16Z,694,"[{'description': 'Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (NCI Drug Dictionary). Erbitux (cetuximab) is FDA approved for use in colorectal cancer and head and neck squamous cell carcinoma (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Cetuximab,2016-06-27T14:45:15Z
0,2016-10-12T19:29:41Z,4819,[],Cetuximab + C75,2016-10-12T19:29:41Z
0,2015-01-06T13:25:57Z,1914,[],Cetuximab + Carboplatin + Fluorouracil,2015-01-06T13:25:57Z
0,2015-02-12T14:31:39Z,2061,[],Cetuximab + CDX-3379,2017-05-24T18:05:40Z
0,2015-01-06T13:29:04Z,1915,[],Cetuximab + Cisplatin,2015-01-06T13:29:04Z
0,2017-09-18T16:02:33Z,6212,[],Cetuximab + Cisplatin + Docetaxel + Fluorouracil,2017-09-18T16:02:33Z
0,2015-01-07T15:29:30Z,1928,[],Cetuximab + Cisplatin + Fluorouracil + Radiotherapy,2017-01-16T22:04:37Z
0,2014-12-17T14:30:40Z,1790,[],Cetuximab + Cisplatin + Paclitaxel,2014-12-17T14:30:40Z
0,2017-08-04T04:07:14Z,6090,[],Cetuximab + Cisplatin + Paclitaxel + Radiotherapy,2017-08-04T04:07:14Z
0,2016-12-16T21:22:19Z,5104,[],Cetuximab + Cisplatin + Vinorelbine,2016-12-16T21:22:19Z
0,2016-08-05T16:15:03Z,4525,[],Cetuximab + Dabrafenib,2016-08-05T16:15:03Z
0,2016-08-08T18:27:45Z,4542,[],Cetuximab + Dabrafenib + SCH772984,2016-08-08T18:27:45Z
0,2016-08-08T18:14:13Z,4541,[],Cetuximab + Dabrafenib + Trametinib,2016-08-08T18:14:13Z
0,2014-12-19T15:46:58Z,1820,[],Cetuximab + Dasatinib,2014-12-19T15:46:58Z
0,2017-08-03T14:46:42Z,6074,[],Cetuximab + Dasatinib + FOLFOX,2017-08-03T14:46:42Z
0,2015-01-06T14:51:42Z,1922,[],Cetuximab + Docetaxel + Methotrexate ,2015-01-06T14:51:42Z
0,2016-08-04T20:09:14Z,4521,[],Cetuximab + EAI045,2016-08-04T20:09:14Z
0,2016-08-12T14:35:22Z,4556,[],Cetuximab + ECF,2016-08-12T14:35:22Z
0,2016-10-12T19:30:20Z,4820,[],Cetuximab + EGCG,2016-10-12T19:30:20Z
0,2015-01-06T13:33:14Z,1916,[],Cetuximab + Encorafenib,2017-06-14T18:55:21Z
0,2015-12-16T03:06:35Z,3292,[],Cetuximab + Fluorouracil + Irinotecan + Floxuridine,2015-12-16T03:06:35Z
0,2017-04-27T16:25:05Z,5578,[],Cetuximab + Fluorouracil + NC-6004,2017-04-27T16:25:05Z
0,2015-02-27T02:46:24Z,2180,[],Cetuximab + FOLFIRI,2015-02-27T02:47:39Z
0,2015-02-27T03:07:36Z,2184,[],Cetuximab + FOLFIRINOX,2015-02-27T03:07:36Z
0,2015-02-27T03:01:46Z,2182,[],Cetuximab + FOLFOX,2015-02-27T03:01:46Z
0,2016-11-13T21:36:42Z,4948,[],Cetuximab + Hu5F9-G4,2016-11-13T21:36:42Z
0,2016-08-12T14:41:25Z,4557,[],Cetuximab + IC,2016-08-12T14:41:25Z
0,2015-02-12T14:42:40Z,2065,[],Cetuximab + Imprime PGG,2015-02-12T14:42:40Z
0,2016-01-10T19:15:06Z,3383,[],Cetuximab + IPH2201,2016-01-10T19:15:06Z
0,2015-01-07T14:50:26Z,1926,[],Cetuximab + Ipilimumab,2015-01-07T14:50:26Z
0,2014-12-30T16:36:31Z,1874,[],Cetuximab + Irinotecan,2014-12-30T16:36:31Z
0,2017-10-02T20:17:38Z,6288,[],Cetuximab + Irinotecan + Utomilumab,2017-10-10T17:45:13Z
0,2017-06-30T14:19:02Z,5951,[],Cetuximab + JNJ 38877605,2017-06-30T14:19:02Z
0,2014-10-28T19:36:49Z,1672,[],Cetuximab + Lapatinib,2014-10-28T19:36:49Z
0,2016-09-06T15:37:31Z,4647,[],Cetuximab + lenalidomide,2016-09-06T15:37:31Z
0,2017-10-18T20:22:59Z,6338,[],Cetuximab + LSN3074753,2017-10-18T20:22:59Z
0,2017-10-10T19:13:37Z,6309,[],Cetuximab + Lumretuzumab,2017-10-10T19:13:37Z
0,2016-08-14T15:30:35Z,4559,[],Cetuximab + Mannitol,2016-08-14T15:30:35Z
0,2014-12-23T14:37:31Z,1840,[],Cetuximab + Methotrexate,2014-12-23T14:37:31Z
0,2017-05-17T15:15:29Z,5679,[],Cetuximab + Motolimod,2017-05-17T15:15:29Z
0,2015-10-15T01:11:33Z,3127,[],Cetuximab + nab-paclitaxel,2015-10-15T01:11:33Z
0,2014-07-27T20:22:59Z,1118,[],Cetuximab + Neratinib,2014-07-27T20:22:59Z
0,2016-09-25T18:03:30Z,4761,[],Cetuximab + Nivolumab,2016-09-25T18:03:30Z
0,2015-01-06T14:37:51Z,1921,[],Cetuximab + Paclitaxel + Carboplatin + Erlotinib,2015-01-06T14:37:51Z
0,2015-02-24T14:06:04Z,2145,[],Cetuximab + PEGPH20,2015-02-24T14:06:04Z
0,2017-09-14T16:30:05Z,6208,[],Cetuximab + PLX4720,2017-09-14T16:32:05Z
0,2015-01-30T15:09:02Z,1993,[],Cetuximab + Prexasertib,2017-08-22T19:04:16Z
0,2017-05-11T16:18:10Z,5661,[],Cetuximab + Prexasertib + Radiotherapy,2017-08-22T19:11:20Z
0,2016-03-21T00:50:25Z,3790,[],Cetuximab + Savolitinib,2017-07-12T17:26:57Z
0,2016-08-08T18:28:24Z,4543,[],Cetuximab + SCH772984,2016-08-08T18:28:24Z
0,2016-08-08T16:04:52Z,4536,[],Cetuximab + Selumetinib,2016-08-08T16:04:52Z
0,2016-08-08T17:51:49Z,4540,[],Cetuximab + Selumetinib + Vemurafenib,2016-08-08T17:51:49Z
0,2016-08-15T16:29:07Z,4568,[],Cetuximab + Sunitinib,2016-08-15T16:29:07Z
0,2016-02-07T01:49:53Z,3505,[],Cetuximab + Trametinib,2016-02-07T01:49:53Z
0,2014-08-31T10:12:32Z,1413,[],Cetuximab + Trastuzumab,2014-08-31T10:12:32Z
0,2015-02-12T14:44:57Z,2066,[],Cetuximab + Urelumab,2015-02-12T14:44:57Z
0,2017-09-14T17:29:49Z,6209,[],Cetuxmab + Sorafenib,2017-09-14T20:11:20Z
0,2015-06-11T19:08:33Z,2825,"[{'description': 'CFG920 inhibits CYP17, resulting in decreased androgen production and potentially leading to reduced proliferation of androgen-dependent tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",CFG920,2015-06-11T19:08:33Z
0,2016-01-26T10:57:00Z,3463,"[{'description': 'CFI-400936 is an inhibitor of TTK (MPS1), which inhibits cell proliferation (PMID: 25043312).', 'references': [{'id': 4447, 'pubMedId': 25043312, 'title': 'Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25043312'}]}]",CFI-400936,2016-01-26T11:04:46Z
0,2016-04-29T18:12:43Z,4029,"[{'description': 'CFI-400945 is a selective Polo-like kinase 4 (PLK4) inhibitor that inhibits cell division and induces apoptosis in tumor cells (PMID: 25043604).', 'references': [{'id': 5283, 'pubMedId': 25043604, 'title': 'Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25043604'}]}]",CFI-400945,2016-04-29T18:12:43Z
0,2016-01-26T11:04:18Z,3464,"[{'description': 'CFI-401870 is an inhibitor of TTK (MPS1), which inhibits cell proliferation (PMID: 25763473).', 'references': [{'id': 4448, 'pubMedId': 25763473, 'title': 'The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25763473'}]}]",CFI-401870,2016-01-26T11:04:18Z
0,2017-06-05T20:33:22Z,5853,"[{'description': 'CFI-402257 selectively inhibits TTK (MPS1), resulting in chromosomal segregation errors, and potentially leading to decreased tumor cell growth (PMID: 28270606).', 'references': []}]",CFI-402257,2017-06-05T20:37:32Z
0,2017-06-06T13:48:05Z,5855,[],CFI-402257 + unspecified PD-1 antibody,2017-06-06T13:48:05Z
0,2015-04-10T15:01:34Z,2523,"[{'description': 'CG0070 is a recombinant adenovirus that selectively infects, replicates and produces GM-CSF in tumor cells, which leads to tumor lysis and cytotoxic T cell-mediated tumor cell death (PMID: 16397056). ', 'references': [{'id': 2446, 'pubMedId': 16397056, 'title': 'CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16397056'}]}]",CG0070,2015-04-17T15:07:11Z
0,2017-03-13T19:30:56Z,5434,"[{'description': 'CG200745 is an HDAC inhibitor, which increases tumor cell apoptosis and decreases tumor cell growth (PMID: 25781604, PMID: 28134290).', 'references': [{'id': 8225, 'pubMedId': 25781604, 'title': 'Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25781604'}, {'id': 8224, 'pubMedId': 28134290, 'title': 'A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28134290'}]}]",CG200745,2017-03-13T19:30:56Z
0,2015-05-15T02:28:57Z,2694,"[{'description': 'CGI1746 binds to BTK and prevents its activation, resulting in decreased proliferation of B-cells (PMID: 21113169).', 'references': [{'id': 2734, 'pubMedId': 21113169, 'title': 'Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21113169'}]}]",CGI1746,2015-05-15T02:28:57Z
0,2015-02-13T20:08:57Z,2077,"[{'description': 'CGM097 binds to the p53 binding region of MDM2 and prevents MDM2-p53 interaction, resulting in activation of p53 signaling and decreased tumor growth (Cancer Res October 1, 2014 74:4638).', 'references': [{'id': 1885, 'pubMedId': None, 'title': 'Abstract 4638: NVP-CGM097: a novel p53-Mdm2 inhibitor exhibiting potent antitumor activity in mouse models of human cancer', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/4638.short'}]}]",CGM097,2015-02-13T20:08:57Z
0,2015-03-04T18:47:30Z,2285,[],CGM097 + LGX818,2015-03-04T18:47:30Z
0,2017-02-13T18:09:39Z,5314,[],CGM097 + Trametinib,2017-02-13T18:09:39Z
0,2016-06-14T19:49:21Z,4285,"[{'description': 'CGP-082996 is an inhibitor of CDK4, which may induce cell cycle arrest and tumor cell death (PMID: 27012813).', 'references': [{'id': 5910, 'pubMedId': 27012813, 'title': 'DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27012813'}]}]",CGP-082996,2016-06-23T17:18:39Z
0,2015-02-18T00:15:22Z,2082,"[{'description': 'CGP049090 inhibits the interaction of CTNNB1 with TCF7L2 to block Wnt signaling and promote apoptosis (PMID: 20360943).', 'references': [{'id': 1913, 'pubMedId': 20360943, 'title': 'Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20360943'}]}]",CGP049090,2015-02-18T00:15:22Z
0,2016-04-06T18:33:10Z,3901,"[{'description': 'CGP57380 inhibits MAPK-interacting protein kinase (MNK) 1 and 2, and may have additional activity against other protein kinases, leading to decreased phosphorylation of eIF4E and potentially resulting in decreased tumor cell growth and migration (PMID: 17850214, PMID: 21406405, PMID: 26609108).', 'references': [{'id': 5112, 'pubMedId': 21406405, 'title': 'MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21406405'}, {'id': 5113, 'pubMedId': 26609108, 'title': 'Differential Regulation of ZEB1 and EMT by MAPK-Interacting Protein Kinases (MNK) and eIF4E in Pancreatic Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26609108'}, {'id': 5111, 'pubMedId': 17850214, 'title': 'The selectivity of protein kinase inhibitors: a further update.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17850214'}]}]",CGP57380,2016-04-06T18:33:10Z
0,2016-03-29T19:06:18Z,3864,"[{'description': 'Ch282-5 is a gossypol derivative that binds to and inhibits BCL2, family proteins, resulting in decreased tumor cell growth and increased sensitivity to chemotherapeutic agents (PMID: 26515494).', 'references': [{'id': 5069, 'pubMedId': 26515494, 'title': 'A Novel Bioavailable BH3 Mimetic Efficiently Inhibits Colon Cancer via Cascade Effects of Mitochondria.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26515494'}]}]",Ch282-5,2016-03-29T19:06:18Z
0,2016-03-29T19:27:17Z,3865,[],Ch282-5 + Oxaliplatin,2016-03-29T19:27:17Z
0,2015-02-24T19:25:01Z,2152,"[{'description': 'CH5132799 inhibits class I PI3Ks, including the PIKC3A mutants E542K, E545K, and H1047R, resulting in decreased PI3K pathway signaling and decreased tumor growth (PMID: 21558396).', 'references': [{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]}]",CH5132799,2016-04-01T14:25:09Z
0,2015-08-21T13:38:33Z,3040,[],CH5132799 + Everolimus,2015-08-21T13:38:33Z
0,2015-08-21T12:58:22Z,3039,[],CH5132799 + Trastuzumab,2015-08-21T12:58:22Z
0,2015-06-10T19:54:02Z,2815,"[{'description': 'CH5137291 is an androgen receptor (AR) antagonist that additionally inhibits the nuclear translocation of AR, potentially resulting in decreased tumor growth (PMID: 21050768, PMID: 25634071).', 'references': [{'id': 3005, 'pubMedId': 21050768, 'title': 'Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21050768'}, {'id': 3004, 'pubMedId': 25634071, 'title': 'CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25634071'}]}]",CH5137291,2015-06-10T19:54:02Z
0,2015-06-03T17:24:59Z,2765,"[{'description': 'CH5138303 is a small molecule inhibitor of HSP90, which may lead to decreased tumor growth (PMID: 24369839).', 'references': [{'id': 2913, 'pubMedId': 24369839, 'title': 'Design and synthesis of 2-amino-6-(1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazines as novel Hsp90 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24369839'}]}]",CH5138303,2015-06-03T17:24:59Z
0,2015-02-02T15:59:01Z,1998,"[{'description': 'Chiauranib (CS2164) is a multi-kinase inhibitor that inhibits AURKB, CSF-1R, VEGFRs, KIT, and PDGFRA, resulting in decreased tumor growth and angiogenesis (PMID: 28004478).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 8299, 'pubMedId': 28004478, 'title': 'CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28004478'}]}]",Chiauranib,2017-04-04T14:07:19Z
0,2015-08-10T16:44:46Z,3003,"[{'description': 'Chidamide (CS055) is an HDAC inhibitor, which may lead to increased apoptosis and decreased proliferation of tumor cells (PMID: 25384499).', 'references': [{'id': 3418, 'pubMedId': 25384499, 'title': 'Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25384499'}]}]",Chidamide,2016-01-13T00:33:23Z
0,2016-09-12T19:02:44Z,4689,[],Chidamide + Nivolumab,2016-09-12T19:02:44Z
0,2015-08-19T01:54:54Z,3035,[],Chlorambucil,2015-08-19T01:54:54Z
0,2015-03-10T15:40:36Z,2342,[],Chlorambucil + Obinutuzumab + TGR-1202,2015-03-10T15:40:36Z
0,2016-09-23T20:01:05Z,4752,[],Chlorambucil + Ofatumumab,2016-09-23T20:01:05Z
0,2017-04-13T19:25:41Z,5544,[],Chlorambucil + Rituximab,2017-04-13T19:25:41Z
0,2015-08-10T17:26:01Z,3005,"[{'description': 'CHR-3996 is a selective Class I HDAC inhibitor, which may result in decreased tumor growth (PMID: 22553374).', 'references': [{'id': 3421, 'pubMedId': 22553374, 'title': 'A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22553374'}]}]",CHR-3996,2015-08-10T17:26:01Z
0,2016-04-27T19:54:35Z,4016,"[{'description': 'CHZ868 is a Type II JAK2 inhibitor, which stabilizes JAK2 in the inactive conformation resulting in decreased downstream signaling and potentially leading to decreased tumor cell growth (PMID: 26175413).', 'references': [{'id': 5260, 'pubMedId': 26175413, 'title': 'CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26175413'}]}]",CHZ868,2016-04-27T19:54:35Z
0,2014-03-12T15:53:16Z,699,"[{'description': 'CI-1040 (PD184352) binds and inhibits Mek1 and Mek2, which may inhibit the activation of downstream signaling targets and reduce tumor cell proliferation (PMID: 14613031).', 'references': [{'id': 2260, 'pubMedId': 14613031, 'title': 'CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/14613031'}]}]",CI-1040,2017-04-06T09:58:23Z
0,2015-10-30T02:21:23Z,3158,"[{'description': 'CID1067700 is a small molecule that inhibits GTP binding to multiple GTPases, including Ras, Rho, and Rab, blocking downstream signaling, and potentially resulting in decreased cell viability in culture (PMID: 26247207).\r\n', 'references': [{'id': 3837, 'pubMedId': 26247207, 'title': 'A Pan-GTPase Inhibitor as a Molecular Probe.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26247207'}]}]",CID1067700,2015-11-17T20:13:21Z
0,2017-07-24T18:28:46Z,6004,"[{'description': 'cIIIA4 is a modified version of the EphA3-targeted monoclonal antibody IIIA4 that has been engineered with a human IgG1 backbone, which binds to EphA3, potentially resulting in decreased growth of EphA3-expressing tumor cells (PMID: 27922598).', 'references': [{'id': 9542, 'pubMedId': 27922598, 'title': 'EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27922598'}]}]",cIIIA4,2017-07-24T19:26:13Z
0,2016-08-08T21:07:43Z,4551,"[{'description': 'CIMAvax-EGF is a cancer vaccine composed of EGF linked to the carrier protein P64, which induces an immune response against EGF, resulting in decreased EGF expression and has potential antitumor activity (PMID: 26927662).', 'references': [{'id': 6453, 'pubMedId': 26927662, 'title': 'A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26927662'}]}]",CIMAvax-EGF,2016-08-08T21:07:43Z
0,2016-11-13T20:45:37Z,4941,[],CIMAvax-EGF + Nivolumab,2016-11-13T20:45:37Z
0,2016-06-17T21:46:46Z,4312,"[{'description': 'Cirmtuzumab is a monoclonal antibody that binds to human receptor tyrosine kinase-like orphan receptor 1 (ROR1) and blocks ROR1 signaling, leading to growth inhibition in tumor cells (PMID: 26297272).', 'references': [{'id': 5964, 'pubMedId': 26297272, 'title': 'Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26297272'}]}]",Cirmtuzumab,2016-06-17T21:46:46Z
0,2017-03-28T02:57:43Z,5480,[],Cirmtuzumab + Ibrutinib,2017-03-28T02:57:43Z
0,2016-06-17T21:47:36Z,4313,[],Cirmtuzumab + Paclitaxel,2016-06-17T21:47:36Z
0,2014-03-12T15:53:16Z,700,"[{'description': 'Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Cisplatin,2014-12-01T02:51:30Z
0,2016-02-26T21:52:09Z,3651,[],Cisplatin + Custirsen + Gemcitabine,2016-02-26T21:52:09Z
0,2015-03-11T15:31:14Z,2354,[],Cisplatin + Cytarabine + Dexamethasone,2015-03-11T15:31:14Z
0,2016-01-10T22:09:27Z,3391,[],Cisplatin + Dexamethasone + Gemcitabine + Rituximab,2016-01-10T22:09:27Z
0,2015-01-29T13:28:50Z,1987,[],Cisplatin + Docetaxel + Cetuximab,2015-01-29T13:28:50Z
0,2015-01-07T16:09:23Z,1930,[],Cisplatin + Docetaxel + Fluorouracil,2015-01-07T16:09:23Z
0,2015-03-12T15:10:23Z,2372,[],Cisplatin + Docetaxel + Nintedanib,2015-03-12T15:10:23Z
0,2015-01-07T15:16:51Z,1927,[],Cisplatin + Doxorubicin + Cyclophosphamide,2015-01-07T15:16:51Z
0,2014-12-24T16:17:17Z,1851,[],Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide,2014-12-24T16:17:17Z
0,2016-11-07T17:46:27Z,4926,[],Cisplatin + DPP-23,2016-11-07T17:46:27Z
0,2017-05-05T19:35:03Z,5630,[],Cisplatin + Durvalumab + Pemetrexed,2017-05-05T19:35:03Z
0,2015-04-24T13:50:07Z,2585,[],Cisplatin + Etoposide,2015-04-24T13:50:07Z
0,2017-07-21T02:11:55Z,6002,[],Cisplatin + Etoposide + GSK3052230,2017-07-21T02:11:55Z
0,2016-11-06T21:38:54Z,4922,[],Cisplatin + Etoposide + Nivolumab,2016-11-06T21:38:54Z
0,2014-08-05T18:10:02Z,1375,[],Cisplatin + Etoposide + Paclitaxel + Carboplatin + Erlotinib,2014-08-05T18:10:02Z
0,2017-01-03T19:58:29Z,5145,[],Cisplatin + Etoposide + Pembrolizumab,2017-01-03T19:58:29Z
0,2015-04-08T01:54:10Z,2504,[],Cisplatin + Etoposide + Sonidegib,2017-06-19T19:32:46Z
0,2017-06-23T04:09:55Z,5920,[],Cisplatin + ETP-46464,2017-06-23T04:09:55Z
0,2015-03-05T15:50:49Z,2296,[],Cisplatin + Everolimus + Gemcitabine,2015-03-05T15:50:49Z
0,2017-08-03T17:41:37Z,6083,[],Cisplatin + Everolimus + Paclitaxel,2017-08-03T17:41:37Z
0,2014-12-22T17:04:41Z,1833,[],Cisplatin + Fluorouracil,2014-12-22T17:04:41Z
0,2014-12-24T15:36:08Z,1849,[],Cisplatin + Fluorouracil + Hydroxyurea,2014-12-24T15:36:08Z
0,2017-07-28T19:23:33Z,6051,[],Cisplatin + Fluorouracil + Pembrolizumab,2017-07-28T19:23:33Z
0,2015-03-05T16:19:18Z,2297,[],Cisplatin + Fluorouracil + Vincristine,2015-03-05T16:19:18Z
0,2016-05-27T17:10:46Z,4176,[],Cisplatin + Gemcitabine + INCB054828,2016-05-27T17:10:46Z
0,2016-06-27T00:44:32Z,4374,[],Cisplatin + Gemcitabine + LY3039478,2016-06-27T00:44:32Z
0,2017-06-29T19:39:01Z,5950,[],Cisplatin + Gemcitabine + Metformin,2017-06-29T19:39:01Z
0,2016-05-06T19:09:38Z,4087,[],Cisplatin + Gemcitabine + nab-paclitaxel + Nivolumab + Paricalcitol,2016-05-06T19:09:38Z
0,2017-04-07T13:11:31Z,5511,[],Cisplatin + Gemcitabine + Nivolumab,2017-04-07T13:11:31Z
0,2017-07-28T02:40:22Z,6025,[],Cisplatin + Gemcitabine + PDR001,2017-07-28T02:40:22Z
0,2015-12-03T03:07:54Z,3248,[],Cisplatin + Gemcitabine + Pembrolizumab,2015-12-03T03:07:54Z
0,2017-08-04T19:36:09Z,6091,[],Cisplatin + Gemcitabine + Silmitasertib,2017-08-04T19:36:09Z
0,2015-03-05T15:00:56Z,2289,[],Cisplatin + Gemcitabine + Sirolimus ,2015-03-05T15:00:56Z
0,2017-03-22T15:33:11Z,5462,[],Cisplatin + Gemcitabine + Sorafenib,2017-03-22T15:33:11Z
0,2015-10-08T02:22:35Z,3110,[],Cisplatin + Gemcitabine + VX-970,2015-10-08T02:22:35Z
0,2016-08-31T17:03:00Z,4631,[],Cisplatin + JQ1,2016-08-31T17:03:00Z
0,2017-04-18T15:20:03Z,5554,[],Cisplatin + KPT-185,2017-04-18T15:20:03Z
0,2015-02-27T16:51:23Z,2205,[],Cisplatin + Metformin,2015-02-27T16:51:23Z
0,2015-10-15T01:10:44Z,3126,[],Cisplatin + nab-paclitaxel,2015-10-15T01:10:44Z
0,2016-09-25T18:02:02Z,4760,[],Cisplatin + Nivolumab,2016-09-25T18:02:02Z
0,2016-09-09T14:01:32Z,4675,[],Cisplatin + NSC59984,2016-09-09T14:01:32Z
0,2017-09-11T18:41:19Z,6195,[],Cisplatin + NU6027,2017-09-11T18:41:19Z
0,2017-05-03T15:25:25Z,5604,[],Cisplatin + NVP-BHG712,2017-05-03T15:25:37Z
0,2016-03-28T19:30:56Z,3860,[],Cisplatin + OPB-31121,2016-03-28T19:30:56Z
0,2014-12-19T05:35:28Z,1812,[],Cisplatin + Paclitaxel,2014-12-19T05:35:28Z
0,2014-09-11T15:26:06Z,1451,[],Cisplatin + Paclitaxel + Bevacizumab + Olaparib ,2014-09-11T15:26:06Z
0,2016-09-21T15:50:29Z,4734,[],Cisplatin + Palbociclib,2016-09-21T15:50:29Z
0,2015-12-03T15:46:15Z,3256,[],Cisplatin + Pembrolizumab,2015-12-03T15:46:15Z
0,2014-12-28T20:39:47Z,1857,[],Cisplatin + Pemetrexed,2014-12-28T20:39:47Z
0,2017-07-28T02:42:02Z,6026,[],Cisplatin + Pemetrexed + PDR001,2017-07-28T02:42:02Z
0,2016-02-24T00:56:25Z,3600,[],Cisplatin + Perifosine,2016-02-24T00:56:25Z
0,2015-01-30T15:09:45Z,1994,[],Cisplatin + Prexasertib,2017-08-22T19:03:37Z
0,2015-08-06T02:32:40Z,2993,[],Cisplatin + Romidepsin ,2015-08-06T02:32:40Z
0,2017-02-22T15:52:03Z,5351,[],Cisplatin + SAR405838,2017-02-22T15:52:03Z
0,2017-04-18T15:17:01Z,5553,[],Cisplatin + Selinexor,2017-04-18T15:17:01Z
0,2015-02-27T20:14:19Z,2212,[],Cisplatin + Sorafenib + Tamoxifen,2015-02-27T20:14:19Z
0,2017-02-14T21:02:38Z,5324,[],Cisplatin + Talazoparib,2017-06-12T16:03:21Z
0,2016-11-11T05:28:19Z,4933,[],Cisplatin + Trabectedin,2016-11-11T05:28:19Z
0,2016-06-08T19:48:18Z,4260,[],Cisplatin + TRX-E-002-1,2016-06-08T19:48:18Z
0,2017-06-23T04:31:24Z,5922,[],Cisplatin + VE-821,2017-06-23T04:31:24Z
0,2016-06-15T16:27:04Z,4286,[],Cisplatin + Veliparib + Vinorelbine,2016-06-15T16:27:04Z
0,2016-04-22T14:24:45Z,3993,[],Cisplatin + Veliparib + VX-970,2016-04-22T14:24:45Z
0,2017-01-21T04:54:19Z,5241,[],Cisplatin + Vinorelbine + Gemcitabine + Docetaxel + Pemetrexed + Carboplatin,2017-01-21T04:54:19Z
0,2015-10-08T02:19:55Z,3109,[],Cisplatin + VX-970,2015-10-08T02:19:55Z
0,2015-12-20T23:00:32Z,3311,"[{'description': 'Citarinostat (ACY-241) selectively inhibits HDAC6, which potentially results in decreased tumor cell viability and reduced tumor growth, particularly in combination with other agents (PMID: 27926524, PMID: 28264055).', 'references': [{'id': 8245, 'pubMedId': 28264055, 'title': 'Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28264055'}, {'id': 8244, 'pubMedId': 27926524, 'title': 'Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27926524'}]}]",Citarinostat,2017-03-16T16:30:26Z
0,2014-03-12T15:53:16Z,701,"[{'description': 'Cixutumumab is an antibody against membrane-bound IGF-1R that prevents IGF-1 binding, inhibiting PI3K/AKT pathway activation and potentially leading to decreased tumor cell proliferation and increased tumor cell death (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Cixutumumab,2015-06-02T13:12:02Z
0,2017-03-01T04:17:58Z,5396,"[{'description': 'CJM112 is a human anti-Interleukin (IL)-17 antibody that inhibits IL-17 downstream signaling (ECTRIMS Oct 8, 2015, Abstract: P655).', 'references': []}]",CJM112,2017-03-01T16:02:47Z
0,2017-02-16T04:21:14Z,5329,"[{'description': 'CK-101 is a third generation EGFR inhibitor that preferentially binds to and inhibits mutant EGFR, particularly T790M, resulting in anti-tumor activity (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",CK-101,2017-02-24T17:21:23Z
0,2014-12-05T04:54:39Z,1767,"[{'description': 'Leustatin (cladribine) is a purine analog that is incorporated into DNA, resulting in DNA single strand breaks and apoptosis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Cladribine,2014-12-05T04:57:03Z
0,2016-06-26T19:54:40Z,4363,[],Cladribine + Cytarabine + Filgrastim + Mitoxantrone,2016-06-26T19:54:40Z
0,2015-11-05T16:42:31Z,3178,[],Cladribine + Cytarabine + Plerixafor,2015-11-05T16:42:31Z
0,2016-02-05T11:00:20Z,3502,"[{'description': 'CLM3 is an small molecule multi-kinase inhibitor with activity against several kinases including Ret, Vegfr2, and Egfr, which potentially leads to decreased tumor cell growth (PMID: 21459081, PMID: 24423321).', 'references': [{'id': 4527, 'pubMedId': 24423321, 'title': 'CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24423321'}]}]",CLM3,2017-04-03T11:46:30Z
0,2015-03-11T15:15:53Z,2350,[],Clobetasol + Regorafenib,2015-03-11T15:15:53Z
0,2014-11-28T23:25:44Z,1746,[],Clofarabine,2014-11-28T23:25:44Z
0,2015-03-12T15:33:04Z,2374,[],Clofarabine + Cytarabine + Sorafenib,2015-03-12T15:33:04Z
0,2014-12-15T17:10:19Z,1782,[],Clofarabine + Etoposide + Cyclophosphamide,2014-12-15T17:10:19Z
0,2015-03-02T16:13:04Z,2236,[],Clofarabine + Melphalan,2015-03-02T16:13:04Z
0,2014-09-12T12:26:03Z,1464,"[{'description': 'CLR457 is a pan-PI3K inhibitor, resulting in apoptosis and growth inhibition in tumor cells overexpressing PI3K (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",CLR457,2015-02-05T18:56:27Z
0,2016-06-06T00:45:27Z,4246,"[{'description': 'CM-24 is a monoclonal antibody that binds to CEA-related cell adhesion molecule 1 (CEACAM1) and blocks immune suppression mediated by CEACAM1, resulting in enhanced anti-tumor immunity (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",CM-24,2016-06-06T00:45:27Z
0,2016-06-06T00:46:37Z,4247,[],CM-24 + Pembrolizumab,2016-06-06T00:46:37Z
0,2016-06-20T00:10:21Z,4318,"[{'description': 'CMB305 is a combination of LV305, a dendritic cell-targeted lentiviral vector encoding NY-ESO-1, and G305, an NY-ESO-1 cancer vaccine, which may synergize to promote anti-tumor immunity (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",CMB305,2016-07-05T14:28:41Z
0,2015-02-25T20:34:29Z,2164,"[{'description': 'cMet RNA CAR T cells are autologous T-cells transfected with RNA that codes for a chimeric antigen receptor comprised of a portion of anti-Met and CD3-zeta chain linked to CD-137, which targets T-cells to c-MET expressing tumor cells, resulting in selective toxicity (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",cMet RNA CAR T cells,2015-02-25T20:41:54Z
0,2016-07-28T14:36:52Z,4503,"[{'description': 'CmpdA is an inhibitor of IKKbeta, which may result in apoptotic activity, inhibition of the mitotic cycle, and anti-tumor activity (PMID: 27196761).', 'references': [{'id': 6383, 'pubMedId': 27196761, 'title': 'Targeting IκB Kinase β/NF-κB Signaling in Human Prostate Cancer by a Novel IκB Kinase β Inhibitor CmpdA.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196761'}]}]",CmpdA,2016-07-28T14:36:52Z
0,2015-05-15T01:49:12Z,2687,"[{'description': 'CNX-774 is a small molecule that binds BTK and prevents its kinase activity (PMID: 24658273).', 'references': [{'id': 580, 'pubMedId': 24658273, 'title': ""Targeting Bruton's tyrosine kinase in B cell malignancies."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24658273'}]}]",CNX-774,2015-05-15T01:49:12Z
0,2014-05-14T14:52:46Z,1003,"[{'description': 'Rociletinib (CO-1686) is a third-generation EGFR TKI inhibitor and inhibits mutant forms of EGFR including T790M (PMID: 24410791).', 'references': [{'id': 194, 'pubMedId': 24410791, 'title': 'Novel agents and strategies for overcoming EGFR TKIs resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24410791'}]}]",CO1686,2015-07-23T16:38:43Z
0,2016-11-15T20:23:26Z,4962,[],CO1686 + Crizotinib,2016-11-15T20:23:26Z
0,2014-05-14T14:52:46Z,1004,"[{'description': 'Cotellic (cobimetinib) is an allosteric inhibitor of MEK1/2, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation (PMID: 22084396, PMID: 27956260). Cotellic (cobimetinib) is FDA approved for melanoma patients with BRAF V600E or V600K, in combination with Zelboraf (vemurafenib) (FDA.gov).', 'references': [{'id': 353, 'pubMedId': 22084396, 'title': 'Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22084396'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Cobimetinib,2017-04-25T19:25:54Z
0,2016-08-27T02:03:33Z,4609,[],Cobimetinib + Bevacizumab + Atezolizumab,2016-08-27T02:03:33Z
0,2014-07-28T15:03:53Z,1160,[],Cobimetinib + GDC-0068,2014-07-28T15:03:53Z
0,2017-04-07T13:17:07Z,5512,[],Cobimetinib + LY3022855 + Vemurafenib,2017-06-14T17:42:51Z
0,2015-02-27T17:02:33Z,2208,[],Cobimetinib + Paclitaxel,2015-02-27T17:02:33Z
0,2016-05-27T16:23:56Z,4171,[],Cobimetinib + Venetoclax,2016-05-27T16:23:56Z
0,2016-04-22T15:09:35Z,3995,[],Cobimetinib + XL888 + Vemurafenib,2016-04-22T15:09:35Z
0,2016-08-03T14:14:31Z,4518,"[{'description': 'Codrituzumab is a monoclonal antibody against Glypican-3 (GPC-3), which may result in cytotoxicity due to its association with CD16/Fc-gamma RIIIa (PMID: 27085251).', 'references': [{'id': 6422, 'pubMedId': 27085251, 'title': 'Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27085251'}]}]",Codrituzumab,2016-08-03T14:14:31Z
0,2016-02-25T15:39:44Z,3607,"[{'description': 'COG112 is a peptide consisting of a fragment of apolipoprotein-E, which binds to SET, leading to increased activity of PP2A and subsequently, inhibition of cell proliferation (PMID: 21297667).', 'references': [{'id': 4698, 'pubMedId': 21297667, 'title': 'Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21297667'}]}]",COG112,2016-02-25T15:39:44Z
0,2016-09-13T16:20:37Z,4701,"[{'description': 'Coltuximab Ravtansine (SAR3419) is an antibody-drug conjugate composed of an anti-CD19 antibody linked to the drug DM4, which delivers the cytotoxic agent to CD19-expressing cells, potentially resulting in increased tumor cell death and decreased tumor growth (PMID: 24023523, PMID: 24132920).', 'references': [{'id': 6608, 'pubMedId': 24023523, 'title': 'Targeting CD19 in B-cell lymphoma: emerging role of SAR3419.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24023523'}, {'id': 6607, 'pubMedId': 24132920, 'title': 'A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24132920'}]}]",Coltuximab Ravtansine,2016-09-13T16:20:37Z
0,2017-06-06T14:33:04Z,5857,"[{'description': 'COM701 is an antibody directed against PVRIG, which interferes with binding to its ligand PVRL2, potentially resulting in increased anti-tumor immune response (J Clin Oncol 35, 2017 (suppl; abstr 3074)).', 'references': [{'id': 9066, 'pubMedId': None, 'title': 'Discovery of COM701, a therapeutic antibody targeting the novel immune checkpoint PVRIG, for the treatment of cancer.', 'url': 'http://abstracts.asco.org/199/AbstView_199_193132.html'}]}]",COM701,2017-06-06T14:33:04Z
0,2014-09-11T19:22:59Z,1458,[],Conatumumab,2014-09-18T13:05:51Z
0,2016-01-12T14:06:06Z,3401,[],Conatumumab + Ganitumab,2016-01-12T14:06:06Z
0,2017-06-26T16:51:52Z,5928,"[{'description': 'Duavee (conjugated estrogens/bazedoxifene) is a drug combined of conjugated estrogens and a selective estrogen receptor modulator, which stimulates estrogen levels and prevents proliferation via estrogen antagonism (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Conjugated estrogens/bazedoxifene,2017-06-26T16:56:55Z
0,2014-05-14T14:52:46Z,995,"[{'description': 'Aliqopa (copanlisib) is a selective PIK3CA and PIK3CD inhibitor that prevents activation of Akt, resulting in inhibition of cell cycle progression and increased apoptosis (PMID: 24013662, PMID: 25528022). Aliqopa (copanlisib) is FDA approved for adult patients with follicular lymphoma (FDA.gov). ', 'references': [{'id': 188, 'pubMedId': 24013662, 'title': 'A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24013662'}]}]",Copanlisib,2017-10-13T18:28:10Z
0,2017-05-02T03:17:14Z,5593,[],Copanlisib + Letrozole,2017-05-02T03:17:14Z
0,2014-07-30T18:10:00Z,1276,[],Copanlisib + Paclitaxel,2014-07-30T18:11:09Z
0,2017-05-02T03:18:25Z,5594,[],Copanlisib + Palbociclib + Letrozole,2017-05-02T03:18:25Z
0,2015-08-13T03:38:48Z,3018,[],Copanlisib + Refametinib,2015-08-13T03:38:48Z
0,2015-07-30T01:53:59Z,2974,"[{'description': 'CAVATAK (coxsackievirus A21) is a naturally occuring enterovirus which infect and lysis tumor cells (PMID: 17391493).', 'references': [{'id': 3357, 'pubMedId': 17391493, 'title': 'Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17391493'}]}]",coxsackievirus A21,2017-05-26T14:49:45Z
0,2015-10-16T23:43:48Z,3136,[],coxsackievirus A21 + Pembrolizumab,2015-10-16T23:43:48Z
0,2016-01-12T17:40:11Z,3404,"[{'description': 'CP-31398 stabilizes wild-type Tp53 conformation, and activates Tp53 activity in cells with wild-type or mutant Tp53, potentially resulting in increased tumor cell death  (PMID: 14614447).', 'references': [{'id': 4306, 'pubMedId': 14614447, 'title': 'CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/14614447'}]}]",CP-31398,2017-05-01T18:05:56Z
0,2015-03-09T20:18:08Z,2335,"[{'description': 'CP-673451 is an inhibitor of PDGFR kinase, which may inhibit tumor angiogenesis and tumor growth (PMID: 15705896). ', 'references': [{'id': 2135, 'pubMedId': 15705896, 'title': 'Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15705896'}]}]",CP-673451,2015-03-09T20:18:08Z
0,2017-01-04T19:46:07Z,5156,"[{'description': 'CP-724,714 is a selective inhibitor of ERBB2 (HER2), which reduces ERBB2 signaling and may decrease growth of ERBB2 (HER2)-over expressing tumors (PMID: 17942920).', 'references': [{'id': 7476, 'pubMedId': 17942920, 'title': 'Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17942920'}]}]","CP-724,714",2017-01-04T19:46:07Z
0,2017-01-04T19:47:08Z,5157,[],"CP-724,714 + XMU-MP-2",2017-01-04T19:47:08Z
0,2016-01-26T11:18:09Z,3465,"[{'description': 'Cpd-5, an analogue of reversine, inhibits TTK (MPS1) to derail the mitotic checkpoint and prevent cell proliferation (PMID: 26364596).', 'references': [{'id': 4449, 'pubMedId': 26364596, 'title': 'Molecular basis underlying resistance to Mps1/TTK inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26364596'}]}]",Cpd-5,2016-01-26T11:18:09Z
0,2015-02-09T23:26:32Z,2033,"[{'description': 'CPI-0610 is a small molecule that binds to BET bromodomains and inhibits interaction with acetylated histones, resulting in regulation of BET-dependent gene expression and anti-tumor effects (PMID: 26815195).', 'references': [{'id': 6629, 'pubMedId': 26815195, 'title': 'Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26815195'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",CPI-0610,2017-03-17T16:15:09Z
0,2016-09-14T17:52:33Z,4714,[],CPI-0610 + Doxorubicin,2016-09-14T17:52:33Z
0,2015-05-28T14:02:02Z,2733,"[{'description': 'CPI-1205 inhibits wild-type and mutant EZH2, potentially resulting in decreased tumor cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",CPI-1205,2015-05-28T14:02:02Z
0,2015-07-22T15:38:13Z,2942,"[{'description': 'CPI-169 inhibits EZH2, resulting in reduced H3K27 tri-methylation, thereby leading to increased tumor cell apoptosis and decreased tumor growth (Cancer Res October 1, 2014 74:1697).', 'references': [{'id': 3292, 'pubMedId': None, 'title': 'Abstract 1697: CPI-169, a novel and potent EZH2 inhibitor, synergizes with CHOP in vivo and achieves complete regression in lymphoma xenograft models', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/1697'}]}]",CPI-169,2015-07-22T15:38:13Z
0,2017-04-06T20:43:18Z,5510,[],CPI-169 + RN-1,2017-04-06T20:43:18Z
0,2016-08-31T19:03:57Z,4633,"[{'description': 'CPI-203 is an inhibitor of BRD4, which may result in downregulation of Myc and inhibit cell proliferation (PMID: 25299775). ', 'references': [{'id': 6546, 'pubMedId': 25299775, 'title': 'The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25299775'}]}]",CPI-203,2016-08-31T19:03:57Z
0,2016-02-19T17:26:29Z,3571,"[{'description': 'CPI-444 is an antagonist of A2aR (ADORA2A), which may increase anti-tumor immune response and inhibit tumor growth (Cancer Immunol Res 2016;4(11 Suppl):Abstract nr PR04).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}, {'id': 9067, 'pubMedId': None, 'title': 'Abstract PR04: CPI-444: A potent and selective inhibitor of A2AR induces antitumor responses alone and in combination with anti-PD-L1 in preclinical and clinical studies', 'url': 'http://cancerimmunolres.aacrjournals.org/content/4/11_Supplement/PR04'}]}]",CPI-444 ,2017-06-06T14:54:01Z
0,2016-07-20T16:51:56Z,4484,"[{'description': 'CPI-455 is an inhibitor of KDM5A, KDM5B, and KDM5C, which may reduce cell survival, in particular those cells that are considered drug resistant (PMID: 27214401). ', 'references': [{'id': 6341, 'pubMedId': 27214401, 'title': 'An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27214401'}]}]",CPI-455,2016-07-20T16:51:56Z
0,2016-07-20T17:20:20Z,4485,[],CPI-455 + Erlotinib,2016-07-20T17:20:20Z
0,2016-07-20T17:24:14Z,4488,[],CPI-455 + Lapatinib,2016-07-20T17:24:14Z
0,2016-07-20T17:21:58Z,4486,[],CPI-455 + Vemurafenib,2016-07-20T17:21:58Z
0,2016-02-22T18:10:46Z,3589,"[{'description': 'CPUY201112 is an N-terminal Hsp90 inhibitor, which leads to decreased expression of Hsp90 client proteins and may result in increased tumor cell apoptosis (PMID: 26743233).', 'references': [{'id': 4657, 'pubMedId': 26743233, 'title': 'CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26743233'}]}]",CPUY201112,2016-02-22T18:10:46Z
0,2016-06-22T02:21:44Z,4341,"[{'description': 'CPX-351 is a liposomal formulation of cytarabine and daunorubicin with anti-tumor activities (PMID: 25223583).', 'references': [{'id': 5981, 'pubMedId': 25223583, 'title': 'Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25223583'}]}]",CPX-351,2016-06-22T02:21:44Z
0,2016-06-28T01:01:41Z,4391,[],CPX-351 + Cytarabine + Filgrastim + Fludarabine ,2016-06-28T01:01:41Z
0,2014-03-12T15:53:16Z,705,"[{'description': 'Crenolanib is a type III receptor tyrosine kinase inhibitor of PDGFR-alpha/beta and FLT3, which results in inhibition of downstream signaling and prevents growth in tumor cells (PMID: 22745105). ', 'references': [{'id': 2167, 'pubMedId': 22745105, 'title': 'Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22745105'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 2134, 'pubMedId': 24227820, 'title': 'Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24227820'}]}]",Crenolanib,2015-04-10T16:23:56Z
0,2015-05-08T01:51:00Z,2637,[],Crenolanib + Cytarabine + Daunorubicin,2015-05-08T01:51:00Z
0,2016-04-29T15:34:38Z,4024,[],Crenolanib + Cytarabine + Mitoxantrone,2016-04-29T15:34:38Z
0,2017-06-29T16:57:42Z,5943,[],Crenolanib + Paclitaxel + Ramucirumab,2017-06-29T16:57:56Z
0,2014-12-29T16:07:54Z,1864,[],Crenolanib + Sorafenib,2014-12-29T16:07:54Z
0,2014-03-12T15:53:16Z,706,"[{'description': 'Xalkori (crizotinib), inhibits ALK kinase, ALK fusion proteins, c-Met, ROS1, and MST1R (RON), resulting in growth inhibition of tumor cells (PMID: 26951079, PMID: 22617245). Xalkori (crizotinib) is FDA approved for use in patients with ALK or ROS1 positive non-small cell lung cancer (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Crizotinib,2017-10-13T15:29:51Z
0,2016-02-24T14:49:30Z,3601,[],Crizotinib + Cyclophosphamide + Topotecan,2016-02-24T14:49:30Z
0,2016-01-10T11:08:02Z,3377,[],Crizotinib + Dacomitinib,2016-01-10T11:08:02Z
0,2014-07-30T15:17:32Z,1252,[],Crizotinib + Dasatinib,2014-07-30T15:17:32Z
0,2015-03-20T15:32:10Z,2446,[],Crizotinib + Enzalutamide,2015-03-20T15:32:10Z
0,2017-07-28T16:24:02Z,6028,[],Crizotinib + Gemcitabine,2017-07-28T16:24:02Z
0,2014-09-23T21:48:38Z,1526,[],Crizotinib + Itraconazole	,2014-09-23T21:48:38Z
0,2016-01-22T01:30:57Z,3440,[],Crizotinib + Lapatinib,2016-01-22T01:30:57Z
0,2017-03-07T18:10:29Z,5411,[],Crizotinib + Navitoclax,2017-08-01T16:00:43Z
0,2016-06-24T14:39:06Z,4355,[],Crizotinib + Onalespib,2016-06-24T14:39:06Z
0,2016-11-15T17:28:59Z,4958,[],Crizotinib + Osimertinib,2016-11-15T17:28:59Z
0,2014-07-28T13:24:08Z,1153,[],Crizotinib + Pazopanib,2014-07-28T13:24:08Z
0,2014-07-28T13:26:51Z,1155,[],Crizotinib + Pazopanib + Pemetrexed,2014-07-28T13:26:51Z
0,2014-07-28T13:22:42Z,1151,[],Crizotinib + Pemetrexed,2014-07-28T13:22:42Z
0,2016-10-05T19:24:56Z,4787,[],Crizotinib + PLX4720,2016-10-05T19:24:56Z
0,2014-09-18T18:28:04Z,1483,[],Crizotinib + Rifampin,2014-09-18T18:28:04Z
0,2014-09-23T21:42:04Z,1525,[],Crizotinib + Rifampin + Itraconazole,2014-09-23T21:42:04Z
0,2016-05-04T12:57:30Z,4070,[],Crizotinib + Rucaparib,2016-05-04T12:57:30Z
0,2016-07-19T18:09:46Z,4480,[],Crizotinib + Trametinib,2016-07-19T18:09:46Z
0,2016-01-22T01:51:49Z,3442,[],Crizotinib + Trastuzumab + Paclitaxel,2016-01-22T01:51:49Z
0,2016-09-06T16:26:07Z,4648,[],Crizotinib + Vemurafenib,2016-09-06T16:26:07Z
0,2014-03-12T15:53:16Z,708,"[{'description': 'CRLX101 is a nanoparticle conjugated to Camptothecin, which inhibits topoisomerase-1 and HIF1-alpha, and when combined with radiotherapy may result in increased sensitivity (PMID: 27784746). ', 'references': [{'id': 7475, 'pubMedId': 27784746, 'title': 'CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27784746'}]}]",CRLX101,2017-01-04T19:02:16Z
0,2014-07-29T18:04:57Z,1213,[],CRLX101 + Bevacizumab,2014-07-29T18:04:57Z
0,2017-01-04T19:27:03Z,5155,[],CRLX101 + Fluorouracil + Radiotherapy,2017-01-04T19:27:03Z
0,2016-06-23T14:10:47Z,4348,[],CRLX101 + Olaparib,2016-06-23T14:11:26Z
0,2017-06-19T13:52:36Z,5906,[],Crofelemer,2017-06-19T13:52:36Z
0,2014-09-11T20:22:45Z,1460,"[{'description': 'Crolibulin (EPC2407) is a small molecule that binds to and prevents tubulin polymerization, which may cause cell cycle arrest, apoptosis and decreased cell proliferation (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Crolibulin,2015-11-19T18:36:43Z
0,2014-09-11T20:26:08Z,1461,[],Crolibulin + Cisplatin,2014-09-11T20:26:08Z
0,2015-05-08T13:32:04Z,2641,"[{'description': 'CRS-207 is a vaccine comprised of a live-attenuated strain of Listeria monocytogenes engineered to express human mesothelin, which induces anti-tumor immune response towards mesothelin-positive tumor cells (PMID: 22147941).', 'references': [{'id': 2671, 'pubMedId': 22147941, 'title': 'A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22147941'}]}]",CRS-207,2015-06-26T02:28:45Z
0,2017-01-09T19:09:58Z,5170,[],CRS-207 + Cyclophosphamide + GVAX panc vaccine + INCB024360 + Pembrolizumab,2017-01-09T19:09:58Z
0,2016-02-11T11:08:17Z,3512,[],CRS-207 + GVAX,2016-02-11T11:08:17Z
0,2017-01-09T18:19:52Z,5169,[],CRS-207 + INCB024360 + Pembrolizumab,2017-01-09T18:19:52Z
0,2017-05-20T01:52:00Z,5716,[],CRS-207 + Pembrolizumab,2017-05-20T01:52:00Z
0,2017-03-15T17:31:07Z,5439,"[{'description': 'CRT 0066101 is a pan-protein kinase D inhibitor that blocks protein kinase D signaling, resulting in inhibition of tumor cell growth and metastasis (PMID: 25852060).', 'references': [{'id': 8228, 'pubMedId': 25852060, 'title': 'Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25852060'}]}]",CRT 0066101,2017-03-15T17:31:07Z
0,2016-01-14T17:02:56Z,3415,"[{'description': 'Cryptotanshinone is an inhibitor of Shp2, which may result in cell growth inhibition and apoptosis (PMID: 23957426). ', 'references': [{'id': 4300, 'pubMedId': 23957426, 'title': 'Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23957426'}]}]",cryptotanshinone,2016-01-14T17:24:48Z
0,2017-09-12T14:43:27Z,6202,"[{'description': 'CS-11 binds to PR55-alpha, the regulatory subunit of PP2A, resulting in decreased nuclear beta-catenin activity and reduced expression of downstream targets and increased cell surface levels of E-cadherin and activated beta-catenin, which may lead to increased tumor cell apoptosis and decreased metastasis (PMID: 28500231).', 'references': [{'id': 9883, 'pubMedId': 28588062, 'title': 'Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28588062'}, {'id': 9888, 'pubMedId': 28500231, 'title': 'Discovery of a Novel Small-Molecule Inhibitor that Targets PP2A-β-Catenin Signaling and Restricts Tumor Growth and Metastasis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28500231'}]}]",CS-11,2017-09-12T15:36:40Z
0,2017-08-22T14:46:54Z,6141,"[{'description': 'CS1001 (WBP3155) targets PD-L1 and inhibits the PD-L1/PD-1 immune checkpoint (PMID: 28679395).', 'references': [{'id': 9760, 'pubMedId': 28679395, 'title': 'Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28679395'}]}]",CS1001,2017-08-22T14:50:20Z
0,2016-12-07T20:14:10Z,5065,"[{'description': 'CT-707 is a kinase inhibitor of FAK, which may result in antitumor activity including inhibition of both tumor growth and metastasis (PMID: 27638856).', 'references': [{'id': 7265, 'pubMedId': 27638856, 'title': 'CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27638856'}]}]",CT-707,2016-12-07T20:14:10Z
0,2016-12-07T20:17:00Z,5067,[],CT-707 + PHA-665752,2016-12-07T20:17:00Z
0,2017-06-30T19:00:20Z,5954,"[{'description': 'CT-P6 is a biosimilar to antibody Herceptin (trastuzumab), which binds HER2 (ERBB2) and potentially reduces growth of ERBB2 (HER2)-expressing tumors (PMID: 28592386).', 'references': [{'id': 9249, 'pubMedId': 28592386, 'title': 'CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28592386'}]}]",CT-P6,2017-06-30T19:00:20Z
0,2017-03-23T17:33:53Z,5472,"[{'description': 'CT16 is an antibody that targets both EGFR and NOTCH2/3, resulting in decreased ligand binding and downstream signaling, and potentially leading to decreased tumor growth and increased sensitivity to radiotherapy (PMID: 28275151).', 'references': [{'id': 8315, 'pubMedId': 28275151, 'title': 'Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28275151'}]}]",CT16,2017-03-23T17:50:21Z
0,2016-09-07T15:33:54Z,4661,"[{'description': 'CT20p is a Bax-derived cytotoxic peptide, which targets chaperonin-containing T-complex polypeptide 1 (CCT), potentially resulting in increased death of CCT-expressing tumor cells (PMID: 27012814).', 'references': [{'id': 6569, 'pubMedId': 27012814, 'title': 'Chaperonin Containing TCP-1 Protein Level in Breast Cancer Cells Predicts Therapeutic Application of a Cytotoxic Peptide.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27012814'}]}]",CT20p,2016-09-07T15:35:21Z
0,2014-07-28T12:54:22Z,1142,[],CTO + Temozolomide,2014-07-28T12:54:22Z
0,2016-04-06T16:30:16Z,3899,"[{'description': 'CTX-1 binds to and inhibits Mdm4 (MdmX), which disrupts the interaction between Tp53 and Mdm4, leading to stabilization of Tp53 and potentially leading to increased tumor cell death (PMID: 26883273).', 'references': [{'id': 5110, 'pubMedId': 26883273, 'title': 'Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26883273'}]}]",CTX-1,2016-04-06T17:48:44Z
0,2016-04-06T16:47:54Z,3900,[],CTX-1 + Nutlin-3,2016-04-06T16:47:54Z
0,2014-05-14T14:52:46Z,1005,"[{'description': 'CUDC-101 is a small-molecule inhibitor of EGFR, ERBB2 (HER2), and class I and II HDACs, which has demonstrated activity in EGFR-inhibitor resistant tumor cell lines (PMID: 20388807, PMID: 23536719).', 'references': [{'id': 1830, 'pubMedId': 23536719, 'title': 'Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23536719'}, {'id': 43, 'pubMedId': 20388807, 'title': 'CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20388807'}]}]",CUDC-101,2015-03-31T13:50:10Z
0,2014-03-12T15:53:16Z,709,"[{'description': 'CUDC-907 is a dual PI3K and HDAC inhibitor, which prevents activation of the PI3K-AKT-mTOR signal transduction pathway, inhibits tumor cell growth, and promotes apoptosis in cancer cells (PMID: 22693356).', 'references': [{'id': 1018, 'pubMedId': 22693356, 'title': 'Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693356'}]}]",CUDC-907,2017-05-19T19:10:41Z
0,2016-07-14T13:35:23Z,4447,[],CUDC-907 + Rituximab,2016-07-14T13:35:23Z
0,2016-02-26T19:41:03Z,3643,"[{'description': 'Custirsen is an antisense oligo targeting Clusterin, which leads to apoptosis in tumor cells (PMID: 23130925).', 'references': [{'id': 4719, 'pubMedId': 23130925, 'title': 'Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23130925'}]}]",Custirsen,2016-02-26T22:05:31Z
0,2016-02-26T20:38:24Z,3648,[],Custirsen + Docetaxel,2016-02-26T20:38:24Z
0,2016-02-26T20:22:54Z,3646,[],Custirsen + Docetaxel + Prednisone,2016-02-26T20:22:54Z
0,2016-02-26T21:35:22Z,3649,[],Custirsen + Mitoxantrone + Prednisone,2016-02-26T21:35:22Z
0,2017-01-24T03:07:29Z,5243,"[{'description': 'Limited information is available on CV301, a putative CEA and MUC-1 targeting immunotherapy (Feb, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",CV301,2017-02-03T19:22:49Z
0,2017-01-24T03:08:13Z,5244,[],CV301 + Nivolumab,2017-01-24T03:08:13Z
0,2017-05-05T03:59:01Z,5618,"[{'description': 'CVX-060 is a peptide-antibody fusion protein that targets Angiopoeitin-2 (Ang2), resulting in decreased angiogenesis, and potentially leading to decreased tumor growth (PMID: 21233403).', 'references': [{'id': 8820, 'pubMedId': 21233403, 'title': 'Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21233403'}]}]",CVX-060,2017-05-05T03:59:01Z
0,2017-05-05T04:22:13Z,5620,[],CVX-060 + Regorafenib,2017-05-05T04:22:13Z
0,2017-05-05T05:24:11Z,5623,[],CVX-060 + Sorafenib,2017-05-05T05:24:11Z
0,2017-05-05T05:23:30Z,5622,[],CVX-060 + Sunitinib,2017-05-05T05:23:30Z
0,2017-05-05T04:11:55Z,5619,"[{'description': 'CVX-241 is a peptide-antibody fusion protein that targets both Angiopoetin-2 (Ang2) and Vegf, potentially resulted in decreased tumor growth (PMID: 21149738).', 'references': [{'id': 8821, 'pubMedId': 21149738, 'title': 'Chemical generation of bispecific antibodies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21149738'}]}]",CVX-241,2017-05-05T04:11:55Z
0,2017-05-05T04:36:53Z,5621,[],CVX-241 + Irinotecan,2017-05-05T04:36:53Z
0,2015-10-08T03:59:40Z,3115,"[{'description': 'CWP232228 is a small molecule that inhibits binding of Ctnnb1 to TCF, resulting in decreased Wnt signaling and inhibition of tumor growth (PMID: 25660951).', 'references': [{'id': 3722, 'pubMedId': 25660951, 'title': 'Wnt/β-Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-like Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25660951'}]}]",CWP232228,2015-10-08T03:59:40Z
0,2015-09-17T16:30:55Z,3081,"[{'description': 'CWP23229 inhibits beta-catenin mediated transcriptional activity, which potentially leads to decreased tumor cell proliferation (PMID: 21317452).', 'references': [{'id': 3656, 'pubMedId': 21317452, 'title': 'Drug discovery approaches to target Wnt signaling in cancer stem cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21317452'}]}]",CWP232291,2015-09-17T16:30:55Z
0,2017-01-15T23:14:39Z,5208,"[{'description': 'Limited information is currently available on CX-072, a putative anti-PD-L1 therapy (Jan, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",CX-072,2017-01-16T18:23:35Z
0,2017-01-15T23:15:32Z,5209,[],CX-072 + Ipilimumab,2017-01-15T23:15:32Z
0,2017-01-15T23:16:57Z,5210,[],CX-072 + Vemurafenib,2017-01-15T23:16:57Z
0,2017-05-19T19:31:21Z,5709,"[{'description': 'Limited information is currently available on CX-2009 (May, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",CX-2009,2017-05-19T19:31:21Z
0,2016-11-16T22:03:41Z,4963,"[{'description': 'CX-5461 is an RNA polymerase I (Pol I) inhibitor that inhibits rRNA synthesis, resulting in growth arrest and apoptosis in cancer cells (PMID: 26472108).', 'references': [{'id': 7057, 'pubMedId': 26472108, 'title': 'Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26472108'}]}]",CX-5461,2016-11-16T22:03:41Z
0,2016-11-18T16:23:34Z,4969,[],CX-5461 + CX-6258,2016-11-18T16:23:34Z
0,2016-03-04T18:33:08Z,3675,"[{'description': 'CX-6258 is an inhibitor of PIM1, PIM2, and PIM3, which may potentially result in antitumor activity (PMID: 24900437).', 'references': [{'id': 4774, 'pubMedId': 24900437, 'title': 'Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24900437'}]}]",CX-6258,2016-03-04T18:33:08Z
0,2014-03-12T15:53:16Z,710,[],CY503,
0,2014-03-12T15:53:16Z,711,"[{'description': 'CYC116 is an Aurora A, B kinase inhibitor, which inhibits cell proliferation (PMID: 20462263).', 'references': [{'id': 2122, 'pubMedId': 20462263, 'title': 'Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20462263'}]}]",CYC116,2017-04-04T12:35:18Z
0,2014-12-09T22:28:40Z,1774,"[{'description': 'Cyclopamine is a plant-derived alkaloid that inhibits the Hedgehog signaling pathway, resulting in growth inhibition in cells with activated SMO or inactivated PTCH (PMID: 10984056).', 'references': [{'id': 1301, 'pubMedId': 10984056, 'title': 'Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10984056'}]}]",Cyclopamine,2015-03-17T17:18:08Z
0,2016-05-12T20:09:24Z,4113,[],Cyclopamine + Posaconazole,2016-05-12T20:09:24Z
0,2014-07-28T13:15:35Z,1148,"[{'description': 'Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Cyclophosphamide,2014-08-13T20:38:01Z
0,2015-02-02T15:56:31Z,1997,[],Cyclophosphamide + Cetuximab,2015-02-02T15:56:31Z
0,2014-12-18T15:52:50Z,1800,[],Cyclophosphamide + Cisplatin + Vincristine ,2014-12-18T15:52:50Z
0,2014-12-15T17:11:34Z,1783,[],Cyclophosphamide + Cytarabine,2014-12-15T17:11:34Z
0,2015-05-15T13:42:24Z,2697,[],Cyclophosphamide + Dasatinib + Temsirolimus,2015-05-15T13:42:24Z
0,2015-02-11T16:18:59Z,2046,[],Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine ,2015-02-11T16:18:59Z
0,2017-06-13T18:39:30Z,5888,[],Cyclophosphamide + Dexamethasone + Lenalidomide,2017-06-13T18:39:30Z
0,2015-03-27T14:04:41Z,2482,[],Cyclophosphamide + Doxorubicin + Etoposide + Vincristine ,2015-03-27T14:04:41Z
0,2017-09-25T13:30:20Z,6236,[],Cyclophosphamide + Doxorubicin + Paclitaxel + MCS110,2017-09-25T13:30:20Z
0,2016-09-12T02:20:46Z,4679,[],Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib,2016-09-12T02:20:46Z
0,2016-06-06T01:08:00Z,4248,[],Cyclophosphamide + Doxorubicin + Prednisone,2016-06-06T01:08:00Z
0,2015-12-04T01:31:54Z,3266,[],Cyclophosphamide + Doxorubicin + Prednisone + Vincristine ,2015-12-04T01:31:54Z
0,2015-03-11T15:26:18Z,2353,[],Cyclophosphamide + Doxorubicin + Vincristine ,2015-03-11T15:26:18Z
0,2016-06-11T18:46:30Z,4280,[],Cyclophosphamide + DPX-Survivac,2016-06-11T18:46:30Z
0,2016-06-04T17:36:59Z,4238,[],Cyclophosphamide + DPX-Survivac + INCB024360 ,2016-06-04T17:36:59Z
0,2015-11-16T17:32:20Z,3217,[],Cyclophosphamide + Etoposide,2015-11-16T17:32:20Z
0,2015-03-21T12:11:06Z,2450,[],Cyclophosphamide + Etoposide + Topotecan,2015-03-21T12:11:06Z
0,2015-03-05T15:13:26Z,2291,[],Cyclophosphamide + Fludarabine,2015-03-05T15:13:26Z
0,2014-08-05T18:02:13Z,1373,[],Cyclophosphamide + Fludarabine + Melphalan + Sirolimus,2014-08-05T18:02:13Z
0,2016-06-03T03:02:04Z,4228,[],Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus,2016-06-03T03:02:04Z
0,2015-03-04T14:19:39Z,2281,[],Cyclophosphamide + Fludarabine + Mycophenolate mofetil,2015-03-04T14:19:39Z
0,2016-02-26T16:48:40Z,3627,[],Cyclophosphamide + Fludarabine + Obinutuzumab,2016-02-26T16:48:40Z
0,2017-03-23T15:33:50Z,5468,[],Cyclophosphamide + Fludarabine + Ofatumumab,2017-03-23T15:33:50Z
0,2015-03-10T15:34:39Z,2339,[],Cyclophosphamide + Fludarabine + Rituximab ,2015-03-10T15:34:39Z
0,2017-09-18T20:09:03Z,6217,[],Cyclophosphamide + Fludarabine phosphate + iC9/CAR.19/IL15-Transduced CB-NK,2017-09-18T20:09:03Z
0,2017-02-16T04:06:07Z,5328,[],Cyclophosphamide + Fludarabine phosphate + Nivolumab,2017-02-16T04:06:07Z
0,2015-01-04T01:11:15Z,1895,[],Cyclophosphamide + Fluorouracil + Docetaxel + Epirubicin  ,2015-01-04T01:11:15Z
0,2016-12-11T18:58:05Z,5079,[],Cyclophosphamide + GVAX colorectal cancer vaccine + Pembrolizumab,2016-12-11T18:58:05Z
0,2016-02-25T21:45:09Z,3622,[],Cyclophosphamide + GVAX pancreatic cancer vaccine ,2016-02-25T21:45:09Z
0,2017-05-26T14:43:38Z,5778,[],Cyclophosphamide + GVAX pancreatic cancer vaccine + LY3022855 + Pembrolizumab,2017-06-14T17:43:47Z
0,2016-07-19T00:53:50Z,4473,[],Cyclophosphamide + GVAX pancreatic cancer vaccine + Pembrolizumab,2016-07-19T00:53:50Z
0,2016-06-26T21:17:12Z,4365,[],Cyclophosphamide + JCAR014 + MEDI4736,2016-06-26T21:17:12Z
0,2016-04-29T14:22:33Z,4019,[],Cyclophosphamide + LCL161,2016-04-29T14:22:33Z
0,2015-05-14T02:26:20Z,2673,[],Cyclophosphamide + Methotrexate + Vincristine  ,2015-05-14T02:26:20Z
0,2014-12-24T15:17:09Z,1848,[],Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase ,2014-12-24T15:17:09Z
0,2017-01-09T19:57:38Z,5173,[],Cyclophosphamide + ONCOS-102 + Pembrolizumab,2017-01-09T19:57:38Z
0,2015-01-27T14:51:41Z,1980,[],Cyclophosphamide + Paclitaxel,2015-01-27T14:51:41Z
0,2015-01-04T01:57:25Z,1898,[],Cyclophosphamide + Paclitaxel + Trastuzumab ,2015-01-04T01:57:25Z
0,2017-06-02T17:55:31Z,5848,[],Cyclophosphamide + PD 0360324,2017-06-02T17:55:31Z
0,2016-09-12T16:20:50Z,4684,[],Cyclophosphamide + Pegaspargase + Vincristine,2016-09-12T16:20:50Z
0,2016-01-14T14:39:11Z,3413,[],Cyclophosphamide + Pegfilgrastim + VTX-2337,2016-01-14T14:39:11Z
0,2016-10-30T20:52:31Z,4891,[],Cyclophosphamide + Pembrolizumab,2016-10-30T20:52:31Z
0,2015-03-06T00:32:30Z,2308,[],Cyclophosphamide + Pentostatin,2015-03-06T00:32:30Z
0,2016-08-28T21:31:35Z,4615,[],Cyclophosphamide + poly ICLC  + Sargramostim,2016-08-28T21:31:35Z
0,2015-04-03T12:32:03Z,2488,[],Cyclophosphamide + Prednisone + Rituximab + Vincristine,2015-04-03T12:32:56Z
0,2015-11-16T18:42:43Z,3221,[],Cyclophosphamide + Prednisone + Vincristine,2015-11-16T18:42:43Z
0,2015-03-12T12:29:56Z,2360,[],Cyclophosphamide + Sorafenib + Topotecan,2015-03-12T12:29:56Z
0,2015-04-24T14:43:22Z,2590,[],Cyclophosphamide + Topotecan,2015-04-24T14:43:22Z
0,2014-09-18T16:46:50Z,1479,[],Cyclophosphamide + Topotecan + Bevacizumab,2014-09-18T16:46:50Z
0,2014-10-14T20:22:56Z,1650,[],Cyclosporine,2014-10-14T20:22:56Z
0,2017-05-20T01:36:20Z,5714,[],Cyclosporine + Fludarabine phosphate + Mycophenolate mofetil + Sirolimus,2017-05-20T01:36:20Z
0,2015-03-03T03:49:12Z,2272,[],Cyclosporine + Mycophenolate mofetil,2015-03-03T03:49:12Z
0,2015-03-03T03:31:58Z,2270,[],Cyclosporine + Mycophenolate mofetil + Sirolimus,2015-03-03T03:31:58Z
0,2016-04-15T19:53:35Z,3948,[],Cyclosporine + Mycophenolate mofetil + Tacrolimus,2016-04-15T19:53:35Z
0,2017-06-23T19:30:41Z,5927,"[{'description': 'CYD-2-11 is a BAX agonist, which binds to and activates BAX, potentially resulting in increased tumor cell apoptosis and decreased tumor growth (PMID: 28381544).', 'references': [{'id': 9215, 'pubMedId': 28381544, 'title': 'Modulation of Bax and mTOR for Cancer Therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28381544'}]}]",CYD-2-11,2017-06-23T19:30:41Z
0,2015-04-10T15:41:14Z,2528,"[{'description': 'ASN001 selectively binds to and inhibits steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17), which potentially leads to decreased androgen production and in turn, growth inhibition of androgen-dependent tumor cells (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",CYP17 lyase inhibitor ASN001,2015-04-17T02:08:27Z
0,2014-03-12T15:53:16Z,712,"[{'description': 'Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Cytarabine,2014-11-28T23:47:14Z
0,2016-12-01T17:43:28Z,5038,[],Cytarabine + Dacinostat,2016-12-01T17:43:28Z
0,2016-03-11T20:23:13Z,3731,[],Cytarabine + Dasatinib + Fludarabine  + Idarubicin,2016-03-11T20:23:13Z
0,2015-03-13T14:56:52Z,2391,[],Cytarabine + Daunorubicin + Etoposide,2015-03-13T14:56:52Z
0,2016-01-21T21:14:18Z,3431,[],Cytarabine + Daunorubicin + Etoposide + Mitoxantrone,2016-01-21T21:14:18Z
0,2016-02-17T20:49:18Z,3543,[],Cytarabine + Daunorubicin + Idarubicin,2016-02-17T20:49:18Z
0,2015-10-20T02:30:23Z,3137,[],Cytarabine + Daunorubicin + Midostaurin,2015-10-20T02:30:23Z
0,2015-11-16T18:17:45Z,3219,[],Cytarabine + Daunorubicin + Pacritinib,2015-11-16T18:17:45Z
0,2015-11-06T02:26:25Z,3185,[],Cytarabine + Daunorubicin + Panobinostat,2015-11-06T02:26:25Z
0,2017-08-04T20:09:40Z,6092,[],Cytarabine + Daunorubicin + PF-06747143,2017-08-04T20:09:40Z
0,2017-04-12T18:07:29Z,5536,[],Cytarabine + Daunorubicin + Samalizumab,2017-04-12T18:07:29Z
0,2016-03-06T21:39:19Z,3686,[],Cytarabine + Dexamethasone + Idarubicin + Mitoxantrone,2016-03-06T21:39:19Z
0,2015-03-11T14:35:07Z,2345,[],Cytarabine + Dexamethasone+ Methotrexate ,2015-03-11T14:35:07Z
0,2015-03-13T15:02:04Z,2392,[],Cytarabine + Etoposide,2015-03-13T15:02:04Z
0,2015-11-06T02:21:23Z,3183,[],Cytarabine + Ficlatuzumab,2015-11-06T02:21:23Z
0,2016-06-10T20:49:35Z,4271,[],Cytarabine + Filgrastim + Fludarabine,2016-06-10T20:49:35Z
0,2017-10-17T19:06:11Z,6329,[],Cytarabine + Filgrastim + Fludarabine + Idarubicin + Venetoclax,2017-10-17T19:06:11Z
0,2015-03-05T15:38:47Z,2294,[],Cytarabine + Fludarabine,2015-03-05T15:38:47Z
0,2015-11-08T22:20:23Z,3193,[],Cytarabine + Fludarabine + Idarubicin,2015-11-08T22:20:23Z
0,2016-03-11T20:49:01Z,3732,[],Cytarabine + Fludarabine + Leucovorin + Panobinostat,2016-03-11T20:49:01Z
0,2016-02-16T21:41:55Z,3535,[],Cytarabine + Fludarabine + Prexasertib,2017-08-22T19:05:54Z
0,2015-11-06T02:15:58Z,3182,[],Cytarabine + GDC-0199,2015-11-06T02:15:58Z
0,2014-10-02T18:30:04Z,1606,[],Cytarabine + Idarubicin,2014-10-02T18:30:04Z
0,2014-12-24T15:41:14Z,1850,[],Cytarabine + Idarubicin + Dasatinib,2014-12-24T15:41:14Z
0,2016-02-19T17:39:48Z,3573,[],Cytarabine + Idarubicin + Ibrutinib,2016-02-19T17:39:48Z
0,2016-07-27T01:26:52Z,4499,[],Cytarabine + Idarubicin + indoximod,2016-07-27T01:26:52Z
0,2016-01-29T03:26:23Z,3470,[],Cytarabine + Idarubicin + LY2510924,2016-01-29T03:26:23Z
0,2015-11-08T22:11:09Z,3192,[],Cytarabine + Idarubicin + Nivolumab,2015-11-08T22:11:09Z
0,2015-03-02T14:50:12Z,2232,[],Cytarabine + Idarubicin + Sirolimus,2015-03-02T14:50:12Z
0,2017-07-03T15:17:33Z,5959,[],Cytarabine + Idarubicin + Venetoclax,2017-07-03T15:17:33Z
0,2015-11-16T16:43:48Z,3213,[],Cytarabine + Idarubicin + Volasertib,2015-11-16T16:43:48Z
0,2016-06-28T01:34:30Z,4395,[],Cytarabine + Idasanutlin,2016-06-28T01:34:30Z
0,2015-11-08T22:45:20Z,3195,[],Cytarabine + Methotrexate ,2015-11-08T22:45:20Z
0,2015-02-11T16:23:26Z,2048,[],Cytarabine + Methotrexate + Ponatinib,2015-02-11T16:23:26Z
0,2015-11-16T17:29:21Z,3216,[],Cytarabine + Methotrexate + Prednisone,2015-11-16T17:29:21Z
0,2017-08-08T16:47:05Z,6095,[],Cytarabine + Midostaurin,2017-08-08T16:47:05Z
0,2015-03-13T15:02:45Z,2393,[],Cytarabine + Mitoxantrone,2015-03-13T15:02:45Z
0,2016-12-01T17:42:25Z,5037,[],Cytarabine + Mocetinostat,2016-12-01T17:42:25Z
0,2016-03-31T17:32:58Z,3887,[],Cytarabine + OXi4503,2016-03-31T17:32:58Z
0,2016-12-01T17:41:32Z,5036,[],Cytarabine + Panobinostat,2016-12-01T17:41:32Z
0,2015-03-26T13:53:19Z,2466,[],Cytarabine + Pri-724,2015-03-26T13:53:19Z
0,2017-04-06T20:41:12Z,5509,[],Cytarabine + RN-1,2017-04-06T20:41:38Z
0,2016-11-18T13:47:27Z,4968,[],Cytarabine + RO6839921,2016-11-18T13:47:27Z
0,2016-12-01T17:38:00Z,5035,[],Cytarabine + Romidepsin,2016-12-01T17:38:00Z
0,2017-09-29T13:49:56Z,6259,[],Cytarabine + Ulocuplumab,2017-09-29T13:49:56Z
0,2014-12-18T16:16:14Z,1802,[],Cytarabine + Vismodegib,2014-12-18T16:16:14Z
0,2016-07-29T13:14:34Z,4506,[],Cytarabine + Volasertib,2016-07-29T13:14:34Z
0,2014-01-20T22:50:47Z,3,"[{'description': 'Tafinlar (dabrafenib) inhibits the activity of BRAF, including V600E, which results in inhibition of tumor cell proliferation (NCI Drug Dictionary). Tafinlar (dabrafenib) is FDA approved for BRAF V600E positive unresectable or metastatic melanoma, and in combination with Mekinist (trametinib) for BRAF V600E/K-mutant melanoma and BRAF V600E-mutant non-small cell lung cancer (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Dabrafenib,2017-06-23T17:17:44Z
0,2016-10-04T14:44:38Z,4778,[],Dabrafenib + Digoxin + Trametinib,2016-10-04T14:44:38Z
0,2014-08-04T07:02:54Z,1357,[],Dabrafenib + Durvalumab + Trametinib,2017-07-06T19:49:51Z
0,2017-05-09T14:39:42Z,5650,[],Dabrafenib + Everolimus + Trametinib,2017-05-09T14:39:42Z
0,2016-08-05T16:08:22Z,4524,[],Dabrafenib + Gefitinib,2016-08-05T16:08:22Z
0,2016-04-25T01:20:54Z,4004,[],Dabrafenib + GSK2126458,2016-04-25T01:21:02Z
0,2015-02-27T16:22:55Z,2200,[],Dabrafenib + GSK2141795,2015-02-27T16:22:55Z
0,2017-09-08T14:43:01Z,6176,[],Dabrafenib + INCB039110 + Trametinib,2017-09-08T14:43:01Z
0,2014-07-30T15:38:53Z,1257,[],Dabrafenib + Ipilimumab,2014-07-30T15:38:53Z
0,2014-07-30T15:39:53Z,1258,[],Dabrafenib + Ipilimumab + Trametinib,2014-07-30T15:39:53Z
0,2015-03-27T09:28:13Z,2478,[],Dabrafenib + Lapatinib,2015-03-27T09:28:13Z
0,2016-09-25T14:24:39Z,4754,[],Dabrafenib + Nivolumab + Trametinib,2016-09-25T14:24:39Z
0,2014-07-29T20:30:13Z,1233,[],Dabrafenib + Pazopanib,2014-07-29T20:30:13Z
0,2014-07-31T08:50:40Z,1302,[],Dabrafenib + Rabeprazole + Rifampin,2014-07-31T08:50:40Z
0,2014-08-06T02:35:40Z,1388,[],Dabrafenib + Rosuvastatin + Midazolam,2014-08-06T02:35:40Z
0,2016-08-08T18:29:24Z,4544,[],Dabrafenib + SCH772984,2016-08-08T18:29:24Z
0,2016-10-05T20:52:58Z,4797,[],Dabrafenib + Selumetinib,2016-10-05T20:52:58Z
0,2015-02-27T16:25:53Z,2201,[],Dabrafenib + Trametinib + GSK2141795,2015-02-27T16:25:53Z
0,2014-09-11T04:03:54Z,1443,[],Dabrafenib + Trametinib + Metformin,2014-09-11T04:03:54Z
0,2017-07-28T02:19:55Z,6023,[],Dabrafenib + Trametinib + PDR001,2017-07-28T02:20:32Z
0,2017-02-01T03:21:21Z,5270,[],Dabrafenib + Trametinib + Phenformin,2017-02-01T03:21:21Z
0,2014-07-28T13:24:33Z,1154,"[{'description': 'Deticene (dacarbazine) alkylates and cross-links DNA, which disrupts the cell-cycle (NCI Drug Dictionary). Dacarbazine is FDA approved for melanoma (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Dacarbazine,2017-04-11T18:47:43Z
0,2017-09-01T20:24:47Z,6157,[],Dacarbazine + Doxorubicin + Pembrolizumab +Vinblastine,2017-09-01T20:24:47Z
0,2017-02-09T15:50:53Z,5296,[],Dacarbazine + Doxorubicin + Vinblastine + Nivolumab,2017-02-09T15:50:53Z
0,2016-12-01T17:09:35Z,5034,"[{'description': 'Dacinostat (LAQ824) is an HDAC inhibitor, which promotes apoptosis of tumor cells via activation of the mitochondrial apoptotic pathway (PMID: 19383971). ', 'references': [{'id': 7223, 'pubMedId': 19383971, 'title': 'The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19383971'}]}]",Dacinostat,2016-12-01T17:09:35Z
0,2015-08-25T01:04:49Z,3048,[],Daclizumab,2015-08-25T01:04:49Z
0,2014-03-12T15:53:16Z,714,"[{'description': 'Dacomitinib is a second-generation EGFR inhibitor and pan-HER inhibitor that inhibits HER2 and multiple EGFR subtypes including EGFR T790M, resulting in decreased proliferation and increased apoptosis in EGFR-expressing and HER2-expressing tumor cells (PMID: 22761403, PMID: 18606718).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 593, 'pubMedId': 22761403, 'title': 'Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22761403'}, {'id': 606, 'pubMedId': 18606718, 'title': 'Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18606718'}]}]",Dacomitinib,2016-09-12T20:44:17Z
0,2015-04-29T01:33:29Z,2601,[],Dactinomycin,2015-04-29T01:33:29Z
0,2017-06-16T19:19:26Z,5900,[],Dactinomycin + Ipilimumab + Melphalan,2017-06-16T19:19:26Z
0,2014-07-30T13:28:04Z,1244,"[{'description': 'Dalantercept (ACE-041) is an ALK1 ligand trap composed of the ALK1 extracellular domain linked to the IgG Fc region, which binds to ALK1 ligands and prevents binding to the receptor, potentially leading to decreased tumor angiogenesis and growth and increased sensitivity to chemotherapeutic agents (PMID: 25708802, PMID: 26373572).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 5020, 'pubMedId': 26373572, 'title': 'Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26373572'}, {'id': 5021, 'pubMedId': 20124460, 'title': 'ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20124460'}]}]",dalantercept  ,2016-03-25T16:26:22Z
0,2014-07-30T13:30:00Z,1245,[],Dalantercept + Axitinib,2014-07-30T13:30:00Z
0,2016-03-25T16:38:25Z,3834,[],Dalantercept + Cisplatin,2016-03-25T16:38:25Z
0,2016-03-25T16:55:42Z,3837,[],Dalantercept + Doxorubicin,2016-03-25T16:55:42Z
0,2015-03-12T12:53:46Z,2364,[],Dalantercept + Sorafenib,2015-03-12T12:53:46Z
0,2014-03-12T15:53:16Z,715,"[{'description': 'Dalotuzumab (MK-0646) binds to and inhibits IGF-1R, resulting in decreased downstream pathway activation and potentially leading to reduced tumor cell proliferation (PMID: 21810918).\r\n', 'references': [{'id': 2844, 'pubMedId': 21810918, 'title': 'A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21810918'}]}]",Dalotuzumab,2015-06-02T13:41:51Z
0,2014-03-12T15:53:16Z,716,"[{'description': 'Danusertib (PHA-739358) is a pan-Aurora kinase with additional activity against ABL, FGFR1, RET, TRKA, and BCR-ABL, including the T315I mutant (PMID: 20072840, PMID: 18089710).', 'references': [{'id': 865, 'pubMedId': 20072840, 'title': 'Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20072840'}]}]",Danusertib,2017-08-01T21:00:26Z
0,2017-08-01T21:00:09Z,6069,[],Danusertib + Fulvestrant,2017-08-01T21:00:09Z
0,2016-11-23T17:18:42Z,4999,[],Danusertib + SCH772984,2016-11-23T17:18:42Z
0,2015-04-17T19:46:39Z,2552,"[{'description': 'DAPT (GSI-IX) is a gamma secretase inhibitor, which blocks Notch cleavage and activation, and may inhibit angiogenesis and tumor growth (PMID: 11145990).', 'references': [{'id': 2514, 'pubMedId': 24900185, 'title': 'Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24900185'}, {'id': 2515, 'pubMedId': 11145990, 'title': 'Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11145990'}]}]",DAPT,2016-08-16T15:56:57Z
0,2014-10-08T20:55:17Z,1630,"[{'description': 'Darzalex (Daratumumab) is an antibody against CD-38 (NCI Drug Dictionary) that is FDA approved for multiple myeloma patients as a monotherapy and in combination with either Revlimid (lenalidomide) and Adexone (dexamethasone) or Velcade (bortezomib) and Adexone (dexamethasone) (FDA.gov). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Daratumumab,2017-06-19T19:51:50Z
0,2017-10-02T17:36:13Z,6282,[],Daratumumab + Dexamethasone + Ixazomib,2017-10-02T17:36:13Z
0,2016-10-20T19:45:36Z,4853,[],Daratumumab + Dexamethasone + Lenalidomide,2016-10-20T19:45:36Z
0,2016-08-07T16:48:34Z,4531,[],Daratumumab + Dexamethasone + MEDI4736 + Pomalidomide,2016-08-07T16:48:34Z
0,2016-08-07T16:42:56Z,4530,[],Daratumumab + MEDI4736,2016-08-07T16:42:56Z
0,2017-04-07T19:27:28Z,5520,[],Daratumumab + Nivolumab ,2017-04-07T19:27:28Z
0,2017-08-18T14:50:01Z,6115,[],Daratumumab + Pembrolizumab,2017-08-18T14:50:01Z
0,2017-07-03T14:15:47Z,5957,[],Daratumumab + TEN-010,2017-07-03T14:15:47Z
0,2014-03-12T15:53:16Z,717,"[{'description': 'Sprycel (dasatinib) is an inhibitor of the SRC-family of protein kinases, and has additional activity against other kinases including KIT, DDR1/2, PDGFRA/B, and EPHA2, which prevents cell growth (PMID: 25709401, PMID: 25284748, PMID: 18797457). Sprycel (dasatinib) is FDA approved for both Philadelphia chromosome positive chronic myelogenous leukemia and acute lymphoblastic leukemia (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Dasatinib,2016-10-27T14:54:28Z
0,2014-08-04T03:52:44Z,1351,[],Dasatinib + Afatinib,2014-08-04T03:52:44Z
0,2015-11-04T18:02:26Z,3174,[],Dasatinib + Cytarabine,2015-11-04T18:02:26Z
0,2014-12-04T23:08:16Z,1760,[],Dasatinib + Decitabine ,2014-12-04T23:08:16Z
0,2017-05-12T17:19:55Z,5671,[],Dasatinib + Demcizumab,2017-05-12T17:19:55Z
0,2015-11-16T18:01:38Z,3218,[],Dasatinib + Dexamethasone + Ruxolitinib,2015-11-16T18:01:38Z
0,2016-03-16T18:22:56Z,3759,[],Dasatinib + Erlotinib,2016-03-16T18:22:56Z
0,2017-08-03T14:49:35Z,6075,[],Dasatinib + FOLFOX,2017-08-03T14:49:35Z
0,2016-01-07T17:48:48Z,3372,[],Dasatinib + Fulvestrant,2016-01-07T17:48:48Z
0,2017-02-07T03:47:39Z,5287,[],Dasatinib + Ganitumab,2017-02-07T03:47:39Z
0,2017-09-21T14:53:43Z,6226,[],Dasatinib + Gefitinib,2017-09-21T14:53:43Z
0,2017-02-08T18:25:34Z,5290,[],Dasatinib + GSK343,2017-02-08T18:25:34Z
0,2016-07-12T12:03:48Z,4438,[],Dasatinib + Ibrutinib + Prednisone,2016-07-12T12:03:48Z
0,2014-12-18T16:42:01Z,1803,[],Dasatinib + Ipilimumab,2014-12-18T16:42:01Z
0,2016-03-23T14:18:32Z,3824,[],Dasatinib + JQ1,2016-03-23T14:18:32Z
0,2017-04-27T09:17:16Z,5576,[],Dasatinib + Lapatinib,2017-04-27T09:17:16Z
0,2014-12-22T14:15:12Z,1825,[],Dasatinib + lenalidomide,2014-12-22T14:15:12Z
0,2014-12-19T13:28:41Z,1813,[],Dasatinib + Nivolumab,2014-12-19T13:28:41Z
0,2016-11-13T21:22:35Z,4946,[],Dasatinib + Osimertinib,2016-11-13T21:22:35Z
0,2014-12-19T15:28:42Z,1819,[],Dasatinib + Paclitaxel + Carboplatin,2014-12-19T15:28:42Z
0,2015-03-26T13:52:45Z,2465,[],Dasatinib + Pri-724,2015-03-26T13:52:45Z
0,2017-06-29T18:31:20Z,5949,[],Dasatinib + PRT062607,2017-06-29T18:31:20Z
0,2014-12-19T16:01:47Z,1821,[],Dasatinib + Rituximab + Fludarabine,2014-12-19T16:01:47Z
0,2016-03-16T16:42:33Z,3757,[],Dasatinib + Saracatinib,2016-03-16T16:42:33Z
0,2016-08-22T16:21:10Z,4601,[],Dasatinib + SCH772984,2016-08-22T16:21:10Z
0,2016-08-22T16:20:23Z,4600,[],Dasatinib + Selumetinib,2016-08-22T16:20:23Z
0,2016-08-22T16:19:46Z,4599,[],Dasatinib + Trametinib,2016-08-22T16:19:46Z
0,2017-04-27T09:12:15Z,5575,[],Dasatinib + Trastuzumab,2017-04-27T09:12:40Z
0,2016-10-27T17:11:52Z,4868,[],Dasatinib + Venetoclax,2016-10-27T17:11:52Z
0,2014-05-14T14:52:46Z,1006,"[{'description': 'Cerubidine (daunorubicin) is an anthracycline, which inhibits DNA replication and repair (NCI Drug Dictionary). Cerubidine (daunorubicin) is FDA approved for AML and MLL (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Daunorubicin,2017-06-29T19:06:00Z
0,2014-11-21T05:00:36Z,1738,[],Daunorubicin + Cytarabine,2014-11-21T05:00:36Z
0,2014-11-21T05:02:12Z,1739,[],Daunorubicin + Cytarabine + Decitabine,2014-11-21T05:02:12Z
0,2016-09-08T18:52:30Z,4669,[],Daunorubicin + Venetoclax,2016-09-08T18:52:30Z
0,2014-05-14T14:52:46Z,1007,"[{'description': 'Daunoxome is a liposomal formulation of the anthracyline, daunorubicin (NCI Drug Dictionary) and is FDA approved for HIV-associated Kaposi’s sarcoma (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Daunoxome,2015-04-10T16:27:36Z
0,2016-05-06T00:25:45Z,4080,"[{'description': 'Dbait is a nanoparticle drug containing short interfering DNA that mimic DNA double strand breaks, which has been demonstrated to result in activation of the DNA damage response with anti-cancer activity in combination with chemotherapeutics (PMID: 26637369).', 'references': []}]",Dbait,2016-05-06T00:29:06Z
0,2016-05-06T00:36:36Z,4081,[],Dbait + Fluorouracil,2016-05-06T00:36:36Z
0,2016-05-06T00:37:53Z,4082,[],Dbait + Fluorouracil + Oxaliplatin,2016-05-06T00:45:34Z
0,2016-04-07T17:19:34Z,3907,"[{'description': 'dBET1 is a phthalimide conjugate that targets Bet proteins for degradation, leading to growth inhibition in tumor cells (PMID: 25999370).', 'references': [{'id': 5123, 'pubMedId': 25999370, 'title': 'DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25999370'}]}]",dBET1,2017-03-17T16:22:02Z
0,2017-02-26T04:46:06Z,5369,"[{'description': 'DC/AML vaccine is generated by fusing patient derived AML cells with autologous dendritic cells, resulting in anti-tumor immune response (Blood 2013 122:3928).', 'references': [{'id': 8204, 'pubMedId': None, 'title': 'Clinical Trial Evaluating DC/AML Fusion Cell Vaccination In AML Patients', 'url': 'http://www.bloodjournal.org/content/122/21/3928?sso-checked=true'}, {'id': 8203, 'pubMedId': 25625926, 'title': 'Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25625926'}]}]",DC/AML Vaccine,2017-03-10T17:54:03Z
0,2017-02-26T04:47:19Z,5370,[],DC/AML Vaccine + MEDI4736,2017-02-26T04:47:19Z
0,2015-02-07T11:07:02Z,2017,"[{'description': 'DCBCI0901 is an inhibitor of PI3K, mTORC1, and mTORC2, which may result in antitumor activity including inhibition of both cell survival and cell proliferation, and inhibition of tumor growth (Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C270).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 3453, 'pubMedId': None, 'title': 'Abstract C270: In vitro and in vivo antitumor activity of DCBCI0901, a potent PI3K/mTORC1/mTORC2 inhibitor.', 'url': 'http://mct.aacrjournals.org/content/12/11_Supplement/C270.short'}]}]",DCBCI0901,2017-04-18T16:51:42Z
0,2016-06-17T22:34:24Z,4316,"[{'description': 'DCC-2618 is a dual inhibitor of KIT and PDGFRa, resulting in growth inhibition and anti-tumor effects (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",DCC-2618,2016-06-17T22:34:24Z
0,2017-05-24T16:40:24Z,5760,"[{'description': 'DCC-3014 inhibits CSF1R, potentially resulting in increased anti-tumor immune response in combination with other agents (Cancer Res 2016;76(14 Suppl):Abstract nr 4889).', 'references': [{'id': 8976, 'pubMedId': None, 'title': 'Abstract 4889: The highly specific CSF1R inhibitor DCC-3014 exhibits immunomodulatory and anti-invasive activities in cancer models', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/4889'}]}]",DCC-3014,2017-05-24T16:40:24Z
0,2015-10-09T01:58:44Z,3122,"[{'description': 'DCR-MYC is a small-interfering RNA (siRNA) against c-Myc, which inhibits c-Myc translation and leads to growth inhibition of tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",DCR-MYC,2015-10-13T16:04:58Z
0,2017-01-15T22:47:20Z,5205,"[{'description': 'DCVax-L is a lung cancer vaccine composed of patient-derived dendritic cells that have been transduced with a patient tumor-specific antigen, potentially resulting in increased anti-tumor immunity (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",DCVax-L,2017-01-16T18:15:47Z
0,2017-01-15T22:48:12Z,5206,[],DCVax-L + Nivolumab,2017-01-15T22:48:12Z
0,2016-10-13T13:31:18Z,4822,"[{'description': 'Debio 0617B is a multi-kinase inhibitor that results in inhibition of Stat3 and Stat5 signaling, leading to inhibition of tumor cell growth and metastasis (PMID: 27439479).', 'references': [{'id': 6765, 'pubMedId': 27439479, 'title': 'Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27439479'}]}]",Debio 0617B,2016-10-13T13:31:18Z
0,2016-10-13T14:33:27Z,4823,[],Debio 0617B + Erlotinib,2016-10-13T14:33:27Z
0,2016-02-22T17:40:46Z,3588,"[{'description': 'Debio0932 is a second-generation Hsp90 inhibitor, which may decrease tumor cell proliferation and increase sensitivity to cytotoxic agents (Cancer Res August 1, 2015 75; 683).', 'references': [{'id': 4655, 'pubMedId': None, 'title': 'Abstract 683: DEBIO0932, an Hsp90 inhibitor downregulates key signaling pathways and sensitizes glioma cells to temozolomide', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/683.short'}]}]",Debio 0932,2016-02-24T16:11:39Z
0,2014-12-18T14:52:50Z,1795,[],DEC-205-NY-ESO-1 + Decitabine ,2014-12-18T14:52:50Z
0,2014-07-31T19:57:19Z,1324,"[{'description': 'DEC-205/NY-ESO-1 fusion protein vaccine constists of a monoclonal antibody directed against the dendritic cell receptor DEC-205 linked to the tumor-associated antigen DEC-205/NY-ESO-1 fusion protein. The vaccine may boost the immune system to attack cancer cells expressing DEC-205/NY-ESO-1 fusion protein (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",DEC-205-NY-ESO-1 fusion protein vaccine,2014-07-31T20:38:04Z
0,2014-03-12T15:53:16Z,650,"[{'description': 'Dacogen (decitabine) is cytidine antimetabolite analogue which incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation and arrest of DNA replication (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Decitabine,2015-06-01T19:39:09Z
0,2014-10-02T18:53:36Z,1609,[],Decitabine + Arsenic trioxide ,2014-10-02T18:53:36Z
0,2014-12-18T15:31:24Z,1798,[],Decitabine + Azacitidine,2014-12-18T15:31:24Z
0,2014-10-02T18:52:45Z,1608,[],Decitabine + Carboplatin,2014-10-02T18:52:45Z
0,2014-11-21T04:06:04Z,1736,[],Decitabine + Cytarabine,2014-11-21T04:06:04Z
0,2014-09-25T03:45:54Z,1531,[],Decitabine + Gefitinib,2014-09-25T03:45:54Z
0,2017-05-22T17:51:38Z,5738,[],Decitabine + Ipilimumab,2017-05-22T17:52:29Z
0,2014-12-05T05:08:38Z,1769,[],Decitabine + Midostaurin,2014-12-05T05:08:38Z
0,2017-01-16T15:45:59Z,5214,[],Decitabine + MLN4924,2017-01-16T15:45:59Z
0,2017-06-19T17:41:40Z,5910,[],Decitabine + Nivolumab + Tetrahydrouridine,2017-06-19T17:41:40Z
0,2017-05-26T18:14:54Z,5794,[],Decitabine + OPB-111077,2017-05-26T18:14:54Z
0,2014-12-18T15:07:24Z,1797,[],Decitabine + Ribavirin,2014-12-18T15:07:24Z
0,2014-11-28T23:38:51Z,1747,[],Decitabine + Sapacitabine,2014-11-28T23:38:51Z
0,2014-12-05T05:03:00Z,1768,[],Decitabine + Selinexor,2014-12-05T05:03:00Z
0,2014-12-18T15:06:27Z,1796,[],Decitabine + Sirolimus,2014-12-18T15:06:27Z
0,2017-06-19T15:13:02Z,5909,[],Decitabine + Talacotuzumab,2017-06-19T15:13:02Z
0,2017-04-12T17:34:41Z,5531,[],Decitabine + Talazoparib,2017-06-12T16:04:17Z
0,2014-11-21T04:49:14Z,1737,[],Decitabine + Temozolomide + Panobinostat,2014-11-21T04:49:14Z
0,2016-02-19T15:08:06Z,3567,[],Decitabine + Tetrahydrouridine,2016-02-19T15:08:06Z
0,2016-08-20T02:36:52Z,4592,[],Decitabine + Tetrahydrouridine + Celecoxib,2016-08-20T02:36:52Z
0,2017-03-13T18:02:25Z,5433,[],Decitabine + TMU-35435,2017-03-13T18:02:25Z
0,2014-12-05T04:51:08Z,1766,[],Decitabine + Vosaroxin,2014-12-05T04:51:08Z
0,2015-09-18T14:04:59Z,3083,[],Defactinib + Gemcitabine + Pembrolizumab,2015-09-18T14:04:59Z
0,2014-12-19T13:34:49Z,1814,[],Degarelix,2014-12-19T13:34:49Z
0,2014-12-19T13:35:47Z,1815,[],Degarelix + Enzalutamide,2014-12-19T13:35:47Z
0,2014-12-29T21:35:19Z,1867,"[{'description': 'Deguelin is a plant-derived rotenoid that is a pan-PI3K inhibitor, which may enhance chemosensitivity (PMID: 15916691).', 'references': [{'id': 1524, 'pubMedId': 12591985, 'title': 'Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12591985'}, {'id': 1836, 'pubMedId': 15916691, 'title': 'Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15916691'}]}]",Deguelin,2015-02-09T17:17:24Z
0,2015-08-13T19:35:22Z,3022,[],Deguelin + Cisplatin,2015-08-13T19:35:22Z
0,2015-06-04T14:38:15Z,2788,"[{'description': 'Dehydrocrenatidine is a selective JAK2 inhibitor, which decreases STAT3 signaling to prevent cell proliferation (PMID: 25583084).', 'references': [{'id': 2951, 'pubMedId': 25583084, 'title': 'Dehydrocrenatidine is a novel janus kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25583084'}]}]",Dehydrocrenatidine,2015-06-04T14:38:15Z
0,2016-03-17T14:37:29Z,3769,"[{'description': 'DEL-22379 inhibits ERK dimerization, resulting in decreased extranuclear ERK signaling and potentially leading to reduced growth of ERK pathway-driven tumors (PMID: 26267534).', 'references': [{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]}]",DEL-22379,2016-03-17T14:40:42Z
0,2017-08-11T19:28:34Z,6107,"[{'description': 'Delanzomib (CEP-18770) inhibits proteosome chymotrypsin-like activity, potentially resulting in increased tumor cell death (PMID: 18057228, PMID: 25935605).', 'references': [{'id': 9702, 'pubMedId': 18057228, 'title': 'CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18057228'}, {'id': 9701, 'pubMedId': 25935605, 'title': 'Proteasome inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25935605'}]}]",Delanzomib,2017-08-11T19:29:58Z
0,2017-08-11T19:38:46Z,6109,[],Delanzomib + EDO-S101,2017-08-11T19:38:46Z
0,2015-02-03T00:27:37Z,2007,"[{'description': 'Demcizumab (OMP-21M18) is a monoclonal antibody that binds DLL4 and prevents its interaction with Notch receptors, thereby inhibiting pathway activation and tumor growth (PMID: 19664991, PMID: 25324140).', 'references': [{'id': 6126, 'pubMedId': 19664991, 'title': 'DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19664991'}, {'id': 5877, 'pubMedId': 25324140, 'title': 'A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25324140'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 2505, 'pubMedId': 21831306, 'title': 'Anti-DLL4, a cancer therapeutic with multiple mechanisms of action.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831306'}]}]",Demcizumab,2017-07-13T18:27:41Z
0,2016-06-27T18:50:17Z,4384,[],Demcizumab + Gemcitabine,2016-06-27T18:50:17Z
0,2015-05-08T02:25:55Z,2639,[],Demcizumab + Gemcitabine + nab-paclitaxel,2015-05-08T02:27:24Z
0,2016-06-27T19:18:53Z,4385,[],Demcizumab + Paclitaxel,2016-06-27T19:18:53Z
0,2016-04-22T14:43:40Z,3994,[],Demcizumab + Pembrolizumab,2016-04-22T14:43:40Z
0,2017-02-03T13:52:25Z,5282,"[{'description': 'Ontak (denileukin diftitox) is an interleukin-2 (IL-2) recombinant fusion protein comprised of the IL-2 protein and the diptheria toxin, and may potentially inhibit the growth and survival of tumor cells expressing the IL-2 receptor (PMID: 11707818, PMID: 27737881). ', 'references': [{'id': 7744, 'pubMedId': 27737881, 'title': 'Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27737881'}, {'id': 7743, 'pubMedId': 11707818, 'title': 'DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11707818'}]}]",Denileukin diftitox,2017-06-19T19:53:57Z
0,2017-02-03T13:53:29Z,5283,[],Denileukin diftitox + Sirolimus,2017-02-03T13:53:29Z
0,2017-02-03T18:35:25Z,5284,[],Denileukin diftitox + Temsirolimus,2017-02-03T18:35:25Z
0,2014-07-29T13:12:15Z,1198,"[{'description': 'Xgeva (denosumab) is an antibody that binds to RANKL protein, inhibiting osteoclast activity (NCI Drug Dictionary). Xgeva (denosumab) is FDA approved for use in patients with giant cell tumor of the bone (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Denosumab,2017-06-19T19:55:17Z
0,2016-05-27T20:19:44Z,4183,[],Denosumab + Enzalutamide,2016-05-27T20:19:44Z
0,2016-10-04T16:02:33Z,4784,[],Denosumab + pamidronate + Zoledronic acid,2017-06-19T18:23:49Z
0,2016-06-03T13:38:39Z,4230,"[{'description': 'DETD-35 is a derivative of plant sesquiterpene lactone that inhibits Mek-Erk signaling and induces reactive oxygen species generation, which may lead to apoptosis in tumor cells (PMID: 27048951).', 'references': []}]",DETD-35,2016-06-06T18:09:17Z
0,2016-06-03T13:59:01Z,4232,[],DETD-35 + Vemurafenib,2016-06-03T13:59:01Z
0,2014-08-06T14:18:20Z,1390,"[{'description': 'Desamethasone is an anti-inflammatory synthetic adrenal corticosteroid that also inhibits NF-kB activation and its suppression of apoptotic pathways (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Dexamethasone,2014-08-06T14:18:20Z
0,2017-04-27T18:54:42Z,5581,[],Dexamethasone + Diphenhydramine + Famotidine + 5FU + Hydroxyurea + Paclitaxel,2017-04-27T18:54:42Z
0,2017-02-20T20:53:24Z,5343,[],Dexamethasone + Docetaxel + Pembrolizumab + Prednisone,2017-02-20T20:53:24Z
0,2016-09-12T16:25:24Z,4685,[],Dexamethasone + Doxorubicin,2016-09-12T16:25:24Z
0,2015-07-23T13:29:33Z,2952,[],Dexamethasone + Doxorubicin + Vincristine,2015-07-23T13:29:33Z
0,2017-08-18T15:06:54Z,6118,[],Dexamethasone + Elotuzumab + Nivolumab + Pomalidomide,2017-08-18T15:06:54Z
0,2016-11-19T23:20:56Z,4977,[],Dexamethasone + Filgrastim + Palifermin + Rituximab,2016-11-19T23:20:56Z
0,2016-06-28T01:11:31Z,4392,[],Dexamethasone + Idasanutlin + Ixazomib,2016-06-28T01:11:31Z
0,2016-08-14T16:54:48Z,4565,[],Dexamethasone + Ixazomib + Panobinostat,2016-08-14T16:54:48Z
0,2016-07-27T01:43:39Z,4500,[],Dexamethasone + Ixazomib + Selinexor,2016-07-27T01:43:39Z
0,2016-11-13T21:58:13Z,4950,[],Dexamethasone + JNJ-42756493,2016-11-13T21:58:13Z
0,2016-04-29T19:42:21Z,4036,[],Dexamethasone + lenalidomide,2016-04-29T19:42:21Z
0,2017-01-19T19:40:20Z,5232,[],Dexamethasone + Lenalidomide + LGH447,2017-01-19T19:40:20Z
0,2016-09-07T14:50:01Z,4660,[],Dexamethasone + Lenalidomide + PAT-SM6,2016-09-07T14:50:01Z
0,2016-08-28T19:42:53Z,4612,[],Dexamethasone + lenalidomide + Pembrolizumab,2016-08-28T19:42:53Z
0,2016-02-19T14:19:50Z,3555,[],Dexamethasone + lenalidomide + Ulocuplumab,2016-02-19T14:19:50Z
0,2017-01-19T19:43:28Z,5234,[],Dexamethasone + LGH447,2017-01-19T19:43:28Z
0,2017-01-19T19:42:06Z,5233,[],Dexamethasone + LGH447 + Pomalidomide,2017-01-19T19:42:06Z
0,2016-06-03T01:03:08Z,4221,[],Dexamethasone + Melphalan + Selinexor,2016-06-03T01:03:08Z
0,2016-09-07T14:49:08Z,4659,[],Dexamethasone + PAT-SM6,2016-09-07T14:49:08Z
0,2015-12-31T16:51:19Z,3356,[],Dexamethasone + pegylated liposomal-doxorubicin + Selinexor,2015-12-31T16:51:19Z
0,2015-12-29T16:09:54Z,3344,[],Dexamethasone + Pembrolizumab + Pomalidomide,2015-12-29T16:09:54Z
0,2016-03-21T01:13:02Z,3792,[],Dexamethasone + Pomalidomide,2016-03-21T01:13:02Z
0,2015-03-27T13:37:11Z,2479,[],Dexamethasone + Selinexor,2015-03-27T13:37:11Z
0,2014-09-18T17:01:29Z,1480,[],Dexamethasone intravitreal implant,2014-09-18T17:04:54Z
0,2017-01-03T21:06:30Z,5153,[],dexrazoxane,2017-01-03T21:06:30Z
0,2016-05-12T13:48:38Z,4106,[],DHA,2016-05-12T13:48:38Z
0,2016-05-12T13:49:37Z,4107,[],DHA + Regorafenib,2016-05-12T13:49:37Z
0,2017-03-29T17:46:38Z,5494,"[{'description': 'DHM25 is an mTOR inhibitor that inhibits the activity of mTORC1 and mTORC2, potentially resulting in decreased tumor growth (PMID: 26237138).', 'references': [{'id': 8367, 'pubMedId': 26237138, 'title': 'A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26237138'}]}]",DHM25,2017-03-29T17:46:38Z
0,2017-02-21T15:35:38Z,5345,"[{'description': 'DIM-C-pPhCO2Me is a diindolylmethane analog that binds to the ligand binding domain of NR4A1, potentially resulting in inhibition of cell growth and apoptotic induction (PMID: 25099012). ', 'references': []}]",DIM-C-pPhCO2Me,2017-02-21T15:35:38Z
0,2014-03-12T15:53:16Z,719,"[{'description': 'Dinaciclib (SCH 727965) inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9, which prevents phosphorylation of downstream targets and may promote cell cycle arrest and apoptosis in cancer cells (PMID: 24900195, PMID: 24004674).', 'references': [{'id': 2862, 'pubMedId': 24900195, 'title': 'Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24900195'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 2783, 'pubMedId': 24004674, 'title': 'Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24004674'}]}]",Dinaciclib,2015-06-01T20:57:23Z
0,2016-11-29T17:47:58Z,5019,[],Dinaciclib + Doxorubicin,2016-11-29T17:47:58Z
0,2015-02-27T13:49:41Z,2193,[],Dinaciclib + MK2206,2015-02-27T13:49:41Z
0,2016-11-03T16:47:19Z,4912,[],Dinaciclib + Paclitaxel,2016-11-03T16:47:19Z
0,2016-06-03T02:25:47Z,4225,[],Dinaciclib + Pembrolizumab,2016-06-03T02:25:47Z
0,2015-03-05T13:38:18Z,2286,"[{'description': 'Unituxin (dinutuximab) is a monoclonal antibody that targets B4GALNT1 (GD2) and increases antibody-dependent and complement-dependent cytotoxicity against GD2-expressing tumor cells (NCI Drug Dictionary). Unituxin (dinutuximab) is FDA approved for pediatric high-risk neuroblastoma (FDA.gov).  ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Dinutuximab  ,2017-06-19T19:56:19Z
0,2014-07-30T17:29:53Z,1275,[],Diphenhydramine,2014-07-30T17:29:53Z
0,2014-12-15T21:39:05Z,1787,"[{'description': 'Dizocilpine (MK-801) is an uncompetitive antagonist against the N-Methyl-D-aspartate ionotropic glutamate receptor (PMID: 3529096), and demonstrates anti-proliferative effects against cancer cells (PMID: 16230611).', 'references': [{'id': 1339, 'pubMedId': 16230611, 'title': 'NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16230611'}, {'id': 1338, 'pubMedId': 3529096, 'title': 'The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/3529096'}]}]",Dizocilpine,2014-12-15T21:39:05Z
0,2017-09-26T20:22:46Z,6244,"[{'description': 'DKN-01 is a monoclonal antibody that binds to and inhibits Dkk1, resulting in restoration of Wnt signaling and tumor growth inhibition (PMID: 28731148).', 'references': [{'id': 10003, 'pubMedId': 28731148, 'title': 'Molecular genetics and targeted therapy of WNT-related human diseases (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28731148'}]}]",DKN-01,2017-09-26T20:22:46Z
0,2017-09-27T14:57:37Z,6254,[],DKN-01 + Paclitaxel,2017-09-27T14:57:37Z
0,2014-12-26T20:20:58Z,1855,"[{'description': 'DMUC5754A is comprised of an antibody directed against Muc16 conjugated to the drug MMEA, which upon binding to Muc16 expressing cells inhibits tubulin polymerization, potentially resulting in cell cycle arrest and apoptosis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",DMUC5754A,2015-07-10T16:34:49Z
0,2014-08-04T03:05:41Z,1345,[],DNIB0600A,2014-08-04T03:05:41Z
0,2014-08-04T03:15:55Z,1346,[],DNIB0600A + Carboplatin,2014-08-04T03:15:55Z
0,2014-08-04T03:22:10Z,1347,[],DNIB0600A + Carboplatin + Bevacizumab,2014-08-04T03:22:38Z
0,2016-07-01T16:56:08Z,4407,"[{'description': 'DNX-2401 is an adenovirus that replicates in Rb1/p16-deficient cells, resulting in lysis of tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",DNX-2401,2016-07-01T16:56:08Z
0,2016-07-12T14:11:38Z,4444,[],DNX-2401 + interferon gamma ,2016-07-12T14:11:38Z
0,2016-07-01T16:57:18Z,4408,[],DNX-2401 + Pembrolizumab,2016-07-01T16:57:18Z
0,2015-01-19T18:30:03Z,1967,"[{'description': 'Dobutamine is a beta-adrenergic receptor agonist, which has recently been demonstrated to inhibit nuclear translocation of the Hippo pathway target, Yap1 (PMID: 21586534). ', 'references': [{'id': 1742, 'pubMedId': 21586534, 'title': 'A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21586534'}]}]",Dobutamine,2015-05-01T18:17:00Z
0,2014-03-12T15:53:16Z,720,"[{'description': 'Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Docetaxel,2017-04-11T18:43:16Z
0,2014-12-22T17:05:36Z,1834,[],Docetaxel + Carboplatin,2014-12-22T17:05:36Z
0,2015-01-07T13:52:30Z,1925,[],Docetaxel + Cetuximab,2015-01-07T13:52:30Z
0,2014-12-22T17:06:22Z,1835,[],Docetaxel + Cisplatin,2014-12-22T17:06:22Z
0,2014-12-31T17:08:10Z,1881,[],Docetaxel + Cyclophosphamide,2014-12-31T17:08:10Z
0,2014-12-31T17:10:48Z,1882,[],Docetaxel + Cyclophosphamide + Trastuzumab,2014-12-31T17:10:48Z
0,2015-01-04T02:31:44Z,1902,[],Docetaxel + Doxorubicin + Cyclophosphamide,2015-01-04T02:31:44Z
0,2017-07-28T18:53:52Z,6040,[],Docetaxel + Doxorubicin + Pembrolizumab,2017-07-28T18:53:52Z
0,2016-09-12T02:59:54Z,4681,[],Docetaxel + Enzalutamide + Prednisone,2016-09-12T02:59:54Z
0,2015-10-08T02:58:13Z,3113,[],Docetaxel + Filgrastim + Prednisone + Ribociclib,2015-10-08T02:58:13Z
0,2015-03-06T16:28:05Z,2321,[],Docetaxel + GDC-0032 ,2015-03-06T16:28:05Z
0,2015-02-19T13:44:44Z,2100,[],Docetaxel + Gemcitabine + Melphalan,2015-02-19T13:44:44Z
0,2016-03-10T14:32:51Z,3701,[],Docetaxel + Icrucumab,2016-03-10T14:32:51Z
0,2016-05-27T17:08:51Z,4174,[],Docetaxel + INCB054828,2016-05-27T17:08:51Z
0,2016-02-19T19:31:23Z,3578,[],Docetaxel + Indoximod,2016-02-19T19:31:23Z
0,2016-06-17T21:34:00Z,4311,[],Docetaxel + Irinotecan,2016-06-17T21:35:09Z
0,2015-03-04T15:16:59Z,2282,[],Docetaxel + Irinotecan + Paclitaxel,2015-03-04T15:16:59Z
0,2015-05-08T14:21:21Z,2646,[],Docetaxel + Irinotecan + Pemetrexed ,2015-05-08T14:21:21Z
0,2016-08-31T17:01:05Z,4629,[],Docetaxel + JQ1,2016-08-31T17:01:05Z
0,2017-08-18T18:28:22Z,6123,[],Docetaxel + L-NMMA,2017-08-18T18:28:22Z
0,2015-10-15T15:32:01Z,3129,[],Docetaxel + Lapatinib + Trastuzumab,2015-10-15T15:32:01Z
0,2016-03-06T21:23:08Z,3683,[],Docetaxel + LB-100,2016-03-06T21:23:08Z
0,2016-03-02T18:57:57Z,3665,[],Docetaxel + Lonafarnib,2016-03-02T18:57:57Z
0,2017-07-28T17:55:25Z,6033,[],Docetaxel + MLN4924,2017-07-28T17:55:39Z
0,2017-02-07T04:09:56Z,5288,[],Docetaxel + Nivolumab,2017-02-07T04:09:56Z
0,2016-11-06T21:34:50Z,4921,[],Docetaxel + ODM-201,2016-11-06T21:34:50Z
0,2017-07-07T04:02:52Z,5977,[],Docetaxel + ONC201,2017-07-07T04:02:52Z
0,2015-08-24T23:44:43Z,3045,[],Docetaxel + Paclitaxel,2015-08-24T23:44:43Z
0,2015-02-11T14:35:39Z,2042,[],Docetaxel + Pazopanib + Pegfilgrastim,2015-02-11T14:35:39Z
0,2017-03-30T17:56:03Z,5496,[],Docetaxel + Pembrolizumab,2017-03-30T17:56:03Z
0,2016-06-20T02:28:31Z,4328,[],Docetaxel + Pemetrexed,2016-06-20T02:28:31Z
0,2016-03-04T21:12:54Z,3679,[],Docetaxel + Plinabulin,2016-03-04T21:12:54Z
0,2015-03-26T13:18:52Z,2462,[],Docetaxel + Prednisone,2015-03-26T13:18:52Z
0,2017-04-12T18:04:38Z,5534,[],Docetaxel + Selinexor,2017-04-12T18:04:38Z
0,2016-06-10T20:25:22Z,4270,[],Docetaxel + Sipuleucel-T,2016-06-10T20:25:22Z
0,2015-03-13T14:31:05Z,2390,[],Docetaxel + Sorafenib,2015-03-13T14:31:05Z
0,2016-04-14T20:18:02Z,3930,[],Docetaxel + T-DM1,2016-04-14T20:18:02Z
0,2016-04-14T20:18:47Z,3931,[],Docetaxel + T-DM1 + Pertuzumab,2016-04-14T20:18:47Z
0,2014-07-30T16:45:10Z,1264,[],Docetaxel + Trametinib,2016-01-14T15:04:37Z
0,2015-07-20T17:00:16Z,2935,[],Docetaxel + Vandetanib,2015-07-20T17:00:32Z
0,2016-07-01T20:07:27Z,4413,[],Docetaxel + Vantictumab,2016-07-01T20:07:27Z
0,2014-12-29T09:22:39Z,1863,"[{'description': 'Dorsomorphin (Compound C) is a AMPK inhibitor, and reduces tumor cell viability by inhibiting proliferation and inducing cell death (PMID: 24419061).', 'references': [{'id': 1505, 'pubMedId': 24419061, 'title': 'The AMPK inhibitor compound C is a potent AMPK-independent antiglioma agent.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419061'}]}]",Dorsomorphin,2014-12-29T09:22:39Z
0,2014-07-31T15:11:19Z,1313,"[{'description': 'DOTAP:chol-Fus1 is a complex of liposomal nanoparticles with a plasmid expression cassette encoding the human FUS1 protein. Expression of Fus1 may induce tumor cell apoptosis and suppress tumor cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",DOTAP:chol-Fus1,2015-04-10T16:30:41Z
0,2014-03-12T15:53:16Z,721,"[{'description': 'Dovitinib (TKI258) targets multiple receptor tyrosine kinases including Flt3, c-Kit, CSF1R, FGFR 1-4, VEGFR 1-3, and PDGFR alpha and beta, potentially resulting in decreased tumor growth (PMID: 15598814, PMID: 25219510, PMID: 23658459).', 'references': [{'id': 754, 'pubMedId': 23658459, 'title': 'Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23658459'}, {'id': 3788, 'pubMedId': 25219510, 'title': 'Structural analysis of the human fibroblast growth factor receptor 4 kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25219510'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 3789, 'pubMedId': 15598814, 'title': 'CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15598814'}]}]",Dovitinib,2015-10-21T20:18:52Z
0,2014-07-29T20:16:37Z,1232,[],Dovitinib + Fluvoxamine,2014-07-29T20:16:37Z
0,2014-08-05T17:02:06Z,1372,[],Dovitinib + Gemcitabine + Abraxane,2014-08-05T17:02:06Z
0,2016-01-19T18:06:17Z,3421,[],Dovitinib + Trabectedin,2016-01-19T18:06:17Z
0,2014-05-14T14:52:46Z,1008,"[{'description': ""Doxil (pegylated liposomal doxorubicin) is doxorubicin encapsulated within a liposome to allow better penetration into tumors, decrease toxicity, and increase the period of effectiveness. Doxorubicin intercalates into DNA, disrupting DNA replication (NCI Drug Dictionary). Doxil is FDA approved for ovarian cancer, AIDS-related Kaposi's sarcoma and multiple myeloma (FDA.gov)."", 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Doxil,2015-04-06T19:01:03Z
0,2014-10-28T19:39:31Z,1673,[],Doxil + Bevacizamub,2014-10-28T19:39:31Z
0,2015-02-26T16:12:29Z,2173,[],Doxil + Letrozole + Tamoxifen + Paclitaxel,2015-02-26T16:12:29Z
0,2016-02-19T17:55:10Z,3574,[],Doxil + Paclitaxel,2016-02-19T17:55:10Z
0,2016-08-13T14:56:45Z,4558,[],Doxil + Pembrolizumab,2016-08-13T14:56:45Z
0,2014-10-28T19:42:31Z,1674,[],Doxil + Pomalidomide,2014-10-28T19:42:31Z
0,2016-11-18T13:46:29Z,4967,[],Doxil + RO6839921,2016-11-18T13:46:29Z
0,2016-01-10T22:32:31Z,3393,[],Doxil + romidepsin ,2016-01-10T22:32:31Z
0,2014-10-28T19:51:59Z,1675,[],Doxil + Temsirolimus,2014-10-28T19:51:59Z
0,2014-05-14T14:52:46Z,1009,"[{'description': 'Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 96, 'pubMedId': 24367159, 'title': 'New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24367159'}]}]",Doxorubicin,2017-04-26T14:58:28Z
0,2014-09-18T15:39:42Z,1473,[],Doxorubicin + Bevacizumab,2014-09-18T15:39:42Z
0,2015-01-26T13:36:34Z,1977,[],Doxorubicin + Cyclophosphamide,2015-01-26T13:36:34Z
0,2017-05-20T03:54:13Z,5729,[],Doxorubicin + Cyclophosphamide + Paclitaxel + Carboplatin,2017-05-20T03:54:13Z
0,2015-03-05T15:16:05Z,2292,[],Doxorubicin + Etoposide + Fludarabine + Vincristine ,2015-03-05T15:17:53Z
0,2015-11-16T16:02:12Z,3212,[],Doxorubicin + Etoposide + Vincristine ,2015-11-16T16:02:12Z
0,2014-11-06T15:53:46Z,1706,[],Doxorubicin + Flourouracil + Cyclophosphamide,2014-11-06T15:53:46Z
0,2016-10-12T18:15:15Z,4816,[],Doxorubicin + FX1,2016-10-12T18:15:15Z
0,2016-03-22T19:32:26Z,3815,[],Doxorubicin + GSK2830371,2016-03-22T19:32:26Z
0,2014-09-18T15:05:46Z,1472,[],Doxorubicin + Ifosfamide,2014-09-18T15:05:46Z
0,2017-10-03T17:05:20Z,6292,[],Doxorubicin + Ifosfamide + Mesna + Olaratumab,2017-10-03T17:05:20Z
0,2017-10-10T20:11:57Z,6311,[],Doxorubicin + Lurbinectedin,2017-10-10T20:11:57Z
0,2017-09-11T18:40:30Z,6194,[],Doxorubicin + NU6027,2017-09-11T18:40:30Z
0,2016-12-02T03:21:15Z,5047,[],Doxorubicin + NU7441,2016-12-02T03:21:15Z
0,2016-05-26T16:41:09Z,4140,[],Doxorubicin + Olaratumab,2016-05-26T16:41:09Z
0,2015-01-05T02:16:42Z,1904,[],Doxorubicin + Paclitaxel,2015-01-05T02:16:42Z
0,2016-09-12T19:33:39Z,4690,[],Doxorubicin + Pembrolizumab,2016-09-12T19:33:39Z
0,2017-08-22T19:14:37Z,6142,[],Doxorubicin + Prexasertib,2017-08-22T19:14:37Z
0,2016-05-12T16:40:37Z,4112,[],Doxorubicin + RG7386,2016-05-12T16:40:37Z
0,2017-01-10T03:45:27Z,5179,[],Doxorubicin + Ribociclib,2017-01-10T03:45:27Z
0,2017-04-26T13:53:59Z,5571,[],Doxorubicin + Safingol,2017-04-26T13:53:59Z
0,2017-05-16T19:46:49Z,5678,[],Doxorubicin + Seliciclib,2017-05-16T19:46:49Z
0,2016-03-02T13:53:29Z,3663,[],Doxorubicin + Sirolimus,2016-03-02T13:53:29Z
0,2016-08-17T17:33:08Z,4577,[],Doxorubicin + SLCB050,2016-08-17T17:33:08Z
0,2015-03-12T12:41:46Z,2363,[],Doxorubicin + Sorafenib,2015-03-12T12:41:46Z
0,2017-05-19T04:22:52Z,5688,[],Doxorubicin + Tozasertib,2017-05-19T04:22:52Z
0,2016-05-26T20:49:14Z,4150,[],Doxorubicin + Trabectedin,2016-05-26T20:49:14Z
0,2016-02-14T01:39:42Z,3527,[],Doxorubicin + Vorinostat,2016-02-14T01:50:05Z
0,2014-08-06T14:27:29Z,1391,"[{'description': 'Doxycycline is a tetracycline antimicrobial that also inhibits metalloproteinases (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Doxycycline,2014-08-06T14:27:52Z
0,2016-11-07T17:00:25Z,4925,"[{'description': 'DPP-23 is a synthetic polyphenol conjugate, (E)-3-(3,5-dimethoxyphenyl)-1-(2-methoxyphenyl)prop-2-en-1-one, that specifically targets cancer cells by inhibiting Nrf2 and introducing ROS in the cell, which leads to apoptotic induction and potential antitumor activity (PMID: 27550943).', 'references': [{'id': 6975, 'pubMedId': 27550943, 'title': 'A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550943'}]}]",DPP-23,2016-11-07T17:00:25Z
0,2016-06-04T17:35:11Z,4237,"[{'description': 'DPX-Survivac is a liposome-encapsulated cancer vaccine that contains Survivin epitopes, which may induce an immune response against Survivin-expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",DPX-Survivac,2016-07-14T13:39:09Z
0,2017-03-16T13:45:39Z,5452,"[{'description': 'Droxinostat inhibits HDAC activity, with selectivity for HDAC3, 6, and 8, potentially resulting in decreased tumor cell growth (PMID: 20053768, PMID: 26947884).', 'references': [{'id': 8237, 'pubMedId': 26947884, 'title': 'Droxinostat, a Histone Deacetylase Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cell Lines via Activation of the Mitochondrial Pathway and Downregulation of FLIP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26947884'}, {'id': 8236, 'pubMedId': 20053768, 'title': 'Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20053768'}]}]",Droxinostat,2017-03-16T13:48:29Z
0,2017-09-21T16:36:35Z,6230,"[{'description': 'DS-1205b inhibits AXL, which potentially results in decreased cell migration, and reduced tumor growth (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #395P).', 'references': [{'id': 9970, 'pubMedId': None, 'title': 'DS-1205b, a novel, selective, small-molecule inhibitor of AXL, delays the onset of resistance and overcomes acquired resistance to EGFR- TKIs in a human EGFR-mutant NSCLC (T790M-negative) xenograft model', 'url': 'http://www.poster-submission.com/esmo2017/visitors/eposter/34996'}]}]",DS-1205b,2017-09-21T16:36:35Z
0,2017-09-21T18:39:41Z,6232,[],DS-1205b + Erlotinib,2017-09-21T18:39:41Z
0,2017-09-21T18:37:16Z,6231,[],DS-1205b + Osimertinib,2017-09-21T18:37:16Z
0,2014-07-28T19:51:16Z,1181,"[{'description': 'DS-2248 inhibits Heat Shock Protein 90, potentially resulting in decreased proliferation of tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 303, 'pubMedId': None, 'title': '', 'url': 'https://clinicaltrials.gov/'}]}]",DS-2248,2015-08-10T15:27:37Z
0,2015-02-13T20:34:08Z,2079,"[{'description': 'DS-3032b binds to MDM2 and prevents binding to p53, resulting in activation of p53 signaling and increased tumor cell apoptosis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",DS-3032b,2015-02-13T20:34:08Z
0,2014-05-14T14:52:46Z,1010,"[{'description': 'DS-3078a is a small molecule that inhibits mTOR kinase activity and downstream signaling, resulting in decreased tumor cell growth (Mol Cancer Ther 2013;12(11 Suppl):B184).', 'references': [{'id': 1988, 'pubMedId': None, 'title': 'Abstract B184: In vitro and in vivo profiling of novel mTORC1/2 inhibitor DS-3078a.', 'url': 'http://mct.aacrjournals.org/content/12/11_Supplement/B184.short'}]}]",DS-3078a,2016-04-01T16:32:01Z
0,2017-05-19T15:09:59Z,5691,"[{'description': 'DS-3201b is an inhibitor of EZH1 and EZH2, thereby inhibiting the methylation of H3K27, which leads to variable gene expression potentially resulting in decreased cell proliferation (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",DS-3201b,2017-05-19T15:09:59Z
0,2014-03-12T15:53:16Z,722,"[{'description': 'DS-7423 inhibits both PI3K kinase and mTORC1/2, which may result in tumor cell apoptosis and suppression of tumor growth (PMID: 24504419).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 4912, 'pubMedId': 24504419, 'title': 'Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24504419'}]}]",DS-7423,2017-04-18T18:31:18Z
0,2016-10-17T17:58:51Z,4844,"[{'description': 'DS-8201a is an antibody-drug conjugate comprising an anti-ERBB2 (HER2) antibody linked to a derivative of the topoisomerase inhibitor DX-8951, which delivers the cytotoxic agent to ERBB2 (HER2)-expressing tumor cells, potentially resulting in decreased growth of tumors, including tumors with low ERBB2 (HER2) expression (PMID: 27026201).', 'references': [{'id': 6780, 'pubMedId': 27026201, 'title': 'DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27026201'}]}]",DS-8201a,2016-10-17T17:58:51Z
0,2016-12-11T05:59:26Z,5077,[],DS-8273a,2016-12-11T05:59:26Z
0,2016-12-11T06:00:15Z,5078,[],DS-8273a + Nivolumab,2016-12-11T06:00:15Z
0,2016-06-22T02:35:47Z,4343,"[{'description': 'DS6051b is an inhibitor of NTRK1/2/3 and ROS1, which inhibits downstream signaling and may lead to decreased tumor cell growth (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",DS6051b,2017-01-18T17:02:22Z
0,2016-10-11T14:02:47Z,4809,"[{'description': 'DSHN is a small molecule activator of SHP that stabilizes and activates the Shp protein by blocking its ubiquitination and degradation, and may result in inhibition of cell migration and invasion (PMID: 27486225). ', 'references': [{'id': 6747, 'pubMedId': 27486225, 'title': 'A Novel Small Molecule Activator of Nuclear Receptor SHP Inhibits HCC Cell Migration via Suppressing Ccl2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27486225'}]}]",DSHN,2016-10-11T14:02:47Z
0,2016-06-20T00:29:36Z,4320,"[{'description': 'DSP-7888 is a peptide vaccine that potentially induces anti-tumor immune response against tumor cells with WT1 over expression (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",DSP-7888,2016-07-05T14:34:35Z
0,2017-07-05T20:19:10Z,5969,"[{'description': 'DT-061 is a small molecule that activates PP2A which results in growth inhibition and apoptosis in tumor cells (PMID: 28504649).', 'references': [{'id': 9273, 'pubMedId': 28504649, 'title': 'Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28504649'}]}]",DT-061,2017-07-05T20:19:10Z
0,2016-05-06T00:22:24Z,4079,"[{'description': 'DT01 consists of nanoparticles containing short interfering DNA that mimics DNA double strand breaks that are linked to cholesterol, resulting in activation of the DNA damage response in the liver, and potentially leading to increased sensitivity to chemotherapeutic agents (PMID: 26637369).', 'references': [{'id': 5384, 'pubMedId': 26637369, 'title': 'The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26637369'}]}]",DT01,2016-05-11T15:07:29Z
0,2016-05-06T00:50:15Z,4083,[],DT01 + Fluorouracil + Oxaliplatin,2016-05-06T00:50:15Z
0,2017-07-27T18:10:49Z,6014,"[{'description': 'DT204 is a SCF/SKP2 inhibitor that targets the ubiquitin/proteasome system, specifically inhibiting SKP1, CUL1, and COMMD1, which may result in restored sensitivity to proteasome inhibitors or overcome proteasome inhibitor resistance (PMID: 27677741). ', 'references': [{'id': 9602, 'pubMedId': 27677741, 'title': 'Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27677741'}]}]",DT204,2017-07-27T18:10:49Z
0,2017-07-27T18:13:41Z,6015,[],DT204 + Bortezomib,2017-07-27T18:13:41Z
0,2017-07-27T18:16:10Z,6017,[],DT204 + Ixazomib,2017-07-27T18:16:10Z
0,2014-08-04T06:44:24Z,1356,"[{'description': 'Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1, potentially resulting in increased immune response to tumors (PMID: 25943534, 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma (FDA.gov) ', 'references': [{'id': 8779, 'pubMedId': 28214651, 'title': 'A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28214651'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 8778, 'pubMedId': 25943534, 'title': 'Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25943534'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Durvalumab,2017-07-06T19:48:45Z
0,2017-05-26T17:46:36Z,5791,[],Durvalumab + MEDI0457,2017-05-26T17:46:36Z
0,2015-07-10T14:43:01Z,2894,[],Durvalumab + Olaparib,2017-05-25T19:37:53Z
0,2017-10-03T16:46:41Z,6291,[],Durvalumab + Oportuzumab monatox,2017-10-03T16:46:41Z
0,2017-06-12T16:33:07Z,5880,[],Durvalumab + Pralatrexate + Romidepsin,2017-06-12T16:33:07Z
0,2017-06-12T16:48:02Z,5882,[],Durvalumab + Romidepsin,2017-06-12T16:48:02Z
0,2017-09-01T14:08:10Z,6146,[],Durvalumab + SGI-110,2017-09-01T14:08:10Z
0,2014-08-04T07:04:28Z,1358,[],Durvalumab + Trametinib,2017-09-21T14:59:32Z
0,2015-03-20T08:55:03Z,2439,[],Durvalumab + Tremelimumab,2017-09-29T19:53:51Z
0,2015-05-08T13:50:24Z,2643,[],Dutasteride,2015-05-08T13:50:24Z
0,2015-08-28T01:58:19Z,3067,[],Dutasteride + Enzalutamide,2015-08-28T01:58:19Z
0,2014-05-14T14:52:46Z,1024,"[{'description': 'Duvelisib (IPI 145) prevents the activation of the PI3K delta/gamma-mediated signaling pathways, resulting in tumor cell death (PMID: 25258342).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 8909, 'pubMedId': 25258342, 'title': 'IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25258342'}]}]",Duvelisib,2017-05-15T18:35:38Z
0,2015-03-10T15:37:00Z,2341,[],Duvelisib + Obinutuzumab,2017-05-15T18:35:59Z
0,2016-01-10T21:28:23Z,3389,[],Duvelisib + Rituximab,2017-05-15T18:36:20Z
0,2016-06-04T22:03:56Z,4239,[],Duvelisib + romidepsin ,2017-05-15T18:37:08Z
0,2017-07-24T20:38:26Z,6005,[],Duvelisib + Unspecified PD-L1 antibody,2017-07-24T20:38:26Z
0,2016-01-07T15:25:59Z,3371,"[{'description': 'Dz13 is a DNAzyme that binds to and cleaves JUN messenger RNA, resulting in decreased JUN expression, and potentially leading to decreased growth of JUN-expressing tumor cells (PMID: 21722318).', 'references': [{'id': 4238, 'pubMedId': 21722318, 'title': 'Dz13: c-Jun downregulation and tumour cell death.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21722318'}]}]",Dz13,2016-01-07T15:25:59Z
0,2015-05-15T19:20:14Z,2702,"[{'description': 'DZNeP (3-Deazaneplanocin A) inhibits S-adenosylhomocysteine hydrolase, resulting in depletion of EZH2 and inhibition of H3K27 methylation, which may promote apoptosis in cancer cells (PMID: 3790170, PMID: 19638619).', 'references': [{'id': 2744, 'pubMedId': 3790170, 'title': '3-Deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/3790170'}, {'id': 2745, 'pubMedId': 19638619, 'title': 'Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19638619'}]}]",DZNeP,2015-05-21T21:43:28Z
0,2016-09-23T17:02:27Z,4747,[],DZNep + MK2206,2016-09-23T17:02:27Z
0,2016-04-13T15:37:54Z,3924,[],DZNeP + radiotherapy,2016-04-13T15:37:54Z
0,2016-09-23T16:57:06Z,4746,[],DZNep + Selumetinib,2016-09-23T16:57:06Z
0,2017-01-05T16:51:50Z,5159,"[{'description': 'E-4031 is a specific blocker of the HERG (KCNH2) potassium channel, which may result in decreased tumor cell proliferation (PMID: 27635088, PMID: 18497958).', 'references': [{'id': 7481, 'pubMedId': 18497958, 'title': 'Pharmacological separation of hEAG and hERG K+ channel function in the human mammary carcinoma cell line MCF-7.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18497958'}, {'id': 7480, 'pubMedId': 27635088, 'title': 'Administration of Non-Torsadogenic human Ether-à-go-go-Related Gene Inhibitors Is Associated with Better Survival for High hERG-Expressing Glioblastoma Patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27635088'}]}]",E-4031,2017-01-05T16:51:50Z
0,2014-05-14T14:52:46Z,1011,"[{'description': 'E6201 is a dual inhibitor of MEK1 and FLT3, which may lead to decreased tumor cell growth (Blood Nov 2013, 122 (21) 2683; PMID: 23039341).', 'references': [{'id': 3838, 'pubMedId': None, 'title': 'Study Of Activity Of E6201, a Dual FLT3 and MEK Inhibitor, In Acute Myelogenous Leukemia With FLT3 Or RAS Mutation', 'url': 'http://www.bloodjournal.org/content/122/21/2683?sso-checked=true'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 1840, 'pubMedId': 23039341, 'title': 'Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23039341'}]}]",E6201,2017-04-06T10:49:54Z
0,2016-04-08T00:38:46Z,3911,[],E6201 + LY294002,2016-04-08T00:38:46Z
0,2015-04-15T18:22:27Z,2539,"[{'description': 'E7016 inhibits poly(ADP-ribose) polymerase (PARP), resulting in accumulation of DNA damage and potentially resulting in increased tumor cell death and increased sensitivity to DNA damaging agents (Mol Cancer Ther 2011;10(11 Suppl):Abstract nr B185).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 8861, 'pubMedId': None, 'title': 'Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor E7016 in combination with temozolomide (TMZ) in patients with advanced solid tumors.', 'url': 'http://mct.aacrjournals.org/content/10/11_Supplement/B185.short'}]}]",E7016,2017-05-10T15:22:42Z
0,2017-05-10T15:23:38Z,5655,[],E7016 + Temozolomide,2017-05-10T15:23:50Z
0,2017-05-19T15:43:18Z,5694,"[{'description': 'E7046 is a small molecule inhibitor of E2 receptor type 4 (EP4), which may result in antitumor activity including inhibition of cell proliferation and reduced tumor growth (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B198).', 'references': [{'id': 8941, 'pubMedId': None, 'title': 'Abstract B198: Pharmacological profile of the PGE2 EP4 receptor antagonist E7046', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/B198.short'}]}]",E7046,2017-05-19T15:43:18Z
0,2017-05-28T03:30:25Z,5798,[],E7046 + mFOLFOX-6,2017-05-28T03:30:25Z
0,2017-05-19T17:39:44Z,5699,[],E7046 + Radiotherapy,2017-05-19T17:39:44Z
0,2016-11-02T20:13:32Z,4911,"[{'description': 'E7090 is a selective inhibitor of FGFR1, FGFR2, and FGFR3, which may result in inhibition of cell proliferation and antitumor activity (PMID: 27535969). ', 'references': [{'id': 6928, 'pubMedId': 27535969, 'title': 'E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535969'}]}]",E7090,2016-11-02T20:13:32Z
0,2016-11-07T19:27:44Z,4927,"[{'description': 'E7107 is a derivative of Pladienolide D, which inhibits assembly of the spliceosome specifically by binding to SF3B1, thereby inhibiting splicing of pre-mRNA and cell-cycle progression (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",E7107,2016-11-07T19:27:44Z
0,2014-03-12T15:53:16Z,724,"[{'description': 'E7449 binds to and inhibits PARP1 and PARP2, as well as TNKS1 and TNKS2, potentially resulting in increased sensitivity to DNA damaging agents and decreased growth of tumor cells with defective DNA damage repair (PMID: 26513298).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 4121, 'pubMedId': 26513298, 'title': 'E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26513298'}]}]",E7449,2017-05-10T15:41:28Z
0,2016-05-26T17:49:56Z,4145,[],E7449 + E6201,2016-05-26T17:49:56Z
0,2016-05-26T17:23:20Z,4142,[],E7449 + Temozolomide,2016-05-26T17:23:20Z
0,2016-03-17T14:09:35Z,3766,"[{'description': 'NeuVax (E75) is a HER2-derived peptide vaccine that induces an anti-HER2 immune response, potentially resulting in decreased tumor recurrence (PMID: 18536917, PMID: 24907636).', 'references': [{'id': 4894, 'pubMedId': 18536917, 'title': 'The E75 HER2/neu peptide vaccine.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18536917'}, {'id': 4895, 'pubMedId': 24907636, 'title': 'Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24907636'}]}]",E75,2017-07-20T16:56:10Z
0,2016-08-04T20:08:22Z,4520,"[{'description': 'EAI045 is a 4th generation epidermal growth factor receptor (EGFR) inhibitor that selectively inhibits L858R/T790M-mutant EGFR, resulting in inhibition of tumor cell proliferation (PMID: 27251290).', 'references': [{'id': 6436, 'pubMedId': 27251290, 'title': 'Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27251290'}]}]",EAI045,2016-08-04T20:08:22Z
0,2016-12-03T22:53:05Z,5057,"[{'description': 'EBV specific T (EB-VST) cells are cytotoxic T-cells that recognize cells containing Epstein-Barr Virus specific antigens, potentially resulting in increased death of EBV-associated tumor cells (PMID: 26807226, PMID: 26428384).\r\n', 'references': [{'id': 7269, 'pubMedId': 26428384, 'title': 'Adoptive T-Cell Immunotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26428384'}, {'id': 7268, 'pubMedId': 26807226, 'title': ""Enhanced antitumor effect of combining chemotherapy with Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes in mice with EBV-related non-Hodgkin's lymphoma."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26807226'}]}]",EB-VST cells,2016-12-09T20:13:29Z
0,2016-12-03T22:54:35Z,5058,[],EB-VST cells + Nivolumab,2016-12-03T22:54:35Z
0,2016-05-08T10:00:58Z,4090,"[{'description': 'EC-70124 is a multi-kinase inhibitor with activity against IKBKB and JAK2 and demonstrates anti-tumor activity in cell lines and animal models (PMID: 26826115).', 'references': [{'id': 5423, 'pubMedId': 26826115, 'title': 'EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26826115'}]}]",EC-70124,2016-05-08T10:00:58Z
0,2015-12-02T20:02:24Z,3244,"[{'description': 'EC0225 is composed of folic acid linked to a vinca alkaloid and mitomycin C, which targets the drugs to folate receptor-expressing cells, resulting in cell death (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",EC0225,2015-12-02T20:02:24Z
0,2015-12-02T18:01:04Z,3242,"[{'description': 'EC0905 is comprised of folic acid linked to desacetylvinblastine  monohydrazide, which binds to the folate receptor, and upon endocytosis interferes with microtubule formation, leading to cell death (PMID: 24249723).', 'references': [{'id': 4017, 'pubMedId': 24249723, 'title': 'Enhanced receptor-mediated endocytosis and cytotoxicity of a folic acid-desacetylvinblastine monohydrazide conjugate in a pemetrexed-resistant cell line lacking folate-specific facilitative carriers but with increased folate receptor expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24249723'}]}]",EC0905,2015-12-02T18:01:04Z
0,2014-10-02T17:51:52Z,1603,"[{'description': 'EC1456 is a small molecule drug comprised of folate conjugated to tubulysin B hydrazide (Tub-B-H), which binds to and is internalized by folate receptor-expressing tumor cells. Once internalized, the Tub-B-H portion of EC1456 acts to prevent microtubule polymerization, inhibiting cell cycle progression and inducing apoptosis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",EC1456,2014-10-02T17:51:52Z
0,2015-12-02T19:49:51Z,3243,"[{'description': 'EC17 is composed of folate conjugated to fluorescein isothiocyanate, which binds to folate receptors and induces an immune response towards folate receptor-expressing cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",EC17,2015-12-02T19:49:51Z
0,2014-11-21T19:35:51Z,1741,"[{'description': 'Edelfosine is an ether lipid that modulates cell membrane properties, inhibits PKC, and inhibits the PI3K-AKT/PKB pathway, activating the pro-apoptotic stress-activated protein kinase SAPK/JNK pathways, thereby inducing apoptosis selectively in tumor cells (NCI Thesaurus, PMID: 9257915).', 'references': [{'id': 1157, 'pubMedId': None, 'title': 'NCI Thesaurus', 'url': 'http://nciterms.nci.nih.gov'}, {'id': 1158, 'pubMedId': 9257915, 'title': 'Dissociation of the effects of the antitumour ether lipid ET-18-OCH3 on cytosolic calcium and on apoptosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/9257915'}]}]",Edelfosine,2014-11-21T19:35:51Z
0,2017-08-11T16:12:24Z,6104,"[{'description': 'EDO-S101 comprises the structure of the DNA alkylating drug bendumustine combined with the pan-HDAC inhibitor vorinostat, which may both induce DNA damage and inhibit DNA repair resulting in increased tumor cell death (PMID: 28753594).', 'references': [{'id': 9700, 'pubMedId': 28753594, 'title': 'The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28753594'}]}]",EDO-S101,2017-08-11T16:14:54Z
0,2017-08-11T19:36:53Z,6108,[],EDO-S101 + Marizomib,2017-08-11T19:36:53Z
0,2017-06-13T15:31:55Z,5886,"[{'description': 'EED226 is a small molecule inhibitor of PRC2 via direct binding to the H3K27me3 pocket of EED, which leads to altered PRC2 targeted gene expression and thus, may result in inhibition of cell proliferation, blockade of tumor growth, and tumor regression (PMID: 28135235).', 'references': []}]",EED226,2017-06-13T16:28:04Z
0,2017-06-13T17:01:42Z,5887,[],EED226 + EI1,2017-06-13T17:01:42Z
0,2015-05-07T03:02:45Z,2629,"[{'description': 'Eflornithine is an ornithine decarboxylase inhibitor that blocks polyamine production, resulting in reduced tumor cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Eflornithine,2015-06-26T02:15:55Z
0,2016-09-06T17:43:30Z,4650,[],Eflornithine + SAM486,2016-09-06T17:43:30Z
0,2016-04-26T17:56:01Z,4005,"[{'description': 'eFT508 inhibits MNK1 and MNK2, potentially resulting in decreased tumor cell proliferation and tumor growth (Blood Dec 2015, 126 (23) 1554).', 'references': [{'id': 5231, 'pubMedId': None, 'title': 'eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)', 'url': 'http://www.bloodjournal.org/content/126/23/1554'}]}]",eFT508,2016-04-26T17:56:01Z
0,2016-10-12T18:50:52Z,4817,"[{'description': 'EGCG inhibits fatty acid synthase (FASN), resulting in apoptosis in FASN over expressing cancer cells (PMID: 27106068).', 'references': [{'id': 6760, 'pubMedId': 27106068, 'title': 'Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27106068'}]}]",EGCG,2016-10-12T18:50:52Z
0,2014-07-31T13:36:39Z,1309,"[{'description': 'EGF816 is a third generation EGFR inhibitor with selectivity towards mutant forms of EGFR (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",EGF816,2017-10-11T19:48:08Z
0,2017-10-02T20:08:21Z,6287,[],EGF816 + Gefitinib,2017-10-02T20:08:21Z
0,2015-03-20T15:02:27Z,2445,[],EGF816 + INC280,2015-03-20T15:02:27Z
0,2015-03-20T14:51:54Z,2443,[],EGF816 + Nivolumab,2015-03-20T14:51:54Z
0,2016-08-17T17:56:02Z,4580,[],EGFR antibody + ERBB3 antibody + IGF-1R antibody,2016-08-17T17:56:02Z
0,2015-02-23T01:23:19Z,2130,"[{'description': 'EGFR antisense DNA is synthetic DNA that runs antisense to the EGFR sequence and suppresses endogenous EGFR expression, potentially resulting in decreased tumor cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",EGFR Antisense DNA,2015-02-25T04:32:29Z
0,2017-02-16T04:57:13Z,5331,"[{'description': 'EGFR(V)-EDV-Dox is a formulation of EGFR bispecific antibodies coupled with nanocellular compounds containing therapeutic dose of doxorubicin, which delivers the cytotoxic doxorubicin to tumor cells over expressing EGFR, leading to anti-tumor activities (PMID: 26279503).', 'references': [{'id': 7997, 'pubMedId': 26279503, 'title': 'First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26279503'}]}]",EGFR(V)-EDV-Dox,2017-02-24T18:28:20Z
0,2014-05-14T14:52:46Z,1012,"[{'description': 'EGFRBi-armed autologous activated T cells are autologous T-cells that have been ""armed"" with a bispecific antibody that binds EGFR and CD3, potentially enhancing T-cell mediated response to EGFR-expressing cells upon antibody binding (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",EGFRBi-armed autologous activated T cells,2016-08-11T15:50:04Z
0,2016-05-11T16:23:36Z,4100,"[{'description': 'Ehop-016 inhibits Rac1 and Rac3, which may result in decreased tumor cell migration (PMID: 22383527).', 'references': []}]",EHop-016,2016-05-11T16:23:36Z
0,2016-11-23T18:52:59Z,5013,[],EHop-016 + IPA-3,2016-11-23T18:52:59Z
0,2016-11-23T18:51:24Z,5012,[],EHop-016 + MLN0128,2016-11-23T18:51:24Z
0,2017-01-17T20:06:02Z,5223,"[{'description': 'EHT 1864 is a small molecule inhibitor of Rac, which potentially results in decreased Rac-mediated cell growth (PMID: 17932039). ', 'references': [{'id': 7584, 'pubMedId': 17932039, 'title': 'Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17932039'}]}]",EHT 1864,2017-01-17T20:06:02Z
0,2015-12-23T17:36:30Z,3332,"[{'description': 'EHT5372 is an inhibitor of DYRK1A and DYRK1B, which may result in increased ROS levels and DNA damage and induce cell death (PMID: 25352950, PMID: 25556849).', 'references': [{'id': 4160, 'pubMedId': 25352950, 'title': 'Mirk kinase inhibition blocks the in vivo growth of pancreatic cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25352950'}]}]",EHT5372,2015-12-23T17:36:30Z
0,2015-07-16T20:58:43Z,2927,"[{'description': 'EI1 is a selective inhibitor of EZH2, which results in reduced H3K27 methylation and reduced expression of EZH2 target genes, and may lead to decreased tumor cell growth (PMID: 23236167).', 'references': [{'id': 2747, 'pubMedId': 23236167, 'title': 'Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23236167'}]}]",EI1,2015-07-16T20:58:43Z
0,2015-07-14T00:48:05Z,2911,"[{'description': 'EKI-285 is a small molecule inhibitor of EGFR, leading to decreased growth of EGFR-expressing tumors (PMID: 10086326, PMID: 11818567).', 'references': [{'id': 3242, 'pubMedId': 10086326, 'title': 'Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10086326'}, {'id': 3241, 'pubMedId': 11818567, 'title': 'Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11818567'}]}]",EKI-285,2015-07-14T00:48:05Z
0,2017-06-13T19:45:28Z,5890,"[{'description': 'Elacestrant (RAD1901) is a selective estrogen receptor degrader that down regulates ER and ER-regulated genes, resulting in anti-tumor activity (PMID: 28473534).', 'references': [{'id': 9124, 'pubMedId': None, 'title': 'Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer.', 'url': 'http://abstracts.asco.org/199/AbstView_199_192812.html'}, {'id': 9125, 'pubMedId': 28473534, 'title': 'Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has anti-tumor activity in multiple ER+ breast cancer patient-derived xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28473534'}]}]",Elacestrant,2017-06-13T19:48:23Z
0,2014-10-28T20:48:24Z,1676,"[{'description': 'Ellipticine produces DNA damage through intercalation into DNA, inhibition of DNA topoisomerase, and formation of ellipticine-DNA adducts, resulting in cell-cycle arrest and growth inhibition in tumor cells (PMID: 21753906).\r\n', 'references': [{'id': 975, 'pubMedId': 21753906, 'title': 'Ellipticine cytotoxicity to cancer cell lines - a comparative study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21753906'}]}]",Ellipticine,2014-10-28T20:48:24Z
0,2015-12-29T16:05:21Z,3343,"[{'description': 'Empliciti (elotuzumab) is a humanized monoclonal antibody against human CS1, which induces antibody-dependent cellular cytotoxicity in CS1-positive cells (PMID: 26005365). Empliciti (elotuzumab) is approved in combination with Revlimid (lenalidomide) and dexamethasone for use in patients with multiple myeloma (FDA.gov).', 'references': [{'id': 4182, 'pubMedId': 26005365, 'title': 'Profile of elotuzumab and its potential in the treatment of multiple myeloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26005365'}]}]",Elotuzumab,2017-02-03T03:43:57Z
0,2015-12-31T16:36:09Z,3353,[],Elotuzumab + Dexamethasone + Lenalidomide,2017-02-03T03:41:11Z
0,2015-12-31T16:46:35Z,3355,[],Elotuzumab + Dexamethasone + Pomalidomide,2015-12-31T16:46:35Z
0,2016-01-21T20:57:17Z,3430,[],Elotuzumab + lenalidomide,2016-01-21T20:57:17Z
0,2017-08-18T15:03:33Z,6117,[],Elotuzumab + Nivolumab,2017-08-18T15:03:33Z
0,2015-06-04T15:14:31Z,2790,"[{'description': 'ELR510444 is a small molecule inhibitor of HIF, which may result in apoptosis and has the potential to disrupt the tumor vasculature environment (PMID: 22295124). ', 'references': [{'id': 2953, 'pubMedId': 22295124, 'title': 'ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22295124'}]}]",ELR510444,2015-06-04T15:14:31Z
0,2014-12-05T04:18:45Z,1764,"[{'description': 'Eltrombopag is a thromobopoeitin receptor agonist that causes increased proliferation and differentiation of megakaryocytic cells and increased platelet production (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Eltrombopag,2015-04-10T16:30:58Z
0,2014-12-05T04:18:17Z,1763,[],Eltrombopag + Decitabine,2014-12-05T04:18:17Z
0,2015-06-18T17:13:04Z,2843,"[{'description': 'Emactuzumab (RG7155) is a monoclonal antibody that inhibits dimerization of CSF1R, resulting in decreased ligand-dependent and ligand-independent signaling, thereby potentially leading to reduced tumor growth (PMID: 24898549).', 'references': [{'id': 3080, 'pubMedId': 24898549, 'title': 'Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24898549'}]}]",Emactuzumab,2016-05-27T20:00:33Z
0,2016-06-06T01:18:08Z,4249,[],Emactuzumab + Paclitaxel,2016-06-06T01:18:08Z
0,2016-05-27T20:01:21Z,4181,[],Emactuzumab + RO7009789,2016-05-27T20:01:21Z
0,2014-03-12T15:53:16Z,725,"[{'description': 'EMD 1204831 is a selective inhibitor of MET, which inhibits MET signaling, potentially resulting in increased cell death in MET-expressing tumors (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",EMD 1204831,2017-07-26T18:01:24Z
0,2014-03-12T15:53:16Z,726,"[{'description': 'EMD 1214063 selectively binds to MET tyrosine kinase and disrupts MET signal transduction pathways, which may induce apoptosis in tumor cells over expressing this kinase (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",EMD 1214063,2015-02-25T17:58:32Z
0,2016-11-29T20:27:05Z,5024,[],EMD 1214063 + Radiotherapy,2016-11-29T20:27:05Z
0,2015-02-24T03:49:02Z,2142,"[{'description': 'Stimuvax (emepepimut-S) is a peptide vaccine comprised of synthetic peptide based on Muc-1 protein, which may enhance immune response to Muc-1 expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Emepepimut-S  ,2015-02-24T03:49:02Z
0,2014-03-12T15:53:16Z,803,"[{'description': 'Emibetuzumab (LY2875358) is MET-targeted antibody, which inhibits binding of the MET ligand HGF and promotes internalization and downregulation of MET, resulting in decreased HGF-dependent and HGF-independent signaling and potentially leading to decreased growth of MET-expressing tumors (PMID: 27803065, PMID: 25231402).', 'references': [{'id': 1762, 'pubMedId': 25231402, 'title': 'LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231402'}, {'id': 8681, 'pubMedId': 27803065, 'title': 'A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27803065'}]}]",Emibetuzumab,2017-07-26T18:38:15Z
0,2014-07-28T19:28:44Z,1179,[],Emibetuzumab + Erlotinib,2017-07-26T18:37:54Z
0,2014-08-06T02:29:47Z,1387,[],Emibetuzumab + Ramucirumab,2017-07-26T18:39:21Z
0,2014-07-28T19:29:44Z,1180,[],Emibetuzumab + Trametinib,2017-07-26T18:38:50Z
0,2016-02-25T21:20:30Z,3619,"[{'description': 'Enadenotucirev is a conditionally-replicating group B adenovirus that has antitumor activity (PMID: 26708004).', 'references': [{'id': 4706, 'pubMedId': 26708004, 'title': 'Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26708004'}]}]",Enadenotucirev,2016-03-11T16:46:26Z
0,2016-02-25T21:30:10Z,3620,[],Enadenotucirev + Pembrolizumab,2016-02-25T21:30:10Z
0,2015-07-30T16:01:30Z,2982,"[{'description': 'Idhifa (enasidenib) inhibits IDH2 to prevent 2HG formation, which may promote differentiation and inhibit proliferation of cancer cells (PMID: 28280273). Idhifa enasidenib) is FDA-approved for use in patients with relapsed or refractory acute myeloid leukemia harboring an IDH2 mutation (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 9212, 'pubMedId': 28280273, 'title': 'A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28280273'}]}]",Enasidenib,2017-08-01T18:22:27Z
0,2015-11-03T18:26:26Z,3172,[],Enasidenib + Quizartinib,2017-06-23T19:00:51Z
0,2014-03-12T15:53:16Z,796,"[{'description': 'Encorafenib (LGX818) is an inhibitor of Raf kinase, a serine/threonine enzyme in the RAF/MEK/ERK signaling pathway. Encorafenib (LGX818) has selective activity against BRAF V600E (PMID: 24864047).', 'references': [{'id': 862, 'pubMedId': 24864047, 'title': 'Transient MEK inhibitor-associated retinopathy in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24864047'}]}]",Encorafenib,2017-06-14T18:51:26Z
0,2014-08-01T02:12:16Z,1337,[],Encorafenib + BKM120,2017-06-14T18:54:01Z
0,2014-07-30T15:51:10Z,1260,[],Encorafenib + Ribociclib,2017-06-14T18:53:02Z
0,2016-05-18T15:40:22Z,4125,"[{'description': 'Enfortumab vedotin is an antibody drug conjugate that fuses together a fully human antibody to Nectin-4 and monomethyl auristatin E, which may result in inhibition of tumor growth and tumor regression (PMID: 27013195). ', 'references': [{'id': 5571, 'pubMedId': 27013195, 'title': 'Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27013195'}]}]",Enfortumab vedotin,2016-05-18T15:40:22Z
0,2014-03-12T15:53:16Z,727,"[{'description': 'ENMD-2076 has selective inhibitory activity against Aurora kinase A and FLT3, with reduced potency against RET, KDR (VEGFR2), FGFR1, and FGFR2, preventing angiogenesis and decreasing cell proliferation (PMID: 21177375, PMID: 22921155).', 'references': [{'id': 47, 'pubMedId': 21177375, 'title': 'ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21177375'}]}]",ENMD-2076,2017-04-04T12:37:26Z
0,2016-11-30T21:02:01Z,5026,"[{'description': 'Ostarine (enobosarm) is a nonsteroidal selective androgen receptor modulator that mimics testosterone function, which is currently used to treat cachexia in cancer patients (PMID: 24490605).', 'references': [{'id': 7217, 'pubMedId': 24490605, 'title': 'Enobosarm (GTx-024, S-22): a potential treatment for cachexia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24490605'}]}]",enobosarm,2017-01-03T15:23:14Z
0,2016-11-30T21:02:53Z,5027,[],enobosarm + Pembrolizumab,2016-11-30T21:02:53Z
0,2015-12-11T03:00:53Z,3278,[],Enoxaparin,2015-12-11T03:00:53Z
0,2014-09-25T16:54:09Z,1541,"[{'description': 'Entinostat (MS-275) inhibits HDAC activity, with selectivity towards HDAC1, 2, and 3, which results in increased histone acetylation, and potentially leads to decreased tumor cell proliferation and tumor growth (PMID: 19724929, PMID: 17383217).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 8256, 'pubMedId': 19724929, 'title': 'Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19724929'}, {'id': 8255, 'pubMedId': 17383217, 'title': 'MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17383217'}]}]",Entinostat,2017-03-17T03:14:09Z
0,2016-12-28T04:05:50Z,5129,[],Entinostat + Atezolizumab,2016-12-28T04:05:50Z
0,2016-07-12T11:59:07Z,4437,[],Entinostat + Exemestane,2016-07-12T11:59:07Z
0,2017-07-28T19:31:10Z,6052,[],Entinostat + Hydroxychloroquine + Regorafenib,2017-07-28T19:31:10Z
0,2016-06-06T18:10:21Z,4255,[],Entinostat + Lapatinib,2016-06-06T18:10:21Z
0,2014-09-25T16:56:22Z,1542,[],Entinostat + Lapatinib + Trastuzumab,2014-09-25T16:56:22Z
0,2017-08-15T16:38:46Z,6114,[],Entinostat + Nivolumab,2017-08-15T16:38:46Z
0,2015-12-31T16:42:19Z,3354,[],Entinostat + Pembrolizumab,2015-12-31T16:42:19Z
0,2017-03-10T16:47:51Z,5431,[],Entinostat + Temozolomide,2017-03-10T16:47:51Z
0,2015-04-10T14:50:35Z,2522,"[{'description': 'Entospletinib is a selective spleen tyrosine kinase (Syk) inhibitor, which in turn inhibits B-cell receptor signaling, leading to suppression of cell migration and inhibition of survival (PMID: 24779514).', 'references': [{'id': 2445, 'pubMedId': 24779514, 'title': 'Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24779514'}]}]",Entospletinib  ,2015-10-21T20:37:38Z
0,2016-03-16T19:25:59Z,3760,[],Entospletinib  + Idelalisib ,2016-03-16T19:25:59Z
0,2014-09-11T16:08:30Z,1455,"[{'description': 'Entrectinib (RXDX-101) is an inhibitor of TrkA/B/C/ROS1/ALK activity, which leads to induction of apoptosis and inhibition of proliferation in cells expressing these kinases (PMID: 27003761). ', 'references': [{'id': 8340, 'pubMedId': 27003761, 'title': 'Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27003761'}]}]",Entrectinib,2017-07-03T16:06:36Z
0,2014-07-30T16:23:19Z,1262,"[{'description': 'XTANDI (enzalutamide) is a second-generation small molecule androgen receptor (AR) inhibitor that inhibits AR signaling, thereby resulting in decreased tumor growth (PMID: 24009414, PMID: 25945058). XTANDI (enzalutamide) is FDA approved for use in patients with metastatic castration-resistant prostate cancer (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Enzalutamide,2017-06-19T19:58:07Z
0,2017-02-26T23:40:29Z,5371,[],Enzalutamide + Abiraterone + Prednisone,2017-02-26T23:40:29Z
0,2015-03-03T02:44:44Z,2264,[],Enzalutamide + Everolimus,2015-03-03T02:44:44Z
0,2017-09-11T13:46:25Z,6183,[],Enzalutamide + Exemestane,2017-09-11T13:46:25Z
0,2016-11-13T20:38:42Z,4940,[],Enzalutamide + Fulvestrant,2016-11-13T20:38:42Z
0,2016-04-20T17:24:44Z,3971,[],Enzalutamide + G1T38,2016-04-20T17:24:44Z
0,2017-07-28T17:58:28Z,6035,[],Enzalutamide + GSK525762,2017-07-28T17:58:28Z
0,2016-10-29T23:48:18Z,4876,[],Enzalutamide + Indomethacin,2016-10-29T23:48:18Z
0,2015-11-06T02:05:10Z,3180,[],Enzalutamide + Leuprolide,2015-11-06T02:05:10Z
0,2017-01-16T16:34:29Z,5217,[],Enzalutamide + MEDI3726,2017-01-16T16:34:29Z
0,2015-02-27T16:39:25Z,2202,[],Enzalutamide + Metformin,2015-02-27T16:39:25Z
0,2016-03-11T19:23:48Z,3725,[],Enzalutamide + Paclitaxel,2016-03-11T19:23:48Z
0,2015-05-13T23:55:21Z,2666,[],Enzalutamide + Pembrolizumab,2015-05-13T23:55:21Z
0,2016-10-30T17:26:28Z,4882,[],Enzalutamide + PROSTVAC-F/TRICOM ,2016-10-30T17:26:28Z
0,2016-10-30T17:36:02Z,4884,[],Enzalutamide + PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM,2016-10-30T17:36:02Z
0,2016-10-30T17:34:02Z,4883,[],Enzalutamide + PROSTVAC-V/TRICOM,2016-10-30T17:34:02Z
0,2017-07-28T01:03:53Z,6022,[],Enzalutamide + Tanespimycin,2017-07-28T01:03:53Z
0,2015-03-13T15:08:48Z,2395,[],Enzalutamide + Tivozanib,2016-10-13T15:09:41Z
0,2014-12-31T15:50:57Z,1878,[],Enzalutamide + Trastuzumab,2014-12-31T15:50:57Z
0,2016-04-29T19:17:28Z,4033,[],Enzalutamide + ZEN003694,2016-04-29T19:17:28Z
0,2014-10-29T20:17:08Z,1682,"[{'description': 'Enzastaurin (LY317615) is a selective inhibitor PKC-beta, with activity against other PKC isoforms at higher concentrations, which decreases downstream signaling and potentially results in reduced tumor growth (PMID: 16103100, PMID: 17671157, PMID: 22253748).', 'references': [{'id': 8674, 'pubMedId': 17671157, 'title': 'Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17671157'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 982, 'pubMedId': 22253748, 'title': 'The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22253748'}, {'id': 2084, 'pubMedId': 16103100, 'title': 'The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16103100'}]}]",Enzastaurin,2017-04-21T17:06:58Z
0,2016-03-29T20:51:09Z,3870,[],Enzastaurin + YK-4-279,2016-03-29T20:51:27Z
0,2015-04-24T01:45:02Z,2575,"[{'description': 'Epacadostat (INCB024360) is an inhibitor of indoleamine 2,3-dioxygenase (IDO1), which leads to activation of T-cell mediated immunity and inhibition of tumor growth (PMID: 20197554).', 'references': [{'id': 2561, 'pubMedId': 20197554, 'title': 'Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20197554'}]}]",Epacadostat,2017-06-23T18:44:01Z
0,2017-09-29T19:57:54Z,6277,[],Epacadostat + INCAGN01876 + Pembrolizumab,2017-09-29T19:57:54Z
0,2016-05-06T19:29:08Z,4088,[],Epacadostat + Pembrolizumab,2017-06-23T18:44:36Z
0,2017-05-04T17:59:27Z,5611,"[{'description': 'EPI-506, the prodrug for EPI-002, is a small molecule that inhibits the N-terminal domain of the androgen receptor (AR), potentially resulting in decreased AR signaling, including in the context of mutant AR (PMID: 27628492).', 'references': [{'id': 8812, 'pubMedId': 27140928, 'title': 'Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27140928'}, {'id': 8813, 'pubMedId': 27628492, 'title': 'Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27628492'}]}]",EPI-506,2017-05-04T18:01:18Z
0,2015-12-21T17:58:23Z,3325,"[{'description': 'Epigallocatechin-gallate is a green tea flavonoid shown to inhibit DYRK1A in a non-ATP competitive manner (PMID: 25795597).', 'references': [{'id': 4143, 'pubMedId': 25795597, 'title': 'DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25795597'}]}]",Epigallocatechin-gallate,2016-10-12T18:39:26Z
0,2014-05-14T14:52:46Z,1013,"[{'description': 'Ellence (epirubicin) is an anthracycline, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159).  Ellence (epirubicin) is FDA approved as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement for primary breast cancer (FDA.gov).', 'references': [{'id': 96, 'pubMedId': 24367159, 'title': 'New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24367159'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",epirubicin,2015-04-24T14:36:22Z
0,2014-07-15T13:50:51Z,1087,[],Epirubicin + Cyclophosphamide,2015-01-28T13:53:01Z
0,2016-06-17T21:24:57Z,4310,[],Epirubicin + Docetaxel,2016-06-17T21:26:05Z
0,2015-03-12T13:51:07Z,2365,[],Epirubicin + Ifosfamide + Sorafenib,2015-03-12T13:51:07Z
0,2015-11-13T19:29:03Z,3203,[],Epirubicin + Valproic acid,2015-11-13T19:29:03Z
0,2016-03-03T10:33:48Z,3667,"[{'description': 'HMPL-813 (Epitinib) is a small molecule inhibitor of EGFR, including T790M (J Clin Oncol 31, 2013 (suppl; abstr e19042).', 'references': [{'id': 4765, 'pubMedId': None, 'title': 'Phase I study of the safety and pharmacokinetics of epitinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/114269-132'}]}]",Epitinib,2016-03-03T10:33:48Z
0,2015-07-17T14:38:27Z,2929,[],Eplerenone,2015-07-17T14:38:27Z
0,2015-02-27T19:57:03Z,2211,[],EPOCH,2015-02-27T19:57:03Z
0,2015-06-18T23:26:34Z,2855,"[{'description': 'EPZ-5676 (pinometostat) inhibits DOT1L histone methyltransferase activity, resulting in decreased growth of leukemia cells with MLL rearrangements (PMID: 23801631, PMID: 26645404).', 'references': [{'id': 3090, 'pubMedId': 23801631, 'title': 'Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801631'}]}]",EPZ-5676,2016-02-19T17:59:07Z
0,2014-11-26T23:36:29Z,1744,"[{'description': 'EPZ004777 is a small molecule that inhibits DOT1L, which results in decreased histone H3 lysine 79 dimethylation, and potentially leads to decreased tumor cell proliferation (PMID: 21741596, PMID: 27535106).', 'references': [{'id': 1170, 'pubMedId': 21741596, 'title': 'Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21741596'}]}]",EPZ004777,2017-07-25T14:09:16Z
0,2015-05-13T18:21:22Z,2663,"[{'description': 'EPZ005687 is an inhibitor of EZH2, which blocks histone methylation and promotes apoptosis in tumor cells (PMID: 23023262). ', 'references': [{'id': 2699, 'pubMedId': 23023262, 'title': 'A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23023262'}]}]",EPZ005687,2015-08-10T15:45:58Z
0,2015-07-16T20:48:11Z,2926,"[{'description': 'EPZ011989 is a selective inhibitor of EZH2, resulting in decreased H3K27 methylation and potentially leading to inhibition of tumor growth (PMID: 26005520).', 'references': [{'id': 3265, 'pubMedId': 26005520, 'title': 'EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26005520'}]}]",EPZ011989,2015-07-16T20:48:11Z
0,2017-08-02T17:29:09Z,6072,"[{'description': 'EPZ030456 is a selective inhibitor of Smyd3 that is orally available, which may have anti-tumor activity (PMID: 26985287).', 'references': [{'id': 9658, 'pubMedId': 26985287, 'title': 'Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26985287'}]}]",EPZ030456,2017-09-25T19:11:31Z
0,2017-08-02T17:28:19Z,6071,"[{'description': 'EPZ031686 is a selective inhibitor of Smyd3 that is orally available, which may have anti-tumor activity (PMID: 26985287).', 'references': [{'id': 9658, 'pubMedId': 26985287, 'title': 'Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26985287'}]}]",EPZ031686,2017-09-25T19:11:46Z
0,2016-04-08T03:54:11Z,3916,"[{'description': 'ER2 is a human monoclonal antibody directed against EGFR, which leads to decreased EGFR signaling and may result in reduced tumor growth (PMID: 27040853).', 'references': [{'id': 5133, 'pubMedId': 27040853, 'title': 'ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27040853'}]}]",ER2,2016-04-08T03:54:11Z
0,2016-08-30T16:07:45Z,4625,[],ER2 + Cisplatin,2016-08-30T16:07:45Z
0,2014-03-12T15:53:16Z,728,[],Eribulin,
0,2015-03-03T00:38:01Z,2252,[],Eribulin + Everolimus,2015-03-03T00:38:01Z
0,2015-12-31T15:42:36Z,3352,[],Eribulin + Lenvatinib,2015-12-31T15:42:36Z
0,2015-08-26T02:52:08Z,3053,[],Eribulin + Mifepristone,2015-08-26T02:52:08Z
0,2015-09-14T00:20:43Z,3080,[],Eribulin + Pembrolizumab,2015-09-14T00:20:43Z
0,2017-06-09T16:07:27Z,5870,[],Eribulin + POL6326,2017-06-09T16:07:27Z
0,2016-07-08T20:13:59Z,4434,[],Eribulin + Rebastinib,2016-07-08T20:13:59Z
0,2015-01-27T15:16:55Z,1981,[],Eribulin + Trastuzumab,2015-01-27T15:16:55Z
0,2014-01-20T22:50:47Z,4,"[{'description': 'Tarceva (erlotinib) is a first-generation EGFR inhibitor, which is FDA approved for non-small cell lung carcinoma patients with EGFR exon 19 deletions and/or EGFR L858R and in combination with gemcitabine for patients with advanced pancreatic cancer (FDA.gov; PMID: 25302162).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 943, 'pubMedId': 25302162, 'title': 'Review of the current targeted therapies for non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25302162'}]}]",Erlotinib,2016-07-01T17:49:16Z
0,2015-03-27T00:56:51Z,2473,[],Erlotinib + Capecitabine + Gemcitabine,2015-03-27T00:56:51Z
0,2014-07-31T07:12:54Z,1291,[],Erlotinib + Carboplatin,2014-07-31T07:12:54Z
0,2014-07-28T13:15:33Z,1147,[],Erlotinib + CC-223,2014-07-28T13:15:33Z
0,2014-07-31T07:14:01Z,1292,[],Erlotinib + Cisplatin,2014-07-31T07:14:01Z
0,2015-03-21T12:12:22Z,2451,[],Erlotinib + Cyclophosphamide + Topotecan,2015-03-21T12:12:22Z
0,2015-03-27T01:06:23Z,2474,[],Erlotinib + Docetaxel,2015-03-27T01:06:23Z
0,2016-10-25T19:29:02Z,4862,[],Erlotinib + Ethacridine,2016-10-25T19:29:16Z
0,2015-06-04T19:35:26Z,2802,[],Erlotinib + Ganetespib,2015-06-04T19:35:26Z
0,2015-03-12T15:55:02Z,2379,[],Erlotinib + Gefitinib,2015-03-12T15:55:02Z
0,2015-03-12T18:02:30Z,2381,[],Erlotinib + Gemcitabine,2015-03-12T18:02:30Z
0,2015-03-20T08:53:34Z,2438,[],Erlotinib + Gemcitabine + Vinorelbine,2015-03-20T08:53:34Z
0,2015-02-20T18:24:14Z,2127,[],Erlotinib + Ibuprofen,2015-02-20T18:24:14Z
0,2017-01-03T17:45:23Z,5135,[],Erlotinib + IRX4204,2017-01-03T17:45:23Z
0,2016-10-30T19:22:47Z,4885,[],Erlotinib + Ixazomib,2016-10-30T19:22:47Z
0,2016-05-03T14:19:32Z,4041,[],Erlotinib + Linsitinib,2016-05-03T14:19:32Z
0,2017-10-10T19:39:15Z,6310,[],Erlotinib + Lumretuzumab,2017-10-10T19:39:15Z
0,2014-07-25T17:31:04Z,1097,[],Erlotinib + MK2206,2014-07-25T17:31:04Z
0,2015-03-12T17:37:47Z,2380,[],Erlotinib + Momelotinib,2015-03-12T17:37:47Z
0,2016-12-21T17:58:35Z,5117,[],Erlotinib + NPS-1034,2016-12-21T17:58:35Z
0,2015-08-30T19:23:07Z,3071,[],Erlotinib + Onalespib,2015-08-30T19:23:07Z
0,2015-03-12T18:09:02Z,2382,[],Erlotinib + Pacritinib,2015-03-12T18:09:02Z
0,2015-02-19T15:15:55Z,2107,[],Erlotinib + Pembrolizumab ,2015-02-19T15:15:55Z
0,2014-07-31T07:11:38Z,1290,[],Erlotinib + Pemetrexed,2014-07-31T07:11:38Z
0,2017-02-28T20:37:31Z,5393,[],Erlotinib + PF-431396,2017-02-28T20:37:31Z
0,2016-12-21T18:18:26Z,5120,[],Erlotinib + PLX4720,2016-12-21T18:18:26Z
0,2014-07-31T21:15:24Z,1328,[],Erlotinib + Pralatrexate,2016-05-25T18:06:33Z
0,2014-07-30T06:21:50Z,1237,[],Erlotinib + Quinacrine,2014-07-30T06:21:50Z
0,2016-10-25T18:38:54Z,4860,[],Erlotinib + S63845,2016-10-25T18:38:54Z
0,2016-01-05T09:57:20Z,3361,[],Erlotinib + Selumetinib,2016-01-05T09:57:20Z
0,2015-03-03T00:59:40Z,2253,[],Erlotinib + Sirolimus,2015-03-03T00:59:40Z
0,2016-10-06T15:15:12Z,4800,[],Erlotinib + Sorafenib,2016-10-06T15:15:12Z
0,2016-03-11T19:26:53Z,3726,[],Erlotinib + Temozolomide,2016-03-11T19:26:53Z
0,2015-03-20T00:38:51Z,2436,[],Erlotinib + Theophylline,2015-03-20T00:38:51Z
0,2014-07-30T16:46:00Z,1265,[],Erlotinib + Trametinib,2016-10-28T17:13:37Z
0,2016-03-21T01:42:14Z,3793,[],Erythromycin + Ibrutinib + Voriconazole,2016-03-21T01:42:14Z
0,2014-10-14T17:51:00Z,1643,[],Estradiol,2014-10-14T17:51:00Z
0,2015-07-23T00:59:02Z,2950,[],Estramustine,2015-07-23T00:59:02Z
0,2017-09-05T15:39:30Z,6163,"[{'description': 'ETBX-011 is an engineered adenoviral vaccine encoding human carcinoembryonic antigen that may stimulate anti-tumor immunity (Journal of Clinical Oncology 32, no. 15_suppl (May 2014) 3093-3093).', 'references': [{'id': 9859, 'pubMedId': None, 'title': 'Immunotherapeutic treatment of metastatic colorectal cancer using ETBX-011.', 'url': 'http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.3093'}]}]",ETBX-011,2017-09-05T15:39:30Z
0,2016-02-15T20:05:04Z,3534,"[{'description': 'ETC-159 is a small molecule inhibitor of PORCN, which is demonstrated to suppress Wnt signaling and may result in inhibition of cell growth and lead to upregulation of genes related to cell differentiation (PMID: 26257057).', 'references': [{'id': 4598, 'pubMedId': 26257057, 'title': 'Wnt addiction of genetically defined cancers reversed by PORCN inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26257057'}]}]",ETC-159,2016-02-15T20:05:04Z
0,2016-10-25T19:24:04Z,4861,[],Ethacridine,2016-10-25T19:24:04Z
0,2015-05-12T17:36:24Z,2661,"[{'description': 'Ethinylestradiol is a synthetic derivative of estrogen, which binds to the estrogen receptor complex and has the potential to result in anti-tumor activity (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Ethinylestradiol,2015-05-12T17:36:24Z
0,2014-07-28T12:18:15Z,1136,"[{'description': 'Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Etoposide,2016-09-06T20:28:25Z
0,2015-11-16T19:02:48Z,3222,[],Etoposide + Filgrastim + Plerixafor,2015-11-16T19:02:48Z
0,2015-02-19T13:45:49Z,2101,[],Etoposide + Ifosfamide,2015-02-19T13:45:49Z
0,2015-04-23T01:33:37Z,2562,[],Etoposide + Melphalan,2015-04-23T01:33:37Z
0,2016-12-02T03:19:44Z,5046,[],Etoposide + NU7441,2016-12-02T03:19:44Z
0,2016-01-12T17:38:11Z,3403,[],Etoposide + NVP-ADW742,2016-01-12T17:38:11Z
0,2016-03-31T12:51:33Z,3881,[],Etoposide + YU238259,2016-03-31T12:51:33Z
0,2017-06-23T03:53:01Z,5918,"[{'description': 'ETP-46464 inhibits ATR, potentially resulting in increased tumor cell sensitivity to other anti-cancer agents (PMID: 25560806, PMID: 21552262).', 'references': [{'id': 9204, 'pubMedId': 25560806, 'title': 'Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25560806'}, {'id': 4396, 'pubMedId': 21552262, 'title': 'A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21552262'}]}]",ETP-46464,2017-06-23T03:53:01Z
0,2017-06-23T04:07:08Z,5919,[],ETP-46464 + Radiotherapy,2017-06-23T04:07:08Z
0,2014-03-12T15:53:16Z,735,"[{'description': 'Afinitor (everolimus) binds to FKBP-12 to generate an immunosuppressive complex that binds and allosterically inhibits mTOR (NCI Drug Dictionary, PMID: 25261369). Afinitor (everolimus) is FDA approved for neuroendocrine tumors of pancreatic, lung or gastrointestinal tract origin, advanced renal cell carcinoma, and subtypes of HER2 negative breast cancer (FDA.gov). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Everolimus,2016-03-08T19:50:24Z
0,2014-07-28T13:08:56Z,1145,[],Everolimus + AMG479,2014-07-28T13:08:56Z
0,2014-07-27T21:53:52Z,1120,[],Everolimus + Bevacizumab,2014-07-27T21:53:52Z
0,2014-07-29T13:13:13Z,1199,[],Everolimus + Denosumab,2014-07-29T13:13:13Z
0,2015-07-06T18:38:21Z,2884,[],Everolimus + Docetaxel,2015-07-06T18:38:21Z
0,2014-12-31T17:13:37Z,1883,[],Everolimus + Erlotinib,2014-12-31T17:13:37Z
0,2015-03-03T02:04:10Z,2258,[],Everolimus + Exemestane + LY2835219,2015-03-03T02:04:10Z
0,2017-01-15T22:52:02Z,5207,[],Everolimus + Fosbretabulin,2017-01-15T22:52:02Z
0,2015-03-04T10:57:34Z,2279,[],Everolimus + Gemcitabine,2015-03-04T10:57:34Z
0,2014-07-30T16:50:05Z,1271,[],Everolimus + GSK1120212,2014-07-30T16:50:05Z
0,2015-03-02T14:39:39Z,2231,[],Everolimus + Hydroxychloroquine,2015-03-02T14:39:39Z
0,2015-02-27T15:43:05Z,2198,[],Everolimus + Imatinib,2015-02-27T15:43:05Z
0,2014-09-25T16:03:34Z,1539,[],Everolimus + Lapatinib,2014-09-25T16:03:34Z
0,2014-11-06T19:31:09Z,1713,[],Everolimus + Lenvatinib,2017-05-12T14:36:22Z
0,2014-10-07T20:02:23Z,1621,[],Everolimus + Letrozole,2014-10-07T20:02:23Z
0,2016-06-16T03:03:04Z,4290,[],Everolimus + Letrozole + Metformin,2016-06-16T03:03:04Z
0,2014-10-02T13:37:51Z,1591,[],Everolimus + Letrozole + Trastuzumab,2014-10-02T13:37:51Z
0,2016-12-16T02:25:08Z,5102,[],Everolimus + Metformin,2016-12-16T02:25:24Z
0,2017-03-07T18:09:16Z,5410,[],Everolimus + MK-1775,2017-03-07T18:09:16Z
0,2017-06-29T18:14:16Z,5944,[],Everolimus + Octreotide,2017-06-29T18:14:16Z
0,2017-04-06T19:12:54Z,5505,[],Everolimus + Paclitaxel,2017-04-06T19:12:54Z
0,2015-01-06T15:01:38Z,1924,[],Everolimus + Paclitaxel + Carboplatin + Cetuximab,2015-01-06T15:01:38Z
0,2016-04-19T19:18:28Z,3958,[],Everolimus + Palbociclib,2016-04-19T19:18:28Z
0,2015-03-03T02:32:44Z,2261,[],Everolimus + Pasireotide,2015-03-03T02:32:44Z
0,2014-12-18T20:53:52Z,1806,[],everolimus + pazopanib,2014-12-18T20:55:24Z
0,2016-09-07T13:12:37Z,4656,[],Everolimus + Pimasertib,2016-09-07T13:13:46Z
0,2016-11-01T21:08:50Z,4902,[],Everolimus + PLX4720,2016-11-01T21:08:50Z
0,2016-12-05T16:08:28Z,5060,[],Everolimus + Radiotherapy,2016-12-05T16:08:28Z
0,2015-03-03T02:37:38Z,2262,[],Everolimus + RX-0201,2015-03-03T02:37:38Z
0,2014-08-01T00:56:40Z,1333,[],Everolimus + Sandostatin LAR Depot,2014-08-01T00:56:40Z
0,2016-11-23T16:51:30Z,4992,[],Everolimus + SCH772984,2016-11-23T16:51:30Z
0,2016-11-01T21:07:55Z,4901,[],Everolimus + Selumetinib,2016-11-01T21:07:55Z
0,2014-12-30T14:16:41Z,1871,[],Everolimus + Sonidegib,2017-06-19T19:29:44Z
0,2015-03-05T16:27:34Z,2299,[],Everolimus + Sorafenib,2015-03-05T16:27:34Z
0,2017-06-15T19:30:13Z,5895,[],Everolimus + Sunitinib,2017-06-15T19:30:13Z
0,2015-03-12T18:59:42Z,2384,[],Everolimus + Tacrolimus,2015-03-12T18:59:42Z
0,2016-04-27T18:34:19Z,4012,[],Everolimus + Talazoparib,2017-06-12T16:01:58Z
0,2015-03-03T02:53:12Z,2267,[],Everolimus + Tamoxifen,2015-03-03T02:53:12Z
0,2015-03-03T02:57:28Z,2269,[],Everolimus + Toremifene,2015-03-03T02:57:28Z
0,2017-03-30T19:51:08Z,5499,[],Everolimus + U0126,2017-03-30T19:51:08Z
0,2014-07-31T18:24:40Z,1317,"[{'description': 'Evofosfamide (TH-302) is a hypoxia-activated prodrug that releases a DNA-alkylating dibromo isophosphoramide mustard moiety within hypoxic regions of tumors, potentially providing antineoplastic activity with reduced systemic toxicity (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Evofosfamide,2017-05-26T14:37:10Z
0,2017-05-22T20:18:37Z,5745,[],Evofosfamide + Ipilimumab,2017-05-26T14:40:07Z
0,2014-07-31T18:25:57Z,1318,[],Evofosfamide + Pazopanib,2017-05-26T14:37:37Z
0,2014-07-31T18:42:24Z,1320,[],Evofosfamide + Sorafenib,2017-05-26T14:38:35Z
0,2016-03-24T20:39:57Z,3831,"[{'description': 'Ex-527 inhibits SIRT1, SIRT2, and SIRT3, potentially resulting in decreased tumor cell growth (PMID: 25486469).', 'references': [{'id': 5015, 'pubMedId': 25486469, 'title': 'Sirtuin deacetylases: a new target for melanoma management.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25486469'}]}]",Ex-527,2016-11-11T19:27:54Z
0,2014-03-12T15:53:16Z,738,"[{'description': 'Aromasin (exemestane) is an aromatase inhibitor, which prevents the conversion of androgenic precursors to estrogens (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Exemestane,2014-09-30T20:37:32Z
0,2015-01-19T16:23:14Z,1966,[],Exemestane + Everolimus,2015-01-19T16:23:14Z
0,2016-08-21T02:13:12Z,4597,[],Exemestane + Everolimus + Palbociclib,2016-08-21T02:13:12Z
0,2016-05-26T17:04:01Z,4141,[],Exemestane + Seribantumab,2016-05-26T17:04:01Z
0,2016-02-25T19:18:15Z,3612,"[{'description': 'EZN-2968 is an antisense oligonucleotide that hybridizes with hypoxia-inducible factor-1alpha (HIF-1alpha) mRNA and inhibits HIF-1alpha protein expression, leading to tumor growth inhibition (PMID: 18974394).', 'references': [{'id': 4703, 'pubMedId': 18974394, 'title': 'A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18974394'}]}]",EZN-2968,2016-03-30T02:21:36Z
0,2016-03-17T14:22:30Z,3767,"[{'description': 'F14512 is composed of a derivative of the topoisomerase II inhibitor etoposide linked to a spermidine chain, which enables cellular uptake through the polyamine transport system, resulting in increased DNA damage and decreased tumor growth  (PMID: 19047165).', 'references': [{'id': 4896, 'pubMedId': 19047165, 'title': 'F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19047165'}]}]",F14512,2016-03-17T14:22:30Z
0,2016-02-25T21:39:42Z,3621,[],FABLOx,2016-02-25T21:39:42Z
0,2014-03-12T15:53:16Z,739,"[{'description': 'Famitinib is an analog of Sutent (sunitinib), a receptor tyrosine kinase (RTK) inhibitor, which inhibits receptor tyrosine kinases including c-Kit, VEGFR2/3, PDGFR-beta, RET, and FLT3 to reduce cell proliferation and tumor growth (PMID: 23126373).', 'references': [{'id': 1860, 'pubMedId': 23126373, 'title': 'Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23126373'}]}]",Famitinib,2017-04-03T14:26:52Z
0,2017-07-06T20:31:49Z,5972,[],Famotidine,2017-07-06T20:31:49Z
0,2014-07-28T13:58:00Z,1157,"[{'description': 'Vigil (FANG vaccine) is a combination of autologous tumor cells expressing recombinant human granulocyte macrophage-colony stimulating factor (GM-CSF) and RNAi against furin convertase.  FANG stimulates cell maturation through GM-CSF and prevents GM-CSF degradation by Tgfb1 and Tgfb2 (PMID: 22186789).', 'references': [{'id': 479, 'pubMedId': 22186789, 'title': 'Phase I trial of ""bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell"" vaccine (FANG) in advanced cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22186789'}]}]",FANG vaccine,2016-02-19T17:35:25Z
0,2014-07-28T13:59:37Z,1158,[],FANG vaccine + Bevacizumab,2014-07-28T13:59:37Z
0,2016-06-28T00:25:46Z,4388,[],FANG vaccine + MEDI4736,2016-06-28T00:25:46Z
0,2016-02-19T17:36:11Z,3572,[],FANG vaccine + Nivolumab,2016-02-19T17:36:11Z
0,2015-12-01T20:54:37Z,3230,"[{'description': 'Farletuzumab (MORab003) is a monoclonal antibody that binds to FolR1, resulting in decreased interaction between FolR1 and Lyn, as well as increased antibody-dependent cytotoxicity and tumor cell lysis (PMID: 26063635).', 'references': [{'id': 4007, 'pubMedId': 26063635, 'title': 'Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26063635'}]}]",Farletuzumab,2016-02-15T14:36:47Z
0,2014-12-12T21:00:59Z,1777,"[{'description': 'Fasudil (HA-1077) is a kinase inhibitor, especially potent against Rho-kinase, preventing downstream signaling and resulting in inhibition of cell proliferation and migration, and induction of apoptosis in cancer cells (PMID: 24908363).', 'references': [{'id': 1328, 'pubMedId': 24908363, 'title': 'The Rho-kinase inhibitor HA-1077 suppresses proliferation/migration and induces apoptosis of urothelial cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24908363'}]}]",Fasudil,2014-12-12T21:00:59Z
0,2016-11-19T22:44:37Z,4971,"[{'description': 'Limited information is currently available on FAZ053, a putative anti-PD-L1 antibody (Nov 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",FAZ053,2016-11-19T22:44:37Z
0,2016-11-19T22:45:40Z,4972,[],FAZ053 + PDR001,2016-11-19T22:45:40Z
0,2016-03-21T00:10:00Z,3789,[],FdCyd + THU,2016-03-21T00:10:06Z
0,2016-07-01T20:41:01Z,4418,[],Fenofibrate,2016-07-01T20:41:11Z
0,2015-05-27T18:40:31Z,2731,"[{'description': 'Fenretinide is a retinol analog that binds and activates retinoic acid receptors, potentially resulting in increased tumor cell apoptosis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Fenretinide,2015-08-10T14:59:02Z
0,2016-04-13T15:09:55Z,3923,[],Fenretinide + Vorinostat,2016-04-13T15:09:55Z
0,2016-03-25T16:37:10Z,3833,"[{'description': 'FF-21101(90Y) is an yttrium Y 90-labeled anti-human cadherin-3 (CDH3) antibody, which selectively delivers radiation to CDH3-positive cancer cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",FF-21101(90Y),2016-03-31T19:52:34Z
0,2014-05-14T14:52:46Z,1014,"[{'description': 'Debio 1347 inhibits FGFR-1, -2, and -3, thus inhibiting FGFR-mediated signal transduction pathways which leads to the inhibition of both tumor cell proliferation and angiogenesis, and causes cell death in FGFR-overexpressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",FF-284,2015-09-10T09:20:04Z
0,2015-02-09T19:32:56Z,2031,"[{'description': 'FGF401 selectively binds and inhibits FGFR4, resulting in decreased proliferation and growth of tumor cells (Cancer Res 2017;77(13 Suppl):Abstract nr 2098).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 10034, 'pubMedId': None, 'title': 'NVP-FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of HCC', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/2098.short'}]}]",FGF401,2017-10-03T15:05:44Z
0,2015-02-18T00:29:36Z,2083,"[{'description': 'FH535 is PPAR antagonist and Wnt/CTNNB1 pathway inhibitor, which prevents cell proliferation (PMID: 18347139).', 'references': [{'id': 1914, 'pubMedId': 18347139, 'title': 'A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18347139'}]}]",FH535,2015-03-20T18:36:39Z
0,2014-03-12T15:53:16Z,740,"[{'description': 'Ficlatuzumab is a monoclonal antibody that targets HGF and inhibits c-MET/HGF signaling, potentially resulting in decreased tumor growth (PMID: 23493885).\r\n', 'references': [{'id': 2003, 'pubMedId': 23493885, 'title': 'Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23493885'}]}]",Ficlatuzumab,2017-07-20T18:12:33Z
0,2015-01-16T15:48:02Z,1959,[],Ficlatuzumab + Cetuximab,2015-01-16T15:48:02Z
0,2015-01-16T15:29:56Z,1955,[],Ficlatuzumab + Cisplatin,2015-01-16T15:29:56Z
0,2015-02-26T15:16:09Z,2169,[],Ficlatuzumab + Erlotinib,2015-02-26T15:16:09Z
0,2015-02-26T15:34:38Z,2172,[],Ficlatuzumab + Gefitinib,2015-02-26T15:34:38Z
0,2014-03-12T15:53:16Z,741,"[{'description': 'Figutumumab is a monoclonal antibody that binds to IGF-1R inhibits  activation, potentially resulting in decreased tumor growth (PMID: 21875414).', 'references': [{'id': 2850, 'pubMedId': 21875414, 'title': 'Insulin-like growth factor: current concepts and new developments in cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21875414'}]}]",Figitumumab,2015-06-02T13:12:45Z
0,2015-04-08T13:54:16Z,2507,"[{'description': 'FIIN-1 is an irreversible pan-FGFR inhibitor which blocks activation and downstream signaling and may inhibit transformation and proliferation in cancer cells (PMID: 20338520).', 'references': [{'id': 2410, 'pubMedId': 20338520, 'title': 'A structure-guided approach to creating covalent FGFR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20338520'}]}]",FIIN-01,2016-01-20T03:52:20Z
0,2017-03-08T16:27:12Z,5421,"[{'description': 'FIIN-2 is a selective, irreversible Fgfr inhibitor that can inhibits Fgfr mutants that confer resistance to first-generation Fgfr inhibitors, resulting in growth inhibition in tumor cells (PMID: 25349422).', 'references': [{'id': 8159, 'pubMedId': 25349422, 'title': 'Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25349422'}]}]",FIIN-2,2017-03-08T16:27:12Z
0,2014-10-08T21:21:04Z,1632,"[{'description': 'Neupogen (filgrastim) is a recombinant analog of granulocyte colony-stimulating factor (G-CSF) isoform B, which binds and activates G-CSF receptors modulating neutrophilic granulocyte progenitor activity, production, and differentiation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Filgrastim,2014-11-21T04:31:51Z
0,2016-04-15T15:20:29Z,3933,[],Filgrastim + Plerixafor,2016-04-15T15:20:29Z
0,2015-05-08T13:51:11Z,2644,[],Finasteride,2015-05-08T13:51:11Z
0,2016-02-25T17:00:20Z,3610,"[{'description': 'Gilenya (fingolimod) is a sphingosine 1-phosphate receptor modulator that activates PP2A, which may result in restoration of tumor suppressor activity thereby leading to apoptosis and inhibition of cell proliferation (PMID: 24448818). Gilenya (fingolimod) is FDA approved for multiple sclerosis (FDA.gov). ', 'references': [{'id': 4696, 'pubMedId': 24448818, 'title': 'PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24448818'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Fingolimod,2016-10-25T14:27:03Z
0,2016-10-25T14:53:19Z,4857,[],Fingolimod + Gemcitabine,2016-10-25T14:53:19Z
0,2016-03-15T15:18:22Z,3739,[],Fingolimod + Sorafenib,2016-03-15T15:18:22Z
0,2017-05-11T18:05:31Z,5662,"[{'description': 'FK866 is an inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), which results in blockade of glycolysis, thereby potentially leading to growth inhibition of cancer cells (PMID: 27076630). ', 'references': [{'id': 8871, 'pubMedId': 27076630, 'title': 'Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27076630'}]}]",FK866,2017-05-11T18:05:31Z
0,2017-06-07T15:18:03Z,5861,"[{'description': 'FKB238 is a biosimilar to Avastin (bevacizumab), which is a VEGFA targeted antibody (J Clin Oncol 35, 2017 (suppl; abstr e14007)).', 'references': [{'id': 9082, 'pubMedId': None, 'title': 'A randomized, double-blind, single dose comparison of pharmacokinetics and safety of FKB238 with bevacizumab.', 'url': 'http://abstracts.asco.org/199/AbstView_199_184952.html'}]}]",FKB238,2017-06-07T15:18:03Z
0,2015-06-12T18:01:20Z,2833,"[{'description': 'FL442 binds to and inhibits the androgen receptor (AR), resulting in  reduction of downstream signaling and decreased tumor growth (PMID: 24565895).', 'references': [{'id': 3036, 'pubMedId': 24565895, 'title': 'Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24565895'}]}]",FL442,2015-06-12T18:01:20Z
0,2016-03-29T17:07:28Z,3862,"[{'description': 'FLLL32 is a small molecule that inhibits Stat3 signaling and suppresses tumor cell growth (PMID: 20215512).', 'references': [{'id': 5066, 'pubMedId': 20215512, 'title': 'Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20215512'}]}]",FLLL32,2016-03-29T17:07:28Z
0,2017-03-24T06:39:38Z,5476,[],Floxiuridine + Panitumumab + Dexamethasone + FOLFIRI,2017-03-24T06:39:38Z
0,2015-01-14T16:59:21Z,1941,[],Floxuridine,2015-01-14T16:59:21Z
0,2015-11-06T14:41:17Z,3186,[],Floxuridine + Fluorouracil + Irinotecan,2015-11-06T14:41:17Z
0,2015-02-04T13:51:22Z,2009,[],Floxuridine + Veliparib,2015-02-04T13:51:22Z
0,2014-10-30T15:59:28Z,1689,[],Fluconazole,2014-10-30T15:59:28Z
0,2015-12-03T19:58:54Z,3261,[],Flucytosine,2015-12-03T19:58:54Z
0,2014-07-28T17:06:04Z,1166,"[{'description': 'Flurdara (fludarabine phosphate) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Fludarabine,2017-06-19T20:02:05Z
0,2015-03-06T00:25:34Z,2307,[],Fludarabine + EPOCH,2015-03-06T00:25:34Z
0,2016-02-26T17:30:20Z,3633,[],Fludarabine + Ibrutinib,2016-02-26T17:30:20Z
0,2017-09-01T20:06:44Z,6154,[],Fludarabine + Ibrutinib + Pembrolizumab,2017-09-01T20:06:44Z
0,2015-03-02T16:18:30Z,2237,[],Fludarabine + Melphalan,2015-03-02T16:18:30Z
0,2016-08-08T20:15:02Z,4550,[],Fludarabine + Olaparib,2016-08-08T20:15:02Z
0,2014-12-23T15:22:09Z,1842,[],Fludarabine + Thiotepa + Cyclophosphamide,2014-12-23T15:22:09Z
0,2015-11-02T21:23:37Z,3169,"[{'description': 'Flumatinib inhibits KIT, PDGFR, and BCR-ABL, potentially resulting in decreased tumor cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Flumatinib,2015-11-02T21:23:37Z
0,2014-11-07T21:49:15Z,1715,[],Fluorouracil,2014-11-07T21:49:15Z
0,2014-09-22T01:14:52Z,1522,[],Fluorouracil + Bevacizumab + Capecitabine + Irinotecan + Leucovorin,2014-09-22T01:14:52Z
0,2014-09-22T01:21:50Z,1524,[],Fluorouracil + Bevacizumab + Capecitabine + Leucovorin + Oxaliplatin,2014-09-22T01:21:50Z
0,2014-09-22T01:19:00Z,1523,[],Fluorouracil + Capecitabine + Irinotecan + Leucovorin + Oxaliplatin,2014-10-02T17:17:09Z
0,2015-02-02T16:23:45Z,2000,[],Fluorouracil + Cetuximab,2015-02-02T16:23:45Z
0,2015-01-27T17:02:04Z,1982,[],Fluorouracil + Epirubicin + Cyclophosphamide,2015-01-27T17:02:04Z
0,2017-05-26T17:37:13Z,5789,[],Fluorouracil + Galunisertib,2017-05-26T17:37:13Z
0,2016-08-07T16:52:44Z,4532,[],Fluorouracil + Irinotecan + Leucovorin + MM-151,2016-08-11T14:01:54Z
0,2015-03-04T10:22:41Z,2278,[],Fluorouracil + Leucovorin,2015-03-04T10:22:41Z
0,2015-04-07T02:50:06Z,2498,[],Fluorouracil + Leucovorin + Irinotecan + Oxaliplatin + Saridegib,2015-04-07T02:50:06Z
0,2016-11-18T17:55:43Z,4970,[],Fluorouracil + Leucovorin + Trastuzumab,2016-11-18T17:55:43Z
0,2014-11-07T21:55:34Z,1716,[],fluorouracil + mitomycin,2014-11-07T21:55:34Z
0,2016-03-28T19:19:50Z,3859,[],Fluorouracil + OPB-31121,2016-03-28T19:19:50Z
0,2016-09-02T15:26:08Z,4643,[],Fluorouracil + Quinacrine + Sorafenib,2016-09-02T15:26:08Z
0,2017-09-05T16:39:09Z,6167,[],Fluorouracil + RU-A1,2017-09-05T16:39:09Z
0,2015-10-09T14:44:22Z,3123,[],Fluorouracil + Tanibirumab,2015-10-09T14:44:22Z
0,2017-09-26T22:10:58Z,6246,[],Fluoruracil + Leucovorin + Prexasertib,2017-09-26T22:13:49Z
0,2015-05-13T18:33:31Z,2664,[],Fluoxymesterone,2015-05-13T18:33:31Z
0,2014-03-12T15:53:16Z,742,"[{'description': 'Eulexin (flutamide) is a nonsteroidal antiandrogen that competitively blocks androgen receptors. Eulexin prevents receptor activation and translocation to the nucleus, thus preventing androgen-dependent DNA and protein synthesis, which may prevent tumor cell growth (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Flutamide,2014-10-29T14:45:37Z
0,2015-04-10T15:49:08Z,2529,"[{'description': 'FLX925 binds to and inhibits both FMS-related tyrosine kinase 3 (FLT3) and cyclin-dependent kinases 4 and 6 (CDK4/6), resulting in cell cycle arrest and inhibition of cell proliferation (NCI Drug Dictionary).  ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",FLX925  ,2015-08-20T20:40:54Z
0,2014-07-31T17:46:25Z,1315,[],FOLFIRI,2014-07-31T17:46:25Z
0,2017-02-09T16:17:44Z,5297,[],FOLFIRI + OMP-305B83,2017-02-09T16:17:44Z
0,2016-04-15T20:19:53Z,3949,[],FOLFIRI + SYM004,2016-04-15T20:19:53Z
0,2015-01-05T01:39:51Z,1903,[],FOLFIRINOX,2015-04-08T02:02:22Z
0,2015-01-06T13:19:44Z,1913,[],FOLTAX,2015-01-06T13:19:44Z
0,2014-03-12T15:53:16Z,743,"[{'description': 'Foretinib (GSK1363089) is a multi-kinase inhibitor with activity against several receptor tyrosine kinases, including MET, MST1R (RON), AXL, and KDR (VEGFR2), as well as ROS1 fusions, which may result in decreased tumor angiogenesis and growth (PMID: 23792360, PMID: 19808973, PMID: 26372962, PMID:19671800).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 4022, 'pubMedId': 26372962, 'title': 'Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26372962'}, {'id': 3959, 'pubMedId': 23792360, 'title': 'MSP-RON signalling in cancer: pathogenesis and therapeutic potential.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23792360'}, {'id': 4023, 'pubMedId': 19808973, 'title': 'Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19808973'}]}]",Foretinib,2017-01-18T17:03:23Z
0,2016-10-05T19:26:22Z,4789,[],Foretinib + PLX4720,2016-10-05T19:26:22Z
0,2016-05-04T12:58:09Z,4071,[],Foretinib + Rucaparib,2016-05-04T12:58:09Z
0,2016-05-04T16:29:21Z,4072,[],Foretinib + Veliparib,2016-05-04T16:29:21Z
0,2016-02-25T15:24:51Z,3605,"[{'description': 'Forskolin is an activator of PP2A, which may induce apoptosis and lead to inhibition of cell proliferation (PMID: 21233840, PMID: 26023836).', 'references': [{'id': 4695, 'pubMedId': 26023836, 'title': 'Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26023836'}, {'id': 4694, 'pubMedId': 21233840, 'title': 'PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21233840'}]}]",Forskolin,2016-02-25T15:24:51Z
0,2014-07-28T20:41:20Z,1186,"[{'description': 'Fosbretabulin is metabolized to combretastatin A4, which binds to tubulin dimers, preventing microtubule polymerization. This causes mitotic arrest and apoptosis in endothelial cells, leading to collapse of tumor blood cells, disrupting blood flow to the tumor and possibly causing tumor necrosis (NCI Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Fosbretabulin,2014-07-28T20:41:20Z
0,2014-09-24T13:51:51Z,1528,"[{'description': 'Fostamatinib (R788) binds and inhibits Syk kinase thus interfering with mast cell, macrophage, and B-cell activation as well as downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis (NCI drug dictionary)', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Fostamatinib,2017-10-10T18:07:21Z
0,2017-10-10T17:59:14Z,6308,[],Fostamatinib + Silmitasertib,2017-10-10T17:59:14Z
0,2017-03-10T16:38:01Z,5428,[],Fotemustine,2017-03-10T16:38:01Z
0,2017-03-10T16:38:46Z,5429,[],Fotemustine + Valproic acid,2017-03-10T16:38:46Z
0,2015-06-18T16:54:38Z,2840,"[{'description': 'FPA008 is a monoclonal antibody that targets the ligand-binding domain of CSF1R (PMID: 26051995). ', 'references': [{'id': 3077, 'pubMedId': 26051995, 'title': 'CSF-1/CSF-1R targeting agents in clinical development for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26051995'}]}]",FPA008,2015-06-18T16:54:38Z
0,2015-07-20T15:19:32Z,2933,"[{'description': 'FPA144 is a monoclonal antibody against FGFR2 isoform B, which prevents ligand interaction and induces cell mediated cytotoxicity, potentially inhibiting proliferation and promoting apoptosis in cancer cells expressing FGFR2 isoform B (J Clin Oncol 32, 2014 (suppl; abstr e15074).', 'references': [{'id': 3278, 'pubMedId': None, 'title': 'FPA144, a humanized monoclonal antibody for both FGFR2-amplified and nonamplified, FGFR2b-overexpressing gastric cancer patients.', 'url': 'http://meetinglibrary.asco.org/content/133812-144'}]}]",FPA144,2015-10-21T20:42:48Z
0,2015-12-22T21:01:53Z,3330,"[{'description': 'FRAX-1063 is an inhibitor of group I PAKs (PAK1, PAK2, and PAK3), which may result in increased tumor cell apoptosis and sensitivity to microtubule-targeted agents (PMID: 25902869).', 'references': [{'id': 4155, 'pubMedId': 25902869, 'title': 'Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25902869'}]}]",FRAX-1063,2015-12-22T21:01:53Z
0,2015-12-22T21:06:56Z,3331,[],FRAX-1063 + Docetaxel,2015-12-22T21:06:56Z
0,2015-12-22T20:43:52Z,3328,"[{'description': 'FRAX597 is a small-molecule inhibitor of the group I PAKs (PAK1, PAK2, and PAK3), which may result in decreased tumor growth (PMID: 23543898).', 'references': [{'id': 4152, 'pubMedId': 23543898, 'title': 'Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23543898'}]}]",FRAX597,2015-12-22T20:43:52Z
0,2015-05-19T15:30:18Z,2707,"[{'description': 'Fresolimumab (GC1008) is a monoclonal antibody that binds TGFB1, TGFB2, and TGFB3, blocking receptor interaction and signaling, which may inhibit proliferation and metastasis of cancer cells (PMID: 24618589).', 'references': [{'id': 2759, 'pubMedId': 24618589, 'title': 'Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24618589'}]}]",fresolimumab,2015-10-29T15:37:14Z
0,2015-02-10T20:53:48Z,2038,"[{'description': 'Fruquintinib (HMPL-013) binds and inhibits VEGFR receptors, 1,2 and 3, resulting in reduced cell proliferation and tumor growth (PMID: 25482937).', 'references': [{'id': 1861, 'pubMedId': 25482937, 'title': 'Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25482937'}]}]",Fruquintinib,2016-03-03T10:13:21Z
0,2016-06-22T01:49:01Z,4336,"[{'description': 'Limited information is currently available on FT-2102 (Jun 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",FT-2102,2016-06-22T01:50:22Z
0,2016-07-14T14:07:52Z,4449,[],FT-2102 + Azacitidine,2016-07-14T14:07:52Z
0,2014-10-29T20:24:52Z,1683,"[{'description': 'FTI-277 is a  farnesyltransferase inhibitor (FTI). Inhibition of  farnesyltransferase blocks H-Ras and K-Ras processing and reduces proliferation in cancer cells (PMID: 7592920).', 'references': [{'id': 1006, 'pubMedId': 7592920, 'title': 'Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/7592920'}]}]",FTI-277,2016-03-11T19:06:17Z
0,2014-03-12T15:53:16Z,744,"[{'description': 'Faslodex (fulvestrant) is a competitive inhibitor of estrogen that binds and deforms estrogen receptors, and causes inhibition of growth in cultured estrogen-sensitive breast cancer cells (NCI Drug Dictionary). Faslodex (fulvestrant) is FDA approved for use in patients with hormone receptor-positive breast cancer (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Fulvestrant,2016-09-14T18:44:45Z
0,2014-09-25T17:58:47Z,1546,[],Fulvestrant + BKM120,2014-09-25T17:58:47Z
0,2015-02-27T05:32:08Z,2189,[],Fulvestrant + Dovitinib,2015-02-27T05:32:08Z
0,2014-10-02T13:27:35Z,1589,[],Fulvestrant + Everolimus,2014-10-02T13:27:35Z
0,2014-10-02T13:28:19Z,1590,[],Fulvestrant + Everolimus + Anastrozole,2014-10-02T13:29:07Z
0,2016-08-15T15:46:52Z,4567,[],Fulvestrant + GDC-0032 ,2016-08-15T15:46:52Z
0,2016-06-24T17:59:38Z,4357,[],Fulvestrant + GDC-0941,2016-06-24T17:59:38Z
0,2015-04-23T02:55:59Z,2568,[],Fulvestrant + Ixazomib,2015-04-23T02:55:59Z
0,2017-08-01T21:11:22Z,6070,[],Fulvestrant + JNJ-7706621,2017-08-01T21:11:22Z
0,2015-03-06T15:29:11Z,2316,[],Fulvestrant + LEE011,2015-03-06T15:29:11Z
0,2016-06-01T18:47:52Z,4189,[],Fulvestrant + MK2206,2016-06-01T18:47:52Z
0,2017-05-19T19:04:55Z,5705,[],Fulvestrant + Neratinib,2017-05-19T19:04:55Z
0,2015-11-14T17:14:54Z,3205,[],Fulvestrant + Palbociclib,2015-11-14T17:14:54Z
0,2017-05-19T03:05:08Z,5684,[],Fulvestrant + Palbociclib + Avelumab,2017-05-19T03:05:08Z
0,2016-04-20T14:56:28Z,3968,[],Fulvestrant + Palbociclib + GDC-0941,2016-04-20T14:56:28Z
0,2017-10-02T18:57:12Z,6285,[],Fulvestrant + PDR001 + Ribociclib,2017-10-02T18:57:12Z
0,2017-07-07T02:56:51Z,5975,[],Fulvestrant + REGN2878-DM1,2017-07-07T02:56:51Z
0,2016-12-07T22:06:46Z,5068,[],Fulvestrant + SAR405838,2016-12-07T22:06:46Z
0,2016-11-28T17:59:53Z,5015,[],Fulvestrant + Selumetinib,2016-11-28T17:59:53Z
0,2017-10-17T18:24:58Z,6327,[],Fulvestrant + Seribantumab,2017-10-17T18:24:58Z
0,2016-10-24T16:22:32Z,4854,[],Fulvestrant + THZ1,2016-10-24T16:22:32Z
0,2016-10-12T18:01:56Z,4815,"[{'description': 'FX1 is a small molecule that binds to Bcl6 and prevents recruitment of Bcl6 corepressors, leading to growth inhibition in Bcl6-dependent tumor cells (PMID: 27482887).', 'references': [{'id': 6759, 'pubMedId': 27482887, 'title': 'Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27482887'}]}]",FX1,2017-06-16T15:50:46Z
0,2016-01-29T03:46:57Z,3471,"[{'description': 'G-631 inhibits Tankyrase 1 and 2, resulting in decreased Wnt/Beta-catenin pathway signaling, but has little anti-tumor activity and leads to intestinal toxicity (PMID: 26692561).', 'references': [{'id': 4481, 'pubMedId': 26692561, 'title': 'Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index < 1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26692561'}]}]",G-631,2016-01-29T03:46:57Z
0,2015-04-29T19:21:14Z,2616,"[{'description': 'G-749 is an inhibitor of both wild-type and mutant forms of FLT3, which may reduce cancer cell proliferation and tumor growth (PMID: 24532805). ', 'references': [{'id': 2617, 'pubMedId': 24532805, 'title': 'G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24532805'}]}]",G-749,2015-04-29T19:23:35Z
0,2017-08-01T14:40:36Z,6063,"[{'description': 'G-TPP is a Gamitrinib variant that inhibits mitochondrial Hsp90, which induces tumor cell death (PMID: 23147571).', 'references': [{'id': 9645, 'pubMedId': 23147571, 'title': 'The targeted inhibition of mitochondrial Hsp90 overcomes the apoptosis resistance conferred by Bcl-2 in Hep3B cells via necroptosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23147571'}]}]",G-TPP,2017-08-01T14:40:36Z
0,2017-08-01T15:42:31Z,6064,[],G-TPP + Navitoclax,2017-08-01T15:58:12Z
0,2017-08-01T15:43:29Z,6065,[],G-TPP + Obatoclax,2017-08-01T15:43:29Z
0,2017-08-01T15:45:23Z,6067,[],G-TPP + Venetoclax,2017-08-01T15:45:23Z
0,2017-08-01T15:44:20Z,6066,[],G-TPP + WEHI-539,2017-08-01T15:44:20Z
0,2015-08-05T14:00:06Z,2991,"[{'description': 'G007-LK inhibits tankyrase, which leads to stabilization of AXIN, thereby resulting in degradation of beta-catenin and decreased growth of APC-deficient tumors (PMID: 23539443).', 'references': [{'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]}]",G007-LK,2015-09-22T19:18:01Z
0,2017-09-18T18:52:28Z,6215,[],G007-LK + Imatinib,2017-09-18T18:53:03Z
0,2016-04-20T16:51:24Z,3970,"[{'description': 'G1T38 is a selective CDK4/6 inhibitor, which results in cell cycle arrest and tumor cell death (AACR, Cancer Res: April 2016; Volume 57, Abstract #2824).', 'references': [{'id': 5183, 'pubMedId': None, 'title': 'Effects of a CDK 4/6 inhibitor, G1T38, in androgen receptor sensitive and resistant models of castrate resistant prostate cancer', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=12eab58f-9b3f-418d-ad0c-e55a553a95b9&cKey=90cf56d3-fe9d-4b4d-8477-6867a79402af&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]}]",G1T38,2016-04-25T14:51:19Z
0,2017-09-12T18:56:54Z,6207,[],G1T38 + G1T48,2017-09-12T18:56:54Z
0,2017-09-12T18:55:54Z,6206,"[{'description': 'G1T48 is an orally bioavailable selective inhibitor of estrogen receptor (ER) that leads to down-regulation of ER and growth inhibition of ER-positive tumor cells (Cancer Res 2017;77(13 Suppl):Abstract nr 5641).', 'references': [{'id': 9895, 'pubMedId': None, 'title': 'Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in animal models of endocrine resistant breast cancer', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5641.short'}]}]",G1T48,2017-09-12T18:55:54Z
0,2015-12-10T03:00:30Z,3272,"[{'description': 'G305 is a mixture of recombinant NY-ESO-1 and synthetic glucopyranosyl lipid A (GLA), which targets dendritic cells and stimulates immune response (http://www.immunedesign.com/wp-content/uploads/2015/05/G305-ASCO-poster-2015.pdf).', 'references': [{'id': 4079, 'pubMedId': None, 'title': '', 'url': 'http://www.immunedesign.com/wp-content/uploads/2015/05/G305-ASCO-poster-2015.pdf'}]}]",G305,2015-12-10T03:00:30Z
0,2015-12-10T03:01:34Z,3273,[],G305 + ID-LV305,2015-12-10T03:01:34Z
0,2015-10-26T15:42:50Z,3154,"[{'description': 'GA201 (RG7160) is a humanized antibody directed against EGFR, which prevents ligand binding and dimerization, resulting in decreased EGFR signaling and increased immune response toward EGFR-expressing tumor cells (PMID: 23209031).', 'references': [{'id': 3814, 'pubMedId': 23209031, 'title': 'GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209031'}]}]",GA201,2015-10-26T15:42:50Z
0,2016-01-08T18:33:39Z,3373,[],GA201 + Irinotecan,2016-01-08T18:33:39Z
0,2014-09-19T04:47:32Z,1508,"[{'description': 'Galeterone functions both as an inhibitor of CYP17A1 and anti-androgen (NCI Drug Dictionary). It binds the androgen receptor, acting as an competitive antagonist and also preventing Ar protein binding to chromatin and enhancing degradation of mutant Ar protein (PMID: 24874833 ).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 778, 'pubMedId': 24874833, 'title': 'Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24874833'}]}]",galeterone,2014-09-19T04:47:32Z
0,2015-03-16T16:55:04Z,2409,"[{'description': 'Galunisertib (LY2157299) is a TGFBR1 antagonist, which inhibits downstream signaling and may suppress tumor growth (PMID: 18039567).', 'references': [{'id': 2221, 'pubMedId': 18039567, 'title': 'Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18039567'}]}]",Galunisertib,2015-05-22T00:17:23Z
0,2016-06-02T22:08:18Z,4211,[],Galunisertib + MEDI4736,2016-06-02T22:08:18Z
0,2016-02-17T20:09:39Z,3541,[],Galunisertib + Paclitaxel,2016-02-17T20:09:39Z
0,2015-03-17T12:38:21Z,2421,[],Galunisertib + Sorafenib,2015-03-17T12:38:21Z
0,2014-03-12T15:53:16Z,745,"[{'description': 'Ganetespib is a small molecule that inhibits Hsp90, resulting in the degradation and inactivation of Hsp90 client proteins and decreased cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Ganetespib,2014-09-30T20:28:12Z
0,2014-10-28T15:39:10Z,1665,[],Ganetespib + Aflibercept,2014-10-28T15:39:10Z
0,2015-02-27T05:54:41Z,2190,[],Ganetespib + Crizotinib,2015-02-27T05:54:41Z
0,2014-09-30T20:22:43Z,1579,[],Ganetespib + Paclitaxel + Trastuzumab,2014-09-30T20:22:43Z
0,2016-12-13T21:25:50Z,5097,[],Ganetespib + Radiotherapy,2016-12-13T21:25:50Z
0,2015-03-03T03:43:08Z,2271,[],Ganetespib + Sirolimus,2015-03-03T03:43:08Z
0,2014-10-29T20:35:29Z,1684,[],Ganetespib + TAK-733,2014-10-29T20:35:29Z
0,2014-03-12T15:53:16Z,746,"[{'description': 'Ganitumab (AMG-479) is a recombinant antibody that binds to and inhibits IGF-1R. Inhibition of IGF-1R prevents activation of the downstream PI3K/Akt pathway, which may inhibit proliferation and induce apoptosis of tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Ganitumab,2016-07-19T17:38:31Z
0,2015-05-07T15:19:39Z,2631,"[{'description': 'GANT58 inhibits GLI, potentially resulting in decreased proliferation and increased tumor cell death (PMID: 24394624).', 'references': [{'id': 2658, 'pubMedId': 24394624, 'title': 'Inhibition of hedgehog signaling by GANT58 induces apoptosis and shows synergistic antitumor activity with AKT inhibitor in acute T cell leukemia cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24394624'}]}]",GANT58,2015-11-19T20:08:23Z
0,2014-12-15T20:40:09Z,1786,"[{'description': 'GANT61 is a small molecule inhibitor of hedgehog signaling that acts on GLI1 and GLI2 to block transcription and has demonstrated antitumor activity in xenograft models (PMID: 17494766).', 'references': [{'id': 1336, 'pubMedId': 17494766, 'title': 'Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17494766'}]}]",GANT61,2015-11-19T20:08:49Z
0,2016-03-10T20:59:49Z,3715,[],GANT61 + Doxorubicin,2016-03-10T20:59:49Z
0,2016-03-10T21:10:23Z,3716,[],GANT61 + Vincristine,2016-03-10T21:10:23Z
0,2015-07-14T01:00:48Z,2913,"[{'description': 'GC1118 is a monoclonal antibody that binds EGFR and prevents ligand binding, potentially resulting in decreased tumor cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",GC1118,2015-07-14T01:00:48Z
0,2014-05-14T14:52:46Z,1015,"[{'description': 'GCS-100 binds lectin galectin-3, which may result in apoptosis mediated through mitochondria/caspase activation cascades and may overcome tumor growth mediated through Bcl2, Hsp2, and NF-kB (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",GCS-100,2014-10-31T14:49:20Z
0,2015-02-11T17:08:40Z,2051,"[{'description': 'GD2Bi-a ATC are autologous T-cells that have been “armed” with bispecific antibodies that target both GD2 and CD3, resulting in cytotoxicity of GD2-expressing tumor cells by cross-linking activated T-cells to GD2-positive tumor cells, and may also enhance CTL-mediated response tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",GD2Bi-a ATC,2015-02-11T17:08:40Z
0,2014-05-14T14:52:46Z,1016,"[{'description': 'Taselisib (GDC-0032) is a beta isoform-sparing PI3K inhibitor, with greater activity against oncogenic mutants of PIK3CA (PMID: 23662903).', 'references': [{'id': 206, 'pubMedId': 23662903, 'title': 'Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23662903'}]}]",GDC-0032,2016-07-01T23:56:45Z
0,2016-05-13T14:31:50Z,4118,[],GDC-0032  + Letrozole,2016-05-13T14:31:50Z
0,2016-10-27T19:27:34Z,4871,[],GDC-0032 + Neratinib,2016-10-27T19:27:34Z
0,2015-03-06T16:28:34Z,2322,[],GDC-0032 + Paclitaxel,2015-03-06T16:28:34Z
0,2016-04-20T14:30:29Z,3967,[],GDC-0032 + Radiotherapy,2016-04-20T14:30:29Z
0,2017-01-10T04:38:23Z,5181,"[{'description': 'Limited information is currently available on GDC-0077 (Jan, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",GDC-0077,2017-01-12T15:12:26Z
0,2017-01-10T04:45:57Z,5184,[],GDC-0077 + Fulvestrant,2017-01-10T04:45:57Z
0,2017-01-10T04:45:01Z,5183,[],GDC-0077 + Letrozole,2017-01-10T04:45:01Z
0,2017-01-10T04:44:02Z,5182,[],GDC-0077 + Letrozole + Palbociclib,2017-01-10T04:44:02Z
0,2015-02-07T11:28:32Z,2018,"[{'description': 'GDC-0084 is a dual pan-PI3K and mTOR inhibitor, which prevents cell proliferation (PMID: 22619466 ).', 'references': [{'id': 1818, 'pubMedId': 22619466, 'title': 'Current clinical development of PI3K pathway inhibitors in glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22619466'}]}]",GDC-0084,2016-04-01T16:33:36Z
0,2017-03-23T20:09:15Z,5475,"[{'description': 'GDC-0152 is a SMAC mimetic compound, which antagonizes inhibitor of apoptosis proteins (IAPs), resulting in increased apoptosis and differentiation of tumor cells (PMID: 27490930).', 'references': [{'id': 8319, 'pubMedId': 27490930, 'title': 'Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27490930'}]}]",GDC-0152,2017-09-25T19:09:36Z
0,2016-04-20T17:36:06Z,3972,[],GDC-0199 + Alisertib,2016-04-20T17:36:06Z
0,2014-10-10T01:14:51Z,1637,[],GDC-0199 + Azacitidine,2014-10-10T01:14:51Z
0,2014-10-10T01:12:16Z,1636,[],GDC-0199 + Decitabine,2014-10-10T01:12:16Z
0,2016-02-25T22:14:22Z,3624,[],GDC-0199 + Duvelisib,2017-05-15T18:36:46Z
0,2016-01-10T22:21:23Z,3392,[],GDC-0199 + Ibrutinib,2016-01-10T22:21:23Z
0,2016-01-29T03:59:21Z,3472,[],GDC-0199 + Ibrutinib + Obinutuzumab,2016-01-29T14:39:10Z
0,2016-02-26T18:12:49Z,3636,[],GDC-0199 + Obinutuzumab,2016-02-26T18:12:49Z
0,2016-04-15T16:12:52Z,3937,[],GDC-0199 + Rituximab,2016-04-15T16:12:52Z
0,2016-04-20T17:45:46Z,3973,[],GDC-0199 + VX-680,2016-04-20T17:45:46Z
0,2017-01-26T16:26:00Z,5252,"[{'description': 'GDC-0326 is a small molecule that inhibits PIK3CA, resulting in decreased downstream signaling and potentially leading to reduced tumor growth (PMID: 27225693).', 'references': [{'id': 7679, 'pubMedId': 27225693, 'title': 'Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27225693'}]}]",GDC-0326,2017-01-26T16:26:00Z
0,2014-05-14T14:52:46Z,1017,"[{'description': 'GDC-0349 is a selective ATP-competitive inhibitor of mTOR kinase activity (PMID: 23473235).', 'references': [{'id': 1824, 'pubMedId': 23473235, 'title': 'Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23473235'}]}]",GDC-0349,2016-04-01T16:33:51Z
0,2015-02-09T01:00:50Z,2028,"[{'description': 'GDC-0425 is a selective CHK1, which may enhance chemosensitivity (PMID: 23594139).', 'references': [{'id': 1828, 'pubMedId': 23594139, 'title': 'Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23594139'}]}]",GDC-0425,2015-02-09T01:00:50Z
0,2017-05-22T16:44:11Z,5734,[],GDC-0425 + Gemcitabine,2017-05-22T16:44:11Z
0,2015-02-09T00:37:27Z,2024,"[{'description': 'GDC-0575 is a selective CHK1 inhibitor, which may enhance response to chemotherapeutics (PMID: 23594139).', 'references': [{'id': 1828, 'pubMedId': 23594139, 'title': 'Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23594139'}]}]",GDC-0575,2015-04-10T17:00:28Z
0,2015-02-20T13:10:21Z,2113,[],GDC-0575 + Gemcitabine,2015-02-20T13:10:21Z
0,2014-03-12T15:53:16Z,748,"[{'description': 'GDC-0623 is a Mek1/2 inhibitor, which results in inhibition of growth factor-mediated signaling and tumor cell proliferation (PMID: 23934108, PMID: 26615130).', 'references': [{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",GDC-0623,2017-04-06T10:01:08Z
0,2015-02-24T18:44:00Z,2150,"[{'description': 'GDC-0810 binds to estrogen receptors and promotes their degradation, potentially resulting in decreased growth of estrogen receptor-expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",GDC-0810,2017-03-09T16:26:06Z
0,2015-05-15T02:12:29Z,2690,"[{'description': 'GDC-0834 is a selective reversible inhibitor of BTK that inhibits B-cell proliferation and differentiation (PMID: 23958373, PMID: 25701252).', 'references': [{'id': 2732, 'pubMedId': 25701252, 'title': ""Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25701252'}, {'id': 2731, 'pubMedId': 23958373, 'title': 'Ibrutinib and novel BTK inhibitors in clinical development.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23958373'}]}]",GDC-0834,2015-05-15T02:12:29Z
0,2016-02-26T19:06:31Z,3639,"[{'description': 'GDC-0917 is a SMAC mimetic, which acts as an antagonist to Inhibitor of Apoptosis Protein (IAP) family proteins, resulting in decreased tumor growth (PMID: 24041744).', 'references': [{'id': 4714, 'pubMedId': 24041744, 'title': 'Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24041744'}]}]",GDC-0917,2017-09-25T19:09:55Z
0,2015-07-08T15:34:02Z,2888,"[{'description': 'GDC-0919 inhibits indolealmine 2,3-dioxygenase (IDO), potentially resulting in enhanced T-cell response to tumor cells (PMID: 25054064).', 'references': [{'id': 3203, 'pubMedId': 25054064, 'title': 'The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25054064'}]}]",GDC-0919,2015-07-08T15:34:02Z
0,2014-03-12T15:53:16Z,749,"[{'description': 'Pictilisib (GDC-0941) inhibits isoforms of PI3K, which inhibits PI3K/AKT signaling resulting in antitumor activity, including inhibition of tumor growth (PMID: 19584227). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 8699, 'pubMedId': 19584227, 'title': 'Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19584227'}]}]",GDC-0941,2017-05-12T20:20:41Z
0,2016-05-03T17:16:26Z,4053,[],GDC-0941 + Binimetinib,2016-05-03T17:16:26Z
0,2014-09-25T20:35:41Z,1554,[],GDC-0941 + Cisplatin,2014-09-25T20:35:41Z
0,2014-11-03T20:15:11Z,1702,[],GDC-0941 + cobimetinib,2014-11-03T20:15:11Z
0,2016-05-03T17:26:11Z,4056,[],GDC-0941 + LGX818,2016-05-03T17:26:11Z
0,2016-09-14T15:22:04Z,4713,[],GDC-0941 + Linsitinib,2016-09-14T15:22:04Z
0,2016-09-30T03:06:51Z,4774,[],GDC-0941 + MS417,2016-09-30T03:06:51Z
0,2016-07-13T19:04:47Z,4446,[],GDC-0941 + Navitoclax,2017-08-01T16:03:12Z
0,2016-05-03T16:18:14Z,4046,[],GDC-0941 + NVP-AEW541,2016-05-03T16:18:14Z
0,2016-06-24T18:52:36Z,4358,[],GDC-0941 + PLX4720,2016-06-24T18:52:36Z
0,2016-04-14T19:21:28Z,3927,[],GDC-0941 + Ruxolitinib,2016-04-14T19:21:36Z
0,2016-11-23T17:39:19Z,5004,[],GDC-0941 + SCH772984,2016-11-23T17:39:19Z
0,2015-08-14T00:48:55Z,3024,[],GDC-0941 + Selumetinib,2015-08-14T00:48:55Z
0,2016-12-19T20:02:31Z,5108,[],GDC-0941 + Venetoclax,2016-12-19T20:02:31Z
0,2015-08-28T09:49:29Z,3070,[],GDC-0941 + vorinostat,2015-08-28T09:49:29Z
0,2014-03-12T15:53:16Z,750,"[{'description': 'Apitolisib (GDC-0980) is an inhibitor of both PI3K and mTOR kinases, resulting in decreased phosphorylation of PI3K/Akt/mTOR pathway markers, which may lead to inhibition of tumor growth and tumor regression (PMID: 21998291). ', 'references': [{'id': 3508, 'pubMedId': 21998291, 'title': 'GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21998291'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",GDC-0980,2017-04-24T18:05:17Z
0,2015-08-14T01:40:39Z,3026,[],GDC-0980 + PD-0325901,2015-08-14T01:40:39Z
0,2015-02-24T18:22:57Z,2149,"[{'description': 'GDC-0994 is a small molecule inhibitor of ERK1 and ERK2, which may decrease tumor growth (Cancer Res October 1, 2014 74:DDT02-03).', 'references': [{'id': 1983, 'pubMedId': None, 'title': 'Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/DDT02-03.short'}]}]",GDC-0994,2015-02-24T18:22:57Z
0,2014-07-25T10:13:39Z,1095,"[{'description': 'GDC0879 is a selective small molecular inhibitor of BRAF and CRAF (RAF1), which inhibits survival of tumor cells (PMID: 19276360).', 'references': [{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]}]",GDC0879,2017-08-15T14:56:17Z
0,2016-08-22T19:59:20Z,4605,[],GDC0879 + GDC-0941,2016-08-22T19:59:20Z
0,2016-01-11T01:12:25Z,3398,[],Gedatolisib + Camptothecin,2016-01-11T01:12:30Z
0,2016-01-11T00:57:03Z,3396,[],Gedatolisib + Irinotecan,2016-01-11T00:57:03Z
0,2016-01-10T12:14:29Z,3379,[],Gedatolisib + Neratinib,2016-01-11T01:10:52Z
0,2016-10-05T02:28:17Z,4785,[],Gedatolisib + Paclitaxel + Carboplatin,2016-10-05T02:28:17Z
0,2016-04-29T19:33:21Z,4034,[],Gedatolisib + Palbociclib,2016-04-29T19:33:21Z
0,2017-08-14T16:02:55Z,6110,[],Gedatolisib + PF-06647020,2017-08-14T16:02:55Z
0,2014-03-12T15:53:16Z,751,"[{'description': 'Iressa (gefitinib) is a first-generation EGFR inhibitor, which is FDA approved for patients with non-small cell lung carcinoma, including those with EGFR exon 19 deletions and L858R exon 21 mutations (FDA.gov; PMID: 25302162).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 943, 'pubMedId': 25302162, 'title': 'Review of the current targeted therapies for non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25302162'}]}]",Gefitinib,2017-04-06T16:56:50Z
0,2017-09-21T15:05:30Z,6228,[],Gefitinib + GDC-0941,2017-09-21T15:06:16Z
0,2017-05-04T15:46:09Z,5610,[],Gefitinib + Golvatinib,2017-05-04T15:46:09Z
0,2015-03-30T16:55:36Z,2483,[],Gefitinib + Imatinib,2015-03-30T16:55:36Z
0,2016-11-15T17:45:33Z,4960,[],Gefitinib + IPA-3,2016-11-15T17:45:33Z
0,2016-04-27T14:26:54Z,4008,[],Gefitinib + Linsitinib,2016-04-27T14:26:54Z
0,2016-12-13T20:45:49Z,5095,[],Gefitinib + Linsitinib + PHA-665752,2016-12-13T20:45:49Z
0,2017-09-21T15:07:11Z,6229,[],Gefitinib + LY294002,2017-09-21T15:07:11Z
0,2016-12-21T16:44:20Z,5116,[],Gefitinib + NPS-1034,2016-12-21T16:44:20Z
0,2016-11-15T17:46:28Z,4961,[],Gefitinib + Obatoclax,2016-11-15T17:46:28Z
0,2017-05-05T03:21:55Z,5616,[],Gefitinib + Osimertinib,2017-05-05T03:21:55Z
0,2015-02-19T15:16:24Z,2108,[],Gefitinib + Pembrolizumab ,2015-02-19T15:16:24Z
0,2016-11-15T17:44:27Z,4959,[],Gefitinib + Perifosine,2016-11-15T17:44:27Z
0,2017-02-28T20:07:22Z,5391,[],Gefitinib + PF-431396,2017-02-28T20:07:22Z
0,2017-02-28T19:46:18Z,5389,[],Gefitinib + PF-573228,2017-02-28T19:46:18Z
0,2016-12-13T20:27:48Z,5094,[],Gefitinib + PHA-665752,2016-12-13T20:27:48Z
0,2015-10-16T00:06:26Z,3131,[],Gefitinib + PLX4720,2015-10-16T00:06:26Z
0,2016-12-06T18:56:02Z,5063,[],Gefitinib + Savolitinib,2017-07-12T17:27:36Z
0,2015-07-31T04:22:30Z,2986,[],Gefitinib + Sonidegib,2017-06-19T19:32:10Z
0,2016-04-04T16:43:14Z,3892,[],Gefitinib + Talniflumate,2016-04-04T16:43:14Z
0,2016-07-19T18:13:01Z,4481,[],Gefitinib + Trametinib,2016-07-19T18:13:01Z
0,2016-04-12T20:29:20Z,3921,[],Gefitinib + WZ4002,2016-04-12T20:29:20Z
0,2016-05-09T10:35:30Z,4092,"[{'description': 'Geldanamycin binds to and inhibits HSP90, potentially resulting in decreased tumor cell growth and increased tumor cell apoptosis  (PMID: 19850405, PMID: 11927289).', 'references': []}]",Geldanamycin,2016-05-18T16:57:37Z
0,2014-03-12T15:53:16Z,755,"[{'description': 'Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Gemcitabine,2017-03-22T17:48:21Z
0,2014-07-31T07:49:24Z,1297,[],Gemcitabine + Bevacizumab,2014-07-31T07:49:24Z
0,2014-07-31T07:33:21Z,1294,[],Gemcitabine + Bevacizumab + Carboplatin,2014-07-31T07:33:21Z
0,2014-07-31T07:45:09Z,1295,[],Gemcitabine + Bevacizumab + Cisplatin,2014-07-31T07:45:09Z
0,2014-07-31T07:48:22Z,1296,[],Gemcitabine + Bevacizumab + Oxaliplatin,2014-07-31T07:48:22Z
0,2015-01-15T16:53:27Z,1943,[],Gemcitabine + Carboplatin + Panitumumab,2015-01-15T16:53:27Z
0,2014-09-18T14:06:44Z,1467,[],Gemcitabine + Cisplatin,2014-09-18T14:06:44Z
0,2014-11-21T19:39:01Z,1742,[],gemcitabine + clofarabine + edelfosine,2014-11-21T19:39:01Z
0,2014-12-19T13:44:59Z,1816,[],Gemcitabine + Dasatinib + Erlotinib,2014-12-19T13:44:59Z
0,2014-09-11T03:30:25Z,1439,[],Gemcitabine + Docetaxel,2014-09-11T03:30:25Z
0,2014-09-18T14:53:25Z,1470,[],Gemcitabine + Docetaxel + Pazopanib,2014-09-18T14:53:25Z
0,2016-06-30T15:15:07Z,4403,[],Gemcitabine + GMI-1271,2016-06-30T15:15:07Z
0,2014-07-30T16:49:22Z,1269,[],Gemcitabine + GSK1120212,2014-07-30T16:49:22Z
0,2015-12-03T15:58:15Z,3259,[],Gemcitabine + Ibrutinib + Paclitaxel,2015-12-03T15:58:15Z
0,2015-04-10T15:05:34Z,2524,[],Gemcitabine + interferon + Mitomycin C + Valrubicin ,2015-04-10T15:05:34Z
0,2015-07-30T00:57:43Z,2970,[],Gemcitabine + Ipilimumab,2015-07-30T00:57:43Z
0,2016-09-01T13:42:04Z,4634,[],Gemcitabine + JQ1,2016-09-01T13:42:14Z
0,2017-09-06T15:27:46Z,6174,[],Gemcitabine + LY2603618,2017-09-06T15:27:46Z
0,2017-09-05T18:48:19Z,6168,[],Gemcitabine + LY2780301,2017-09-05T18:48:19Z
0,2016-06-06T19:39:51Z,4257,[],Gemcitabine + Masitinib,2016-06-06T19:39:51Z
0,2015-10-30T14:29:13Z,3163,[],Gemcitabine + MEDI4736 + nab-paclitaxel,2015-10-30T14:29:13Z
0,2015-02-27T17:27:08Z,2210,[],Gemcitabine + MEK162 + Oxaliplatin,2015-02-27T17:27:08Z
0,2017-09-06T13:12:54Z,6170,[],Gemcitabine + MK-8776,2017-09-06T13:12:54Z
0,2015-10-15T01:36:42Z,3128,[],Gemcitabine + Mocetinostat,2015-10-15T01:36:42Z
0,2017-09-08T17:44:12Z,6181,[],Gemcitabine + MU380,2017-09-08T17:44:12Z
0,2017-06-29T16:40:27Z,5940,[],Gemcitabine + Nab-Paclitaxel + mFOLFOX-6,2017-06-29T16:42:26Z
0,2016-06-06T15:41:22Z,4252,[],Gemcitabine + nab-paclitaxel + Necuparanib,2016-06-06T15:41:22Z
0,2017-07-28T19:16:08Z,6047,[],Gemcitabine + nab-paclitaxel + Nivolumab,2017-07-28T19:16:08Z
0,2016-06-22T02:15:08Z,4340,[],Gemcitabine + nab-paclitaxel + PF-04136309,2016-06-22T02:15:08Z
0,2015-04-22T03:19:33Z,2560,[],Gemcitabine + nab-paclitaxel + Selinexor,2015-04-22T03:19:33Z
0,2015-04-07T02:32:35Z,2497,[],Gemcitabine + nab-paclitaxel + Sonidegib,2017-06-19T19:30:48Z
0,2016-07-01T19:58:25Z,4412,[],Gemcitabine + nab-paclitaxel + Vantictumab,2016-07-01T19:58:25Z
0,2016-06-22T02:30:56Z,4342,[],Gemcitabine + nab-paclitaxel + VS-4718,2016-06-22T02:30:56Z
0,2017-05-05T18:54:16Z,5626,[],Gemcitabine + NC-6004,2017-05-05T18:54:16Z
0,2017-10-20T04:13:32Z,6340,[],Gemcitabine + Nimotuzumab,2017-10-20T04:13:32Z
0,2017-10-08T00:25:33Z,6297,[],Gemcitabine + Nivolumab,2017-10-08T00:25:33Z
0,2015-06-11T18:53:18Z,2823,[],Gemcitabine + ON01910,2015-06-11T18:53:18Z
0,2014-10-02T19:18:37Z,1611,[],Gemcitabine + Oxaliplatin + Dexamethasone,2014-10-02T19:18:37Z
0,2016-12-13T18:10:22Z,5090,[],Gemcitabine + Oxaliplatin + Rituximab,2016-12-13T18:10:22Z
0,2014-09-18T16:34:19Z,1478,[],Gemcitabine + Pazopanib,2014-09-18T16:34:19Z
0,2017-05-31T15:11:26Z,5821,[],Gemcitabine + Prexasertib,2017-08-22T19:11:53Z
0,2015-04-23T02:37:02Z,2566,[],Gemcitabine + Pri-724,2015-04-23T02:37:02Z
0,2016-05-09T16:55:32Z,4093,[],Gemcitabine + Radiotherapy,2016-05-09T16:55:32Z
0,2017-09-12T17:16:49Z,6205,[],Gemcitabine + Radiotherapy + VX-970,2017-09-12T17:16:49Z
0,2017-04-13T20:01:22Z,5545,[],Gemcitabine + Refametinib,2017-04-13T20:01:22Z
0,2015-04-03T14:45:17Z,2491,[],Gemcitabine + Regorafenib,2015-04-03T14:45:17Z
0,2015-07-10T15:16:04Z,2898,[],Gemcitabine + Ribociclib,2015-07-10T15:16:04Z
0,2016-12-08T16:54:46Z,5070,[],Gemcitabine + SRA737,2017-06-05T20:13:11Z
0,2017-03-15T18:09:45Z,5442,[],Gemcitabine + Tacedinaline,2017-03-15T18:09:45Z
0,2017-01-03T20:15:24Z,5148,[],Gemcitabine + TAK-659,2017-01-03T20:15:24Z
0,2015-01-03T21:55:19Z,1889,[],Gemcitabine + Trastuzumab,2015-01-03T21:55:19Z
0,2014-10-02T13:57:08Z,1592,[],Gemcitabine + Trastuzumab + Pertuzumab,2014-10-02T13:57:08Z
0,2014-03-12T15:53:16Z,756,"[{'description': 'Mylotarg (gemtuzumab ozogamicin) is comprised of an anti-CD33 antibody conjugated to the calicheamicin, which results in DNA damage in CD33-expressing tumor cells (PMID: 28607471). Mylotarg (gemtuzumab ozogamicin) is FDA approved for CD33-positive acute myeloid leukemia (FDA.gov).', 'references': [{'id': 9977, 'pubMedId': 28607471, 'title': 'Gemtuzumab ozogamicin in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28607471'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Gemtuzumab ozogamicin,2017-09-22T17:27:27Z
0,2014-03-12T15:53:16Z,757,"[{'description': 'Genistein binds to protein tyrosine kinase, inhibiting downstream signaling and promoting differentiation, and also inhibits topoisomerase leading to cell cycle arrest and apoptosis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Genistein,2014-11-21T03:55:36Z
0,2014-11-21T03:57:10Z,1734,[],Genistein + Decitabine,2014-11-21T03:57:10Z
0,2015-03-05T15:28:29Z,2293,"[{'description': 'GF109203X is a pan-protein kinase C (PKC) inhibitor which may result in the induction of apoptosis and regression of tumors (PMID: 1874734, PMID: 8826855).', 'references': [{'id': 2090, 'pubMedId': 1874734, 'title': 'The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/1874734'}, {'id': 2091, 'pubMedId': 8826855, 'title': 'Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/8826855'}]}]",GF109203X,2017-05-01T18:01:58Z
0,2014-05-14T14:52:46Z,1018,"[{'description': 'GI-4000 vaccine elicits an immune response by stimulating a specific cytotoxic T-cell response against the mutated forms of Ras (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",GI-4000,2016-02-08T23:30:28Z
0,2015-06-25T13:16:36Z,2865,"[{'description': 'Gilteritinib (ASP2215) is a small molecule inhibitor of FLT3 and AXL that has activity against FLT3-ITD, FLT3 F691L, and FLT3 D835 mutations, potentially resulting in decreased tumor growth (J Clin Oncol 32:5s, 2014 (suppl; abstr 7070), PMID: 25891481).', 'references': [{'id': 3121, 'pubMedId': 25891481, 'title': 'Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25891481'}, {'id': 3122, 'pubMedId': None, 'title': 'ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML)', 'url': 'http://meetinglibrary.asco.org/content/131170-144'}]}]",Gilteritinib,2017-03-16T16:11:08Z
0,2015-02-23T00:52:46Z,2129,"[{'description': 'Girentuximab is a monoclonal antibody that targets G250, an antigen expressed by renal cell carcinoma cells, with potential utility as a carrier for other therapeutic agents (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",girentuximab,2017-07-17T18:57:21Z
0,2015-05-12T14:49:42Z,2657,"[{'description': 'Givinostat (ITF2357) is a pan-HDAC inhibitor, which promotes cell-cycle arrest and apoptosis of tumor cells (PMID: 24648290).', 'references': [{'id': 2688, 'pubMedId': 24648290, 'title': 'Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24648290'}]}]",Givinostat,2015-05-12T14:49:42Z
0,2016-02-19T18:24:35Z,3576,"[{'description': 'GLA-SE is an immune adjuvant that binds to and activates toll-like receptor 4 (TLR4), leading to activation of innate immunity (PMID: 22147791).', 'references': [{'id': 4633, 'pubMedId': 22147791, 'title': 'GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22147791'}]}]",GLA-SE,2016-02-19T18:24:35Z
0,2016-03-31T18:14:15Z,3889,[],GLA-SE + MART-1 antigen,2016-03-31T18:14:15Z
0,2016-02-19T18:26:19Z,3577,[],GLA-SE + Pembrolizumab,2016-02-19T18:26:19Z
0,2016-04-06T20:54:19Z,3904,"[{'description': 'Glabrescione B is a compound that has inhibitory activity against both SMO and GLI1, resulting in decreased Hedgehog pathway signaling and potentially leading to decreased cell proliferation and tumor growth (PMID: 26666870).', 'references': [{'id': 5117, 'pubMedId': 26666870, 'title': 'Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26666870'}]}]",Glabrescione B,2016-04-06T21:06:57Z
0,2016-02-23T20:50:55Z,3597,"[{'description': 'Glembatumumab vedotin is a conjugate of human anti-glycoprotein NMB (GPNMB) antibody and the cytotoxic agent monomethyl auristatin E (MMAE), which induces cell death in Gpnmb-overexpressing tumor cells (PMID: 25847941).', 'references': [{'id': 4670, 'pubMedId': 25847941, 'title': 'EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847941'}]}]",Glembatumumab vedotin,2016-02-23T20:50:55Z
0,2015-06-03T20:30:34Z,2776,"[{'description': 'Solcitinib (GLPG0778) is a selective inhibitor of JAK1 (PMID: 25587654).', 'references': [{'id': 2928, 'pubMedId': 25587654, 'title': 'The JAK-STAT pathway: impact on human disease and therapeutic intervention.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25587654'}]}]",GLG0778,2015-06-04T14:52:02Z
0,2015-06-01T17:47:44Z,2752,"[{'description': 'Filgotinib (GLPG0634) is a selective JAK1 inhibitor, which may be efficacious in immune-inflammatory diseases (PMID: 24006460).', 'references': [{'id': 2876, 'pubMedId': 24006460, 'title': 'Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24006460'}]}]",GLPG0634,2015-06-04T10:17:56Z
0,2017-08-22T14:10:00Z,6139,"[{'description': 'GLS-010 targets PD-1 and inhibits the PD-L1/PD-1 immune checkpoint (PMID: 28679395).', 'references': [{'id': 9760, 'pubMedId': 28679395, 'title': 'Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28679395'}]}]",GLS-010,2017-08-22T14:48:36Z
0,2016-06-30T14:48:25Z,4402,"[{'description': 'GMI-1271 is a small molecule that binds to E-selectin and prevents E-selectin mediated cell-cell interaction, therefore, modulating inflammation and tumor progression (PMID: 26834953).', 'references': []}]",GMI-1271,2016-07-08T18:54:39Z
0,2017-05-11T18:29:52Z,5666,"[{'description': 'GMX1778 is an inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), which results in blockade of glycolysis, thereby potentially leading to growth inhibition of cancer cells (PMID: 27076630). ', 'references': [{'id': 8871, 'pubMedId': 27076630, 'title': 'Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27076630'}]}]",GMX1778,2017-05-11T18:29:52Z
0,2016-03-28T18:46:20Z,3856,"[{'description': 'GNE-317 is a dual PI3K/mTOR inhibitor that crosses the blood-brain barrier, resulting in decreased downstream signaling and potentially leading to reduced growth of tumors, including brain tumors (PMID: 22992516).', 'references': [{'id': 5039, 'pubMedId': 22992516, 'title': 'Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22992516'}]}]",GNE-317,2017-05-01T18:34:54Z
0,2015-05-11T19:57:40Z,2653,"[{'description': 'GNF-4256 inhibits TRK receptor activation, potentially resulting in decreased tumor growth (PMID: 25394774).', 'references': [{'id': 2684, 'pubMedId': 25394774, 'title': 'TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25394774'}]}]",GNF-4256,2015-05-14T17:32:18Z
0,2016-01-12T19:50:12Z,3407,[],GNF-4256 + Irinotecan + Temozolomide,2016-01-12T19:50:12Z
0,2014-12-30T20:07:38Z,1875,"[{'description': 'GNF-5837 is a small molecule inhibitor of tropomyosin receptor kinases NTRK1 (TRKA), NTRK2 (TRKB), and NTRK3 (TRKC), preventing proliferation of cancer cell models (PMID: 24900443).', 'references': [{'id': 1540, 'pubMedId': 24900443, 'title': 'Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24900443'}]}]",GNF-5837,2014-12-30T20:07:38Z
0,2015-03-10T16:08:17Z,2343,"[{'description': 'Go6976 binds and inhibits the calcium-dependent protein kinase C (PKC) isoforms, as well as Flt3, and mutant and wild-type Jak2, which may promote apoptosis and tumor regression (PMID: 8486620, PMID: 16956345).', 'references': [{'id': 2147, 'pubMedId': 8486620, 'title': 'Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/8486620'}, {'id': 2148, 'pubMedId': 16956345, 'title': 'Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16956345'}]}]",Go 6976,2017-04-26T16:18:08Z
0,2015-03-05T15:08:20Z,2290,"[{'description': 'Go 6983 is a pan protein kinase C (PKC) inhibitor, which may decrease tumor cell growth (PMID: 8772178, PMID: 23562764, PMID: 10209967).', 'references': [{'id': 2089, 'pubMedId': 16252018, 'title': 'Gö 6983: a fast acting protein kinase C inhibitor that attenuates myocardial ischemia/reperfusion injury.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16252018'}, {'id': 2087, 'pubMedId': 8772178, 'title': 'Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/8772178'}, {'id': 2088, 'pubMedId': 23562764, 'title': 'Upregulation of PKCη by PKCε and PDK1 involves two distinct mechanisms and promotes breast cancer cell survival.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23562764'}]}]",Go 6983,2017-05-01T18:19:23Z
0,2016-01-21T19:04:25Z,3426,"[{'description': 'GO-203-2C is a small peptide that binds to mucin at cell membrane, thereby blocking mucin homodimerization and downstream signaling, which leads to antitumor effects (PMID: 26267657).', 'references': [{'id': 4402, 'pubMedId': 26267657, 'title': 'Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267657'}]}]",GO-203-2C,2016-01-28T02:10:01Z
0,2014-05-14T14:52:46Z,1019,"[{'description': 'Golvatinib (E7050) is a dual kinase inhibitor of c-Met and KDR (VEGFR2), which inhibits cell growth and proliferation (PMID: 25458359).  ', 'references': [{'id': 4337, 'pubMedId': 25458359, 'title': 'Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25458359'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Golvatinib,2017-05-04T14:04:03Z
0,2014-03-12T15:53:16Z,758,"[{'description': 'Gonadorelin is a synthetic version of gonatotropin-releasing hormone (GnRH) that binds GnRH receptors and induces gonatotropic hormone release, and leads to down-regulation of GnRH receptor expression and reduced hormone release following sustained exposure (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Gonadorelin,2017-05-22T20:01:39Z
0,2014-03-12T15:53:16Z,759,"[{'description': 'Zoladex (goserelin) is a synthetic analog of lutenizing hormone-releasing hormone, which causes decreased testosterone production in males and decreased estradiol production in females (NCI Drug Dictionary). Zoladex (goserelin) is FDA approved for use in prostate carcinoma (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Goserelin,2016-06-30T19:23:55Z
0,2014-09-25T18:37:32Z,1548,[],Goserelin + MK2206,2014-09-25T18:37:32Z
0,2015-02-11T14:31:20Z,2041,"[{'description': 'GPX-150 is a doxorubicin analogue that intercalates DNA and leads to apoptosis in tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",GPX-150,2015-02-11T14:31:20Z
0,2015-07-30T02:11:31Z,2975,"[{'description': 'GR-MD-02 is a galectin inhibitor, which leads to apoptosis in galectin over expressing cells (PMID: 24130706).', 'references': [{'id': 3358, 'pubMedId': 24130706, 'title': 'Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24130706'}]}]",GR-MD-02,2015-10-21T14:33:10Z
0,2015-02-11T18:15:00Z,2053,"[{'description': 'GRN1005 consists of paclitaxel bound to a peptide that binds LRP-1, which allows the drug-peptide conjugate to cross the blood-brain barrier and delivers paclitaxel to LRP-1 expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",GRN1005,2015-02-11T18:15:00Z
0,2016-01-14T17:24:04Z,3416,"[{'description': 'GS-493 is an inhibitor of Shp2, which may result in decreased cell growth and inhibition of tumor growth (PMID: 25877780).', 'references': [{'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]}]",GS-493,2016-01-14T17:24:04Z
0,2015-12-21T03:11:48Z,3320,"[{'description': 'GS-5745 is a monoclonal antibody  that binds to and inhibits matrix metalloproteinase 9 (MMP-9), which may leads to inhibition of matrix degradation and tumor metastasis (PMID: 25961845).', 'references': [{'id': 4141, 'pubMedId': 25961845, 'title': 'Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25961845'}]}]",GS-5745,2015-12-29T17:11:23Z
0,2016-09-21T17:04:30Z,4736,[],GS-5745 + Nivolumab,2016-09-21T17:04:30Z
0,2017-02-02T18:16:03Z,5276,"[{'description': 'GS-5829 is a BET bromodomain inhibitor, potentially resulting in inhibition of cell growth and apoptotic activity (Blood 2016 128:5104). ', 'references': [{'id': 7727, 'pubMedId': None, 'title': 'Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines', 'url': 'http://www.bloodjournal.org/content/128/22/5104?sso-checked=true'}]}]",GS-5829,2017-03-17T16:24:16Z
0,2016-02-19T14:51:00Z,3561,"[{'description': 'Limited information is currently available GS-5829, a putative BET inhibitor (Jun, 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",GS-5829 + Exemestane,2016-12-11T05:01:42Z
0,2016-12-11T05:02:44Z,5074,[],GS-5829 + Fulvestrant,2016-12-11T05:02:44Z
0,2017-02-02T18:38:17Z,5277,[],GS-5829 + Venetoclax,2017-02-02T18:38:17Z
0,2014-05-14T14:52:46Z,1020,"[{'description': 'Simtuzumab (GS-6634) is a humanized monoclonal antibody against lysyl oxidase-like 2 (LOXL2), with potential antineoplastic activity (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",GS-6634,2015-04-10T16:34:16Z
0,2014-05-14T14:52:46Z,1021,"[{'description': 'Acalisib (GS-9820) is a selective PI3K-delta inhibitor that may affect cell survival and differentiation (PMID: 24133210).', 'references': [{'id': 4810, 'pubMedId': 24133210, 'title': 'Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24133210'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",GS-9820,2016-03-16T18:58:50Z
0,2016-07-15T01:38:21Z,4454,"[{'description': 'GS87 inhibits GSK3, resulting in decreased downstream signaling and increased differentiation and reduced growth of acute myeloid leukemia cells (PMID: 27196775).', 'references': [{'id': 6309, 'pubMedId': 27196775, 'title': 'A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196775'}]}]",GS87,2016-07-15T01:38:21Z
0,2014-10-24T11:49:58Z,1662,"[{'description': 'GSI-18 is a small molecule compound that binds and inhibits Gamma-secretase inhibiting its activity on downstream targets including NOTCH signaling proteins thus blocking pathway activation in cancer (PMID: 15603957).', 'references': [{'id': 970, 'pubMedId': 15603957, 'title': 'A novel series of potent gamma-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15603957'}]}]",GSI-18,2016-07-15T14:19:07Z
0,2016-02-12T08:26:02Z,3525,"[{'description': 'GSK-J4 is a specific inhibitor of KDM6, which results in increased H3K27 tri-methylation and induction of DNA damage response and cell death (PMID: 22842901, PMID: 26759175).', 'references': [{'id': 4570, 'pubMedId': 22842901, 'title': 'A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22842901'}, {'id': 4524, 'pubMedId': 26759175, 'title': 'Inhibition of KDM6 activity during murine ESC differentiation induces DNA damage.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26759175'}]}]",GSK-J4,2016-02-12T08:26:02Z
0,2017-09-12T16:08:39Z,6203,[],GSK-J4 + PKF118-310,2017-09-12T16:08:39Z
0,2015-03-02T19:26:42Z,2248,"[{'description': 'GSK1059615 is a dual pan-PI3K/mTOR inhibitor, which prevents cell proliferation (PMID: 24900173).', 'references': [{'id': 1819, 'pubMedId': 24900173, 'title': 'Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24900173'}]}]",GSK1059615,2017-05-01T18:33:57Z
0,2014-03-12T15:53:16Z,760,"[{'description': 'GSK1070916 is a selective inhibitor of Aurora B/C kinases, which induces inhibition of tumor cell proliferation in culture and in xenograft models (PMID: 19567821).', 'references': [{'id': 1801, 'pubMedId': 19567821, 'title': 'GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19567821'}]}]",GSK1070916,2017-04-04T14:09:34Z
0,2014-07-28T23:19:21Z,1191,[],GSK1120212 + Dabrafenib,2014-07-28T23:19:21Z
0,2014-07-28T13:20:15Z,1150,[],GSK1120212 + GSK2141795,2014-07-28T13:20:15Z
0,2015-07-16T18:30:14Z,2925,"[{'description': 'GSK126 selectively inhibits EZH2, which may result in decreased tumor cell proliferation and reduced tumor growth (PMID: 25686104).', 'references': [{'id': 3263, 'pubMedId': 25686104, 'title': 'Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25686104'}]}]",GSK126,2015-10-01T02:51:53Z
0,2015-05-29T03:32:14Z,2739,"[{'description': 'GSK1838705A inhibits IGF-1R, potentially leading to increased apoptosis and reduced tumor growth (PMID: 25926740).', 'references': [{'id': 2849, 'pubMedId': 25926740, 'title': 'GSK1838705A, an insulin-like growth factor-1 receptor/insulin receptor inhibitor, induces apoptosis and reduces viability of docetaxel-resistant prostate cancer cells both in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25926740'}]}]",GSK1838705A,2015-05-29T03:32:14Z
0,2015-05-29T04:19:33Z,2743,"[{'description': 'GSK1904529A inhibits IGF-IR and IR, resulting in cell-cycle arrest and decreased tumor growth (PMID: 19383820).', 'references': [{'id': 2857, 'pubMedId': 19383820, 'title': 'Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19383820'}]}]",GSK1904529A,2015-05-29T04:19:33Z
0,2014-03-12T15:53:16Z,763,"[{'description': 'GSK2126458 is a dual pan-PI3K and mTOR inhibitor, which blocks PI3K/AKT signaling to prevent cell proliferation (PMID: 24900173).', 'references': [{'id': 1819, 'pubMedId': 24900173, 'title': 'Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24900173'}]}]",GSK2126458,2015-04-02T23:51:12Z
0,2015-08-14T02:37:08Z,3027,[],GSK2126458 + Trametinib,2015-08-14T02:37:08Z
0,2014-03-12T15:53:16Z,764,"[{'description': 'Uprosertib (GSK2141795) is an ATP-competitive inhibitor of AKT, which leads to inhibition of PI3K/AKT signaling potentially resulting in inhibition of cell proliferation and anti-tumor growth (PMID: 24978597). ', 'references': [{'id': 962, 'pubMedId': 24978597, 'title': 'Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24978597'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",GSK2141795,2017-03-17T18:24:48Z
0,2016-01-08T19:24:48Z,3374,[],GSK2141795 + Cisplatin,2016-01-08T19:24:48Z
0,2016-03-15T15:39:58Z,3741,"[{'description': 'GSK2194069 is a fatty acid synthase inhibitor that suppresses tumor cell growth in culture (PMID: 25086508).', 'references': [{'id': 4863, 'pubMedId': 25086508, 'title': 'A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25086508'}]}]",GSK2194069,2016-03-15T15:39:58Z
0,2016-04-19T19:32:08Z,3962,[],GSK2194069 + Palbociclib,2016-04-19T19:32:08Z
0,2015-09-06T21:53:32Z,3078,"[{'description': 'GSK2256098 is an inhibitor of focal adhesion kinase (FAK), which blocks integrin signaling and therefore, has antitumor activities (PMID: 21787277).', 'references': [{'id': 3604, 'pubMedId': 21787277, 'title': 'Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21787277'}]}]",GSK2256098,2016-02-23T20:13:58Z
0,2016-04-06T12:26:03Z,3898,[],GSK2256098 + Cisplatin,2016-04-06T12:26:03Z
0,2016-04-06T12:23:30Z,3896,[],GSK2256098 + Paclitaxel,2016-04-06T12:23:30Z
0,2016-04-06T12:24:29Z,3897,[],GSK2256098 + Topotecan,2016-04-06T12:24:29Z
0,2016-06-02T19:28:00Z,4205,[],GSK2256098 + Trametinib,2016-06-02T19:28:00Z
0,2016-03-01T18:29:00Z,3662,"[{'description': 'GSK2334470 is a small molecule inhibitor of PDPK1, which subsequently results in suppression of Akt and may result in antiproliferative activity (Cancer Res April 15, 2010 70; LB-116). ', 'references': [{'id': 4753, 'pubMedId': None, 'title': 'Abstract LB-116: GSK2334470: A potent and highly selective inhibitor of PDK1', 'url': 'http://cancerres.aacrjournals.org/content/70/8_Supplement/LB-116.short'}]}]",GSK2334470,2016-03-01T18:29:00Z
0,2017-09-12T13:44:40Z,6201,[],GSK2334470 + Idelalisib ,2017-09-12T13:44:40Z
0,2017-06-28T16:51:35Z,5936,[],GSK2334470 + Osimertinib,2017-06-28T16:51:35Z
0,2016-04-19T19:22:05Z,3959,[],GSK2334470 + Palbociclib,2016-04-19T19:22:05Z
0,2014-03-12T15:53:16Z,765,"[{'description': 'GSK2636771 is a selective inhibitor of PIK3CB, which potentially increases apoptosis and decreases growth in tumors expressing PI3K beta (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",GSK2636771,2015-02-08T10:59:46Z
0,2016-05-03T17:15:14Z,4052,[],GSK2636771 + Binimetinib,2016-05-03T17:15:53Z
0,2016-05-03T17:25:38Z,4055,[],GSK2636771 + LGX818,2016-05-03T17:25:38Z
0,2016-05-03T19:14:13Z,4069,[],GSK2636771 + LGX818 + unspecified IGF-1R antibody,2016-05-03T19:14:13Z
0,2016-05-03T16:17:22Z,4045,[],GSK2636771 + NVP-AEW541,2016-05-03T16:17:22Z
0,2016-02-11T20:05:37Z,3518,[],GSK2636771 + Pembrolizumab,2016-02-11T20:05:37Z
0,2016-05-03T19:12:47Z,4067,[],GSK2636771 + unspecified IGF-1R antibody,2016-05-03T19:12:47Z
0,2017-05-15T16:46:43Z,5673,[],GSK2636771 + unspecified PD-1 antibody,2017-05-15T16:46:43Z
0,2015-05-28T14:05:10Z,2734,"[{'description': 'GSK2816126 inhibits EZH2, resulting in decreased histone methylation and reduced tumor cell proliferation (PMID: 23016851).', 'references': [{'id': 2823, 'pubMedId': 23016851, 'title': 'Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23016851'}]}]",GSK2816126,2015-05-28T14:05:10Z
0,2016-03-14T19:31:26Z,3735,"[{'description': 'GSK2830371 is an allosteric, small molecule inhibitor of PPM1D, which results in increased phosphorylation Ppm1d substrates and may result in tumor growth inhibition (PMID: 24390428). ', 'references': [{'id': 4845, 'pubMedId': 24390428, 'title': 'Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24390428'}]}]",GSK2830371,2016-03-14T19:31:26Z
0,2016-03-15T14:07:26Z,3736,[],GSK2830371 + Nutlin-3,2016-03-15T14:07:26Z
0,2016-03-15T14:10:21Z,3737,[],GSK2830371 + RG7388,2016-03-15T14:10:21Z
0,2015-07-14T01:58:57Z,2919,"[{'description': 'GSK2849330 is a monoclonal antibody that targets HER3 (ERBB3), potentially resulting in decreased proliferation of HER3-expressing tumors (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",GSK2849330,2015-07-14T01:58:57Z
0,2015-08-12T02:38:36Z,3014,"[{'description': 'GSK2879552 binds to and inhibits lysine specific demethylase 1 (LSD1), thereby suppressing tumor cell proliferation (PMID: 26175415).', 'references': [{'id': 3430, 'pubMedId': 26175415, 'title': 'A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26175415'}]}]",GSK2879552 ,2015-09-09T02:26:45Z
0,2015-07-10T15:27:46Z,2899,"[{'description': 'GSK3052230 (FP-1039) is an FGF ligand trap which prevents FGF1, FGF2, and FGF4 from binding corresponding receptors thereby preventing downstream signaling and activation (PMID: 26078430).', 'references': [{'id': 3211, 'pubMedId': 26078430, 'title': 'Targeting FGFR Signaling in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26078430'}]}]",GSK3052230,2017-07-13T20:42:05Z
0,2017-01-09T20:24:51Z,5177,"[{'description': 'GSK3174998 is a antibody that targets OX40, which may result in enhanced antitumor immune response (Cancer Res July 15 2016 (76) (14 Supplement) CT027).', 'references': [{'id': 7512, 'pubMedId': None, 'title': 'Abstract CT027: A phase I, open-label study of GSK3174998 administered alone and in combination with pembrolizumab in patients (pts) with selected advanced solid tumors (ENGAGE-1)', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/CT027'}]}]",GSK3174998,2017-01-09T20:24:51Z
0,2016-09-14T15:21:23Z,4712,"[{'description': 'GSK3178022 is an antibody that targets LRP6 and blocks both Wnt binding domains, resulting in decreased Wnt-mediated signaling and potentially leading to decreased tumor growth (PMID: 27401612). ', 'references': [{'id': 6625, 'pubMedId': 27401612, 'title': 'Novel Bispecific Domain Antibody to LRP6 Inhibits Wnt and R-spondin Ligand-Induced Wnt Signaling and Tumor Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27401612'}]}]",GSK3178022,2016-09-14T15:21:23Z
0,2016-07-01T17:27:45Z,4409,"[{'description': 'GSK3359609 is an antibody that binds to the inducible T-cell co-stimulator, resulting in stimulation of T-cell proliferation and immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",GSK3359609,2016-07-01T17:27:45Z
0,2016-07-01T17:28:59Z,4410,[],GSK3359609 + Pembrolizumab,2016-07-01T17:28:59Z
0,2015-05-15T18:01:59Z,2701,"[{'description': 'GSK343 is an inhibitor of EZH2, which blocks methylation of H3K27 and may promote apoptosis in tumor cells (PMID: 23759589).', 'references': [{'id': 2699, 'pubMedId': 23023262, 'title': 'A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23023262'}, {'id': 2802, 'pubMedId': 23759589, 'title': 'Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23759589'}]}]",GSK343,2015-05-21T21:38:52Z
0,2016-09-23T18:00:43Z,4751,[],GSK343 + MK2206,2016-09-23T18:00:43Z
0,2016-09-23T17:57:43Z,4750,[],GSK343 + Selumetinib,2016-09-23T17:57:43Z
0,2014-03-12T15:53:16Z,766,"[{'description': 'GSK461364 is a specific ATP-competitive inhibitor of PLK1 that induces mitotic arrest, leading to cell death in many cancer cell lines (PMID: 19474163).', 'references': [{'id': 1021, 'pubMedId': 19474163, 'title': 'Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19474163'}]}]",GSK461364,2015-06-08T17:25:16Z
0,2014-09-19T08:44:46Z,1511,[],GSK461364 + PD0332991,2014-09-19T08:44:46Z
0,2014-03-12T15:53:16Z,784,"[{'description': 'GSK525762 is a JQ1 derivative which binds to the bromodomain of BET proteins preventing their interaction with acetylated histone peptides, thus disrupting chromatin remodeling, gene expression, and cell proliferation (PMID: 24015967).', 'references': [{'id': 8266, 'pubMedId': 24015967, 'title': 'Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24015967'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",GSK525762,2017-03-17T16:29:29Z
0,2017-01-21T05:16:21Z,5242,[],GSK525762 + Fulvestrant,2017-01-21T05:16:21Z
0,2017-04-27T19:15:59Z,5585,[],GSK525762 + Selumetinib,2017-04-27T19:15:59Z
0,2017-04-06T20:02:31Z,5507,"[{'description': 'GSK690 is a reversible inhibitor of KDM1A, which potentially reduces tumor cell growth (PMID: 26837761).', 'references': [{'id': 8467, 'pubMedId': 26837761, 'title': 'Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26837761'}]}]",GSK690,2017-06-16T15:53:09Z
0,2015-08-31T13:43:13Z,3073,"[{'description': 'GSK690693 is a ATP-competitive pan-AKT inhibitor, which inhibits AKT signaling, resulting in decreased proliferation and increased  apoptosis of tumor cells (PMID: 18381444).', 'references': [{'id': 3576, 'pubMedId': 18381444, 'title': 'Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18381444'}]}]",GSK690693,2015-08-31T13:43:13Z
0,2017-01-24T18:09:09Z,5247,"[{'description': 'GTCpFE is a prodrug of acetylsalicylic acid (aspirin), which inhibits the activity of NF-kappa B, potentially leading to decreased tumor cell viability and a reduction in cancer stem cells (PMID: 26530254).', 'references': [{'id': 7653, 'pubMedId': 26530254, 'title': 'A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26530254'}]}]",GTCpFE,2017-01-24T18:09:09Z
0,2015-03-02T14:32:42Z,2230,"[{'description': 'GTP-14564 is a selective inhibitor of FLT3, c-Fms, c-Kit, and PDGFR-beta, which may result in reduced downstream signaling and subsequent reductions in cell proliferation and tumor growth (PMID: 12815052).', 'references': [{'id': 2061, 'pubMedId': 12815052, 'title': 'Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12815052'}]}]",GTP-14564,2015-11-20T04:01:19Z
0,2015-05-14T17:00:01Z,2675,"[{'description': 'GTx-186 inhibits ROS1 and TRKA, potentially resulting in decreased growth of ROS1 and TRKA over expressing tumors (PMID: 24386191).', 'references': [{'id': 2718, 'pubMedId': 24386191, 'title': 'Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24386191'}]}]",GTx-186,2017-01-18T17:04:03Z
0,2015-07-30T03:08:36Z,2977,"[{'description': 'GVAX colorectal cancer vaccine is composed of irradiated colorectal cancer (CRC) cells engineered to express GM-CSF, which induces T-cell response against CRC cells (PMID: 24832153).', 'references': [{'id': 3360, 'pubMedId': 24832153, 'title': 'Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24832153'}]}]",GVAX colorectal cancer vaccine,2015-07-30T03:08:36Z
0,2015-05-08T13:46:00Z,2642,"[{'description': 'GVAX pancreatic cancer vaccine is composed of irradiated pancreatic ductal adenocarcinoma (PDA) cells engineered to express GM-CSF, which induces T-cell response against PDA cells (PMID: 21217520).', 'references': [{'id': 2672, 'pubMedId': 21217520, 'title': 'A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21217520'}]}]",GVAX pancreatic cancer vaccine  ,2015-06-26T02:23:36Z
0,2015-06-18T13:59:31Z,2836,"[{'description': 'GW2580 is an ATP-competitive selective inhibitor of CSF-1R, which may lead to decreased tumor cell growth (PMID: 16249345, PMID: 23372702).', 'references': [{'id': 3069, 'pubMedId': 16249345, 'title': 'Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16249345'}, {'id': 3070, 'pubMedId': 23372702, 'title': 'Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23372702'}]}]",GW2580,2015-06-18T13:59:31Z
0,2014-09-25T06:17:47Z,1533,"[{'description': 'GW441756 is a selective inhibitor of TrkA and blocks cellular processes caused by TrkA overexpression (PMID: 23319303).', 'references': [{'id': 824, 'pubMedId': 23319303, 'title': 'Proteomic analysis of novel targets associated with TrkA-mediated tyrosine phosphorylation signaling pathways in SK-N-MC neuroblastoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23319303'}]}]",GW441756,2014-09-25T06:17:47Z
0,2016-01-08T20:07:42Z,3375,"[{'description': 'GW5074 inhibits C-Raf resulting in decreased downstream signaling, and potentially leading to reduced tumor cell growth (PMID: 16546979, PMID: 19737955).', 'references': [{'id': 4257, 'pubMedId': 16546979, 'title': 'Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16546979'}, {'id': 4258, 'pubMedId': 19737955, 'title': 'C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19737955'}]}]",GW5074,2016-01-08T20:07:42Z
0,2016-01-08T20:57:07Z,3376,[],GW5074 + Sorafenib,2016-01-08T20:57:07Z
0,2015-06-05T16:31:36Z,2805,"[{'description': 'GW843682X is an inhibitor of Plk1, resulting in inhibition of cell growth (PMID: 21637161).', 'references': [{'id': 2978, 'pubMedId': 21637161, 'title': 'An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21637161'}]}]",GW843682X,2015-06-08T17:24:14Z
0,2016-03-21T18:20:53Z,3795,[],GW843682X + Vincristine,2016-03-21T18:20:53Z
0,2016-07-19T00:18:57Z,4468,"[{'description': 'GWN 323 is a monoclonal antibody binds to and activates glucocorticoid-induced tumor necrosis factor receptor, resulting in activation of anti-tumor immunity (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",GWN 323,2016-07-19T00:18:57Z
0,2016-07-19T00:20:44Z,4469,[],GWN 323 + PDR001,2016-07-19T00:20:44Z
0,2016-05-26T20:48:09Z,4149,"[{'description': 'GZD856 inhibits PDGFRA and PDGFRB, potentially resulting in decreased tumor growth (PMID: 26940138).', 'references': []}]",GZD856,2016-05-26T20:48:09Z
0,2017-09-01T17:25:12Z,6150,"[{'description': 'H3B-6545 is a Selective Estrogen Receptor Covalent Antagonist (SERCA) that targets both wild-type and mutant ESR1, and may result in antitumor activity (Cancer Res 2017;77(13 Suppl):Abstract nr DDT01-04).', 'references': [{'id': 9849, 'pubMedId': None, 'title': 'Abstract DDT01-04: Discovery and development of H3B-6545: A novel, oral, selective estrogen receptor covalent antagonist (SERCA) for the treatment of breast cancer', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/DDT01-04'}]}]",H3B-6545,2017-09-01T17:25:12Z
0,2015-12-11T17:35:57Z,3289,"[{'description': 'HA14-1 is a BCL2 antagonist, which may induce tumor cell apoptosis and increase sensitivity to chemotherapeutics (PMID: 16510597, PMID: 16213584).\r\n', 'references': [{'id': 4099, 'pubMedId': 16213584, 'title': 'HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16213584'}, {'id': 4098, 'pubMedId': 16510597, 'title': 'The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16510597'}]}]",HA14-1,2015-12-11T17:35:57Z
0,2015-12-21T17:35:10Z,3324,"[{'description': 'Harmine is an ATP-competitive inhibitor of DYRK1A, which may result in repression of cell self-renewal and inhibition of tumor growth and survival (PMID: 23635774). ', 'references': [{'id': 4144, 'pubMedId': 23635774, 'title': 'Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23635774'}]}]",Harmine,2015-12-22T20:33:48Z
0,2016-04-27T18:22:21Z,4011,"[{'description': 'HD105 is a bi-specific antibody that targets VEGF and DLL4, resulting in decreased ligand-receptor binding and potentially leading to reduced tumor progression (PMID: 27049350).', 'references': [{'id': 5258, 'pubMedId': 27049350, 'title': 'Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27049350'}]}]",HD105,2017-07-13T18:25:36Z
0,2015-07-10T16:45:25Z,2902,"[{'description': 'HD125 is an immunoadhesin that binds MUC16 (CA125) and prevents interaction with mesothelin, as well as inducing an immune response against MUC16-expressing tumor cells, potentially resulting in increased tumor cell death (PMID: 21611109).', 'references': [{'id': 3212, 'pubMedId': 21611109, 'title': 'HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21611109'}]}]",HD125,2015-07-10T16:45:25Z
0,2015-02-27T04:41:50Z,2186,"[{'description': 'HDM201 binds to MDM2 and inhibits its interaction with p53, which prevents p53 degradation and potentially leads to restoration of p53 signaling and increased tumor cell death (NCI Drug Dictionary).\r\n', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",HDM201,2015-02-27T04:41:50Z
0,2015-03-27T13:52:32Z,2481,[],HDM201 + LEE011,2015-03-27T13:52:32Z
0,2016-07-07T16:11:59Z,4424,"[{'description': 'Hemay022 inhibits EGFR, potentially resulting in decreased growth of EGFR over expressing tumors (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Hemay022,2016-07-07T16:11:59Z
0,2014-09-25T20:54:02Z,1555,"[{'description': 'HER-2/neu intracellular domain protein is the cytoplasmic domain of the Her-2 protein, which may enhance the T-cell response against Her-2 expressing tumor cells when administered with trastuzumab (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",HER-2/neu intracellular domain protein ,2015-04-10T16:34:47Z
0,2014-09-25T20:56:16Z,1556,[],HER-2/neu intracellular domain protein + Trastuzumab ,2014-09-25T20:56:16Z
0,2014-09-26T02:16:57Z,1558,[],HER-2/neu intracellular domain protein + Trastuzumab + Polysaccharide-K,2014-09-26T02:16:57Z
0,2017-07-25T21:03:14Z,6007,"[{'description': 'HER2 CAR-T cells are T-cells that are modified to express a chimeric antigen receptor recognizing ERBB2 (HER2), which may result in increased death of ERBB2 (HER2)-expressing tumor cells upon infusion (PMID: 25800760, PMID: 25711536).', 'references': [{'id': 9563, 'pubMedId': 25800760, 'title': 'Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25800760'}, {'id': 9564, 'pubMedId': 25711536, 'title': 'CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25711536'}]}]",HER2 CAR-T cells,2017-07-25T21:03:14Z
0,2015-07-21T15:42:53Z,2940,"[{'description': 'HER2 sensitized T-cells are autologous T-cells that have been sensitized to HER2 antigen, potentially resulting in increased immune response against HER2-expressing tumor cells upon transplantation (PMID: 24162107, PMID: 20068073).', 'references': [{'id': 3287, 'pubMedId': 24162107, 'title': 'HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24162107'}, {'id': 3288, 'pubMedId': 20068073, 'title': 'HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20068073'}]}]",HER2 sensitized T-cells,2015-07-21T15:42:53Z
0,2014-08-27T18:19:16Z,1404,"[{'description': 'A variety of ERBB2 (HER2) vaccines are under development and are designed to stimulate active immunity against tumor cells overexpressing ERBB2 (HER2) (PMID: 23585514).', 'references': [{'id': 595, 'pubMedId': 23585514, 'title': 'Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23585514'}]}]",HER2 Vaccine,2017-07-20T16:56:30Z
0,2017-01-16T21:12:33Z,5222,"[{'description': 'HER2-pulsed DC1 vaccine is a cancer vaccine comprising patient-derived dendritic cells exposed to ERBB2 (HER2)-derived peptides, which potentially enhances anti-tumor immune response against ERBB2 (HER2)-expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",HER2-pulsed DC1 vaccine,2017-07-20T16:56:48Z
0,2016-08-18T14:02:12Z,4583,"[{'description': 'Hertuzumab-vc-MMAE is an antibody-drug conjugate comprising a monoclonal antibody that targets HER2 (Hertuzumab) linked to the cytotoxic drug MMAE, which delivers the cytotoxic agent to HER2-expressing tumor cells, potentially resulting in increased cell death (PMID: 27509865).', 'references': [{'id': 6501, 'pubMedId': 27509865, 'title': 'HER2-targeted antibody drug conjugates for ovarian cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27509865'}]}]",Hertuzumab-vc-MMAE,2016-08-18T14:02:12Z
0,2016-04-19T18:21:58Z,3954,"[{'description': 'Hexamethylene bisacetamide is a polar-planar compound that inhibits BET through BD2 binding, resulting in growth inhibition and apoptosis in tumor cells (PMID: 26941288).', 'references': [{'id': 5180, 'pubMedId': 26941288, 'title': 'Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26941288'}]}]",hexamethylene bisacetamide,2017-03-17T18:26:51Z
0,2015-02-02T22:05:27Z,2002,"[{'description': 'HF10 is a spontaneous herpes simplex virus (HSV) type I mutant variant, which is capable of infecting and lysing tumor cells, and may also lead to non-infected tumor cell death by increasing host immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",HF10,2015-02-02T22:07:41Z
0,2015-02-02T22:09:55Z,2003,[],HF10 + Ipilimumab,2015-02-02T22:10:09Z
0,2017-09-01T16:34:38Z,6149,[],HF10 + Nivolumab,2017-09-01T16:34:38Z
0,2016-03-16T20:26:31Z,3762,"[{'description': 'HG-6-63-01 inhibits RET, resulting in decreased downstream signaling and reduced tumor cell proliferation (PMID: 26046350).\r\n', 'references': [{'id': 4887, 'pubMedId': 26046350, 'title': 'Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26046350'}]}]",HG-6-63-01,2017-04-03T14:28:27Z
0,2016-02-26T20:30:07Z,3647,"[{'description': 'HGS1029 inhibits Inhibitor of Apoptosis Protein (IAP) family proteins, potentially overcoming resistance to apoptosis in combination with cytotoxic agents (PMID: 28039268).', 'references': [{'id': 9601, 'pubMedId': 28039268, 'title': 'Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28039268'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",HGS1029,2017-07-27T18:06:59Z
0,2015-02-11T16:22:48Z,2047,"[{'description': 'Histrelin acetate is an analog of gonadotropin-releasing hormone (GnRH), which binds to and activates GnRH receptors, resulting in reduced testosterone production in males, and thus may inhibit growth of androgen-receptor positive tumors (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Histrelin acetate,2015-02-11T16:30:48Z
0,2017-09-11T18:55:48Z,6198,"[{'description': 'HKT288 is an antibody-drug conjugate comprising a human antibody targeting cadherin-6 (CDH6) linked to a maytansine-derived drug, which delivers the cytotoxic agent to CDH6-expressing tumor cells, potentially resulting in decreased tumor growth (PMID: 28526733).', 'references': [{'id': 9886, 'pubMedId': 28526733, 'title': 'Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28526733'}]}]",HKT288,2017-09-11T18:55:48Z
0,2016-04-15T16:36:39Z,3938,"[{'description': 'Limited information is currently available on HLX07, a putative EGFR antibody (Apr 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",HLX07,2016-04-15T16:36:39Z
0,2016-09-26T20:11:03Z,4765,"[{'description': 'HM-3 is a synthetic peptide derived from endostatin, which targets integrin alpha v beta 3, possibly resulting in inhibition of angiogenesis and tumor growth (PMID: 27633584). ', 'references': [{'id': 6675, 'pubMedId': 27633584, 'title': 'In vitro and in vivo activities of an antitumor peptide HM-3: A special dose-efficacy relationship on an HCT‑116 xenograft model in nude mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27633584'}]}]",HM-3,2016-09-26T20:11:03Z
0,2015-05-15T02:20:07Z,2692,"[{'description': 'HM-71224 is a small molecule inhibitor of BTK (PMID: 23958373).', 'references': [{'id': 2731, 'pubMedId': 23958373, 'title': 'Ibrutinib and novel BTK inhibitors in clinical development.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23958373'}]}]",HM-71224,2015-05-15T02:20:07Z
0,2015-02-23T17:35:17Z,2137,"[{'description': 'BI 1482694 (HM61713) is a third-generation EGFR inhibitor that inhibits activating mutations in EGFR, including those occurring with T790M, and spares wild-type EGFR, potentially resulting in decreased tumor growth (PMID: 25027951, PMID: 25521095).', 'references': [{'id': 1963, 'pubMedId': 25027951, 'title': 'Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25027951'}, {'id': 1845, 'pubMedId': 25521095, 'title': 'The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25521095'}]}]",HM61713,2016-01-05T15:08:16Z
0,2014-09-19T09:04:56Z,1513,"[{'description': 'HMN-214 is a prodrug of the active agent HMN-176, which interferes with the location of PLK1, leading to cell cycle arrest, destruction of the spindle polar bodies, and DNA fragmentation (PMID: 19474163).', 'references': [{'id': 1021, 'pubMedId': 19474163, 'title': 'Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19474163'}]}]",HMN-214,2015-06-08T17:26:09Z
0,2014-09-19T09:06:31Z,1514,[],HMN-214 + PD0332991,2014-09-19T09:06:31Z
0,2016-03-03T10:50:29Z,3670,"[{'description': 'Limited information is currently available on HMPL-453, a putative Fgfr 1,2,3 inhibitor (Mar, 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",HMPL-453,2016-03-03T10:50:29Z
0,2017-02-02T20:31:33Z,5279,"[{'description': 'HMPL-523 inhibits SYK, resulting in decreased tumor cell proliferation and migration (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",HMPL-523,2017-02-02T20:31:33Z
0,2016-03-03T10:47:23Z,3669,"[{'description': 'Limited information is currently available on HMPL-689, a putative phosphatidylinositide-3-kinase (PIK3CD) delta inhibitor (Mar, 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",HMPL-689,2016-03-03T10:47:23Z
0,2016-06-27T14:59:09Z,4382,"[{'description': 'HO-3867 is an inhibitor of STAT3, which blocks phosphorylation and may result in apoptotic induction and inhibition of tumor growth (PMID: 24590057).', 'references': []}]",HO-3867,2016-06-27T14:59:09Z
0,2016-03-23T02:21:57Z,3817,"[{'description': 'HPI-1 inhibits GLI1/2, which may result in decreased tumor cell growth (PMID: 19666565, PMID: 26683772).', 'references': [{'id': 4991, 'pubMedId': 26683772, 'title': 'Bromodomain and hedgehog pathway targets in small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26683772'}, {'id': 4990, 'pubMedId': 19666565, 'title': 'Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19666565'}]}]",HPI-1,2016-03-23T02:21:57Z
0,2017-02-14T03:45:09Z,5320,[],HPVSTs,2017-02-14T03:45:09Z
0,2017-02-14T03:47:09Z,5321,[],HPVSTs + Cyclophosphamide + Fludarabine phosphate + Nivolumab,2017-02-14T03:47:09Z
0,2017-06-01T14:57:27Z,5830,"[{'description': 'Limited information is currently available on HS-10296, a small molecule inhibitor of EGFR activating mutations and EGFR T790M (PMID: 28149837). ', 'references': [{'id': 9038, 'pubMedId': 28149837, 'title': 'Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28149837'}]}]",HS-10296,2017-06-01T14:57:27Z
0,2015-03-25T14:30:40Z,2457,"[{'description': 'HS-110 (Viagenpumatucel-L) is a tumor cell vaccine comprised of irradiated tumor cells expressing recombinant gp96-Ig, which is secreted and induces an immune response to endogenous tumor cells (NCI Drug Dictionary).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",HS-110,2016-02-15T15:17:35Z
0,2015-03-27T00:52:07Z,2472,[],HS-110 + Cyclophosphamide,2015-03-27T00:52:07Z
0,2015-05-14T17:23:33Z,2677,"[{'description': 'HS-345 inhibits TRKA, potentially resulting in decreased growth and increased apoptosis of TRKA expressing tumor cells (PMID: 23587795).', 'references': [{'id': 2719, 'pubMedId': 23587795, 'title': 'Anti-cancer effect of HS-345, a new tropomyosin-related kinase A inhibitor, on human pancreatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23587795'}]}]",HS-345,2015-05-14T17:33:10Z
0,2015-06-03T19:06:31Z,2774,"[{'description': 'HSP990 inhibits HSP90, which may lead to decreased tumor growth (PMID: 22246440).', 'references': [{'id': 2926, 'pubMedId': 22246440, 'title': 'The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22246440'}]}]",HSP990,2015-06-03T19:06:31Z
0,2017-02-01T16:22:17Z,5272,"[{'description': 'HTH-01-015 selectively inhibits NUAK1, resulting in decreased cell proliferation and migration (PMID: 24171924).', 'references': [{'id': 7717, 'pubMedId': 24171924, 'title': 'Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24171924'}]}]",HTH-01-015,2017-02-01T16:22:17Z
0,2015-03-25T14:44:33Z,2458,"[{'description': 'Hu14.18K322A is a monoclonal antibody that binds GD2 and activates immune response to tumor cells expressing GD2, potentially resulting in increased tumor cell death (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Hu14.18K322A,2015-03-25T14:44:33Z
0,2016-11-13T21:35:43Z,4947,"[{'description': 'Hu5F9-G4 is a humanized monoclonal antibody against CD47 that binds to and blocks CD47 downstream signaling, leading to antitumor activities (PMID: 26390038).', 'references': [{'id': 7028, 'pubMedId': 26390038, 'title': 'Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26390038'}]}]",Hu5F9-G4,2016-11-13T21:35:43Z
0,2016-11-14T21:13:48Z,4955,[],Hu5F9-G4 + Rituximab,2016-11-14T21:13:48Z
0,2017-06-07T20:16:14Z,5864,"[{'description': 'HuMax-Axl-ADC is an antibody-drug conjugate comprising an AXL targeted antibody linked to the anti-microtubule compound MMAE, which potentially decreases tumor growth (J Clin Oncol 35, 2017 (suppl; abstr TPS2605)).', 'references': []}]",HuMax-Axl-ADC,2017-06-07T20:22:14Z
0,2014-07-31T17:52:13Z,1316,"[{'description': 'Plaquenil (hydroxychloroquine sulfate) increases intralysosomal pH, resulting in inhibition of autophagic protein degradation and accumulation of autophagosomes, which potentially leads to cell death in autophagy-dependent tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Hydroxychloroquine,2015-01-21T16:43:40Z
0,2017-03-30T14:12:06Z,5495,[],Hydroxychloroquine + Itraconazole,2017-03-30T14:12:06Z
0,2015-03-05T16:39:39Z,2302,[],Hydroxychloroquine + Temsirolimus ,2015-03-05T16:39:39Z
0,2014-11-29T00:08:23Z,1750,[],Hydroxyurea,2014-11-29T00:08:23Z
0,2017-09-08T17:56:59Z,6182,[],Hydroxyurea + MU380 ,2017-09-08T17:56:59Z
0,2017-09-11T18:38:02Z,6192,[],Hydroxyurea + NU6027,2017-09-11T18:38:02Z
0,2017-06-30T18:31:24Z,5953,"[{'description': 'I-BET151 is a small molecule that blocks Brd3/4 binding to chromatin, resulting in transcription inhibition, therefore lead to tumor cell death (PMID: 21964340).', 'references': [{'id': 9248, 'pubMedId': 21964340, 'title': 'Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21964340'}]}]",I-BET151,2017-06-30T18:31:24Z
0,2017-07-05T15:30:23Z,5966,[],I-BET151 + SGC0946,2017-07-05T15:30:23Z
0,2015-12-17T16:27:49Z,3297,"[{'description': 'I-CBP112 is a small molecule that selectively inhibits the bromodomains of CREBBP and EP300, potentially resulting in decreased tumor cell growth (PMID: 26552700).', 'references': [{'id': 4120, 'pubMedId': 26552700, 'title': 'Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26552700'}]}]",I-CBP112,2015-12-17T16:27:49Z
0,2015-12-18T19:03:20Z,3299,[],I-CBP112 + Doxorubicin,2015-12-18T19:03:24Z
0,2015-12-18T18:55:23Z,3298,[],I-CBP112 + JQ1,2015-12-18T18:55:23Z
0,2017-09-29T17:36:04Z,6267,"[{'description': 'IACS-010759 inhibits complex I of the electron transport chain, therefore disrupts energy metabolism, resulting in growth inhibition in tumor cells (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr LB-A15).', 'references': [{'id': 10023, 'pubMedId': None, 'title': 'IACS-010759 is a novel inhibitor of oxidative phosphorylation that selectively targets AML cells by inducing a metabolic catastrophe', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/LB-A15'}]}]",IACS-010759,2017-09-29T17:36:04Z
0,2017-08-22T14:05:24Z,6138,"[{'description': 'IBI308 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 and PD-L2 ligands, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",IBI308,2017-08-22T14:05:24Z
0,2016-07-08T17:14:48Z,4429,"[{'description': 'IBR2 is a small molecule that binds to and inhibits Rad51 function, resulting in growth inhibition and apoptosis in tumor cells (PMID: 23341130).', 'references': [{'id': 6267, 'pubMedId': 23341130, 'title': 'A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23341130'}]}]",IBR2,2017-09-25T19:05:02Z
0,2014-03-12T15:53:16Z,767,[],Ibritumomab,
0,2014-03-12T15:53:16Z,768,"[{'description': ""Imbruvica (ibrutinib) is a selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK), which promotes apoptosis and inhibits B-cell mediated signaling pathways, and has additional activity against ERBB2 (HER2) and EGFR (PMID: 20615965, PMID: 21422473, PMID: 27678331). Imbruvica (Ibrutinib) is approved for mantle cell lymphoma and first line treatment of chronic lymphocytic leukemia (FDA.gov)."", 'references': [{'id': 750, 'pubMedId': 20615965, 'title': 'The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20615965'}, {'id': 751, 'pubMedId': 21422473, 'title': 'Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21422473'}]}]",Ibrutinib,2017-08-25T17:58:37Z
0,2017-01-03T20:31:05Z,5151,[],Ibrutinib + INCB039110,2017-01-03T20:31:05Z
0,2016-05-27T14:50:40Z,4167,[],Ibrutinib + JNJ-64052781,2016-05-27T14:50:40Z
0,2016-02-19T19:48:05Z,3580,[],Ibrutinib + lenalidomide,2016-02-19T19:48:12Z
0,2017-01-21T04:45:04Z,5240,[],Ibrutinib + Lenalidomide + Dexamethasone,2017-01-21T04:45:04Z
0,2017-09-11T15:38:36Z,6189,[],Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax,2017-09-11T15:38:36Z
0,2015-04-24T01:16:05Z,2573,[],Ibrutinib + MEDI4736,2015-04-24T01:16:05Z
0,2017-06-02T17:53:26Z,5847,[],Ibrutinib + MOR208,2017-06-02T17:53:26Z
0,2015-11-09T00:58:24Z,3198,[],Ibrutinib + Nivolumab,2015-11-09T00:58:24Z
0,2016-01-29T14:39:43Z,3476,[],Ibrutinib + Obinutuzumab,2016-01-29T14:39:43Z
0,2016-11-17T18:40:01Z,4965,[],Ibrutinib + ONC201,2016-11-17T18:40:01Z
0,2016-09-21T18:44:23Z,4744,[],Ibrutinib + Otlertuzumab,2016-09-21T18:44:23Z
0,2016-02-25T22:06:27Z,3623,[],Ibrutinib + Pacritinib,2016-02-25T22:06:27Z
0,2014-11-19T15:38:38Z,1729,[],ibrutinib + palbociclib,2014-11-19T15:38:38Z
0,2015-07-30T00:54:25Z,2969,[],Ibrutinib + Plerixafor,2015-07-30T00:54:25Z
0,2015-12-11T03:18:18Z,3280,[],Ibrutinib + Rituximab,2015-12-11T03:18:18Z
0,2015-02-27T03:13:10Z,2185,[],Ibrutinib + Rituximab + Cyclophosphamide + Fludarabine,2015-02-27T03:13:10Z
0,2017-05-26T14:25:00Z,5777,[],Ibrutinib + Rituximab + Venetoclax,2017-05-26T14:25:00Z
0,2016-09-27T00:09:33Z,4768,[],Ibrutinib + Ruxolitinib,2016-09-27T00:09:33Z
0,2017-10-04T14:49:45Z,6296,[],Ibrutinib + Sapanisertib,2017-10-04T14:49:45Z
0,2016-10-14T21:31:38Z,4828,[],Ibrutinib + SD-101 + Radiotherapy,2016-10-14T21:31:38Z
0,2016-02-19T19:35:35Z,3579,[],Ibrutinib + Selinexor,2016-02-19T19:35:35Z
0,2017-10-10T17:57:56Z,6307,[],Ibrutinib + Silmitasertib,2017-10-10T17:57:56Z
0,2016-10-04T14:53:18Z,4780,[],Ibrutinib + SNX-5422,2016-10-04T14:53:18Z
0,2017-01-03T20:16:18Z,5149,[],Ibrutinib + TAK-659,2017-01-03T20:16:18Z
0,2015-02-11T15:40:04Z,2044,[],Ibrutinib + TGR-1202,2015-02-11T15:40:04Z
0,2016-03-17T14:33:11Z,3768,[],Ibrutinib + TGR-1202 + Ublituximab,2016-03-17T14:33:11Z
0,2017-09-15T14:43:24Z,6211,[],Ibrutinib + unspecified CTLA4 antibody,2017-09-15T14:43:24Z
0,2017-09-15T14:09:25Z,6210,[],Ibrutinib + unspecified PD-L1 antibody,2017-09-15T14:09:25Z
0,2016-12-01T17:54:54Z,5040,[],Ibrutinib + VLX1570,2016-12-01T17:54:54Z
0,2016-02-06T12:08:25Z,3504,"[{'description': 'IC87114 is a small molecule selective PIK3CD inhibitor, which may result in decreased tumor cell survival (PMID: 23275335, PMID: 22391131).', 'references': [{'id': 3492, 'pubMedId': 22391131, 'title': 'High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22391131'}, {'id': 4540, 'pubMedId': 23275335, 'title': 'Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23275335'}, {'id': 3346, 'pubMedId': 19033389, 'title': 'Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19033389'}]}]",IC87114,2016-02-09T19:41:06Z
0,2017-09-18T18:43:07Z,6213,"[{'description': 'iC9/CAR.19/IL15-Transduced CB-NK cells are cord blood-derived natural killer cells that have modified to express a chimeric antigen receptor directed to CD19, as well as IL-15 and inducible caspase-9, which may result in increased death of CD19-expressing tumor cells  (PMID: 28725044).', 'references': [{'id': 9932, 'pubMedId': 28725044, 'title': 'Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28725044'}]}]",iC9/CAR.19/IL15-Transduced CB-NK,2017-09-18T18:43:07Z
0,2015-02-18T00:48:45Z,2084,"[{'description': 'ICG-001 disrupts the interaction of CTNNB1 and c-AMP response element-binding protein, thereby preventing downstream CTNNB1 signaling to promote apoptosis (PMID: 15314234).', 'references': [{'id': 1915, 'pubMedId': 15314234, 'title': 'A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected].', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15314234'}]}]",ICG-001,2015-03-18T20:24:38Z
0,2014-03-12T15:53:16Z,769,"[{'description': 'Icotinib is a selective EGFR inhibitor that inhibits both wild-type and mutant forms of EGFR, which may result in decreased tumor cell proliferation (PMID: 22112293). ', 'references': [{'id': 1831, 'pubMedId': 22112293, 'title': 'Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22112293'}]}]",Icotinib,2017-06-13T18:55:10Z
0,2015-03-23T18:37:50Z,2453,"[{'description': 'iCRT-14 inhibits the interaction of CTNNB1 with TCF7L2 to block Wnt signaling and results in inhibition of cell proliferation (PMID: 24188694).', 'references': [{'id': 2217, 'pubMedId': 24188694, 'title': 'Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24188694'}]}]",iCRT-14,2015-03-23T18:37:50Z
0,2015-03-16T15:42:56Z,2404,"[{'description': 'iCRT-3 inhibits the interaction of CTNNB1 with TCF7L2 to block Wnt signaling and results in apoptosis and inhibition of cell proliferation (PMID: 24188694).', 'references': [{'id': 2217, 'pubMedId': 24188694, 'title': 'Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24188694'}]}]",iCRT-3,2015-03-16T15:42:56Z
0,2015-03-23T18:34:42Z,2452,"[{'description': 'iCRT-5 inhibits the interaction of CTNNB1 with TCF7L2 to block Wnt signaling and results in inhibition of cell proliferation (PMID: 23155232). ', 'references': [{'id': 2297, 'pubMedId': 23155232, 'title': 'Antagonistic effect of small-molecule inhibitors of Wnt/β-catenin in multiple myeloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23155232'}]}]",iCRT-5,2015-03-23T18:34:42Z
0,2015-07-30T14:32:39Z,2979,"[{'description': 'Icrucumab (IMC-18F1) is a monoclonal antibody that binds FLT1 (VEGFR1) to prevent ligand-based activation, which may result in decreased angiogenesis and tumor growth (PMID: 17085673). ', 'references': [{'id': 3361, 'pubMedId': 17085673, 'title': 'Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17085673'}]}]",Icrucumab,2015-09-21T16:52:04Z
0,2015-12-10T02:54:33Z,3271,"[{'description': 'ID-LV305 is a lentiviral vector encoding human tumor-associated cancer-testis antigen (NY-ESO-1) which binds to dendritic cells and stimulates cytotoxic immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",ID-LV305,2015-12-10T02:54:33Z
0,2016-09-13T13:07:35Z,4696,"[{'description': 'ID09C3 is a human monoclonal IgG4-type antibody targeting HLA-DR and may result in apoptotic activity in lymphoma tumors (PMID: 23090290). ', 'references': [{'id': 6601, 'pubMedId': 23090290, 'title': 'Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23090290'}]}]",ID09C3,2016-09-13T13:07:35Z
0,2014-05-14T14:52:46Z,1022,"[{'description': 'Idarubicin is an anthracycline, which inhibits DNA replication thereby preventing RNA and protein synthesis (NCI Drug Dictionary).  Idarubicin, in combination with other approved drugs, is FDA approved for acute myelogenous leukemia (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Idarubicin,2014-08-27T15:20:37Z
0,2016-06-28T01:16:39Z,4393,[],Idasanutlin + Obinutuzumab,2016-06-28T01:16:39Z
0,2017-05-08T15:13:05Z,5645,[],Idasanutlin + Obinutuzumab + Rituximab + Venetoclax,2017-05-08T15:13:05Z
0,2017-05-08T15:12:27Z,5644,[],Idasanutlin + Obinutuzumab + Venetoclax,2017-05-08T15:12:27Z
0,2017-05-08T15:14:11Z,5646,[],Idasanutlin + Rituximab + Venetoclax,2017-05-08T15:14:11Z
0,2014-05-14T14:52:46Z,1023,"[{'description': 'Zydelig (idelalisib) inhibits PI3K-delta, preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival (NCI Drug Dictionary). Zydelig (idelalisib) is FDA approved for follicular B-cell non-Hodgkin lymphoma, relapsed small lymphocytic lymphoma, and chronic lymphocytic leukemia (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Idelalisib,2017-06-19T20:24:44Z
0,2017-09-12T13:43:47Z,6200,[],Idelalisib + MK2206,2017-09-12T13:43:47Z
0,2017-05-26T17:13:36Z,5784,[],Idelalisib + MOR208,2017-05-26T17:14:32Z
0,2014-10-14T20:08:22Z,1647,[],Idelalisib + Obinutuzumab,2014-10-14T20:08:22Z
0,2015-03-06T16:43:55Z,2326,[],Idelalisib + Ofatumumab,2015-03-06T16:43:55Z
0,2017-09-11T19:04:40Z,6199,[],Idelalisib + ONO-4059,2017-09-11T19:04:40Z
0,2016-09-21T18:45:55Z,4745,[],Idelalisib + Otlertuzumab + Rituximab,2016-09-21T18:45:55Z
0,2017-09-01T14:00:26Z,6145,[],Idelalisib + Pembrolizumab,2017-09-01T14:00:26Z
0,2015-03-06T16:42:23Z,2325,[],Idelalisib + Rituximab,2015-03-06T16:42:23Z
0,2015-07-30T15:49:56Z,2981,"[{'description': 'IDH305 specifically targets IDH1 with mutations at amino acid 321 to prevent 2HG formation, which may promote differentiation and inhibit proliferation of cancer cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",IDH305,2015-07-30T15:49:56Z
0,2015-10-28T01:21:24Z,3156,"[{'description': 'Betaseron (IFN-B) is recombinant interferon beta, which induces interferon-regulated gene expression, potentially resulting in immune response and decreased proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",IFN-B,2015-10-29T19:52:11Z
0,2014-09-11T03:36:29Z,1441,"[{'description': 'Cyfos (ifosfamide) is an alkylating agent, which cross-links DNA, thereby inhibiting DNA replication (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Ifosfamide,2014-10-03T17:49:36Z
0,2016-06-20T01:31:56Z,4325,"[{'description': 'Limited information is available on IGF-1R/AS ODN, a putative anti-sense oligodeoxynucleotide against IGF-1R (Jun 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",IGF-1R/AS ODN,2016-06-20T01:31:56Z
0,2017-05-23T18:39:53Z,5750,"[{'description': 'IGFBP-2 vaccine is a DNA plasmid vaccine that targets IGFBP-2 and potentially results in Type I immunity against tumor cells expressing IGFBP-2 (J Clin Oncol 34, 2016 (suppl; abstr 5542).', 'references': [{'id': 8966, 'pubMedId': None, 'title': 'Vaccination targeting insulin-like growth factor binding protein-2 (IGFBP-2) in advanced ovarian cancer: Safety and immunogenicity', 'url': 'http://meetinglibrary.asco.org/content/165931-176'}]}]",IGFBP-2 vaccine,2017-05-23T18:39:53Z
0,2017-07-31T16:22:59Z,6058,"[{'description': 'IHSF115 binds to Hsf1 and prevents transcription of target genes, which results in apoptosis in tumor cells (PMID: 28369544).', 'references': [{'id': 9634, 'pubMedId': 28369544, 'title': 'New inhibitor targeting human transcription factor HSF1: effects on the heat shock response and tumor cell survival.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28369544'}]}]",IHSF115,2017-07-31T16:22:59Z
0,2015-07-29T19:03:33Z,2963,"[{'description': 'II-B08 is an inhibitor of Shp2, which may result in inhibition of Erk1/2 and decrease cell proliferation (PMID: 20170098). ', 'references': [{'id': 3348, 'pubMedId': 20170098, 'title': 'Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20170098'}]}]",II-B08,2016-01-14T17:14:24Z
0,2015-08-05T03:26:02Z,2990,"[{'description': 'IL-12 gene is the plasmid DNA encoding interleukin 12 (IL-12) which induces IL-12 expression when introduced into tumor cells and subsequently leads to anti-tumor immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",IL-12 gene,2015-08-05T03:26:02Z
0,2016-10-16T20:51:15Z,4834,"[{'description': 'IMA950 is a cancer vaccine consisting of 11 glioblastoma multiforme-associated peptides, which may lead to anti-tumor immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",IMA950,2016-10-16T20:51:15Z
0,2016-10-16T20:52:34Z,4835,[],IMA950 + poly ICLC ,2016-10-16T20:52:34Z
0,2016-06-08T14:56:29Z,4258,"[{'description': 'Claudiximab (IMAB362) is a monoclonal antibody that binds to the tight junction molecule CLDN18.2, thereby blocking proliferation of tumor cells (PMID: 23900716, PMID: 26811601).', 'references': []}]",IMAB362,2016-06-14T14:06:11Z
0,2015-08-06T03:25:15Z,2996,"[{'description': 'Imalumab is a monoclonal antibody binds to and inhibits macrophage migration inhibitory factor (MIF) signaling therefore inhibits tumor cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Imalumab,2015-08-06T03:25:15Z
0,2014-03-12T15:53:16Z,770,"[{'description': 'Gleevec (imatinib mesylate) is a multi-target inhibitor of c-Kit, Pdgfr, and Bcr-Abl (NCI Drug Dictionary). Gleevec (imatinib mesylate) is FDA approved for c-KIT positive GIST and dermatofibrosarcoma protuberans, as well as several hematological tumor types (FDA.gov). ', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Imatinib,2016-07-01T18:29:32Z
0,2017-06-01T18:15:49Z,5833,[],Imatinib + Carboplatin + Paclitaxel,2017-06-01T18:15:49Z
0,2015-03-26T14:22:54Z,2467,[],Imatinib + Interferon alfa-2b ,2015-03-26T14:22:54Z
0,2017-01-05T18:14:04Z,5163,[],Imatinib + MK2206,2017-01-05T18:14:04Z
0,2016-06-27T01:20:57Z,4376,[],Imatinib + Pembrolizumab,2016-06-27T01:20:57Z
0,2017-09-18T19:00:57Z,6216,[],Imatinib + PKF118-310,2017-09-18T19:00:57Z
0,2016-12-21T18:01:44Z,5118,[],Imatinib + PLX4720,2016-12-21T18:01:44Z
0,2017-05-02T16:23:23Z,5602,[],Imatinib + Serdemetan,2017-05-02T16:23:23Z
0,2016-10-27T17:09:46Z,4867,[],Imatinib + Venetoclax,2016-10-27T17:09:46Z
0,2017-09-18T18:48:13Z,6214,[],Imatinib + XAV939,2017-09-18T19:22:32Z
0,2016-11-01T14:23:54Z,4897,"[{'description': 'IMC-20D7S is a monoclonal antibody that targets TYRP1, which may result in antitumor activity including inhibition of tumor growth (PMID: 27797971).', 'references': [{'id': 6907, 'pubMedId': 27797971, 'title': 'An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27797971'}]}]",IMC-20D7S,2016-11-01T14:23:54Z
0,2015-07-30T15:16:46Z,2980,"[{'description': 'IMC-3C5 is a monoclonal antibody, which binds FLT4 (VEGFR3) to prevent ligand based activation, which may result in decreased angiogenesis and tumor growth (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",IMC-3C5,2015-10-21T20:40:28Z
0,2015-12-03T15:12:02Z,3253,"[{'description': 'IMC-41A10 is a monoclonal antibody that targets RON and inhibits binding of its ligand MSP, resulting in inhibition of downstream signaling and cell migration, and reduced growth of RON-expressing tumors (PMID: 16982759).', 'references': [{'id': 4026, 'pubMedId': 16982759, 'title': 'Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16982759'}]}]",IMC-41A10 ,2015-12-03T15:13:01Z
0,2016-03-25T20:01:43Z,3847,"[{'description': 'IMCgp100 is a gp100 antigen-specific human T-cell receptor (TCR) linked to an anti-CD3 antibody fragment, which activates cytotoxic immune response against gp100-expressing tumor cells (PMID: 24531387).', 'references': [{'id': 5025, 'pubMedId': 24531387, 'title': 'ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24531387'}]}]",IMCgp100,2016-04-01T01:37:15Z
0,2016-03-10T20:20:59Z,3710,"[{'description': 'Imetelstat inhibits telomerase activity, resulting in telomere shortening and potentially leading to increased tumor cell death (PMID: 20048334).', 'references': [{'id': 4825, 'pubMedId': 20048334, 'title': 'The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20048334'}]}]",Imetelstat,2016-03-10T20:27:05Z
0,2017-08-25T16:58:06Z,6144,[],Imetelstat + Radiotherapy,2017-08-25T16:58:06Z
0,2015-06-25T15:03:47Z,2868,"[{'description': 'IMG-2005-5 inhibits MYD88 homodimerization, which results in decreased MYD88 signaling, thereby potentially leading to decreased survival of tumor cells with activated MYD88 signaling (PMID: 22931316).', 'references': [{'id': 3127, 'pubMedId': 22931316, 'title': ""MYD88 L265P somatic mutation in Waldenström's macroglobulinemia."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931316'}]}]",IMG-2005-5,2015-07-30T01:08:50Z
0,2015-12-01T21:12:24Z,3232,"[{'description': 'IMGN853 is an antibody-drug conjugate comprised of an antibody directed against Folr1 linked to the tubulin polymerization-inhibiting drug DM4, leading to cell death in Folr1-expressing tumors (PMID: 26136852, PMID: 25904506). ', 'references': [{'id': 4008, 'pubMedId': 26136852, 'title': 'Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26136852'}, {'id': 4009, 'pubMedId': 25904506, 'title': 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25904506'}]}]",IMGN853,2017-06-02T16:38:29Z
0,2017-09-19T15:35:33Z,6220,[],Imiquimod + Pembrolizumab,2017-09-19T15:35:33Z
0,2016-06-05T23:55:43Z,4243,"[{'description': 'IMO-2125 is an immunomodulatory oligonucleotide (IMO) that targets toll-like receptor 9 (TLR9), resulting in activation of anti-tumor immunity (PMID: 23207140).', 'references': [{'id': 5749, 'pubMedId': 23207140, 'title': 'Sequential induction of type I and II interferons mediates a long-lasting gene induction in the liver in response to a novel toll-like receptor 9 agonist.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23207140'}]}]",IMO-2125,2016-06-05T23:55:43Z
0,2016-06-05T23:56:59Z,4244,[],IMO-2125 + Ipilimumab,2016-06-05T23:56:59Z
0,2016-06-05T23:58:48Z,4245,[],IMO-2125 + Pembrolizumab,2016-06-05T23:58:48Z
0,2015-06-25T14:18:54Z,2866,"[{'description': 'IMO-8400 is a TLR 7, 8 and 9 antagonist, which leads to decreased growth of tumors with activated TLR signaling (Cancer Res October 1, 2014 74:2570). ', 'references': [{'id': 3125, 'pubMedId': None, 'title': 'Abstract 2570: IMO-8400, a selective antagonist of TLRs 7, 8 and 9, inhibits MYD88 L265P mutation-driven signaling and cell survival: A potential novel approach for treatment of B-cell lymphomas harboring MYD88 L265P mutation', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/2570.short'}]}]",IMO-8400,2015-06-25T14:18:54Z
0,2015-02-11T19:21:58Z,2056,"[{'description': 'Imprime PGG (PGG beta-glucan) binds to and promotes cytotoxicity of neutrophils bound to tumor cells via complement receptor 3 (CR3) (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Imprime PGG,2015-02-12T14:41:30Z
0,2017-01-09T20:01:06Z,5174,[],Imprime PGG + Pembrolizumab,2017-01-09T20:01:06Z
0,2016-06-24T02:24:30Z,4352,"[{'description': 'IMR-1 (inhibitor of mastermind recruitment-1) is a small molecule inhibitor of the Notch transcriptional activation complex, resulting in repression of Notch target gene expression and possibly leading to inhibition of tumor growth (PMID: 27197169).', 'references': [{'id': 6043, 'pubMedId': 27197169, 'title': 'The Small Molecule IMR-1 Inhibits the Notch Transcriptional Activation Complex to Suppress Tumorigenesis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27197169'}]}]",IMR-1,2016-06-24T02:24:30Z
0,2015-06-01T19:05:08Z,2759,"[{'description': 'IN-1130 is an inhibitor of TGFBR1, ACVR1B, and ACVR1C, which may promote immune response and inhibit tumor growth (PMID: 18951571, PMID: 24887560).', 'references': [{'id': 2882, 'pubMedId': 18951571, 'title': 'Effect of IN-1130, a small molecule inhibitor of transforming growth factor-beta type I receptor/activin receptor-like kinase-5, on prostate cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18951571'}, {'id': 2883, 'pubMedId': 24887560, 'title': 'An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24887560'}]}]",IN-1130,2015-06-01T19:08:51Z
0,2014-10-02T20:47:53Z,1618,[],INC280 + Cetuximab ,2014-10-02T20:47:53Z
0,2015-03-20T14:52:30Z,2444,[],INC280 + Nivolumab,2015-03-20T14:52:30Z
0,2016-07-22T19:07:17Z,4492,[],INC280 + PDR001,2016-07-22T19:07:17Z
0,2017-08-09T21:10:46Z,6103,[],INC280 + Trametinib,2017-08-09T21:10:46Z
0,2016-06-20T00:43:12Z,4321,"[{'description': 'INCAGN01876 is a monoclonal antibody that binds to human glucocorticoid-induced tumor necrosis factor receptor (GITR), which leads to activation of GITRs and potentially results in activation of anti-tumor immunity (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",INCAGN01876,2017-08-25T09:35:34Z
0,2017-05-02T04:12:40Z,5597,[],INCAGN01876 + Ipilimumab,2017-05-02T04:12:40Z
0,2017-05-02T04:13:58Z,5598,[],INCAGN01876 + Nivolumab,2017-05-02T04:13:58Z
0,2017-05-02T04:14:49Z,5599,[],INCAGN01876 + Nivolumab + Ipilimumab,2017-05-02T04:14:49Z
0,2017-06-01T15:24:06Z,5831,"[{'description': 'INCAGN01949 is an anti-OX40 agonist antibody that activates OX40, resulting in activation of the NFkB pathway and potential enhancement of tumor T-cell immunity (Cancer Res 2016;76(14 Suppl):Abstract nr 3204).', 'references': [{'id': 9039, 'pubMedId': None, 'title': 'Abstract 3204: INCAGN01949: an anti-OX40 agonist antibody with the potential to enhance tumor-specific T-cell responsiveness, while selectively depleting intratumoral regulatory T cells', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/3204'}]}]",INCAGN01949,2017-08-25T09:36:31Z
0,2017-08-18T15:12:25Z,6120,[],INCAGN01949 + Ipilimumab,2017-08-18T15:12:25Z
0,2017-08-18T15:13:14Z,6121,[],INCAGN01949 + Ipilimumab + Nivolumab,2017-08-18T15:13:14Z
0,2017-08-18T15:11:03Z,6119,[],INCAGN01949 + Nivolumab,2017-08-18T15:11:03Z
0,2015-08-12T03:23:24Z,3015,[],INCB024360 + MEDI4736,2015-08-12T03:23:24Z
0,2015-08-27T02:18:15Z,3059,[],INCB024360 + Nivolumab,2015-08-27T02:18:15Z
0,2017-03-28T03:43:15Z,5484,[],INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel,2017-03-28T03:43:15Z
0,2017-03-28T03:39:37Z,5483,[],INCB024360 + Nivolumab + mFOLFOX6,2017-03-28T03:39:37Z
0,2017-03-28T03:44:27Z,5485,[],INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel,2017-03-28T03:44:27Z
0,2017-03-28T03:45:53Z,5486,[],INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed,2017-03-28T03:45:53Z
0,2017-03-28T03:47:15Z,5487,[],INCB024360 + Pembrolizumab + Cyclophosphamide,2017-03-28T03:47:15Z
0,2014-03-12T15:53:16Z,776,"[{'description': 'INCB028060 is a MET inhibitor, which may induce cell death in cells overexpressing c-MET (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",INCB028060,2015-08-14T13:26:49Z
0,2014-07-31T05:10:12Z,1284,[],INCB028060 + Erlotinib,2014-07-31T05:10:12Z
0,2015-03-16T16:09:14Z,2406,"[{'description': 'INCB039110 is a selective inhibitor of Janus kinase 1 (JAK1), which may inhibit cell proliferation (PMID: 25605813).', 'references': [{'id': 2216, 'pubMedId': 25605813, 'title': 'Impact on creatinine renal clearance by the interplay of multiple renal transporters: a case study with INCB039110.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605813'}]}]",INCB039110,2015-06-01T18:18:43Z
0,2015-10-05T17:06:23Z,3096,[],INCB039110 + INCB024360,2015-10-05T17:06:23Z
0,2015-03-17T12:30:50Z,2420,[],INCB039110 + INCB040093,2015-03-17T12:30:50Z
0,2015-10-05T17:07:17Z,3097,[],INCB039110 + INCB050465,2015-10-05T17:07:17Z
0,2016-10-04T14:36:57Z,4777,[],INCB039110 + Osimertinib,2016-10-04T14:36:57Z
0,2015-02-08T11:04:31Z,2021,"[{'description': 'INCB040093 is a specific inhibitor of PIK3CD, which blocks PI3K/AKT signaling to prevent cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",INCB040093,2015-02-08T11:04:31Z
0,2015-06-01T18:00:19Z,2753,"[{'description': 'INCB047986 is a pan-JAK inhibitor with potential activity against tumors (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",INCB047986,2015-06-01T18:00:19Z
0,2015-09-30T02:57:18Z,3088,"[{'description': 'INCB050465 inhibits PI3K-delta, blocking activation of AKT signaling pathway and leading to apoptosis of PIK3CD expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",INCB050465 ,2017-05-19T19:11:38Z
0,2016-06-03T02:22:14Z,4224,[],INCB050465 + Ruxolitinib,2016-06-03T02:22:14Z
0,2015-05-29T13:59:48Z,2747,"[{'description': 'INCB052793 is a Janus-associated kinase 1 inhibitor which inhibits JAK 1-mediated cell proliferation in tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",INCB052793,2015-05-29T13:59:48Z
0,2016-03-08T18:01:54Z,3696,"[{'description': 'INCB053914 is an ATP-competitive small molecule inhibitor of PIM kinases 1, 2, and 3, which may inhibit cell proliferation by blocking the phosphorylation of downstream targets (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",INCB053914,2016-03-08T18:01:54Z
0,2015-06-10T09:50:18Z,2812,"[{'description': 'INCB054329 is BET inhibitor, which inhibits cell proliferation (Proceedings of the 106th Annual Meeting of the AACR; 2015; Abstract nr 3525).', 'references': [{'id': 6115, 'pubMedId': None, 'title': 'The BET inhibitor INCB054329 is efficacious as a single agent or in combination with targeted agents in colorectal cancer models', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/3525.short'}]}]",INCB054329,2017-07-24T18:42:11Z
0,2017-03-22T18:51:01Z,5465,[],INCB054329 + INCB059872,2017-03-22T18:51:01Z
0,2016-05-27T17:07:41Z,4173,"[{'description': 'INCB054828 is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR1/2/3 signaling, which results in growth inhibition in tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",INCB054828,2016-09-19T14:14:12Z
0,2016-05-27T17:09:38Z,4175,[],INCB054828 + Pembrolizumab,2016-05-27T17:09:38Z
0,2016-06-20T00:23:21Z,4319,"[{'description': 'Limited information is currently available on INCB057643 (Jun 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",INCB057643 ,2016-06-20T00:23:21Z
0,2017-03-22T18:47:55Z,5464,"[{'description': 'INCB059872 is a specific inhibitor of Lysine specific demethylase 1 (LSD1) that increases tumor-suppressor gene expression through enhancing Histone H3 methylation, leading to anti-tumor effects (Cancer Res 2016;76(14 Suppl):Abstract nr 4704).', 'references': []}]",INCB059872,2017-03-22T18:47:55Z
0,2017-06-01T15:38:49Z,5832,"[{'description': 'Limited information is currently available on INCB062079 (Jun 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",INCB062079,2017-06-01T15:38:49Z
0,2015-06-04T17:24:39Z,2796,"[{'description': 'INCB16562 is a selective JAK1/2 inhibitor, which inhibits STAT signaling to prevent cell proliferation (PMID: 20072651).', 'references': [{'id': 2963, 'pubMedId': 20072651, 'title': 'INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20072651'}]}]",INCB16562,2015-06-04T17:24:39Z
0,2015-06-04T17:42:07Z,2798,"[{'description': 'INCB20 is a pan-JAK inhibitor, which decreases tumor cell growth (PMID: 19139110).', 'references': [{'id': 2966, 'pubMedId': 19139110, 'title': 'Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19139110'}]}]",INCB20,2015-06-04T17:42:07Z
0,2015-07-30T02:45:05Z,2976,"[{'description': 'Indoximod inhibits indoleamine 2,3-dioxygenase (IDO), resulting in decreased tryptophan degradation, and potentially leading to increased anti-tumor immune response and reduced tumor growth (PMID: 26033215, PMID: 17234791).', 'references': [{'id': 3359, 'pubMedId': 26033215, 'title': 'Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26033215'}]}]",indoximod,2017-05-30T18:40:27Z
0,2015-12-21T18:15:02Z,3326,"[{'description': 'INDY is an ATP-competitive inhibitor of DYRK1A, which has been shown to repress self-renewal of cells in glioblastomas (PMID: 23635774).', 'references': [{'id': 4144, 'pubMedId': 23635774, 'title': 'Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23635774'}]}]",INDY,2015-12-22T20:35:12Z
0,2014-07-28T17:19:13Z,1168,"[{'description': 'Iniparib appears to modify cysteine-containing proteins in tumor cells, and has minimal activity as a PARP inhibitor (PMID: 22128301, PMID: 22291137).', 'references': [{'id': 478, 'pubMedId': 22128301, 'title': 'Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22128301'}]}]",Iniparib,2016-02-17T14:49:47Z
0,2014-07-28T17:26:40Z,1173,[],Iniparib + doxorubicin + carboplatin,2014-07-28T17:26:40Z
0,2014-07-28T17:20:53Z,1169,[],Iniparib + Gemcitabine + Carboplatin,2014-07-28T17:20:53Z
0,2014-07-28T17:23:42Z,1171,[],Iniparib + Irinotecan,2014-07-28T17:23:42Z
0,2014-07-28T17:24:37Z,1172,[],Iniparib + Paclitaxel,2014-07-28T17:24:37Z
0,2014-07-28T17:21:49Z,1170,[],Iniparib + Topotecan,2014-07-28T17:21:49Z
0,2015-07-22T16:27:06Z,2944,"[{'description': 'INO-1001 inhibits PARP, resulting in increased sensitivity of tumor cells to radiation and chemotherapeutics (PMID: 15036647, PMID: 17628743).', 'references': [{'id': 3295, 'pubMedId': 15036647, 'title': 'Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15036647'}, {'id': 3296, 'pubMedId': 17628743, 'title': 'INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17628743'}]}]",INO-1001,2017-05-10T17:47:34Z
0,2017-05-10T18:09:23Z,5657,[],INO-1001 + Radiotherapy,2017-05-10T18:09:23Z
0,2017-05-30T16:33:11Z,5807,"[{'description': 'INO-1400 is a plasmid encoding hTERT with two mutations, which may increase anti-tumor immune response against hTERT-expressing tumor cells (NCI Drug Dictionary).', 'references': []}]",INO-1400,2017-05-30T16:33:11Z
0,2017-06-02T17:44:18Z,5844,[],INO-1400 + INO-9012,2017-06-02T17:44:18Z
0,2017-06-02T17:44:34Z,5845,"[{'description': 'INO-3106 is a plasmid comprising E6 and E7 of HPV-6, which may result in antitumor activity via induction of a cytotoxic T-lymphocyte immune response against tumor cells (NCI Drug Dictionary). ', 'references': []}]",INO-3106,2017-06-02T17:44:34Z
0,2017-06-02T17:47:37Z,5846,[],INO-3106 + INO-9012,2017-06-02T17:47:37Z
0,2017-05-30T16:40:16Z,5808,"[{'description': 'INO-9012 is a plasmid encoding IL-12, which may increase anti-tumor immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",INO-9012,2017-05-30T16:40:16Z
0,2015-11-09T01:39:56Z,3199,"[{'description': 'Besponsa (inotuzumab ozogamicin) consists of calecheamicin covalently linked to anti-CD22 antibody, which delivers calecheamicin into CD22-positive cells, leading to DNA damage and apoptosis (PMID: 24389139). Besponsa (inotuzumab ozogamicin) is FDA approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (FDA.gov).', 'references': [{'id': 3891, 'pubMedId': 24389139, 'title': 'Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24389139'}]}]",inotuzumab ozogamicin,2017-09-22T00:16:45Z
0,2016-10-11T16:51:33Z,4813,[],inotuzumab ozogamicin + cyclophosphamide + prednisone + rituximab + vincristine,2016-10-11T16:51:33Z
0,2014-07-31T08:16:55Z,1299,[],Interferon alfa-2b ,2014-07-31T08:16:55Z
0,2016-06-03T08:33:01Z,4229,[],Interferon alfa-2b + Fluorouracil,2016-06-03T08:33:01Z
0,2015-03-26T14:23:34Z,2468,[],Interferon alfa-2b + Nilotinib ,2015-03-26T14:23:34Z
0,2014-11-20T20:32:59Z,1733,"[{'description': 'Interferon gamma is a cytokine that binds IFN-gamma receptors, leading to pleiotropic effects, including stimulating antibody-dependent cytotoxicity and enhanced natural killer cell activity against tumor cells and the activation of caspases, leading to apoptosis of malignant cells (NCI Drug Dictionary, PMID: 14525967).', 'references': [{'id': 1150, 'pubMedId': 14525967, 'title': 'Interferon-gamma: an overview of signals, mechanisms and functions.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/14525967'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",interferon gamma ,2015-04-10T16:35:17Z
0,2017-04-17T20:24:59Z,5548,[],Interferon gamma + Paclitaxel + Pertuzumab + Trastuzumab,2017-04-17T20:24:59Z
0,2016-11-19T23:05:08Z,4975,[],interferon gamma + peginterferon alfa-2b,2016-11-19T23:05:08Z
0,2017-01-31T04:19:54Z,5262,"[{'description': 'Interleukin-12 (NM-IL-12) is a recombinant version of Interleukin-12 (IL-12), which may decrease tumor angiogenesis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Interleukin-12,2017-02-03T19:41:45Z
0,2017-03-04T05:42:41Z,5405,"[{'description': 'Limited information is currently available on Intuvax (Mar 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",Intuvax,2017-03-10T17:38:38Z
0,2017-03-04T05:43:46Z,5406,[],Intuvax + Sunitinib,2017-03-04T05:43:46Z
0,2017-09-26T14:20:32Z,6241,"[{'description': 'INU-152 is a small molecule pan-RAF inhibitor, which reduces downstream MAPK pathway signaling and may inhibit growth of BRAF-mutant tumors (PMID: 28645859).', 'references': [{'id': 9993, 'pubMedId': 28645859, 'title': 'Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF(V600E) mutant cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28645859'}]}]",INU-152,2017-09-26T14:20:32Z
0,2015-12-22T20:52:09Z,3329,"[{'description': 'IPA-3 is a selective inhibitor of PAK1, which results in decreased PAK1 signaling, and may result in decreased tumor cell growth(PMID: 18420139, PMID: 23894351).', 'references': [{'id': 4153, 'pubMedId': 18420139, 'title': 'An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18420139'}, {'id': 4154, 'pubMedId': 23894351, 'title': 'IPA-3 inhibits the growth of liver cancer cells by suppressing PAK1 and NF-κB activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23894351'}]}]",IPA-3,2015-12-22T20:52:09Z
0,2015-03-13T16:59:17Z,2396,"[{'description': 'Ipafricept (OMP-54F28) is a fusion protein comprised of the ligand binding domain of the Frizzled family receptor 8 and the human immunoglobulin Fc domain, which binds Wnt and prevents downstream signaling, thereby inhibiting tumor growth (PMID: 25172549).', 'references': [{'id': 6129, 'pubMedId': 25172549, 'title': 'Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25172549'}, {'id': 2197, 'pubMedId': None, 'title': 'A first-in-human Phase 1 study of anti-cancer stem cell (CSC) agent OMP-54F28 (FZD8-Fc) targeting the WNT pathway in patients with advanced solid tumors', 'url': 'http://mct.aacrjournals.org/content/12/11_Supplement/B79.short'}]}]",Ipafricept,2016-06-28T16:56:57Z
0,2016-06-28T16:56:25Z,4400,[],Ipafricept + Carboplatin + Paclitaxel,2016-06-28T16:56:25Z
0,2015-03-16T19:08:26Z,2413,[],Ipafricept + Sorafenib,2016-06-28T16:56:46Z
0,2014-03-12T15:53:16Z,747,"[{'description': 'Ipatasertib (GDC-0068) binds to and inhibits the activity of AKT in an ATP-competitive manner, which may result in the inhibition of the PI3K/AKT signaling pathway and tumor cell proliferation (PMID: 22934575).', 'references': [{'id': 2282, 'pubMedId': 22934575, 'title': 'Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22934575'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Ipatasertib,2017-03-17T18:18:41Z
0,2016-12-19T19:56:48Z,5106,[],Ipatasertib + Navitoclax,2017-08-01T16:04:57Z
0,2014-10-02T13:18:10Z,1588,[],Ipatasertib + Paclitaxel,2014-10-02T13:18:10Z
0,2016-11-23T16:53:06Z,4993,[],Ipatasertib + SCH772984,2016-11-23T16:53:06Z
0,2016-11-23T18:22:40Z,5009,[],Ipatasertib + Selumetinib,2016-11-23T18:22:40Z
0,2016-11-02T14:25:00Z,4906,"[{'description': 'IPH2101 is a monoclonal antibody that binds to killer cell immunoglobulin-like receptors (KIR), thereby blocking the KIR-ligand inhibitory interaction and thus, promoting natural killer cell cytotoxicity of cancer cells (PMID: 22031859). ', 'references': [{'id': 6917, 'pubMedId': 22031859, 'title': 'IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22031859'}]}]",IPH2101,2016-11-02T14:25:00Z
0,2016-01-10T19:14:01Z,3382,"[{'description': 'IPH2201 is a humanized monoclonal antibody against NKG2A that blocks NKG2A ligand binding, which in turn induces cell-mediated immune response against cancer cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",IPH2201,2016-01-10T19:14:01Z
0,2015-06-03T18:44:58Z,2773,"[{'description': 'IPI-493 inhibits HSP90, which may result in increased apoptosis and decreased tumor growth (PMID: 21737509).', 'references': [{'id': 2923, 'pubMedId': 21737509, 'title': 'The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21737509'}]}]",IPI-493,2015-06-03T18:44:58Z
0,2016-01-06T14:08:32Z,3363,"[{'description': 'IPI-549 is a selective PI3Kgamma inhibitor that enhances anti-tumor immune response and inhibits tumor growth in animal models (Cancer Immunol Res January 2016 4; B029).', 'references': [{'id': 4210, 'pubMedId': None, 'title': '', 'url': 'http://cancerimmunolres.aacrjournals.org/content/4/1_Supplement/B029.abstract?sid=af20e2c0-b945-4273-b2ee-f353d1973d72'}]}]",IPI-549,2016-01-28T02:07:51Z
0,2014-03-12T15:53:16Z,779,"[{'description': 'Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (NCI Drug Dictionary). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Ipilimumab,2017-09-25T18:20:44Z
0,2014-07-31T08:26:10Z,1301,[],Ipilimumab + Bevacizumab,2014-07-31T08:26:10Z
0,2014-08-04T03:30:27Z,1349,[],Ipilimumab + Crizotinib,2014-08-04T03:30:27Z
0,2014-08-04T03:26:46Z,1348,[],Ipilimumab + Erlotinib,2014-08-04T03:26:46Z
0,2014-07-30T14:16:06Z,1250,[],Ipilimumab + Imatinib Mesylate,2014-07-30T14:16:06Z
0,2015-08-06T02:09:25Z,2992,[],Ipilimumab + lenalidomide,2015-08-06T02:09:25Z
0,2015-08-27T02:00:50Z,3058,[],Ipilimumab + MGA271,2015-08-27T02:00:50Z
0,2015-07-30T03:12:24Z,2978,[],Ipilimumab + nab-paclitaxel,2015-07-30T03:12:24Z
0,2016-06-02T18:42:08Z,4202,[],Ipilimumab + Nivolumab + Vedolizumab ,2016-06-02T18:42:08Z
0,2015-02-19T15:15:27Z,2106,[],Ipilimumab + Pembrolizumab ,2015-02-19T15:15:27Z
0,2016-08-05T14:23:33Z,4523,[],Ipilimumab + Radiotherapy,2016-08-05T14:23:33Z
0,2016-03-25T20:23:49Z,3848,[],Ipilimumab + SD-101,2016-03-25T20:23:49Z
0,2017-05-22T18:26:32Z,5741,[],Ipilumumab + Lefitolimod,2017-05-22T18:28:22Z
0,2017-01-13T19:01:34Z,5196,"[{'description': 'IRAK1/4 is an inhibitor of interleukin-1 receptor associated kinases 1 and 4, which results in stabilization of wild-type KMT2A, thereby potentially leading to inhibition of cell growth and delayed disease progression in KMT2A fusion specific cancers (PMID: 28065413). ', 'references': [{'id': 7540, 'pubMedId': 28065413, 'title': 'Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28065413'}]}]",IRAK1/4,2017-01-19T15:24:56Z
0,2014-06-09T21:39:01Z,1074,"[{'description': 'Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death (NCI Drug Dictionary). Camptosar (irinotecan) is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Irinotecan,2016-01-22T02:57:45Z
0,2014-07-31T06:29:18Z,1288,[],Irinotecan + Alisertib,2014-07-31T06:29:18Z
0,2014-10-01T18:51:48Z,1584,[],Irinotecan + AZD7762,2014-10-01T18:51:48Z
0,2015-01-06T14:31:09Z,1920,[],Irinotecan + Cetuximab + Ramucirumab,2015-01-06T14:31:09Z
0,2016-10-10T18:04:09Z,4806,[],Irinotecan + Nimotuzumab,2016-10-10T18:04:09Z
0,2017-05-10T19:13:59Z,5659,[],Irinotecan + Niraparib,2017-05-10T19:13:59Z
0,2015-01-06T14:26:11Z,1919,[],Irinotecan + Oxaliplatin + Cetuximab,2015-01-06T14:26:11Z
0,2016-05-26T16:26:41Z,4138,[],Irinotecan + Panitumumab,2016-05-26T16:26:41Z
0,2017-05-08T14:55:28Z,5643,[],Irinotecan + Pembrolizumab,2017-05-08T14:55:28Z
0,2017-05-05T21:29:38Z,5633,[],Irinotecan + Ramucirumab,2017-05-05T21:29:38Z
0,2017-05-15T18:18:31Z,5674,[],Irinotecan + Reolysin,2017-05-15T18:18:31Z
0,2016-05-12T16:39:26Z,4111,[],Irinotecan + RG7386,2016-05-12T16:39:26Z
0,2016-06-20T01:10:30Z,4323,[],Irinotecan + RRx-001,2016-06-20T01:10:30Z
0,2015-04-24T14:26:28Z,2588,[],Irinotecan + Selinexor,2015-04-24T14:26:28Z
0,2015-06-16T20:33:08Z,2835,[],Irinotecan + Selumetinib,2015-06-16T20:33:15Z
0,2014-08-06T01:04:38Z,1378,[],Irinotecan + Talazoparib,2017-06-12T15:56:35Z
0,2015-03-05T16:22:34Z,2298,[],Irinotecan + Temsirolimus + Vincristine,2015-03-05T16:22:34Z
0,2015-12-21T01:01:07Z,3314,[],Irinotecan + Veliparib,2015-12-21T01:01:07Z
0,2016-02-25T20:50:38Z,3618,[],Irinotecan + Vincristine,2016-02-25T20:50:38Z
0,2017-01-03T17:44:10Z,5134,"[{'description': 'IRX4204 is a rexanoid, which binds to retinoid X receptors and acts as an agonist (PMID: 27158387).', 'references': [{'id': 7463, 'pubMedId': 27158387, 'title': 'Treatment with retinoid X receptor agonist IRX4204 ameliorates experimental autoimmune encephalomyelitis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27158387'}]}]",IRX4204,2017-01-03T17:44:10Z
0,2017-09-01T15:03:47Z,6147,"[{'description': 'ISA101b is an HPV16 vaccine comprised of a peptide string that includes the E6 and E7 HPV proteins and T cell epitopes, allowing for T-cell activation, and may result in antitumor activity (PMID: 27669306). ', 'references': [{'id': 9848, 'pubMedId': 27669306, 'title': 'Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27669306'}]}]",ISA101b,2017-09-01T15:03:47Z
0,2017-09-01T15:04:46Z,6148,[],ISA101b + Utomilumab,2017-09-01T15:04:46Z
0,2017-10-17T20:13:32Z,6331,"[{'description': 'Isatuximab (SAR650984) is a humanized monoclonal antibody against CD38 that induces anti-tumor immune reaction against CD38-positive tumor cells (PMID: 24987056).', 'references': [{'id': 10135, 'pubMedId': 24987056, 'title': 'SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24987056'}]}]",Isatuximab,2017-10-17T20:14:40Z
0,2017-10-18T15:14:27Z,6335,[],Isatuximab + REGN2810,2017-10-18T15:14:27Z
0,2014-03-12T15:53:16Z,780,[],ISIS 5132,
0,2014-05-14T14:52:46Z,1025,"[{'description': 'ISIS 13650 is a second-generation Raf-1 antisense oligonucleotide (PMID: 16184551).', 'references': [{'id': 163, 'pubMedId': 16184551, 'title': 'Comparison of strategies targeting Raf-1 mRNA in ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16184551'}]}]",ISIS-13650,
0,2015-04-15T14:46:45Z,2536,"[{'description': 'ISIS-FGFR4Rx is an antisense oligonucleotide which blocks production of FGFR4 and may inhibit tumor cell proliferation (PMID: 23922646). ', 'references': [{'id': 2474, 'pubMedId': 23922646, 'title': 'Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23922646'}]}]",ISIS-FGFR4Rx,2015-04-15T14:46:45Z
0,2017-04-19T15:07:29Z,5563,"[{'description': 'IsoA is a novel ent-kaurane diterpernoid derived from an Isodon plant, which may result in inhibition of cancer cell growth via suppression of Trx1, which leads to ROS build up (PMID: 28011619). ', 'references': [{'id': 8632, 'pubMedId': 28011619, 'title': 'The Natural Diterpenoid Isoforretin A Inhibits Thioredoxin-1 and Triggers Potent ROS-Mediated Antitumor Effects.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28011619'}]}]",IsoA,2017-04-19T15:07:29Z
0,2017-05-02T03:37:01Z,5595,[],Isotretinoin,2017-05-02T03:37:01Z
0,2016-03-10T15:29:57Z,3702,"[{'description': 'IST5-002 is a small molecule that inhibits dimerization and activation of Stat5a and Stat5b, potentially resulting in decreased tumor growth (PMID: 26026053).', 'references': [{'id': 4451, 'pubMedId': 26026053, 'title': 'Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26026053'}]}]",IST5-002,2016-03-10T15:29:57Z
0,2017-09-27T19:43:54Z,6256,"[{'description': 'ISTH0047 is a locked nucleic acid antisense oligonucleotide that targets TGF-beta2, which may result in decreased stromal TGF-beta2 expression and reduced tumor metastasis (PMID: 28911087).', 'references': [{'id': 10015, 'pubMedId': 28911087, 'title': 'An antisense oligonucleotide targeting TGF-β2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28911087'}]}]",ISTH0047,2017-09-27T19:43:54Z
0,2016-02-18T19:53:03Z,3551,"[{'description': 'IT-901 is a small molecule inhibitor of c-REL, which leads to decreased NF-kappaB activity and may result in decreased tumor cell growth (PMID: 26744524).', 'references': [{'id': 4622, 'pubMedId': 26744524, 'title': 'Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress Responses.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26744524'}]}]",IT-901,2016-02-18T19:53:03Z
0,2014-05-14T14:52:46Z,1026,"[{'description': 'Itraconazole is an antifungal, which indirectly targets mTOR (PMID: 20176935).', 'references': [{'id': 166, 'pubMedId': 20176935, 'title': 'Cholesterol trafficking is required for mTOR activation in endothelial cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20176935'}]}]",Itraconazole,2014-11-07T11:55:48Z
0,2014-07-15T12:03:39Z,1085,[],Itraconazole + Pemetrexed,2014-07-15T12:03:39Z
0,2015-03-23T18:44:09Z,2455,"[{'description': 'IWR-1 selectively inhibits Wnt/beta-catenin mediated signaling by inhibiting tankyrase1/2, thus stabilizing Axin and stimulating beta-catenin degradation (PMID: 23621985). ', 'references': [{'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]}]",IWR-1,2015-09-22T19:18:27Z
0,2016-03-14T17:44:52Z,3733,[],IWR-1 + Everolimus,2016-03-14T17:44:52Z
0,2014-03-12T15:53:16Z,781,[],Ixabepilone,
0,2016-07-29T00:37:13Z,4505,[],Ixabepilone + Sunitinib,2016-07-29T00:37:13Z
0,2014-07-30T16:39:25Z,1263,[],ixabepilone + temsirolimus,2014-07-30T16:39:25Z
0,2014-08-04T07:42:08Z,1359,"[{'description': 'Ninlaro (ixazomib) inhibits proteosome activity, resulting in accumulation of misfolded proteins, inhibition of pathway signaling, and potentially leading to cell death (PMID: 20160034).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 9167, 'pubMedId': 20160034, 'title': 'Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20160034'}]}]",Ixazomib,2017-06-19T18:34:58Z
0,2016-06-02T16:39:27Z,4192,[],Ixazomib + JQ1,2016-06-02T16:39:27Z
0,2014-08-04T07:46:00Z,1360,[],Ixazomib + Vorinostat,2017-05-17T13:26:49Z
0,2016-11-21T16:24:45Z,4981,"[{'description': 'J591 is a monoclonal antibody that specifically targets the extracellular domain of the prostate-specific membrane antigen (PSMA), which may result in antitumor activity (PMID: 15837970).', 'references': [{'id': 7104, 'pubMedId': 15837970, 'title': 'Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15837970'}]}]",J591,2016-11-21T16:24:45Z
0,2015-06-08T21:39:40Z,2808,"[{'description': 'JANEX-1 (WHI-P131) is a dual JAK3/EGFR inhibitor, whic may prevent the development of intestinal tumors (PMID: 20924972, PMID: 20486473).', 'references': [{'id': 2982, 'pubMedId': 20486473, 'title': 'Prevention of UVB-induced skin inflammation, genotoxicity, and photocarcinogenesis in mice by WHI-P131, a dual-function inhibitor of Janus kinase 3 and EGF receptor kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20486473'}, {'id': 2983, 'pubMedId': 20924972, 'title': 'Chemoprevention of colorectal cancer by targeting Janus kinase 3 with a rationally designed small molecule inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20924972'}]}]",JANEX-1,2015-06-08T21:39:40Z
0,2016-06-26T20:57:39Z,4364,"[{'description': 'JCAR014 is composed of autologous memory T-cells expressing a chimeric antigen receptor (CAR) comprised of a CD19 scFv-4-1BB-CD3zeta fusion protein and truncated EGFR, which may stimulate anti-tumor immunity (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",JCAR014,2016-07-14T14:47:07Z
0,2017-07-07T17:26:31Z,5980,"[{'description': 'JCAR017 comprises equal amount of CD4+ and CD8+ autologous T lymphocytes engineered to express chimeric antigen receptors containing an anti-CD19 fragment fused to the 4-1BB (CD137) signaling domain, which may results in immune modulating and anti-tumor activities (J Clin Oncol 35, 2017 (suppl; abstr 7513)).', 'references': [{'id': 9301, 'pubMedId': None, 'title': 'CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001).', 'url': 'http://abstracts.asco.org/199/AbstView_199_185939.html'}]}]",JCAR017,2017-07-07T17:26:31Z
0,2014-03-12T15:53:16Z,782,"[{'description': 'JI-101 inhibits KDR (VEGFR2), PDGFR-beta, and EphB4, resulting in anti-tumor activity (PMID: 26365907).', 'references': [{'id': 8802, 'pubMedId': 26365907, 'title': 'A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26365907'}]}]",JI-101,2017-05-03T18:00:03Z
0,2015-01-06T14:17:35Z,1918,"[{'description': 'JIB-04 is a selective small molecule inhibitor of the histone demethylases KDM4A, KDM4B, KDM4C, KDM4D, KDM4E, KDM5A, and KDM6B, demonstrating specific activity in cancer cells not seen in matched normal controls. Jib-04 treatment induced transcriptional changes reducing cellular proliferation and promoting apoptosis of cancer cells (PMID: 23792809).', 'references': [{'id': 1583, 'pubMedId': 23792809, 'title': 'A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23792809'}]}]",JIB-04,2015-01-06T14:17:35Z
0,2016-06-16T19:43:57Z,4292,"[{'description': 'JMS-17-2 is a small molecule antagonist of CX3CR1 that blocks CX3CR1 downstream signaling, resulting in inhibition of tumor dissemination and metastasis (PMID: 27001765).', 'references': [{'id': 5955, 'pubMedId': 27001765, 'title': 'Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27001765'}]}]",JMS-17-2,2016-06-16T19:43:57Z
0,2014-03-12T15:53:16Z,783,"[{'description': 'JNJ 38877605 binds to MET and prevents its activation, resulting in decreased downstream signaling and potentially resulting in increased cell death of MET-overexpressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",JNJ 38877605,2015-02-25T18:33:38Z
0,2017-06-30T14:20:58Z,5952,[],JNJ 38877605 + Panitumumab,2017-06-30T14:20:58Z
0,2014-05-14T14:52:46Z,1027,"[{'description': 'JNJ-26483327 is a multi-kinase inhbitor, which inhibits wild-type and mutant EGFR, RET, and has activity against VEGFR3, ERBB2 (HER2), ERBB4, and SRC family members (PMID: 20823884).', 'references': [{'id': 45, 'pubMedId': 20823884, 'title': 'Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20823884'}]}]",JNJ-26483327,2017-04-03T14:31:01Z
0,2015-06-18T16:31:33Z,2839,"[{'description': 'JNJ-40346527 is a small molecule inhibitor of CSF1R, which may inhibit growth of CSF1R-expressing tumor cells (PMID: 25628399).', 'references': [{'id': 3076, 'pubMedId': 25628399, 'title': 'An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25628399'}]}]",JNJ-40346527,2015-06-18T16:31:33Z
0,2014-05-14T14:52:46Z,1028,"[{'description': 'JNJ-42756493 (erdafitinib) selectively inhibits FGFR1-4, resulting in decreased downstream signaling, and potentially leading to reduced growth of tumors with activated FGFR signaling (PMID: 28341788).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 9140, 'pubMedId': 28341788, 'title': 'Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28341788'}]}]",JNJ-42756493,2017-06-15T02:50:16Z
0,2017-08-08T19:42:17Z,6099,[],JNJ-42756493 + Fulvestrant + Palbociclib,2017-08-08T19:43:21Z
0,2016-03-15T15:47:42Z,3742,"[{'description': 'JNJ-54302833 is a fatty acid synthase inhibitor that suppresses tumor cell growth in culture ( Cancer Res October 1, 2014 74; 4747 ).', 'references': [{'id': 4864, 'pubMedId': None, 'title': 'Design and synthesis of a series highly potent and bioavailable FASN KR domain inhibitors for cancer', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/4747'}]}]",JNJ-54302833 ,2016-03-15T15:47:42Z
0,2016-07-21T04:12:40Z,4491,"[{'description': 'JNJ-61186372 is a bi-specific antibody that targets EGFR and MET, resulting in inhibition of downstream signaling and potentially leading to decreased growth of EGFR and/or MET-expressing tumors (PMID: 27216193).', 'references': []}]",JNJ-61186372,2016-07-21T04:12:40Z
0,2016-02-25T19:42:05Z,3614,"[{'description': 'Limited information is currently available on JNJ-61610588 (Feb, 2016). ', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",JNJ-61610588 ,2016-02-25T19:42:05Z
0,2017-05-19T19:28:45Z,5708,"[{'description': 'JNJ-64007957 is a bispecific antibody that targets CD3 and BCMA, potentially resulting in increased immune response against BCMA-expressing tumor cells (Blood Dec 2016, 128 (22) 5668).', 'references': [{'id': 8950, 'pubMedId': None, 'title': 'Exploratory Pharmacokinetic/Pharmacodynamic and Tolerability Study of BCMAxCD3 in Cynomolgus Monkeys', 'url': 'http://www.bloodjournal.org/content/128/22/5668'}]}]",JNJ-64007957,2017-05-19T19:28:45Z
0,2016-10-30T20:45:11Z,4889,"[{'description': 'JNJ-64041809 is an attenuated strain of Listeria monocytogenes encoding multiple tumor antigens which may stimulate anti-tumor immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",JNJ-64041809,2016-10-30T20:45:11Z
0,2016-05-27T14:49:37Z,4166,"[{'description': 'JNJ-64052781 is an antibody-like protein that binds to both CD3 and CD19, resulting in cross-linking of tumor B-cells and cytotoxic T-lymphocytes, potentially leading to immune response against B-cell malignancies (NCI Drug Dictionary).', 'references': []}]",JNJ-64052781,2016-06-03T18:25:22Z
0,2015-03-08T21:20:09Z,2329,"[{'description': 'JNJ-7706621 is a dual inhibitor of CDK1/2 and AURKA, B, which induces cell cycle arrest (PMID: 16204078).', 'references': [{'id': 2119, 'pubMedId': 16204078, 'title': 'The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16204078'}]}]",JNJ-7706621,2017-04-04T12:40:30Z
0,2016-01-06T19:21:53Z,3369,"[{'description': 'JNK-In-8 is a covalent inhibitor of JNK1, 2, and 3, which results in decreased downstream signaling (PMID: 22284361).', 'references': [{'id': 4220, 'pubMedId': 22284361, 'title': 'Discovery of potent and selective covalent inhibitors of JNK.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22284361'}]}]",JNK-In-8,2016-01-06T19:21:53Z
0,2016-12-02T04:18:27Z,5048,"[{'description': 'JPH203 (KYT-0353) inhibits LAT1, potentially resulting in decreased tumor cell growth (PMID: 24492461, PMID: 19900191).', 'references': [{'id': 7236, 'pubMedId': 19900191, 'title': 'L-type amino acid transporter 1 inhibitors inhibit tumor cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19900191'}, {'id': 7237, 'pubMedId': 24492461, 'title': 'JPH203, an L-type amino acid transporter 1-selective compound, induces apoptosis of YD-38 human oral cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24492461'}]}]",JPH203,2016-12-02T04:18:27Z
0,2016-12-02T04:20:52Z,5049,[],JPH203 + Metformin,2016-12-02T04:20:52Z
0,2014-09-30T19:18:55Z,1574,"[{'description': 'JQ1 is a BET bromodomain inhibitor with greatest specificity towards BRD4, resulting in decreased Myc expression and cell death (PMID: 24231268).', 'references': [{'id': 878, 'pubMedId': 24231268, 'title': 'BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24231268'}]}]",JQ1,2017-03-17T19:19:00Z
0,2016-09-16T02:28:52Z,4717,[],JQ1 + MRK-003,2016-09-16T02:28:52Z
0,2017-03-07T18:25:18Z,5415,[],JQ1 + Paclitaxel,2017-03-07T18:25:18Z
0,2016-05-28T01:03:58Z,4185,[],JQ1 + Panobinostat,2016-05-28T01:03:58Z
0,2017-04-27T19:12:38Z,5584,[],JQ1 + SCH772984,2017-04-27T19:12:38Z
0,2017-08-03T18:32:19Z,6085,[],JQ1 + Silmitasertib,2017-08-03T18:32:19Z
0,2017-04-27T19:10:13Z,5582,[],JQ1 + Trametinib,2017-04-27T19:10:13Z
0,2017-03-07T20:31:30Z,5417,[],JQ1 + VE-821,2017-03-07T20:31:30Z
0,2017-04-27T19:11:21Z,5583,[],JQ1 + Vemurafenib,2017-04-27T19:11:21Z
0,2016-08-31T17:02:02Z,4630,[],JQ1 + Vinorelbine,2016-08-31T17:02:02Z
0,2016-06-24T05:11:17Z,4354,"[{'description': 'JQEZ5 inhibits EZH2, which may result in decreased growth of EZH2-expressing tumors (PMID: 27312177).', 'references': [{'id': 6049, 'pubMedId': 27312177, 'title': 'Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312177'}]}]",JQEZ5,2016-06-24T05:11:17Z
0,2017-06-14T16:49:21Z,5891,"[{'description': 'JS001 is a monoclonal antibody directed against PD-1, which potentially enhances immune response and decreases tumor growth (PMID: 28317872; J Clin Oncol 35, 2017 (suppl; abstr e14581)).', 'references': [{'id': 9133, 'pubMedId': None, 'title': 'A phase 1 trial of JS001, a monoclonal antibody targeting programmed death-1 (PD-1) in patients with advanced or recurrent malignancies.', 'url': 'http://abstracts.asco.org/199/AbstView_199_188639.html'}, {'id': 9132, 'pubMedId': 28317872, 'title': 'Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28317872'}]}]",JS001,2017-06-14T16:49:21Z
0,2015-06-04T15:02:03Z,2789,"[{'description': 'JTE-052 is an ATP-competitive inhibitor of JAK1, 2, and 3, which suppresses inflammation (PMID: 25387665).', 'references': [{'id': 2952, 'pubMedId': 25387665, 'title': 'Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25387665'}]}]",JTE-052,2015-06-08T18:07:58Z
0,2016-09-20T02:45:21Z,4719,"[{'description': 'JTX-2011 is a humanized monoclonal antibody against ICOS (inducible co-stimulator molecule) that regulates anti-tumor immune response (Cancer Res 2016;76(14 Suppl):Abstract nr 573).', 'references': [{'id': 6661, 'pubMedId': None, 'title': 'Preclinical evaluation of JTX-2011, an anti-ICOS agonist antibody', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/573'}]}]",JTX-2011,2016-09-20T20:49:26Z
0,2016-09-20T02:48:35Z,4720,[],JTX-2011 + Nivolumab,2016-09-20T02:48:35Z
0,2015-03-16T17:38:57Z,2411,"[{'description': 'JW55 selectively inhibits Wnt/beta-catenin-mediated signaling by inhibiting tankyrase1/2, thus stabilizing axin and stimulating beta-catenin degradation, which prevents cell division and decreases tumor growth (PMID: 22440753).', 'references': [{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}]}]",JW55,2015-09-22T19:13:30Z
0,2015-10-07T17:03:28Z,3103,"[{'description': 'JW67 is a small molecule that inhibits canonical Wnt signaling, potentially resulting in decreased tumor cell growth (PMID: 21199802).', 'references': [{'id': 755, 'pubMedId': 21199802, 'title': 'Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21199802'}]}]",JW67,2015-10-07T17:03:28Z
0,2015-10-07T17:04:28Z,3104,"[{'description': 'JW74 is a small molecule that inhibits canonical Wnt signaling, potentially resulting in decreased tumor cell growth (PMID: 21199802).', 'references': [{'id': 755, 'pubMedId': 21199802, 'title': 'Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21199802'}]}]",JW74,2015-10-07T17:04:28Z
0,2015-12-29T15:25:07Z,3341,"[{'description': 'JX-594 is a thymidine kinase-inactivated oncolytic vaccinia virus expressing human GM-CSF, which selectively infects transformed cells and induces cell death (PMID: 22186794).', 'references': [{'id': 4181, 'pubMedId': 22186794, 'title': 'The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22186794'}]}]",JX-594,2015-12-29T15:25:07Z
0,2015-12-16T04:04:10Z,3293,"[{'description': 'JX06 is a selective inhibitor of PDK1, which potentially leads to increased death of glycolysis-dependent tumor cells (PMID: 26483203).', 'references': [{'id': 4110, 'pubMedId': 26483203, 'title': 'JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26483203'}]}]",JX06,2015-12-16T04:04:10Z
0,2016-02-11T10:07:20Z,3509,"[{'description': 'JY-3-094 inhibits Myc-Max dimerization to prevent transcription of Myc (PMID: 25332683).', 'references': [{'id': 4549, 'pubMedId': 25332683, 'title': 'Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25332683'}]}]",JY-3-094,2016-02-11T10:07:20Z
0,2015-06-12T16:46:17Z,2832,"[{'description': 'K-7174 is a homopiperazine derivative that inhibits GATA1 and GATA2, which may reduce tumor mediated inflammation and reduce tumor growth (PMID:17604001, PMID:10833420).', 'references': [{'id': 3035, 'pubMedId': 10833420, 'title': 'A novel cell adhesion inhibitor, K-7174, reduces the endothelial VCAM-1 induction by inflammatory cytokines, acting through the regulation of GATA.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10833420'}, {'id': 3034, 'pubMedId': 17604001, 'title': 'Suppression of cytokine response by GATA inhibitor K-7174 via unfolded protein response.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17604001'}]}]",K-7174,2015-08-10T15:47:26Z
0,2016-07-07T20:20:05Z,4427,"[{'description': 'K-756 inhibits Tankyrase, resulting in decreased Wnt/beta-catenin pathway signaling, and potentially leading to decreased tumor cell growth in combination with other agents (PMID: 27196752).', 'references': [{'id': 6261, 'pubMedId': 27196752, 'title': 'The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196752'}]}]",K-756,2016-07-07T20:20:05Z
0,2016-07-07T20:30:38Z,4428,[],K-756 + Gefitinib,2016-07-07T20:30:38Z
0,2016-03-03T20:25:48Z,3674,"[{'description': 'K00135 is a small molecule inhibitor of PIM1, which may reduce cell growth (PMID: 21993851).', 'references': [{'id': 4427, 'pubMedId': 21993851, 'title': 'Clinical and therapeutic relevance of PIM1 kinase in gastric cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21993851'}]}]",K00135,2016-03-03T20:25:48Z
0,2014-07-16T05:05:43Z,1088,[],K252a,2014-07-16T05:05:43Z
0,2015-07-23T17:55:36Z,2954,"[{'description': 'KB004 is a recombinant antibody that binds to EphA3, which may result in increased apoptosis of EphA3 expressing tumor cells (PMID: 27736729).', 'references': [{'id': 9290, 'pubMedId': 27736729, 'title': 'KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27736729'}, {'id': 3318, 'pubMedId': None, 'title': 'A Recombinant Antibody to EphA3 with Pro-Apoptotic and Enhanced ADCC Activity Against Various Hematologic Malignancies Shows Selective Inhibition of Colony Formation From Long-Term Culture-Initiating Cells (LTC-ICs) In Primary Leukemia Samples', 'url': 'http://www.bloodjournal.org/content/116/21/2897'}]}]",KB004,2017-07-24T19:22:06Z
0,2014-11-03T14:28:00Z,1699,"[{'description': 'KD018 is an herbal formulation whose mechanism of action is unclear, but which results in inhibition of CYP3A4, MMP, NF-KB, beta-glucuronidase, and the NK-1 receptor, as well as modulation of certain cytokines, macrophages and lymphocytes (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",KD018,2015-10-13T17:45:30Z
0,2014-11-03T14:29:38Z,1700,[],KD018 + Irinotecan,2014-11-03T14:30:05Z
0,2015-02-11T15:56:49Z,2045,"[{'description': 'KD020 is a reversible multi-kinase inhibitor which binds EGFR, ERBB2 (HER2), VEGFR2 (KDR), VEGFR3, and SRC to reduce cell proliferation, angiogenesis, and tumor growth (PMID: 24520092).', 'references': [{'id': 1864, 'pubMedId': 24520092, 'title': 'Molecular pathways: HER3 targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24520092'}]}]",KD020,2015-02-11T15:56:49Z
0,2017-05-10T19:35:54Z,5660,"[{'description': 'KDM5-C70 is an inhibitor of KDM5B, which may result in antiproliferative activity in tumor cells (PMID: 27214403). ', 'references': [{'id': 8868, 'pubMedId': 27214403, 'title': 'Structural analysis of human KDM5B guides histone demethylase inhibitor development.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27214403'}]}]",KDM5-C70,2017-05-10T19:35:54Z
0,2015-06-19T13:08:46Z,2858,[],Ketoconazole,2015-06-19T13:08:46Z
0,2015-06-18T14:54:25Z,2837,"[{'description': 'Ki20227 inhibits CSF1R, which may result in decreased CSF-dependent cell growth (PMID: 17121910).', 'references': [{'id': 3072, 'pubMedId': 17121910, 'title': 'A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121910'}]}]",Ki20227,2015-06-18T14:54:25Z
0,2015-04-29T17:30:02Z,2611,"[{'description': 'Ki23819 inhibits both wild-type FLT3 and FLT3 containing activating internal tandem duplications, which may prevent downstream signaling and induce apoptosis in cancer cells (PMID: 15815726). ', 'references': [{'id': 2607, 'pubMedId': 15815726, 'title': 'Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15815726'}]}]",Ki23819,2015-04-29T17:36:28Z
0,2015-05-19T20:56:40Z,2714,"[{'description': 'Ki26894 is an inhibitor of TGFBR1, which blocks activation of downstream signaling targets and may prevent migration and anchorage independent growth of cancer cells (PMID: 17129361).', 'references': [{'id': 2770, 'pubMedId': 17129361, 'title': 'Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17129361'}]}]",Ki26894,2015-05-22T00:38:56Z
0,2017-05-26T18:57:49Z,5795,"[{'description': 'KITE-585 (Anti-TNFRSF17 CAR T cells) targets the TNFRSF17 (BCMA) protein on multiple myeloma cells, plasma cells, and mature B cell subsets, which may lead to cell death and delayed disease progression (AACR Meeting, 2017, abstract nr 4979). ', 'references': [{'id': 9007, 'pubMedId': None, 'title': 'Development of KITE-585: a fully human BCMA CAR T-cell therapy for the treatment of multiple myeloma', 'url': 'http://www.aacr.org/Documents/AACR2017_Proceedings.pdf'}]}]",KITE-585,2017-05-26T19:38:49Z
0,2017-05-30T15:12:07Z,5803,"[{'description': 'KITE-718 comprises autologous T-cells engineered to express a T-cell receptor that recognizes MAGE-A3 and MAGE-A6, which may decrease growth of MAGE-A3 and MAGE-A6-expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",KITE-718,2017-09-01T19:35:41Z
0,2017-05-30T14:50:39Z,5802,"[{'description': 'Limited information is currently available on KITE-796, putative Anti-CLL-1 CAR T cells (May, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",KITE-796,2017-05-30T14:50:39Z
0,2016-04-06T19:08:37Z,3903,"[{'description': 'KJ-Pyr-9 is a pyridine compound that inhibits Myc activity, leading to tumor cell growth inhibition in culture and in animal models (PMID: 25114221).', 'references': [{'id': 5115, 'pubMedId': 25114221, 'title': 'Inhibitor of MYC identified in a Kröhnke pyridine library.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25114221'}]}]",KJ-Pyr-9,2016-04-06T19:08:37Z
0,2017-08-22T14:36:12Z,6140,"[{'description': 'KN035 is a nanobody that targets PD-L1 and prevents interaction with PD-1 (PDCD1), potentially resulting in decreased tumor growth (PMID: 28280600).', 'references': [{'id': 9761, 'pubMedId': 28280600, 'title': 'Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28280600'}]}]",KN035,2017-08-22T14:36:12Z
0,2017-05-23T16:46:04Z,5747,"[{'description': 'KO-947 is an inhibitor of both ERK 1 and 2, which results in inhibition of Erk signaling, thereby potentially blocking cell proliferation and inducing tumor regression (EJC Dec 2016, 69:1; S126). ', 'references': [{'id': 8965, 'pubMedId': None, 'title': 'KO-947, a potent and selective ERK inhibitor with slow dissociation kinetics', 'url': 'http://www.ejcancer.com/article/S0959-8049(16)32974-4/abstract'}]}]",KO-947,2017-05-23T16:46:04Z
0,2017-03-07T18:52:19Z,5416,"[{'description': 'KP372-1 is an inhibitor of AKT that results in inhibition of downstream signaling, thereby leading to apoptotic activity and blockade of cell proliferation (PMID: 15870708).', 'references': []}]",KP372-1,2017-03-07T18:52:19Z
0,2016-10-12T15:28:51Z,4814,"[{'description': 'KPT-185 is a small molecule inhibitor of the nuclear export, XPO1 (CRM1), preventing export of tumor suppressor proteins thereby possibly restoring tumor suppressor function in the cell and thus, leading to apoptotic activity (PMID: 25579209). KPT-185 has been demonstrated to be unsuitable for in vivo studies due to weak pharmacokinetic properties (PMID: 23373539).', 'references': [{'id': 6754, 'pubMedId': 25579209, 'title': 'Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25579209'}, {'id': 6755, 'pubMedId': 23373539, 'title': 'KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23373539'}]}]",KPT-185,2016-10-12T15:52:26Z
0,2017-05-19T04:09:43Z,5687,"[{'description': 'KPT-8602 inhibits exportin-1 (XPO1), resulting in decreased nuclear export and potentially resulting in increased tumor cell death (PMID: 27780859).', 'references': [{'id': 8936, 'pubMedId': 27780859, 'title': 'The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780859'}]}]",KPT-8602,2017-05-19T04:09:43Z
0,2016-09-07T15:43:14Z,4662,"[{'description': 'KPT-9274 is a dual inhibitor of PAK4 and NAMPT, which blocks the PAK4 and NAD pathways, possibly resulting in inhibition of tumor growth (PMID: 27390344). ', 'references': [{'id': 6570, 'pubMedId': 27390344, 'title': 'Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27390344'}]}]",KPT-9274,2016-09-07T15:43:14Z
0,2016-09-12T18:42:32Z,4688,[],KPT-9274 + Niacin,2016-09-12T18:42:32Z
0,2016-12-20T20:34:17Z,5112,"[{'description': 'KRAS-mutant specific autologous tumor-infiltrating cells are patient-derived tumor-infiltrating cells that contain cytotoxic T-cells that target KRAS-mutant tumor cells, which upon expansion and infusion potentially induce regression of KRAS-mutant tumors (PMID: 27959684).', 'references': [{'id': 7358, 'pubMedId': 27959684, 'title': 'T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27959684'}]}]",KRAS mutant-specific TIL,2016-12-20T20:34:17Z
0,2016-03-30T01:23:15Z,3872,"[{'description': 'KRC-00509 is a selective small molecule inhibitor of Met, which reduces Met activation potentially leading to decreased growth of Met-expressing tumor cells (PMID: 26801760).', 'references': [{'id': 5073, 'pubMedId': 26801760, 'title': 'Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26801760'}]}]",KRC-00509,2016-03-30T01:23:15Z
0,2016-03-30T01:21:21Z,3871,"[{'description': 'KRC-00715 is a selective small molecule inhibitor of Met, which reduces Met activation potentially leading to decreased growth of Met-expressing tumor cells (PMID: 26801760).', 'references': [{'id': 5073, 'pubMedId': 26801760, 'title': 'Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26801760'}]}]",KRC-00715,2016-03-30T01:21:38Z
0,2017-07-31T15:15:32Z,6056,"[{'description': 'KRIBB11 binds to Hsf1 and prevents transcription of target genes, which results in apoptosis and growth inhibition of tumor cells (PMID: 21078672).', 'references': []}]",KRIBB11,2017-07-31T15:15:32Z
0,2017-07-31T15:17:20Z,6057,[],KRIBB11 + MK2206,2017-07-31T15:17:20Z
0,2016-10-16T20:08:22Z,4829,"[{'description': 'KTE-C19 (Yescarta) is an immunotherapy consisted of peripheral T-lymphocytes engineered to express a chimeric antigen receptor targeting CD19, CD28 and CD3zeta, resulting in immunostimulating and antineoplastic activities (Blood 2015 126:3991).', 'references': [{'id': 6768, 'pubMedId': None, 'title': 'Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)', 'url': 'http://www.bloodjournal.org/content/126/23/3991'}]}]",KTE-C19,2017-10-19T10:14:33Z
0,2016-12-14T03:28:17Z,5098,[],KTE-C19 + Fludarabine phosphate + Cyclophosphamide,2016-12-14T03:28:17Z
0,2016-10-06T15:29:24Z,4802,"[{'description': 'KTN0073-IgG1 is a chimeric anti-MET antibody comprised of a rodent variable region and human IgG1 region, which inhibits phosphorylation of MET and induces MET degradation, potentially resulting in decreased proliferation of tumor cells harboring wild-type or mutant MET (PMID: 27550450).', 'references': [{'id': 6713, 'pubMedId': 27550450, 'title': 'Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550450'}]}]",KTN0073-IgG1,2017-07-26T18:39:53Z
0,2016-10-06T14:20:57Z,4799,"[{'description': 'KTN0073-IgG2 is a MET targeted antibody engineered to an IgG2 isotype, which inhibits ligand binding and induces degradation of both wild-type and mutant forms of MET, resulting in decreased tumor cell proliferation, including tumor cells harboring MET mutations and/or amplification (PMID: 27550450).', 'references': [{'id': 6713, 'pubMedId': 27550450, 'title': 'Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550450'}]}]",KTN0073-IgG2,2017-07-26T18:40:06Z
0,2015-03-02T10:30:53Z,2228,"[{'description': 'KU-0063794 is an mTOR inhibitor with activity against both mTORC1 and mTORC2, which prevents cell proliferation (PMID: 19402821).', 'references': [{'id': 2059, 'pubMedId': 19402821, 'title': 'Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19402821'}]}]",KU-0063794,2016-04-01T16:41:58Z
0,2016-04-27T18:35:07Z,4013,[],KU-0063794 + Talazoparib,2017-06-12T16:02:51Z
0,2015-10-08T04:31:00Z,3116,"[{'description': 'KU-55933 inhibits ATM, resulting in decreased activation of ATM targets and increased sensitivity of tumor cells to DNA damaging agents (PMID: 15604286).', 'references': [{'id': 3723, 'pubMedId': 15604286, 'title': 'Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15604286'}]}]",KU-55933,2015-10-08T04:31:00Z
0,2016-03-30T18:55:21Z,3879,[],KU-55933 + Radiotherapy,2016-03-30T18:55:21Z
0,2016-02-28T02:42:03Z,3652,"[{'description': 'KU-60019 is a small molecule specific inhibitor of ATM, with anti-cancer activity in vitro (PMID: 19808981).', 'references': [{'id': 4737, 'pubMedId': 19808981, 'title': 'Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19808981'}]}]",KU-60019,2016-02-28T02:42:03Z
0,2015-10-29T23:41:59Z,3157,"[{'description': 'KU004 is a quinazoline derivative with structural similarity to lapatinib inhibiting both Egfr and Erbb2 (Her2) in vitro (PMID: 26437915).', 'references': [{'id': 3826, 'pubMedId': 26437915, 'title': 'A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26437915'}]}]",KU004,2015-10-29T23:41:59Z
0,2017-07-05T18:48:18Z,5967,"[{'description': 'KU60648 is a DNA protein kinase inhibitor, which may lead to impairment of double stranded break repair, thereby resulting in decreased cell viability (PMID: 28224663). ', 'references': [{'id': 9237, 'pubMedId': 28224663, 'title': 'Loss of MLH1 sensitizes colon cancer cells to DNA-PKcs inhibitor KU60648.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28224663'}]}]",KU60648,2017-07-05T18:48:18Z
0,2017-07-05T19:19:58Z,5968,[],KU60648 + Radiotherapy,2017-07-05T19:19:58Z
0,2015-04-29T17:57:02Z,2614,"[{'description': 'KW-2449 is a multikinase inhibitor with activity against FLT3, FLT3 D385Y, ABL1, ABL1 T315I, FGFR1, and AURKA, which may inhibit cancer cell proliferation and tumor growth (PMID: 19541823).', 'references': [{'id': 2612, 'pubMedId': 19541823, 'title': 'KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19541823'}]}]",KW-2449,2017-04-04T12:44:17Z
0,2014-03-12T15:53:16Z,785,"[{'description': 'KW-2450 is a multitargeted kinase inhibitor with activity against Aurora A and B, and IGF-1R, which potentially results in decreased tumor cell growth (PMID: 26443806).', 'references': [{'id': 4114, 'pubMedId': 26443806, 'title': 'Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26443806'}]}]",KW-2450,2017-04-04T12:44:55Z
0,2015-12-16T18:53:24Z,3295,[],KW-2450 + Selumetinib,2015-12-16T18:53:24Z
0,2015-06-03T16:58:42Z,2762,"[{'description': 'KW-2478 inhibits HSP90, which may result in increased apoptosis and decreased growth of tumor cells (PMID: 20406843).', 'references': [{'id': 2908, 'pubMedId': 20406843, 'title': 'New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20406843'}]}]",KW-2478,2015-06-03T17:11:06Z
0,2014-03-12T15:53:16Z,786,"[{'description': 'KX2-391 is a peptidomimetic dual inhibitor of Src and pretubulin, which result in tumor growth inhibition and metastasis prevention (PMID: 22784709). ', 'references': [{'id': 5190, 'pubMedId': 22784709, 'title': 'Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22784709'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",KX2-391,2017-04-27T10:16:28Z
0,2016-04-21T18:47:26Z,3979,[],KX2-391 + Oxaliplatin,2016-04-21T18:47:26Z
0,2016-04-21T18:14:17Z,3978,[],KX2-391 + Paclitaxel,2016-04-21T18:14:17Z
0,2014-10-29T19:47:04Z,1681,"[{'description': 'L-685458 is a small molecule which selectively binds and inhibits gamma-secretase inhibiting proteolytic cleavage of downstream targets including NOTCH receptor proteins thus blocking pathway activation in cancer (PMID: 10913280).', 'references': [{'id': 980, 'pubMedId': 10913280, 'title': 'L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10913280'}]}]",L-685458,2015-08-10T15:30:32Z
0,2017-08-08T19:11:36Z,6096,"[{'description': 'L-NMMA is a pan-nitric oxide synthase inhibitor, which may decrease proliferation and migration of tumor cells (PMID: 25849745).', 'references': [{'id': 9689, 'pubMedId': 25849745, 'title': 'Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25849745'}]}]",L-NMMA,2017-08-08T19:11:36Z
0,2017-08-08T19:12:40Z,6097,[],L-NMMA + Pembrolizumab,2017-08-08T19:12:40Z
0,2016-02-19T20:03:01Z,3582,"[{'description': 'L779450 is a pan-RAF inhibitor, which may lead to decreased tumor cell proliferation and increased apoptosis (PMID: 23955071, PMID: 12970777).', 'references': [{'id': 4636, 'pubMedId': 23955071, 'title': 'RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23955071'}, {'id': 4637, 'pubMedId': 12970777, 'title': 'Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12970777'}]}]",L779450,2016-03-23T23:21:08Z
0,2015-07-08T15:10:36Z,2887,"[{'description': 'LAG525 is a monoclonal antibody that targets LAG-3 and blocks interaction with MHC class II molecules, leading to enhanced T-cell response to tumor cells and decreased tumor growth (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",LAG525,2015-07-08T15:10:36Z
0,2017-08-18T19:17:09Z,6128,"[{'description': 'Lanreotide depot is a somatostatin analog peptide-based drug, which may decrease growth of neuroendocrine tumors (PMID: 27619395).', 'references': [{'id': 9754, 'pubMedId': 27619395, 'title': 'Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27619395'}]}]",Lanreotide Depot,2017-08-18T19:17:09Z
0,2017-10-02T15:17:15Z,6279,[],Lanreotide Depot + Octreotide,2017-10-02T15:17:15Z
0,2017-08-18T19:18:06Z,6129,[],Lanreotide Depot + Pembrolizumab,2017-08-18T19:18:06Z
0,2014-03-12T15:53:16Z,787,"[{'description': 'Tykerb (lapatinib) reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ERBB2 (HER2), and the ERK-1 and-2 and AKT kinases (NCI Drug Dictionary). Tykerb (lapatinib) is FDA approved for HER2 positive breast cancer (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Lapatinib,2015-03-31T13:44:38Z
0,2016-02-01T19:51:51Z,3496,[],Lapatinib + A3,2016-02-01T19:51:57Z
0,2014-08-06T14:43:10Z,1394,[],Lapatinib + bortezomib,2014-08-06T14:43:10Z
0,2014-08-12T15:15:10Z,1399,[],Lapatinib + Capecitabine,2014-08-12T15:15:10Z
0,2014-09-25T19:13:07Z,1552,[],Lapatinib + Capecitabine + Everolimus,2014-09-25T19:13:07Z
0,2015-03-27T09:21:49Z,2477,[],Lapatinib + Carboplatin + Cisplatin + Paclitaxel,2015-03-27T09:21:49Z
0,2015-03-27T09:19:25Z,2476,[],Lapatinib + Carboplatin + Paclitaxel,2015-03-27T09:19:25Z
0,2015-03-27T08:53:17Z,2475,[],Lapatinib + Cisplatin,2015-03-27T08:53:17Z
0,2014-09-18T20:30:26Z,1500,[],Lapatinib + Docetaxel,2014-09-18T20:30:26Z
0,2014-09-18T20:29:19Z,1499,[],Lapatinib + Gemcitabine,2014-09-18T20:29:19Z
0,2014-09-18T20:33:59Z,1502,[],Lapatinib + Irinotecan + Leucovorin + Fluorouracil,2014-09-18T20:33:59Z
0,2014-09-18T20:26:28Z,1497,[],Lapatinib + Letrozole,2014-09-18T20:26:28Z
0,2014-07-28T12:43:23Z,1140,[],Lapatinib + Metformin,2014-07-28T12:43:23Z
0,2016-04-27T12:44:14Z,4007,[],Lapatinib + MK2206,2016-04-27T12:44:14Z
0,2014-09-18T20:27:50Z,1498,[],Lapatinib + Oxaliplatin + Capecitabine,2014-09-18T20:27:50Z
0,2014-09-18T20:32:09Z,1501,[],Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil,2014-09-18T20:32:09Z
0,2014-08-29T09:46:40Z,1410,[],Lapatinib + Paclitaxel,2014-08-29T09:46:40Z
0,2015-08-21T15:40:19Z,3042,[],Lapatinib + Palbociclib,2015-08-21T15:40:19Z
0,2014-11-06T16:34:56Z,1708,[],Lapatinib + Panobinostat,2014-11-06T16:35:26Z
0,2017-07-03T14:26:25Z,5958,[],Lapatinib + Pertuzumab,2017-07-03T14:26:25Z
0,2016-03-15T17:42:57Z,3745,[],Lapatinib + RU-SKI 43,2016-03-15T17:42:57Z
0,2016-10-25T18:38:00Z,4859,[],Lapatinib + S63845,2016-10-25T18:38:00Z
0,2014-07-28T12:42:38Z,1139,[],Lapatinib + Sirolimus,2014-07-28T12:42:38Z
0,2015-03-20T12:23:55Z,2440,[],Lapatinib + Temozolomide,2015-03-20T12:23:55Z
0,2016-08-18T17:49:44Z,4584,[],Lapatinib + Torkinib,2017-07-07T18:43:58Z
0,2016-09-08T16:59:30Z,4668,[],Lapatinib + Trametinib,2016-09-08T16:59:48Z
0,2015-04-17T02:01:59Z,2543,[],Lapatinib + Veliparib,2015-04-17T02:01:59Z
0,2014-11-06T16:17:05Z,1707,[],Lapatinib + Vemurafenib,2014-11-06T16:17:05Z
0,2016-06-22T15:43:12Z,4344,"[{'description': 'Neuvenge (lapuleucel-T) is a cellular vaccine of antigen-presenting cells cultured with recombinant Erbb2 (Her2) antigen linked to GMCSF, which stimulates anti-tumor response against Erbb2 (Her2) expressing tumor cells (J Clin Oncol 34, 2016 (suppl; abstr 4513)).', 'references': [{'id': 5991, 'pubMedId': None, 'title': 'Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts).', 'url': 'http://meetinglibrary.asco.org/content/162594-176'}]}]",lapuleucel-T,2016-06-22T15:43:12Z
0,2016-02-11T17:16:41Z,3514,"[{'description': 'LB100 is a small molecule that inhibits PP2A activity, resulting in increased  sensitivity of  tumor cells to DNA damaging agents (PMID: 25376608).', 'references': [{'id': 4553, 'pubMedId': 25376608, 'title': 'The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25376608'}]}]",LB-100,2016-02-11T17:16:41Z
0,2016-02-11T17:25:52Z,3515,[],LB-100 + Cisplatin,2016-02-11T17:25:52Z
0,2016-02-25T15:41:02Z,3608,"[{'description': 'LB100 is a small molecule inhibitor of PP2A, which may enhance the effects of chemotherapeutics resulting in inhibition of tumor growth and prolonged survival (PMID: 25939762).', 'references': [{'id': 4699, 'pubMedId': 25939762, 'title': 'Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25939762'}]}]",LB100,2016-02-25T15:41:02Z
0,2016-02-26T19:30:16Z,3641,"[{'description': 'LCL161 is a SMAC mimetic that inhibits Inhibitor of Apoptosis Protein (IAP) family proteins, potentially leading to increased tumor cell death (PMID: 21681929, PMID: 24976294).', 'references': [{'id': 4717, 'pubMedId': 21681929, 'title': 'Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21681929'}, {'id': 4718, 'pubMedId': 24976294, 'title': 'Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24976294'}]}]",LCL161,2017-09-25T19:10:17Z
0,2016-02-26T19:35:14Z,3642,[],LCL161 + Paclitaxel,2016-02-26T19:35:14Z
0,2016-03-25T17:45:24Z,3845,[],LCL161 + Topotecan,2016-03-25T17:45:24Z
0,2015-12-03T16:29:08Z,3260,"[{'description': 'LCRF-0004 inhibits MST1R (RON) and MET, which may result in decreased tumor cell proliferation (PMID: 25953155).', 'references': [{'id': 4030, 'pubMedId': 25953155, 'title': 'Design and synthesis of close analogs of LCRF-0004, a potent and selective RON receptor tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25953155'}]}]",LCRF-0004,2015-12-03T16:30:04Z
0,2016-12-20T21:29:59Z,5113,"[{'description': 'LDC1267 is a specific TAM kinase inhibitor, with activity against Tyro3, AXL, and MERTK, which potentially enhances anti-tumor immune response and decreases tumor metastasis (PMID: 24553136).', 'references': [{'id': 7359, 'pubMedId': 24553136, 'title': 'The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24553136'}]}]",LDC1267,2017-03-16T16:12:52Z
0,2017-08-04T02:20:33Z,6089,"[{'description': 'LDN-193189 is a small molecule that inhibits the BMP type I receptors ALK2 (ACVR1) and ALK3 (BMPR1A), potentially leading to increased apoptosis and decreased proliferation of tumor cells with activated BMP signaling (PMID: 19029982, PMID: 28611046).', 'references': [{'id': 9682, 'pubMedId': 21670081, 'title': 'BMP4 promotes prostate tumor growth in bone through osteogenesis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21670081'}, {'id': 9681, 'pubMedId': 28611046, 'title': 'Autocrine BMP-4 Signaling Is a Therapeutic Target in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28611046'}]}]",LDN-193189,2017-08-04T02:22:21Z
0,2015-11-05T16:25:19Z,3175,[],LEE001 + Tamoxifen,2015-11-05T16:25:19Z
0,2014-10-02T14:23:22Z,1594,[],LEE011 + BKM120 + Letrozole,2014-10-02T14:23:22Z
0,2014-09-30T18:25:40Z,1569,[],LEE011 + BYL719 + Letrozole,2014-09-30T18:25:40Z
0,2017-02-19T23:34:51Z,5333,[],LEE011 + Carboplatin + Paclitaxel,2017-02-19T23:34:51Z
0,2015-03-03T02:47:30Z,2265,[],LEE011 + Everolimus + Exemestane,2015-03-03T02:47:30Z
0,2015-03-03T02:47:53Z,2266,[],LEE011 + Exemestane,2015-03-03T02:47:53Z
0,2014-09-30T18:24:25Z,1568,[],LEE011 + Letrozole,2014-09-30T18:24:25Z
0,2017-05-22T18:25:29Z,5740,"[{'description': 'Lefitolimod (MGN1703) is a TLR-9 agonist, which results in increased anti-tumor immune response, and may lead to decreased tumor growth (PMID: 25577571).', 'references': [{'id': 8961, 'pubMedId': 25577571, 'title': 'MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25577571'}]}]",Lefitolimod,2017-05-22T18:28:04Z
0,2014-03-12T15:53:16Z,791,[],Lefunomide,
0,2014-07-28T16:46:12Z,1164,"[{'description': 'Revlimid (lenalidomide) inhibits angiogenesis and promotes G1 cell cycle arrest and apoptosis of malignant cells. It is a thalidomide analog which inhibits TNF-alpha production, stimulates T cells, and reduces serum levels of the cytokines VEGF and bFGF (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",lenalidomide,2017-06-19T18:37:43Z
0,2014-12-23T16:05:11Z,1847,[],lenalidomide + Fludarabine + Melphalan,2014-12-23T16:05:11Z
0,2016-04-15T15:24:03Z,3934,[],lenalidomide + MEDI4736,2016-04-15T15:24:10Z
0,2016-06-11T18:30:26Z,4278,[],lenalidomide + MEDI4736 + Rituximab,2016-06-11T18:30:26Z
0,2017-06-02T17:21:46Z,5843,[],Lenalidomide + MOR208,2017-06-02T17:21:46Z
0,2017-01-21T04:24:52Z,5239,[],Lenalidomide + Nivolumab,2017-01-21T04:24:52Z
0,2017-10-08T15:48:06Z,6302,[],Lenalidomide + Obinutuzumab	,2017-10-08T15:48:06Z
0,2016-06-28T01:23:11Z,4394,[],lenalidomide + Obinutuzumab + Polatuzumab Vedotin,2016-06-28T01:23:11Z
0,2017-01-03T17:32:15Z,5133,[],Lenalidomide + Obinutuzumab + Venetoclax,2017-01-03T17:32:15Z
0,2016-05-18T14:47:05Z,4124,[],Lenalidomide + Ofatumumab,2016-05-18T14:47:05Z
0,2016-09-07T14:47:27Z,4658,[],Lenalidomide + PAT-SM6,2016-09-07T14:47:37Z
0,2015-12-21T15:47:25Z,3322,[],lenalidomide + Pembrolizumab,2015-12-21T15:47:25Z
0,2015-12-31T18:48:21Z,3357,[],lenalidomide + Pidilizumab,2015-12-31T18:48:21Z
0,2015-03-11T14:59:15Z,2349,[],Lenalidomide + Rituximab + Romidepsin ,2015-03-11T14:59:15Z
0,2017-08-03T16:25:07Z,6080,[],Lenalidomide + SJB3-019A,2017-08-03T16:25:07Z
0,2016-07-12T14:48:24Z,4445,[],lenalidomide + Sonidegib,2017-06-19T19:31:16Z
0,2016-07-07T18:50:55Z,4426,[],Lenalidomide + Sorafenib,2016-07-07T18:50:55Z
0,2017-01-03T20:17:15Z,5150,[],Lenalidomide + TAK-659,2017-01-03T20:17:15Z
0,2017-02-20T01:51:32Z,5337,[],Lenalidomide + Vorinostat,2017-02-20T01:51:32Z
0,2014-03-12T15:53:16Z,792,"[{'description': 'Lenvima (lenvatinib) inhibits VEGFR, FGFR, PDGFR, KIT, and RET, and suppresses cell proliferation and angiogenesis (PMID: 21781317, PMID: 25295214, PMID: 17943726). Lenvima (lenvatinib) is FDA approved for use in patients with radioactive iodine-refractory differentiated thyroid cancer, and in combination with Afinitor (everolimus) for renal cell carcinoma (FDA.gov).', 'references': [{'id': 307, 'pubMedId': 21781317, 'title': 'E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21781317'}]}]",Lenvatinib,2017-04-03T14:33:38Z
0,2014-12-31T19:06:25Z,1885,[],Lenvatinib + Carboplatin + Paclitaxel,2014-12-31T19:06:25Z
0,2016-03-11T19:48:58Z,3730,[],Lenvatinib + Midazolam,2016-03-11T19:48:58Z
0,2016-06-04T16:35:47Z,4236,[],Lenvatinib + Paclitaxel,2016-06-04T16:35:47Z
0,2016-10-04T15:19:03Z,4782,[],Lenvatinib + Pembrolizumab,2016-10-04T15:19:03Z
0,2015-03-17T01:52:12Z,2416,"[{'description': 'LEQ506 is a small molecule that binds to and inhibits Smoothened (SMO), potentially resulting in inhibition of downstream Hedgehog signaling and decreased tumor growth (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",LEQ506,2015-03-17T01:52:12Z
0,2014-03-12T15:53:16Z,793,"[{'description': 'Lestaurtinib (CEP-701) inhibits JAK2, FLT3 and NTRK1-3, resulting in antiproliferative activity (PMID: 17143529, PMID: 17442779, PMID: 17984313).', 'references': [{'id': 1041, 'pubMedId': 10415871, 'title': 'The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10415871'}, {'id': 1042, 'pubMedId': 17442779, 'title': 'Effect of FLT3 inhibition on normal hematopoietic progenitor cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17442779'}, {'id': 1043, 'pubMedId': 17984313, 'title': 'Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17984313'}]}]",Lestaurtinib,2016-01-08T18:50:43Z
0,2014-03-12T15:53:16Z,794,"[{'description': 'Femara (letrozole) is an aromatase inhibitor, which inhibits estrogen synthesis (NCI Drug Dictionary). Femara (letrozole) is approved for postmenopausal women with hormone receptor positive breast cancer (FDA.gov). ', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Letrozole,2015-06-23T17:50:07Z
0,2014-09-25T20:11:00Z,1553,[],Letrozole + BYL719,2014-09-25T20:11:00Z
0,2016-06-03T01:38:17Z,4222,[],Letrozole + Palbociclib + Pembrolizumab,2016-06-03T01:38:17Z
0,2016-09-25T15:12:47Z,4756,[],Letrozole + Palbociclib + Trastuzumab,2016-09-25T15:13:54Z
0,2016-03-30T18:43:48Z,3878,[],Letrozole + Seribantumab,2016-03-30T18:43:48Z
0,2014-10-14T17:28:59Z,1642,"[{'description': 'Wellcovorin (leucovorin) is a metabolite of folate that enhances the efficacy of fluoruracil (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Leucovorin,2015-04-06T19:44:41Z
0,2015-03-11T14:39:05Z,2347,[],Leucovorin + Pegaspargase  + Vincristine,2015-03-11T14:39:05Z
0,2014-03-12T15:53:16Z,795,"[{'description': 'Lupron (leuprolide) is an agonist of gonadotropin releasing hormone (GnRH), which results decreased testosterone production in males and decreased estradiol production in females, potentially leading to decreased growth of androgen-positive tumors (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Leuprolide,2015-10-13T16:27:56Z
0,2015-05-07T02:34:19Z,2627,[],Levetiracetam,2015-05-07T02:34:19Z
0,2016-10-17T19:17:14Z,4846,"[{'description': 'LF3 is a small molecule that inhibits the interaction between Beta-catenin and TCF, resulting in reduced Wnt target gene expression, decreased migration of tumor cells, and potentially resulting in decreased tumor growth (PMID: 26645562).', 'references': [{'id': 6784, 'pubMedId': 26645562, 'title': 'A Small-Molecule Antagonist of the β-Catenin/TCF4 Interaction Blocks the Self-Renewal of Cancer Stem Cells and Suppresses Tumorigenesis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26645562'}]}]",LF3,2016-10-17T19:19:13Z
0,2015-05-15T01:40:54Z,2686,"[{'description': 'LFM-A13 inhibits BTK, with additional activity against JAK2 and PLK, potentially resulting in increased tumor cell apoptosis (PMID: 17098432, PMID: 15196000, PMID: 10092645).\r\n', 'references': [{'id': 2726, 'pubMedId': 17098432, 'title': 'Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17098432'}, {'id': 2727, 'pubMedId': 15196000, 'title': 'The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15196000'}, {'id': 2728, 'pubMedId': 10092645, 'title': ""Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10092645'}]}]",LFM-A13,2015-05-15T02:33:27Z
0,2015-03-16T15:32:44Z,2402,"[{'description': 'LGH447 is a pan-PIM protein kinase inhibitor, which leads to cell cycle arrest and growth inhibition in PIM-expressing tumor cells (PMID: 24474669).', 'references': [{'id': 2215, 'pubMedId': 24474669, 'title': 'Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24474669'}]}]",LGH447 ,2016-03-08T17:40:22Z
0,2016-03-04T20:44:59Z,3677,[],LGH447 + Cytarabine,2016-03-04T20:44:59Z
0,2015-01-14T03:20:07Z,1937,"[{'description': 'LGK974 binds to and inhibits porcupine (PORCN), resulting in decreased secretion of Wnt ligands and concomitant decrease in Wnt signaling, potentially resulting in reduced cell growth in tumors with dysregulated Wnt signaling (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",LGK974,2015-08-12T09:10:32Z
0,2015-02-04T13:22:00Z,2008,[],LGK974 + LGX818 + Cetuximab,2015-02-04T13:22:00Z
0,2015-01-06T13:34:24Z,1917,[],LGX818 + Cetuximab + BYL719,2015-01-06T13:34:24Z
0,2015-02-28T01:44:43Z,2214,[],LGX818 + MEK162 + BGJ398,2015-02-28T01:45:28Z
0,2015-02-28T01:47:05Z,2215,[],LGX818 + MEK162 + BKM120,2015-02-28T01:47:05Z
0,2015-02-28T01:49:20Z,2216,[],LGX818 + MEK162 + INC280,2015-02-28T01:49:20Z
0,2016-05-03T19:13:23Z,4068,[],LGX818 + unspecified IGF-1R antibody,2016-05-03T19:13:23Z
0,2017-10-08T00:38:43Z,6298,"[{'description': 'Limited information is currently available on LHC165 (Oct 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",LHC165,2017-10-08T00:38:43Z
0,2017-10-08T00:40:20Z,6299,[],LHC165 + PDR001,2017-10-08T00:40:20Z
0,2014-03-12T15:53:16Z,797,"[{'description': 'Linifanib (ABT-869) is a receptor tyrosine kinase inhibitor with specificity against FLT1 (VEGFR1), CSF-1R, KDR (VEGFR2), FLT3, and KIT (PMID: 16648571).', 'references': [{'id': 972, 'pubMedId': 16648571, 'title': 'Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16648571'}]}]",Linifanib,2015-06-18T14:42:38Z
0,2015-03-06T04:28:28Z,2310,[],Linifanib + Paclitaxel + Carboplatin,2015-03-06T04:28:28Z
0,2014-03-12T15:53:16Z,798,"[{'description': 'Linsitinib (OSI-906) is a small molecule dual inhibitor of IGF-1R and IR, which leads to decreased tumor cell proliferation (PMID: 21425998).', 'references': [{'id': 887, 'pubMedId': 21425998, 'title': 'Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21425998'}]}]",Linsitinib,2015-05-29T03:38:06Z
0,2014-12-22T16:27:08Z,1831,[],Linsitinib + Bortezomib + Dexamethasone,2014-12-22T16:27:08Z
0,2017-02-28T16:40:40Z,5380,[],Linsitinib + Midostaurin,2017-02-28T16:40:40Z
0,2016-04-19T19:12:08Z,3955,[],Linsitinib + Palbociclib,2016-04-19T19:12:08Z
0,2016-09-08T02:36:29Z,4666,[],Linsitinib + PF-4708671,2016-09-08T02:36:29Z
0,2016-11-23T17:28:51Z,5002,[],Linsitinib + SCH772984,2016-11-23T17:28:51Z
0,2015-05-14T03:13:58Z,2674,"[{'description': 'Triostat (liothyronine sodium) is a synthetic version of T3, which induces thyroid hormone responsive gene expression to promote normal development and growth (NCI Drug DIctionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",liothyronine sodium  ,2015-05-19T14:32:07Z
0,2015-04-24T12:45:47Z,2583,"[{'description': 'Lirilumab is a monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), which leads to increased NK cell-mediated cytotoxicity towards tumor cells (PMID: 24326534).', 'references': [{'id': 2570, 'pubMedId': 24326534, 'title': 'Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24326534'}]}]",Lirilumab ,2015-04-24T19:36:08Z
0,2015-04-24T12:46:43Z,2584,[],Lirilumab + Nivolumab,2015-04-24T12:46:43Z
0,2015-01-04T02:08:16Z,1900,[],Lisinopril,2015-01-04T02:08:16Z
0,2015-02-10T18:22:28Z,2036,"[{'description': 'LJM716 is a monoclonal antibody that targets ErbB3 (Her3) and prevents its transition into an active conformation, resulting in inhibition of ligand-dependent and ligand-independent downstream signaling and decreased tumor cell proliferation (PMID: 23928993).\r\n', 'references': [{'id': 1859, 'pubMedId': 23928993, 'title': 'An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23928993'}]}]",LJM716,2015-02-11T20:53:46Z
0,2017-07-27T16:39:59Z,6012,[],LJM716 + Neratinib,2017-07-27T16:39:59Z
0,2015-02-10T18:31:03Z,2037,[],LJM716 + Trastuzumab,2015-02-10T18:31:03Z
0,2016-02-23T10:18:40Z,3592,"[{'description': 'LLL12 is a small molecule inhibitor of Stat3 with anti-cancer activity in cell line and xenograft models (PMID: 25883212).', 'references': [{'id': 4664, 'pubMedId': 25883212, 'title': 'LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25883212'}]}]",LLL12,2016-02-23T10:18:40Z
0,2016-02-26T16:24:16Z,3626,"[{'description': 'LMP400 inhibits Top1, resulting in decreased proliferation of tumor cells (PMID: 23215354).', 'references': [{'id': 4709, 'pubMedId': 23215354, 'title': 'Identification, synthesis, and biological evaluation of metabolites of the experimental cancer treatment drugs indotecan (LMP400) and indimitecan (LMP776) and investigation of isomerically hydroxylated indenoisoquinoline analogues as topoisomerase I poisons.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23215354'}]}]",LMP400,2016-07-06T18:09:59Z
0,2017-05-23T17:47:31Z,5749,"[{'description': 'LMP744 is an inhibitor of TOP1, which upon binding results in stability of cleaved Top1, thereby potentially leading to cell cycle arrest and apoptosis of cancer cells (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",LMP744,2017-05-23T17:47:31Z
0,2016-07-06T18:15:25Z,4423,"[{'description': 'LMP776 inhibits TOP1 and has anti-proliferation activities (PMID: 24517248).', 'references': [{'id': 6218, 'pubMedId': 24517248, 'title': 'Synthesis and biological evaluation of new carbohydrate-substituted indenoisoquinoline topoisomerase I inhibitors and improved syntheses of the experimental anticancer agents indotecan (LMP400) and indimitecan (LMP776).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24517248'}]}]",LMP776,2016-07-06T18:15:25Z
0,2015-02-13T16:22:57Z,2075,[],Lomustine,2015-02-13T16:22:57Z
0,2014-03-12T15:53:16Z,799,"[{'description': 'Lonafarnib (SCH66336) is a farnesyl transferase inhibitor, which alters post-translational modification and activation of Ras proteins (PMID: 25323927).', 'references': [{'id': 2048, 'pubMedId': 25323927, 'title': 'Drugging the undruggable RAS: Mission possible?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25323927'}]}]",Lonafarnib,2016-03-11T19:05:57Z
0,2016-03-02T18:53:39Z,3664,[],Lonafarnib + Tamoxifen,2016-03-02T18:53:39Z
0,2015-06-11T18:32:07Z,2818,"[{'description': 'Lonaprisan is a progesterone receptor antagonist, which has been demonstrated to result in antiproliferative activity and cell cycle arrest (PMID: 21138753).', 'references': [{'id': 3016, 'pubMedId': 21138753, 'title': 'The antiprogestin Lonaprisan inhibits breast cancer cell proliferation by inducing p21 expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21138753'}]}]",Lonaprisan,2015-06-19T12:07:45Z
0,2015-08-12T00:51:50Z,3009,"[{'description': 'Long peptide vaccine 7 is a cancer vaccine that contains synthetic peptides based on cancer-testis antigens and melanocytic differentiation proteins, which may induce an anti-tumor immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Long peptide vaccine 7,2015-09-10T13:41:47Z
0,2015-05-15T15:26:59Z,2700,[],Loperamide,2015-05-15T15:26:59Z
0,2015-08-06T04:08:12Z,2998,[],Losartan,2015-08-06T04:08:12Z
0,2015-05-11T19:34:40Z,2650,"[{'description': 'LOXO-101 binds to and prevents activation of TRK receptors, potentially resulting in decreased growth and increased apoptosis in Trk-expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",LOXO-101,2017-06-05T08:48:23Z
0,2017-06-21T20:34:22Z,5917,"[{'description': 'LOXO-195 is an inhibitor of NTRK1, NTRK2, and NTRK3, which may result in inhibition of tumor growth and tumor regression (PMID: 28578312).', 'references': [{'id': 9187, 'pubMedId': 28578312, 'title': 'A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28578312'}]}]",LOXO-195,2017-06-21T20:34:22Z
0,2017-05-19T18:22:36Z,5702,"[{'description': 'LOXO-292 is an inhibitor of RET, specifically targeting RET mutations and fusions, and may block the growth of cells with Ret activity (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",LOXO-292,2017-09-19T17:55:23Z
0,2016-02-10T16:01:15Z,3506,"[{'description': 'LQZ-7F is a small molecule inhibitor of survivin, which may induce cell cycle arrest and apoptosis, and inhibit tumor growth (PMID: 26744521).', 'references': [{'id': 4545, 'pubMedId': 26744521, 'title': 'Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26744521'}]}]",LQZ-7F,2016-02-10T16:01:15Z
0,2015-06-04T16:35:53Z,2793,"[{'description': 'LS104 is a non-ATP competitive inhibitor of JAK2 and JAK2 (V617F), which induces apoptosis (PMID: 18483305).', 'references': [{'id': 2957, 'pubMedId': 18483305, 'title': 'LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18483305'}]}]",LS104,2015-06-04T16:35:53Z
0,2017-10-18T19:06:51Z,6337,"[{'description': 'LSN3074753 is a Pan-RAF inhibitor that inhibits signaling of all RAF isoforms and RAF dimers, which leads to inhibition of tumor cell growth (PMID: 28611205).', 'references': [{'id': 10143, 'pubMedId': 28611205, 'title': 'Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28611205'}]}]",LSN3074753,2017-10-18T19:06:51Z
0,2016-07-12T12:52:49Z,4439,"[{'description': 'Limited information is currently available on LSZ 102 (Jul, 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",LSZ 102,2016-07-12T12:52:49Z
0,2016-07-12T12:53:56Z,4440,[],LSZ 102 + Ribociclib,2016-07-12T12:53:56Z
0,2014-05-14T14:52:46Z,1029,"[{'description': 'Lucitanib (E-3810) is dual tyrosine kinase receptor inhibitor of VEGFR 1-3, DDR, and FGFR1-2, that may inhibit tumor angiogenesis, prevent tumor cell proliferation and induce tumor cell death (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Lucitanib,2016-10-28T09:23:17Z
0,2016-02-18T13:32:43Z,3546,"[{'description': 'Lumretuzumab is a humanized anti-Her3 antibody that binds to and inhibits human epidermal growth factor receptor signaling, leading to growth inhibition in tumors (PMID: 26463709).', 'references': [{'id': 4617, 'pubMedId': 26463709, 'title': 'First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26463709'}]}]",Lumretuzumab,2016-02-18T13:32:43Z
0,2014-07-29T09:34:18Z,1195,"[{'description': 'Lurbinectedin is an alkaloid analogue that binds to the minor groove of DNA, resulting in delayed cell cycle progression and cell death (PMID: 20977459).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 10141, 'pubMedId': 20977459, 'title': 'PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20977459'}]}]",Lurbinectedin,2017-10-18T17:21:20Z
0,2016-11-21T14:56:26Z,4979,[],Lurbinectedin + Irinotecan,2016-11-21T14:56:26Z
0,2014-07-29T09:40:13Z,1197,[],Lurbinectedin + Paclitaxel,2014-07-29T09:40:13Z
0,2014-07-29T09:38:10Z,1196,[],Lurbinectedin + Paclitaxel + Bevacizumab,2014-07-29T09:38:10Z
0,2016-07-12T13:13:20Z,4442,"[{'description': 'LXH 254 is a pan-RAF inhibitor that inhibits proliferation of tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",LXH 254,2016-07-12T13:13:20Z
0,2016-07-12T13:14:18Z,4443,[],LXH 254 + PDR001,2016-07-12T13:14:18Z
0,2015-05-19T18:41:02Z,2711,"[{'description': 'LY2109761 is a pan-TGFBR inhibitor, which prevents downstream signaling and may block proliferation and migration in cancer cells (PMID: 18413796). ', 'references': [{'id': 2766, 'pubMedId': 18413796, 'title': 'LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413796'}]}]",LY2109761,2015-05-19T18:41:02Z
0,2016-03-22T18:19:37Z,3809,[],LY2109761 + Paclitaxel,2016-03-22T18:19:37Z
0,2016-02-12T07:26:12Z,3522,"[{'description': 'LY2275796 is an antisense oligonucleotide targeted against eukaryotic initiation factor 4E (eIF-4E), which results in decreased eIF-4E expression and potentially leads to reduced growth of eIF-4E-expressing tumors (PMID: 17786246, PMID: 21831956).', 'references': [{'id': 4565, 'pubMedId': 17786246, 'title': 'Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17786246'}, {'id': 4564, 'pubMedId': 21831956, 'title': 'A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831956'}]}]",LY2275796,2016-02-12T07:28:22Z
0,2015-06-18T19:47:04Z,2846,"[{'description': 'LY2510924 is a selective CXCR4 antagonist that prevents SDF-1 binding, potentially resulting in decreased tumor cell migration (PMID: 25504752).', 'references': [{'id': 3083, 'pubMedId': 25504752, 'title': 'Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25504752'}]}]",LY2510924,2015-06-25T20:56:25Z
0,2016-06-02T22:06:13Z,4210,[],LY2510924 + MEDI4736,2016-06-02T22:06:13Z
0,2016-10-11T14:02:54Z,4810,[],LY2510924 + Sunitinib,2016-10-11T14:02:54Z
0,2017-09-06T15:17:30Z,6173,"[{'description': 'LY2603618 is a small molecule inhibitor of CHEK1, which may result in DNA synthesis disruption, early mitosis, and subsequently, cell death (PMID: 24114124). ', 'references': [{'id': 9870, 'pubMedId': 24114124, 'title': 'Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24114124'}]}]",LY2603618,2017-09-06T15:17:30Z
0,2017-09-06T15:39:54Z,6175,[],LY2603618 + Pemetrexed,2017-09-06T15:39:54Z
0,2014-03-12T15:53:16Z,800,"[{'description': 'LY2780301 is an inhibitor of AKT and P70S6 kinases, which prevents signaling of the PI3K/AKT pathway thereby possibly resulting in antitumor activity (PMID: 25902900). ', 'references': [{'id': 3473, 'pubMedId': 25902900, 'title': 'A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25902900'}]}]",LY2780301,2017-03-17T19:47:21Z
0,2014-03-12T15:53:16Z,801,"[{'description': 'Gandotinib (LY2784544) is an ATP-competitive inhibitor of JAK2, including JAK2 V617F, which may prevent cell proliferation of tumor cells (PMID: 23584399).', 'references': [{'id': 2931, 'pubMedId': 23584399, 'title': 'Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23584399'}]}]",LY2784544,2015-06-08T17:16:55Z
0,2014-05-14T14:52:46Z,1030,"[{'description': 'LY2801653 inhibits several receptor tyrosine kinases including MET, MST1R (RON), FLT3, AXL, MERTK, TEK, ROS1, DDR1/2, MKNK1/2, and with minimal activity against KDR (VEGFR2), which may result in decreased tumor growth (PMID: 23275061, PMID: 24305878). ', 'references': [{'id': 65, 'pubMedId': 22869872, 'title': 'Targeting the hepatocyte growth factor-cMET axis in cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869872'}, {'id': 331, 'pubMedId': 23275061, 'title': 'LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23275061'}]}]",LY2801653,2017-03-16T17:11:44Z
0,2017-05-22T20:09:51Z,5744,[],LY2801653 + LY2874455,2017-05-22T20:09:51Z
0,2016-06-02T21:48:36Z,4208,[],LY2801653 + Ramucirumab,2016-06-02T21:48:36Z
0,2015-02-09T20:26:19Z,2032,"[{'description': 'LY2874455, a pan-FGFR inhibitor, has equivalent potency against FGFR1-4 and inhibits FGF/FGFR mediated signaling to reduce tumor growth (PMID: 21900693).', 'references': [{'id': 1842, 'pubMedId': 21900693, 'title': 'A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21900693'}]}]",LY2874455,2015-02-10T13:03:03Z
0,2016-06-17T22:24:13Z,4315,"[{'description': 'Limited information is available on LY2880070 (Jun 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",LY2880070,2016-06-17T22:24:13Z
0,2016-07-05T14:20:40Z,4420,[],LY2880070 + Gemcitabine,2016-07-05T14:20:40Z
0,2014-05-22T18:51:35Z,1062,"[{'description': 'LY294002 is a specific inhibitor of PI3K alpha, beta, and delta, which leads to inhibition of PI3K-Akt/PKB signaling (PMID: 12060641).', 'references': [{'id': 292, 'pubMedId': 12060641, 'title': ""The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12060641'}]}]",LY294002,2015-03-02T10:19:28Z
0,2016-03-15T17:50:13Z,3746,[],LY294002 + RU-SKI 43,2016-03-15T17:50:13Z
0,2015-12-08T20:43:42Z,3268,"[{'description': 'LY3009120 is a Pan-RAF inhibitor that inhibits signaling of all RAF isoforms and RAF dimers, which leads to inhibition of tumor cell growth (PMID: 26343583).', 'references': [{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",LY3009120,2017-10-18T19:05:40Z
0,2015-02-02T22:17:25Z,2004,"[{'description': 'LY3022855 (IMC-CS4) is a monoclonal antibody against colony stimulating factor 1 receptor (CSF1R), which potentially induces antibody-dependent cell-mediated cytotoxicity (ADCC) in tumor cells over expressing CSF1R (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",LY3022855,2017-06-14T17:41:32Z
0,2016-06-02T23:59:48Z,4215,[],LY3022855 + MEDI4736,2017-06-14T17:41:54Z
0,2016-06-03T00:00:38Z,4216,[],LY3022855 + Tremelimumab,2017-06-14T17:42:28Z
0,2014-06-09T15:23:14Z,1069,"[{'description': 'LY3023414 is an ATP competitive inhibitor of PI3K/mTOR, inhibits signaling of the PI3K/mTOR pathway, and has demonstrated antiproliferative activity against tumor cells (PMID: 24387334).', 'references': [{'id': 1046, 'pubMedId': None, 'title': 'Abstract 3020', 'url': ''}, {'id': 356, 'pubMedId': 24387334, 'title': 'Therapeutic targeting of cancers with loss of PTEN function.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387334'}]}]",LY3023414,2016-05-09T02:08:30Z
0,2014-07-29T18:29:11Z,1214,[],LY3023414 + Midazolam ,2014-07-29T18:29:11Z
0,2017-09-26T22:12:07Z,6247,[],LY3023414 + Prexasertib,2017-09-26T22:12:07Z
0,2015-07-24T02:19:46Z,2958,"[{'description': 'LY3039478 is a pan-NOTCH inhibitor, which may limit growth and survival of cancer cells (Cancer Res April 15, 2013 73; 1131).', 'references': [{'id': 3325, 'pubMedId': None, 'title': 'Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.', 'url': 'http://cancerres.aacrjournals.org/content/73/8_Supplement/1131.short'}]}]",LY3039478,2015-07-24T02:19:46Z
0,2016-06-27T00:41:44Z,4372,[],LY3039478 + LY3023414,2016-06-27T00:41:44Z
0,2016-06-27T18:01:54Z,4383,[],LY3039478 + NSC156529,2016-06-27T18:01:54Z
0,2016-06-27T00:40:27Z,4371,[],LY3039478 + Taladegib,2017-06-08T19:06:04Z
0,2015-10-30T16:19:47Z,3164,"[{'description': 'LY3076226 is comprised of an FGFR3-directed monoclonal antibody conjugated to a toxic compound, which may result in death of FGFR3-expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",LY3076226,2015-10-30T16:19:47Z
0,2016-02-19T14:52:35Z,3562,"[{'description': 'LY3127804 is an antibody that targets Angiopoietin-2 (Ang2), resulting in reduced angiogenesis, and potentially resulting in decreased tumor growth in combination with other agents (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3259).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}, {'id': 6823, 'pubMedId': None, 'title': 'Abstract 3259: LY3127804, a novel anti-Angiopoietin-2 antibody in combination with an anti-VEGFR2 antibody potently inhibits angiogenesis, tumor growth and metastasis', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/3259'}]}]",LY3127804 ,2016-10-21T20:08:03Z
0,2015-01-22T02:22:10Z,1969,"[{'description': 'LY3164530 is a bispecific antibody that targets EGFR and c-Met and inhibits activation of downstream signaling, resulting in decreased proliferation of EGFR and c-Met over expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",LY3164530,2015-04-30T13:23:57Z
0,2017-05-30T17:51:07Z,5811,"[{'description': 'LY3200882 is a small molecule that inhibits TGFBR1, potentially resulting in increased anti-tumor immune response and decreased tumor growth (AACR Annual Meeting 2017, Abstract nr 955).', 'references': [{'id': 9016, 'pubMedId': None, 'title': 'LY3200882, a novel, highly selective TGFbetaRI small molecule inhibitor', 'url': 'http://www.abstractsonline.com/pp8/#!/4292/presentation/7901'}]}]",LY3200882,2017-07-26T17:29:58Z
0,2016-08-20T02:03:41Z,4588,"[{'description': 'LY3214996 inhibits ERK1/2, potentially resulting in decreased growth of tumors with alterations in the RAS/MAPK pathway (AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4973).', 'references': [{'id': 9939, 'pubMedId': None, 'title': 'Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/4973'}]}]",LY3214996,2017-09-19T04:19:06Z
0,2016-08-20T02:09:15Z,4591,[],LY3214996 + Abemaciclib,2016-08-20T02:09:15Z
0,2016-08-20T02:05:18Z,4589,[],LY3214996 + Midazolam,2016-08-20T02:06:39Z
0,2016-08-20T02:08:21Z,4590,[],LY3214996 + nab-paclitaxel + Gemcitabine,2016-08-20T02:08:21Z
0,2016-06-27T00:33:39Z,4368,"[{'description': 'Limited information is currently available on LY3300054, a putative anti-PD-L1 antibody (Jun 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",LY3300054,2016-06-27T00:36:48Z
0,2017-04-19T02:22:17Z,5557,[],LY3300054 + LY3321367,2017-04-19T02:22:17Z
0,2016-06-27T00:36:14Z,4370,[],LY3300054 + Necitumumab,2016-06-27T00:36:14Z
0,2016-06-27T00:35:26Z,4369,[],LY3300054 + Ramucirumab,2016-06-27T00:35:26Z
0,2017-04-19T02:11:53Z,5556,"[{'description': 'Limited information is currently available on LY3321367, a putative anti-TIM3 antibody (Apr 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",LY3321367,2017-04-19T02:11:53Z
0,2015-12-07T21:09:44Z,3267,"[{'description': 'LY341495 is a Group II glutamate receptor antagonist, which may inhibit growth of tumor cells expressing mGlu2 and/or mGlu3 (GRM3) (PMID: 23724064, PMID: 16053698).', 'references': [{'id': 4064, 'pubMedId': 16053698, 'title': 'Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16053698'}, {'id': 4063, 'pubMedId': 23724064, 'title': 'Synergistic inhibition of survival, proliferation, and migration of U87 cells with a combination of LY341495 and Iressa.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23724064'}]}]",LY341495,2015-12-07T21:09:44Z
0,2015-05-19T17:54:11Z,2709,"[{'description': 'LY364947 is an ATP competitive inhibitor of TGFBR1, which may block downstream signaling, proliferation, and migration in cancer cells (PMID: 16539403, PMID: 15709742).', 'references': [{'id': 2762, 'pubMedId': 16539403, 'title': 'Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16539403'}, {'id': 2763, 'pubMedId': 15709742, 'title': 'Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15709742'}]}]",LY364847,2015-05-22T00:15:38Z
0,2015-06-04T15:49:19Z,2792,"[{'description': 'LY379196 inhibits the activity of PKC-beta1 and PKC-beta2, which may result in cell growth inhibition and disruption of the cell cycle (PMID: 17145886)', 'references': [{'id': 2955, 'pubMedId': 17145886, 'title': 'Protein kinase C beta enhances growth and expression of cyclin D1 in human breast cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17145886'}]}]",LY379196,2015-06-04T15:49:19Z
0,2015-04-17T19:14:51Z,2549,"[{'description': 'LY411575 is a gamma secretase inhibitor, which blocks Notch cleavage and activation, and may inhibit angiogenesis and tumor growth (PMID: 14709552).', 'references': [{'id': 2512, 'pubMedId': 14709552, 'title': 'Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/14709552'}]}]",LY411575,2015-04-27T12:39:20Z
0,2016-10-17T16:29:39Z,4841,[],LY411575 + Paclitaxel,2016-10-17T16:29:39Z
0,2016-03-21T20:13:14Z,3798,"[{'description': 'LY5 is a small molecule Stat3 inhibitor that induces apoptosis and suppresses proliferation and migration of tumor cells (PMID: 26883202).', 'references': [{'id': 4959, 'pubMedId': 26883202, 'title': 'A novel small molecule STAT3 inhibitor, LY5, inhibits cell viability, colony formation, and migration of colon and liver cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26883202'}]}]",LY5,2016-03-21T20:13:14Z
0,2016-03-29T19:49:36Z,3866,[],LY5 + Selumetinib,2016-03-29T19:49:36Z
0,2016-03-29T18:14:44Z,3863,[],LY5 + Trametinib,2016-03-29T18:14:44Z
0,2015-05-19T18:28:47Z,2710,"[{'description': 'LY550410 is an inhibitor of TGFBR1 kinase activity, which prevents downstream signaling and may block proliferation and migration in cancer cells (PMID: 15177479, PMID: 15573100).\r\n', 'references': [{'id': 2764, 'pubMedId': 15177479, 'title': 'Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15177479'}, {'id': 2765, 'pubMedId': 15573100, 'title': 'Development of TGF-beta signalling inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15573100'}]}]",LY550410,2015-05-22T17:23:39Z
0,2017-05-10T14:34:40Z,5653,"[{'description': 'LY900009 inhibits gamma secretase, resulting in decreased Notch signaling and potentially leading to reduced tumor growth (PMID: 26798966).', 'references': [{'id': 8858, 'pubMedId': 26798966, 'title': 'A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26798966'}]}]",LY900009,2017-05-10T14:36:35Z
0,2017-05-30T18:01:15Z,5812,"[{'description': 'LYC-55716 is a retinoic acid-related orphan receptor gamma agonist, which may increase T-cell mediated anti-tumor immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",LYC-55716,2017-05-30T18:01:15Z
0,2015-02-17T11:44:29Z,2080,"[{'description': 'LYS6KAKT1 is an ATP-competitive inhibitor of AKT and p70 S6 kinases, which prevents signaling of the PI3K/AKT pathway and may result in decreased tumor volume and slowed tumor growth (Mol Cancer Ther 2011;10(11 Suppl):Abstract nr B117). ', 'references': [{'id': 1906, 'pubMedId': None, 'title': 'Early detection of a metabolic tumor response to p70S6 kinase/AKT inhibition by LYS6KAKT1 using in vivo choline proton magnetic resonance spectroscopy.', 'url': 'http://mct.aacrjournals.org/content/10/11_Supplement/B117.short'}]}]",LYS6KAKT1,2017-03-17T17:05:06Z
0,2017-10-02T16:10:47Z,6281,"[{'description': 'Limited information is currently available on LZM009, a putative anti-PD-1 antibody (Oct 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",LZM009,2017-10-02T16:10:47Z
0,2016-08-05T03:43:39Z,4522,"[{'description': 'M-COPA is a small-molecule that inhibits Arf1 activation, which interferes with function of the Golgi apparatus and leads to decreased tumor growth (PMID: 27197184).', 'references': [{'id': 6440, 'pubMedId': 27197184, 'title': 'M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27197184'}]}]",M-COPA,2016-08-05T03:43:39Z
0,2017-07-31T16:47:42Z,6059,"[{'description': 'Limited information is currently available on M3541 (Jul, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",M3541,2017-07-31T16:47:42Z
0,2017-06-14T19:22:56Z,5892,"[{'description': 'M7583 inhibits BTK, which may result in decreased tumor growth (J Clin Oncol 35, 2017 (suppl; abstr e14101)).', 'references': []}]",M7583,2017-06-14T19:22:56Z
0,2017-06-06T19:39:23Z,5860,"[{'description': 'M7824 is a human PD-L1 antibody fused with transforming growth factor-beta (TGF-beta) receptor II extracellular domain, which blocks two immuno-inhibitory pathways simultaneously, therefore enhances anti-tumor immunity (J Clin Oncol 35, 2017 (suppl; abstr 3006)).', 'references': [{'id': 9078, 'pubMedId': None, 'title': 'Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-?, in advanced solid tumors.', 'url': 'http://abstracts.asco.org/199/AbstView_199_187226.html'}]}]",M7824,2017-07-20T17:08:31Z
0,2016-08-28T21:27:46Z,4614,"[{'description': 'MAGE-A3 vaccine is a large peptide vaccine containing a membrane translocation sequence that is delivered into the endoplasmic reticulum where it facilitates the formation of MHC class 1 complexes (PMID: 24520093).', 'references': [{'id': 6530, 'pubMedId': 24520093, 'title': 'Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24520093'}]}]",MAGE-A3 vaccine,2016-08-28T21:27:46Z
0,2015-11-01T18:52:38Z,3166,[],Maraviroc,2015-11-01T18:52:38Z
0,2015-02-24T04:02:08Z,2143,"[{'description': 'Marizomib (NPI-0052) is an irreversible inhibitor of the 20S proteasome, which leads to cell cycle arrest and apoptosis in tumor cells (PMID: 16891470).', 'references': [{'id': 1977, 'pubMedId': 16891470, 'title': 'The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16891470'}]}]",Marizomib,2017-08-11T19:37:45Z
0,2016-03-22T18:30:51Z,3813,[],Marizomib + Panobinostat,2016-03-22T18:30:51Z
0,2016-03-22T18:30:12Z,3812,[],Marizomib + Vorinostat,2016-03-22T18:30:12Z
0,2016-03-20T22:22:11Z,3787,"[{'description': 'MART-1 antigen is a melanocyte differentiation antigen that is recognized by cytotoxic T cells (PMID: 9706977).', 'references': [{'id': 4938, 'pubMedId': 9706977, 'title': 'Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/9706977'}]}]",MART-1 antigen,2016-03-20T22:22:11Z
0,2014-03-12T15:53:16Z,804,"[{'description': 'Masitinib (AB1010) inhibits several receptor tyrosine kinases including c-KIT, PDGFR, and LYN thereby inhibiting tumor growth (PMID: 19789626).', 'references': [{'id': 1966, 'pubMedId': 19789626, 'title': 'Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19789626'}]}]",Masitinib,2015-02-27T19:56:13Z
0,2016-02-19T14:48:49Z,3560,"[{'description': 'Limited information is currently available on MBG453, a putative TIM3 antibody (Feb, 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",MBG453,2016-02-25T17:00:47Z
0,2017-05-09T19:38:05Z,5652,"[{'description': 'MBQ-167 inhibits Rac1 and Cdc42, resulting in decreased downstream signaling, increased cell-cycle arrest, and reduced tumor growth and metastasis (PMID: 28450422).', 'references': [{'id': 8855, 'pubMedId': 28450422, 'title': 'Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28450422'}]}]",MBQ-167,2017-05-09T19:38:05Z
0,2015-12-08T21:57:34Z,3270,"[{'description': 'MCCK1 is a small molecule that inhibits IKBKE, resulting in decreased growth of IKBKE-over expressing tumors (Cancer Res April 15, 2013 73:LB-310).', 'references': [{'id': 4065, 'pubMedId': None, 'title': 'Abstract LB-310: Small molecule inhibitors of IKBKE with antitumor activity in cancer cells overexpressing IKBKE', 'url': 'http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-310.short'}]}]",MCCK1,2015-12-08T21:57:34Z
0,2017-05-24T19:27:33Z,5771,"[{'description': 'MCLA-128 is a bispecific antibody that targets Erbb2 (Her2) and Erbb3, resulting in antibody-dependent cell-mediated cytotoxicity against tumor cells (Cancer Res 2016;76(14 Suppl):Abstract nr CT050).', 'references': []}]",MCLA-128,2017-05-24T19:27:33Z
0,2015-06-18T16:18:40Z,2838,"[{'description': 'MCS110 is a monoclonal antibody that binds CSF1 and prevents receptor binding and subsequent receptor activation, and leads to reduction of tumor-related bone destruction (Cancer Res; 2009 Apr 18-22; Abstract nr DDT02-2).', 'references': [{'id': 3075, 'pubMedId': None, 'title': 'Abstract #DDT02-2: MCS110: a monoclonal antibody with potent neutralizing activity against macrophage colony-stimulating factor for the treatment of tumor-induced osteolysis', 'url': 'http://cancerres.aacrjournals.org/content/69/9_Supplement/DDT02-2.abstract'}]}]",MCS110,2017-07-20T16:47:07Z
0,2016-12-08T17:17:02Z,5072,[],MCS110 + PDR001,2016-12-08T17:17:02Z
0,2015-01-22T11:49:02Z,1970,"[{'description': 'ME-344 is an isoflavone derivative which interferes with mitochondrial energy production in tumor cells resulting in caspase-independent cell death (PMID: 25411085).', 'references': [{'id': 1753, 'pubMedId': 25411085, 'title': 'Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25411085'}]}]",ME-344 ,2015-07-06T17:01:48Z
0,2015-02-26T16:21:58Z,2174,[],ME-344 + Topotecan,2015-02-26T16:21:58Z
0,2016-01-31T00:00:30Z,3479,"[{'description': 'ME22S is a bispecific antibody that targets EGFR and MET, which results in decreased tumor cell proliferation and migration (PMID: 26812910).', 'references': [{'id': 4488, 'pubMedId': 26812910, 'title': 'The Dual Inhibition of Met and EGFR by ME22S, a Novel Met/EGFR Bispecific Monoclonal Antibody, Suppresses the Proliferation and Invasion of Laryngeal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26812910'}]}]",ME22S,2017-07-26T18:42:29Z
0,2015-02-23T09:23:29Z,2133,[],Mebendazole + Bevacizumab + Irinotecan,2015-02-23T09:23:29Z
0,2015-02-23T09:30:35Z,2134,[],Mebendazole + Vincristine + Carboplatin + Temozolomide,2015-02-23T09:30:35Z
0,2016-06-17T19:22:57Z,4303,[],Mechlorethamine,2016-06-17T19:22:57Z
0,2015-03-16T16:35:04Z,2407,"[{'description': 'MEDI-551 is a monoclonal antibody directed against CD19, which binds CD19 and enhances antibody-dependent cytotoxic immune response against CD19-positive B-cells (PMID: 20605905).', 'references': [{'id': 2219, 'pubMedId': 20605905, 'title': 'B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20605905'}]}]",MEDI-551,2015-03-16T16:35:04Z
0,2016-09-25T18:28:10Z,4762,"[{'description': 'MEDI-570 is a human monoclonal antibody against the inducible T-cell co-stimulator (ICOS, CD278) that blocks ICOS activation, resulting in reduced immune suppression and enhanced anti-tumor immune response (PMID: 23566679).', 'references': [{'id': 6672, 'pubMedId': 23566679, 'title': 'B-cell targeted therapeutics in clinical development.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23566679'}]}]",MEDI-570,2016-09-25T18:28:10Z
0,2016-09-13T20:16:11Z,4708,"[{'description': 'MEDI-573 is an antibody that targets IGF-1 and IGF-2, resulting in decreased IGF-mediated signaling and potentially leading to decreased tumor growth (PMID: 25193511).', 'references': [{'id': 6622, 'pubMedId': 25193511, 'title': 'MEDI-573, alone or in combination with mammalian target of rapamycin inhibitors, targets the insulin-like growth factor pathway in sarcomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25193511'}]}]",MEDI-573,2017-07-20T17:13:39Z
0,2016-09-13T20:36:59Z,4710,[],MEDI-573 + Sirolimus,2016-09-13T20:36:59Z
0,2016-09-13T20:35:19Z,4709,[],MEDI-573 + Vistusertib,2017-06-09T14:59:34Z
0,2014-03-12T15:53:16Z,805,[],Medi-575,
0,2017-05-26T17:45:10Z,5790,"[{'description': 'Limited information is currently available on MEDI0457 (May 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",MEDI0457,2017-05-26T17:45:10Z
0,2016-03-25T17:00:49Z,3838,"[{'description': 'MEDI0562 is a monoclonal antibody against OX40 (CD134), which may induce lymphocyte proliferation and enhanced anti-tumor immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MEDI0562,2016-03-31T20:01:04Z
0,2016-03-25T17:01:43Z,3839,[],MEDI0562 + MEDI4736,2016-03-25T17:01:43Z
0,2016-03-25T17:02:09Z,3840,[],MEDI0562 + Tremelimumab,2016-03-25T17:02:09Z
0,2015-04-17T17:34:14Z,2546,"[{'description': 'MEDI0639 is a monoclonal antibody which binds DLL4 and prevents its interaction with Notch receptors, thereby inhibiting pathway activation, angiogenesis, and tumor growth (PMID: 22679110).\r\n\r\n', 'references': [{'id': 2504, 'pubMedId': 22679110, 'title': 'MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22679110'}]}]",MEDI0639,2017-07-13T18:25:25Z
0,2015-10-09T01:36:35Z,3120,"[{'description': 'MEDI0680 is a monoclonal antibody binds to and inhibits PD-1 signaling, leading to T-cell activation and antitumor immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MEDI0680,2016-01-28T02:25:01Z
0,2015-10-09T01:37:43Z,3121,[],MEDI0680 + MEDI4736,2015-10-09T01:37:43Z
0,2014-07-28T17:48:44Z,1176,"[{'description': 'MEDI3617 is an human monoclonal antibody that prevents the binding of Angiopoietin 2 to the Tie2 receptor in vitro, and inhibits angiogenesis and tumor growth in vivo (PMID: 22327175).', 'references': [{'id': 477, 'pubMedId': 22327175, 'title': 'MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22327175'}]}]",MEDI3617,2014-07-28T17:48:44Z
0,2017-01-16T16:32:08Z,5216,"[{'description': 'Limited information is currently available on MEDI3726 (Jan, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",MEDI3726,2017-01-16T16:32:08Z
0,2017-01-15T20:53:36Z,5199,[],MEDI4736 + Azacitidine + Tremelimumab,2017-01-15T20:53:36Z
0,2017-02-12T15:56:52Z,5306,[],MEDI4736 + Carboplatin + Cisplatin + Etoposide,2017-02-12T15:56:52Z
0,2017-04-28T15:01:43Z,5589,[],MEDI4736 + MEDI5083,2017-04-28T15:01:43Z
0,2016-09-21T14:36:17Z,4727,[],MEDI4736 + MEDI9090,2016-09-21T14:36:17Z
0,2016-01-14T15:11:15Z,3414,[],MEDI4736 + MK-1775,2016-01-14T15:11:15Z
0,2016-06-27T01:50:44Z,4378,[],MEDI4736 + Mocetinostat,2016-06-27T01:50:44Z
0,2015-10-06T00:04:20Z,3100,[],MEDI4736 + nab-paclitaxel,2015-10-06T00:05:02Z
0,2016-11-13T21:52:48Z,4949,[],MEDI4736 + Olaparib + Tremelimumab,2016-11-13T21:52:48Z
0,2016-01-10T19:35:39Z,3385,[],MEDI4736 + poly ICLC ,2016-01-10T19:35:39Z
0,2016-07-18T01:29:03Z,4466,[],MEDI4736 + PVX-410 + poly ICLC ,2016-07-18T01:29:03Z
0,2017-02-22T00:32:55Z,5350,[],MEDI4736 + R2-CHOP,2017-02-22T00:32:55Z
0,2015-12-03T15:49:55Z,3257,[],MEDI4736 + Ramucirumab,2015-12-03T15:49:55Z
0,2017-02-22T00:23:04Z,5349,[],MEDI4736 + Rituximab + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone,2017-02-22T00:23:04Z
0,2015-10-30T14:19:26Z,3162,[],MEDI4736 + Selumetinib,2015-10-30T14:20:05Z
0,2016-05-27T19:06:33Z,4180,[],MEDI4736 + TPIV 200,2016-05-27T19:06:33Z
0,2016-06-03T00:12:35Z,4218,[],MEDI4736 + Trastuzumab,2016-06-03T00:12:35Z
0,2017-02-12T15:55:23Z,5305,[],MEDI4736 + Tremelimumab + Carboplatin + Cisplatin + Etoposide,2017-02-12T15:55:23Z
0,2016-09-21T15:08:18Z,4730,[],MEDI4736 + X-396,2016-09-21T15:08:18Z
0,2017-04-28T14:59:33Z,5588,"[{'description': 'Limited information is currently available on MEDI5083 (Apr 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",MEDI5083,2017-04-28T14:59:33Z
0,2016-01-31T01:35:02Z,3481,"[{'description': 'MEDI5117 is an anti-IL6 monoclonal antibody, which inhibits IL6 autocrine signaling, potentially leading to decreased tumor cell growth (PMID: 26744529).', 'references': [{'id': 4491, 'pubMedId': 26744529, 'title': 'A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26744529'}]}]",MEDI5117,2016-03-21T16:20:05Z
0,2016-01-31T18:07:30Z,3486,[],MEDI5117 + Cisplatin + Gemcitabine,2016-01-31T18:07:30Z
0,2016-01-31T13:31:45Z,3484,[],MEDI5117 + Docetaxel,2016-01-31T13:51:10Z
0,2016-01-31T18:16:12Z,3487,[],MEDI5117 + Doxorubucin,2016-02-01T02:49:40Z
0,2016-01-31T11:34:50Z,3483,[],MEDI5117 + Gefitinib,2016-01-31T11:34:50Z
0,2016-01-31T02:22:20Z,3482,[],MEDI5117 + Paclitaxel,2016-01-31T02:22:20Z
0,2016-01-31T18:46:04Z,3489,[],MEDI5117 + Pemetrexed,2016-01-31T18:46:04Z
0,2016-01-31T18:37:56Z,3488,[],MEDI5117 + Topotecan,2016-01-31T18:37:56Z
0,2015-10-09T01:21:27Z,3119,"[{'description': 'MEDI6383 is a monoclonal antibody binds to and activates OX40 (CD134), leading to proliferation of T cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MEDI6383,2015-10-09T01:21:27Z
0,2014-10-14T21:05:47Z,1653,"[{'description': 'MEDI6469 is a monoclonal antibody that binds programmed cell death-1 ligand 1 (PD-L1), inhibiting downstream activity and potentially enhancing T-cell response to tumor cells and reversing T-cell inactivation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MEDI6469,2016-01-28T02:26:00Z
0,2017-05-24T17:08:32Z,5762,"[{'description': 'Limited information is currently available on MEDI7247 (May, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",MEDI7247,2017-05-24T17:08:32Z
0,2016-09-21T14:35:10Z,4726,"[{'description': 'Limited information is currently available on MEDI9090 (Sep, 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",MEDI9090 ,2016-09-21T14:35:10Z
0,2017-03-17T01:44:59Z,5457,"[{'description': 'MEDI9197 acts an an agonist for the TLR7 and TLR8, potentially resulting in increased anti-tumor immune response (J Clin Oncol 34, 2016 (suppl; abstr TPS3095)).', 'references': []}]",MEDI9197,2017-03-30T19:20:09Z
0,2017-03-17T01:46:01Z,5458,[],MEDI9197 + MEDI4736,2017-03-17T01:46:01Z
0,2015-09-30T03:15:37Z,3089,"[{'description': 'MEDI9447 is a monoclonal antibody against CD73 which may increase antitumor immunity in tumor microenvironment (http://cancerres.aacrjournals.org/content/75/15_Supplement/285.abstract).', 'references': [{'id': 3680, 'pubMedId': None, 'title': '', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/285.abstract'}]}]",MEDI9447,2015-09-30T03:15:37Z
0,2015-03-16T15:16:02Z,2401,"[{'description': 'Depo-Provera (medroxyprogesterone) is a synthetic progesterone derivative that acts as an anti-estrogen by binding to and activating nuclear receptors, stimulating downstream signaling and potentially resulting in decreased growth of estrogen-sensitive tumor cells (NCI Drug Dictionary).\r\n\r\n ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Medroxyprogesterone,2015-03-16T15:22:13Z
0,2017-01-15T21:58:44Z,5203,[],Medroxyprogesterone + Entinostat,2017-01-15T21:58:59Z
0,2014-12-15T17:41:02Z,1785,[],Mefloquine,2014-12-15T17:41:02Z
0,2014-12-30T13:44:34Z,1869,[],Megestrol,2014-12-30T13:44:34Z
0,2014-03-12T15:53:16Z,806,"[{'description': 'MEHD7945A is a two-in-one antibody that inhibits both ERBB3 (HER3) and EGFR signaling, resulting in greater efficacy than monospecific HER antibodies against multiple tumor models (PMID: 22014573).', 'references': [{'id': 1045, 'pubMedId': 22014573, 'title': 'A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22014573'}]}]",MEHD7945A,2016-09-12T14:56:44Z
0,2014-08-01T08:20:06Z,1342,[],MEHD7945A + Cobimetinib,2014-08-01T08:20:06Z
0,2016-09-12T14:13:06Z,4683,[],MEHD7945A + Radiotherapy,2016-09-12T14:13:06Z
0,2014-07-27T19:23:17Z,1114,[],MEK162 + AEB071,2014-07-27T19:23:17Z
0,2015-02-28T01:31:19Z,2213,[],MEK162 + Carboplatin + Pemetrexed,2015-02-28T01:31:19Z
0,2014-07-30T15:23:01Z,1253,[],MEK162 + Erlotinib,2014-07-30T15:23:01Z
0,2015-02-28T01:58:54Z,2217,[],MEK162 + FOLFOX,2015-02-28T01:58:54Z
0,2015-02-28T02:05:46Z,2218,[],MEK162 + Gemcitabine + Cisplatin,2015-02-28T02:05:46Z
0,2015-02-28T10:36:20Z,2220,[],MEK162 + Idarubicin + Cytarabine,2015-02-28T10:37:07Z
0,2014-09-11T02:07:30Z,1430,[],MEK162 + Imatinib mesylate,2014-09-11T02:07:30Z
0,2015-02-28T02:14:26Z,2219,[],MEK162 + Nilotinib,2015-02-28T02:14:26Z
0,2015-02-04T13:58:46Z,2010,[],MEK162 + Paclitaxel,2015-02-04T13:58:46Z
0,2015-08-12T01:48:11Z,3012,"[{'description': 'Melan-A/MART-1 peptide vaccine is a vaccine against melanocyte differentiation antigen Melan-A (MART-1), which may enhance the humoral and cytotoxic immune responses against tumor cells expressing Melan-A (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Melan-A/MART-1 peptide vaccine,2015-12-11T18:05:33Z
0,2015-08-12T03:54:08Z,3016,"[{'description': 'MELITAC 12.1 peptide vaccine is a cancer vaccine that contains both melanoma peptides and helper peptides, which may stimulate an immune response against melanoma tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MELITAC 12.1 Peptide Vaccine ,2015-09-10T13:45:01Z
0,2014-07-29T16:28:39Z,1207,"[{'description': 'Alkeran (melphalan) is an antineoplastic alkylating agent, which cross-links DNA and induces cell toxicity (NCI Drug Dictionary). Alkeran (melphalan) is FDA approved for multiple myeloma and epithelial ovarian carcinoma (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Melphalan,2015-04-24T14:39:49Z
0,2014-12-24T16:18:56Z,1852,[],Melphalan + Bortezomib + Thalidomide + Dexamethasone,2014-12-24T16:18:56Z
0,2017-02-20T21:04:12Z,5344,[],Melphalan + PVX-410,2017-02-20T21:04:12Z
0,2014-12-15T17:39:59Z,1784,[],Memantine,2014-12-15T17:39:59Z
0,2014-10-14T17:26:07Z,1640,[],Mercaptopurine,2014-10-14T17:26:07Z
0,2015-11-08T22:43:35Z,3194,[],Mercaptopurine + Methotrexate + Prednisone + Vincristine,2015-11-08T22:43:35Z
0,2015-03-11T14:37:17Z,2346,[],Mercaptopurine + Thioguanine,2015-03-11T14:37:17Z
0,2017-05-18T03:54:10Z,5682,[],Mesna,2017-05-18T03:54:10Z
0,2015-07-10T17:03:08Z,2903,"[{'description': 'Meso-TR3 is a fusion protein between mesothelin and a TRAIL trimer (TR3), which binds MUC-16 and induces cell death of MUC16-expressing tumor cells (PMID: 24447304).', 'references': [{'id': 3214, 'pubMedId': 24447304, 'title': 'Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24447304'}]}]",Meso-TR3,2015-07-10T17:03:08Z
0,2017-07-28T17:21:02Z,6029,"[{'description': 'Mesothelin CAR-T cells are T-cells that have been modified to express a chimeric antigen receptor targeting Mesothelin (MSLN), which may result in decreased growth of MSLN-expressing tumors, upon delivery (PMID: 22127019).', 'references': [{'id': 9614, 'pubMedId': 22127019, 'title': 'Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22127019'}, {'id': 4641, 'pubMedId': 26503962, 'title': 'Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26503962'}]}]",Mesothelin CAR-T cells,2017-07-28T17:22:49Z
0,2014-05-14T14:52:46Z,1031,"[{'description': 'Glucophage (metformin) inhibits part of the mitochondrial respiratory chain and may exert antineoplastic effects through inhibition of mTOR (NCI Drug Dictionary). Glucophage (metformin) is FDA approved for type 2 diabetes (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Metformin,2017-09-19T12:58:18Z
0,2016-03-18T19:35:11Z,3784,[],Metformin + AGI-5198,2016-03-18T19:35:11Z
0,2015-06-11T18:00:11Z,2817,[],Metformin + Aldoxorubicin,2015-06-11T18:00:11Z
0,2014-12-17T14:46:36Z,1792,[],Metformin + Cytarabine,2014-12-17T14:46:36Z
0,2016-08-27T02:22:43Z,4610,[],Metformin + Doxycycline,2016-08-27T02:22:43Z
0,2014-12-22T15:38:21Z,1828,[],Metformin + Erlotinib,2014-12-22T15:38:21Z
0,2017-02-11T23:03:37Z,5302,[],Metformin + Nivolumab,2017-02-11T23:03:37Z
0,2017-08-08T20:01:11Z,6101,[],Metformin + Pertuzumab + Trastuzumab + Carboplatin + Docetaxel,2017-08-08T20:01:11Z
0,2016-03-07T17:33:29Z,3689,[],Metformin + PEXG,2016-03-07T17:33:29Z
0,2016-11-06T20:40:01Z,4919,[],Metformin + Ritonavir,2016-11-06T20:40:01Z
0,2014-12-22T15:50:29Z,1829,[],Metformin + Simvastatin,2014-12-22T15:50:29Z
0,2016-11-21T18:53:14Z,4982,[],Metformin + Sorafenib,2016-11-21T18:53:14Z
0,2015-07-28T00:14:08Z,2959,[],Metformin + Vandetanib,2015-07-28T00:14:08Z
0,2014-10-14T17:24:42Z,1639,[],Methotrexate,2014-10-14T17:24:42Z
0,2015-03-21T12:07:56Z,2449,[],Methotrexate + Cisplatin + Cyclophosphamide + Vincristine,2015-03-21T12:07:56Z
0,2014-12-29T16:09:56Z,1865,[],Methotrexate + Cytarabine + Leucovorin,2014-12-29T16:09:56Z
0,2017-03-23T18:42:53Z,5474,[],Methotrexate + UNC2025,2017-03-23T18:42:53Z
0,2014-05-14T14:52:46Z,1032,"[{'description': 'Relistor (methylnaltrexone) is a mu-type opioid receptor inhibitor and is approved for constipation, but it has also been shown to inhibit VEGFRs and angiogenesis (PMID: 16820176). ', 'references': [{'id': 36, 'pubMedId': 16820176, 'title': 'Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16820176'}]}]",methylnaltrexone,2015-08-10T15:09:25Z
0,2014-10-24T07:58:22Z,1661,[],Methylnaltrexone + 5-FU,2014-10-24T07:58:22Z
0,2017-01-09T16:20:45Z,5167,[],Methylprednisolone,2017-01-09T16:20:45Z
0,2017-04-17T20:50:17Z,5550,[],Methylprednisolone + Lenalidomide + Ruxolitinib,2017-04-17T20:50:17Z
0,2015-02-18T11:23:24Z,2089,"[{'description': 'MF tricyclic is a COX-2 inhibitor that may reduce tumor burden and prevent metastasis in cancer (PMID: 16003752, PMID: 17213821).', 'references': [{'id': 1923, 'pubMedId': 17213821, 'title': 'COX-2 involvement in breast cancer metastasis to bone.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17213821'}, {'id': 1922, 'pubMedId': 16003752, 'title': 'MF tricyclic and sulindac retard tumor formation in an animal model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16003752'}]}]",MF tricyclic,2015-02-18T20:38:25Z
0,2015-07-20T17:14:33Z,2936,"[{'description': 'MFGR1877S is a monoclonal antibody against FGFR3 that prevents ligand binding and may inhibit proliferation and promote apoptosis in cancer cells (Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 4029).', 'references': [{'id': 3280, 'pubMedId': None, 'title': 'A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive', 'url': 'http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/4029'}]}]",MFGR1877S,2015-07-24T21:53:10Z
0,2017-06-04T01:41:09Z,5850,[],mFOLFOX-6,2017-06-04T01:41:09Z
0,2017-09-29T19:28:02Z,6275,[],mFOLFOX-6 + Atezolizumab,2017-09-29T19:28:02Z
0,2017-09-29T19:26:59Z,6274,[],mFOLFOX-6 + Atezolizumab + Cobimetinib,2017-09-29T19:26:59Z
0,2014-07-28T16:14:55Z,1161,[],mFOLFOX-6 + Pembrolizumab,2016-11-06T21:05:44Z
0,2016-10-17T15:35:31Z,4839,[],mFOLFOX-6 + Tivozanib,2016-10-17T15:35:31Z
0,2017-06-14T19:36:06Z,5893,"[{'description': 'MG 98 is an oligonucleotide antisense that inhibits DNMT1, thereby resulting in altered expression of DNMT1 targeted genes due to decreased methylation and thus, potentially resulting in tumor growth inhibition (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MG 98,2017-06-14T19:36:06Z
0,2016-12-13T04:33:33Z,5084,[],MG1-MAGEA3,2016-12-13T04:33:33Z
0,2017-05-30T18:04:38Z,5813,"[{'description': 'Limited information is currently available on MGA012, a putative PD-1 antibody (May, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",MGA012,2017-05-30T18:04:38Z
0,2015-06-24T00:50:50Z,2863,"[{'description': 'MGA271 is a monoclonal antibody against B7-H3, which induces an anti-tumor immune response (PMID: 22615450).', 'references': [{'id': 3118, 'pubMedId': 22615450, 'title': 'Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22615450'}]}]",MGA271,2017-05-30T14:41:22Z
0,2015-06-24T00:52:25Z,2864,[],MGA271 + Pembrolizumab,2015-06-24T00:52:25Z
0,2014-03-12T15:53:16Z,808,"[{'description': 'Margetuximab (MGAH22) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cell cytotoxicity (PMID: 22129105). ', 'references': [{'id': 2311, 'pubMedId': 22129105, 'title': 'Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22129105'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MGAH22,2015-03-24T18:27:43Z
0,2016-03-11T19:32:33Z,3728,[],MGAH22 + Pembrolizumab,2016-03-11T19:32:33Z
0,2014-03-12T15:53:16Z,809,"[{'description': 'Glesatinib (MGCD265) inhibits several tyrosine kinases including MET, MST1R (RON), and AXL, as well as VEGFR1-3, and TIE2, which may result in decreased tumor growth (PMID: 25806189, PMID: 26555154). ', 'references': [{'id': 6207, 'pubMedId': 26555154, 'title': 'AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26555154'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 7370, 'pubMedId': 25806189, 'title': 'MET inhibitors in combination with other therapies in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806189'}]}]",MGCD265,2016-12-21T21:24:16Z
0,2014-07-28T00:17:06Z,1127,[],MGCD265 + Docetaxel,2014-07-28T00:17:06Z
0,2014-07-28T00:16:20Z,1126,[],MGCD265 + Erlotinib,2014-07-28T00:16:20Z
0,2016-11-13T20:53:55Z,4942,[],MGCD265 + Nivolumab,2016-11-13T20:53:55Z
0,2014-10-16T20:48:44Z,1655,"[{'description': 'MGCD516 (Sitravatinib) inhibits several receptor tyrosine kinases including MET, KIT, VEGFR1-3, RET family members, TRK family members, DDR, and Eph family members, resulting in abrogation of downstream signaling and decreased cell proliferation in tumors overexpressing these proteins (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MGCD516,2017-04-03T14:38:23Z
0,2016-11-13T20:54:57Z,4943,[],MGCD516 + Nivolumab,2016-11-13T20:54:57Z
0,2015-10-02T12:53:11Z,3093,"[{'description': 'MGD007 is a bispecific monoclonal antibody binds to and crosslinks CD3-positive T-cells and gpA33-positive tumor cells, therefore promotes antitumor immunity (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MGD007,2015-10-02T12:53:11Z
0,2017-07-31T17:10:44Z,6060,"[{'description': 'MGD013 is an engineered protein that targets both PD-1 and LAG3 and inhibits PD-1 and LAG-3 mediated signaling, potentially resulting in enhanced antitumor immune response (Cancer Res July 15 2016 (76) (14 Supplement) 3217).', 'references': [{'id': 9638, 'pubMedId': None, 'title': 'Abstract 3217: MGD013, a bispecific PD-1 x LAG-3 Dual-Affinity Re-Targeting (DART) protein with T-cell immunomodulatory activity for cancer treatment', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/3217'}]}]",MGD013,2017-07-31T17:10:44Z
0,2015-07-10T15:12:23Z,2897,"[{'description': 'MGFR1877S is a monoclonal antibody selective for Fgfr3, which induces antitumor activity (PMID: 26078430).', 'references': [{'id': 3211, 'pubMedId': 26078430, 'title': 'Targeting FGFR Signaling in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26078430'}]}]",MGFR1877S,2015-07-10T16:26:17Z
0,2017-07-25T14:28:05Z,6006,"[{'description': 'MI-503 inhibits the interaction between Menin and MLL (KMT2A), potentially resulting in increased differentiation and decreased growth of tumor cells harboring MLL (KMT2A) rearrangements or NPM1 mutations (PMID: 25817203, PMID: 27535106).', 'references': [{'id': 9548, 'pubMedId': 25817203, 'title': 'Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25817203'}, {'id': 9547, 'pubMedId': 27535106, 'title': 'Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535106'}]}]",MI-503,2017-07-25T14:32:30Z
0,2014-09-30T20:41:55Z,1582,"[{'description': 'MI-63 is a small molecule, high-affinity, non-peptide inhibitor of MDM2 and in cancer cells with wild type Tp53, MI-63 treatment results in reactivation of Tp53 (PMID: 19707204).', 'references': [{'id': 879, 'pubMedId': 19707204, 'title': 'MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19707204'}]}]",MI-63,2014-10-03T09:53:33Z
0,2015-05-15T01:02:16Z,2685,[],Midazolam,2015-05-15T01:02:16Z
0,2014-03-12T15:53:16Z,810,"[{'description': 'Rydapt (midostaurin) is a multi-kinase inhibitor with activity against FLT3, KIT, PDGFRB, KDR (VEGFR2) and PKC, with higher selectivity for conventional PKC isoforms, which induces cell cycle arrest and apoptosis (PMID: 12124173, PMID: 23127174, PMID: 15914319). Rydapt (midostaurin) is FDA approved for FLT3-mutant AML in combination with chemotherapy (FDA.gov).', 'references': [{'id': 985, 'pubMedId': 12124173, 'title': 'Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12124173'}]}]",Midostaurin,2017-05-01T19:10:37Z
0,2016-11-23T17:44:14Z,5008,[],Midostaurin + SCH772984,2016-11-23T17:44:14Z
0,2015-04-29T02:02:49Z,2603,"[{'description': 'Mifepristone is a progesterone receptor antagonist, which may inhibit cellular proliferation and induce apoptosis (PMID: 23180967).', 'references': [{'id': 3017, 'pubMedId': 23180967, 'title': 'A study of mifepristone/IFN-γ-induced apoptosis of human cholangiocarcinoma cell line FRH-0201 in vitro.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23180967'}]}]",Mifepristone,2015-06-19T12:05:54Z
0,2016-06-23T14:49:11Z,4350,[],Mifepristone + Nab-paclitaxel,2016-06-23T14:49:11Z
0,2017-07-28T17:29:26Z,6030,[],Mifepristone + Pembrolizumab,2017-07-28T17:29:26Z
0,2017-05-30T18:16:01Z,5814,"[{'description': 'MIK-665 (S64315) inhibits MCL1, potentially resulting in increased apoptosis of MCL-1 expressing tumor cells (NCI Drug DIctionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MIK665,2017-05-30T18:16:01Z
0,2014-10-02T20:37:32Z,1616,[],MINT1526A,2014-10-02T20:37:32Z
0,2016-06-22T02:05:54Z,4338,"[{'description': 'Mipsagargin is a prodrug that is activated in prostate specific membrane antigen (PSMA)-positive cells, resulting in apoptosis in tumor cells (PMID: 27115568).', 'references': [{'id': 5979, 'pubMedId': 27115568, 'title': 'Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27115568'}]}]",mipsagargin,2016-06-24T17:47:45Z
0,2014-08-08T19:56:55Z,1397,"[{'description': 'Mithracin (plicamycin) is an antineoplastic antibiotic, which binds to DNA and prevents cells from making RNA and proteins (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Mithramycin,2014-10-31T05:55:00Z
0,2016-07-08T18:54:05Z,4432,"[{'description': 'MitoMet-10 is a mitochondria-targeted analog of Metformin with increased potency, which may decrease tumor cell proliferation and increase sensitivity to radiotherapy (PMID: 27216187).', 'references': [{'id': 6271, 'pubMedId': 27216187, 'title': 'Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27216187'}]}]",MitoMet-10,2016-07-08T18:54:05Z
0,2016-07-14T16:59:45Z,4451,[],MitoMet-10 + Radiotherapy,2016-07-14T16:59:45Z
0,2014-07-28T12:07:42Z,1133,"[{'description': 'Mitomycin C is an antibiotic alkylating agent, which cross-links DNA to prevent DNA synthesis (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Mitomycin C,2017-06-19T18:44:23Z
0,2016-06-17T19:21:33Z,4302,[],Mitotane,2016-06-17T19:21:33Z
0,2014-11-21T05:27:48Z,1740,"[{'description': 'Novantrone (Mitoxantrone) binds to and inhibits topoisomerase II, leading to DNA double strand breaks and decreased DNA repair (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Mitoxantrone,2017-06-19T18:45:47Z
0,2014-11-29T00:21:22Z,1752,[],Mitoxantrone + Etoposide + Cytarabine,2014-11-29T00:21:22Z
0,2017-01-16T16:10:35Z,5215,[],mitoxantrone hydrochloride,2017-01-16T16:10:35Z
0,2017-09-19T15:07:44Z,6218,"[{'description': 'MIW815 (ADUS100) is a synthetic cyclic dinucleotide that acts as an activator for the stimulation of interferon gene signaling, resulting in T cell differentiation and infiltration of the tumor, thereby possibly resulting in tumor regression (PMID: 28483787).', 'references': [{'id': 9940, 'pubMedId': 28483787, 'title': 'A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28483787'}]}]",MIW815,2017-09-19T15:07:44Z
0,2017-09-19T15:08:58Z,6219,[],MIW815 + PDR001,2017-09-19T15:08:58Z
0,2017-07-28T18:29:03Z,6038,"[{'description': 'Limited information is currently available on MK-1308, a putative CTLA4 antagonist (Jul 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",MK-1308,2017-07-28T18:29:03Z
0,2017-07-28T18:29:56Z,6039,[],MK-1308 + Pembrolizumab,2017-07-28T18:29:56Z
0,2017-02-22T00:11:06Z,5347,"[{'description': 'Limited information is currently available on MK-1454 (Feb 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",MK-1454,2017-02-24T14:57:04Z
0,2017-02-22T00:12:24Z,5348,[],MK-1454 + Pembrolizumab,2017-02-22T00:12:24Z
0,2014-03-12T15:53:16Z,822,"[{'description': 'MK-1775 is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MK-1775,2014-09-05T16:31:46Z
0,2014-07-29T07:05:44Z,1194,[],MK-1775 + Carboplatin ,2014-07-29T07:05:44Z
0,2016-03-22T09:31:55Z,3800,[],MK-1775 + Carboplatin + Paclitaxel,2016-03-22T09:31:55Z
0,2014-11-12T23:11:52Z,1725,[],MK-1775 + Cisplatin,2014-11-12T23:11:52Z
0,2016-06-14T17:26:48Z,4284,[],MK-1775 + Doxorubicin,2016-06-14T17:26:48Z
0,2014-07-30T18:58:07Z,1279,[],MK-1775 + Gemcitabine,2014-09-25T15:55:48Z
0,2014-08-05T06:48:10Z,1361,[],MK-1775 + Irinotecan,2014-08-05T06:48:10Z
0,2015-10-21T00:13:30Z,3140,[],MK-1775 + Olaparib,2015-10-21T00:13:30Z
0,2014-09-30T17:21:16Z,1567,[],MK-1775 + Paclitaxel,2014-09-30T17:21:16Z
0,2014-09-30T17:04:40Z,1566,[],MK-1775 + PF-00477736,2014-09-30T17:04:40Z
0,2016-06-01T04:14:11Z,4186,[],MK-1775 + Radiotherapy,2016-06-01T04:14:11Z
0,2015-05-19T20:51:08Z,2713,[],MK-1775 + Temozolomide,2015-05-19T20:51:08Z
0,2016-07-19T00:29:05Z,4470,"[{'description': 'MK-1966 down-regulates IL-10 activity and enhances anti-tumor immunity (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MK-1966,2016-07-19T00:29:05Z
0,2016-07-19T00:33:39Z,4471,[],MK-1966 + SD-101,2016-07-19T00:33:39Z
0,2017-08-18T19:31:06Z,6130,"[{'description': 'Limited information is currently available on MK-2118 (Aug, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",MK-2118,2017-08-18T19:31:06Z
0,2017-08-18T19:32:37Z,6131,[],MK-2118 + Pembrolizumab,2017-08-18T19:32:37Z
0,2016-06-03T16:40:19Z,4233,"[{'description': 'MK-4101 binds to SMO and inhibits downstream signaling, resulting in anti-proliferation and anti-tumor activities (PMID: 26960983).', 'references': [{'id': 5731, 'pubMedId': 26960983, 'title': 'MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26960983'}]}]",MK-4101,2016-06-03T16:40:19Z
0,2015-06-12T15:02:31Z,2829,"[{'description': 'MK-4166 is an activating monoclonal antibody against glucocorticoid-induced tumor necrosis factor receptor (GITR), which leads to enhanced cytotoxic immune response against tumor cells (PMID: 22019729).', 'references': [{'id': 3266, 'pubMedId': 20201988, 'title': 'Enhancement of humoral and cellular immunity with an anti-glucocorticoid-induced tumour necrosis factor receptor monoclonal antibody.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20201988'}, {'id': 3032, 'pubMedId': 22019729, 'title': 'Attention induces conservative subjective biases in visual perception.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22019729'}]}]",MK-4166,2017-08-22T17:09:21Z
0,2016-06-02T22:12:30Z,4212,"[{'description': 'Limited information is currently available on MK-4280 (Jun, 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",MK-4280,2016-06-02T22:12:30Z
0,2016-06-02T22:13:27Z,4213,[],MK-4280 + Pembrolizumab,2016-06-02T22:13:27Z
0,2015-03-08T21:31:45Z,2331,"[{'description': 'MK-5108 is a selective Aurora A kinase inhibitor, which inhibits cell proliferation (PMID: 20053775).', 'references': [{'id': 2121, 'pubMedId': 20053775, 'title': 'MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20053775'}]}]",MK-5108,2017-04-04T12:47:09Z
0,2016-04-27T17:44:38Z,4010,[],MK-5108 + Docetaxel,2016-04-27T17:44:38Z
0,2017-01-16T16:54:13Z,5218,"[{'description': 'Limited information is currently available on MK-7684 (Jan, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",MK-7684,2017-01-16T16:54:13Z
0,2017-01-16T16:55:31Z,5219,[],MK-7684 + Pembrolizumab,2017-01-16T16:55:31Z
0,2015-10-26T15:19:08Z,3153,"[{'description': 'MK-8242 binds MDM2 and prevents its interaction with p53, thereby inhibiting degradation of p53 and potentially resulting in increased tumor cell apoptosis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MK-8242,2015-10-26T15:19:08Z
0,2015-12-18T20:08:24Z,3302,"[{'description': 'MK-8353 is an analog of SCH772984, which targets both Erk1 and Erk2 and may inhibit cell growth (PMID: 25142146). ', 'references': [{'id': 4128, 'pubMedId': 25142146, 'title': 'Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25142146'}]}]",MK-8353,2015-12-18T20:08:24Z
0,2017-02-01T01:12:05Z,5269,[],MK-8353 + Pembrolizumab,2017-02-01T01:12:05Z
0,2015-03-08T21:13:17Z,2328,"[{'description': 'MK-8745 is selective Aurora A kinase inhibitor, which induces cell cycle arrest (PMID: 21879811).', 'references': [{'id': 2118, 'pubMedId': 21879811, 'title': 'A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21879811'}]}]",MK-8745,2017-04-04T12:47:34Z
0,2015-02-09T00:57:40Z,2027,"[{'description': 'MK-8776 is a selective CHK1 inhibitor, which may enhance chemosensitivity (PMID: 23594139).', 'references': [{'id': 1828, 'pubMedId': 23594139, 'title': 'Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23594139'}]}]",MK-8776,2015-02-09T00:57:40Z
0,2014-03-12T15:53:16Z,812,[],MK0646,
0,2014-03-12T15:53:16Z,815,"[{'description': 'MK-0752 is a gamma secretase inhibitor, which blocks Notch cleavage and activation, and may inhibit angiogenesis and tumor growth (PMID: 20463236, PMID: 23340294). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 2508, 'pubMedId': 20463236, 'title': 'Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20463236'}, {'id': 2509, 'pubMedId': 23340294, 'title': 'Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23340294'}]}]",MK0752,2015-04-27T12:38:00Z
0,2014-03-12T15:53:16Z,816,"[{'description': 'MK2206 binds to and inhibits the activity of AKT in a non-ATP competitive manner, which may result in the inhibition of the PI3K/AKT signaling pathway and tumor cell proliferation (PMID: 20571069).', 'references': [{'id': 2283, 'pubMedId': 20571069, 'title': 'MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20571069'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MK2206,2017-03-17T18:20:55Z
0,2014-08-06T14:40:20Z,1393,[],MK2206 + hydroxychloroquine,2014-08-06T14:40:20Z
0,2016-04-05T02:46:12Z,3893,[],MK2206 + Paclitaxel,2016-04-05T02:46:12Z
0,2016-04-19T19:16:43Z,3957,[],MK2206 + Palbociclib,2016-04-19T19:16:43Z
0,2015-06-30T02:58:29Z,2875,[],MK2206 + Romidepsin,2015-06-30T02:58:29Z
0,2016-11-23T16:56:14Z,4997,[],MK2206 + SCH772984,2016-11-23T16:56:14Z
0,2014-07-25T17:33:57Z,1098,[],MK2206 + Selumetinib,2014-07-25T17:33:57Z
0,2016-09-23T17:47:00Z,4749,[],MK2206 + Tazemetostat,2016-09-23T17:47:00Z
0,2016-09-07T18:39:11Z,4664,[],MK2206 + Temsirolimus,2016-09-07T18:39:11Z
0,2016-09-06T19:33:41Z,4653,[],MK2206 + Trametinib,2016-09-06T19:33:41Z
0,2014-09-18T19:57:04Z,1494,[],MK2206 + Trastuzumab,2014-09-18T19:57:04Z
0,2016-09-01T15:08:41Z,4635,[],MK2206 + Vemurafenib,2016-09-01T15:08:41Z
0,2014-03-12T15:53:16Z,817,"[{'description': 'MK2461 inhibits wild-type and activated forms of MET, and also has activity against VEGFR1 (FLT1), MST1R (RON), and PDGFR resulting in inhibition of downstream signaling and decreased tumor growth (PMID: 20145145).', 'references': [{'id': 2014, 'pubMedId': 20145145, 'title': 'MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20145145'}]}]",MK2461,2015-12-03T16:38:49Z
0,2015-12-03T15:03:56Z,3251,"[{'description': 'MK8033 inhibits MET and MST1R (RON), potentially resulting in decreased downstream signaling and reduced tumor growth (PMID: 23379595, PMID: 23792360).', 'references': [{'id': 4024, 'pubMedId': 23379595, 'title': 'Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23379595'}, {'id': 3959, 'pubMedId': 23792360, 'title': 'MSP-RON signalling in cancer: pathogenesis and therapeutic potential.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23792360'}]}]",MK8033,2015-12-03T16:39:26Z
0,2016-03-31T14:53:11Z,3884,"[{'description': 'ML264 is a small molecule that inhibits KLF5 expression by an unknown mechanism, potentially resulting in decreased tumor cell proliferation (PMID: 26621868).', 'references': [{'id': 5089, 'pubMedId': 26621868, 'title': 'ML264, A Novel Small-Molecule Compound That Potently Inhibits Growth of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26621868'}]}]",ML264,2016-03-31T14:53:11Z
0,2015-05-13T16:26:15Z,2662,"[{'description': 'ML323 blocks the deubiquitinase activity of USP1 and UAF1, which may inhibit proliferation and sensitize cancer cells to chemotherapy (PMID: 24531842, PMID: 24130053).  ', 'references': [{'id': 2698, 'pubMedId': 24531842, 'title': 'A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24531842'}, {'id': 2693, 'pubMedId': 24130053, 'title': 'Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24130053'}]}]",ML323,2015-05-13T16:26:15Z
0,2016-10-11T14:50:43Z,4811,"[{'description': 'ML364 is a small molecule that reversibly inhibits ubiquitin\r\n-specific protease 2  (USP2), leading to cyclin D1 degradation and anti-proliferation effects (PMID: 27681596).', 'references': [{'id': 6749, 'pubMedId': 27681596, 'title': 'Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27681596'}]}]",ML364,2016-10-11T14:50:43Z
0,2014-09-11T04:11:12Z,1444,[],MLN0128 + Bevacizumab,2014-09-11T04:11:12Z
0,2014-09-30T20:39:13Z,1580,[],MLN0128 + Exemestane,2014-09-30T20:39:13Z
0,2014-09-30T20:40:35Z,1581,[],MLN0128 + Fulvestrant,2014-09-30T20:40:35Z
0,2017-01-14T04:49:26Z,5197,[],MLN0128 + Metformin,2017-01-14T04:49:26Z
0,2015-02-26T16:49:23Z,2175,[],MLN0128 + MLN2480,2015-02-26T16:49:23Z
0,2016-09-29T23:49:53Z,4771,[],MLN0128 + PD-0325901,2016-09-29T23:49:53Z
0,2016-03-28T20:29:37Z,3861,[],MLN0128 + Phenformin,2016-03-28T20:29:37Z
0,2016-10-17T20:34:20Z,4849,[],MLN0128 + SBI-0206965,2016-10-17T20:34:20Z
0,2016-07-26T19:55:41Z,4497,[],MLN0128 + Sirolimus,2016-07-26T19:55:41Z
0,2017-01-03T19:16:17Z,5141,[],MLN0128 + Tamoxifen,2017-01-03T19:16:39Z
0,2017-02-28T17:18:35Z,5386,[],MLN0128 + WEHI-539,2017-02-28T17:18:35Z
0,2016-03-17T19:14:59Z,3777,"[{'description': 'MLN0905 is a small molecule inhibitor of PLK1, which may result in cell cycle arrest and antitumor activity (PMID: 22609854).', 'references': [{'id': 4909, 'pubMedId': 22609854, 'title': 'MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22609854'}]}]",MLN0905,2016-03-17T19:14:59Z
0,2016-03-17T19:33:39Z,3778,[],MLN0905 + Rituximab,2016-03-17T19:33:39Z
0,2014-05-14T14:52:46Z,1033,"[{'description': 'MLN1117 (INK1117) selectively inhibits PI3K alpha kinase, including mutations of PIK3CA, and therefore, targets the PI3K/Akt/mTOR pathway with potentially less toxicity than pan-PI3K inhibitors (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MLN1117,2017-09-05T19:14:00Z
0,2014-07-31T04:37:40Z,1283,[],MLN1117 + Sapanisertib,2017-07-07T20:18:24Z
0,2015-12-21T02:47:10Z,3318,[],MLN1117 + TAK-659,2015-12-21T02:47:10Z
0,2016-06-02T18:26:56Z,4199,"[{'description': 'MLN1202 is a monoclonal antibody that binds to and inhibits human chemokine receptor 2 (CCR2), potentially resulting in decreased tumor cell migration and proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MLN1202,2016-06-03T18:38:01Z
0,2016-06-02T18:27:52Z,4200,[],MLN1202 + Nivolumab,2016-06-02T18:27:52Z
0,2014-05-14T14:52:46Z,1034,"[{'description': 'MLN2480 is an inhibitor of pan-Raf kinases, which interrupts RAF/MEK/ERK signal transduction pathways to inhibit tumor cell growth (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MLN2480,2016-07-26T16:53:06Z
0,2015-02-26T16:50:16Z,2176,[],MLN2480 + Alisertib,2015-02-26T16:50:16Z
0,2016-06-02T18:20:35Z,4198,[],MLN2480 + Nivolumab,2016-06-02T18:20:35Z
0,2015-02-26T16:50:43Z,2177,[],MLN2480 + Paclitaxel,2015-02-26T16:50:43Z
0,2016-10-05T20:33:51Z,4794,[],MLN2480 + Selumetinib,2016-10-05T20:33:51Z
0,2014-10-30T15:54:55Z,1688,"[{'description': 'MLN4924 binds and inhibits NEDD8, a ubiquitin-like protein, leading to inhibition of NFKB signaling, reduced transcription of target genes, and increased apoptosis in cancer cells with increased NFKB activity (PMID: 24634471).', 'references': [{'id': 990, 'pubMedId': 24634471, 'title': 'The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24634471'}]}]",MLN4924,2017-07-28T17:54:09Z
0,2016-11-29T15:31:41Z,5017,[],MLN4924 + PLX4720,2016-11-29T15:31:41Z
0,2015-03-09T09:16:56Z,2333,"[{'description': 'MLN8054 is a selective Aurora A kinase inhibitor, which prevents cell proliferation (PMID: 17360485).', 'references': [{'id': 2124, 'pubMedId': 17360485, 'title': 'Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17360485'}]}]",MLN8054,2017-04-04T12:58:54Z
0,2014-03-12T15:53:16Z,819,"[{'description': 'MM-111 is a bispecific antibody that binds simultaneously to ERBB2 (HER2) and ERBB3 (HER3) which may block signaling and inhibit tumor growth (PMID: 22248472). ', 'references': [{'id': 2312, 'pubMedId': 22248472, 'title': 'Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22248472'}]}]",MM-111,2015-10-13T20:27:07Z
0,2014-06-09T18:19:05Z,1073,"[{'description': 'MM-141 (Istiratumab) is a monoclonal antibody, which binds to human epidermal growth factor receptor B3 (ERBB3) and the human insulin-like growth factor-1 receptor (IGF-1R), blocking ligand binding and preventing activation of PI3K/AKT signaling (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MM-141,2016-05-14T11:19:14Z
0,2014-07-30T14:05:50Z,1249,[],MM-141 + Abraxane + Gemcitabine,2014-07-30T14:05:50Z
0,2014-07-30T14:02:43Z,1248,[],MM-141 + Everolimus,2014-07-30T14:02:43Z
0,2014-03-12T15:53:16Z,821,"[{'description': 'MM-151 is a combination of three human monoclonal antibodies targeting distinct, non-overlapping epitopes of epidermal growth factor receptor (EGFR), thereby preventing the binding of ligands and inhibiting EGFR-ERK-mediated signaling (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MM-151,2015-06-15T18:17:04Z
0,2014-08-27T00:50:51Z,1401,"[{'description': 'MM-302 is a liposome containing doxorubicin and conjugated to a monoclonal antibody against the ERBB2 (HER2) receptor, which improves efficacy while reducing toxicity (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MM-302,2014-12-22T06:26:33Z
0,2015-01-03T21:53:15Z,1888,[],MM-302 + Trastuzumab,2015-01-03T21:53:15Z
0,2017-05-24T02:26:25Z,5758,"[{'description': 'MM-310 is a nanoliposomal formulation of docetaxel that targets EphA2-expressing cells via EphA2-directed antibody fragments on the liposomal surface, potentially resulting in decreased tumor growth (Cancer Res July 15 2016 (76) (14 Supplement) 3912).', 'references': [{'id': 8972, 'pubMedId': None, 'title': 'Abstract 3912: MM-310, a novel EphA2-targeted docetaxel nanoliposome', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/3912'}]}]",MM-310,2017-05-24T16:22:37Z
0,2016-05-11T17:08:44Z,4102,"[{'description': 'MN58b inhibits Choline Kinase alpha (CHKA), resulting in decreased growth  and increased apoptosis of tumor cells with high CHKA expression (PMID: 26769123).', 'references': [{'id': 5504, 'pubMedId': 26769123, 'title': 'Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26769123'}]}]",MN58b,2016-05-11T17:11:41Z
0,2016-05-11T17:18:42Z,4104,[],MN58b + Fluorouracil,2016-05-11T17:21:45Z
0,2016-05-11T17:17:33Z,4103,[],MN58b + Gemcitabine,2016-05-11T17:17:33Z
0,2016-05-11T17:21:27Z,4105,[],MN58b + Oxaliplatin,2016-05-11T17:21:27Z
0,2015-08-10T16:33:25Z,3002,"[{'description': 'Mocetinostat (MGCD0103) selectively inhibits Class I histone-deacetelyases (HDACs), which may result in increased tumor cell death (PMID: 21317455, PMID: 20538840).', 'references': [{'id': 3416, 'pubMedId': 21317455, 'title': 'The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21317455'}, {'id': 3417, 'pubMedId': 20538840, 'title': 'The histone deacetylase inhibitor MGCD0103 has both deacetylase and microtubule inhibitory activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538840'}]}]",Mocetinostat,2017-03-17T03:21:17Z
0,2016-11-13T20:56:22Z,4944,[],Mocetinostat + Nivolumab,2016-11-13T20:56:22Z
0,2017-07-28T19:02:41Z,6042,[],Mocetinostat + Pembrolizumab + SGI-110,2017-07-28T19:02:41Z
0,2015-07-30T00:31:46Z,2968,"[{'description': 'Mogamulizumab is a monoclonal antibody that binds to and inhibits C-C chemokine receptor 4 (CCR4) signaling, which leads to inhibition of Tregs and enhancement of host antitumor immunity (PMID: 25496334).', 'references': [{'id': 3355, 'pubMedId': 25496334, 'title': 'Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25496334'}]}]",Mogamulizumab ,2017-10-18T14:42:37Z
0,2016-03-25T17:32:45Z,3843,[],Mogamulizumab + Nivolumab,2016-03-25T17:32:45Z
0,2017-10-18T14:43:40Z,6332,[],Mogamulizumab + Utomilumab,2017-10-18T14:43:40Z
0,2014-03-12T15:53:16Z,823,"[{'description': 'Momelotinib (CYT387) is an ATP-competitive and selective inhibitor of JAK1 and JAK2, which inhibits cell proliferation and promotes apoptosis (PMID: 19295546).', 'references': [{'id': 2875, 'pubMedId': 19295546, 'title': 'CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19295546'}]}]",Momelotinib,2015-06-08T17:15:32Z
0,2014-12-28T21:50:11Z,1860,[],Momelotinib + Trametinib,2014-12-28T21:50:11Z
0,2015-12-21T16:01:39Z,3323,[],Montelukast,2015-12-21T16:01:39Z
0,2017-05-26T17:05:00Z,5783,"[{'description': 'MOR208 is an CD19-targeted antibody with an engineered Fc region, which may result in an increased antibody-dependent cell-mediated cytotoxicity response against CD19-expressing tumor cells (PMID: 23277329).', 'references': [{'id': 9006, 'pubMedId': 23277329, 'title': 'The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23277329'}]}]",MOR208,2017-05-26T17:12:04Z
0,2017-05-26T17:15:08Z,5785,[],MOR208 + Venetoclax,2017-05-26T17:15:55Z
0,2016-09-06T18:52:12Z,4651,"[{'description': 'MOR209/ES414 is a humanized bispecific antibody that binds to prostate specific membrane antigen (PSMA) and CD3 complex simultaneously, therefore crosslinking PSMA-expressing tumor cells and cytotoxic T-lymphocytes, resulting in tumor cell death (PMID: 27406985).', 'references': [{'id': 6564, 'pubMedId': 27406985, 'title': 'MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27406985'}]}]",MOR209/ES414,2016-09-06T18:52:12Z
0,2014-03-12T15:53:16Z,824,"[{'description': 'Motesanib (AMG 706) is a multi-kinase inhibitor, which inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), Kit, and Ret receptors, thereby inhibiting angiogenesis and inducing tumor regression (PMID: 16951187, PMID: 21422803).', 'references': [{'id': 996, 'pubMedId': 21422803, 'title': 'Anti-tumor activity of motesanib in a medullary thyroid cancer model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21422803'}, {'id': 995, 'pubMedId': 16951187, 'title': 'AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16951187'}]}]",Motesanib,2017-04-03T14:44:25Z
0,2014-10-31T08:03:23Z,1694,[],Motesanib + Carboplatin,2014-10-31T08:03:23Z
0,2014-10-31T08:04:56Z,1695,[],Motesanib + Paclitaxel,2014-10-31T08:04:56Z
0,2015-02-23T00:46:23Z,2128,"[{'description': 'Motexafin gadolinium creates reactive oxygen species in tumor cells, sensitizing them to radiation and chemotherapy (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",motexafin gadolinium,2015-02-23T00:46:23Z
0,2015-10-01T01:28:58Z,3091,"[{'description': 'Motolimod (VTX-2337) binds to and activates Toll-like receptor 8 (TLR8), resulting in enhanced antibody-dependent cell-mediated cytotoxicity (PMID: 22128302, PMID: 28453702).', 'references': [{'id': 3684, 'pubMedId': 22128302, 'title': 'VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22128302'}]}]",Motolimod,2017-05-17T15:12:20Z
0,2017-05-04T13:27:51Z,5609,[],Motolimod + Pegylated liposomal-doxorubicin,2017-05-04T13:27:51Z
0,2015-12-02T15:29:41Z,3236,"[{'description': 'MOv18IgE is an IgE antibody directed against Folr1, which induces immune response toward Folr1-expressing tumor cells (PMID: 26312875).', 'references': [{'id': 4014, 'pubMedId': 26312875, 'title': 'Potential for monocyte recruitment by IgE immunotherapy for cancer in a rat model of tumour metastasis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26312875'}]}]",MOv18IgE,2015-12-02T18:01:22Z
0,2015-05-21T02:18:27Z,2729,"[{'description': 'MOXR0916 is an activating antibody against OX40, which results in increased T-cell response against tumor cells (PMID: 25763356).', 'references': [{'id': 2796, 'pubMedId': 25763356, 'title': 'OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25763356'}]}]",MOXR0916,2015-06-26T02:53:44Z
0,2015-04-15T18:57:54Z,2540,"[{'description': 'MP-124 is an competitive inhibitor of PARP-1, potentially resulting in increased DNA damage (PMID: 25868125)', 'references': [{'id': 2484, 'pubMedId': 25868125, 'title': 'Chromosomal damage and micronucleus induction by MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor: Evidence for a non-DNA-reactive mode of action.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25868125'}]}]",MP-124,2015-04-15T18:57:54Z
0,2017-05-24T19:06:12Z,5769,"[{'description': 'MP7 is an inhibitor of PDK1, which, when combined with other agents, may result in inhibition of cell proliferation and reduced viability of cancer cells (PMID: 27797168).', 'references': [{'id': 8978, 'pubMedId': 27797168, 'title': 'Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27797168'}]}]",MP7,2017-05-24T19:06:12Z
0,2015-06-03T18:30:19Z,2772,"[{'description': 'MPC-3100 is a synthetic HSP90 inhibitor, which may lead to decreased tumor cell growth and survival (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MPC-3100,2015-06-03T18:30:19Z
0,2016-01-25T19:52:57Z,3458,"[{'description': 'MPI-0479605, an ATP-competitive inhibitor of TTK (MPS1), derails the spindle assembly checkpoint to inhibit tumor growth (PMID: 21980130).', 'references': [{'id': 4435, 'pubMedId': 21980130, 'title': 'Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21980130'}]}]",MPI-0479605,2016-01-25T19:52:57Z
0,2016-01-25T10:33:55Z,3449,"[{'description': 'Mps-BAY1, is a triazolopyridine that inhibits TTK (MPS1) to derail the spindle assembly checkpoint and induce cell cycle arrest (PMID: 23933817).', 'references': [{'id': 4417, 'pubMedId': 23933817, 'title': 'Characterization of novel MPS1 inhibitors with preclinical anticancer activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23933817'}]}]",Mps-BAY1,2016-01-25T10:33:55Z
0,2016-01-25T10:51:27Z,3453,[],Mps-BAY1 + Paclitaxel,2016-01-25T10:51:27Z
0,2016-01-25T10:35:11Z,3450,"[{'description': 'Mps-BAY2a, is an imidazopyrazine that inhibits TTK (MPS1) to derail the spindle assembly checkpoint and induce cell cycle arrest (PMID: 23933817).', 'references': [{'id': 4417, 'pubMedId': 23933817, 'title': 'Characterization of novel MPS1 inhibitors with preclinical anticancer activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23933817'}]}]",Mps-BAY2a,2016-01-25T10:35:11Z
0,2016-01-25T10:52:28Z,3454,[],Mps-BAY2a + Paclitaxel,2016-01-25T10:52:28Z
0,2016-01-25T10:35:49Z,3451,"[{'description': 'Mps-BAY2b, is an imidazopyrazine that inhibits TTK (MPS1) to derail the spindle assembly checkpoint and induce cell cycle arrest (PMID: 23933817).', 'references': [{'id': 4417, 'pubMedId': 23933817, 'title': 'Characterization of novel MPS1 inhibitors with preclinical anticancer activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23933817'}]}]",Mps-BAY2b,2016-01-25T10:35:49Z
0,2016-01-25T10:46:09Z,3452,[],Mps-BAY2b + Paclitaxel,2016-01-25T10:46:09Z
0,2016-01-21T11:52:40Z,3424,"[{'description': 'Mps1-IN-1 is an ATP-competitive inhibitor of TTK (MPS1), which decreases cell proliferation (PMID: 20383151).', 'references': [{'id': 4400, 'pubMedId': 20383151, 'title': 'Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20383151'}]}]",Mps1-IN-1,2016-01-21T11:52:40Z
0,2016-01-21T12:02:09Z,3425,"[{'description': 'Mps1-IN-2, an ATP-competitive inhibitor of Ttk (Mps1) and Plk1, abolishes the spindle assembly checkpoint (PMID: 20383151).', 'references': [{'id': 4400, 'pubMedId': 20383151, 'title': 'Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20383151'}]}]",Mps1-IN-2,2016-01-21T12:02:09Z
0,2016-01-25T11:05:15Z,3455,"[{'description': 'MPS1-IN-3, inhibits TTK (MPS1) to derail the spindle assembly checkpoint and induce cell cycle arrest (PMID: 23940287).', 'references': [{'id': 4420, 'pubMedId': 23940287, 'title': 'Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23940287'}]}]",MPS1-IN-3,2016-01-25T11:05:15Z
0,2016-01-25T11:08:31Z,3456,[],MPS1-IN-3 + Vincristine,2016-01-25T11:08:31Z
0,2015-05-12T14:58:26Z,2658,"[{'description': 'MPT0E028 inhibits histone deacetylases as well as Akt phosphorylation, resulting in increased tumor cell death and inhibition of tumor growth (PMID: 25669976).', 'references': [{'id': 2689, 'pubMedId': 25669976, 'title': 'Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25669976'}]}]",MPT0E028,2015-08-17T16:41:01Z
0,2014-07-14T08:00:39Z,1084,"[{'description': 'MRK-003 is a gamma-secretase inhibitor which inhibits Notch3 signaling and induces apoptosis in cancer cells (PMID: 17804716).', 'references': [{'id': 979, 'pubMedId': 17804716, 'title': 'Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17804716'}]}]",MRK-003,2015-02-23T19:21:20Z
0,2016-02-01T17:22:40Z,3491,[],MRK-003 + Paclitaxel,2016-02-01T17:22:40Z
0,2016-09-16T02:27:58Z,4716,[],MRK-003 + Radiotherapy,2016-09-16T02:27:58Z
0,2016-02-01T17:23:21Z,3492,[],MRK-003 + SCH772984,2016-02-01T17:23:21Z
0,2015-03-17T02:08:47Z,2418,"[{'description': 'MRT-92 binds to and inhibits Smoothened (SMO), resulting in decreased Hedgehog (Hh) pathway signaling and reduced tumor cell proliferation (PMID: 25636740).', 'references': [{'id': 2240, 'pubMedId': 25636740, 'title': 'MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25636740'}]}]",MRT-92,2015-03-17T02:08:47Z
0,2016-11-28T20:28:34Z,5016,"[{'description': 'MRX-2843 is a small molecule inhibitor of both Mertk and Flt3, resulting in apoptosis and anti-tumor effects (PMID: 27158668).', 'references': [{'id': 7187, 'pubMedId': 27158668, 'title': 'The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27158668'}]}]",MRX-2843,2016-11-28T20:28:34Z
0,2014-05-14T14:52:46Z,1035,"[{'description': 'MRX34 is a liposomal formulation containing a nucleotide that mimics the human tumor suppressor microRNA (miRNA) miR-34, with potential antineoplastic activity through inhibition of MYC, MET, BCL2, CCND1 and CTNNB1 (NCI Drug Dictionary; PMID: 24657911).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 617, 'pubMedId': 24657911, 'title': 'miR-34: from bench to bedside.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24657911'}]}]",MRX34,2015-12-10T19:20:32Z
0,2017-10-17T15:00:58Z,6314,"[{'description': 'Limited information is currently available on MS201408-0005A (Oct 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",MS201408-0005A,2017-10-17T15:00:58Z
0,2017-10-17T15:10:25Z,6317,[],MS201408-0005A + MS201408-0005B,2017-10-17T15:10:25Z
0,2017-10-17T15:13:22Z,6318,[],MS201408-0005A + MS201408-0005C,2017-10-17T15:13:22Z
0,2017-10-17T15:04:38Z,6315,"[{'description': 'Limited information is currently available on MS201408-0005B (Oct 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",MS201408-0005B,2017-10-17T15:04:38Z
0,2017-10-17T15:06:38Z,6316,"[{'description': 'Limited information is currently available on MS201408-0005C (Oct 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",MS201408-0005C,2017-10-17T15:06:38Z
0,2015-12-28T15:29:07Z,3335,"[{'description': 'MS417 is a BET bromodomain inhibitor with specificity for BRD4, which may result in cell cycle arrest thereby inhibiting cell proliferation (PMID: 23950209, PMID: 22645123). ', 'references': [{'id': 4173, 'pubMedId': 22645123, 'title': 'Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22645123'}, {'id': 4172, 'pubMedId': 23950209, 'title': 'BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23950209'}]}]",MS417,2017-03-17T19:21:28Z
0,2015-12-28T15:49:13Z,3336,"[{'description': 'MS436 is a BET bromodomain inhibitor with specificity for BRD4, which may result in cell cycle arrest thereby inhibiting cell proliferation (PMID: 23950209, PMID: 24144283). ', 'references': [{'id': 4174, 'pubMedId': 24144283, 'title': 'Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24144283'}, {'id': 4172, 'pubMedId': 23950209, 'title': 'BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23950209'}]}]",MS436,2017-03-17T20:04:13Z
0,2017-03-16T14:24:41Z,5453,"[{'description': 'M344 is an HDAC inhibitor, which may decrease proliferation and induce apoptosis of tumor cells (PMID: 17230517).', 'references': []}]",MS44,2017-03-16T14:26:00Z
0,2014-05-14T14:52:46Z,1036,"[{'description': 'MSC2015103B inhibits the activity of MEK1/2 (MAP2K1/2), which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MSC2015103B,2017-04-06T10:02:16Z
0,2014-08-12T13:31:30Z,1398,"[{'description': 'Tepotinib (MSC2156119J) selectively binds to the proto-oncogene hepatocyte growth factor receptor (HGFR or c-Met), which inhibits c-Met phosphorylation and disrupts c-Met-mediated signaling pathways, thereby suppressing tumor growth in tumor cells with activated or overexpression of c-Met protein  (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MSC2156119J,2015-09-21T09:53:53Z
0,2014-05-14T14:52:46Z,1037,"[{'description': 'M2698 (MSC2363318A) binds to and inhibits the activity of P70S6K and AKT, which prevents the activation of the PI3K/AKT/P70S6K signaling pathway, thereby inhibiting tumor cell proliferation (PMID: 27186432).', 'references': [{'id': 7643, 'pubMedId': 27186432, 'title': 'M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27186432'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MSC2363318A,2017-03-17T18:05:49Z
0,2016-02-25T20:19:49Z,3616,"[{'description': 'MSC2490484A is a DNA-dependent protein kinase (DNA-PK) inhibitor that blocks DNA damage repair, which may lead to antitumor activity (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MSC2490484A ,2017-06-14T18:45:26Z
0,2017-04-17T20:12:39Z,5546,[],MSC2490484A  + Cisplatin + Etoposide,2017-04-17T20:12:39Z
0,2015-06-18T20:23:09Z,2848,"[{'description': 'MSX-122 is a CXCR4 antagonist, which inhibits SDF-1(CXCL12)-CXCR4 mediated signaling and may inhibit tumor cell metastasis (PMID: 22485156).', 'references': [{'id': 3085, 'pubMedId': 22485156, 'title': 'Development of a unique small molecule modulator of CXCR4.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22485156'}]}]",MSX-122,2015-06-25T20:58:18Z
0,2016-10-28T19:37:30Z,4875,"[{'description': 'MT1 is a bivalent BET bromodomain inhibitor, which may result in tumor cell death and decreased tumor growth (PMID: 27775715).', 'references': [{'id': 6900, 'pubMedId': 27775715, 'title': 'Design and characterization of bivalent BET inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27775715'}]}]",MT1,2016-10-28T19:37:30Z
0,2016-06-10T20:22:01Z,4268,"[{'description': 'Limited information is currently available on MTIG7192A (Jun 2016).', 'references': []}]",MTIG7192A ,2016-06-10T20:22:01Z
0,2017-09-08T17:40:49Z,6180,"[{'description': 'MU380 is a selective inhibitor of CHK1, which increases sensitivity of tumor cells to DNA damaging agents, potentially resulting in decreased tumor growth (PMID: 28619751).', 'references': [{'id': 9884, 'pubMedId': 28619751, 'title': 'Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28619751'}]}]",MU380,2017-09-08T17:40:49Z
0,2015-07-11T12:37:39Z,2904,"[{'description': 'MUC16ecto CAR T cells are autologous T-cells that recognize the cytoplasmic domain of MUC16 (CA125) as well as secrete IL-2, potentially resulting in enhanced immune response against MUC16-expressing tumor cells (PMID: 25890361).', 'references': [{'id': 3219, 'pubMedId': 25890361, 'title': 'A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25890361'}]}]",MUC16ecto CAR T cells,2015-07-11T12:37:39Z
0,2017-08-18T18:56:02Z,6125,"[{'description': 'MV-NIS is a oncolytic strain of measles virus that expresses human sodium iodide symporter, which may increase anti-tumor immune response (PMID: 25398436, PMID: 22185260).', 'references': [{'id': 9753, 'pubMedId': 22185260, 'title': 'Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22185260'}, {'id': 9752, 'pubMedId': 25398436, 'title': 'Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25398436'}]}]",MV-NIS,2017-08-18T18:56:02Z
0,2017-08-18T18:57:27Z,6127,[],MV-NIS + Atezolizumab,2017-08-18T18:58:11Z
0,2014-07-30T17:14:27Z,1273,"[{'description': 'MVA-MUC1-IL2 is a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2), for immunotherapy in cancer patients whose tumors express the MUC1 antigen (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",MVA-MUC1-IL2 vaccine,2014-07-30T17:14:27Z
0,2016-07-08T20:34:13Z,4435,[],MVA-MUC1-IL2 vaccine + Nivolumab,2016-07-08T20:34:13Z
0,2014-05-14T14:52:46Z,1038,"[{'description': 'MVAp53 is a modified vaccinia virus Ankara-based vaccine that may induce a T-cell mediated immune response against p53-expressing tumor cells (PMID: 21843052).', 'references': [{'id': 56, 'pubMedId': 21843052, 'title': 'Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21843052'}]}]",MVAp53,2015-11-17T14:25:31Z
0,2015-01-16T15:43:10Z,1958,[],MVAp53 + Gemcitabine,2017-04-17T20:21:09Z
0,2017-04-17T20:20:38Z,5547,[],MVAp53 + Pembrolizumab,2017-04-17T20:20:38Z
0,2017-05-19T19:15:08Z,5706,"[{'description': 'MVT-1075 is a radiolabeled IgG1 antibody that binds to the sialyl Lewis A epitope of CA19-9 and is conjugated to a bifunctional chelator, which may result in tumor growth inhibition and tumor regression (AACR 2017, Abstract nr5204). ', 'references': [{'id': 8949, 'pubMedId': None, 'title': 'Preclinical development of MVT-1075 as radioimmunotherapy for pancreatic cancer and other CA19-9 positive malignancies', 'url': 'http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=105&DetailItemID=539#.WR9AdvMo9Qo'}]}]",MVT-1075,2017-05-19T19:58:44Z
0,2017-05-30T00:37:09Z,5801,[],MVT-1075 + MVT-5873,2017-05-30T00:37:09Z
0,2017-05-19T19:58:14Z,5712,"[{'description': 'MVT-5873 is an IgG1 antibody that binds to the sialyl Lewis A epitope of CA19-9, which may result in antitumor activity including tumor growth inhibition (Cancer Res 2016;76(24 Suppl):Abstract nr A73). ', 'references': [{'id': 8955, 'pubMedId': None, 'title': 'Abstract A73: Antitumor activity of MVT-5873, a monoclonal antibody targeting sialyl Lewisa, alone and in combination with gemcitabine/nab-paclitaxel in a BxPC3 human pancreatic cancer xenograft model', 'url': 'http://cancerres.aacrjournals.org/content/76/24_Supplement/A73.short'}]}]",MVT-5873,2017-05-19T19:58:14Z
0,2017-05-19T20:07:35Z,5713,[],MVT-5873 + Gemcitabine + nab-paclitaxel,2017-05-19T20:07:35Z
0,2016-10-03T19:40:34Z,4775,"[{'description': 'MX69 is an inhibitor of the interaction between MDM2 and XIAP, which results in MDM2 degradation and subsequent repression of TP53 activation thereby possibly leading to antitumor activity (PMID: 27666947). ', 'references': [{'id': 6705, 'pubMedId': 27666947, 'title': 'Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27666947'}]}]",MX69,2016-10-03T19:40:34Z
0,2015-05-20T18:33:36Z,2722,"[{'description': 'MYB vaccine is a DNA vaccine comprised of a modified full-length MYB coding region linked to tetanus peptides, which results in enhanced immune response to MYB expressing tumor cells (PMID: 25671128).', 'references': [{'id': 2786, 'pubMedId': 25671128, 'title': 'Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25671128'}]}]",MYB vaccine,2015-05-20T18:33:36Z
0,2014-12-23T15:51:55Z,1845,"[{'description': 'Cellcept (mycophenolate mofetil) is metabolized to mycophenolic acid, which interferes with proliferation of B- and T-lymphocytes, resulting in immunosuppresion (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Mycophenolate mofetil,2014-12-31T05:04:12Z
0,2016-02-11T09:22:22Z,3507,"[{'description': 'Mycro3 inhibits Myc-Max dimerization to prevent tumor growth (PMID: 25306215).', 'references': [{'id': 4548, 'pubMedId': 25306215, 'title': 'Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25306215'}]}]",Mycro3,2016-02-11T09:22:22Z
0,2016-06-09T13:19:18Z,4262,"[{'description': 'MYL-1401O is a biosimilar of trastuzumab that demonstrates comparable safety and efficacy in ERBB2 (HER2)-positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr LBA503)).', 'references': []}]",MYL-1401O,2016-06-09T13:19:18Z
0,2016-06-09T13:26:35Z,4263,[],MYL-1401O + Paclitaxel,2016-06-09T13:26:35Z
0,2016-02-11T10:09:53Z,3510,"[{'description': 'MYRA-A inhibits Myc-Max complex from binding DNA and inducing gene transcription, which promotes apoptosis (PMID: 25332683).', 'references': [{'id': 4549, 'pubMedId': 25332683, 'title': 'Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25332683'}]}]",MYRA-A,2016-02-11T10:11:36Z
0,2017-01-10T18:49:31Z,5185,"[{'description': 'N-Arachidonoyl Dopamine (NADA) is an endocannabinoid that inhibits translocation of RAS proteins to the cellular membrane, thereby reducing RAS signaling and potentially inhibiting growth of RAS-dependent tumor cells (PMID: 27760835).', 'references': [{'id': 7517, 'pubMedId': 27760835, 'title': 'N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane Translocation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27760835'}]}]",N-Arachidonoyl Dopamine ,2017-01-10T18:57:50Z
0,2014-12-10T20:20:56Z,1776,[],N/A,2014-12-10T20:20:56Z
0,2014-09-18T19:23:22Z,1489,[],Nab-paclitaxel + Carboplatin + Bevacizumab,2014-09-18T19:23:22Z
0,2014-09-18T19:24:57Z,1490,[],Nab-paclitaxel + Carboplatin + Trastuzumab,2014-09-18T19:24:57Z
0,2014-12-15T16:29:44Z,1779,[],Nab-paclitaxel + Gemcitabine,2014-12-15T16:29:44Z
0,2014-07-30T16:48:44Z,1268,[],nab-paclitaxel + GSK1120212,2014-07-30T16:48:44Z
0,2015-10-08T02:52:04Z,3112,[],nab-paclitaxel + Palbociclib,2015-10-08T02:52:04Z
0,2016-04-29T15:06:46Z,4023,[],nab-paclitaxel + Pembrolizumab,2016-04-29T15:06:46Z
0,2016-01-10T17:51:24Z,3380,"[{'description': 'Nab-Rapamycin is nanoparticle albumin-bound rapamycin that has immunosuppressant and anti-tumor activities (PMID: 24089446).', 'references': [{'id': 4266, 'pubMedId': 24089446, 'title': 'Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24089446'}]}]",Nab-Rapamycin,2016-03-28T16:51:15Z
0,2017-06-26T18:30:14Z,5931,[],Nab-Rapamycin + Nivolumab,2017-06-26T18:30:14Z
0,2016-12-01T04:50:12Z,5030,[],Nab-Rapamycin + Temozolomide + Irinotecan,2016-12-01T04:50:12Z
0,2016-03-23T02:41:04Z,3818,"[{'description': 'NanoHHI is a formulation of the GLI1/2 inhibitor HP1-1 encapsulated in polymer nanoparticles to increase bioavailability, which inhibits Hh pathway signaling and potentially leads to decreased tumor growth and metastasis (PMID: 21868763, PMID: 22027695).\r\n', 'references': [{'id': 4992, 'pubMedId': 22027695, 'title': 'A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22027695'}, {'id': 4993, 'pubMedId': 21868763, 'title': 'Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21868763'}]}]",NanoHHI,2016-03-23T02:41:04Z
0,2015-12-02T21:35:53Z,3246,"[{'description': 'Narnatumab (IMC-RON8) is a monoclonal antibody directed against RON, which potentially results in decreased proliferation of RON-expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",Narnatumab,2015-12-02T21:35:53Z
0,2016-06-30T15:57:00Z,4404,[],Natalizumab,2016-06-30T15:57:00Z
0,2017-04-20T18:38:03Z,5564,"[{'description': 'NAV-2729 binds to and inhibits ARF6, which may result in decreased tumor growth (PMID: 27265506).', 'references': [{'id': 8662, 'pubMedId': 27265506, 'title': 'ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27265506'}]}]",NAV-2729,2017-04-20T18:39:20Z
0,2017-05-24T20:36:27Z,5773,"[{'description': 'Limited information is currently available on Navicixizumab, a putative bispecific antibody targeting Dll4 and Vegf (May, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",Navicixizumab,2017-05-24T20:36:27Z
0,2014-03-12T15:53:16Z,825,"[{'description': 'Navitoclax (ABT-263) is a BCL2, BCL-XL, and BCL-W inhibitor, which may enhance the efficacy of chemotherapeutics (PMID: 25787766).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 2473, 'pubMedId': 25787766, 'title': 'Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25787766'}]}]",Navitoclax,2017-08-01T15:57:11Z
0,2014-09-19T12:57:37Z,1521,[],navitoclax + gemcitabine ,2014-09-19T12:57:37Z
0,2017-01-24T14:22:46Z,5245,[],Navitoclax + ONC201,2017-08-01T16:05:28Z
0,2015-08-28T01:28:47Z,3065,[],Navitoclax + Osimertinib,2017-08-01T16:02:14Z
0,2017-03-07T18:22:01Z,5413,[],Navitoclax + Paclitaxel,2017-08-01T15:59:40Z
0,2016-11-23T17:17:08Z,4998,[],Navitoclax + SCH772984,2017-08-01T16:03:49Z
0,2014-12-30T14:50:47Z,1872,[],Navitoclax + Sorafenib,2014-12-30T14:50:47Z
0,2017-06-30T19:51:58Z,5955,[],Navitoclax + TAK-901,2017-08-01T15:58:42Z
0,2016-02-14T18:07:00Z,3530,[],Navitoclax + Vemurafenib,2016-02-14T18:07:00Z
0,2017-09-11T15:32:34Z,6187,[],Navitoclax + Venetoclax,2017-09-11T15:32:34Z
0,2015-07-30T19:54:35Z,2984,"[{'description': 'NAX014 is a synthetic derivative of berberine, which has the potential to induce apoptotic activity and decrease tumor growth (PMID: 24000115, PMID: 26168818).', 'references': [{'id': 3370, 'pubMedId': 24000115, 'title': 'Antitumor effect of novel berberine derivatives in breast cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24000115'}, {'id': 3369, 'pubMedId': 26168818, 'title': 'Antiangiogenic and antitumor activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26168818'}]}]",NAX014,2015-07-30T19:54:35Z
0,2014-09-11T02:00:18Z,1429,"[{'description': 'NC-4016 is comprised of polymeric micellar nanoparticles of 1,2-diaminocyclohexane platinum, which cause cross-linking of DNA leading to apoptosis (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",NC-4016,2015-04-10T16:37:55Z
0,2017-04-27T16:06:01Z,5577,"[{'description': 'NC-6004 comprises the platinum-based chemotherapeutic cisplatin incorporated into polymeric micellar nanocarriers, which may inhibit tumor growth (PMID: 16222314, PMID: 18406004).', 'references': [{'id': 8739, 'pubMedId': 18406004, 'title': 'Poly (amino acid) micelle nanocarriers in preclinical and clinical studies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18406004'}, {'id': 8738, 'pubMedId': 16222314, 'title': 'Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16222314'}]}]",NC-6004,2017-04-27T16:06:01Z
0,2015-03-16T16:00:33Z,2405,"[{'description': 'NC043 inhibits the interaction of CTNNB1 with TCF7L2 to block Wnt signaling resulting in apoptosis and interruption of the cell cycle (PMID: 21321609).', 'references': [{'id': 2218, 'pubMedId': 21321609, 'title': 'A diterpenoid derivative 15-oxospiramilactone inhibits Wnt/β-catenin signaling and colon cancer cell tumorigenesis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21321609'}]}]",NC043,2015-03-16T16:00:33Z
0,2015-08-28T01:58:56Z,3068,"[{'description': 'NCDM-32B inhibits KDM4, with selectivity towards KDM4C and KDM4A, potentially resulting in decreased tumor cell growth (PMID: 26101715). ', 'references': [{'id': 3566, 'pubMedId': 26101715, 'title': 'Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26101715'}]}]",NCDM-32B,2015-08-28T01:58:56Z
0,2015-06-25T16:03:09Z,2870,"[{'description': 'ND-2110 inhibits IRAK4, potentially resulting in decreased tumor cell survival (Blood Nov 2013, 122 (21) 4132).', 'references': [{'id': 3131, 'pubMedId': None, 'title': 'Effect Of MYD88 Mutation In CLL On IRAK4 and BTK Inhibition In Vitro', 'url': 'http://www.bloodjournal.org/content/122/21/4132?sso-checked=true'}]}]",ND-2110,2015-06-25T16:03:09Z
0,2015-06-25T15:51:10Z,2869,"[{'description': 'ND-2158 is a selective inhibitor of IRAK4, which may lead to decreased survival in tumor cells with activated MYD88 signaling (Blood Nov 2013, 122 (21) 3833).', 'references': [{'id': 3130, 'pubMedId': None, 'title': 'Synergistic Blockade Of Activated B Cell-Like DLBCL Proliferation With a Selective Inhibitor Of IRAK4 In Combination With Inhibition Of The B-Cell Receptor Signaling Network', 'url': 'http://www.bloodjournal.org/content/122/21/3833?sso-checked=true'}]}]",ND-2158,2015-06-25T15:51:10Z
0,2015-06-25T16:07:42Z,2871,"[{'description': 'ND-346 is a selective inhibitor of IRAK4, with efficacy in models of autoimmune disease (PMID: 25290089).', 'references': [{'id': 3132, 'pubMedId': 25290089, 'title': 'IRAK signalling in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25290089'}]}]",ND-346,2015-06-25T16:09:05Z
0,2014-03-12T15:53:16Z,826,"[{'description': 'Portrazza (necitumumab) is a fully human IgG1 mAb targeting EGFR, leading to the inhibition of downstream targets in the EGFR pathway, and thereby inhibiting cellular proliferation and invasion (PMID: 21154125). Portrazza (necitumumab) is approved for patients with metastatic squamous non-small cell lung cancer (FDA.gov).', 'references': [{'id': 1016, 'pubMedId': 21154125, 'title': 'Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21154125'}]}]",Necitumumab,2017-06-19T18:51:09Z
0,2016-02-02T15:42:50Z,3498,[],Necitumumab + FOLFOX,2016-02-02T15:42:50Z
0,2016-11-19T22:51:56Z,4973,[],Necitumumab + Gemcitabine + Carboplatin,2016-11-19T22:51:56Z
0,2015-07-02T18:11:26Z,2882,[],Necitumumab + Gemcitabine + Cisplatin,2015-07-02T18:11:26Z
0,2016-06-27T01:54:07Z,4380,[],Necitumumab + Osimertinib,2016-06-27T01:54:07Z
0,2015-09-21T09:25:03Z,3085,[],Necitumumab + Pemetrexed + Cisplatin,2015-09-21T09:25:03Z
0,2016-06-06T15:35:59Z,4251,"[{'description': 'Necuparanib is heparan sulfate mimetic that inhibits multiple heparin-binding factors, resulting in inhibition of tumor growth and metastasis (PMID: 21698156).', 'references': [{'id': 5757, 'pubMedId': 21698156, 'title': 'M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21698156'}]}]",Necuparanib,2016-06-06T15:35:59Z
0,2015-10-30T13:01:36Z,3160,[],Nelarabine,2015-10-30T13:01:36Z
0,2014-03-12T15:53:16Z,827,[],Nelfinavir,
0,2017-02-11T22:50:41Z,5301,[],Nelfinavir + Nivolumab,2017-02-11T22:50:41Z
0,2016-04-19T17:39:14Z,3953,[],Nelfinavir + Radiotherapy,2016-04-19T17:39:14Z
0,2017-01-03T20:53:23Z,5152,"[{'description': 'Nelipepimut-S Plus GM-CSF comprises a ERBB2 (HER2) targeted peptide vaccine (E75) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), which potentially results in increased immune response against ERBB2 (HER2) expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Nelipepimut-S Plus GM-CSF,2017-07-20T16:58:19Z
0,2016-09-21T15:34:04Z,4732,"[{'description': 'Limited information is currently available on NEO-PV-01, a putative personalized cancer vaccine (Sep, 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",NEO-PV-01,2016-09-21T15:34:04Z
0,2016-09-21T15:35:07Z,4733,[],NEO-PV-01 + poly ICLC,2016-09-21T15:35:07Z
0,2015-08-12T00:01:14Z,3006,"[{'description': 'NeoVax melanoma vaccine combines patient-derived melanoma neoantigen with the immunostimulant poly-ICLC, which stimulates anti-tumor immune response against tumor cells expressing the neoantigen (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",NeoVax melanoma vaccine,2015-08-12T00:01:14Z
0,2014-03-12T15:53:16Z,828,"[{'description': 'Nerlynx (neratinib) inhibits the ERBB2 (HER2) receptor as well as EGFR, resulting in decreased proliferation of HER2 and EGFR expressing tumor cells (PMID: 15173008). Nerlynx (neratinib) is FDA approved for breast cancer patients with ERBB2 (HER2) overexpression and/or amplification (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 2313, 'pubMedId': 15173008, 'title': 'Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15173008'}]}]",Neratinib,2017-07-26T15:07:10Z
0,2017-03-04T04:54:51Z,5401,[],Neratinib + Everolimus,2017-03-04T04:54:51Z
0,2016-12-15T16:58:10Z,5101,[],Neratinib + Paclitaxel,2016-12-15T16:58:10Z
0,2015-11-08T21:09:14Z,3187,[],Neratinib + Paclitaxel + Pertuzumab + Trastuzumab,2015-11-08T21:10:11Z
0,2017-03-04T04:55:47Z,5402,[],Neratinib + Palbociclib,2017-03-04T04:55:47Z
0,2017-07-27T16:51:05Z,6013,[],Neratinib + Pertuzumab,2017-07-27T16:51:05Z
0,2016-11-23T18:26:16Z,5011,[],Neratinib + Selumetinib,2016-11-23T18:26:16Z
0,2016-12-01T03:29:35Z,5029,[],Neratinib + Temozolomide,2016-12-01T03:29:35Z
0,2017-03-04T04:56:53Z,5403,[],Neratinib + Trametinib,2017-03-04T04:56:53Z
0,2016-06-24T20:52:09Z,4359,[],Neratinib + Trastuzumab,2016-06-24T20:52:09Z
0,2015-01-05T14:00:21Z,1906,[],Neratinib + trastuzumab emtansine,2015-01-05T14:00:21Z
0,2016-03-21T20:53:35Z,3799,"[{'description': 'Nesvacumab is a human monoclonal antibody against angiopoietin 2 (ANG2), which inhibits tumor angiogenesis and tumor cell proliferation (PMID: 23149917).', 'references': [{'id': 4961, 'pubMedId': 23149917, 'title': 'Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23149917'}]}]",Nesvacumab,2016-03-21T20:53:35Z
0,2015-02-24T14:22:24Z,2146,[],Neuradiab + Bevacizumab,2015-02-24T14:22:24Z
0,2016-11-15T15:03:03Z,4957,"[{'description': 'NGI-1 inhibits the activity of oligosacchyltransferase, which results in reduced N-linked glycosylation and may lead to decreased proliferation of tumor cells with dependence on receptor tyrosine kinase signaling (PMID: 27694802).', 'references': [{'id': 7042, 'pubMedId': 27694802, 'title': 'Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27694802'}]}]",NGI-1,2016-11-15T15:03:03Z
0,2016-05-05T20:22:57Z,4078,"[{'description': 'NGR-TNF is a vascular disrupting recombinant protein that forms from the fusion of the TNF-alpha N terminal domain and the peptide, CNGRCG, which specifically targets CD13 possibly resulting in the interruption of tumor growth (PMID: 23828516).', 'references': [{'id': 5382, 'pubMedId': 23828516, 'title': 'NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23828516'}]}]",NGR-TNF,2016-05-05T20:34:11Z
0,2017-01-03T16:41:46Z,5130,"[{'description': 'NHS-IL12 is an immunocytokine composed of IL-12 linked to human tumor necrosis factor targeted IgG1, which may result in enhanced anti-tumor immune response (PMID: 24681847)', 'references': [{'id': 7461, 'pubMedId': 24681847, 'title': 'The immunocytokine NHS-IL12 as a potential cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24681847'}]}]",NHS-IL12,2017-01-03T16:41:46Z
0,2015-06-09T09:06:58Z,2809,"[{'description': 'NIBR3049 is a selective ATP-competitive inhibitor of JAK3 (PMID: 25217444).', 'references': [{'id': 2991, 'pubMedId': 25217444, 'title': 'Selective inhibitors of the Janus kinase Jak3--Are they effective?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25217444'}]}]",NIBR3049,2015-06-09T09:06:58Z
0,2015-08-30T19:29:39Z,3072,"[{'description': 'Niclosamide inhibits Wnt signaling, potentially resulting in decreased tumor growth (PMID: 21531761).', 'references': [{'id': 3654, 'pubMedId': 21531761, 'title': 'Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21531761'}]}]",Niclosamide,2015-09-17T01:32:57Z
0,2017-05-04T01:32:13Z,5607,[],Niclosamide + Enzalutamide,2017-05-04T01:32:13Z
0,2014-03-12T15:53:16Z,829,"[{'description': 'Tasigna (nilotinib) inhibits several tyrosine kinases including BCR-ABL, PDGFR, KIT, DDR and CSF-1R, potentially resulting in reduced tumor cell proliferation (PMID: 21419934, PMID: 25284748). Tasigna (nilotinib) is FDA approved for use in patients with Ph+ chronic myeloid leukemia (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Nilotinib,2016-02-14T22:29:29Z
0,2015-01-07T15:57:14Z,1929,[],Nilotinib + Cetuximab,2015-01-07T15:57:14Z
0,2016-03-16T16:31:51Z,3756,[],Nilotinib + Saracatinib,2016-03-16T16:31:51Z
0,2016-11-23T17:32:56Z,5003,[],Nilotinib + SCH772984,2016-11-23T17:32:56Z
0,2017-02-08T18:53:02Z,5292,[],Nilotinib + Tazemetostat,2017-02-08T18:53:02Z
0,2016-09-13T19:38:58Z,4707,[],Nilotinib + Venetoclax,2016-09-13T19:38:58Z
0,2014-09-19T03:54:52Z,1506,"[{'description': 'Nilandron (nilutamide) is a nonsteroidal antiandrogen, binding to the androgen receptor and blocking agonists, thereby inhibiting androgen-dependent tumor growth (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",nilutamide,2014-12-22T07:20:52Z
0,2014-03-12T15:53:16Z,830,"[{'description': 'Nimotuzumab is a humanized anti-EGFR antibody that blocks EGFR signaling, resulting in anti-tumor activity (PMID: 25842083).', 'references': []}]",Nimotuzumab,2016-05-03T12:46:42Z
0,2016-11-06T20:51:47Z,4920,[],Nimotuzumab + Nivolumab,2016-11-06T20:51:47Z
0,2014-03-12T15:53:16Z,831,"[{'description': 'Ofev (nintedanib) is a triple angiokinase inhibitor that acts by blocking VEGFR, FGFR, RET, and PDGFR, thereby preventing tumorigenesis (PMID: 24947258, PMID: 24561444). Ofev (nintedanib) is FDA approved for use in patients with idiopathic pulmonary fibrosis (FDA.gov). ', 'references': [{'id': 1017, 'pubMedId': 24947258, 'title': 'Targeting multiple angiogenic pathways simultaneously: experience with nintedanib in non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24947258'}]}]",Nintedanib,2017-04-03T18:13:53Z
0,2015-12-02T10:16:44Z,3234,[],Nintedanib + Carboplatin + Paclitaxel,2015-12-02T10:16:44Z
0,2015-11-25T17:02:30Z,3225,[],Nintedanib + Docetaxel,2015-11-25T17:02:30Z
0,2016-09-20T03:55:25Z,4723,[],Nintedanib + Gemcitabine + nab-paclitaxel,2016-09-20T03:55:25Z
0,2014-03-12T15:53:16Z,832,"[{'description': 'Zejula (niraparib) binds and inhibits poly (ADP-ribose) polymerase (PARP) which may result in accumulation of DNA damage and apoptosis of tumor cells (PMID: 23810788). Zejula (niraparib) is FDA-approved as maintenance therapy in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to platinum-based chemotherapy (FDA.gov).', 'references': [{'id': 1986, 'pubMedId': 23810788, 'title': 'The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23810788'}]}]",Niraparib,2017-05-10T18:41:13Z
0,2017-05-20T22:04:56Z,5732,[],Niraparib + Everolimus,2017-05-20T22:04:56Z
0,2016-04-15T15:35:06Z,3935,[],Niraparib + Pembrolizumab,2016-04-15T15:35:06Z
0,2016-10-27T16:48:54Z,4866,[],Niraparib + Radiotherapy,2016-10-27T16:48:54Z
0,2017-03-15T04:25:22Z,5436,[],Niraparib + radium Ra 223 dichloride,2017-03-15T04:25:22Z
0,2016-04-21T19:59:28Z,3985,[],Niraparib + SN-38,2016-04-21T19:59:28Z
0,2017-05-19T18:09:09Z,5701,[],Niraparib + SY-1365,2017-05-19T18:09:09Z
0,2014-09-11T03:21:23Z,1437,[],Niraparib + Temozolomide,2014-09-11T03:21:23Z
0,2017-10-17T16:18:29Z,6321,[],Niraparib + TSR-042,2017-10-17T16:18:29Z
0,2017-05-05T19:41:46Z,5631,"[{'description': 'NIS793 is a monoclonal anti-transforming growth factor beta (TGF-beta) antibody that blocks TGF-beta signaling, leading to tumor growth inhibiion (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",NIS793,2017-05-05T19:41:46Z
0,2017-05-05T19:42:45Z,5632,[],NIS793 + PDR001,2017-05-05T19:42:45Z
0,2015-07-16T00:11:55Z,2924,[],Nitroglycerin,2015-07-16T00:11:55Z
0,2014-07-31T14:58:05Z,1312,"[{'description': ""Opdivo (nivolumab) is an antibody that targets PD-1, which results in increased T-cell activation and enhanced anti-tumor immune response (NCI Drug Dictionary). Opdivo (nivolumab) is FDA approved for metastatic melanoma, squamous NSCLC, renal cell carcinoma, head and neck squamous cell carcinoma, urothelial carcinoma, Hodgkin's lymphoma, hepatocellular carcinoma, and for dMMR and MSI-H colorectal cancer (FDA.gov)."", 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Nivolumab,2017-09-27T18:15:32Z
0,2017-02-11T23:53:04Z,5303,[],Nivolumab + Carboplatin + Paclitaxel,2017-02-11T23:53:04Z
0,2017-05-28T04:10:20Z,5799,[],Nivolumab + Cisplatin + Fluorouacil,2017-05-28T04:10:20Z
0,2017-01-14T05:07:37Z,5198,[],Nivolumab + Etoposide + Ifosfamide + Carboplatin,2017-01-14T05:07:37Z
0,2014-10-07T20:49:04Z,1627,[],Nivolumab + Ipilimumab,2016-08-21T00:17:56Z
0,2017-02-11T23:54:39Z,5304,[],Nivolumab + Ipilimumab + Carboplatin + Paclitaxel,2017-02-11T23:54:57Z
0,2016-12-28T03:44:06Z,5128,[],Nivolumab + Lenalidomide + Dexamethasone,2016-12-28T03:44:06Z
0,2017-05-18T03:27:30Z,5681,[],Nivolumab + Pazopanib,2017-05-18T03:27:30Z
0,2016-11-05T22:48:15Z,4918,[],Nivolumab + Pembrolizumab,2016-11-05T22:48:15Z
0,2017-07-28T19:59:03Z,6055,[],Nivolumab + Pembrolizumab + Trigriluzole,2017-07-28T19:59:03Z
0,2016-07-31T16:10:41Z,4512,[],Nivolumab + Plinabulin,2016-07-31T16:10:41Z
0,2017-04-28T18:40:26Z,5592,[],Nivolumab + poly ICLC + Rituximab,2017-04-28T18:40:26Z
0,2015-05-07T01:34:42Z,2626,[],Nivolumab + Sunitinib,2015-05-07T01:34:42Z
0,2016-10-16T20:37:55Z,4833,[],Nivolumab + SYM004,2016-10-16T20:37:55Z
0,2017-08-08T19:47:02Z,6100,[],Nivolumab + Tadalafil,2017-08-08T19:47:02Z
0,2016-09-12T02:30:52Z,4680,[],Nivolumab + TAK-659,2016-09-12T02:30:52Z
0,2016-03-11T19:10:47Z,3724,[],Nivolumab + Temozolomide,2016-03-11T19:10:47Z
0,2016-09-25T14:23:46Z,4753,[],Nivolumab + Trametinib,2016-09-25T14:23:46Z
0,2016-08-14T15:48:15Z,4560,[],Nivolumab + trifluridine/tipiracil hydrochloride,2017-06-19T19:43:39Z
0,2015-04-23T02:43:40Z,2567,[],Nivolumab + Urelumab,2015-04-23T02:43:40Z
0,2016-06-03T00:17:03Z,4219,[],Nivolumab + Valproic acid,2016-06-03T00:17:03Z
0,2015-04-10T15:25:10Z,2526,[],Nivolumab + Varlilumab,2015-04-10T15:25:10Z
0,2016-04-29T14:28:33Z,4020,[],Nivolumab + WT1 vaccine,2016-04-29T14:28:33Z
0,2016-10-16T21:21:07Z,4837,[],Nivolumab + X4P-001,2016-10-16T21:21:07Z
0,2017-07-28T17:40:43Z,6031,"[{'description': 'Limited information is currently available on NIZ985 (July, 2017).', 'references': []}]",NIZ985,2017-07-28T17:40:43Z
0,2017-07-17T16:26:50Z,5998,"[{'description': 'NKR-2 cells are T-lymphocytes engineered to express a chimeric antigen receptor consists of human natural killer receptor (NKG2D) and the human CD3 zeta signaling domain, which may results in anti-tumor immunity (J Clin Oncol 35, 2017 (suppl; abstr TPS3093)).', 'references': [{'id': 9447, 'pubMedId': None, 'title': 'A NKG2D-based CAR-T therapy in a multinational phase I dose escalation and expansion study targeting multiple solid and hematologic tumor types.', 'url': 'http://abstracts.asco.org/199/AbstView_199_189080.html'}]}]",NKR-2 cells,2017-07-17T16:28:26Z
0,2016-12-11T05:24:19Z,5075,"[{'description': 'NKTR-214 comprises IL2 bound to polyethylene glycol, which stimulates anti-tumor immune response, potentially resulting in decreased tumor growth (PMID: 26832745).', 'references': [{'id': 8311, 'pubMedId': 26832745, 'title': 'NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26832745'}]}]",NKTR-214,2017-03-23T14:24:06Z
0,2016-12-11T05:27:31Z,5076,[],NKTR-214 + Nivolumab,2016-12-11T05:27:31Z
0,2017-05-05T18:09:09Z,5625,[],NKTR-214 + Pembrolizumab,2017-05-05T18:09:09Z
0,2017-05-30T18:26:50Z,5815,"[{'description': 'NLG802 is a prodrug of indoxomid, which inhibits IDO, potentially resulting in increased anti-tumor immune response (AACR Annual Meeting 2017, Abstract nr 4076).', 'references': [{'id': 9017, 'pubMedId': None, 'title': 'A novel prodrug of indoximod with enhanced pharmacokinetic properties', 'url': 'http://www.abstractsonline.com/pp8/#!/4292/presentation/1270'}]}]",NLG802,2017-05-30T18:26:50Z
0,2014-03-12T15:53:16Z,833,[],NMS-1286937,
0,2015-06-03T16:41:30Z,2761,"[{'description': 'NMS-E973 binds to and inhibits HSP90, resulting in decreased tumor cell proliferation (PMID: 23674492).\r\n', 'references': [{'id': 2905, 'pubMedId': 23674492, 'title': 'NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674492'}]}]",NMS-E973,2015-06-03T17:11:30Z
0,2016-07-06T15:15:03Z,4422,"[{'description': 'NMS-P118 selectively inhibits PARP1, potentially resulting in decreased tumor growth (PMID: 26222319, PMID: 26896565).', 'references': [{'id': 6204, 'pubMedId': 26896565, 'title': 'DNA repair targeted therapy: The past or future of cancer treatment?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26896565'}, {'id': 6203, 'pubMedId': 26222319, 'title': 'Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26222319'}]}]",NMS-P118,2016-07-06T15:15:03Z
0,2015-08-24T20:03:59Z,3044,"[{'description': 'NMS-P626 is an inhibitor of TRKA, TRKB, and TRKC, which has been demonstrated to inhibit cell proliferation, induce apoptosis, and inhibit tumor growth (PMID: 24962792). ', 'references': [{'id': 3485, 'pubMedId': 24962792, 'title': 'The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24962792'}]}]",NMS-P626,2015-08-24T20:03:59Z
0,2015-10-07T18:43:13Z,3107,"[{'description': 'NMS-P715 is a selective inhibitor of TTK (MPS1) that inhibits spindle assembly checkpoint thereby preventing cell proliferation (PMID: 21159646).', 'references': [{'id': 3716, 'pubMedId': 21159646, 'title': 'Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21159646'}]}]",NMS-P715,2015-10-07T18:43:13Z
0,2015-06-05T16:33:11Z,2806,"[{'description': 'NMS-P937 is an inhibitor of Plk1, resulting in disruption of mitosis, apoptosis, and inhibition of tumor growth (PMID: 22319201). ', 'references': [{'id': 2979, 'pubMedId': 22319201, 'title': 'NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22319201'}]}]",NMS-P937,2015-08-10T15:46:45Z
0,2014-07-25T17:38:30Z,1099,[],Not Applicable,
0,2017-09-19T18:20:09Z,6222,"[{'description': 'NOX66 is a suppository formulation of idronoxil, which leads to inhibition of PI3K/Akt signaling via blockade of ENOX2, thereby potentially increasing the sensitivity of cancer cells to chemotherapeutics (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",NOX66,2017-09-19T18:20:09Z
0,2016-08-02T20:33:21Z,4516,"[{'description': 'NP-004255 is an inhibitor of RAD52, which inhibits RAD52 from binding to ssDNA, and may result in cell death (PMID: 27434671). ', 'references': [{'id': 6419, 'pubMedId': 27434671, 'title': 'Small-molecule inhibitors identify the RAD52-ssDNA interaction as critical for recovery from replication stress and for survival of BRCA2 deficient cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27434671'}]}]",NP-004255,2016-08-02T20:33:21Z
0,2016-12-21T16:08:34Z,5115,"[{'description': 'NPS-1034 inhibits AXL and MET, including mutant forms of MET, as well as other kinases, which potentially results in decreased tumor cell growth and may overcome MET or AXL mediated drug resistance (PMID: 24173966, PMID: 24165158).', 'references': [{'id': 7366, 'pubMedId': 24173966, 'title': 'NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24173966'}]}]",NPS-1034,2017-03-16T17:09:31Z
0,2016-06-30T16:25:38Z,4405,"[{'description': 'NRR2Mab is a monoclonal antibody that binds to Notch2 and inhibits downstream signaling, resulting in anti-tumor activities (PMID: 26769750).', 'references': [{'id': 6173, 'pubMedId': 26769750, 'title': 'Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26769750'}]}]",NRR2Mab,2016-07-15T14:19:58Z
0,2015-06-03T21:37:22Z,2780,"[{'description': 'NS-018 is an inhibitor of SRC, JAK2, and JAK2 V617F, which inhibits cell proliferation (PMID: 24413068, PMID: 22829185).', 'references': [{'id': 2935, 'pubMedId': 24413068, 'title': 'Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24413068'}, {'id': 2936, 'pubMedId': 22829185, 'title': 'Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22829185'}]}]",NS-108,2015-06-08T17:21:55Z
0,2017-01-19T15:47:45Z,5228,"[{'description': 'NS1 is a synthetic monobody that binds to GTP and GDP states of HRAS and KRAS, thereby inhibiting RAS dimerization and subsequent RAF activity, which may result in inhibition of cell transformation (PMID: 27820802). ', 'references': [{'id': 7600, 'pubMedId': 27820802, 'title': 'Inhibition of RAS function through targeting an allosteric regulatory site.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27820802'}]}]",NS1,2017-01-19T15:47:45Z
0,2015-01-12T20:18:08Z,1935,"[{'description': 'NSC-658497 binds to SOS1 to competitively suppress SOS1-Ras interaction, and dose-dependently inhibit SOS1 GEF activity blocking RAS downstream signaling activation and associated cell proliferation (PMID: 25455859).', 'references': [{'id': 1644, 'pubMedId': 25455859, 'title': 'Rational design of small molecule inhibitors targeting the Ras GEF, SOS1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455859'}]}]",NSC-658497,2015-01-12T20:18:08Z
0,2015-07-29T19:46:33Z,2966,"[{'description': 'NSC-87877 is an inhibitor of Shp2, which may result in inhibition of Erk1/2 activation and decreased cell proliferation (PMID: 16717135). ', 'references': [{'id': 3353, 'pubMedId': 16717135, 'title': 'Discovery of a novel shp2 protein tyrosine phosphatase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16717135'}]}]",NSC-87877,2015-08-17T18:59:26Z
0,2016-10-05T19:27:08Z,4790,[],NSC-87877 + PLX4720,2016-10-05T19:27:08Z
0,2015-05-14T18:31:32Z,2682,"[{'description': 'NSC109555 is an ATP competitive inhibitor of Chk2 with the potential to enhance antitumor effects of chemotherapeutic agents (PMID: 23855452). ', 'references': [{'id': 2692, 'pubMedId': 23855452, 'title': 'Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23855452'}]}]",NSC109555,2015-05-14T18:31:32Z
0,2015-05-20T15:40:50Z,2716,"[{'description': 'NSC124854 is a small molecule inhibitor of polymerase beta, which may enhance the cytotoxicity of chemotherapeutics resulting in tumor growth inhibition (PMID: 21311763). ', 'references': [{'id': 2778, 'pubMedId': 21311763, 'title': 'DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21311763'}]}]",NSC124854,2015-05-20T15:40:50Z
0,2015-05-20T17:02:33Z,2720,[],NSC124854 + Temozolomide,2015-05-20T17:02:33Z
0,2016-10-05T20:04:39Z,4792,"[{'description': 'NSC126405 is a small molecule inhibitor of DEPTOR, which prevents binding to Mtor, possibly resulting in apoptotic activity and cell cycle arrest (PMID: 27530328). ', 'references': [{'id': 6710, 'pubMedId': 27530328, 'title': 'Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27530328'}]}]",NSC126405,2016-10-05T20:09:41Z
0,2016-05-06T10:05:42Z,4085,"[{'description': 'NSC156529 is a small molecule that blocks the interaction between Pdpk1 and Akt1 resulting in inhibition of Akt1 signaling, which may result in decreased tumor growth (PMID: 26294745).', 'references': [{'id': 5386, 'pubMedId': 26294745, 'title': 'A Novel Inhibitor of AKT1-PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26294745'}]}]",NSC156529,2016-05-11T15:01:00Z
0,2015-04-29T17:17:52Z,2608,"[{'description': 'NSC207895 is a small molecule that inhibits expression of MDM4 (MDMX), resulting in activation of p53 and increased tumor cell death (PMID: 21075910).', 'references': [{'id': 2606, 'pubMedId': 21075910, 'title': 'A small-molecule inhibitor of MDMX activates p53 and induces apoptosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21075910'}]}]",NSC207895,2015-06-03T19:18:45Z
0,2017-03-21T15:22:28Z,5461,"[{'description': 'NSC23766 is a small molecule that inhibits Rac1 activation, potentially resulting in decreased tumor cell growth (PMID: 15128949, PMID: 20515940)', 'references': []}]",NSC23766,2017-03-21T15:22:28Z
0,2016-02-11T10:11:02Z,3511,"[{'description': 'NSC308848 inhibits Myc-Max complex from binding DNA and inducing gene transcription, which promotes apoptosis (PMID: 25332683).', 'references': [{'id': 4549, 'pubMedId': 25332683, 'title': 'Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25332683'}]}]",NSC308848,2016-02-11T10:11:02Z
0,2016-01-12T17:56:08Z,3405,"[{'description': 'NSC319726 restores wild-type conformation to mutant Tp53, resulting in reactivation of Tp53 signaling in Tp53-mutant cells, and potentially leading to increased tumor cell death (PMID: 22624712).', 'references': [{'id': 4308, 'pubMedId': 22624712, 'title': 'Allele-specific p53 mutant reactivation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22624712'}]}]",NSC319726,2017-05-01T18:08:42Z
0,2015-07-13T19:06:20Z,2905,"[{'description': 'NSC348884 is a small molecule inhibitor of nucleophosmin 1, which has the potential to attenuate oligomerization and induce apoptosis in cancer cells (PMID: 18345031). ', 'references': [{'id': 3229, 'pubMedId': 18345031, 'title': 'NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18345031'}]}]",NSC348884,2015-07-13T19:06:20Z
0,2016-01-12T17:28:24Z,3402,"[{'description': 'NSC59984 is a small molecule that both induces degradation of mutant Tp53 and reactivates Tp53 pathway signaling through Tp73, which may result in increased cell death in Tp53-mutant tumor cells (PMID: 26294215).', 'references': [{'id': 4303, 'pubMedId': 26294215, 'title': 'Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26294215'}]}]",NSC59984,2017-05-02T13:17:45Z
0,2015-05-20T15:49:50Z,2717,"[{'description': 'NSC666715 is a small molecule inhibitor of polymerase beta, which may enhance the sensitivity of chemotherapeutics via S-phase cell cycle arrest, leading to senescence and apoptosis (PMID: 25933036). ', 'references': [{'id': 2779, 'pubMedId': 25933036, 'title': 'NSC666715 and Its Analogs Inhibit Strand-Displacement Activity of DNA Polymerase β and Potentiate Temozolomide-Induced DNA Damage, Senescence and Apoptosis in Colorectal Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25933036'}]}]",NSC666715,2015-05-20T15:49:50Z
0,2015-05-20T16:46:47Z,2718,[],NSC666715 + Temozolomide,2015-05-20T16:46:47Z
0,2016-01-25T20:51:47Z,3461,"[{'description': 'NTRC 0066-0 inhibits TTK (MPS1) activity thereby preventing cell proliferation (PMID: 26153498).', 'references': [{'id': 4439, 'pubMedId': 26153498, 'title': 'Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26153498'}]}]",NTRC 0066-0,2016-01-25T20:51:47Z
0,2016-01-25T20:56:29Z,3462,[],NTRC 0066-0 + Docetaxel,2016-01-25T20:56:29Z
0,2017-05-23T19:37:54Z,5754,"[{'description': 'NU-0129 comprises sphericle nucleic acid gold nanoparticles made up of siRNAs that specifically target BCL2L12, thereby blocking translation of BCL2L12 and subsequently, resulting in apoptotic activity (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",NU-0129,2017-05-23T19:37:54Z
0,2015-07-22T16:41:03Z,2946,"[{'description': 'NU1025 inhibits PARP, potentially resulting in cell death in DNA-repair deficient tumor cells (PMID: 25981734, PMID: 15829966).', 'references': [{'id': 3298, 'pubMedId': 25981734, 'title': 'Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25981734'}]}]",NU1025,2017-05-10T19:19:38Z
0,2015-07-02T14:35:00Z,2878,"[{'description': 'NU6027 is a small molecule inhibitor of ATR, which may enhance the sensitivity of chemotherapeutic agents and result in decreased cell survival (PMID: 21730979). ', 'references': [{'id': 3171, 'pubMedId': 21730979, 'title': 'Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21730979'}]}]",NU6027,2015-07-10T12:08:17Z
0,2017-09-11T18:45:30Z,6197,[],NU6027 + Rucaparib,2017-09-11T18:45:30Z
0,2017-09-11T18:44:04Z,6196,[],NU6027 + Temozolomide,2017-09-11T18:44:04Z
0,2016-12-01T20:31:28Z,5042,"[{'description': 'NU7026 is an ATP-competitive inhibitor of DNA-PKcs, which may increase sensitivity of tumor cells to radiotherapy (PMID: 26716839, PMID: 16249792).', 'references': [{'id': 7230, 'pubMedId': 26716839, 'title': 'DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26716839'}, {'id': 7229, 'pubMedId': 16249792, 'title': 'Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16249792'}]}]",NU7026,2016-12-01T20:32:42Z
0,2016-12-01T20:32:17Z,5043,[],NU7026 + Radiotherapy,2016-12-01T20:32:17Z
0,2016-12-02T03:11:02Z,5044,"[{'description': 'NU7441 inhibits DNA-PK, which may result in increased sensitivity of tumor cells to radiation and chemotherapy (PMID: 16707462).', 'references': [{'id': 7234, 'pubMedId': 16707462, 'title': 'Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16707462'}]}]",NU7441,2016-12-02T03:11:02Z
0,2016-12-02T03:12:25Z,5045,[],NU7441 + Radiotherapy,2016-12-02T03:12:25Z
0,2016-04-28T18:38:35Z,4018,[],Nutlin-3 + Cisplatin,2016-04-28T18:38:35Z
0,2016-04-28T18:29:58Z,4017,[],Nutlin-3 + Etoposide,2016-04-28T18:29:58Z
0,2017-03-07T18:23:39Z,5414,[],Nutlin-3 + Paclitaxel,2017-03-07T19:06:16Z
0,2014-08-28T08:21:44Z,1405,"[{'description': 'Nutlin-3 is an MDM2 inhibitor which activates p53 and results in cancer cells undergoing apoptosis and cellular senescence. Nutlin-3  is a candidate for neoadjuvant therapy in cancers with a functional p53 (PMID: 18451145).', 'references': [{'id': 598, 'pubMedId': 18451145, 'title': 'Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18451145'}]}]",Nutlin-3a,2015-05-05T15:19:04Z
0,2015-05-29T03:59:43Z,2742,"[{'description': 'NVP-ADW742 is a small molecule IGF-1R inhibitor, which potentially leads to increased tumor cell apoptosis and decreased tumor growth (PMID: 16740780, PMID: 21141739).', 'references': [{'id': 2854, 'pubMedId': 16740780, 'title': 'Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16740780'}, {'id': 2853, 'pubMedId': 21141739, 'title': 'The insulin-like growth factor-1 receptor kinase inhibitor, NVP-ADW742, suppresses survival and resistance to chemotherapy in acute myeloid leukemia cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21141739'}]}]",NVP-ADW742,2015-05-29T03:59:43Z
0,2016-05-03T16:15:19Z,4043,"[{'description': 'NVP-AEW541 is a small molecule inhibitor of IGF1R that blocks IGF-I-mediated signaling, therefore inhibits tumor cell growth (PMID: 15050915).', 'references': []}]",NVP-AEW541,2016-05-03T16:15:19Z
0,2016-01-14T22:14:02Z,3417,"[{'description': 'NVP-BHG712 is a small kinase inhibitor of EphB4, which has been shown to indirectly inhibit VEGF signaling thereby repressing angiogenesis (PMID: 20803239). ', 'references': [{'id': 4329, 'pubMedId': 20803239, 'title': 'The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20803239'}]}]",NVP-BHG712,2016-01-14T22:14:02Z
0,2015-06-04T10:03:34Z,2785,"[{'description': 'NVP-BSK805 is a selective ATP-competitive inhibitor of JAK2 and JAK2 V617F, which promotes apoptosis (PMID: 20587663).', 'references': [{'id': 2943, 'pubMedId': 20587663, 'title': 'Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20587663'}]}]",NVP-BSK805,2015-06-08T18:33:28Z
0,2016-04-22T09:29:06Z,3991,[],NVP-BSK805 + paclitaxel,2016-04-22T09:29:06Z
0,2015-06-13T09:38:56Z,2834,"[{'description': 'NVP-BVB808 is a selective ATP-competitive inhibitor of JAK2 (PMID: 22271575).', 'references': [{'id': 3030, 'pubMedId': 22271575, 'title': 'Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22271575'}]}]",NVP-BVB808,2015-08-10T15:47:45Z
0,2017-02-28T16:15:42Z,5378,"[{'description': 'NVP-BVU972 inhibits MET, potentially resulting in decreased growth of MET-driven tumor cells (PMID: 21697284).', 'references': [{'id': 8018, 'pubMedId': 21697284, 'title': 'A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21697284'}]}]",NVP-BVU972,2017-02-28T16:15:42Z
0,2017-03-23T15:03:11Z,5467,"[{'description': 'NVP-TNKS656 is a small molecule that inhibits Tankyrase, resulting in decreased Beta-catenin signaling, and potentially leading to reduced tumor growth (PMID: 26224873).', 'references': [{'id': 8313, 'pubMedId': 26224873, 'title': 'Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26224873'}]}]",NVP-TNKS656,2017-03-23T15:03:11Z
0,2017-03-23T15:42:20Z,5469,[],NVP-TNKS656 + Triciribine,2017-03-23T15:42:20Z
0,2015-06-03T18:12:24Z,2770,"[{'description': 'NXD30001 inhibits HSP90, potentially resulting in decreased tumor growth (PMID: 23714726, PMID: 20643786).', 'references': [{'id': 2921, 'pubMedId': 20643786, 'title': 'The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20643786'}, {'id': 2920, 'pubMedId': 23714726, 'title': 'Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23714726'}]}]",NXD30001,2015-06-03T18:12:24Z
0,2015-05-15T12:55:08Z,2696,"[{'description': 'NY-ESO-1 peptide vaccine is a vaccine against cancer-testis antigen (NY-ESO-1), which may enhance the humoral and cytotoxic immune responses against tumor cells expressing NY-ESO-1 (PMID: 12488431).', 'references': [{'id': 2738, 'pubMedId': 17652518, 'title': 'Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17652518'}]}]",NY-ESO-1 peptide vaccine,2015-06-03T20:02:28Z
0,2016-07-17T22:24:40Z,4460,[],NY-ESO-1 peptide vaccine + Sirolimus,2016-07-17T22:24:40Z
0,2017-06-12T15:43:07Z,5877,"[{'description': 'NY-ESO-1-c259T are autologous, engineered T cells that recognize the cancer testis antigen, CTAG1B (NY-ESO-1), which may result in an immune response against CTAG1B and/or CTAG2 (LAGE-1) expressing cancer cells (PMID: 26193344).', 'references': [{'id': 9102, 'pubMedId': 26193344, 'title': 'NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26193344'}]}]",NY-ESO-1-c259T,2017-06-12T15:43:07Z
0,2017-06-12T15:44:12Z,5878,[],NY-ESO-1-c259T + Pembrolizumab,2017-06-12T15:44:12Z
0,2015-04-22T02:47:44Z,2556,"[{'description': 'O6-benzylguanine is a guanine analogue that binds and inhibits O6-alkylguanine-DNA alkyltransferase (AGT), thereby inhibiting DNA repair (PMID: 9815757).', 'references': [{'id': 2535, 'pubMedId': 9815757, 'title': 'O6-benzylguanine and its role in chemotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/9815757'}]}]",O6-benzylguanine,2015-04-24T18:48:13Z
0,2015-07-30T01:04:42Z,2972,[],O6-benzylguanine + Temozolomide,2015-07-30T01:04:42Z
0,2014-03-12T15:53:16Z,834,"[{'description': 'Obatoclax (GX015-070) is a pan-BCL2 family inhibitor, which leads to induction of tumor cell apoptosis (PMID: 18040043, PMID: 17332241).', 'references': [{'id': 2564, 'pubMedId': 17332241, 'title': 'Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17332241'}, {'id': 2565, 'pubMedId': 18040043, 'title': 'Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18040043'}]}]",Obatoclax,2015-04-24T04:44:00Z
0,2016-11-11T05:29:40Z,4934,[],Obatoclax + Trabectedin,2016-11-11T05:30:08Z
0,2014-10-14T20:07:07Z,1646,"[{'description': 'Gazyva (obinutuzumab) is a glycoengineered anti-CD20 antibody that binds to CD20 on malignant B-cells and induces antibody-dependent cellular cytotoxicity and apoptosis (NCI Drug Dictionary). Gazyva (obinutuzumab) is FDA approved in combination with Ambochlorin (chlorambucil) for chronic lymphocytic leukemia and in combination with Bendamustine for follicular lymphoma (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Obinutuzumab,2017-01-18T18:43:06Z
0,2014-10-14T20:09:38Z,1648,[],Obinutuzumab + Chlorambucil,2014-10-14T20:09:38Z
0,2017-09-28T16:23:32Z,6257,[],Obinutuzumab + CHOP,2017-09-28T16:23:32Z
0,2016-09-21T18:40:44Z,4743,[],Obinutuzumab + Otlertuzumab,2016-09-21T18:40:44Z
0,2016-07-01T20:31:29Z,4415,[],Obinutuzumab + Pinatuzumab Vedotin + Rituximab,2016-07-01T20:31:29Z
0,2016-07-01T20:33:40Z,4417,[],Obinutuzumab + Polatuzumab Vedotin,2016-07-01T20:33:40Z
0,2016-06-03T02:51:56Z,4227,[],Obinutuzumab + Polatuzumab Vedotin + Venetoclax,2016-06-03T02:51:56Z
0,2017-09-05T14:53:14Z,6162,[],Obinutuzumab + RO7082859 + Tocilizumab,2017-09-05T14:53:14Z
0,2017-10-08T15:45:19Z,6301,[],Obinutuzumab + TGR-1202,2017-10-08T15:45:19Z
0,2014-03-12T15:53:16Z,835,"[{'description': 'Genasense (oblimersen) is an antisense oligonucleotide that targets BCL-2, resulting in decreased protein expression, which potentially leads to increased tumor cell apoptosis (NCI Drug Dictionary).\r\n', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Oblimersen,2015-12-10T16:52:33Z
0,2015-04-24T05:49:15Z,2582,[],Oblimersen + Temozolomide + nab-paclitaxel,2015-04-24T05:49:15Z
0,2015-07-13T20:11:54Z,2906,"[{'description': 'OBP-801 is a histone deacetylase inhibitor belonging to the cyclic peptide class, which may induce both cell cycle arrest and apoptosis (PMID: 18292931, PMID: 23900601). ', 'references': [{'id': 3231, 'pubMedId': 18292931, 'title': 'YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18292931'}, {'id': 3232, 'pubMedId': 23900601, 'title': 'A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23900601'}]}]",OBP-801,2015-07-13T20:11:54Z
0,2015-11-04T12:23:56Z,3173,[],OBP-801 + 5-FU,2015-11-04T12:23:56Z
0,2014-07-29T19:02:52Z,1222,"[{'description': ""OC-DC vaccine is a vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from the patient's tumor cells that have been oxidized with hypochlorous acid (PMID: 23838316)."", 'references': [{'id': 483, 'pubMedId': 23838316, 'title': 'A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23838316'}]}]",OC-DC vaccine,2014-07-29T19:02:52Z
0,2015-08-12T00:34:29Z,3008,"[{'description': 'OC-L is a cancer vaccine prepared by loading dendritic cells with oxidized tumor lysate, which induces anti-tumor immune response (PMID: 23777306).', 'references': [{'id': 3428, 'pubMedId': 23777306, 'title': 'A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23777306'}]}]",OC-L,2015-09-10T13:37:31Z
0,2016-09-12T18:06:30Z,4687,"[{'description': 'Ocaratuzumab (AME-133v) is a monoclonal antibody directed against CD20, which may result in antibody-dependent cell-mediated cytotoxicity and decreased tumor cell growth (PMID: 22223529).', 'references': [{'id': 6594, 'pubMedId': 22223529, 'title': 'Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22223529'}]}]",Ocaratuzumab,2016-09-12T18:10:38Z
0,2015-04-29T14:54:57Z,2605,"[{'description': 'Oclacitinib is a pan-JAK inhibitor with selective affinity towards Jak1. Oclacitinib has effectiveness in canine allergic skin disease, but is not currently being studied in humans (PMID: 24495176).', 'references': [{'id': 2601, 'pubMedId': 24495176, 'title': 'Oclacitinib (APOQUEL(®)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495176'}]}]",Oclacitinib,2015-04-29T14:54:57Z
0,2016-06-10T19:46:15Z,4266,[],Octreotide + Ramucirumab,2016-06-10T19:46:15Z
0,2016-04-07T15:16:30Z,3906,[],Octreotide acetate + Cixutumumab + Everolimus,2016-04-07T15:27:51Z
0,2014-03-12T15:53:16Z,836,"[{'description': 'ODM-201 (BAY1841788) is an androgen receptor antagonist that binds to and inhibits activation of the androgen receptor, thereby inhibiting expression of genes downstream of androgen receptor signaling that regulate proliferation of prostate cancer cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",ODM-201,2015-08-12T10:22:42Z
0,2016-04-20T18:09:48Z,3974,"[{'description': 'ODM-207 is a BET inhibitor that demonstrates anti-proliferative effects in tumor cells (AACR, Cancer Res: April 2016; Volume 57, Abstract #4649).', 'references': [{'id': 5186, 'pubMedId': None, 'title': 'ODM-207, a novel BET-bromodomain inhibitor as a therapeutic approach for the treatment of prostate and breast cancer', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=177af784-a1f1-406c-9aa8-67b47302d29b&cKey=a3591182-1c63-4601-8452-da8fc4cf389d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]}]",ODM-207,2016-04-25T14:52:13Z
0,2014-07-17T21:40:47Z,1090,"[{'description': 'Arzerra (ofatumumab) is a monoclonal antibody that binds to CD20 and induces cytotoxic immune response against CD20 over-expressing cells (PMID: 26855591). Arzerra (ofatumumab) is FDA approved for chronic lymphocytic leukemia (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 6668, 'pubMedId': 26855591, 'title': 'New developments in the management of chronic lymphocytic leukemia: role of ofatumumab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26855591'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Ofatumumab,2017-06-19T18:56:18Z
0,2014-07-17T21:44:12Z,1091,[],Ofatumumab + GSK2110183,2016-03-09T17:59:57Z
0,2014-12-18T21:07:34Z,1807,"[{'description': 'OGX-427 is an antisense oligonucleotide that targets HSBP1 (HSP27), which reduces Hsbp1 expression, potentially resulting in increased tumor cell apoptosis and improved sensitivity to other antitumor therapies (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",OGX-427,2015-08-10T15:32:02Z
0,2014-12-18T21:09:58Z,1808,[],OGX-427 + Gemcitabine,2014-12-18T21:09:58Z
0,2016-02-25T15:42:17Z,3609,"[{'description': 'Okadaic acid is an inhibitor of PP2A, which may result in suppression of cell growth and induction of cell differentiation (PMID: 19564615).', 'references': [{'id': 4700, 'pubMedId': 19564615, 'title': 'Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19564615'}]}]",Okadaic acid,2016-02-25T15:42:17Z
0,2014-03-12T15:53:16Z,837,"[{'description': 'Lynparza (olaparib) binds to and inhibits PARP, resulting in inhibition of DNA repair and lethality in homologous-recombination deficient cells, and may be a sensitizing agent for chemotherapy and radiotherapy (PMID: 25028150, PMID: 24225019). Lynparza (olaparib) is FDA approved for use in patients with germline BRCA-mutated advanced ovarian cancer (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 1024, 'pubMedId': 25028150, 'title': 'Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25028150'}]}]",Olaparib,2017-10-18T09:36:32Z
0,2015-02-02T16:12:27Z,1999,[],Olaparib + Cetuximab,2015-02-02T16:12:27Z
0,2016-03-10T19:37:55Z,3704,[],Olaparib + Cisplatin,2016-03-10T19:37:55Z
0,2016-04-27T18:36:11Z,4014,[],Olaparib + Everolimus,2016-04-27T18:36:11Z
0,2015-05-20T18:48:27Z,2723,[],Olaparib + Irinotecan,2015-05-20T18:48:27Z
0,2016-04-27T18:36:52Z,4015,[],Olaparib + KU-0063794,2016-04-27T18:36:52Z
0,2016-09-21T15:02:52Z,4729,[],Olaparib + Onalespib,2016-09-21T15:02:52Z
0,2016-10-10T18:49:01Z,4807,[],Olaparib + Paclitaxel,2016-10-10T18:49:01Z
0,2017-02-20T20:50:56Z,5342,[],Olaparib + Pembrolizumab,2017-02-20T20:50:56Z
0,2017-02-19T23:29:51Z,5332,[],Olaparib + Prexasertib,2017-08-22T19:07:13Z
0,2017-01-09T15:18:57Z,5165,[],Olaparib + Ramucirumab,2017-01-09T15:18:57Z
0,2017-05-26T18:07:33Z,5793,[],Olaparib + Selumetinib,2017-05-26T18:07:33Z
0,2016-04-21T19:58:41Z,3984,[],Olaparib + SN-38,2016-04-21T19:58:41Z
0,2014-09-11T03:24:43Z,1438,[],Olaparib + Temozolomide,2014-09-11T03:24:43Z
0,2016-04-21T20:34:10Z,3988,[],Olaparib + Temozolomide + SN-38,2016-04-21T20:34:10Z
0,2017-01-12T16:24:38Z,5188,[],Olaparib + TP-0903,2017-01-12T16:24:38Z
0,2016-08-08T20:08:49Z,4549,[],Olaparib + Valproic Acid,2016-08-08T20:08:49Z
0,2015-10-21T00:14:19Z,3141,[],Olaparib + Vistusertib,2017-06-09T14:58:26Z
0,2016-03-31T12:52:42Z,3883,[],Olaparib + YU238259,2016-03-31T12:52:42Z
0,2015-12-08T20:50:45Z,3269,"[{'description': 'Lartruvo (olaratumab) is a monoclonal antibody that targets PDGFR-alpha and prevents ligand binding, potentially leading to decreased angiogenesis and reduced proliferation of tumor cells (NCI Drug Dictionary). Lartruvo (olaratumab) is FDA approved for patients with soft tissue sarcoma (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Olaratumab,2017-06-19T18:57:36Z
0,2017-03-28T03:34:03Z,5482,[],Olaratumab + nab-paclitaxel + Gemcitabine,2017-03-28T03:34:03Z
0,2017-05-20T01:43:43Z,5715,[],Olaratumab + Pembrolizumab,2017-05-20T01:43:43Z
0,2016-09-12T19:44:21Z,4691,"[{'description': 'OM-174 is an analog of lipid A, which may result in an enhanced anti-tumor immune response (PMID: 23547558).', 'references': [{'id': 6595, 'pubMedId': 23547558, 'title': 'Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23547558'}]}]",OM-174,2016-09-12T19:44:21Z
0,2014-12-04T23:50:40Z,1761,"[{'description': 'Omacetaxine mepesuccinate is a semisynthetic plant alkaloid that binds the 80S ribosome, inhibiting protein translation by interfering with chain elongation. Omacetaxine also promotes apoptosis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",omacetaxine,2017-06-19T18:58:57Z
0,2014-12-18T14:41:30Z,1794,[],Omacetaxine + Cytarabine + Decitabine,2014-12-18T14:41:30Z
0,2014-12-04T23:52:53Z,1762,[],Omacetaxine + Decitabine,2014-12-04T23:52:53Z
0,2015-05-28T02:29:00Z,2732,"[{'description': 'OMP-305B83 is a bispecific antibody that binds both DLL4 and VEGF, which inhibits NOTCH and VEGFR signaling and may prevent angiogenesis and tumor growth (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",OMP-305B83 ,2017-07-13T18:25:58Z
0,2017-01-31T04:29:37Z,5264,[],OMP-305B83 + Paclitaxel,2017-01-31T04:29:37Z
0,2017-05-19T16:10:57Z,5696,"[{'description': 'OMP-313M32 is an anti-human TIGIT (T cell immunoreceptor with Ig ITIM domain) antibody that potentially has anti-tumor activities through modulating immune response to tumors (Proceedings of the AACR, Vol 58, April 2017, Abstract #599).', 'references': [{'id': 8942, 'pubMedId': None, 'title': 'Pharmacodynamic biomarkers for anti-TIGIT treatment and prevalence of TIGIT expression in multiple solid tumor types', 'url': 'http://publications.oncomed.com/Pharmacodynam-biomarkers-anti-TIGIT-treatment-and-expression-solid-tumor-AACR-2017.pdf'}]}]",OMP-313M32,2017-05-19T16:10:57Z
0,2017-09-29T16:16:08Z,6264,"[{'description': 'OMP-336B11 is a fusion protein consisting GITRL (Glucocorticoid-Induced Tumor Necrosis Factor Receptor Ligand, TNFSF18) and the Fc domain of immunoglobulin, which activates GITR signaling and promotes anti-tumor immunity (Cancer Res 2017;77(13 Suppl): Abstract nr 5621).', 'references': [{'id': 10022, 'pubMedId': None, 'title': 'Abstract 5621: Prevalence of GITR expression and pharmacodynamic (PD) biomarkers in syngeneic tumor models treated by a GITR agonist (GITRL-Fc)', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5621'}]}]",OMP-336B11,2017-09-29T16:16:08Z
0,2014-09-19T09:01:17Z,1512,[],ON-01910 + PD0332991,2014-09-19T09:01:17Z
0,2015-06-05T16:37:01Z,2807,"[{'description': 'ON01910 is a small molecule inhibitor of Plk1, resulting in mitotic cell-cycle arrest and inhibition of tumor growth (PMID: 15766665). ', 'references': [{'id': 2980, 'pubMedId': 15766665, 'title': 'ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15766665'}]}]",ON01910,2015-06-08T17:25:40Z
0,2015-06-11T18:51:10Z,2821,[],ON01910 + Aldoxorubicin,2015-06-11T18:51:10Z
0,2015-06-11T18:54:33Z,2824,[],ON01910 + Oxaliplatin,2015-06-11T18:54:33Z
0,2015-06-04T15:19:59Z,2791,"[{'description': 'ON044580 is a non-ATP competitive inhibitor of BCR-ABL, BCR-ABL (T315I), JAK2, and JAK2(V617F), which may inhibit cell proliferation through inhibition of STAT5 signaling (PMID: 20717479).', 'references': [{'id': 2954, 'pubMedId': 20717479, 'title': 'A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20717479'}]}]",ON044580,2015-06-04T15:19:59Z
0,2016-03-10T20:04:17Z,3705,"[{'description': 'ON123300 inhibits CDK4 and ARK5 (NUAK1), resulting in decreased downstream signaling and increased tumor cell death (PMID: 24417566, PMID: 26873845).', 'references': [{'id': 4821, 'pubMedId': 24417566, 'title': 'Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24417566'}, {'id': 4822, 'pubMedId': 26873845, 'title': 'Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26873845'}]}]",ON123300,2016-03-10T20:04:17Z
0,2015-12-21T01:58:12Z,3317,[],Onalespib + Talazoparib,2017-06-12T15:58:08Z
0,2015-01-02T03:46:41Z,1886,"[{'description': 'Onapristone (ZK299) binds to and inhibits progesterone receptors, potentially resulting in decreased proliferation of progesterone receptor expressing cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Onapristone,2015-09-01T13:07:43Z
0,2014-03-12T15:53:16Z,838,"[{'description': 'Onartuzumab is a monovalent antibody that binds MET and inhibits MET/HGF signaling, potentially resulting in decreased tumor growth (PMID: 23882082).', 'references': [{'id': 2006, 'pubMedId': 23882082, 'title': 'Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23882082'}]}]",Onartuzumab,2015-04-30T13:24:37Z
0,2014-07-31T10:27:34Z,1307,[],Onartuzumab + Cobimetinib,2014-07-31T10:27:34Z
0,2014-07-31T10:28:52Z,1308,[],Onartuzumab + Cobimetinib + Vemurafenib,2014-07-31T10:28:52Z
0,2014-07-31T02:47:04Z,1280,[],Onartuzumab + Erlotinib,2014-07-31T02:47:04Z
0,2014-08-05T16:52:48Z,1371,[],Onartuzumab + Erlotinib + Paclitaxel + Carboplatin,2014-08-05T16:52:48Z
0,2017-05-16T17:53:54Z,5676,[],Onartuzumab + mFOLFOX6,2017-05-16T17:53:54Z
0,2014-08-05T16:48:34Z,1370,[],Onartuzumab + Paclitaxel + Carboplatin,2014-08-05T16:48:34Z
0,2014-07-31T10:25:36Z,1306,[],Onartuzumab + Vemurafenib,2014-07-31T10:25:36Z
0,2014-10-30T15:33:21Z,1687,"[{'description': 'ONC201 (TIC-10) binds to the G-protein coupled receptor, DRD2, leading to inactivation of AKT and ERK, which relocates Foxo3a to the nucleus and then leads to tumor cell apoptosis mediated by (TNF)-related apoptosis-inducing ligand (TRAIL) signaling (PMID: 23390247). ', 'references': [{'id': 989, 'pubMedId': 23390247, 'title': 'Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23390247'}]}]",ONC201,2017-08-02T18:42:16Z
0,2017-07-07T04:04:01Z,5978,[],ONC201 + Paclitaxel,2017-07-07T04:04:01Z
0,2016-11-17T18:34:22Z,4964,[],ONC201 + Venetoclax,2016-11-17T18:34:22Z
0,2016-02-23T15:09:44Z,3594,"[{'description': 'ONCOII is a diaminopyridine that inhibits activity of TTK (MPS1) (PMID: 26202014).', 'references': [{'id': 3711, 'pubMedId': 26202014, 'title': 'Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26202014'}]}]",ONCOII,2016-02-23T15:09:44Z
0,2016-11-21T15:03:34Z,4980,[],ONCOS-102,2016-11-21T15:03:34Z
0,2016-11-20T23:43:15Z,4978,[],ONCOS-102 + MEDI4736,2016-11-20T23:43:58Z
0,2015-05-15T02:15:58Z,2691,"[{'description': ""ONO-4059 inhibits Bruton's Tyrosine Kinase (BTK), which leads to decreased B-cell proliferation and differentiation, and may have antitumor activity in B-cell malignancies (PMID: 23958373, PMID: 27776353)."", 'references': [{'id': 2731, 'pubMedId': 23958373, 'title': 'Ibrutinib and novel BTK inhibitors in clinical development.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23958373'}]}]",ONO-4059,2016-10-26T15:32:37Z
0,2015-08-26T02:38:28Z,3051,"[{'description': 'ONT-10 is a cancer vaccine that consists of encapsulated glycoprotein MUC1 and the synthetic Toll-like receptor 4 (TLR-4) agonist PET lipid A, which may lead to immune stimulation and antitumor effects (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",ONT-10,2015-12-11T18:04:01Z
0,2016-02-25T15:38:01Z,3606,"[{'description': 'OP449 is an activator of PP2A via inhibition of SET, which may reduce tumor size and block cell proliferation (PMID: 26563471).', 'references': [{'id': 4697, 'pubMedId': 26563471, 'title': 'Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26563471'}]}]",OP449,2016-02-25T15:38:01Z
0,2017-05-22T18:20:33Z,5739,"[{'description': 'OPB-111077 is an inhibitor of STAT3, which may result in antitumor activity (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118).', 'references': []}]",OPB-111077,2017-05-22T18:20:33Z
0,2016-03-28T18:00:43Z,3852,"[{'description': 'OPB-31121 is a small molecule inhibitor of Stat3 that demonstrates antitumor activity (PMID: 23402820).', 'references': [{'id': 5045, 'pubMedId': 23402820, 'title': 'OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23402820'}, {'id': 5034, 'pubMedId': None, 'title': 'Novel small molecule inhibitors of signal transducer and activator of transcription (STAT3) for cancer treatment.', 'url': 'http://mct.aacrjournals.org/content/12/11_Supplement/C180.short'}]}]",OPB-31121,2016-03-28T19:15:08Z
0,2016-03-28T18:00:08Z,3851,"[{'description': 'OPB-51602 is a small molecule inhibitor of Stat3 that demonstrates antitumor activity (Mol Cancer Ther November 2013 12; C180 ).', 'references': [{'id': 5034, 'pubMedId': None, 'title': 'Novel small molecule inhibitors of signal transducer and activator of transcription (STAT3) for cancer treatment.', 'url': 'http://mct.aacrjournals.org/content/12/11_Supplement/C180.short'}]}]",OPB-51602,2016-03-28T18:00:08Z
0,2017-06-19T14:52:41Z,5907,[],OPC,2017-06-19T14:52:41Z
0,2017-06-19T14:53:38Z,5908,[],OPC + Metformin,2017-06-19T14:53:38Z
0,2017-10-03T16:41:46Z,6290,"[{'description': 'Oportuzumab monatox comprises an EpCAM-targeted monoclonal antibody fragment linked to Pseudomonas endotoxin A, which may result in decreased protein synthesis in EpCAM-expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Oportuzumab monatox,2017-10-03T16:41:46Z
0,2015-03-17T13:21:15Z,2422,"[{'description': 'Oprozomib (ONX 0912) is a proteasome inhibitor that inhibits CT-L proteosome activity, leading to induction of autophagy and apoptosis in tumor cells (PMID: 22929803).', 'references': [{'id': 2243, 'pubMedId': 22929803, 'title': 'Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22929803'}]}]",Oprozomib,2017-08-11T19:35:43Z
0,2014-03-12T15:53:16Z,840,"[{'description': 'Orantinib (SU6668) inhibits several receptor tyrosine kinases KDR, PDGFRB, FGFR1, and KIT, thereby resulting in tumor growth inhibition (PMID: 17367541, PMID: 16144927).', 'references': [{'id': 1026, 'pubMedId': 17367541, 'title': 'Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17367541'}]}]",Orantinib,2015-11-03T15:32:02Z
0,2016-12-01T14:34:41Z,5031,"[{'description': 'Oraxol consists of paclitaxel and HM30181A, a multidrug resistance efflux pump P-glycoprotein (P-gp) inhibitor, which may increase the bioavailability of paclitaxel (PMID: 26112004).', 'references': [{'id': 7218, 'pubMedId': 26112004, 'title': 'Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26112004'}]}]",Oraxol ,2016-12-01T14:34:41Z
0,2016-12-01T14:35:59Z,5032,[],Oraxol + Ramucirumab,2016-12-01T14:35:59Z
0,2014-07-28T23:10:34Z,1189,"[{'description': 'Oregovomab is a monoclonal antibody which targets the tumor antigen MUC16 (CA125) promoting an immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Oregovomab,2015-07-10T16:35:20Z
0,2014-07-28T23:13:45Z,1190,[],Oregovomab + Carboplatin + Paclitaxel,2014-07-28T23:13:45Z
0,2017-05-26T17:58:26Z,5792,[],Oregovomab + poly ICLC ,2017-05-26T17:58:26Z
0,2015-06-12T15:59:08Z,2830,"[{'description': 'ORG-31710 is a selective progesterone receptor modulator, which may inhibit cellular proliferation via inhibition of cyclin D1 and decrease tumor size (PMID: 11108884). ', 'references': [{'id': 3033, 'pubMedId': 11108884, 'title': 'Preclinical experience with two selective progesterone receptor modulators on breast and endometrium.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11108884'}]}]",ORG-31710,2015-06-19T12:08:46Z
0,2015-06-12T16:15:24Z,2831,"[{'description': 'ORG-33628 is a selective progesterone receptor modulator, which may result in decreased tumor mass (PMID: 11108884).', 'references': [{'id': 3033, 'pubMedId': 11108884, 'title': 'Preclinical experience with two selective progesterone receptor modulators on breast and endometrium.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11108884'}]}]",ORG-33628,2015-06-19T12:09:08Z
0,2016-08-30T14:17:51Z,4624,"[{'description': 'Oridonin is a natural product-derived drug that may decrease tumor cell growth (PMID: 27563888).', 'references': [{'id': 6538, 'pubMedId': 27563888, 'title': 'Oridonin, a Promising ent-Kaurane Diterpenoid Lead Compound.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27563888'}]}]",Oridonin,2016-08-30T14:19:25Z
0,2015-05-14T01:49:56Z,2671,"[{'description': 'Orteronel inhibits CYP17A1, resulting in reduced androgen production and potentially leading to decreased growth of androgen-dependent tumors (PMID: 24799061).', 'references': [{'id': 2709, 'pubMedId': 24799061, 'title': 'Orteronel for the treatment of prostate cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24799061'}]}]",Orteronel ,2015-06-26T02:20:35Z
0,2016-06-20T02:27:22Z,4327,"[{'description': 'OSE 2101 is an DNA vaccine consisting of epitopes from CEA, ERBB2 (Her2), TP53, and MAGE 2/3, which may stimulate anti-tumor immunity (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",OSE 2101 ,2016-07-05T15:06:20Z
0,2014-03-12T15:53:16Z,841,"[{'description': 'OSI-027 is an ATP-competitive inhibitor of mTOR that blocks mTORC1/2 signaling, which leads to inhibition of cell proliferation (PMID: 21363918).', 'references': [{'id': 2049, 'pubMedId': 21363918, 'title': 'Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21363918'}]}]",OSI-027,2017-07-07T20:25:36Z
0,2016-11-23T16:54:28Z,4995,[],OSI-027 + SCH772984,2016-11-23T16:54:28Z
0,2016-10-24T19:25:11Z,4855,"[{'description': 'OSI-296 selectively inhibits MET and MST1R (RON), potentially resulting in decreased tumor cell proliferation (PMID: 23773865).', 'references': [{'id': 6832, 'pubMedId': 23773865, 'title': 'Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23773865'}]}]",OSI-296,2016-10-24T19:25:11Z
0,2015-02-23T20:54:25Z,2138,"[{'description': 'OSI-930 binds and inhibits Kdr (Vegfr2) and Kit reducing cell proliferation and tumor growth (PMID: 16424037).', 'references': [{'id': 1967, 'pubMedId': 16424037, 'title': 'OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16424037'}]}]",OSI-930,2015-02-23T20:54:25Z
0,2014-03-12T15:53:16Z,660,"[{'description': 'Tagrisso (osimertinib) is a third-generation EGFR inhibitor that selectively binds mutant forms of the EGF receptor, inhibiting downstream signaling and potentially reducing cell proliferation and growth in EGFR overexpressing tumors (NCI Drug Dictionary). Tagrisso (osimertinib) is FDA-approved for use in patients with EGFR T790M-positive non-small cell lung cancer (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Osimertinib,2017-10-17T18:30:30Z
0,2017-06-28T17:30:46Z,5939,[],Osimertinib + Bosutinib + PF-573328,2017-06-28T17:30:46Z
0,2017-06-28T16:56:08Z,5938,[],Osimertinib + PF-573328 + Saracatinib,2017-06-28T17:22:42Z
0,2016-06-27T01:53:08Z,4379,[],Osimertinib + Ramucirumab,2016-06-27T01:53:08Z
0,2014-10-14T17:59:47Z,1644,[],Osimertinib + Rifampin,2017-10-17T18:30:55Z
0,2015-02-28T11:20:13Z,2224,[],Osimertinib + Savolitinib,2017-10-17T18:33:52Z
0,2015-02-28T11:21:41Z,2225,[],Osimertinib + Selumetinib,2017-06-28T17:18:20Z
0,2014-10-14T18:06:34Z,1645,[],Osimertinib + Simvastatin,2017-10-17T18:31:18Z
0,2017-06-28T16:54:06Z,5937,[],Osimertinib + TAK-632,2017-06-28T16:54:06Z
0,2016-06-17T19:29:28Z,4306,[],Ospemifene,2016-06-17T19:29:28Z
0,2015-03-16T16:39:08Z,2408,"[{'description': 'OSU03012 is an inhibitor of PDPK1, which can indirectly inhibit beta-catenin by blocking Akt signaling resulting in apoptosis and anti-tumor activity (PMID: 20028853). ', 'references': [{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]}]",OSU03012,2017-06-21T20:18:09Z
0,2016-09-12T20:07:05Z,4692,"[{'description': 'Otlertuzumab (TRU-016) is a anti-CD37 therapeutic protein, which may result in increased antibody-dependent cellular cytotoxicity and decreased tumor cell growth (PMID: 24381226, PMID: 25146490).', 'references': [{'id': 6597, 'pubMedId': 24381226, 'title': 'A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24381226'}, {'id': 6596, 'pubMedId': 25146490, 'title': 'Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25146490'}]}]",Otlertuzumab,2016-09-12T20:07:05Z
0,2016-09-21T18:39:28Z,4742,[],Otlertuzumab + Rituximab,2016-09-21T18:39:28Z
0,2016-04-19T16:08:04Z,3951,"[{'description': 'OTS167 is a selective inhibitor of maternal embryonic leucine zipper kinase (MELK), which can lead to anti-tumor activity (PMID: 26918358).', 'references': [{'id': 5177, 'pubMedId': 26918358, 'title': 'Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26918358'}]}]",OTS167,2016-04-19T19:52:25Z
0,2017-01-30T21:13:35Z,5258,"[{'description': 'OTS514 inhibits PBK (TOPK), potentially resulting in decreased tumor cell growth (PMID: 27334838).', 'references': [{'id': 7683, 'pubMedId': 27334838, 'title': 'T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27334838'}]}]",OTS514,2017-01-30T21:13:35Z
0,2017-01-30T21:14:23Z,5259,"[{'description': 'OTS964 inhibits PBK (TOPK), potentially resulting in decreased tumor cell growth (PMID: 27334838).', 'references': [{'id': 7683, 'pubMedId': 27334838, 'title': 'T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27334838'}]}]",OTS964,2017-01-30T21:14:23Z
0,2015-02-10T00:52:37Z,2034,"[{'description': 'OTX015 (MK-8628) is an inhibitor of the BET bromodomain proteins BRD3, BRD4, and BRD5, which inhibits interaction with acetylated histone H4, potentially resulting in decreased tumor cell proliferation (Mol Cancer Ther November 2013 12:C244).', 'references': [{'id': 1848, 'pubMedId': None, 'title': 'Abstract C244: Development of the BET bromodomain inhibitor OTX015.', 'url': 'http://mct.aacrjournals.org/content/12/11_Supplement/C244.short'}]}]",OTX015,2017-03-17T20:11:51Z
0,2014-07-25T21:34:39Z,1104,"[{'description': 'Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity (NCI Drug Dictionary). Eloxatin (oxaliplatin) is FDA approved for colorectal cancer (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Oxaliplatin,2014-12-08T11:39:54Z
0,2014-12-09T11:15:00Z,1773,[],Oxaliplatin + ABT-737,2014-12-09T11:15:00Z
0,2017-06-15T04:18:21Z,5894,[],Oxaliplatin + Resminostat,2017-06-15T04:18:21Z
0,2016-02-12T08:07:00Z,3524,"[{'description': 'OXi4503 is a vascular disrupting agent that causes microtubule instability, resulting in blood vessel collapse and decreased tumor growth (PMID: 20974154, PMID: 26751478).', 'references': [{'id': 4568, 'pubMedId': 26751478, 'title': 'Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26751478'}, {'id': 4569, 'pubMedId': 20974154, 'title': 'Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20974154'}]}]",OXi4503,2016-02-12T08:07:00Z
0,2017-10-02T15:45:41Z,6280,"[{'description': 'P-BCMA-101 CAR-T cells are Centyrin-based CAR-T cells targeting B cell maturation antigen (BCMA), which results in immune response against BCMA-positive tumor cells (Blood 2016 128 (22):2127).', 'references': [{'id': 10031, 'pubMedId': None, 'title': 'A Novel Bcma-Specific, Centyrin-Based CAR-T Product for the Treatment of Multiple Myeloma', 'url': 'http://www.bloodjournal.org/content/128/22/2127?sso-checked=true'}]}]",P-BCMA-101 CAR-T cells,2017-10-02T15:45:41Z
0,2017-03-09T16:04:33Z,5425,"[{'description': 'P10 is a pyridazine derivative that inhibits PARP1 activity, which may result in inhibition of cell proliferation and cell-cycle arrest, thereby increasing levels of DNA damage (PMID: 27188390). ', 'references': []}]",P10,2017-03-09T16:04:33Z
0,2017-03-09T16:05:47Z,5426,[],P10 + Vorinostat,2017-03-09T16:05:47Z
0,2015-06-03T17:05:56Z,2763,"[{'description': 'P276-00 is an inhibitor of CDK1, CDK4, and CDK9, which may induce cell cycle arrest and apoptosis in cancer cells (PMID: 17363486). ', 'references': [{'id': 2909, 'pubMedId': 17363486, 'title': 'In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17363486'}]}]",P276-00,2015-06-03T17:05:56Z
0,2016-09-12T20:27:41Z,4694,"[{'description': 'p28 is a peptide derived from the protein azurin, which enters the nucleus, binds to Tp53, and prevents Tp53 degradation, potentially leading to increased cell-cycle arrest and decreased tumor growth (PMID: 23449360).', 'references': [{'id': 6598, 'pubMedId': 23449360, 'title': 'A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23449360'}]}]",p28,2016-09-12T20:29:01Z
0,2014-05-14T14:52:46Z,1039,"[{'description': 'A vaccine consisting of synthetic peptides derived from the middle part of p53 used to stimulate the host immune system to mount a cytotoxic T-cell lymphocyte response against p53-expressing tumor cells (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",p53-SLP vaccine,2015-11-17T14:26:12Z
0,2014-03-12T15:53:16Z,857,"[{'description': 'Panulisib (P7170) is an inhibitor of PI3K, mTOR, ALK-1, and DNA-PK, resulting in inhibition of cancer cell growth (PMID: 25466244). ', 'references': [{'id': 8341, 'pubMedId': 25466244, 'title': 'P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25466244'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",P7170,2017-03-24T20:21:13Z
0,2016-08-22T17:38:47Z,4602,"[{'description': 'PAC-1 is a small molecule activator of procaspase 3, which occurs via inhibition of zinc ions, resulting in autoactivation and thus, may lead to apoptotis and anti-tumor activity (PMID: 19281821, PMID: 27297867). ', 'references': [{'id': 6518, 'pubMedId': 27297867, 'title': 'The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27297867'}, {'id': 6517, 'pubMedId': 19281821, 'title': 'PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19281821'}]}]",PAC-1,2016-08-22T17:38:47Z
0,2016-08-22T17:40:36Z,4603,[],PAC-1 + Trametinib + Vemurafenib,2016-08-22T17:40:36Z
0,2016-08-22T17:41:18Z,4604,[],PAC-1 + Vemurafenib,2016-08-22T17:41:18Z
0,2014-07-25T19:03:39Z,1103,"[{'description': 'Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Paclitaxel,2014-10-28T18:24:59Z
0,2014-07-28T00:08:17Z,1124,[],Paclitaxel + Carboplatin,2014-07-28T00:08:17Z
0,2014-12-22T15:05:45Z,1827,[],Paclitaxel + Carboplatin + Docetaxel,2014-12-22T15:05:45Z
0,2014-09-18T18:56:25Z,1488,[],Paclitaxel + Carboplatin + Hydroxychloroquine,2014-09-18T18:56:25Z
0,2014-08-06T01:33:33Z,1381,[],Paclitaxel + Carboplatin + Metformin,2014-08-06T01:33:33Z
0,2015-01-03T21:45:14Z,1887,[],Paclitaxel + Carboplatin + Trastuzumab,2015-01-03T21:45:14Z
0,2015-01-29T13:48:23Z,1988,[],Paclitaxel + Cetuximab,2015-01-29T13:48:23Z
0,2014-09-18T19:59:31Z,1495,[],Paclitaxel + Doxorubicin + Cyclophosphamide,2014-09-18T19:59:31Z
0,2014-07-28T00:09:08Z,1125,[],Paclitaxel + Ifosfamide,2014-07-28T00:09:08Z
0,2015-10-15T15:37:17Z,3130,[],Paclitaxel + Lapatinib + Trastuzumab,2015-10-15T15:37:17Z
0,2017-05-20T21:56:25Z,5731,[],Paclitaxel + MLN0128 + MLN1117,2017-05-20T21:56:25Z
0,2014-09-18T20:49:49Z,1505,[],Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide,2014-09-18T20:49:49Z
0,2016-04-29T14:49:59Z,4021,[],Paclitaxel + Pembrolizumab,2016-04-29T14:49:59Z
0,2017-06-30T21:31:17Z,5956,[],Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab,2017-06-30T21:31:55Z
0,2016-03-22T18:14:23Z,3808,[],Paclitaxel + Plicamycin,2016-03-22T18:14:23Z
0,2016-07-08T20:13:07Z,4433,[],Paclitaxel + Rebastinib,2016-07-08T20:13:07Z
0,2015-11-14T17:24:21Z,3206,[],Paclitaxel + Ribociclib,2015-11-14T17:24:21Z
0,2017-05-03T20:25:08Z,5605,[],Paclitaxel + sEphB4-HSA,2017-05-03T20:25:08Z
0,2014-10-07T19:48:12Z,1620,[],Paclitaxel + Sonidegib,2017-06-19T19:29:15Z
0,2017-06-08T19:07:41Z,5867,[],Paclitaxel + Taladegib,2017-06-08T19:07:41Z
0,2014-09-18T20:43:55Z,1503,[],Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide,2014-09-18T20:43:55Z
0,2015-01-04T00:27:03Z,1892,[],Paclitaxel + Trastuzumab + MM-111,2015-01-04T00:27:03Z
0,2014-09-18T20:46:36Z,1504,[],Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide,2014-09-18T20:48:34Z
0,2017-06-12T14:37:28Z,5874,[],Paclitaxel + Trastuzumab + TVB-2640,2017-06-12T14:37:28Z
0,2017-03-23T16:13:55Z,5470,[],Paclitaxel + trastuzumab emtansine,2017-03-23T16:13:55Z
0,2015-08-27T00:18:34Z,3054,[],Paclitaxel + Triciribine,2015-08-27T00:18:34Z
0,2016-06-08T19:52:54Z,4261,[],Paclitaxel + TRX-E-002-1,2016-06-08T19:52:54Z
0,2016-10-10T14:13:24Z,4805,[],Paclitaxel + TS-1,2016-10-10T14:13:24Z
0,2016-03-15T16:47:43Z,3743,[],Paclitaxel + TVB-2640,2016-03-15T16:47:51Z
0,2015-02-03T00:11:13Z,2006,"[{'description': 'Pacritinib (SB1518) is an inhibitor of JAK2 and FLT3, with activity against JAK2 V617F and FLT3 ITD, which potentially increases tumor cell apoptosis, cell cycle arrest, and decreases tumor growth (PMID: 22829080, PMID: 21691275).', 'references': [{'id': 1803, 'pubMedId': 21691275, 'title': 'SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21691275'}, {'id': 1802, 'pubMedId': 22829080, 'title': 'Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22829080'}]}]",Pacritinib,2015-06-08T17:15:57Z
0,2015-11-05T16:35:05Z,3176,[],Pacritinib + Cytarabine,2015-11-05T16:35:05Z
0,2015-11-05T16:35:49Z,3177,[],Pacritinib + Decitabine,2015-11-05T16:35:49Z
0,2014-03-12T15:53:16Z,850,"[{'description': 'Ibrance (palbociclib) is a selective inhibitor of cyclin-dependent kinase 4 (CDK4) and 6 (CDK6) (PMID: 19874578). Ibrance (palbociclib) is approved, in combination with Femara (letrozole) and in combination with Faslodex (fulvestrant), in ER positive, HER2 negative metastatic breast cancer (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 805, 'pubMedId': 19874578, 'title': 'PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19874578'}]}]",Palbociclib,2017-06-19T19:16:09Z
0,2014-11-05T00:34:02Z,1705,[],Palbociclib + Cetuximab,2014-11-05T21:57:49Z
0,2017-05-05T23:16:50Z,5637,[],Palbociclib + Decitabine,2017-05-05T23:16:50Z
0,2017-05-05T23:15:10Z,5636,[],Palbociclib + Dexamethasone,2017-05-05T23:15:10Z
0,2014-11-04T21:27:07Z,1703,[],Palbociclib + Fluorouracil + Oxaliplatin,2014-11-05T21:55:56Z
0,2016-04-19T19:14:58Z,3956,[],Palbociclib + GDC-0941,2016-04-19T19:14:58Z
0,2015-07-14T16:44:19Z,2922,[],Palbociclib + Letrozole,2015-07-14T16:44:19Z
0,2016-04-19T19:43:33Z,3965,[],Palbociclib + PD173074,2016-04-19T19:43:33Z
0,2016-04-19T19:24:44Z,3960,[],Palbociclib + PF-04691502,2016-04-19T19:24:44Z
0,2015-02-06T16:21:27Z,2016,[],Palbociclib + Pimasertib,2015-02-06T16:21:27Z
0,2016-05-27T02:21:02Z,4161,[],Palbociclib + Quizartinib,2016-05-27T02:21:02Z
0,2017-10-03T17:47:23Z,6294,[],Palbociclib + SAR439859,2017-10-03T17:47:23Z
0,2016-05-28T00:45:57Z,4184,[],Palbociclib + SGI-1776,2016-05-28T00:46:06Z
0,2016-05-24T19:42:16Z,4130,[],Palbociclib + Sirolimus,2016-05-24T19:42:16Z
0,2017-05-05T23:17:37Z,5638,[],Palbociclib + Sorafenib,2017-05-05T23:17:37Z
0,2016-02-17T20:43:36Z,3542,[],Palbociclib + Tamoxifen,2016-02-17T20:43:36Z
0,2016-05-27T02:22:23Z,4162,[],Palbociclib + Tandutinib,2016-05-27T02:22:23Z
0,2016-04-19T19:53:15Z,3966,[],Palbociclib + Tanespimycin,2016-04-19T19:53:15Z
0,2016-05-27T02:19:20Z,4160,[],Palbociclib + TCS 359,2016-05-27T02:19:20Z
0,2014-08-05T15:42:23Z,1368,[],Palbociclib + Trametinib,2014-11-05T21:54:56Z
0,2015-08-21T15:13:07Z,3041,[],Palbociclib + Trastuzumab,2015-08-21T15:13:07Z
0,2014-11-19T15:51:30Z,1730,[],Palbociclib + Velcade,2014-11-19T15:51:30Z
0,2016-05-24T18:50:28Z,4129,"[{'description': 'Ibrance (palbociclib) is a selective inhibitor of cyclin-dependent kinase 4 (CDK4) and 6 (CDK6) (PMID: 19874578). Ibrance (palbociclib) is approved, in combination with Femara (letrozole), in ER positive, HER2 negative metastatic breast cancer (FDA.gov).', 'references': [{'id': 805, 'pubMedId': 19874578, 'title': 'PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19874578'}]}]",Palbociclib + Vemurafenib,2016-05-24T18:50:28Z
0,2016-04-19T19:38:36Z,3963,[],Palbociclib + Vorinostat,2016-04-19T19:38:36Z
0,2016-04-19T19:40:47Z,3964,[],Palbociclib + XAV939,2016-04-19T19:40:47Z
0,2015-03-12T15:30:17Z,2373,[],Palifermin,2015-03-12T15:30:17Z
0,2015-03-02T20:08:01Z,2250,"[{'description': 'RES-529 (Palomid 529) inhibits mTOR signaling though mTORC1 and mTORC2, which prevents cell proliferation (PMID: 19010932).', 'references': [{'id': 2071, 'pubMedId': 19010932, 'title': 'Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19010932'}]}]",Palomid 529,2016-03-21T20:12:41Z
0,2016-10-04T16:01:02Z,4783,[],pamidronate,2016-10-04T16:01:02Z
0,2017-05-19T18:57:00Z,5704,"[{'description': 'Limited information is currently available on PAN-301-1, a putative  HAAH directed nanoparticle vaccine (May, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",PAN-301-1,2017-05-19T18:57:00Z
0,2016-03-31T15:47:01Z,3885,"[{'description': 'Pan-HER is a mixture of synergistic pairs of a total of 6 antibodies against EGFR, HER2, and Her3, which simultaneously blocks all HER family signaling and inhibits tumor growth (PMID: 25908781).', 'references': [{'id': 5090, 'pubMedId': 25908781, 'title': 'Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25908781'}]}]",Pan-HER,2017-02-24T16:31:43Z
0,2016-03-31T17:09:53Z,3886,[],Pan-HER + Radiotherapy,2016-04-05T13:35:52Z
0,2014-03-12T15:53:16Z,845,"[{'description': 'Vectibix (panitumumab) is a monoclonal antibody directed against EGFR, which inhibits cell proliferation (NCI Drug Dictionary). Vectibix (panitumumab) is FDA approved for metastatic colorectal cancer patients with wild-type KRAS (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Panitumumab,2014-09-02T19:35:33Z
0,2015-01-28T16:32:33Z,1984,[],Panitumumab + Abraxane + Carboplatin,2015-01-28T16:32:33Z
0,2015-01-28T16:36:47Z,1985,[],Panitumumab + cabozantinib,2015-01-28T16:36:47Z
0,2014-11-09T04:49:35Z,1718,[],Panitumumab + Dabrafenib,2014-11-09T04:50:25Z
0,2015-01-14T15:40:27Z,1940,[],Panitumumab + Erlotinib,2015-01-14T15:40:27Z
0,2017-04-26T18:20:53Z,5573,[],Panitumumab + FOLFIRI,2017-04-26T18:20:53Z
0,2015-01-28T16:44:54Z,1986,[],Panitumumab + FOLFOX,2015-01-28T16:44:54Z
0,2015-11-28T00:55:59Z,3226,[],Panitumumab + Gemcitabine + Oxaliplatin,2015-11-28T00:55:59Z
0,2015-01-14T15:00:57Z,1938,[],Panitumumab + Oxaliplatin + Fluorouracil,2015-01-14T15:00:57Z
0,2015-10-06T15:02:31Z,3102,[],Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan,2015-10-06T15:02:31Z
0,2015-01-30T16:38:00Z,1995,[],Panitumumab + Paclitaxel,2015-01-30T16:38:00Z
0,2015-01-30T13:20:01Z,1991,[],Panitumumab + Trametinib,2015-01-30T13:20:01Z
0,2015-01-30T13:22:12Z,1992,[],Panitumumab + Trametinib + Dabrafenib,2015-01-30T13:22:12Z
0,2014-06-16T12:17:02Z,1080,"[{'description': 'Farydak (panobinostat) is an HDAC inhibitor, which induces cell-cycle arrest and decreases growth of tumor cells (PMID: 18349321, PMID: 19671764, PMID: 27802904). Farydak (panobinostat) is FDA approved, in combination with Velcade (Bortezomib) and dexamethasone, for multiple myeloma (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 8260, 'pubMedId': 18349321, 'title': 'The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18349321'}, {'id': 8259, 'pubMedId': 27802904, 'title': 'Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27802904'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 8258, 'pubMedId': 19671764, 'title': 'The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19671764'}]}]",Panobinostat,2017-03-17T04:09:25Z
0,2014-10-02T18:03:40Z,1604,[],Panobinostat + Bortezomib + Dexamethasone,2014-10-02T18:03:40Z
0,2015-11-13T18:40:53Z,3202,[],Panobinostat + Carboplatin + Paclitaxel,2015-11-13T18:40:53Z
0,2016-03-07T18:47:16Z,3690,[],Panobinostat + Epirubicin,2016-03-07T18:47:16Z
0,2015-01-19T15:32:47Z,1964,[],Panobinostat + Everolimus,2015-01-19T15:32:47Z
0,2015-08-24T23:55:08Z,3046,[],Panobinostat + Pazopanib,2015-08-24T23:55:08Z
0,2016-11-23T17:25:37Z,5001,[],Panobinostat + SCH772984,2016-11-23T17:25:37Z
0,2014-07-28T11:50:56Z,1131,[],Panobinostat + Sorafenib,2014-07-28T11:50:56Z
0,2016-03-30T14:30:32Z,3874,[],Panobinostat + WP1066,2016-03-30T14:31:04Z
0,2016-04-21T17:00:11Z,3977,"[{'description': 'Panvotinib-401 is a small molecule Hsp90 inhibitor that is mitochondrial inner membrane-permeable, resulting in cancer cell toxicity (AACR, Cancer Res: April 2016; Volume 57, Abstract #3896).', 'references': [{'id': 5189, 'pubMedId': None, 'title': 'Novel in vivo pan-Hsp90 family protein inhibitor, Panvotinib-401, showed potent anticancer activities without HSF1 activation', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=d0cbfd99-0744-49e4-a827-562c416014d8&cKey=5b87c7e4-79ec-456c-9ca0-037f038f5114&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]}]",Panvotinib-401,2016-04-25T15:01:45Z
0,2015-06-19T13:07:55Z,2857,[],Paricalcitol,2015-06-19T13:07:55Z
0,2017-02-14T15:59:28Z,5322,"[{'description': 'Parthenolide is derived from Tanacetum parthenium and is an inhibitor of NF-kB and IL-1, which potentially results in apoptosis by blocking the activation of NF-kB in cancer cells (PMID: 21603970, PMID: 28108625). ', 'references': [{'id': 7795, 'pubMedId': 21603970, 'title': 'Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21603970'}, {'id': 7783, 'pubMedId': 28108625, 'title': 'Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-κB Activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28108625'}]}]",Parthenolide,2017-02-14T15:59:28Z
0,2015-03-03T02:30:00Z,2260,[],Pasireotide,2015-03-03T02:30:00Z
0,2016-09-01T20:47:39Z,4641,"[{'description': 'PAT-SM6 is a monoclonal antibody directed against GRP78, which may result in increased apoptosis and decreased growth of GRP78-expressing tumor cells, especially in combination with other agents (PMID: 23667612, PMID: 27029491).', 'references': [{'id': 6555, 'pubMedId': 27029491, 'title': 'A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27029491'}, {'id': 6554, 'pubMedId': 23667612, 'title': 'The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23667612'}]}]",PAT-SM6,2016-09-01T20:47:39Z
0,2015-03-24T00:57:17Z,2456,"[{'description': 'Patritumab (U3-1287) is a monoclonal antibody that targets HER3 and inhibits ligand binding, potentially resulting in decreased activation of downstream signaling and reduced tumor growth (PMID: 24442032).', 'references': [{'id': 2300, 'pubMedId': 24442032, 'title': 'Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24442032'}]}]",Patritumab,2015-04-10T17:04:23Z
0,2015-04-10T17:02:52Z,2530,[],Patritumab + Erlotinib,2015-04-10T17:02:52Z
0,2014-03-12T15:53:16Z,848,"[{'description': 'Votrient (pazopanib) inhibits VEGFR-1, -2 and -3, KIT, and PDGFR, and FGFR1, 2, and 3, leading to decreased tumor angiogenesis and growth (PMID: 17620431, PMID: 23786770). Votrient (pazopanib) is approved for renal cell carcinoma and soft tissue sarcoma (FDA.gov).  ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Pazopanib,2016-01-18T18:04:10Z
0,2014-07-25T18:51:57Z,1102,[],Pazopanib + Abexinostat,2014-07-25T18:51:57Z
0,2014-07-29T20:10:54Z,1230,[],Pazopanib + Bevacizumab,2014-07-29T20:10:54Z
0,2014-11-07T04:09:08Z,1714,[],Pazopanib + Carboplatin + Paclitaxel,2014-11-07T04:09:08Z
0,2014-12-23T14:12:05Z,1838,[],Pazopanib + Cetuximab,2014-12-23T14:12:05Z
0,2014-09-18T15:04:11Z,1471,[],Pazopanib + Doxorubicin + Ifosfamide,2014-09-18T15:04:11Z
0,2017-05-05T22:24:32Z,5635,[],Pazopanib + Irinotecan + Temozolomide,2017-05-05T22:24:32Z
0,2014-07-28T13:00:21Z,1143,[],Pazopanib + Paclitaxel,2014-07-28T13:00:21Z
0,2017-10-02T13:48:17Z,6278,[],Pazopanib + Pembrolizumab,2017-10-02T13:48:17Z
0,2014-07-28T13:28:03Z,1156,[],Pazopanib + Pemetrexed,2014-07-28T13:28:03Z
0,2015-02-11T14:12:21Z,2040,[],Pazopanib + Temozolomide,2015-02-11T14:12:21Z
0,2014-07-31T14:02:35Z,1310,[],Pazopanib + Trametinib,2016-10-28T17:13:00Z
0,2014-07-29T17:24:36Z,1211,[],Pazopanib + Vorinostat,2014-07-29T17:24:36Z
0,2016-04-20T18:23:44Z,3975,"[{'description': 'PBA2 is a dual BCR-ABL and GSK3-beta inhibitor that inhibits tumor cell growth (AACR, Cancer Res: April 2016; Volume 57, Abstract #3915).', 'references': [{'id': 5187, 'pubMedId': None, 'title': 'PBA2, a dual BCR-ABL and GSK3?kinases inhibitor, represses a wide array of Imatinib resistant cell lines in chronic myeloid leukemia', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=d0cbfd99-0744-49e4-a827-562c416014d8&cKey=72e71da1-be1f-4d1d-9554-e10537c87463&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]}]",PBA2,2016-04-25T14:55:37Z
0,2016-09-21T18:29:57Z,4740,"[{'description': 'PBF-509 binds to and inhibits adenosine A2A receptor on T-cells, resulting in activation of anti-tumor immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",PBF-509,2016-09-21T18:29:57Z
0,2016-09-21T18:31:09Z,4741,[],PBF-509 + PDR001,2016-09-21T18:31:09Z
0,2017-05-30T18:53:01Z,5816,"[{'description': 'PD 0360324 is a monoclonal antibody that targets CSF1 (M-CSF) and interferes with CSF1 receptor binding, which may result in increased anti-tumor immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",PD 0360324,2017-07-20T16:47:27Z
0,2014-03-12T15:53:16Z,849,"[{'description': 'PD-0325901, a derivative of CI-1040, is a pan-MEK inhibitor, which inhibits activation of MAPK/ERK resulting in decreased tumor cell proliferation (PMID: 18952427).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 2276, 'pubMedId': 18952427, 'title': 'The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18952427'}]}]",PD-0325901,2017-04-06T10:03:19Z
0,2014-12-19T21:27:16Z,1822,[],PD-0325901 + GDC-0941,2014-12-19T21:27:16Z
0,2015-08-14T01:36:26Z,3025,[],PD-0325901 + Gedatolisib,2015-08-14T01:36:26Z
0,2014-12-19T21:29:53Z,1823,[],PD-0325901 + Palbociclib,2014-12-19T21:29:53Z
0,2015-03-19T13:41:49Z,2434,[],PD-0325901 + PF-04691502,2015-03-19T13:41:49Z
0,2014-11-19T17:16:16Z,1731,[],PD-0332991 + T-DM1,2014-11-19T17:16:16Z
0,2014-03-12T15:53:16Z,851,"[{'description': 'PD0166285 inhibits WEE1 kinase activity and abrogates the irradiation-induced G2 arrest, thus enhancing cell death after irradiation treatment (PMID: 21529352, 11719452).', 'references': [{'id': 209, 'pubMedId': 11719452, 'title': 'Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11719452'}, {'id': 1039, 'pubMedId': 21529352, 'title': 'WEE1 inhibition sensitizes osteosarcoma to radiotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21529352'}]}]",PD0166285,2014-12-22T13:47:58Z
0,2014-09-19T07:45:38Z,1509,[],PD0332991 + 5-FU,2014-09-19T07:45:38Z
0,2014-09-19T11:20:45Z,1517,[],PD0332991 + AZD6244,2014-09-19T11:20:45Z
0,2014-09-19T11:29:29Z,1520,[],PD0332991 + AZD8055,2015-03-20T17:46:42Z
0,2014-09-19T10:43:55Z,1515,[],PD0332991 + BEZ235,2014-09-19T10:43:55Z
0,2014-09-19T10:48:48Z,1516,[],PD0332991 + GDC0980,2014-09-19T10:48:48Z
0,2014-09-19T07:55:32Z,1510,[],PD0332991 + Gemcitabine,2014-09-19T07:55:32Z
0,2015-04-28T20:03:18Z,2594,"[{'description': 'PD166326 is a dual kinase inhibitor of Src and Abl, which can inhibit cellular growth and induce apoptosis (PMID: 12684394, PMID: 15657179). ', 'references': [{'id': 2592, 'pubMedId': 15657179, 'title': 'PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15657179'}, {'id': 2593, 'pubMedId': 12684394, 'title': 'A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12684394'}]}]",PD166326,2015-04-28T20:17:48Z
0,2015-07-22T19:34:15Z,2948,"[{'description': 'PD173074 is an ATP-competitive inhibitor of FGFR1, FGFR3, FGFR4, and KDR (VEGFR2), which may reduce proliferation and induce apoptosis in cancer cells (PMID: 9774334, PMID: 24126887, PMID: 14715624).', 'references': [{'id': 3303, 'pubMedId': 9774334, 'title': 'Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/9774334'}]}]",PD173074,2015-10-21T18:37:12Z
0,2016-12-01T20:04:55Z,5041,[],PD173074 + Quizartinib,2016-12-01T20:04:55Z
0,2016-01-19T18:08:42Z,3422,[],PD173074 + Trabectedin,2016-01-19T18:08:42Z
0,2015-04-29T17:07:19Z,2606,"[{'description': 'PD173955 is a tyrosine kinase inhibitor of Src and Bcr-Abl, which can result in anti-mitotic activity, induce apoptosis, and inhibit cell growth (PMID: 12154026, PMID: 10626805). ', 'references': [{'id': 2602, 'pubMedId': 12154026, 'title': 'Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12154026'}, {'id': 2603, 'pubMedId': 10626805, 'title': 'Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10626805'}]}]",PD173955,2015-04-29T17:07:19Z
0,2015-04-29T17:29:14Z,2610,"[{'description': 'PD180970 is an ATP-competitive tyrosine kinase inhibitor of Src and Abl, which can result in the inhibition of autophosphorylation and induce apoptosis (PMID: 10974196, PMID: 12499247). ', 'references': [{'id': 2609, 'pubMedId': 10974196, 'title': 'Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10974196'}, {'id': 2610, 'pubMedId': 12499247, 'title': 'Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12499247'}]}]",PD180970,2015-04-29T17:29:14Z
0,2017-05-02T16:14:34Z,5601,[],PD180970 + Serdemetan,2017-05-02T16:14:34Z
0,2015-04-30T17:43:02Z,2617,"[{'description': 'PD98059 inhibits MEK1, resulting in decreased MAPK phosphorylation and potentially leading to increased tumor cell death (PMID: 7644477, PMID: 17161815).', 'references': [{'id': 2632, 'pubMedId': 7644477, 'title': 'A synthetic inhibitor of the mitogen-activated protein kinase cascade.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/7644477'}, {'id': 2631, 'pubMedId': 17161815, 'title': 'PD98059 triggers G1 arrest and apoptosis in human leukemic U937 cells through downregulation of Akt signal pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17161815'}]}]",PD98059,2017-04-06T10:50:54Z
0,2015-05-12T15:05:02Z,2659,"[{'description': 'PDR001 is a monoclonal antibody that targets PD-1, potentially resulting in activation of T-cell mediated immune response against tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",PDR001,2016-01-28T02:24:09Z
0,2017-03-01T04:15:38Z,5395,[],PDR001 + Canakinumab,2017-03-01T04:15:38Z
0,2017-03-01T04:19:35Z,5397,[],PDR001 + CJM112,2017-03-01T04:19:35Z
0,2017-03-01T04:22:40Z,5399,[],PDR001 + EGF816,2017-03-01T04:22:40Z
0,2017-02-12T17:13:21Z,5312,[],PDR001 + Everolimus,2017-02-12T17:13:21Z
0,2017-02-12T17:12:26Z,5311,[],PDR001 + LCL161,2017-02-12T17:12:26Z
0,2017-07-28T17:41:32Z,6032,[],PDR001 + NIZ985,2017-07-28T17:41:32Z
0,2017-02-12T17:14:24Z,5313,[],PDR001 + Panobinostat,2017-02-12T17:14:24Z
0,2017-06-26T17:48:04Z,5930,[],PDR001 + Regorafenib,2017-06-26T17:48:04Z
0,2017-10-02T18:56:39Z,6284,[],PDR001 + Ribociclib,2017-10-02T18:56:39Z
0,2017-04-28T15:28:54Z,5590,[],PDR001 + Sorafenib,2017-04-28T15:28:54Z
0,2017-03-01T04:21:03Z,5398,[],PDR001 + Trametinib,2017-03-01T04:21:03Z
0,2017-01-05T16:52:18Z,5160,"[{'description': 'PDZ1i is an inhibitor of SDCBP that binds to the PDZ1 domain of the protein and may result in decreased cell invasion and enhanced sensitization to radiotherapy (PMID: 28011764). ', 'references': [{'id': 7482, 'pubMedId': 28011764, 'title': 'Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28011764'}]}]",PDZ1i,2017-01-05T16:52:18Z
0,2017-01-05T17:01:53Z,5161,[],PDZ1i + Radiotherapy,2017-01-05T17:01:53Z
0,2017-09-26T22:33:06Z,6251,"[{'description': 'Pegasys (peg-interferon alfa-2a) comprises interferon alfa-2a conjugated to polyethylene glycol (PEG), which may decrease tumor cell proliferation and enhance anti-tumor immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Peg-interferon alfa-2a,2017-09-26T22:37:43Z
0,2014-10-14T17:21:46Z,1638,"[{'description': 'Oncaspar (pegaspargase) is a pegylated version of L-asparaginase, which converts L-asparagine to ammonia and L-aspartic acid, reducing available asparagine resulting in decreased protein synthesis, inhibition of tumor cell proliferation, and increased apoptosis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Pegaspargase,2015-02-27T16:53:23Z
0,2014-09-18T16:17:09Z,1476,"[{'description': 'Pegfilgrastim is a pegylated version of filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF), which enhances proliferation, differentiation, and activity of neutrophils (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Pegfilgrastim,2015-02-27T16:33:02Z
0,2015-05-07T00:44:10Z,2624,"[{'description': 'Sylatron (peginterferon alfa-2b) is polyethylene glycol (PEG)-conjugated recombinant interferon alpha, subtype 2b,  which may have antitumor activity (PMID: 23002124, PMID: 16953837).', 'references': [{'id': 2656, 'pubMedId': 24741445, 'title': 'Human interferon alpha-2b: a therapeutic protein for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24741445'}]}]",peginterferon alfa-2b,2017-06-19T19:18:00Z
0,2015-05-07T00:45:55Z,2625,[],peginterferon alfa-2b + Pembrolizumab,2015-05-07T00:45:55Z
0,2015-02-24T03:20:10Z,2140,"[{'description': 'PEGPH20 is a pegylated version of hyaluronidase, which degrades endogenous hyaluronic acid within tumors, potentially resulting in decreased growth of tumor cells and increased penetration of other therapeutic agents (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",PEGPH20,2017-04-03T17:38:34Z
0,2017-05-26T14:59:14Z,5779,[],PEGPH20 + Pembrolizumab,2017-05-26T14:59:14Z
0,2015-02-26T14:15:17Z,2167,[],pegylated liposomal doxorubicin + Veliparib,2015-02-26T14:15:17Z
0,2017-05-11T18:37:52Z,5667,[],Pegylated liposomal-doxorubicin + Trebananib,2017-08-08T20:14:07Z
0,2014-03-12T15:53:16Z,852,"[{'description': 'Pelitinib is a nonselective inhibitor of EGFR, ERBB2 (HER2), and HER4, which induces apoptosis and inhibits cell proliferation (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Pelitinib,2015-03-31T13:28:14Z
0,2014-09-11T15:10:44Z,1447,"[{'description': 'Keytruda (pembrolizumab) is an antibody that binds to and inhibits PD-1, resulting in activation of T-cell mediated immune response against tumor cells (NCI Drug Dictionary). Keytruda (pembrolizumab) is approved for use in patients with melanoma, head and neck squamous cell carcinoma, urothelial carcinoma, classical Hodgkin lymphoma, MSI-H or MMR-deficient solid tumors, and PD-L1 expressing non-small cell lung cancer, gastric cancer, and GEJ adenocarcinoma (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Pembrolizumab,2017-09-25T16:53:42Z
0,2016-12-13T04:41:16Z,5085,[],Pembrolizumab + Ad-MAGEA3 + MG1-MAGEA3,2016-12-13T04:41:16Z
0,2017-05-02T03:46:24Z,5596,[],Pembrolizumab + Anetumab ravtansine,2017-05-02T03:46:24Z
0,2017-05-18T03:14:55Z,5680,[],Pembrolizumab + Cabozantinib,2017-05-18T03:14:55Z
0,2015-01-05T14:48:42Z,1910,[],Pembrolizumab + Cetuximab,2015-01-05T14:48:42Z
0,2014-09-11T15:13:42Z,1448,[],Pembrolizumab + Dabrafenib,2014-09-11T15:13:42Z
0,2014-09-11T15:15:07Z,1449,[],Pembrolizumab + Dabrafenib + Trametinib,2014-09-11T15:15:07Z
0,2016-12-28T02:51:10Z,5127,[],Pembrolizumab + Decitabine,2016-12-28T02:51:10Z
0,2017-01-31T04:54:39Z,5266,[],Pembrolizumab + DPX-Survivac + Cyclophosphamide,2017-01-31T04:54:39Z
0,2017-03-15T04:03:22Z,5435,[],Pembrolizumab + Etoposide + Carboplatin + Ifosfamide,2017-03-15T04:03:22Z
0,2017-03-30T17:57:48Z,5497,[],Pembrolizumab + Gemcitabine,2017-03-30T17:57:48Z
0,2016-11-05T22:17:25Z,4917,[],Pembrolizumab + Ibrutinib,2016-11-05T22:17:25Z
0,2017-02-26T03:51:26Z,5367,[],Pembrolizumab + interferon gamma,2017-02-26T03:51:26Z
0,2017-01-31T04:21:04Z,5263,[],Pembrolizumab + Interleukin-12,2017-01-31T04:21:04Z
0,2016-11-02T01:30:03Z,4903,[],Pembrolizumab + Paricalcitol,2016-11-02T01:30:03Z
0,2016-11-02T01:31:56Z,4904,[],Pembrolizumab + Paricalcitol + Gemcitabine + nab-paclitaxel,2016-11-02T01:31:56Z
0,2015-05-29T02:46:53Z,2736,[],Pembrolizumab + PLX3397,2015-05-29T02:46:53Z
0,2016-07-17T22:13:55Z,4458,[],Pembrolizumab + poly ICLC ,2016-07-17T22:13:55Z
0,2017-04-07T19:22:42Z,5519,[],Pembrolizumab + Preladenant,2017-04-07T19:22:42Z
0,2016-04-22T19:23:23Z,4001,[],Pembrolizumab + QbG10,2016-04-22T19:23:23Z
0,2017-04-12T20:39:00Z,5542,[],Pembrolizumab + Ra 223,2017-04-12T20:39:00Z
0,2016-04-15T17:51:43Z,3943,[],Pembrolizumab + rAd.CD40L,2016-04-15T17:51:43Z
0,2015-07-10T15:11:14Z,2896,[],Pembrolizumab + Ramucirumab,2015-07-10T15:11:14Z
0,2015-12-11T03:16:12Z,3279,[],Pembrolizumab + Rituximab,2015-12-11T03:16:12Z
0,2017-01-19T06:02:15Z,5227,[],Pembrolizumab + Ruxolitinib,2017-01-19T06:02:15Z
0,2016-06-03T00:07:14Z,4217,[],Pembrolizumab + Sargramostim,2016-06-03T00:07:14Z
0,2017-01-09T15:26:47Z,5166,[],Pembrolizumab + SD-101,2017-01-09T15:26:47Z
0,2017-05-26T15:58:11Z,5781,[],Pembrolizumab + SEA-CD40,2017-05-26T15:58:11Z
0,2016-09-21T14:17:59Z,4725,[],Pembrolizumab + SGI-110,2016-09-21T14:17:59Z
0,2017-07-28T18:59:13Z,6041,[],Pembrolizumab + Sorafenib,2017-07-28T18:59:13Z
0,2017-05-26T17:34:47Z,5787,[],Pembrolizumab + SX-682,2017-05-26T17:34:47Z
0,2016-04-29T19:37:24Z,4035,[],Pembrolizumab + talimogene laherparepvec ,2016-04-29T19:37:24Z
0,2015-10-08T03:09:04Z,3114,[],Pembrolizumab + Tamoxifen + vorinostat,2015-10-08T03:09:50Z
0,2017-01-16T17:49:43Z,5221,[],Pembrolizumab + Temozolomide,2017-01-16T17:49:43Z
0,2017-01-16T17:45:49Z,5220,[],Pembrolizumab + Temozolomide + Vitespen,2017-01-16T17:45:49Z
0,2017-09-25T14:38:49Z,6237,[],Pembrolizumab + TGR-1202,2017-09-25T14:38:49Z
0,2016-01-29T14:00:35Z,3475,[],Pembrolizumab + TGR-1202 + Ublituximab,2016-01-29T14:00:35Z
0,2017-04-12T17:40:13Z,5532,[],Pembrolizumab + Topotecan,2017-04-12T17:40:13Z
0,2014-09-11T15:15:53Z,1450,[],Pembrolizumab + Trametinib,2014-09-11T15:15:53Z
0,2015-01-05T14:46:34Z,1908,[],Pembrolizumab + Trastuzumab,2015-01-05T14:46:34Z
0,2015-01-05T14:47:31Z,1909,[],Pembrolizumab + trastuzumab emtansine,2015-01-05T14:47:31Z
0,2017-08-08T20:16:23Z,6102,[],Pembrolizumab + Trebananib,2017-08-08T20:16:23Z
0,2017-07-13T03:23:59Z,5988,[],Pembrolizumab + Tretinoin,2017-07-13T03:23:59Z
0,2017-10-10T17:05:56Z,6306,[],Pembrolizumab + Utomilumab,2017-10-10T17:05:56Z
0,2016-07-01T16:22:35Z,4406,[],Pembrolizumab + Vemurafenib,2016-07-01T16:22:35Z
0,2016-03-11T19:28:20Z,3727,[],Pembrolizumab + Vismodegib,2016-03-11T19:28:20Z
0,2015-09-06T21:19:10Z,3077,[],Pembrolizumab + Vorinostat,2015-09-06T21:19:10Z
0,2016-07-08T20:46:39Z,4436,[],Pembrolizumab + X4P-001,2016-07-08T20:46:39Z
0,2017-04-12T17:58:55Z,5533,[],Pembrolizumab + XL888,2017-04-12T17:58:55Z
0,2014-03-12T15:53:16Z,854,"[{'description': 'Alimta (pemetrexed) is an antifolate, which inhibits thymidylate synthase (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Pemetrexed,2015-09-21T09:22:56Z
0,2014-12-18T15:54:04Z,1801,[],Pemetrexed + Gemcitabine,2014-12-18T15:54:04Z
0,2014-07-30T16:46:49Z,1266,[],Pemetrexed + GSK1120212,2014-07-30T16:46:49Z
0,2017-07-28T02:36:56Z,6024,[],Pemetrexed + PDR001 + Cisplatin + Carboplatin,2017-07-28T02:38:34Z
0,2017-03-30T17:59:00Z,5498,[],Pemetrexed + Pembrolizumab,2017-03-30T17:59:00Z
0,2017-09-26T22:13:08Z,6248,[],Pemetrexed + Prexasertib,2017-09-26T22:13:08Z
0,2014-12-31T17:49:55Z,1884,[],Pemetrexed + Sirolimus,2014-12-31T17:49:55Z
0,2014-09-18T17:57:05Z,1482,[],Pemetrexed + Sorafenib,2014-09-18T17:57:05Z
0,2014-09-18T17:53:47Z,1481,"[{'description': 'ALIMTA (permatrexed) is an antifolate that acts by inhibiting the enzymes thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GCRFT) (PMID: 9067281). ALIMTA has been demonstrated to inhibit proliferation in cultured tumor cells (PMID: 9067281).', 'references': [{'id': 757, 'pubMedId': 9067281, 'title': 'LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/9067281'}]}]",Pemetrexed disodium,2014-09-18T17:53:47Z
0,2017-05-31T14:01:11Z,5819,"[{'description': 'PEN-221 is a small peptide targeting Sstr2 in conjugation with DM1, which may target Sstr2-positive tumor cells for cytotoxicity (Proceedings of the AACR, Vol 58, Apr 2017, Abstract # 39).', 'references': [{'id': 9027, 'pubMedId': None, 'title': 'Discovery of PEN-221, an SSTR2-targetign maytansinoid conjugate with potent activity in vitro and in vivo', 'url': 'https://books.google.com/books?id=4UFUDgAAQBAJ&pg=PT48&lpg=PT48&dq=PEN-221+aacr&source=bl&ots=qSIl2V4wHV&sig=dN3Z-YpHN0nqfJevoJVo3FKstS4&hl=en&sa=X&ved=0ahUKEwjnlZ-Dn5rUAhUr6YMKHbuSCMkQ6AEIVzAJ#v=onep'}]}]",PEN-221,2017-05-31T14:01:11Z
0,2015-10-30T13:03:27Z,3161,[],Pentostatin,2015-10-30T13:03:27Z
0,2014-10-09T20:49:53Z,1635,"[{'description': 'PEPIDH1M vaccine is a peptide vaccine based on isocitrate dehydrogenase 1 (IDH1) harboring the R132H point mutation, which may induce a host immune response against tumor cells expressing IDH1 R132H (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",PEPIDH1M vaccine,2014-10-09T20:49:53Z
0,2014-03-12T15:53:16Z,855,"[{'description': 'Perifosine is a synthetic alkylphospholipid that inhibits AKT resulting in apoptotic induction and antitumor activity (PMID: 16418332). ', 'references': [{'id': 8268, 'pubMedId': 16418332, 'title': 'Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16418332'}]}]",Perifosine,2017-03-17T18:23:27Z
0,2015-02-27T14:39:18Z,2194,[],Perifosine + Temsirolimus,2015-02-27T14:39:18Z
0,2015-01-04T01:14:46Z,1896,[],Perindopril,2015-01-04T01:14:46Z
0,2016-01-14T14:15:56Z,3410,[],Perindopril + Regorafenib,2016-01-14T14:15:56Z
0,2014-03-12T15:53:16Z,856,"[{'description': 'Perjeta (pertuzumab) is a monoclonal antibody that binds ERBB2 (HER2) to prevent HER signaling and induce apoptosis (NCI Drug Dictionary). Perjeta (pertuzumab) is FDA approved for ERBB2 (HER2) positive breast cancer and as part of a neoadjuvant breast cancer treatment (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Pertuzumab,2016-05-31T17:40:33Z
0,2017-05-08T16:04:24Z,5648,[],Pertuzumab + Tocilizumab + Trastuzumab,2017-05-08T16:04:24Z
0,2014-12-31T16:43:35Z,1879,[],Pertuzumab + Trastuzumab + Carboplatin + Docetaxel,2014-12-31T16:43:35Z
0,2015-01-26T15:13:19Z,1978,[],Pertuzumab + Trastuzumab + Docetaxel,2015-01-26T15:13:19Z
0,2014-09-25T18:54:20Z,1550,[],Pertuzumab + Trastuzumab + Fluorouracil + Epirubicin + Cyclophosphamide,2014-09-25T18:54:20Z
0,2014-09-25T18:52:25Z,1549,[],Pertuzumab + Trastuzumab + Paclitaxel,2014-09-25T18:52:25Z
0,2014-10-28T15:53:06Z,1666,[],Pertuzumab + Trastuzumab + Vinorelbine,2014-10-28T15:53:06Z
0,2017-05-23T19:32:21Z,5752,"[{'description': 'PET-16 binds to the substrate-binding domain of Hsp70 and inhibits Hsp70 functions, resulting in decreased tumor metastasis and growth (PMID: 26984758).', 'references': [{'id': 8968, 'pubMedId': 26984758, 'title': 'HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26984758'}]}]",PET-16,2017-05-23T19:32:21Z
0,2017-06-19T17:46:59Z,5911,[],PET-16 + Vemurafenib,2017-06-19T17:46:59Z
0,2016-03-07T17:30:50Z,3688,[],PEXG,2016-03-07T17:30:50Z
0,2016-08-17T16:36:37Z,4574,"[{'description': 'Pexmetinib (ARRY-614) is a dual inhibitor of Angpt1, Mapk14, and Mapk11, which may result in inhibition of cell proliferation (PMID: 27287719).\r\n', 'references': [{'id': 6492, 'pubMedId': 27287719, 'title': 'Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27287719'}]}]",Pexmetinib,2016-08-17T16:36:37Z
0,2014-09-30T17:03:56Z,1565,"[{'description': 'PF-00477736 is an ATP-competitive inhibitor of Chk1, which induces cell cycle arrest (PMID: 18723486).', 'references': [{'id': 875, 'pubMedId': 18723486, 'title': 'Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18723486'}]}]",PF-00477736,2017-03-15T18:11:44Z
0,2016-01-27T18:04:12Z,3466,[],PF-00477736 + Gemcitabine,2016-01-27T18:04:12Z
0,2014-03-12T15:53:16Z,858,"[{'description': 'PF-00562271 is an ATP-competitive inhibitor of FAK and PYK2, which may result in inhibition of cell proliferation and migration, and reduce cell survival (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",PF-00562271,2016-02-23T20:58:56Z
0,2016-02-23T21:13:08Z,3598,[],PF-00562271 + Docetaxel,2016-02-23T21:13:08Z
0,2014-03-12T15:53:16Z,859,"[{'description': 'PF-03084014 is a small molecule that selectively binds and inhibits Gamma-secretase inhibiting its proteolytic activity on downstream targets including NOTCH receptor proteins thus blocking pathway activation in cancer (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",PF-03084014,2015-04-06T03:02:25Z
0,2014-07-27T20:04:00Z,1115,[],PF-03084014 + Docetaxel,2014-07-27T20:04:00Z
0,2015-02-09T04:01:48Z,2029,"[{'description': 'PF-03446962 is a monoclonal antibody that binds and inhibits ALK-1, potentially resulting in decreased tumor angiogenesis and proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",PF-03446962,2015-02-09T04:01:48Z
0,2015-02-10T16:51:36Z,2035,[],PF-03446962 + Regorafenib,2015-02-10T16:51:36Z
0,2014-03-12T15:53:16Z,863,"[{'description': 'PF-03814735 is an inhibitor of Aurora kinases A and B, which prevents cell division and proliferation (PMID: 20354118).', 'references': [{'id': 868, 'pubMedId': 20354118, 'title': 'PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20354118'}]}]",PF-03814735,2017-04-04T13:07:11Z
0,2016-06-22T02:13:28Z,4339,"[{'description': 'PF-04136309 is a CCR2 antagonist that inhibits CCR2 signaling, resulting in inhibition of tumor progression (PMID: 27055731).', 'references': [{'id': 5980, 'pubMedId': 27055731, 'title': 'Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27055731'}]}]",PF-04136309,2016-06-22T02:13:28Z
0,2014-03-12T15:53:16Z,864,"[{'description': 'PF-04217903 binds to MET and inhibits its activation, resulting in decreased activation of downstream signaling, and potentially resulting in decreased tumor cell growth and migration and increased tumor cell death (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",PF-04217903,2015-02-25T18:44:21Z
0,2014-11-28T23:51:08Z,1748,"[{'description': 'PF-04449913 inhibits Smoothened (SMO), resulting in decreased Hedgehog (Hh) pathway signalling, and potentially inhibiting Hh-mediated tumor growth (PMID: 24900436, PMID: 25388167).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 2237, 'pubMedId': 24900436, 'title': 'Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24900436'}, {'id': 2238, 'pubMedId': 25388167, 'title': 'A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25388167'}]}]",PF-04449913,2016-02-05T02:16:14Z
0,2016-06-20T17:10:17Z,4333,"[{'description': 'PF-04518600 is a monoclonal antibody that binds to and activates OX40, resulting in activation of anti-tumor immunity (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",PF-04518600,2016-06-20T17:10:17Z
0,2016-07-14T14:03:38Z,4448,[],PF-04518600 + Utomilumab,2017-10-10T17:43:00Z
0,2015-10-23T17:36:09Z,3151,"[{'description': 'PF-0461903 is a kinase inhibitor of c-Met, which may result in inhibition of the Mapk signaling pathway (PMID: 22745804). ', 'references': [{'id': 3751, 'pubMedId': 22745804, 'title': 'A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22745804'}]}]",PF-0461903,2015-10-23T17:36:09Z
0,2014-03-12T15:53:16Z,865,"[{'description': 'PF-04691502 is a PI3K/mTOR dual inhibitor with broad antitumor activity (PMID: 21750219).', 'references': [{'id': 226, 'pubMedId': 21750219, 'title': 'PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21750219'}]}]",PF-04691502,2015-04-02T23:52:24Z
0,2016-11-23T17:40:17Z,5005,[],PF-04691502 + SCH772984,2016-11-23T17:40:17Z
0,2015-10-23T17:25:56Z,3150,"[{'description': 'PF-04880594 is a Raf inhibitor, which has been shown to inhibit tumor growth in xenograft models (PMID: 19764794). ', 'references': [{'id': 3807, 'pubMedId': 19764794, 'title': 'Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19764794'}]}]",PF-04880594,2015-10-23T17:25:56Z
0,2015-10-23T17:37:35Z,3152,[],PF-04880594 + PF-0461903,2015-10-23T17:37:35Z
0,2015-06-03T20:27:01Z,2775,"[{'description': 'PF-04965842 is a selective inhibitor of JAK1 (PMID: 25587654).', 'references': [{'id': 2928, 'pubMedId': 25587654, 'title': 'The JAK-STAT pathway: impact on human disease and therapeutic intervention.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25587654'}]}]",PF-04965842,2015-06-03T20:27:01Z
0,2014-05-14T14:52:46Z,1040,"[{'description': 'Gedatolisib (PF-05212384) is an ATP-competitive inhibitor that targets phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, and may result in antitumor activity, including inhibition of tumor growth and tumor regression (PMID: 21325073).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}]}]",PF-05212384,2017-04-24T18:33:07Z
0,2014-07-31T05:21:52Z,1286,[],PF-05212384 + Cisplatin,2014-07-31T05:21:52Z
0,2014-07-31T05:23:03Z,1287,[],PF-05212384 + Dacomitinib,2014-07-31T05:23:03Z
0,2014-07-31T05:20:43Z,1285,[],PF-05212384 + Docetaxel,2014-07-31T05:20:43Z
0,2016-02-19T03:50:51Z,3554,"[{'description': 'PF-05280014 is a biosimilar to the ERBB2 (HER2)-targeted monoclonal antibody Herceptin (trastuzumab), which binds to the extracellular domain of ERBB2 (HER2) and leads to decreased growth of ERBB2 (HER2)-over expressing tumor cells (PMID: 25001079, PMID: 25041377).', 'references': [{'id': 4629, 'pubMedId': 25001079, 'title': 'Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®)).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25001079'}, {'id': 4630, 'pubMedId': 25041377, 'title': 'A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25041377'}]}]",PF-05280014,2016-02-19T03:54:06Z
0,2015-06-03T22:08:21Z,2781,"[{'description': 'PF-06263276 is a pan-JAK inhibitor (PMID: 25587654).', 'references': [{'id': 2928, 'pubMedId': 25587654, 'title': 'The JAK-STAT pathway: impact on human disease and therapeutic intervention.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25587654'}]}]",PF-06263276,2015-06-03T22:08:21Z
0,2016-02-26T15:52:28Z,3625,"[{'description': 'PF-06459988 is a third-generation irreversible EGFR inhibitor that is selective towards mutant EGFR, including T790M, and demonstrates little activity towards wild-type EGFR (PMID: 23456430).', 'references': [{'id': 4708, 'pubMedId': 23456430, 'title': 'Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23456430'}]}]",PF-06459988,2016-02-26T15:52:28Z
0,2014-03-12T15:53:16Z,869,"[{'description': 'Lorlatinib (PF-06463922) is a small molecule inhibitor of Alk and Ros1, which may result in suppression of Alk and Ros1-mediated signaling thereby inhibiting cell growth and causing tumor regression (PMID: 26144315). ', 'references': [{'id': 3367, 'pubMedId': 26144315, 'title': 'PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144315'}]}]",PF-06463922,2017-03-24T19:05:56Z
0,2017-04-27T18:42:15Z,5580,[],PF-06463922 + Cyclophosphamide + Topotecan,2017-04-27T18:42:15Z
0,2016-07-05T15:34:52Z,4421,"[{'description': 'PF-06647020 is an antibody-drug conjugate comprising a monoclonal antibody against PTK7 linked to Aur0101, which delivers the cytotoxic agent to PTK7-expressing tumor cells, leading to cell death (PMID: 28077676).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 7557, 'pubMedId': 28077676, 'title': 'A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28077676'}]}]",PF-06647020,2017-01-16T18:52:36Z
0,2016-06-20T01:20:53Z,4324,"[{'description': 'PF-06647263 is an antibody-drug conjugate consisting of an anti-Ephrin-A4 monoclonal antibody linked to the drug calicheamicin, which may result in tumor growth inhibition (PMID: 26015513).', 'references': [{'id': 5967, 'pubMedId': 26015513, 'title': 'Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26015513'}]}]",PF-06647263 ,2016-07-05T14:57:50Z
0,2017-08-03T20:27:59Z,6087,"[{'description': 'PF-06747143 is a CXCR4 antagonist, which inhibits CXCR4 and CXCL12-mediated cell signaling, potentially resulting in cell death and inhibition of tumor cell metastasis (PMID: 28526063). ', 'references': []}]",PF-06747143,2017-08-03T20:27:59Z
0,2015-04-10T15:33:15Z,2527,"[{'description': 'PF-06747775 is a specific inhibitor of EGFR T790M, which causes cell death in EGFR T790M-positive tumor cells, while sparing wild-type EGFR (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",PF-06747775  ,2015-04-17T02:11:41Z
0,2016-02-19T14:57:19Z,3564,"[{'description': 'Limited information is currently available on PF-06755990 (Feb, 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",PF-06755990,2016-02-25T17:32:27Z
0,2016-02-19T14:59:36Z,3565,[],PF-06755990 + PF-06755992 + Sunitinib + Tremelimumab,2016-02-19T14:59:36Z
0,2016-02-19T14:56:28Z,3563,"[{'description': 'Limited information is currently available on PF-06755992 (Feb, 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",PF-06755992 ,2016-02-25T17:32:53Z
0,2015-12-22T20:39:46Z,3327,"[{'description': 'PF-3758309 is a p21-activated kinase (PAK) inhibitor with activity against PAK1 and PAK4, potentially resulting in decreased tumor growth (PMID: 20439741, PMID: 23543898).', 'references': [{'id': 4152, 'pubMedId': 23543898, 'title': 'Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23543898'}, {'id': 4151, 'pubMedId': 20439741, 'title': 'Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439741'}]}]",PF-3758309,2015-12-22T20:39:46Z
0,2016-01-25T20:39:07Z,3460,"[{'description': 'PF-3837 inhibits TTK (MPS1) activity to induce apoptosis through disruption of the mitotic spindle assembly checkpoint (PMID: 26398286).', 'references': [{'id': 4438, 'pubMedId': 26398286, 'title': 'Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26398286'}]}]",PF-3837,2016-01-25T20:39:07Z
0,2017-02-28T20:00:27Z,5390,"[{'description': 'PF-431396 is a dual inhibitor of FAK and PTK2B (PYK2), which may result in inhibition of cell growth (PMID: 27793840).', 'references': [{'id': 8020, 'pubMedId': 27793840, 'title': 'Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27793840'}]}]",PF-431396,2017-02-28T20:21:54Z
0,2016-09-08T02:34:12Z,4665,"[{'description': 'PF-4708671 inhibits p70S6K, potentially resulting in decreased proliferation and migration of tumor cells  (PMID: 26771549).', 'references': [{'id': 6579, 'pubMedId': 26771549, 'title': 'The p70S6K Specific Inhibitor PF-4708671 Impedes Non-Small Cell Lung Cancer Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26771549'}]}]",PF-4708671,2016-09-08T02:34:12Z
0,2015-06-03T18:16:58Z,2771,"[{'description': 'PF-4942847 inhibits HSP90, resulting in the degradation of HSP90 client proteins, which may lead to decreased proliferation and increased apoptosis of tumor cells (PMID: 21715568).', 'references': [{'id': 2922, 'pubMedId': 21715568, 'title': 'Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21715568'}]}]",PF-4942847,2015-06-03T18:20:12Z
0,2014-03-12T15:53:16Z,867,"[{'description': 'PF-4989216 is a selective inhibitor of PIK3CA and PIK3CD that has demonstrated anti-tumor activity in animal models (PMID: 24240111).', 'references': [{'id': 4923, 'pubMedId': 24900269, 'title': 'Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24900269'}, {'id': 4924, 'pubMedId': 24240111, 'title': 'Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24240111'}]}]",PF-4989216,2016-03-18T15:39:43Z
0,2015-03-17T02:03:05Z,2417,"[{'description': 'PF-5274857 is a Smoothened (SMO) antagonist capable of crossing the blood-brain barrier, which inhibits downstream Hedgehog (Hh) pathway signaling and potentially leads to decreased tumor growth (PMID: 22084163).', 'references': [{'id': 2239, 'pubMedId': 22084163, 'title': 'Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22084163'}]}]",PF-5274857,2015-03-17T02:03:05Z
0,2015-02-18T03:03:25Z,2087,"[{'description': 'PF-562271 inhibits FAK and PYK2 activity, resulting in decreased tumor growth (PMID: 18339875).', 'references': [{'id': 1919, 'pubMedId': 18339875, 'title': 'Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18339875'}]}]",PF-562271,2016-01-28T17:12:40Z
0,2016-02-22T17:32:24Z,3587,"[{'description': 'PF-573228 is a small molecule inhibitor of PTK2 (FAK), which may reduce cell migration and decrease focal adhesion cellular turnover, thus suppressing metastasis (PMID: 17395594). ', 'references': [{'id': 4654, 'pubMedId': 17395594, 'title': 'Cellular characterization of a novel focal adhesion kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17395594'}]}]",PF-573228,2016-02-22T17:32:24Z
0,2016-01-25T20:38:12Z,3459,"[{'description': 'PF-7006 inhibits TTK (MPS1) activity to induce apoptosis through disruption of the mitotic spindle assembly checkpoint (PMID: 26398286).', 'references': [{'id': 4438, 'pubMedId': 26398286, 'title': 'Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26398286'}]}]",PF-7006 ,2016-01-25T20:38:12Z
0,2015-06-04T16:50:37Z,2794,"[{'description': 'PF-956980 is a selective inhibitor of JAK3, which inhibits cell proliferation (PMID: 18094329).', 'references': [{'id': 2958, 'pubMedId': 18094329, 'title': 'The specificity of JAK3 kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18094329'}]}]",PF-956980,2015-06-04T16:50:37Z
0,2017-03-15T18:09:38Z,5441,"[{'description': 'PF3644022 is an ATP-competitive MAPK-activated protein kinase-2 (MK2) inhibitor that induces apoptosis in tumor cells (PMID: 26140595).', 'references': [{'id': 8232, 'pubMedId': 26140595, 'title': 'A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26140595'}]}]",PF3644022,2017-03-15T18:09:38Z
0,2017-03-15T18:33:13Z,5443,[],PF3644022 + PF-477736,2017-03-15T18:33:13Z
0,2016-05-13T17:01:20Z,4120,"[{'description': 'PF4942847 is a HSP90 inhibitor that affects oncogenic protein maturation and stability, leading to growth inhibition in tumor cells (PMID: 26712686).', 'references': [{'id': 5536, 'pubMedId': 26712686, 'title': 'Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26712686'}]}]",PF4942847,2016-05-13T17:01:20Z
0,2016-05-13T17:48:52Z,4121,[],PF4942847 + Zoledronic acid,2017-06-19T18:22:58Z
0,2015-01-08T15:21:27Z,1931,"[{'description': 'PFI-2 is a selective methyltransferase inhibitor with specificity for SETD7. PFI-2 binds to the substrate binding groove of Setd7 inhibiting its influence over Hippo pathway signaling thus influencing cell proliferation and differentiation (PMID: 25136132).', 'references': [{'id': 1601, 'pubMedId': 25136132, 'title': '(R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25136132'}]}]",PFI-2,2015-01-08T15:21:27Z
0,2016-05-08T10:24:05Z,4091,"[{'description': 'PG-S3-001 inhibits Stat3 inhibitor, which may result in increased tumor cell death and decreased tumor growth (PMID: 26873728).', 'references': [{'id': 5424, 'pubMedId': 26873728, 'title': 'Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26873728'}]}]",PG-S3-001,2016-05-11T15:26:09Z
0,2015-07-09T15:47:30Z,2890,"[{'description': 'PG545 is a heparan sulfate mimetic capable of inhibiting both heparanase and angiogenesis, which may result in tumor growth inhibition and anti-metastatic activity (PMID: 21285983).', 'references': [{'id': 3205, 'pubMedId': 21285983, 'title': 'PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21285983'}]}]",PG545,2015-07-09T15:47:30Z
0,2015-07-09T16:56:50Z,2891,[],PG545 + Gemcitabine,2015-07-09T16:56:50Z
0,2016-02-22T18:17:42Z,3590,"[{'description': 'PH11 is an ATP-competitive inhibitor of PTK2 (FAK), which may increase the sensitivity to TRAIL therapies, resulting in apoptosis (PMID: 25684663).', 'references': [{'id': 4658, 'pubMedId': 25684663, 'title': 'Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cells by a novel FAK inhibitor, PH11.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25684663'}]}]",PH11,2016-02-22T18:28:15Z
0,2015-05-20T18:16:35Z,2721,"[{'description': 'PHA-533533 is an inhibitor of CDK1, CDK2, CDK4, CDK5, and GSK3B, which inhibits phosphorylation of downstream targets and may promote cell cycle arrest and apoptosis in cancer cells (PMID: 15828833, PMID: 24004674).', 'references': [{'id': 2782, 'pubMedId': 15828833, 'title': '3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15828833'}, {'id': 2783, 'pubMedId': 24004674, 'title': 'Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24004674'}]}]",PHA-533533,2015-05-20T18:29:34Z
0,2015-02-25T18:27:33Z,2162,"[{'description': 'PHA-665752 is a small molecule inhibitor of MET, which inhibits MET kinase activity and downstream signaling, potentially resulting in increased apoptosis and decreased proliferation and migration of tumor cells (PMID: 14612533).', 'references': [{'id': 2012, 'pubMedId': 14612533, 'title': 'A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/14612533'}]}]",PHA-665752,2015-02-25T18:28:01Z
0,2015-07-31T04:31:45Z,2987,[],PHA-665752 + Sonidegib,2017-06-19T19:31:42Z
0,2015-03-08T21:27:09Z,2330,"[{'description': 'PHA-680632 is a pan-Aurora A,B, C kinase inhibitor, which inhibits cell proliferation (PMID: 16818708).', 'references': [{'id': 2120, 'pubMedId': 16818708, 'title': 'PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16818708'}]}]",PHA-680632,2017-04-04T11:17:24Z
0,2017-04-04T11:25:17Z,5504,[],PHA-680632 + Cisplatin,2017-04-04T11:25:17Z
0,2017-04-04T11:18:27Z,5503,[],PHA-680632 + Radiotherapy,2017-04-04T11:18:27Z
0,2015-05-11T20:10:59Z,2654,"[{'description': 'Milciclib (PHA-848125AC) is a TRKA inhibitor with additional activity against CDK1, CDK2, CDK4, CDK5, and CDK7, potentially resulting in decreased tumor cell growth (PMID: 22160853).', 'references': [{'id': 2685, 'pubMedId': 22160853, 'title': 'Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22160853'}]}]",PHA-848125AC,2015-05-22T00:59:38Z
0,2014-09-11T19:08:12Z,1457,[],phenethyl isothiocyanate,2014-09-18T13:05:21Z
0,2015-06-25T20:45:28Z,2872,"[{'description': 'Phenformin is a metabolic drug that inhibits mitochondrial complex I, which may lead to decreased tumor growth (PMID: 23352126). ', 'references': [{'id': 3133, 'pubMedId': 23352126, 'title': 'LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23352126'}]}]",Phenformin,2015-06-25T20:46:23Z
0,2016-02-23T19:36:51Z,3595,"[{'description': 'PHM16 is an ATP competitive inhibitor of PTK2 (FAK) and FGFR2, which may result in decreased cell adhesion, inhibition of cell growth, and induction of apoptosis (PMID: 24657306).', 'references': [{'id': 4667, 'pubMedId': 24657306, 'title': 'Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24657306'}]}]",PHM16,2016-02-23T19:36:51Z
0,2015-10-22T15:07:00Z,3148,"[{'description': 'PHT-427 is an AKT inhibitor, which binds to the PH domain of AKT and has demonstrated antitumor activity in xenograft models (PMID: 19491272, PMID: 20197390). ', 'references': [{'id': 3794, 'pubMedId': 19491272, 'title': 'In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19491272'}]}]",PHT-427,2017-03-17T18:23:53Z
0,2014-03-12T15:53:16Z,870,"[{'description': 'PI-103 is a dual pan-PI3K/mTOR inhibitor, which inhibits cell proliferation (PMID: 16697955).', 'references': [{'id': 2067, 'pubMedId': 16697955, 'title': 'A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16697955'}]}]",PI-103,2015-03-02T19:14:08Z
0,2015-08-18T09:32:01Z,3031,[],PI-103 + 5-FU,2015-08-18T09:32:01Z
0,2015-07-29T19:36:49Z,2965,"[{'description': 'PI-3065 inhibits PIK3CD, which may block activation of the PI3K signaling pathway and inhibit tumor cell proliferation (PMID: 24919154).', 'references': [{'id': 3350, 'pubMedId': 24919154, 'title': 'Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24919154'}]}]",PI-3065,2015-07-29T19:44:24Z
0,2016-03-22T15:14:09Z,3802,"[{'description': 'PI-88 is a heparanase inhibitor that suppresses angiogenesis, which may lead to anti-tumor activity (PMID: 22773903).', 'references': [{'id': 4967, 'pubMedId': 22773903, 'title': 'Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22773903'}]}]",PI-88,2016-03-22T18:00:57Z
0,2016-03-18T19:32:28Z,3783,"[{'description': 'Piceatannol inhibits SYK, resulting in decreased downstream signaling, and potentially leading to reduced tumor cell proliferation and viability (PMID: 7961959, PMID: 26251761).', 'references': [{'id': 4933, 'pubMedId': 26251761, 'title': 'Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26251761'}, {'id': 4935, 'pubMedId': 7961959, 'title': 'Inhibition of mast cell Fc epsilon R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/7961959'}]}]",Piceatannol,2016-03-18T19:32:28Z
0,2015-12-28T19:23:26Z,3338,"[{'description': 'Pidilizumab is a PD-1 human monoclonal antibody, which results in the activation of T-cells and cell-mediated immune responses against tumor cells (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Pidilizumab,2016-01-28T02:23:40Z
0,2014-03-12T15:53:16Z,871,"[{'description': 'Pimasertib (MSC1936369B) binds to and inhibits MEK1/2, preventing activation of downstream targets and potentially reducing tumor cell proliferation (PMID: 23587417).', 'references': [{'id': 1838, 'pubMedId': 23587417, 'title': 'MEK and the inhibitors: from bench to bedside.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23587417'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Pimasertib,2017-04-06T10:10:23Z
0,2014-10-24T03:25:02Z,1660,[],Pimasertib + BEZ235,2014-10-24T03:25:02Z
0,2016-02-12T08:32:38Z,3526,[],Pimasertib + Gemcitabine,2016-02-12T08:32:38Z
0,2016-09-07T13:14:28Z,4657,[],Pimasertib + Regorafenib,2016-09-07T13:14:28Z
0,2014-10-24T03:24:08Z,1659,[],Pimasertib + Sorafenib,2014-10-24T03:24:08Z
0,2016-02-03T15:30:13Z,3499,[],Pimozide,2016-02-03T15:30:13Z
0,2016-07-01T20:30:05Z,4414,"[{'description': 'Pinatuzumab Vedotin is an antibody drug conjugate (ADC) comprising a monoclonal antibody against CD22 attached to the drug monomethyl auristatin E, potentially resulting in increased death of CD22-positive tumor cells (PMID: 25708834).', 'references': [{'id': 6362, 'pubMedId': 25708834, 'title': 'Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25708834'}, {'id': 6184, 'pubMedId': None, 'title': 'Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma', 'url': 'http://www.bloodjournal.org/content/124/21/4457.abstract?sso-checked=true'}]}]",Pinatuzumab Vedotin,2016-07-22T18:59:10Z
0,2015-10-15T01:03:46Z,3125,[],Pioglitazone,2015-10-15T01:03:46Z
0,2015-11-14T23:58:12Z,3207,"[{'description': 'Pipendoxifene (ERA-923) is a selective estrogen receptor modulator, which potently inhibits estrogen binding to Esr1 (ER alpha) in breast cancer cells (PMID: 11595711).', 'references': [{'id': 3923, 'pubMedId': 11595711, 'title': 'A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11595711'}]}]",pipendoxifene,2015-12-17T15:28:04Z
0,2015-11-15T20:34:03Z,3208,[],pipendoxifene + palbociclib,2015-11-15T20:34:03Z
0,2015-07-14T00:29:32Z,2908,"[{'description': 'Pirotinib (KBP-5209) inhibits EGFR, ERBB2 (HER2), and ERBB4 (HER4), potentially resulting in decreased tumor growth (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Pirotinib,2015-07-14T00:29:32Z
0,2015-04-15T20:34:07Z,2541,"[{'description': 'PJ34 is a small molecule that inhibits PARP, potentially resulting in increased tumor cell death (PMID: 25531448).', 'references': [{'id': 2485, 'pubMedId': 25531448, 'title': 'PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25531448'}]}]",PJ34,2017-05-11T13:59:40Z
0,2017-06-07T15:36:46Z,5862,"[{'description': 'PK11007 stabilizes and reactivates mutant Tp53, which induces cell death in tumor cells (PMID: 27551077).', 'references': [{'id': 9084, 'pubMedId': 27551077, 'title': '2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27551077'}]}]",PK11007,2017-06-07T15:36:46Z
0,2015-02-17T23:41:58Z,2081,"[{'description': 'PKF115-584 inhibits the interaction of CTNNB1 with TCF7L2 to block Wnt signaling and promote apoptosis (PMID: 20360943).', 'references': [{'id': 1913, 'pubMedId': 20360943, 'title': 'Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20360943'}]}]",PKF115-584,2015-02-17T23:41:58Z
0,2015-03-16T14:01:31Z,2397,"[{'description': 'PKF118-310 inhibits KDM4A activity (PMID: 27767379) and the CTNNB1/TCF interaction, which results in apoptosis and anti-tumor activity (PMID: 19662654).', 'references': [{'id': 2208, 'pubMedId': 19662654, 'title': 'Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19662654'}]}]",PKF118-310,2017-08-23T18:53:31Z
0,2014-03-12T15:53:16Z,872,"[{'description': 'PKI-179 is a dual PI3K/mTORC1/2 inhibitor, and inhibits the PI3K/mTOR signaling pathway, thereby inducing apoptosis and inhibiting tumor growth (PMID: 20797855).', 'references': [{'id': 1040, 'pubMedId': 20797855, 'title': 'PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20797855'}, {'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}]}]",PKI-179,2017-04-28T18:38:25Z
0,2016-03-28T18:53:20Z,3857,"[{'description': 'PKI-402 is a dual ATP-competitive mTOR/PI3K inhibitor, which leads to reduced downstream signaling, potentially resulting in decreased tumor growth (PMID: 20371716).', 'references': [{'id': 5041, 'pubMedId': 20371716, 'title': 'Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20371716'}]}]",PKI-402,2016-03-28T18:53:20Z
0,2014-12-01T19:50:01Z,1756,"[{'description': 'Mozobil (plerixafor) inhibits CXCR4 and CXCL12-mediated cell signaling to influence tumor metastasis (PMID: 19641136, PMID: 16815309). ', 'references': [{'id': 1227, 'pubMedId': 16815309, 'title': 'Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16815309'}, {'id': 1226, 'pubMedId': 19641136, 'title': 'Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19641136'}]}]",Plerixafor,2015-06-25T20:57:54Z
0,2014-12-05T05:22:56Z,1770,[],Plerixafor + Decitabine,2014-12-05T05:22:56Z
0,2016-03-04T21:03:10Z,3678,"[{'description': 'Plinabulin is a diketopiperazine derivative that disrupts microtubule organization, leading to cell cycle arrest in tumor cells and collapse of tumor vasculature (PMID: 16317287).', 'references': [{'id': 4775, 'pubMedId': 16317287, 'title': 'NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16317287'}]}]",Plinabulin,2016-03-11T18:59:43Z
0,2015-05-15T02:25:10Z,2693,"[{'description': 'PLS-123 is a selective irreversible inhibitor of BTK, which promotes apoptosis and inhibits proliferation of tumor cells (PMID: 25944695).', 'references': [{'id': 2733, 'pubMedId': 25944695, 'title': 'Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25944695'}]}]",PLS-123,2015-05-15T02:25:10Z
0,2017-10-17T17:44:41Z,6324,"[{'description': 'Limited information is currently available on PLX2853 (Oct 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",PLX2853,2017-10-17T17:44:41Z
0,2014-03-12T15:53:16Z,874,"[{'description': 'PLX3397 (pexidartinib) inhibits multiple receptor tyrosine kinases, including KIT, CSF1R, FLT3, and FLT3/ITD, which may inhibit growth in cancer cells (PMID: 22294205, PMID: 25993548, PMID: 25847190).', 'references': [{'id': 3025, 'pubMedId': 22294205, 'title': 'Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22294205'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 3026, 'pubMedId': 25993548, 'title': 'Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25993548'}, {'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]}]",PLX3397,2017-05-23T01:39:55Z
0,2014-08-06T14:45:30Z,1395,[],PLX3397 + Paclitaxel,2014-08-06T14:45:30Z
0,2015-10-28T00:52:15Z,3155,[],PLX3397 + Sirolimus,2015-10-28T00:52:15Z
0,2014-08-01T02:24:56Z,1339,[],PLX3397 + Vemurafenib,2014-08-01T02:24:56Z
0,2014-01-28T20:53:17Z,340,[],PLX4032,
0,2014-05-20T17:55:12Z,1060,"[{'description': 'PLX4720 is a 7-azaindole derivative and RAF kinase inhibitor with greater affinity for BRAF V600E than BRAF wild-type (PMID: 18287029).', 'references': [{'id': 291, 'pubMedId': 18287029, 'title': 'Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18287029'}]}]",PLX4720,2014-12-22T13:53:34Z
0,2016-12-21T18:22:41Z,5122,[],PLX4720 + Doxorubicin,2016-12-21T18:22:41Z
0,2015-07-28T00:29:35Z,2960,[],PLX4720 + Navitoclax,2015-07-28T00:29:35Z
0,2016-10-05T19:25:41Z,4788,[],PLX4720 + SGX523,2016-10-05T19:25:41Z
0,2016-08-25T16:20:02Z,4607,[],PLX4720 + TAK-632,2016-08-25T16:20:02Z
0,2016-03-10T13:29:14Z,3700,[],PLX4720 + Tivozanib,2016-03-10T13:29:14Z
0,2016-12-21T18:21:47Z,5121,[],PLX4720 + Vorinostat,2016-12-21T18:21:47Z
0,2016-06-20T16:51:29Z,4332,"[{'description': 'Limited information is currently available on PLX73086 (Jun 2016). ', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",PLX73086,2016-06-20T16:51:29Z
0,2015-05-11T19:39:11Z,2651,"[{'description': 'PLX7486 binds to and inhibits CSF1R, TRKA, TRKB, and TRKC, which potentially results in decreased tumor cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",PLX7486,2015-06-18T17:15:11Z
0,2017-04-21T14:49:48Z,5566,[],PLX7486 + unspecified CTLA4 antibody,2017-04-21T14:49:48Z
0,2017-04-21T14:51:04Z,5567,[],PLX7486 + unspecified PD-1 antibody,2017-04-21T14:51:19Z
0,2016-08-23T17:10:11Z,4606,"[{'description': 'PLX7904 is a small molecule inhibitor that preferentially inhibits BRAF V600E over wild-type BRAF and CRAF without activating MAPK signaling, therefore leads to growth inhibition in tumor cells (PMID: 26466569).', 'references': [{'id': 6521, 'pubMedId': 26466569, 'title': 'RAF inhibitors that evade paradoxical MAPK pathway activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26466569'}]}]",PLX7904,2016-08-23T17:10:11Z
0,2014-05-14T14:52:46Z,1041,"[{'description': 'PLX8394 is a RAF inhibitor that inhibits wild-type and mutant BRAF, as well as CRAF, and does not paradoxically activate MAPK signaling, potentially resulting in decreased proliferation of BRAF-mutant tumor cells (PMID: 26466569, PMID: 24283590).', 'references': [{'id': 1371, 'pubMedId': 24283590, 'title': 'Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24283590'}, {'id': 10004, 'pubMedId': 28659148, 'title': 'PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28659148'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 6521, 'pubMedId': 26466569, 'title': 'RAF inhibitors that evade paradoxical MAPK pathway activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26466569'}]}]",PLX8394,2017-09-26T20:56:57Z
0,2015-04-29T01:53:14Z,2602,"[{'description': 'PLX9486 is an inhibitor of specific c-Kit mutants, which may lead to growth inhibition in tumor cells expressing mutant c-Kit (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",PLX9486,2015-05-12T14:59:56Z
0,2014-09-11T19:44:47Z,1459,"[{'description': 'PM060184 is an anti-tubulin, which also binds to the minor groove of DNA, which may cause delayed progression through S-phase, premature cell cycle arrest, and cell death (NCI Drug Dictionary; PMID: 24486569).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 748, 'pubMedId': 24486569, 'title': 'PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24486569'}]}]",PM060184,2014-09-18T09:35:49Z
0,2016-01-07T11:04:45Z,3370,"[{'description': 'PMED-1 inhibits Ctnnb1 and CBP interactions to decrease Wnt signalling thereby inhibiting cell proliferation (PMID:  24819961).', 'references': [{'id': 4232, 'pubMedId': 24819961, 'title': 'Identification and characterization of a novel small-molecule inhibitor of β-catenin signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24819961'}]}]",PMED-1,2016-01-07T11:04:45Z
0,2015-04-24T05:41:14Z,2581,"[{'description': 'PNT2258 is an oligonucleotide that binds to DNA upstream of BCL-2 and prevents its transcription, potentially resulting in increased tumor cell apoptosis (PMID: 24832107).', 'references': [{'id': 2567, 'pubMedId': 24832107, 'title': 'Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24832107'}]}]",PNT2258,2015-12-10T16:53:03Z
0,2015-03-23T18:41:18Z,2454,"[{'description': 'PNU-74654 inhibits the interaction of CTNNB1 with TCF7L2 to block Wnt signaling thereby preventing transcription of downstream target genes (PMID: 21565795). ', 'references': [{'id': 2298, 'pubMedId': 21565795, 'title': 'Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21565795'}]}]",PNU-74654,2015-03-23T18:41:18Z
0,2016-04-08T03:17:11Z,3914,"[{'description': 'POL5551 is an antagonist of CXCR4, which may lead to decreased tumor cell migration and increased sensitivity to chemotherapeutic agents (PMID: 26269605).', 'references': [{'id': 5132, 'pubMedId': 26269605, 'title': 'CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26269605'}]}]",POL5551,2016-04-08T03:17:11Z
0,2016-04-08T03:38:15Z,3915,[],POL5551 + Eribulin,2016-04-08T03:38:15Z
0,2015-06-18T21:17:51Z,2854,"[{'description': 'POL6326 binds to CXCR4 and inhibits SDF-1 (CXCL12) binding, potentially resulting in increased mobilization of hematopoietic cells (NCI Drug Dictionary). \r\n', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",POL6326 ,2017-06-09T15:53:01Z
0,2016-06-03T02:50:24Z,4226,"[{'description': 'Polatuzumab Vedotin is a monoclonal antibody against B-cell antigen receptor complex-associated protein beta chain (CD79B) linked to monomethyl auristatin E (MMAE), which may deliver the cytotoxic MMAE to tumor cells over expressing CD798 (PMID: 26194424).', 'references': [{'id': 5726, 'pubMedId': 26194424, 'title': 'Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26194424'}]}]",Polatuzumab Vedotin,2016-06-03T18:45:42Z
0,2016-07-01T20:32:25Z,4416,[],Polatuzumab Vedotin + Pinatuzumab Vedotin + Rituximab,2016-07-01T20:32:25Z
0,2016-03-18T20:06:28Z,3786,"[{'description': 'Poloxin is a small molecule inhibitor of PLK1 that specifically targets the polo-box domain, resulting in interruption of mitotic function and apoptotic activity (PMID: 21839059).', 'references': [{'id': 4937, 'pubMedId': 21839059, 'title': 'Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21839059'}]}]",Poloxin,2016-03-18T20:06:28Z
0,2016-07-29T20:04:37Z,4508,"[{'description': 'Poloxin-2, an analog of Poloxin, is a small molecule inhibitor of PLK1, which may result in apoptotic activity and induction of cell-cycle arrest (PMID: 26279064). ', 'references': [{'id': 6403, 'pubMedId': 26279064, 'title': 'Optimized Plk1 PBD Inhibitors Based on Poloxin Induce Mitotic Arrest and Apoptosis in Tumor Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26279064'}]}]",Poloxin-2,2016-07-29T20:04:37Z
0,2015-04-28T21:41:09Z,2595,"[{'description': 'Hiltonol (poly ICLC) is a synthetic double stranded RNA complex, which induces interferon production and stimulates anti-tumor immune response (PMID: 22126373).', 'references': [{'id': 2595, 'pubMedId': 22126373, 'title': 'Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22126373'}]}]",poly ICLC  ,2015-05-19T13:36:23Z
0,2014-09-26T02:13:45Z,1557,"[{'description': 'Krestin (polysaccharide-K) is a mushroom-derived immunomodulator that has been demonstrated to reduce immunosuppression and enhance anti-tumor immunity. Krestin has also been shown to reduce proliferation and induce apoptosis in tumor cells (PMID: 22139128). ', 'references': [{'id': 844, 'pubMedId': 22139128, 'title': 'Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN(®)): review of development and future perspectives.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22139128'}]}]",Polysaccharide-K,2014-09-26T02:13:45Z
0,2014-10-07T20:09:58Z,1622,"[{'description': 'Pomalyst (pomalidomide) is a thalidomide derivative that may act to inhibit production of TNF-a, increase T-cell and NK cell activity, increase antibody-dependent cellular toxicity, as well as inhibit angiogenesis and promote cell-cycle arrest in tumors (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Pomalidomide,2014-10-07T20:17:41Z
0,2016-01-11T11:44:21Z,3399,[],Pomalidomide + ACY-241,2016-01-11T11:44:21Z
0,2015-03-06T13:52:27Z,2312,[],Pomalidomide + Everolimus + Dexamethasone,2015-03-06T13:52:27Z
0,2017-08-03T16:26:32Z,6081,[],Pomalidomide + SJB3-019A,2017-08-03T16:26:32Z
0,2017-06-12T15:36:08Z,5875,[],Pomalidomide + TEW 7197,2017-06-12T15:36:08Z
0,2014-03-12T15:53:16Z,877,"[{'description': 'Iclusig (ponatinib) inhibits the Bcr-Abl fusion, and other tyrosine kinases, such as RET, DDR, VEGFR, FGFR, KIT, and FLT3 (PMID: 23526464, PMID: 25284748). Iclusig (ponatinib) is FDA approved for chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph positive ALL) as well as ABL1 T315I CML and ABL1 T315 Ph positive ALL (FDA.gov).  ', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 312, 'pubMedId': 23526464, 'title': 'Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23526464'}]}]",Ponatinib,2017-07-18T13:26:17Z
0,2016-03-16T16:44:08Z,3758,[],Ponatinib + Saracatinib,2016-03-16T16:44:08Z
0,2016-07-19T17:55:33Z,4477,[],Ponatinib + Trametinib,2016-07-19T17:55:33Z
0,2016-10-27T17:13:26Z,4869,[],Ponatinib + Venetoclax,2016-10-27T17:13:26Z
0,2015-02-11T16:27:32Z,2049,[],Ponatinib + Vincristine,2015-02-11T16:27:32Z
0,2016-05-12T14:35:42Z,4108,[],Posaconazole,2016-05-12T14:35:42Z
0,2016-05-12T20:14:36Z,4114,[],Posaconazole + Vismodegib,2016-05-12T20:14:36Z
0,2014-05-14T14:52:46Z,1042,"[{'description': 'Poziotinib (HM781-36B) is a pan-ErbB inhibitor that inhibits EGFR (HER1), ERBB2 (HER2) and ERBB4 (HER4), thereby reducing proliferation of tumor cells that overexpress these receptors (PMID: 21306821).', 'references': [{'id': 2314, 'pubMedId': 21306821, 'title': 'Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21306821'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",poziotinib,2015-07-02T18:26:24Z
0,2015-03-02T20:14:46Z,2251,"[{'description': 'PP-121 inhibits several types of kinases including, PDGFR, Hck, mTOR, KDR (VEGFR2), Src and Abl to prevent cell proliferation (PMID: 24867098).', 'references': [{'id': 2072, 'pubMedId': 24867098, 'title': 'PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24867098'}]}]",PP-121,2015-04-03T00:31:48Z
0,2015-03-02T18:55:49Z,2241,"[{'description': 'PP30 inhibits mTOR signaling through mTORC1 and mTORC2, thereby preventing cell proliferation (PMID: 19209957).', 'references': [{'id': 2064, 'pubMedId': 19209957, 'title': 'Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19209957'}]}]",PP30,2016-04-01T16:38:12Z
0,2015-05-29T04:25:25Z,2744,"[{'description': 'PQ401 inhibits IGF-1R, potentially leading to decreased tumor cell growth (PMID: 16648580).', 'references': [{'id': 2858, 'pubMedId': 16648580, 'title': 'Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16648580'}]}]",PQ401,2015-05-29T04:25:25Z
0,2015-02-07T12:52:02Z,2019,"[{'description': 'PQR309 is a dual pan-PI3K and mTORC1/2 inhibitor, which blocks PI3K/mTOR signaling, potentially resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 4514).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 8761, 'pubMedId': None, 'title': 'Abstract 4514: PQR309: A potent, brain-penetrant, dual pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/4514.short'}]}]",PQR309,2017-04-28T19:06:12Z
0,2015-08-14T14:19:41Z,3029,"[{'description': 'PR-104 is a hypoxia-activated prodrug that causes DNA cross-linking within hypoxic regions of tumors, potentially providing antineoplastic activity (PMID: 17606726).', 'references': [{'id': 3470, 'pubMedId': 17606726, 'title': 'Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17606726'}]}]",PR-104,2015-08-14T14:19:41Z
0,2014-05-14T14:52:46Z,1043,"[{'description': 'PR610 is a prodrug that is converted to a pan-HER inhibitor in hypoxic tumor conditions, thus inhibiting cellular proliferation and differentiation of tumor cells overexpressing HER kinases and potentially sparing healthy normal tissue (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",PR610,2015-02-09T16:05:13Z
0,2014-12-04T22:41:10Z,1758,"[{'description': 'Pracinostat (SB939) is a histone deacetylase (HDAC) inhibitor, with limited activity against HDAC6, which may reduce tumor cell proliferation and tumor growth (PMID: 20197387).', 'references': [{'id': 8261, 'pubMedId': 20197387, 'title': 'SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20197387'}]}]",Pracinostat,2017-03-17T04:17:08Z
0,2014-07-31T21:14:15Z,1327,"[{'description': 'Pralatrexate is folate analogue inhibitor of dihydrofolate reductase that is selective for cells expressing RFC-1 (which may be overexpressed on cancer cells). Pralatrexate causes depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Pralatrexate,2017-06-19T19:20:14Z
0,2015-11-08T22:04:07Z,3190,[],Pravastatin,2015-11-08T22:04:07Z
0,2017-01-09T16:21:28Z,5168,[],Prednisolone,2017-01-09T16:21:28Z
0,2015-02-27T05:21:42Z,2188,"[{'description': 'Prednisone is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Prednisone,2015-02-27T05:25:29Z
0,2017-04-07T19:20:56Z,5518,"[{'description': 'Preladenant is a selective antagonist of the adenosine A2A receptor (PMID: 22676397, PMID 19109019).', 'references': [{'id': 8474, 'pubMedId': 22676397, 'title': 'Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22676397'}, {'id': 8473, 'pubMedId': 19109019, 'title': 'Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19109019'}]}]",Preladenant,2017-04-07T19:20:56Z
0,2014-10-14T20:32:32Z,1651,"[{'description': 'Prexasertib (LY2606368) inhibits checkpoint kinase 1 (Chk1), which may result in accumulation of DNA damage and decreased tumor grwoth (PMID: 26141948, PMID: 28270495).', 'references': [{'id': 6628, 'pubMedId': 26141948, 'title': 'LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26141948'}, {'id': 9764, 'pubMedId': 28270495, 'title': 'The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28270495'}]}]",Prexasertib,2017-08-22T19:19:38Z
0,2016-08-20T01:40:40Z,4587,[],Prexasertib + Ralimetinib,2017-08-22T19:06:29Z
0,2014-07-02T18:45:41Z,1083,"[{'description': 'PRI-724 is a Wnt signaling pathway inhibitor which antagonistically inhibits the recruiting of beta-catenin with its coactivator CBP, thereby inhibiting tumor growth (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Pri-724,2015-09-11T16:58:53Z
0,2016-09-02T15:57:34Z,4645,"[{'description': 'PRN1109 is a pan-FGFR inhibitor that blocks FGF/FGFR signaling, leading to anti-tumor activities (Eu J Cancer 2014 Vol 50, Suppl 6:157).', 'references': [{'id': 4638, 'pubMedId': None, 'title': 'Irreversible Covalent Pan-FGFR Inhibitors are Highly Efficacious Against FGFR-dependent Cancers', 'url': 'http://www.ejcancer.com/article/S0959-8049%2814%2970609-4/pdf'}]}]",PRN1109,2016-09-02T15:57:34Z
0,2016-02-19T20:36:13Z,3583,"[{'description': 'PRN1371 is an irreversible inhibitor of FGFR1-4 that blocks FGFR signaling, leading to apoptosis and tumor regression in animal models (Eu J Cancer 2014 Vol 50, Suppl 6:157).', 'references': [{'id': 4638, 'pubMedId': None, 'title': 'Irreversible Covalent Pan-FGFR Inhibitors are Highly Efficacious Against FGFR-dependent Cancers', 'url': 'http://www.ejcancer.com/article/S0959-8049%2814%2970609-4/pdf'}]}]",PRN1371,2016-02-19T20:36:13Z
0,2016-04-13T17:20:25Z,3925,"[{'description': 'Prodigiosin is a small molecule that restores Tp53 function through activation of Tp73, resulting in tumor suppression (PMID: 24247721).', 'references': [{'id': 5149, 'pubMedId': 24247721, 'title': 'Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24247721'}]}]",Prodigiosin,2017-05-02T13:34:15Z
0,2015-01-05T16:35:02Z,1912,[],Propranolol,2015-01-05T16:35:02Z
0,2015-08-28T02:25:24Z,3069,"[{'description': 'PROSTVAC-F/TRICOM  is a cancer vaccine consists of a recombinant fowlpox virus encoding PSA and TRICOM (a combination of B7.1, ICAM-1, and LFA-3) which induces antitumor immune response against PSA-positive tumors (PMID: 16390546).', 'references': [{'id': 3567, 'pubMedId': 16390546, 'title': 'A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16390546'}]}]",PROSTVAC-F/TRICOM ,2015-08-28T02:25:24Z
0,2016-11-01T01:33:23Z,4892,[],PROSTVAC-V/F,2016-11-01T01:33:23Z
0,2016-11-01T01:38:57Z,4895,[],PROSTVAC-V/F + Ipilimumab,2016-11-01T01:38:57Z
0,2016-11-01T01:37:37Z,4894,[],PROSTVAC-V/F + Nivolumab,2016-11-01T01:37:37Z
0,2016-11-01T01:36:26Z,4893,[],PROSTVAC-V/F + Nivolumab + Ipilimumab,2016-11-01T01:36:26Z
0,2016-10-30T00:57:08Z,4877,"[{'description': 'PROSTVAC-V/TRICOM  is a cancer vaccine consists of a recombinant vaccinia virus encoding PSA and TRICOM (a combination of B7.1, ICAM-1, and LFA-3) which induces antitumor immune response against PSA-positive tumors (PMID: 16390546).', 'references': [{'id': 3567, 'pubMedId': 16390546, 'title': 'A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16390546'}]}]",PROSTVAC-V/TRICOM,2016-10-30T17:31:34Z
0,2016-10-30T01:01:58Z,4880,[],PROSTVAC-V/TRICOM + Ipilimumab,2016-10-30T17:33:05Z
0,2016-10-30T01:01:01Z,4879,[],PROSTVAC-V/TRICOM + Nivolumab,2016-10-30T17:32:36Z
0,2016-10-30T00:58:38Z,4878,[],PROSTVAC-V/TRICOM + Nivolumab + Ipilimumab,2016-10-30T17:32:12Z
0,2016-03-18T17:59:20Z,3781,"[{'description': 'PRT062607 is a selective inhibitor of SYK, which may lead to decreased tumor cell growth and increased sensitivity to chemotherapeutics (PMID: 23220742).', 'references': [{'id': 4930, 'pubMedId': 23220742, 'title': 'The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220742'}]}]",PRT062607,2016-03-18T17:59:20Z
0,2016-03-18T19:37:29Z,3785,"[{'description': 'PRT318 is a selective inhibitor of SYK, which leads to decreased B-cell receptor signaling and decreased tumor cell viability (PMID: 22362000).', 'references': [{'id': 4936, 'pubMedId': 22362000, 'title': 'Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22362000'}]}]",PRT318,2016-03-18T19:38:26Z
0,2017-04-11T19:19:22Z,5527,"[{'description': 'PRX177561 is a CXCR4 antagonist, which may decrease tumor growth in combination with other agents (PMID: 28057017).', 'references': [{'id': 8533, 'pubMedId': 28057017, 'title': 'The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28057017'}]}]",PRX177561,2017-04-11T19:19:22Z
0,2017-04-11T19:27:37Z,5529,[],PRX177561 + Sunitinib,2017-04-11T19:27:37Z
0,2017-05-31T14:53:31Z,5820,"[{'description': 'Limited information is currently available on PT 2977, a putative HIF-2a inhibitor (May 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",PT 2977,2017-09-28T10:47:59Z
0,2015-07-14T02:56:14Z,2920,"[{'description': 'PT-112 is a phosphoplatin that may result in decreased tumor cell growth (PMID: 19020081).', 'references': [{'id': 3245, 'pubMedId': 19020081, 'title': 'Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19020081'}]}]",PT-112,2015-08-10T15:51:51Z
0,2016-05-26T18:17:13Z,4146,"[{'description': 'PT2385 is a hypoxia inducible factor (HIF)-2alpha inhibitor that suppresses HIF-2alpha downstream gene expression, resulting in anti-tumor activity (J Clin Oncol 34, 2016 (suppl; abstr 2506)).', 'references': []}]",PT2385,2016-05-26T18:17:13Z
0,2016-06-23T13:59:54Z,4347,[],PT2385 + Nivolumab,2016-06-23T13:59:54Z
0,2016-09-08T19:48:07Z,4670,"[{'description': 'PT2399 is a small molecule that inhibits Hif2-alpha, resulting in decreased downstream signaling and potentially leading to reduced growth of tumors with defective VHL (PMID: 27595393).', 'references': [{'id': 6586, 'pubMedId': 27595393, 'title': 'On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27595393'}]}]",PT2399,2016-09-08T19:52:04Z
0,2015-07-20T18:47:36Z,2939,"[{'description': 'PTC299 binds VEGF mRNA to prevent translation and protein synthesis, which may inhibit migration, proliferation, and survival in cancer cells (NCI Drug Dictionary).  ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",PTC299,2015-07-27T17:37:10Z
0,2017-03-06T20:02:02Z,5407,"[{'description': 'PTC596 is a small molecule inhibitor of BMI-1, which may result in mitochondrial induced apoptosis in cancer cells (PMID: 28211885). ', 'references': [{'id': 8142, 'pubMedId': 28211885, 'title': 'The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28211885'}]}]",PTC596,2017-03-06T20:02:02Z
0,2016-06-17T18:44:11Z,4297,"[{'description': 'pTVG-AR  is a DNA vaccine encoding the ligand binding domain of the androgen receptor (AR) that stimulates immune response against AR-expressiong prostate cancer cells (PMID: 23108626).', 'references': [{'id': 5963, 'pubMedId': 23108626, 'title': 'The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23108626'}]}]",pTVG-AR ,2016-06-17T18:44:11Z
0,2015-05-15T14:08:43Z,2698,"[{'description': 'pTVG-HP plasmid DNA vaccine contains human prostatic acid phosphatase (PAP)-encoding plasmid DNA, which induces cytotoxic immune response towards tumor cells expressing PAP (PMID: 17102977).', 'references': [{'id': 2740, 'pubMedId': 17102977, 'title': 'Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17102977'}]}]",pTVG-HP plasmid DNA vaccine,2015-06-26T02:49:05Z
0,2014-07-28T16:39:16Z,1162,"[{'description': 'PU-H71 specifically inhibits active Heat shock protein 90 (Hsp90), preventing its chaperone function and promoting the proteasomal degradation of oncogenic proteins (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",PU-H71,2015-06-03T19:00:42Z
0,2017-05-28T02:18:44Z,5796,[],PU-H71 + nab-paclitaxel,2017-05-28T02:18:44Z
0,2017-05-31T15:20:13Z,5822,"[{'description': 'pUMVC3-hIGFBP-2 vaccine is a DNA vaccine engineered to encode human insulin-like growth factor-binding protein 2 (hIGFBP-2) epitopes, which may stimulate anti-tumor immunity (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",pUMVC3-hIGFBP-2 vaccine,2017-05-31T15:20:13Z
0,2015-05-20T19:34:14Z,2724,"[{'description': 'Purvalanol A inhibits CDC2, CDK2, and CDK4, which may promote cell cycle arrest and induction of apoptosis in cancer cells (PMID: 9677190, PMID: 24190492).', 'references': [{'id': 2791, 'pubMedId': 24190492, 'title': 'Purvalanol A is a strong apoptotic inducer via activating polyamine catabolic pathway in MCF-7 estrogen receptor positive breast cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24190492'}, {'id': 2790, 'pubMedId': 9677190, 'title': 'Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/9677190'}]}]",Purvalanol A,2015-05-20T19:43:29Z
0,2014-03-12T15:53:16Z,879,[],PV-10,
0,2015-04-10T17:39:40Z,2532,"[{'description': 'PV1019 is a ATP-competitive inhibitor of CHK2, which leads to reduced CHK2 kinase activity and decreased tumor cell growth (PMID: 19741151).', 'references': [{'id': 2452, 'pubMedId': 19741151, 'title': 'Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19741151'}]}]",PV1019,2015-04-10T17:39:40Z
0,2016-02-26T16:58:20Z,3631,"[{'description': 'PV1162 is a selective inhibitor of Chk2, which may result in chromosome instability in tumor cells (PMID: 21907711, PMID: 26837770).', 'references': [{'id': 4710, 'pubMedId': 21907711, 'title': 'X-ray structures of checkpoint kinase 2 in complex with inhibitors that target its gatekeeper-dependent hydrophobic pocket.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21907711'}, {'id': 4711, 'pubMedId': 26837770, 'title': 'Effects of Anticancer Drugs on Chromosome Instability and New Clinical Implications for Tumor-Suppressing Therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26837770'}]}]",PV1162,2016-02-26T16:58:20Z
0,2016-07-18T01:27:21Z,4465,"[{'description': 'PVX-410 is a multipeptide vaccine that may stimulate anti-tumor immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",PVX-410,2016-07-18T01:27:21Z
0,2016-12-13T04:08:43Z,5082,[],PVX-410 + MEDI4736,2016-12-13T04:08:43Z
0,2016-12-13T04:06:57Z,5081,[],PVX-410 + MEDI4736 + lenalidomide,2016-12-13T04:07:34Z
0,2015-07-29T18:47:17Z,2961,"[{'description': 'PW12 inhibits PIK3CA, preventing the activation of the PI3K signaling pathway and potentially inhibiting tumor cell proliferation (PMID: 19033389).', 'references': [{'id': 3346, 'pubMedId': 19033389, 'title': 'Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19033389'}]}]",PW12,2015-09-11T15:51:52Z
0,2014-03-12T15:53:16Z,880,"[{'description': 'PWT33597 is a dual PIK3CA and mTOR inhibitor, which may induce apoptosis in cells with activated PI3K or mTOR pathways (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",PWT33597,2016-04-01T16:39:02Z
0,2016-09-12T20:55:41Z,4695,"[{'description': 'PX-12 inhibits thioredoxin-1 (Trx-1), potentially resulting in decreased growth and migration of tumor cells (PMID: 22711542, PMID: 25483731).', 'references': [{'id': 6600, 'pubMedId': 25483731, 'title': 'Thioredoxin-1 inhibitor, 1-methylpropyl 2-imidazolyl disulfide, inhibits the growth, migration and invasion of colorectal cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25483731'}, {'id': 6599, 'pubMedId': 22711542, 'title': 'A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22711542'}]}]",PX-12,2016-09-12T20:55:41Z
0,2014-03-12T15:53:16Z,881,"[{'description': 'Oncothyreon (PX-866) is a PI3K inhibitor, which inhibits the activation of the PI3K/Akt signaling pathway, thereby inhibiting cancer cell motility and growth (PMID: 17766839).', 'references': [{'id': 1075, 'pubMedId': 15252137, 'title': 'Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15252137'}, {'id': 1076, 'pubMedId': 17766839, 'title': 'The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17766839'}]}]",PX-866,2017-04-28T19:19:26Z
0,2016-07-26T19:45:20Z,4494,[],PX-866 + Sorafenib,2016-07-26T19:45:40Z
0,2016-08-18T01:38:11Z,4582,"[{'description': 'Pyr1 inhibits LIM kinase (LIMK), potentially resulting in decreased tumor cell proliferation and tumor growth (PMID: 27216191).', 'references': [{'id': 6500, 'pubMedId': 27216191, 'title': 'LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27216191'}]}]",Pyr1,2016-08-18T01:38:11Z
0,2015-06-04T17:38:47Z,2797,"[{'description': 'Pyridone 6 (CMP6) is an ATP-competitive inhibitor of JAK1, 2, 3 and TYK2, which inhibits growth of cancer cells (PMID: 17018630).', 'references': [{'id': 2965, 'pubMedId': 17018630, 'title': 'Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17018630'}]}]",Pyridone 6,2015-06-08T17:26:02Z
0,2015-12-11T03:00:13Z,3277,[],Pyridoxine,2015-12-11T03:00:13Z
0,2015-09-18T02:34:48Z,3082,"[{'description': 'Pyrotinib inhibits EGFR and ERBB2 (HER2), potentially resulting in decreased growth of EGFR and/or HER2-positive tumors (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Pyrotinib,2015-09-18T03:02:16Z
0,2015-03-16T18:40:05Z,2412,"[{'description': 'Pyrvinium activates CK1-alpha, which leads to CTNNB1 degradation and inhibition of Wnt signaling thereby inducing apoptosis (PMID: 20890287).', 'references': [{'id': 2226, 'pubMedId': 20890287, 'title': 'Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20890287'}]}]",Pyrvinium,2015-03-16T18:40:05Z
0,2016-05-06T23:16:42Z,4089,"[{'description': 'Pz-1 is an inhibitor with activity against Ret and Kdr, which may result in tumor growth inhibition (PMID: 26126987).', 'references': [{'id': 5385, 'pubMedId': 26126987, 'title': 'Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26126987'}]}]",Pz-1,2017-04-03T14:51:15Z
0,2016-04-22T19:22:15Z,4000,"[{'description': 'QbG10 is a Toll-like receptor 9 (TLR-9) agonist that may enhance the TH1-mediated immune response (PMID: 23384679).', 'references': [{'id': 5213, 'pubMedId': 23384679, 'title': 'The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23384679'}]}]",QbG10,2016-05-11T13:21:49Z
0,2016-03-25T02:27:17Z,3832,"[{'description': 'QS11 is a small molecule inhibitor of ARF GTPase-activating protein 1 (ARFGAP1), which synergizes with Wnt to activate downstream beta-catenin signaling, potentially leading to decreased migration of ARFGAP1-expressing tumor cells (PMID: 26152429, PMID: 17460038).', 'references': [{'id': 5018, 'pubMedId': 26152429, 'title': 'Structure-activity relationship studies of QS11, a small molecule Wnt synergistic agonist.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26152429'}, {'id': 5019, 'pubMedId': 17460038, 'title': 'Small-molecule synergist of the Wnt/beta-catenin signaling pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17460038'}]}]",QS11,2016-03-25T02:27:17Z
0,2016-02-11T10:02:19Z,3508,"[{'description': 'Quarfloxin (CX-3543) stabilizes G-quadruplexes in the promoter region of MYC to prevent expression and induce apoptosis (PMID: 25332683).', 'references': [{'id': 4549, 'pubMedId': 25332683, 'title': 'Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25332683'}]}]",Quarfloxin,2016-02-11T10:02:19Z
0,2014-05-14T14:52:46Z,1044,"[{'description': 'Acrichine (quinacrine) inhibits the transcription and activity of NF-kappaB, which may result in the induction of tumor suppressor p53 transcription and tumor cell apoptosis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Quinacrine,2015-02-08T11:21:58Z
0,2014-11-12T03:32:47Z,1719,[],Quinacrine + 5-fluorouracil ,2014-11-12T03:32:47Z
0,2014-11-12T03:41:39Z,1720,[],Quinacrine + Sorafenib,2014-11-12T03:41:43Z
0,2015-08-10T17:01:24Z,3004,"[{'description': 'Quisinostat (JNJ-26481585) is a second-generation HDAC inhibitor, which increases histone acetlyation, and may increase tumor cell apoptosis and inhibit tumor growth (PMID: 24038993, PMID: 19861438).', 'references': [{'id': 3419, 'pubMedId': 24038993, 'title': 'Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24038993'}, {'id': 3420, 'pubMedId': 19861438, 'title': 'JNJ-26481585, a novel ""second-generation"" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19861438'}]}]",Quisinostat,2017-03-17T04:35:59Z
0,2014-03-12T15:53:16Z,882,"[{'description': 'Quizartinib (AC220) targets both wild-type and mutant FLT3 containing activating internal tandem duplications, as well as PDGFRA, RET, and KIT, which may induce apoptosis and inhibit tumor growth (PMID: 19654408, PMID: 23497317).', 'references': [{'id': 2613, 'pubMedId': 19654408, 'title': 'AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19654408'}]}]",Quizartinib,2017-04-03T17:40:16Z
0,2015-02-27T14:55:20Z,2195,[],R-CHOP,2015-02-27T14:55:20Z
0,2017-09-08T15:08:16Z,6177,[],R-CHP,2017-09-08T15:08:16Z
0,2016-01-10T23:08:14Z,3395,[],R-EPOCH,2016-01-10T23:08:14Z
0,2014-03-12T15:53:16Z,883,"[{'description': 'R1507 is a monoclonal antibody that targets IGF-1R, resulting in decreased tumor growth (PMID: 21875414).', 'references': [{'id': 2850, 'pubMedId': 21875414, 'title': 'Insulin-like growth factor: current concepts and new developments in cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21875414'}]}]",R1507,2015-06-02T13:15:59Z
0,2015-06-01T18:35:42Z,2756,"[{'description': 'R333 is a dual JAK/SYK inhibitor, which may prevent cell proliferation through inhibition of STAT3 signaling (Neuro Oncol, 2014:16, suppl 3: iii35).', 'references': [{'id': 2879, 'pubMedId': None, 'title': 'BRAIN TUMOUR INITIATING CELLS AND TARGETING STAT3 ONCOGENIC SIGNALLING IN GBM', 'url': 'http://neuro-oncology.oxfordjournals.org/content/16/suppl_3/iii35.2.abstract'}]}]",R333,2015-10-21T20:38:15Z
0,2014-09-17T19:38:37Z,1465,"[{'description': 'R3Mab is a monoclonal antibody, which specifically targets FGFR3 to block signaling and tumor growth (PMID: 23657946, PMID: 19381019)', 'references': [{'id': 741, 'pubMedId': 23657946, 'title': 'Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23657946'}, {'id': 742, 'pubMedId': 19381019, 'title': 'Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19381019'}]}]",R3Mab,2016-01-20T15:16:41Z
0,2016-03-18T19:19:45Z,3782,"[{'description': 'R406 inhibits SYK, resulting in decreased downstream signaling and and potentially leading to reduced tumor cell proliferation and viability (PMID: 16946104, PMID: 26251761).', 'references': [{'id': 4934, 'pubMedId': 16946104, 'title': 'R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16946104'}, {'id': 4933, 'pubMedId': 26251761, 'title': 'Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26251761'}]}]",R406,2016-03-18T19:32:51Z
0,2016-02-01T20:46:55Z,3497,"[{'description': 'R547 is a small molecule that selectively inhibits cyclin-dependent kinases, leading to cell cycle arrest and apoptosis in cancer cells (PMID: 17121911).', 'references': [{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]}]",R547,2016-02-09T12:06:19Z
0,2017-10-20T00:52:10Z,6339,"[{'description': 'R916562 is a small molecule that inhibits both Axl and Vegfr2, therefore results in synergistic inhibition of tumor angiogenesis and metastasis (PMID: 28711351).', 'references': [{'id': 10145, 'pubMedId': 28711351, 'title': 'Discovery of dual Axl/VEGF-R2 inhibitors as potential anti-angiogenic and anti-metastatic drugs for cancer chemotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28711351'}]}]",R916562,2017-10-20T00:52:10Z
0,2016-04-15T17:41:46Z,3942,"[{'description': 'rAd-hCD40L is a recombinant adenovirus vector expressing human CD40 ligand, which activates CD40 signaling and leads to apoptosis and growth inhibition in tumor cells (PMID: 19461675).', 'references': [{'id': 5165, 'pubMedId': 19461675, 'title': 'Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19461675'}]}]",rAd-hCD40L,2016-06-03T18:14:03Z
0,2014-10-29T16:06:26Z,1680,"[{'description': 'Gendicine (rAD-p53) is a replication-defective adenoviral vector encoding wild-type TP53, which induces tumor cells to produce wild-type Tp53 and potentially induce apoptosis. Gendicine may also stimulate a cytotoxic T-lymphocyte immune response against tumor cells, and activate natural killer cells (NCI Drug Dictionary).\r\n', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",rAD-p53,2015-06-03T19:15:55Z
0,2016-03-25T17:24:07Z,3841,[],Radiotherapy,2016-03-25T17:24:07Z
0,2016-10-06T19:12:20Z,4803,[],Radiotherapy + RO4929097 + Temozolomide,2016-10-06T19:12:20Z
0,2017-01-15T21:16:25Z,5202,[],Radiotherapy + Temozolomide + Pembrolizumab,2017-01-15T21:16:25Z
0,2016-03-31T12:52:05Z,3882,[],Radiotherapy + YU238259,2016-03-31T12:52:05Z
0,2015-02-02T21:30:16Z,2001,"[{'description': 'Radium Ra 223 dichloride is a radium-based radiopharmaceutical that targets bone via incorporation into bony matrix, and results in DNA double strand breaks and tumor regression in bone (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",radium Ra 223 dichloride,2015-02-02T21:30:16Z
0,2014-03-12T15:53:16Z,884,"[{'description': 'RAF265 inhibits the activities of several intracellular kinases, including BRAF(V600E), BRAF(wild type), c-RAF (RAF1), VEGF receptor 2 (VEGFR2/KDR), platelet-derived growth factor receptor (PDGFR), colony-stimulating factor (CSF)1R, RET and c-KIT, SRC, STE20, which may result in a reduction of tumor cell growth and proliferation, and tumor cell death (PMID: 22351689; NCI Drug Dictionary).', 'references': [{'id': 61, 'pubMedId': 22351689, 'title': 'RAF265 inhibits the growth of advanced human melanoma tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22351689'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",RAF265,2016-11-04T14:39:26Z
0,2016-10-05T20:23:57Z,4793,[],RAF265 + Selumetinib,2016-10-05T20:23:57Z
0,2014-03-12T15:53:16Z,885,[],Rafametinib,
0,2015-12-17T10:49:33Z,3296,"[{'description': 'Ralimetinib (LY2228820) is a selective ATP competitive inhibitor of p38 MAPK alpha (MAPK14) and beta (MAPK11), which inhibits tumor growth (PMID: 26581242, PMID: 24356814).', 'references': [{'id': 4115, 'pubMedId': 26581242, 'title': 'A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26581242'}]}]",Ralimetinib,2015-12-29T17:39:14Z
0,2016-11-23T17:21:23Z,5000,[],Ralimetinib + SCH772984,2016-11-23T17:21:23Z
0,2017-05-19T03:07:49Z,5685,[],Raloxifene,2017-05-19T03:07:49Z
0,2017-05-19T03:08:26Z,5686,[],Raloxifene + Bicalutamide,2017-05-19T03:08:26Z
0,2014-03-12T15:53:16Z,886,"[{'description': 'Cyramza (ramucirumab) is a monoclonal antibody, which binds and inhibits VEGFR2 (KDR) resulting in decreased angiogenesis (NCI Drug Dictionary). Cyramza (ramucirumab) is approved for gastric and gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and colorectal cancer (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Ramucirumab,2017-06-19T19:20:55Z
0,2014-11-12T05:40:58Z,1723,[],Ramucirumab + Dacarbazine,2014-11-12T05:40:58Z
0,2014-09-09T17:06:05Z,1423,[],Ramucirumab + Docetaxel,2014-09-09T17:06:05Z
0,2015-05-07T19:55:06Z,2633,[],Ramucirumab + FOLFIRI,2015-05-07T19:55:06Z
0,2014-11-12T05:30:47Z,1722,[],Ramucirumab + FOLFOX,2014-11-12T05:30:47Z
0,2014-11-12T05:20:07Z,1721,"[{'description': 'Cyramza (ramucirumab) in combination with paclitaxel is FDA approved for the treatment of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Ramucirumab + Paclitaxel,2014-11-13T17:58:00Z
0,2014-11-13T01:50:47Z,1726,[],Ramucirumab + Paclitaxel + Carboplatin,2014-11-13T01:50:47Z
0,2016-04-22T18:29:23Z,3998,[],Ramucirumab + Trastuzumab,2016-04-22T18:29:23Z
0,2016-07-26T14:57:01Z,4493,"[{'description': 'RapaLink-1 is a hybrid inhibitor of both mTORC1 and mTORC2 that binds to both ATP and FRB sites, and may result in inhibition of mtor signaling and decreased tumor growth (PMID: 27279227). ', 'references': [{'id': 6367, 'pubMedId': 27279227, 'title': 'Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27279227'}]}]",RapaLink-1,2016-07-26T14:57:01Z
0,2015-03-06T14:30:38Z,2313,[],Rasburicase,2015-03-06T14:30:38Z
0,2014-03-12T15:53:16Z,887,[],RDEA119,
0,2016-01-12T18:00:06Z,3406,"[{'description': 'ReACp53 is a peptide that inhibits Tp53 aggregation, resulting in reactivation of Tp53 pathway signaling in Tp53-mutant cells, and potentially resulting in increased tumor cell death (PMID: 26748848)', 'references': [{'id': 4309, 'pubMedId': 26748848, 'title': 'A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26748848'}]}]",ReACp53,2016-01-12T18:00:06Z
0,2014-05-14T14:52:46Z,1045,"[{'description': 'Rebastinib (DCC-2036) inhibits the Bcr-Abl fusion and to a lesser extent, the receptor tyrosine kinases TIE-2, FLT3, and VEGFR2 (PMID: 21481795).', 'references': [{'id': 1865, 'pubMedId': 21481795, 'title': 'Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21481795'}]}]",rebastinib,2015-02-11T16:34:59Z
0,2014-03-12T15:53:16Z,888,"[{'description': 'Refametinib (BAY86-9766) is an inhibitor of MEK1 and MEK2, which prevents growth-factor mediated cell proliferation (PMID: 24204195).', 'references': [{'id': 863, 'pubMedId': 24204195, 'title': 'Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24204195'}]}]",Refametinib,2017-04-06T10:11:46Z
0,2015-02-28T10:44:49Z,2221,[],Refametinib + Sorafenib,2015-02-28T10:44:49Z
0,2014-06-09T18:05:44Z,1072,"[{'description': 'REGN1400 is a monoclonal antibody, which binds to epidermal growth factor receptor B3 (Her3), preventing neuregulin 1 ligand binding, thereby inhibiting PI3K/Akt signaling and hence cellular proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",REGN1400,2015-08-10T15:25:34Z
0,2014-07-30T13:39:32Z,1247,[],REGN1400 + Cetuximab,2014-07-30T13:39:32Z
0,2014-07-30T13:38:46Z,1246,[],REGN1400 + Erlotinib,2014-07-30T13:38:46Z
0,2017-09-01T18:50:39Z,6151,"[{'description': 'REGN1979 is a CD20/CD3 bispecific antibody, which targets CD20 expressing cells via T-cell activation, and subsequently leads to cell death (PMID: 26659273).', 'references': [{'id': 9852, 'pubMedId': 26659273, 'title': 'A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26659273'}]}]",REGN1979,2017-09-01T18:50:39Z
0,2017-09-01T18:52:06Z,6152,[],REGN1979 + REGN2810,2017-09-01T18:52:06Z
0,2017-05-10T16:52:04Z,5656,"[{'description': 'REGN2810 is a human antibody that targets PD-1 and prevents interaction with PD-L1 and PD-L2, potentially resulting in increased anti-tumor immune response and decreased tumor growth (PMID: 28265006).', 'references': [{'id': 8864, 'pubMedId': 28265006, 'title': 'Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28265006'}]}]",REGN2810,2017-05-10T16:52:04Z
0,2017-05-20T02:56:04Z,5722,[],REGN2810 + Carboplatin + Docetaxel,2017-05-20T02:56:04Z
0,2017-05-20T02:53:40Z,5720,[],REGN2810 + Carboplatin + Paclitaxel,2017-05-20T02:53:40Z
0,2017-05-20T02:55:08Z,5721,[],REGN2810 + Carboplatin + Pemetrexed,2017-05-20T02:55:08Z
0,2017-05-20T02:51:55Z,5718,[],REGN2810 + Cyclophosphamide,2017-05-20T02:51:55Z
0,2017-05-20T02:52:42Z,5719,[],REGN2810 + Docetaxel,2017-05-20T02:52:42Z
0,2017-05-20T02:57:07Z,5723,[],REGN2810 + GM-CSF + Cyclophosphamide,2017-05-20T02:57:07Z
0,2017-07-07T02:38:08Z,5974,"[{'description': 'REGN2878-DM1 is an antibody-drug conjugate comprising an antibody targeting the Prolactin Receptor (PRLR) linked to DM1, which delivers the cytotoxic agent to PRLR-expressing tumor cells, potentially resulting in increased cell-cycle arrest and decreased tumor growth (PMID: 28377489).', 'references': [{'id': 9291, 'pubMedId': 28377489, 'title': 'Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody-Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28377489'}]}]",REGN2878-DM1,2017-07-07T02:40:16Z
0,2017-05-22T17:07:10Z,5735,"[{'description': 'REGN3767 is a monoclonal antibody that targets LAG-3, potentially resulting in increased anti-tumor immune response (NCI Drug Dictionary). ', 'references': []}]",REGN3767,2017-05-22T17:07:10Z
0,2017-05-22T17:09:18Z,5736,[],REGN3767 + REGN2810,2017-05-22T17:09:18Z
0,2014-03-12T15:53:16Z,889,"[{'description': 'Enoticumab (REGN421) is a monoclonal Dll4 antibody that inhibits Notch signaling, which may prevent Vegf induced angiogenesis (PMID: 25724527).', 'references': [{'id': 3066, 'pubMedId': 25724527, 'title': 'A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25724527'}]}]",REGN421,2017-07-13T18:26:17Z
0,2014-03-12T15:53:16Z,890,"[{'description': 'Stivarga (regorafenib) is an inhibitor of several kinases including VEGFR, RET, KIT, PDGFR and RAF, thereby inhibiting tumor angiogenesis and tumor cell proliferation (PMID: 24756792). Stivarga (regorafenib) is FDA approved for colorectal cancer, hepatocellular carcinoma, and GIST (FDA.gov). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Regorafenib,2017-05-01T14:51:19Z
0,2014-07-31T09:40:49Z,1305,[],Regorafenib + Cetuximab,2014-07-31T09:40:49Z
0,2015-02-06T13:16:49Z,2014,[],Regorafenib + FOLFOX,2015-02-06T13:16:49Z
0,2014-10-02T20:42:35Z,1617,[],Regorafenib + Panitumumab,2014-10-02T20:42:35Z
0,2014-09-11T01:03:00Z,1424,[],Regorafenib + Refametinib,2014-09-11T01:03:00Z
0,2017-02-02T16:20:42Z,5275,[],Regorafenib + Sorafenib,2017-02-02T16:20:42Z
0,2014-11-13T03:06:43Z,1727,[],Regorafenib + Sorafenib + MK2206,2014-11-13T03:13:40Z
0,2017-03-29T03:55:03Z,5492,[],Relugolix,2017-03-29T03:55:03Z
0,2014-03-12T15:53:16Z,893,"[{'description': 'Reolysin (pelareorep) is a reovirus, which specifically infects and replicates in RAS-activated cells to induce apoptosis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Reolysin,2016-12-12T19:26:39Z
0,2014-07-27T18:15:45Z,1111,[],Reolysin + Docetaxel,2014-07-27T18:15:45Z
0,2015-08-13T19:08:56Z,3020,[],Reolysin + Gemcitabine,2015-08-13T19:08:56Z
0,2014-07-27T18:15:09Z,1110,[],Reolysin + Pemetrexed,2014-07-27T18:15:09Z
0,2017-02-07T02:00:12Z,5285,[],Repaglinide + Omeprazole + Tazemetostat,2017-02-07T02:00:12Z
0,2015-07-17T15:13:53Z,2930,"[{'description': 'Reparixin binds to and inhibits signaling of CXC chemokine receptor type 1 (CXCR1), which may lead to depletion of cancer stem cells (PMID: 20051626).', 'references': [{'id': 3272, 'pubMedId': 20051626, 'title': 'CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20051626'}]}]",Reparixin,2015-07-21T16:40:36Z
0,2016-05-26T15:08:24Z,4134,"[{'description': 'Resminostat (4SC-201) is a histone deacetylase inhibitor that induces chromatin remodeling, leading to growth inhibition and apoptosis in tumor cells (PMID: 20201941).', 'references': [{'id': 5682, 'pubMedId': 20201941, 'title': 'The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20201941'}]}]",Resminostat,2017-06-15T04:17:30Z
0,2016-05-26T15:15:39Z,4135,[],Resminostat + Sorafenib,2016-05-26T15:15:39Z
0,2014-03-12T15:53:16Z,894,"[{'description': 'Retaspimycin (IPI-504) inhibits HSP90, potentially resulting in increased tumor cell apoptosis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Retaspimycin,2015-06-03T18:52:16Z
0,2015-03-08T21:10:40Z,2327,"[{'description': 'Reversine is an A3 adenosine receptor antagonist and pan-Aurora kinase and TTK (MPS1) inhibitor, which prevents cell proliferation (PMID: 14719906, PMID: 18483302, PMID: 25043312). ', 'references': [{'id': 2117, 'pubMedId': 18483302, 'title': 'Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18483302'}, {'id': 2116, 'pubMedId': 14719906, 'title': 'Dedifferentiation of lineage-committed cells by a small molecule.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/14719906'}]}]",Reversine,2017-04-04T11:28:47Z
0,2015-06-01T19:48:02Z,2760,"[{'description': 'RG108 binds and inhibits DNMT1, which leads to decreased DNA methylation and may result in the activation of silenced tumor suppressor genes (PMID: 16024632).', 'references': [{'id': 2884, 'pubMedId': 16024632, 'title': 'Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16024632'}]}]",RG108,2017-06-14T18:48:04Z
0,2015-02-13T18:59:44Z,2076,"[{'description': 'RG7112 (RO5045337) binds to the p53-binding region of MDM2 and inhibits MDM2-p53 interaction, resulting in activation of p53 signaling, and decreased tumor cell growth (PMID: 24900694, PMID: 23400593).', 'references': [{'id': 1883, 'pubMedId': 24900694, 'title': 'Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24900694'}]}]",RG7112,2015-02-13T19:01:39Z
0,2016-05-12T16:36:17Z,4110,"[{'description': 'RG7386 is a bi-specific antibody that targets FAP and TNFRSF10B (DR5), which induces apoptosis possibly leading to tumor growth inhibition (PMID: 27037412).', 'references': [{'id': 5521, 'pubMedId': 27037412, 'title': 'RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27037412'}]}]",RG7386,2016-05-12T16:36:17Z
0,2015-02-09T00:21:13Z,2023,"[{'description': 'Idasanutlin (RG7388) binds to MDM2 to block subsequent interaction with p53, which restores p53 activity (PMID: 23808545).', 'references': [{'id': 1827, 'pubMedId': 23808545, 'title': 'Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23808545'}]}]",RG7388,2016-06-22T12:35:13Z
0,2015-01-12T19:20:56Z,1934,"[{'description': 'RI-1 is a small molecule inhibitor of Rad51, which disrupts Rad51 activity in DNA repair, potentially resulting in increased sensitivity to chemotherapeutics (PMID: 22573178).', 'references': [{'id': 1640, 'pubMedId': 22573178, 'title': 'RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22573178'}]}]",RI-1,2017-09-25T19:04:48Z
0,2016-07-07T17:39:50Z,4425,"[{'description': 'RI-BPI is a retro-inverted peptide inhibitor of BCL6, which results in interruption of the BCL6 repression complexes thereby possible leading to decreased cell survival and reduced tumor volume (PMID: 18927431).', 'references': []}]",RI-BPI,2017-06-16T15:51:11Z
0,2015-11-01T20:08:35Z,3167,[],Ribavirin,2015-11-01T20:08:35Z
0,2014-03-12T15:53:16Z,790,"[{'description': 'Kisqali (ribociclib) is a dual CDK4/6 inhibitor, which may induce cell cycle arrest and reduce proliferation in cancer cells (PMID: 24045179). Kisqali (ribociclib) is FDA-approved in combination with an aromatase inhibitor in patients with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (FDA.gov).', 'references': [{'id': 828, 'pubMedId': 24045179, 'title': 'Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045179'}]}]",Ribociclib,2017-06-19T19:21:35Z
0,2017-02-22T16:17:19Z,5354,[],Ribociclib + Asparaginase,2017-02-22T16:17:19Z
0,2017-03-28T02:40:11Z,5479,[],Ribociclib + Bicalutamide,2017-03-28T02:40:11Z
0,2017-02-22T16:21:49Z,5358,[],Ribociclib + Bortezomib,2017-02-22T16:21:49Z
0,2017-02-22T16:18:26Z,5355,[],Ribociclib + Dexamethasone,2017-02-22T16:18:26Z
0,2016-12-11T04:15:26Z,5073,[],Ribociclib + Everolimus,2016-12-11T04:15:26Z
0,2017-01-10T04:21:25Z,5180,[],Ribociclib + Everolimus + Letrozole,2017-01-10T04:21:25Z
0,2017-02-22T16:20:15Z,5357,[],Ribociclib + JQ1,2017-02-22T16:20:15Z
0,2017-02-12T16:56:32Z,5310,[],Ribociclib + Letrozole + Goserelin,2017-02-12T16:56:32Z
0,2017-02-22T16:06:54Z,5353,[],Ribociclib + Mercaptopurine,2017-02-22T16:06:54Z
0,2017-02-22T16:05:38Z,5352,[],Ribociclib + Methotrexate,2017-02-22T16:05:38Z
0,2017-02-22T16:19:16Z,5356,[],Ribociclib + Prednisolone,2017-02-22T16:19:16Z
0,2016-07-19T00:37:24Z,4472,[],Ribociclib + Trametinib,2016-07-19T00:37:24Z
0,2017-08-03T16:28:13Z,6082,[],Ricolinostat + SJB3-019A,2017-08-03T16:28:13Z
0,2014-03-12T15:53:16Z,895,"[{'description': 'Ridaforolimus (MK-8669) is a rapamycin analogue, which allosterically inhibits mTOR to inhibit cell proliferation (PMID: 21482695).', 'references': [{'id': 2057, 'pubMedId': 21482695, 'title': 'Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21482695'}]}]",Ridaforolimus,2015-04-02T23:55:05Z
0,2016-01-30T21:28:04Z,3478,[],Ridaforolimus + MK2206,2016-01-30T21:28:09Z
0,2015-08-18T14:07:11Z,3032,[],Ridaforolimus + Paclitaxel,2015-08-18T14:07:11Z
0,2016-11-23T16:50:48Z,4991,[],Ridaforolimus + SCH772984,2016-11-23T16:50:48Z
0,2014-07-30T15:33:52Z,1256,[],Rifampin + Vemurafenib,2014-07-30T15:33:52Z
0,2014-05-14T14:52:46Z,1046,"[{'description': 'Estybon (rigosertib) inhibits polo-like kinase 1 (Plk1) and PI3K pathways, which induces selective G2/M arrest and apoptosis in tumor cells (PMID: 24777753).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 1820, 'pubMedId': 24777753, 'title': 'Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24777753'}]}]",rigosertib,2017-04-28T19:25:40Z
0,2015-08-13T19:19:09Z,3021,[],Rigosertib + Gemcitabine,2015-08-13T19:19:09Z
0,2015-10-20T19:03:11Z,3138,[],Rilotumumab + Capecitibine + Cisplatin + Epirubicin,2015-10-20T19:03:11Z
0,2014-12-10T04:07:08Z,1775,[],Rilotumumab + Panitumumab,2016-05-27T02:17:18Z
0,2014-05-14T14:52:46Z,1047,"[{'description': 'Rilutek (riluzole) inhibits metabotropic glutamate receptors, which results in decreased signaling through the MAPK pathway and the PI3K/AKT pathway (PMID: 19458050), and also inhibits voltage-gated ion channels and may directly inhibit protein kinase C (PMID: 10964608).', 'references': [{'id': 160, 'pubMedId': 10964608, 'title': 'A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10964608'}, {'id': 1079, 'pubMedId': 19458050, 'title': 'A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19458050'}]}]",Rilutek,2017-04-25T20:39:51Z
0,2014-11-12T15:35:41Z,1724,[],Rilutek + Sorafenib,2014-11-12T15:35:41Z
0,2014-07-28T20:33:53Z,1185,[],riluzole + sorafenib,2014-07-28T20:33:53Z
0,2017-07-14T17:45:34Z,5992,"[{'description': 'Rimiducid is a tacrolimus analogue drug that contains an analogue of FKBP12, which allows homodimerization of genetically engineered receptors containing an FKBP12 binding domain, thereby, inducing apoptosis when necessary (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Rimiducid,2017-07-14T17:45:34Z
0,2014-09-24T18:22:08Z,1530,[],RIST,2014-09-24T18:22:08Z
0,2014-03-12T15:53:16Z,897,[],Rituximab,
0,2014-10-14T20:14:04Z,1649,[],Rituximab + Bortezomib,2014-10-14T20:14:04Z
0,2015-03-06T00:20:55Z,2306,[],Rituximab + Fludarabine + EPOCH,2015-03-06T00:20:55Z
0,2014-10-02T19:04:29Z,1610,[],Rituximab + Lenalidomide + Ibrutinib,2014-10-02T19:04:29Z
0,2015-11-16T17:07:03Z,3215,[],Rituximab + sapacitabine,2015-11-16T17:07:03Z
0,2017-09-08T17:08:07Z,6179,[],Rituximab + TEN-010 + Venetoclax,2017-09-08T17:08:07Z
0,2016-05-13T15:51:43Z,4119,[],Rivaroxaban,2016-06-03T00:45:22Z
0,2016-11-01T14:35:42Z,4898,"[{'description': 'RK-33 is a small molecule that inhibits DDX3X, resulting in decreased proliferation of DDX3Xexpressing tumor cells and increased sensitivity to radiotherapy (PMID: 27634756).', 'references': [{'id': 6908, 'pubMedId': 27634756, 'title': 'RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27634756'}]}]",RK-33,2016-11-01T14:37:14Z
0,2016-11-01T14:39:05Z,4899,[],RK-33 + Radiotherapy,2016-11-01T14:39:05Z
0,2017-06-29T18:18:43Z,5946,"[{'description': 'Limited information is available on RK22446, a putative LCK inhibitor (PubMed, Jun 2017). ', 'references': []}]",RK22446,2017-06-29T18:18:43Z
0,2015-07-14T01:49:11Z,2918,"[{'description': 'RM-1929 is comprised of the EGFR antibody cetuximab conjugated to the dye IR700, which binds to EGFR-expressing cells and disrupts the cell membrane upon exposure to near-infared light (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",RM-1929,2015-07-14T01:49:11Z
0,2017-04-06T19:51:31Z,5506,"[{'description': 'RN-1 irreversibly inhibits KDM1A, potentially resulting in decreased tumor cell growth (PMID: 26837761).', 'references': [{'id': 8467, 'pubMedId': 26837761, 'title': 'Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26837761'}]}]",RN-1,2017-06-16T15:53:46Z
0,2017-04-06T20:40:39Z,5508,[],RN-1 + Tretinoin,2017-04-06T20:40:39Z
0,2015-05-15T02:00:06Z,2688,"[{'description': 'RN486 is a selective BTK inhibitor that inhibits proliferation of B-cells (PMID: 22228807).', 'references': [{'id': 2729, 'pubMedId': 22228807, 'title': ""RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22228807'}]}]",RN486,2015-05-15T02:00:06Z
0,2016-11-03T18:38:54Z,4913,"[{'description': 'RN927C is an antibody-drug conjugate comprising an anti-Trop-2 (Tacstd2) antibody linked to the microtubule polymerization-disrupting drug PF-06380101, which delivers PF-06380101to Trop-2 (Tacstd2)-expressing tumor cells, potentially leading to increased tumor cell death and decreased tumor growth (PMID: 27582525).', 'references': [{'id': 6932, 'pubMedId': 27582525, 'title': 'RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27582525'}]}]",RN927C,2016-11-04T03:19:53Z
0,2017-05-31T15:38:56Z,5823,"[{'description': 'Limited information is currently available on RNA CART-cMET, a putative preparation of autologous T cells electroporated with RNA encoding chimeric cMet (May 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",RNA CART-cMET,2017-05-31T15:38:56Z
0,2017-07-17T18:22:44Z,6000,"[{'description': 'Limited information is currently available on RNA CART19 cells, putative autologous T cells electroporated with RNA expressing CD19 chimeric antigen receptors consists of TCR zeta and 4-1BB costimulatory domains (Jul 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",RNA CART19 cells,2017-07-17T18:22:44Z
0,2015-03-10T15:36:38Z,2340,"[{'description': 'Ro 31-8220 is a pan-protein kinase C (PKC) inhibitor, with additional activity against additional kinases including GSK3-beta, which may increase apoptosis and decrease growth of tumor cells (PMID: 8373348, PMID: 10998351, PMID: 18281471).', 'references': [{'id': 2144, 'pubMedId': 8373348, 'title': 'Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/8373348'}, {'id': 2145, 'pubMedId': 18281471, 'title': 'Growth suppression of lung cancer cells by targeting cyclic AMP response element-binding protein.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18281471'}]}]",Ro 31-8220,2017-05-01T18:04:05Z
0,2016-03-18T16:37:35Z,3779,"[{'description': 'RO3280 is an inhibitor of PLK1, which may result in apoptotic activity and inhibition of cell growth (PMID: 25574601).', 'references': [{'id': 4925, 'pubMedId': 25574601, 'title': 'Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25574601'}]}]",RO3280,2016-03-18T16:37:35Z
0,2016-08-10T16:26:19Z,4552,"[{'description': 'RO4927350 is a non-ATP competitive inhibitor of MEK1/2, which may result in inhibition of cell proliferation and antitumor activity (PMID: 19244124). ', 'references': [{'id': 6459, 'pubMedId': 19244124, 'title': 'Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19244124'}]}]",RO4927350,2017-04-06T10:13:34Z
0,2014-03-12T15:53:16Z,902,"[{'description': 'RO4929097 is a gamma secretase inhibitor, which blocks Notch cleavage and activation, and may inhibit angiogenesis and tumor growth (PMID: 19773430).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 2510, 'pubMedId': 19773430, 'title': 'Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19773430'}]}]",RO4929097,2015-04-27T12:38:29Z
0,2016-10-17T16:28:15Z,4840,[],RO4929097 + Paclitaxel,2016-10-17T16:28:15Z
0,2014-03-12T15:53:16Z,903,"[{'description': 'RO4987655 is a dual MEK1/2 inhibitor, which blocks RAS/RAF/MEK/ERK signaling to prevent cell proliferation (PMID: 21316218).', 'references': [{'id': 1815, 'pubMedId': 21316218, 'title': 'Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21316218'}]}]",RO4987655,2017-04-21T20:11:30Z
0,2014-03-12T15:53:16Z,904,[],RO5083945,
0,2015-02-06T11:13:45Z,2011,"[{'description': 'RO5126766 is dual RAF-MEK1/2 inhibitor with effectiveness against both BRAF and RAS mutated cells (PMID: 25422890).', 'references': [{'id': 1814, 'pubMedId': 25422890, 'title': 'The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25422890'}]}]",RO5126766,2017-04-21T20:13:24Z
0,2014-03-12T15:53:16Z,905,"[{'description': 'PLX3603 (RO5212054) is a BRAF inhibitor (PMID: 23617957, PMID: 25204436).', 'references': [{'id': 1812, 'pubMedId': 23617957, 'title': 'B-Raf and the inhibitors: from bench to bedside.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23617957'}, {'id': 1971, 'pubMedId': 25204436, 'title': 'Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25204436'}]}]",RO5212054,2015-04-10T16:55:32Z
0,2015-12-23T18:16:43Z,3334,"[{'description': 'RO5454948 is a small molecule inhibitor of DYRK1B, which has been shown to preferentially target quiescent cancer cells resulting in cell death (PMID: 23114871).', 'references': [{'id': 4163, 'pubMedId': 23114871, 'title': 'Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23114871'}]}]",RO5454948,2015-12-23T18:16:43Z
0,2015-02-24T19:34:50Z,2153,"[{'description': 'RO5503781 binds to MDM2 and inhibits its interaction with p53, preventing degradation of p53, thereby resulting in restoration of wild-type p53 activity and potentially promoting apoptosis of tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",RO5503781,2015-02-24T19:34:50Z
0,2016-05-27T16:25:28Z,4172,[],RO5503781 + Venetoclax,2016-05-27T16:25:28Z
0,2014-10-02T15:46:43Z,1598,"[{'description': 'Vanucizumab (RO5520985) is a bispecific human antibody that binds to both Angiopoeitin-2 and VEGF-A, inhibiting tumor angiogenesis and metastasis in xenograft models (PMID: 24097868).', 'references': [{'id': 884, 'pubMedId': 24097868, 'title': 'Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24097868'}]}]",RO5520985,2016-07-27T13:49:09Z
0,2014-10-02T15:54:44Z,1600,[],RO5520985 + Leucovorin + Fluorouracil,2014-10-02T15:54:44Z
0,2016-01-29T02:44:56Z,3468,[],RO5520985 + RO7009789,2016-01-29T02:44:56Z
0,2015-02-24T19:53:29Z,2155,"[{'description': 'RO6839921 binds to MDM2 and inhibits its interaction with p53, preventing degradation of p53, thereby potentially resulting in restoration of wild-type p53 activity and apoptosis of tumor cells (NCI Drug Dictionary).\r\n', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",RO6839921,2015-02-24T19:53:29Z
0,2017-02-26T03:34:37Z,5364,"[{'description': 'RO6874281 is a fusion protein consists of a human anti-fibroblast activation protein-alpha (FAP) antibody and an engineered interleukin-2, which may stimulate local immune response against FAP-positive tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",RO6874281,2017-03-10T18:02:08Z
0,2017-02-26T03:36:41Z,5365,[],RO6874281 + Obinutuzumab + Atezolizumab,2017-02-26T03:36:41Z
0,2017-02-26T03:39:00Z,5366,[],RO6874281 + Obinutuzumab + Atezolizumab + Bevacizumab,2017-02-26T03:39:00Z
0,2016-06-20T16:22:50Z,4330,"[{'description': 'Limited information is currently available on RO6874813 (Jun 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",RO6874813,2016-06-20T16:22:50Z
0,2015-07-08T15:03:40Z,2886,"[{'description': 'RO6895882 (RG7813) is a bispecific antibody that binds carcinoembyronic antigen (CEA) and CD3, potentially resulting in enhanced T-cell response to CEA-expresssing tumor cells (European Journal of Cancer, Volume 51, Supplement 1, March 2015, Page S13).', 'references': [{'id': 3202, 'pubMedId': None, 'title': 'ITOC2 – 037. CEA TCB, A novel T-cell bispecific antibody with potent in vitro and in vivo antitumour activity against solid tumours', 'url': '(http://www.sciencedirect.com/science/article/pii/S0959804915000817)'}]}]",RO6895882,2015-07-08T15:03:40Z
0,2016-01-14T14:32:47Z,3411,"[{'description': 'RO6958688 is a bispecific antibody that binds to CD3 and human anti-carcinoembryonic antigen (CEA) simultaneously, which may lead to cytotoxic immune response against CEA-positive tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",RO6958688 ,2016-01-14T14:32:47Z
0,2015-05-14T02:11:14Z,2672,"[{'description': 'RO7009789 is an anti-CD40 monoclonal antibody, which potentially induces an enhanced immune response and apoptosis in tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",RO7009789,2015-05-19T14:16:29Z
0,2017-05-24T17:22:05Z,5764,"[{'description': 'Limited information is currently available on RO7082859 (May, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",RO7082859,2017-05-24T17:22:05Z
0,2017-09-25T00:22:16Z,6234,"[{'description': 'Limited information is currently available on RO7198457 (Sep 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",RO7198457,2017-09-25T00:22:52Z
0,2015-05-29T04:45:18Z,2746,"[{'description': 'Robatumumab (SCH 717454) is a monoclonal antibody that binds to and inhibits IGF-1R, potentially resulting in deceased tumor growth (PMID: 20124453).', 'references': [{'id': 2859, 'pubMedId': 20124453, 'title': 'A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20124453'}]}]",Robatumumab,2015-06-02T13:13:04Z
0,2015-02-09T17:32:55Z,2030,"[{'description': 'Rogaratinib (BAY 1163877) is a selective small molecule inhibitor of FGFR1, FGFR2 and FGFR3, which reduces downstream signaling, potentially resulting in decreased tumor cell proliferation (PMID: 27429073).', 'references': [{'id': 9936, 'pubMedId': 27429073, 'title': 'Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27429073'}, {'id': 1837, 'pubMedId': None, 'title': 'Abstract 1739: Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/1739'}]}]",Rogaratinib,2017-09-21T13:30:21Z
0,2014-06-14T11:54:05Z,1075,"[{'description': 'Istodax (romidepsin) inhibits Class I HDACs, resulting in cell cycle arrest, apoptosis, and decreased tumor cell growth (PMID: 12208741, PMID: 12234611, PMID: 21258344). Istodax (romidepsin) is FDA approved for patients with cutaneous T-cell lymphoma (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 8264, 'pubMedId': 12234611, 'title': 'Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12234611'}, {'id': 8263, 'pubMedId': 21258344, 'title': 'Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21258344'}, {'id': 8262, 'pubMedId': 12208741, 'title': 'FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12208741'}]}]",romidepsin,2017-06-19T19:24:02Z
0,2017-05-20T03:33:08Z,5728,[],Romidepsin + Pembrolizumab,2017-05-20T03:33:08Z
0,2016-06-28T17:43:54Z,4401,"[{'description': 'Rosmantuzumab (OMP-131R10) is a monoclonal antibody that targets R-spondin 3 (RSPO3), which results in decreased pathway activation and may lead to reduced tumor cell proliferation and decreased survival of cancer stem cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Rosmantuzumab,2017-05-24T18:03:55Z
0,2015-07-17T14:11:04Z,2928,[],Rosuvastatin,2015-07-17T14:11:04Z
0,2016-02-17T21:28:06Z,3544,"[{'description': 'Rovalpituzumab Tesirine is a conjugate of pyrrolobenzodiazepine (PBD) cytotoxin D6.5 and human anti-delta-like 3 (DLL3) antibody, which targets and kills DLL-3 expressing tumor cells (PMID: 26311731).', 'references': [{'id': 4615, 'pubMedId': 26311731, 'title': 'A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26311731'}]}]",Rovalpituzumab Tesirine,2016-02-17T21:28:06Z
0,2016-10-13T19:24:00Z,4827,[],Rovalpituzumab Tesirine + Cisplatin + Etoposide,2016-10-13T19:24:00Z
0,2017-02-12T16:20:25Z,5307,[],Rovalpituzumab Tesirine + Dexamethasone,2017-02-12T16:20:25Z
0,2017-05-07T18:33:05Z,5641,[],Rovalpituzumab Tesirine + Nivolumab,2017-05-07T18:33:05Z
0,2017-05-07T18:32:14Z,5640,[],Rovalpituzumab Tesirine + Nivolumab + Ipilimumab,2017-05-07T18:32:14Z
0,2017-05-24T17:03:04Z,5761,"[{'description': 'Limited information is currently available on RP4010 (May, 2017).', 'references': []}]",RP4010,2017-05-24T17:03:04Z
0,2015-02-08T10:55:57Z,2020,"[{'description': 'RP6530 is an inhibitor of PIK3CG and PIK3CD, which blocks PI3K/AKT signaling to prevent cell proliferation (Blood 122(21): 4411).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 4893, 'pubMedId': None, 'title': 'Dual PI3Kdelta/gamma Inhibition By RP6530 Induces Apoptosis and Cytotoxicity In B-Lymphoma Cells', 'url': 'http://www.bloodjournal.org/content/122/21/4411?sso-checked=true'}]}]",RP6530,2016-03-17T14:08:22Z
0,2016-03-17T13:58:08Z,3765,[],RP6530 + Ruxolitinib,2016-03-17T13:58:08Z
0,2016-03-04T21:38:26Z,3680,"[{'description': 'RRx-001 is a nitric oxide donor that is activated by hypoxia, leading to increased oxygen level in tumor and sensitizes tumor to radiotherapy (PMID: 26164533).', 'references': [{'id': 4777, 'pubMedId': 26164533, 'title': 'NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26164533'}]}]",RRx-001,2016-03-04T21:38:26Z
0,2016-08-21T02:02:18Z,4596,[],RRx-001 + Temozolomide,2016-08-21T02:02:18Z
0,2015-08-28T01:06:28Z,3062,"[{'description': 'RTA 408 is an activator of Nrf2 which inhibits tumor growth through regulating antioxidant and pro-inflammatory gene expression (PMID: 25897966).', 'references': [{'id': 3563, 'pubMedId': 25897966, 'title': 'RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25897966'}]}]",RTA 408,2015-08-28T01:06:28Z
0,2016-03-10T20:35:43Z,3713,"[{'description': 'RTA-408 is an antioxidant inflammation modulator (AIM) that has anti-inflammatory activity and additionally inhibits tumor cell growth (PMID: 25897966).', 'references': [{'id': 3563, 'pubMedId': 25897966, 'title': 'RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25897966'}]}]",RTA-408,2016-03-10T20:35:43Z
0,2017-09-05T15:56:33Z,6165,"[{'description': 'RU-A1 is a small molecule inhibitor of BMI1, which may result in inhibition of cell proliferation and migration, and increased sensitization to chemotherapeutics (PMID: 28589491). ', 'references': [{'id': 9860, 'pubMedId': 28589491, 'title': 'Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28589491'}]}]",RU-A1,2017-09-05T15:56:33Z
0,2016-03-15T17:14:18Z,3744,"[{'description': 'RU-SKI 43 is a Hedgehog acyltransferase (Hhat) inhibitor that blocks Sonic hedgehog (Shh) signaling in culture (PMID: 23416332).', 'references': [{'id': 4867, 'pubMedId': 23416332, 'title': 'Inhibitors of Hedgehog acyltransferase block Sonic Hedgehog signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23416332'}]}]",RU-SKI 43,2016-03-15T17:14:18Z
0,2016-03-15T17:55:56Z,3747,[],RU-SKI 43 + Sirolimus,2016-03-15T17:55:56Z
0,2016-03-15T18:06:54Z,3748,[],RU-SKI 43 + Tamoxifen,2016-03-15T18:06:54Z
0,2017-03-09T15:47:05Z,5424,"[{'description': 'RU58668 is an anti-estrogen that binds estrogen receptors and leads to increased estrogen receptor degradation, potentially resulting in decreased tumor growth (PMID: 8142294, PMID: 17909066).', 'references': [{'id': 8171, 'pubMedId': 8142294, 'title': 'RU 58,668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/8142294'}, {'id': 8170, 'pubMedId': 17909066, 'title': 'Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17909066'}]}]",RU58668,2017-03-09T15:47:05Z
0,2014-03-12T15:53:16Z,906,"[{'description': 'Rubraca (rucaparib) binds and inhibits Poly(ADP-ribose) polymerase (PARP), which may result in accumulation of DNA damage and chemosensitization of tumor cells (PMID: 17363489). Rubraca (rucaparib) is FDA approved for use in ovarian cancer patients with deleterious BRCA mutations (FDA.gov).', 'references': [{'id': 1987, 'pubMedId': 17363489, 'title': 'Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17363489'}]}]",Rucaparib,2017-05-11T16:18:45Z
0,2016-08-11T15:11:43Z,4553,[],Rucaparib + Temozolomide,2016-08-11T15:11:43Z
0,2015-02-24T19:52:48Z,2154,[],Rucaparib + Topotecan,2015-02-24T19:52:48Z
0,2014-03-12T15:53:16Z,907,"[{'description': 'Jakafi (ruxolitinib) is an inhibitor of protein tyrosine kinases JAK1 and JAK2, thus resulting in reduced inflammation and reduced proliferation (NCI Drug Dictionary). Jakafi (ruxolitinib) is FDA approved to treat bone marrow cancer, specifically intermediate or high-risk myelofibrosis (FDA.gov)', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Ruxolitinib,2015-07-09T13:41:12Z
0,2014-10-02T20:06:39Z,1615,[],Ruxolitinib + Capecitabine,2014-10-02T20:06:39Z
0,2014-12-28T20:39:06Z,1856,[],Ruxolitinib + Cisplatin + Pemetrexed,2014-12-28T20:39:06Z
0,2014-11-21T04:00:59Z,1735,[],Ruxolitinib + Decitabine,2014-11-21T04:00:59Z
0,2014-12-28T20:44:42Z,1858,[],Ruxolitinib + Erlotinib,2014-12-28T20:44:42Z
0,2014-07-27T14:11:28Z,1108,[],Ruxolitinib + Exemestane,2014-07-27T14:11:28Z
0,2014-07-27T20:10:47Z,1116,[],Ruxolitinib + Nilotinib,2014-07-27T20:10:47Z
0,2014-08-05T16:14:17Z,1369,[],Ruxolitinib + Paclitaxel,2014-08-05T16:14:17Z
0,2016-03-29T20:14:10Z,3869,[],Ruxolitinib + Selumetinib,2016-03-29T20:14:10Z
0,2016-02-18T17:58:34Z,3549,[],Ruxolitinib + SGI-1776,2016-02-18T17:58:34Z
0,2015-11-06T02:08:54Z,3181,[],Ruxolitinib + Sirolimus + Tacrolimus,2015-11-06T02:08:54Z
0,2016-04-14T19:46:22Z,3929,[],Ruxolitinib + TGX-221,2016-04-14T19:46:22Z
0,2016-03-29T20:13:35Z,3868,[],Ruxolitinib + Trametinib,2016-03-29T20:13:35Z
0,2014-09-30T20:16:20Z,1578,[],Ruxolitinib + Trastuzumab,2014-09-30T20:16:20Z
0,2016-04-14T18:15:10Z,3926,[],Ruxolitinib + ZSTK474,2016-04-14T18:15:10Z
0,2016-06-24T17:21:43Z,4356,"[{'description': 'RVX-208 is a bromo and extraterminal (BET) protein inhibitor that selectively binds to the second bromodomain found on BET proteins, resulting in inhibition of downstream gene transcription (PMID: 24248379).', 'references': [{'id': 6066, 'pubMedId': 24248379, 'title': 'RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24248379'}]}]",RVX-208,2017-03-17T20:14:12Z
0,2017-03-07T20:43:57Z,5418,"[{'description': 'RVX2135 is a small molecule inhibitor of BET that binds to BRD2, BRD3, and BRD4, and may result in inhibition of cell proliferation, cell cycle arrest, and induced apoptosis (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-92).', 'references': [{'id': 8151, 'pubMedId': None, 'title': 'Abstract LB-92: RVX-2135 is a novel, orally bioavailable epigenetic BET inhibitor that synergizes with cytarabine and idarubicin to inhibit proliferation of acute myeloid leukemia cells.', 'url': 'http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-92'}]}]",RVX2135,2017-03-07T20:43:57Z
0,2017-03-07T20:45:55Z,5419,[],RVX2135 + VE-821,2017-03-07T20:45:55Z
0,2014-03-12T15:53:16Z,908,"[{'description': 'Archexin (RX-0201) is an antisense oligonucleotide, which inhibits Akt1 translation and may inhibit cell proliferation and promote apoptosis in cancer (PMID: 20846000).', 'references': [{'id': 2285, 'pubMedId': 20846000, 'title': 'Akt inhibitors in clinical development for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20846000'}]}]",RX-0201,2015-03-20T12:49:44Z
0,2017-09-19T20:19:09Z,6224,"[{'description': 'RX-5902 binds to and inhibits Ddx5, which in turn inhibits beta-catenin signaling, results in down-regulation of gene expression and tumor cell growth inhibition (PMID: 25649741).', 'references': [{'id': 9955, 'pubMedId': 25649741, 'title': 'A Novel Anti-Cancer Agent, 1-(3,5-Dimethoxyphenyl)-4-[(6-Fluoro-2-Methoxyquinoxalin-3-yl)Aminocarbonyl] Piperazine (RX-5902), Interferes With β-Catenin Function Through Y593 Phospho-p68 RNA Helicase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25649741'}]}]",RX-5902,2017-09-19T20:19:09Z
0,2017-06-08T14:28:42Z,5865,"[{'description': 'RXC004 inhibits Porcupine (Porcn), thereby inhibits Wnt signaling, resulting in tumor growth inhibition (J Clin Oncol 35, 2017 (suppl; abstr e14094)).', 'references': []}]",RXC004,2017-06-08T14:28:42Z
0,2017-02-09T19:46:53Z,5298,"[{'description': 'REDX08608 is an inhibitor of BTK, which targets both wild-type and C481, thereby potentially resulting in inhibition of cell growth (Blood 2016 128:4399). ', 'references': []}]",RXC005,2017-06-01T15:26:15Z
0,2017-05-19T19:51:22Z,5710,"[{'description': 'RXDX-106 is a small molecule inhibitor of TAM family kinases (Axl, Mer, and Tyro3) and cMet that promotes anti-tumor immune response, resulting in tumor growth inhibition (Eur J Cancer, Vol 69, Supplement 1, December 2016, Page S31).', 'references': [{'id': 8954, 'pubMedId': None, 'title': 'Immuno-oncologic efficacy of RXDX-106, a selective, TAM family small molecule kinase inhibitor', 'url': 'http://www.sciencedirect.com/science/article/pii/S0959804916326739?via%3Dihub'}]}]",RXDX-106,2017-05-19T19:51:22Z
0,2017-05-24T17:23:49Z,5765,[],RXDX-106 + unspecified PD-1 antibody,2017-05-24T17:23:49Z
0,2014-05-14T14:52:46Z,1048,"[{'description': 'S-222611 is a dual inhibitor of EGFR and ERBB2 (HER2), leading to decreased kinase activity and potentially inhibiting growth of tumors expressing EGFR and/or ERBB2 (HER2) (PMID: 24837299).', 'references': [{'id': 1835, 'pubMedId': 24837299, 'title': 'Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24837299'}]}]",S-222611,2015-03-31T14:11:19Z
0,2015-02-25T16:50:53Z,2158,"[{'description': 'S-49076 is a multi-kinase inhibitor that inhibits wild-type and mutant forms of MET and FGFR1/2, as well as FGFR3, AXL, and MER, resulting in decreased downstream signaling, and potentially resulting in decreased tumor growth (PMID: 23804704).', 'references': [{'id': 2007, 'pubMedId': 23804704, 'title': 'S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23804704'}]}]",S-49076,2017-03-16T17:08:12Z
0,2015-02-26T19:05:10Z,2178,[],S-49076 + Bevacizumab,2015-02-26T19:05:10Z
0,2015-04-28T22:35:39Z,2596,"[{'description': 'S-equol is a plant-derived estrogen receptor agonist, which may decrease tumor cell growth (PMID: 21790611, PMID: 24487643).', 'references': [{'id': 2596, 'pubMedId': 21790611, 'title': 'Emerging evidence of the health benefits of S-equol, an estrogen receptor β agonist.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21790611'}]}]",S-equol  ,2015-04-30T02:22:25Z
0,2017-07-27T16:28:43Z,6011,"[{'description': 'S2101 inhibits Lysine-specific demethylase 1 (LSD1/KDM1), which results in changes in gene expression profile and cell death in tumor cells (PMID: 20568732, PMID: 27879268, PMID: 27914215).', 'references': [{'id': 9598, 'pubMedId': 27879268, 'title': 'Transcriptional Selectivity of Epigenetic Therapy in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27879268'}, {'id': 9599, 'pubMedId': 20568732, 'title': 'Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20568732'}]}]",S2101,2017-07-27T17:18:26Z
0,2015-10-14T10:04:00Z,3124,"[{'description': 'S3I-201 (NSC 74859) is an inhibitor of Stat3 activity blocking Stat3 homodimer formation and Stat3 DNA binding (PMID: 17463090).', 'references': [{'id': 3756, 'pubMedId': 17463090, 'title': 'Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17463090'}]}]",S3I-201,2015-10-14T10:04:00Z
0,2016-10-25T15:37:21Z,4858,"[{'description': 'S63845 is a small molecule binds to and inhibits Mcl1, leading to apoptosis in tumor cells (PMID: 27760111).', 'references': [{'id': 6851, 'pubMedId': 27760111, 'title': 'The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27760111'}]}]",S63845,2016-10-25T15:37:21Z
0,2016-10-27T15:39:01Z,4864,[],S63845 + Trametinib,2016-10-27T15:39:01Z
0,2016-10-27T15:43:17Z,4865,[],S63845 + Vemurafenib,2016-10-27T15:43:17Z
0,2017-05-25T18:33:00Z,5775,"[{'description': 'SA16 is a dual inhibitor of PDK1 and AURKA, which may result in cell proliferation blockade and induction of apoptosis (PMID: 22753075). ', 'references': [{'id': 5160, 'pubMedId': 22753075, 'title': 'Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22753075'}]}]",SA16,2017-05-25T18:33:00Z
0,2015-04-24T04:31:52Z,2577,"[{'description': 'Sabutoclax is a Pan-BCL2 family inhibitor, which inhibits BCL-2, BCL-XL, MCL-1, and BFL-1, resulting in decreased tumor cell growth (PMID: 20443627).', 'references': [{'id': 2563, 'pubMedId': 20443627, 'title': 'BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20443627'}]}]",Sabutoclax,2015-12-10T16:51:44Z
0,2015-11-28T23:12:24Z,3227,"[{'description': 'Sacituzumab govitecan is an antibody-drug conjugate composed of a monoclonal anti-TROP2 antibody linked to the active metabolite of irinotecan (SN-38), which binds to TROP2 positive cancer cells and induces DNA breakage and apoptosis (PMID: 26541586).', 'references': [{'id': 3993, 'pubMedId': 26541586, 'title': 'Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26541586'}]}]",Sacituzumab govitecan,2015-12-04T21:06:27Z
0,2014-05-14T14:52:46Z,1049,"[{'description': 'Kynacyte (safingol) inhibits protein kinase C (PKC), potentially resulting in increased tumor cell death and increased sensitivity to other anti-cancer agents (PMID: 15929099, PMID: 9815717).', 'references': [{'id': 159, 'pubMedId': 9815717, 'title': 'A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/9815717'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 8724, 'pubMedId': 15929099, 'title': 'Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15929099'}]}]",Safingol,2017-05-01T18:18:23Z
0,2014-12-22T20:17:49Z,1836,"[{'description': 'SAH-p53-8 is a synthetic peptide stabilized by hydrocarbon crosslinking that preferentially binds MDM-4, disrupting p53-MDM4 binding, thus releasing sequestered p53 protein (PMID: 21075307).', 'references': [{'id': 1452, 'pubMedId': 21075307, 'title': 'A stapled p53 helix overcomes HDMX-mediated suppression of p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21075307'}]}]",SAH-p53-8,2015-06-03T19:20:38Z
0,2016-08-11T17:02:10Z,4554,[],SAH-p53-8 + Vemurafenib,2016-08-11T17:02:10Z
0,2014-03-12T15:53:16Z,909,"[{'description': 'Salirasib, S-trans,trans-farnesylthiosalycilic acid, disrupts the interaction of RAS with the cell membrane, thereby preventing RAS signaling (PMID: 20528225).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 2047, 'pubMedId': 20528225, 'title': 'Salirasib in the treatment of pancreatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20528225'}]}]",Salirasib,2016-02-08T23:29:04Z
0,2016-09-06T17:42:31Z,4649,"[{'description': 'SAM486 is an inhibitor of AMD1, which may result in delay of tumor development (PMID: 27012811). ', 'references': [{'id': 6562, 'pubMedId': 27012811, 'title': 'Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27012811'}]}]",SAM486,2016-09-06T17:42:31Z
0,2017-04-12T18:05:51Z,5535,"[{'description': 'Samalizumab (ALXN6000) is a humanized antibody against CD200 which blocks CD200-CD200R interaction, resulting in enhanced immune response (Blood 2010 116:2465).', 'references': [{'id': 8547, 'pubMedId': None, 'title': 'First-In-Human Phase I Dose Escalation Study of a Humanized Anti-CD200 Antibody (Samalizumab) In Patients with Advanced Stage B Cell Chronic Lymphocytic Leukemia (B-CLL) or Multiple Myeloma (MM)', 'url': 'http://www.bloodjournal.org/content/116/21/2465?sso-checked=true'}]}]",Samalizumab,2017-04-12T18:05:51Z
0,2016-03-10T21:31:31Z,3722,"[{'description': 'SAN1GSC consists of a derivative of Sunitinib, SAN1, conjugated to a gonadotropin-releasing hormone receptor (GnRH-R) targeting peptide, which results in decreased angiogenic signaling and may inhibit growth of GnRH-expressing tumors (PMID: 26645560).', 'references': [{'id': 4829, 'pubMedId': 26645560, 'title': 'Peptide-Drug Conjugate GnRH-Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26645560'}]}]",SAN1GSC,2016-03-10T21:42:11Z
0,2016-04-21T21:01:51Z,3990,"[{'description': 'SANT1 is a small molecule that binds to and inhibits SMO, resulting in Sonic hedgehog signaling inhibition and anti-tumor activities (PMID: 20024066).', 'references': [{'id': 5201, 'pubMedId': 20024066, 'title': 'Small-molecule modulators of the Sonic Hedgehog signaling pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20024066'}]}]",SANT1,2016-04-21T21:01:51Z
0,2014-07-28T11:24:44Z,1128,"[{'description': 'Sapacitabine is a nucleoside analog, which interferes with DNA synthesis to induce cell cycle arrest (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",sapacitabine,2014-07-28T11:24:44Z
0,2014-07-28T11:30:46Z,1130,[],Sapacitabine + Seliciclib,2014-07-28T11:30:46Z
0,2014-07-31T04:35:41Z,1282,"[{'description': 'Sapanisertib (MLN0128) is an ATP-competitive mTOR kinase inhibitor that induces apoptosis and inhibits growth in tumor cells (PMID: 25519700). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 9306, 'pubMedId': 25519700, 'title': 'MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25519700'}]}]",Sapanisertib,2017-07-07T19:09:06Z
0,2014-03-12T15:53:16Z,910,"[{'description': 'Sapitinib (AZD8931) binds to and inhibits the ERBB family members EGFR, ERBB2 (HER2), and ERBB3, which may lead to decreased tumor cell proliferation and increased apoptosis (PMID: 20145185).', 'references': [{'id': 42, 'pubMedId': 20145185, 'title': 'AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20145185'}]}]",Sapitinib,2015-05-15T19:22:44Z
0,2015-08-19T13:51:03Z,3036,[],Sapitinib + Fluorouracil + Cisplatin,2015-08-19T13:51:03Z
0,2014-08-31T15:34:19Z,1416,[],Sapitinib + Paclitaxel,2014-08-31T15:34:19Z
0,2015-02-25T17:14:55Z,2159,"[{'description': 'SAR125844 is a selective inhibitor of MET, which inhibits MET activation and downstream pathway signaling, and potentially results in decreased growth of MET-driven tumors (PMID: 25504634).', 'references': [{'id': 2009, 'pubMedId': 25504634, 'title': 'The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25504634'}]}]",SAR125844,2015-02-25T17:14:55Z
0,2014-07-28T16:55:54Z,1165,[],SAR245408 + SAR245409,2014-07-28T16:55:54Z
0,2014-05-14T14:52:46Z,1051,"[{'description': 'XL765 (SAR245409) inhibits both PI3K and mTOR kinases and results in inhibition of PI3K pathway signaling, thereby possibly leading to inhibition of cell proliferation, reduced tumor vascularization, and inhibition of tumor growth (PMID: 24634413). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 8768, 'pubMedId': 24634413, 'title': 'Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24634413'}]}]",SAR245409,2017-05-01T18:29:36Z
0,2015-08-13T20:01:31Z,3023,[],SAR245409 + Pimasertib,2015-08-13T20:01:31Z
0,2014-05-14T14:52:46Z,1052,"[{'description': 'SAR260301 is PI3K beta-selective inhibitor, which has been demonstrated to inhibit tumor growth in xenograft models (PMID: 24387221).', 'references': [{'id': 4811, 'pubMedId': 24387221, 'title': 'Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387221'}, {'id': 1788, 'pubMedId': None, 'title': 'Discovery and characterization of SAR260301, a novel PI3K?-selective inhibitor in clinical development for the treatment of PTEN-deficient tumors', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3086&sKey=baf1d502-5e79-4f22-a1ac-1645d0d388ca&cKey=c0b15ace-d738-4283-82a9-33fb6b20024e&mKey=9b2d28e7-24a0-466f-a3c9-07c21f6e9bc9'}]}]",SAR260301,2016-03-10T15:38:07Z
0,2016-08-17T15:48:05Z,4573,[],SAR260301 + Selumetinib,2016-08-17T15:48:15Z
0,2014-07-29T19:16:30Z,1225,[],SAR260301 + Vemurafenib,2014-07-29T19:16:30Z
0,2014-03-12T15:53:16Z,911,"[{'description': 'Fedratinib (SAR302503) binds and inhibits Jak2, Flt3, and Ret kinases, which may inhibit cell proliferation and tumor growth (PMID: 17541402). ', 'references': [{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}]}]",SAR302503,2017-04-03T16:32:03Z
0,2015-02-13T20:14:04Z,2078,"[{'description': 'SAR405838 binds to MDM2 and inhibits MDM2-p53 interaction, resulting in activation of wild-type p53 signaling and decreased tumor growth (PMID: 25145672).', 'references': [{'id': 1886, 'pubMedId': 25145672, 'title': 'SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25145672'}]}]",SAR405838,2017-02-22T15:12:03Z
0,2016-04-29T17:19:03Z,4026,"[{'description': 'SAR428926 is a antibody-drug conjugate that contains an anti-lysosome-associated membrane protein 1 (LAMP1) monoclonal antibody linked to the cytotoxic anti-microtubule agent DM4, which inhibits growth of LAMP1-expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",SAR428926,2016-05-11T14:39:47Z
0,2017-06-27T17:47:02Z,5933,"[{'description': 'Limited information is currently available on SAR439459 (Jun, 2017). ', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",SAR439459,2017-06-27T17:47:02Z
0,2017-06-27T17:54:12Z,5934,[],SAR439459 + REGN2810,2017-06-27T17:54:12Z
0,2017-10-03T17:45:55Z,6293,"[{'description': 'SAR439859 is a selective estrogen receptor degrader that down-regulates ER expression and signaling, resulting in tumor cell growth inhibition (Cancer Res 2017;77(4 Suppl):Abstract nr P3-04-05).', 'references': [{'id': 10042, 'pubMedId': None, 'title': 'Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models', 'url': 'http://cancerres.aacrjournals.org/content/77/4_Supplement/P3-04-05'}]}]",SAR439859,2017-10-03T17:45:55Z
0,2017-05-31T17:46:55Z,5825,"[{'description': 'SAR566658 is a monoclonal antibody against CA6 in conjugation with maytansinoid, which may deliver targeted cytotoxicity to MUC-1 over expressing tumor cells (J Clin Oncol 34, 2016 (suppl; abstr 2511).', 'references': []}]",SAR566658,2017-05-31T17:46:55Z
0,2014-03-12T15:53:16Z,912,"[{'description': 'Saracatinib (AZD0530) is a multi-kinase inhibitor with activity against ABL and SRC, which may block proliferation, metastasis, and survival in cancer cells (PMID: 19393585).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 2642, 'pubMedId': 19393585, 'title': 'Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19393585'}]}]",Saracatinib,2015-05-04T15:37:10Z
0,2015-01-14T15:12:52Z,1939,[],Saracatinib + Ceritinib,2015-01-14T15:19:08Z
0,2016-11-23T17:42:23Z,5006,[],Saracatinib + SCH772984,2016-11-23T17:42:23Z
0,2016-11-23T18:24:59Z,5010,[],Saracatinib + Selumetinib,2016-11-23T18:24:59Z
0,2014-12-30T16:11:02Z,1873,[],Sargramostim,2014-12-30T16:11:02Z
0,2015-03-17T00:48:10Z,2414,"[{'description': 'Saridegib (IPI-926) is a Smoothened (SMO) antagonist that inhibits downstream signaling, potentially resulting in decreased growth of tumors with dysregulation of Hedgehog pathway signaling (PMID: 19522463, PMID: 24608250).', 'references': [{'id': 2231, 'pubMedId': 19522463, 'title': 'Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19522463'}, {'id': 2232, 'pubMedId': 24608250, 'title': 'Impact of the Smoothened inhibitor, IPI-926, on smoothened ciliary localization and Hedgehog pathway activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608250'}]}]",Saridegib,2015-06-15T09:45:46Z
0,2015-02-25T17:48:03Z,2161,"[{'description': 'Savolitinib (AZD6094) is a selective MET inhibitor, which inhibits MET kinase activity, resulting in decreased downstream signaling, and may inhibit growth of MET-expressing tumors (PMID: 25248999).', 'references': [{'id': 2010, 'pubMedId': 25248999, 'title': 'Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25248999'}]}]",Savolitinib,2017-07-12T17:25:47Z
0,2015-02-27T16:53:33Z,2207,[],Saxagliptin,2015-02-27T16:53:42Z
0,2015-05-19T20:32:01Z,2712,"[{'description': 'SB-431542 is an inhibitor of TGFBR1, which blocks activation of downstream signaling targets and may prevent migration and anchorage independent growth of cancer cells (PMID: 15967103).', 'references': [{'id': 2768, 'pubMedId': 15967103, 'title': 'A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15967103'}]}]",SB-431542 ,2015-05-22T17:26:10Z
0,2017-09-26T18:17:34Z,6242,"[{'description': 'SB3 is a Herceptin (trastuzumab) biosimilar that binds to Erbb2 (Her2) and induces anti-tumor immune response against Erbb2 (Her2)-positive tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 153PD).', 'references': [{'id': 9997, 'pubMedId': None, 'title': 'One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]}]",SB3,2017-09-26T19:13:41Z
0,2016-06-12T00:50:44Z,4281,"[{'description': 'SB590885 is a RAF kinase inhibitor with greater specificity for BRAF over CRAF, and has significant activity in culture against BRAF mutants including V600E (PMID: 17145850).', 'references': []}]",SB590885,2016-06-12T09:22:26Z
0,2016-03-21T19:18:24Z,3796,"[{'description': 'SBE13 is a type II kinase inhibitor that targets the inactive conformation of PLK1 and may result in decreased cell proliferation and disruption of the mitotic cycle (PMID: 20139717).', 'references': [{'id': 4953, 'pubMedId': 20139717, 'title': 'Biological impact of freezing Plk1 in its inactive conformation in cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20139717'}]}]",SBE13,2016-03-21T19:18:24Z
0,2016-10-17T20:25:44Z,4847,"[{'description': 'SBI-0206965 is a small molecule that selectively inhibits ULK1, resulting in decreased phosphorylation of ULK1 targets, and potentially leading to increased tumor cell death in combination with mTOR inhibitors (PMID: 26118643).', 'references': [{'id': 6785, 'pubMedId': 26118643, 'title': 'Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26118643'}]}]",SBI-0206965,2016-10-17T20:25:44Z
0,2016-10-17T20:27:57Z,4848,[],SBI-0206965 + AZD8055,2016-10-17T20:27:57Z
0,2015-12-19T14:20:18Z,3307,"[{'description': 'SBI-0640726, a structural analog of the eIF4F complex inhibitor SBI-0640756, inhibits Akt/mTOR signaling in cells in culture (PMID: 26603897).', 'references': [{'id': 4137, 'pubMedId': 26603897, 'title': 'SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26603897'}]}]",SBI-0640726,2015-12-21T15:04:51Z
0,2015-12-19T14:16:18Z,3306,"[{'description': 'SBI-0640756 inhibits the eIF4F complex, thereby inhibiting mRNA translation as well as inhibition of Akt/mTOR signaling (PMID: 26603897).', 'references': [{'id': 4137, 'pubMedId': 26603897, 'title': 'SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26603897'}]}]",SBI-0640756,2015-12-21T15:00:45Z
0,2015-12-20T01:20:25Z,3309,"[{'description': 'SBI-755199, a structural analog of the eIF4F complex inhibitor SBI-0640756, inhibits mRNA initiation and induces cell death in human cancer cell lines (PMID: 26603897).', 'references': [{'id': 4137, 'pubMedId': 26603897, 'title': 'SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26603897'}]}]",SBI-755199,2015-12-20T01:20:25Z
0,2017-05-23T17:03:49Z,5748,"[{'description': 'Limited information is currently available on SC-006 (May, 2017).', 'references': []}]",SC-006,2017-05-23T17:03:49Z
0,2015-04-30T20:48:40Z,2618,"[{'description': 'SCH772984 is an ATP-competitive inhibitor of both ERK1 and ERK2, which may result in growth inhibition and tumor regression (PMID: 23614898).', 'references': [{'id': 2633, 'pubMedId': 23614898, 'title': 'Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23614898'}]}]",SCH772984,2015-04-30T20:48:40Z
0,2016-11-22T18:39:58Z,4988,[],SCH772984 + Temsirolimus,2016-11-22T18:39:58Z
0,2016-07-19T16:55:04Z,4476,[],SCH772984 + Trametinib,2016-07-19T16:55:04Z
0,2016-11-23T16:55:35Z,4996,[],SCH772984 + Vistusertib,2017-06-09T15:04:24Z
0,2015-06-01T17:01:39Z,2750,"[{'description': 'SD-093 is an ATP competitive inhibitor of TGFBR1, which may promote immune response and inhibit tumor growth (PMID: 15183116, PMID: 15289325).', 'references': [{'id': 2872, 'pubMedId': 15183116, 'title': 'Selective inhibitors of type I receptor kinase block cellular transforming growth factor-beta signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15183116'}, {'id': 2873, 'pubMedId': 15289325, 'title': 'Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15289325'}]}]",SD-093,2015-06-01T17:01:39Z
0,2015-09-18T14:28:07Z,3084,"[{'description': 'SD-101 is an oligonucleotide which interacts with Toll-Like Receptor 9 (TLR9) and activates memory T helper cells 1 (Th1) (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",SD-101,2015-09-18T14:28:07Z
0,2015-06-01T16:04:07Z,2749,"[{'description': 'SD-208 is an ATP competitive inhibitor of TGFBR1, which may promote immune response and inhibit tumor growth (PMID: 15520202).', 'references': [{'id': 2871, 'pubMedId': 15520202, 'title': 'SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15520202'}]}]",SD-208,2015-06-01T21:05:57Z
0,2016-10-07T19:29:09Z,4804,"[{'description': 'SD-7300 is an inhibitor of MMP-2, 9, and 13 that results in chelation of the zinc ion thereby inhibiting the active site and possibly resulting in decreased metastasis and improved survival (PMID: 27466357). ', 'references': [{'id': 6722, 'pubMedId': 27466357, 'title': 'Inhibition of Breast Cancer Metastasis by Presurgical Treatment with an Oral Matrix Metalloproteinase Inhibitor: A Preclinical Proof-of-Principle Study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27466357'}]}]",SD-7300,2016-10-07T19:29:09Z
0,2016-06-20T02:20:36Z,4326,"[{'description': 'Limited information is currently available on SDX-7320, a putative MetAP2 inhibitor (Jun 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",SDX-7320,2016-06-20T02:20:36Z
0,2017-05-26T15:57:14Z,5780,"[{'description': 'SEA-CD40 is a non-fucosylated monoclonal anti-CD40 antibody that has enhanced affinity, resulting in activation of immune response and increased anti-tumor immunity (Cancer Res 2015;75(15 Suppl), Abstract nr 2472).', 'references': [{'id': 9004, 'pubMedId': None, 'title': 'SEA-CD40, a sugar engineered non-fucosylated anti-CD40 antibody with improved immune activating capabilities', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/2472'}]}]",SEA-CD40,2017-05-26T15:57:14Z
0,2017-05-12T17:28:19Z,5672,"[{'description': 'SEL120-34A selectively inhibits CDK8, resulting in decreased STAT5 and STAT1 phosphorylation and downstream signaling, and potentially leading to reduced tumor cell growth (PMID: 28422713).', 'references': [{'id': 8888, 'pubMedId': 28422713, 'title': 'SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28422713'}]}]",SEL120-34A,2017-05-12T17:28:19Z
0,2016-03-08T17:25:37Z,3693,"[{'description': 'SEL24-B489 is an inhibitor of PIM kinases 1, 2, 3, and FLT3, which may suppress cell growth and induce apoptosis (Blood 126 (23):706.December 2015).', 'references': [{'id': 4788, 'pubMedId': None, 'title': 'A Novel Pan-PIM Kinase Inhibitor, SEL24-B489, Induces Apoptosis and Inhibits Proliferation of Diffuse Large B-Cell Lymphoma Cells through Inhibition of Protein Translation and Attenuation of Myc and NFkB Activity', 'url': 'https://ash.confex.com/ash/2015/webprogram/Paper84427.html'}]}]",SEL24-B489,2017-05-24T16:57:57Z
0,2016-03-08T17:34:14Z,3694,[],SEL24-B489 + Ibrutinib,2016-03-08T17:34:14Z
0,2016-09-13T16:41:19Z,4702,"[{'description': 'Selectikine (EMD 521873) is composed of a DNA-targeted antibody linked to the cytokine IL-2, which potentially results in an increased anti-tumor immune response (PMID: 22918078).', 'references': [{'id': 6609, 'pubMedId': 22918078, 'title': 'A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22918078'}]}]",Selectikine,2016-09-13T16:41:19Z
0,2016-01-29T13:53:51Z,3473,"[{'description': 'Selenomethionine is a naturally occurring amino acid that may have antioxidant activity (PMID: 10867031).', 'references': [{'id': 4482, 'pubMedId': 10867031, 'title': 'Selenomethionine: a review of its nutritional significance, metabolism and toxicity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10867031'}]}]",Selenomethionine,2016-01-29T13:53:51Z
0,2014-07-28T11:29:44Z,1129,"[{'description': 'Roscovotine (seliciclib) inhibits Cdc2, Cdk2 and Cdk5, which results in disruption of cell-cycle progression and decreased cell proliferation (PMID: 9030781, PMID: 9366565)', 'references': [{'id': 1998, 'pubMedId': 9366565, 'title': 'Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/9366565'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 1997, 'pubMedId': 9030781, 'title': 'Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/9030781'}]}]",Seliciclib,2015-02-25T15:22:45Z
0,2015-06-10T18:14:13Z,2814,[],Seliciclib + Aldoxorubicin,2015-06-10T18:14:13Z
0,2015-06-10T20:56:42Z,2816,[],Seliciclib + Alvocidib,2015-06-10T20:56:42Z
0,2014-11-29T00:00:53Z,1749,"[{'description': 'Selinexor inhibits CRM1, preventing CRM1-mediated nuclear export of tumor suppressor proteins and potentially restoring normal tumor suppressor function (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Selinexor,2014-11-29T00:04:11Z
0,2017-05-07T17:48:42Z,5639,[],Selinexor + Bortezomib + Dexamethasone,2017-05-07T17:48:42Z
0,2017-02-07T03:25:49Z,5286,[],Selinexor + Doxorubicin,2017-02-07T03:25:49Z
0,2017-03-16T03:09:42Z,5448,[],Selinexor + Fludarabine phosphate + Cytarabine + Methotrexate + Prednisone,2017-03-16T03:09:42Z
0,2015-11-08T21:51:34Z,3189,[],Selinexor + Sorafenib,2015-11-08T21:51:34Z
0,2014-03-12T15:53:16Z,913,"[{'description': 'Selumetinib (AZD6244) inhibits mitogen-activated protein kinase kinases (MEK or MAPK/ERK kinases) 1 and 2, which may prevent the activation of MEK1/2-dependent effector proteins and transcription factors, reducing cellular proliferation in various cancers (PMID: 27467210).', 'references': [{'id': 8453, 'pubMedId': 27467210, 'title': 'Selumetinib in the treatment of non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27467210'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Selumetinib,2017-04-06T10:25:40Z
0,2014-09-05T04:51:01Z,1420,[],Selumetinib + BEZ235,2014-09-05T04:51:01Z
0,2015-02-28T10:57:05Z,2222,[],Selumetinib + Cisplatin + Gemcitabine,2015-02-28T10:57:05Z
0,2014-09-11T02:26:16Z,1432,[],Selumetinib + Dacarbazine,2014-09-11T02:26:16Z
0,2014-07-27T20:16:41Z,1117,[],Selumetinib + Docetaxel,2014-07-27T20:16:41Z
0,2016-06-12T23:41:01Z,4282,[],Selumetinib + Paclitaxel,2016-06-12T23:41:01Z
0,2014-05-21T16:24:32Z,1061,[],Selumetinib + PLX4720,
0,2016-10-06T15:23:59Z,4801,[],Selumetinib + Sorafenib,2016-10-06T15:23:59Z
0,2016-09-23T17:45:59Z,4748,[],Selumetinib + Tazemetostat,2016-09-23T17:45:59Z
0,2017-03-30T20:25:01Z,5501,[],Selumetinib + Torkinib,2017-07-07T18:45:11Z
0,2016-03-17T17:17:58Z,3773,[],Selumetinib + Vemurafenib,2016-03-17T17:17:58Z
0,2016-03-17T17:14:41Z,3771,[],Selumetinib + ZSTK474,2016-03-17T17:14:41Z
0,2015-04-17T19:11:16Z,2548,"[{'description': 'Semagacestat (LY450139) is a gamma secretase inhibitor, which blocks Notch cleavage and activation, and may inhibit angiogenesis and tumor growth (PMID: 22323718).', 'references': [{'id': 2511, 'pubMedId': 22323718, 'title': 'Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22323718'}]}]",Semagasestat,2015-04-27T12:44:26Z
0,2015-04-24T01:15:07Z,2572,"[{'description': 'Semaxanib (SU5416) is an inhibitor of FLT1 (VEGFR1), KDR (VEGFR2), and FLT3, which inhibits tumor vascularization and growth (PMID: 9892193, PMID: 12351406).', 'references': [{'id': 2559, 'pubMedId': 9892193, 'title': 'SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/9892193'}]}]",Semaxanib,2015-04-24T01:16:17Z
0,2016-03-23T02:55:52Z,3819,"[{'description': 'SEN-450 is a SMO antagonist, which inhibits Hh pathway signaling and may result in decreased tumor cell growth (PMID: 22072503).', 'references': [{'id': 4991, 'pubMedId': 26683772, 'title': 'Bromodomain and hedgehog pathway targets in small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26683772'}, {'id': 4994, 'pubMedId': 22072503, 'title': 'In vitro and in vivo characterization of a novel Hedgehog signaling antagonist in human glioblastoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22072503'}]}]",SEN-450,2016-03-23T03:50:38Z
0,2016-03-23T04:13:04Z,3821,[],SEN-450 + Temozolomide,2016-03-23T04:13:04Z
0,2016-01-06T14:17:27Z,3364,"[{'description': 'Senexin A is a protein kinase inhibitor of CDK8 and the CDK8 paralog, CDK19, and has been demonstrated to prevent the tumor promoting paracrine effects of DNA damaging chemotherapeutic agents (PMID: 22869755).', 'references': [{'id': 4209, 'pubMedId': 22869755, 'title': 'Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869755'}]}]",Senexin A,2016-01-07T19:06:56Z
0,2016-01-06T14:42:31Z,3365,"[{'description': 'Senexin B is a protein kinase inhibitor of CDK8 and the CDK8 paralog, CDK19, which may result in tumor growth inhibition and enhance the effects of chemotherapeutic agents (Cancer Res January 1, 2015 75; PR08). ', 'references': [{'id': 4211, 'pubMedId': None, 'title': 'Targeting tumor microenvironment with selective small-molecule inhibitors of CDK8/19', 'url': 'http://cancerres.aacrjournals.org/content/75/1_Supplement/PR08.abstract'}]}]",Senexin B,2016-01-07T19:07:09Z
0,2015-08-12T02:07:47Z,3013,"[{'description': 'sEphB4-HSA is a fusion protein that consists of the extracellular domain of human ephrin type-B receptor 4 (EphB4) and human serum albumin (HSA), which acts as a decoy to inhibit EphB4 signaling, leading to inhibition of tumor cell growth (PMID: 23721559, PMID: 25148033).', 'references': [{'id': 3429, 'pubMedId': 23721559, 'title': 'EphB4 as a therapeutic target in mesothelioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23721559'}]}]",sEphB4-HSA,2016-01-14T18:20:17Z
0,2016-07-18T19:06:03Z,4467,[],sEphB4-HSA + Bevacizumab,2016-07-18T19:06:03Z
0,2016-04-15T17:59:08Z,3944,[],sEphB4-HSA + Pembrolizumab,2016-04-15T17:59:08Z
0,2015-03-06T02:12:18Z,2309,"[{'description': 'Serdemetan (JNJ-26854165) is a small molecule that regulates ABCA1 expression and inhibits cholesterol transport, resulting in activation of p53 and increased cell death in p53 wild-type and mutant cells (PMID: 23820125).', 'references': [{'id': 2107, 'pubMedId': 23820125, 'title': 'The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23820125'}]}]",Serdemetan,2017-05-02T15:31:12Z
0,2014-03-12T15:53:16Z,820,"[{'description': 'Seribantumab (SAR256212) is a human monoclonal antibody that binds ERBB3 (HER3) and prevents ligand binding and heterodimerization with other ERBB family members, resulting in decreased activation of downstream signaling and potentially leading to reduced tumor growth (PMID: 26310543).', 'references': [{'id': 5081, 'pubMedId': 26310543, 'title': 'Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26310543'}, {'id': 3323, 'pubMedId': None, 'title': 'An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation', 'url': 'http://cancerres.aacrjournals.org/content/70/6/2485.short'}]}]",Seribantumab,2017-07-24T16:32:03Z
0,2017-07-24T16:20:37Z,6003,[],Seribantumab + XL147,2017-07-24T16:20:37Z
0,2014-03-12T15:53:16Z,915,"[{'description': 'SF1126 is a prodrug of LY294002, a pan PI3K inhibitor with additional activity against BRD4, which potentially leads to decreased tumor growth (PMID: 23355037, PMID: 27496136).', 'references': [{'id': 7039, 'pubMedId': 27496136, 'title': 'Single Agent and Synergistic Activity of the ""First-in-Class"" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27496136'}, {'id': 7040, 'pubMedId': 23355037, 'title': 'An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23355037'}, {'id': 2058, 'pubMedId': 25215588, 'title': 'Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25215588'}]}]",SF1126,2017-05-01T18:28:29Z
0,2016-11-14T21:36:39Z,4956,[],SF1126 + Sorafenib,2016-11-14T21:36:39Z
0,2014-12-08T14:24:31Z,1771,"[{'description': 'SGC-CBP30 is a small molecule probe that inhibits the bromodomains of CREBBP and EP300 (PMID: 24946055).\r\n', 'references': [{'id': 1279, 'pubMedId': 24946055, 'title': 'Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24946055'}]}]",SGC-CBP30,2014-12-08T14:24:31Z
0,2015-06-19T00:27:31Z,2856,"[{'description': 'SGC0946 inhibits DOT1L, resulting in reduced viability of leukemia cells with MLL fusions (PMID: 23250418).', 'references': [{'id': 3092, 'pubMedId': 23250418, 'title': 'Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23250418'}]}]",SGC0946,2016-02-19T17:59:34Z
0,2015-01-16T05:57:06Z,1949,"[{'description': 'SGI-110 is antimetabolite of a decitabine, which upon activation inhibits DNA methyltransferase, resulting in hypomethylation and cell-cycle arrest (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",SGI-110,2016-02-16T21:17:47Z
0,2015-02-06T13:58:13Z,2015,[],SGI-110 + Irinotecan,2015-02-06T13:58:13Z
0,2017-03-28T04:02:57Z,5488,[],SGI-110 + MEDI4736 + Tremelimumab,2017-03-28T04:02:57Z
0,2016-02-15T16:06:20Z,3533,"[{'description': 'SGI-1776 is a small molecule inhibitor of PIMs 1, 2, 3, and FLT-3, which may result in cell death via indirect inhibition of Mcl-1 transcription and protein synthesis (PMID: 21628411).', 'references': [{'id': 4596, 'pubMedId': 21628411, 'title': 'Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21628411'}]}]",SGI-1776,2016-02-15T16:06:20Z
0,2016-12-20T22:04:24Z,5114,"[{'description': 'SGI-7079 inhibits AXL, which potentially results in decreased tumor cell growth and migration (PMID: 23091115, PMID: 24014597).', 'references': [{'id': 7361, 'pubMedId': 23091115, 'title': 'An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23091115'}, {'id': 7360, 'pubMedId': 24014597, 'title': 'TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24014597'}]}]",SGI-7079,2017-03-16T16:21:06Z
0,2014-09-25T04:46:27Z,1532,"[{'description': 'SGI-1027 binds and inhibits DNMT1, DNMT3A, and DNMT3B, which leads to decreased DNA methylation and may result the activation of silenced tumor suppressor genes (PMID: 19417133).', 'references': [{'id': 823, 'pubMedId': 19417133, 'title': 'A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19417133'}]}]",SGI_1027,2015-06-01T20:08:54Z
0,2017-06-16T15:07:08Z,5896,"[{'description': 'SGN-2FF is an analog of fucose that inhibits protein fucosylation, potentially affects multiple protein functions and inhibits tumor cell growth (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",SGN-2FF,2017-06-16T15:07:08Z
0,2016-02-25T20:12:32Z,3615,"[{'description': 'SGN-LIV1A is a conjugate of anti-zinc transporter LIV-1 antibody and monomethyl auristatin E (MMAE), which delivers the cytotoxic agent to LIV1-positive cells, resulting in antitumor activity (PMID: 25253783).', 'references': [{'id': 4705, 'pubMedId': 25253783, 'title': 'SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25253783'}]}]",SGN-LIV1A ,2016-02-25T20:12:32Z
0,2015-04-10T01:36:51Z,2518,"[{'description': 'SGT-53 is a cationic liposomal complex that is linked to an antibody targeting the transferrin receptor (Tff) and contains wild-type Tp53 plasmid, thereby delivering wild-type Tp53 to tumor cells expressing Tff and potentially restoring wild-type Tp53 activity (PMID: 23470564)', 'references': [{'id': 2440, 'pubMedId': 23470564, 'title': 'Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23470564'}]}]",SGT-53,2015-04-10T16:41:37Z
0,2016-02-25T20:39:51Z,3617,[],SGT-53 + Cyclophosphamide + Topotecan,2016-02-25T20:39:51Z
0,2014-03-12T15:53:16Z,916,"[{'description': 'SGX523 is a highly selective, ATP-competitive inhibitor of MET that blocks Met signaling, resulting in cell death in tumor cells (PMID: 19934279).', 'references': [{'id': 6981, 'pubMedId': 19934279, 'title': 'SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19934279'}]}]",SGX523,2016-11-07T19:41:38Z
0,2016-02-19T02:07:53Z,3552,"[{'description': 'SH-1242 is an analog of deguelin that binds the C-terminus of Hsp90 and inhibits its function, resulting in decreased tumor cell growth (PMID: 26645561).', 'references': [{'id': 4627, 'pubMedId': 26645561, 'title': 'Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26645561'}]}]",SH-1242,2016-02-19T02:07:53Z
0,2016-02-01T19:10:32Z,3493,"[{'description': 'SH4-54 is the benzoic analogue of BP-1-102, which inhibits Stat3 signaling and leads to antitumor effects (PMID: 26088127).', 'references': [{'id': 4499, 'pubMedId': 26088127, 'title': 'Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26088127'}]}]",SH4-54,2016-02-01T19:10:32Z
0,2016-02-01T19:11:31Z,3494,"[{'description': 'SH5-07 is the hydroxamic acid analogue of BP-1-102, which inhibits Stat3 signaling and leads to antitumor effects (PMID: 26088127).', 'references': [{'id': 4499, 'pubMedId': 26088127, 'title': 'Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26088127'}]}]",SH5-07,2016-02-01T19:11:31Z
0,2016-07-28T19:52:11Z,4504,"[{'description': 'SHP099 is an allosteric inhibitor of SHP2, which reduces downstream signaling and potentially leads to decreased growth of receptor tyrosine kinase-driven tumors (PMID: 27362227).', 'references': [{'id': 6394, 'pubMedId': 27362227, 'title': 'Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27362227'}]}]",SHP099,2016-07-28T20:41:21Z
0,2017-08-22T13:58:01Z,6137,"[{'description': 'SHR-1210 is an antibody that targets PD-1 (PDCD1) and inhibits binding of PD-L1 and PD-L2, potentially resulting in decreased tumor growth (J Clin. Onc. 2017 35:15_suppl, e15572-e15572).', 'references': [{'id': 9759, 'pubMedId': None, 'title': 'Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.', 'url': 'http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e15572'}]}]",SHR-1210,2017-08-22T14:06:51Z
0,2016-07-08T18:17:06Z,4430,"[{'description': 'Si306 inhibits SRC, which may result in decreased tumor cell growth (PMID: 27196762).', 'references': [{'id': 6269, 'pubMedId': 27196762, 'title': 'Suppression of SRC Signaling Is Effective in Reducing Synergy between Glioblastoma and Stromal Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196762'}]}]",Si306,2016-07-08T18:17:06Z
0,2016-07-08T18:29:58Z,4431,[],Si306 + Radiotherapy,2016-07-08T18:29:58Z
0,2016-03-23T04:01:52Z,3820,"[{'description': 'SIBI-C1 inhibits SMO, resulting in decreased Hedgehog pathway signaling and may lead to reduced tumor growth (PMID: 23825539).', 'references': [{'id': 4995, 'pubMedId': 23825539, 'title': 'Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825539'}]}]",SIBI-C1,2016-03-23T04:01:52Z
0,2015-08-28T01:39:34Z,3066,[],Sildenafil,2015-08-28T01:39:34Z
0,2017-08-03T18:31:01Z,6084,"[{'description': 'Silmitasertib (CX-4945) inhibits CK2, potentially resulting in decreased growth of tumor cells, alone and in combination with other agents (PMID: 21159648, PMID: 27758824).', 'references': [{'id': 9677, 'pubMedId': 21159648, 'title': 'CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21159648'}, {'id': 9675, 'pubMedId': 27758824, 'title': 'CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27758824'}]}]",Silmitasertib,2017-08-03T18:31:01Z
0,2016-01-31T14:05:12Z,3485,"[{'description': ""Sylvant (siltuxmab) is an anti-IL-6 chimeric monoclonal antibody, which inhibits IL6 signaling and may lead to decreased tumor cell growth (PMID: 26170629, PMID: 26744529). Sylvant (siltuximab) is FDA approved for patients with multicentric Castleman's disease who do not have HIV or HHV-8 (FDA.gov)."", 'references': [{'id': 4492, 'pubMedId': 26170629, 'title': 'Siltuximab (CNTO 328): a promising option for human malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26170629'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",siltuximab,2016-03-21T16:27:32Z
0,2017-05-09T13:42:51Z,5649,"[{'description': 'SIM-89 is an inhibitor of c-MET, TRKA, and AMPK, which may result in antitumor activity including inhibition of cell proliferation and suppression of cell migration (PMID: 28332364). ', 'references': [{'id': 8847, 'pubMedId': 28332364, 'title': 'Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28332364'}]}]",SIM-89,2017-05-09T13:42:51Z
0,2014-11-04T22:49:26Z,1704,[],simtuzumab + FOLFIRI,2014-11-04T22:49:26Z
0,2015-03-02T16:30:27Z,2239,[],Simvastatin,2015-03-02T16:30:49Z
0,2015-05-08T15:10:42Z,2648,"[{'description': 'Provenge (sipuleucel-T) is composed of autologous dendritic cells exposed to a PAP-GCSF fusion protein (PA2024), which stimulates a cytotoxic immune response towards PAP-expressing tumor cells (PMID: 25565923).', 'references': [{'id': 2674, 'pubMedId': 25708576, 'title': 'Immunotherapy: Sipuleucel-T induces humoral antigen spread in patients with mCRPC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25708576'}, {'id': 3139, 'pubMedId': 25565923, 'title': 'Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25565923'}]}]",Sipuleucel-T,2017-06-19T19:25:09Z
0,2014-03-12T15:53:16Z,917,"[{'description': 'Rapamune (sirolimus) binds to the FKBP-12 to generate an immunosuppressive complex that binds and allosterically inhibits mTOR (NCI Drug Dictionary, PMID: 25261369). Rapamune (sirolimus) is FDA approved for the prevention of renal transplant rejection (FDA.gov). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Sirolimus,2015-04-02T21:08:47Z
0,2015-08-18T16:46:18Z,3033,[],Sirolimus + Celecoxib,2015-08-18T16:46:18Z
0,2017-04-07T18:42:10Z,5513,[],Sirolimus + Cyclophosphamide,2017-04-07T18:42:10Z
0,2015-03-12T19:20:06Z,2385,[],Sirolimus + Cyclophosphamide + Dexamethasone + Hydroxychloroquine,2015-03-12T19:20:06Z
0,2014-07-29T19:13:07Z,1224,[],Sirolimus + Cyclophosphamide + Topotecan,2014-07-29T19:13:07Z
0,2014-07-28T18:38:19Z,1177,"[{'description': 'A combination of the mTOR inhibitor Sirolimus and the antimalarial Hydroxychloroquine as antineoplastic therapy. Hydorxychloroquine may enhance the effectiveness of targeted therapy by disrupting autophagy-mediated cell survival (PMID: 21959046).', 'references': [{'id': 480, 'pubMedId': 21959046, 'title': 'Chloroquine enhances the cytotoxicity of topotecan by inhibiting autophagy in lung cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21959046'}]}]",Sirolimus + Hydroxychloroquine,2014-07-28T18:38:19Z
0,2015-05-14T17:12:04Z,2676,[],Sirolimus + LY294002,2015-05-14T17:12:04Z
0,2014-10-02T14:03:05Z,1593,[],Sirolimus + Metformin,2014-10-02T14:03:05Z
0,2015-03-06T00:05:33Z,2304,[],Sirolimus + Methotrexate,2015-03-06T00:05:33Z
0,2016-10-17T20:36:35Z,4850,[],Sirolimus + SBI-0206965,2016-10-17T20:36:35Z
0,2015-03-02T16:19:35Z,2238,[],Sirolimus + Tacrolimus + Methotrexate,2015-03-10T04:25:37Z
0,2016-02-23T20:27:22Z,3596,[],Sirolimus + Trametinib,2016-02-23T20:27:22Z
0,2015-01-27T14:47:54Z,1979,[],Sirolimus + Trastuzumab,2015-01-27T14:47:54Z
0,2015-06-10T18:10:30Z,2813,[],Sirolimus + UCN-01,2015-06-10T18:10:30Z
0,2014-07-31T21:24:43Z,1329,[],Sirolimus + Vismodegib,2014-07-31T21:24:43Z
0,2017-02-28T17:20:32Z,5387,[],Sirolimus + WEHI-539,2017-02-28T17:20:32Z
0,2015-04-26T10:20:16Z,2592,[],Sirolimus + X-396,2015-04-26T10:20:16Z
0,2016-03-24T20:06:09Z,3830,"[{'description': 'Sirtinol inhibits SIRT1 and SIRT2, with higher activity towards SIRT2, which may result in decreased tumor cell growth (PMID: 25486469).', 'references': [{'id': 5015, 'pubMedId': 25486469, 'title': 'Sirtuin deacetylases: a new target for melanoma management.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25486469'}]}]",Sirtinol,2016-11-11T19:30:36Z
0,2015-04-29T17:27:51Z,2609,"[{'description': 'SJ-172550 inhibits the binding of MDM4 (MDMX) to p53, potentially resulting in activation of p53 and increased tumor cell death (PMID: 20080970)', 'references': [{'id': 2608, 'pubMedId': 20080970, 'title': 'Identification and characterization of the first small molecule inhibitor of MDMX.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20080970'}]}]",SJ-172550,2015-06-03T19:19:15Z
0,2015-06-18T20:42:11Z,2850,"[{'description': 'SJA5 is a CXCR4 antagonist, which binds to and inhibits CXCR4, potentially resulting in decreased tumor cell migration (PMID: 25775124).', 'references': [{'id': 3087, 'pubMedId': 25775124, 'title': 'IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25775124'}]}]",SJA5,2015-06-25T21:00:03Z
0,2015-05-21T17:59:50Z,2730,"[{'description': 'SJB2-043 is an inhibitor of USP1, which blocks deubiquitination and promotes degradation of target genes and may inhibit growth in cancer cells (PMID: 24130053).', 'references': [{'id': 2693, 'pubMedId': 24130053, 'title': 'Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24130053'}]}]",SJB2-043,2015-05-22T01:16:54Z
0,2017-08-03T15:41:52Z,6078,"[{'description': 'SJB3-019A irreversibly inhibits USP1, resulting in decreased USP1 deubiquitinylating activity and downstream DNA repair pathway signaling, and reduced tumor cell viability (PMID: 28270494).', 'references': [{'id': 9668, 'pubMedId': 28270494, 'title': 'Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28270494'}]}]",SJB3-019A,2017-08-03T15:41:52Z
0,2016-01-31T01:03:55Z,3480,"[{'description': 'SKF-96365 is a non-specific inhibitor of store-operated calcium entry, leading to cell-cycle arrest and suppression of tumor cell growth (PMID: 23383239, PMID: 20590636, PMID: 26803057).', 'references': [{'id': 4489, 'pubMedId': 23383239, 'title': 'Protective effects of SKF-96365, a non-specific inhibitor of SOCE, against MPP+-induced cytotoxicity in PC12 cells: potential role of Homer1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23383239'}, {'id': 4490, 'pubMedId': 20590636, 'title': 'The transient receptor potential channel antagonist SKF96365 is a potent blocker of low-voltage-activated T-type calcium channels.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20590636'}]}]",SKF-96365,2016-02-12T15:40:13Z
0,2016-03-30T02:06:52Z,3873,"[{'description': 'SKLB646 is a multi-kinase inhibitor with activity against Src, Kdr (Vegfr2), Braf and Craf, resulting in decreased downstream signaling and potentially leading to reduced tumor growth (PMID: 26721945).', 'references': [{'id': 5074, 'pubMedId': 26721945, 'title': 'Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26721945'}]}]",SKLB646,2016-03-30T02:06:52Z
0,2015-02-02T22:33:11Z,2005,"[{'description': 'SL-401 is a fusion protein of human interleukin 3 (IL3) and the first 388 amino acids of diphtheria toxin [DT(388)], which binds to IL3 receptors and is transported into the cytosol where it inhibits protein translation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",SL-401,2015-02-02T22:33:11Z
0,2015-08-12T01:00:32Z,3010,"[{'description': 'SL-701is a cancer vaccine prepared by pulsing dendritic cells with glioma-associated antigens, which may have anti-tumor activity (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",SL-701,2015-08-12T01:00:32Z
0,2017-09-19T20:13:28Z,6223,"[{'description': 'SL-801 is a small molecule inhibitor of XPO1, which prevents substrates from binding to XPO1, thereby disrupting the nuclear export of proteins, and thus, may lead to inhibition of tumor growth (Journal of Clinical Oncology 33, no. 15_suppl).', 'references': [{'id': 9954, 'pubMedId': None, 'title': 'Preclinical activity of SL-801, a reversible inhibitor of Exportin-1 (XPO1)/Chromosome Region Maintenance-1 (CRM1) in solid and hematologic cancers', 'url': 'http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.e13543'}]}]",SL-801,2017-09-19T20:13:28Z
0,2016-11-14T16:42:14Z,4954,"[{'description': 'SL0101 is an allosteric inhibitor of the N-terminal kinase domain of RSK1/2, which potentially results in reduced tumor cell proliferation (PMID: 27528706).', 'references': [{'id': 7031, 'pubMedId': 27528706, 'title': 'Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27528706'}]}]",SL0101,2016-11-14T17:21:40Z
0,2017-04-11T16:19:54Z,5525,"[{'description': 'SL327 inhibits MEK1 and MEK2, potentially resulting in decreased  viability and increased apoptosis of tumor cells (PMID: 10969080, PMID: 28178630).', 'references': [{'id': 8530, 'pubMedId': 10969080, 'title': 'Regulation of cyclooxygenase-2 induction in the mouse uterus during decidualization. An event of early pregnancy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10969080'}, {'id': 8529, 'pubMedId': 28178630, 'title': 'Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28178630'}]}]",SL327,2017-04-21T20:12:28Z
0,2017-04-11T16:31:27Z,5526,[],SL327 + Sunitinib,2017-04-11T16:31:27Z
0,2016-05-18T15:44:58Z,4126,"[{'description': 'SLC-0111 (U-104) inhibits the carbonic anhydrase CA-IX, potentially leading to decreased growth and metastasis of hypoxic tumors (PMID: 27066484, PMID: 21415165).', 'references': [{'id': 5572, 'pubMedId': 27066484, 'title': 'Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27066484'}, {'id': 5573, 'pubMedId': 21415165, 'title': 'Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21415165'}]}]",SLC-0111,2016-05-18T15:44:58Z
0,2016-08-16T18:35:09Z,4572,"[{'description': 'SLCB050 is an inhibitor that blocks the AIMP2 splice variant (DX2) from interacting with CDKN2A (p14/ARF), thereby possibly resulting in repression of tumor growth and apoptosis (PMID: 27302160). ', 'references': []}]",SLCB050,2016-08-16T18:35:09Z
0,2015-06-01T18:21:42Z,2754,"[{'description': 'SM16 is a TGFBR1 kinase inhibitor, which may block downstream signaling, proliferation, and migration in cancer cells (PMID: 17332368).', 'references': [{'id': 2877, 'pubMedId': 17332368, 'title': 'A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17332368'}]}]",SM16,2015-06-01T18:25:37Z
0,2017-06-08T19:00:56Z,5866,"[{'description': 'SM88 is a 4-component combination consists of tyrosine isomers and 3 low dose repurposed drugs including modulators of Cyp3a4, mTOR, and oxidative stress, which may selectively kill tumor cells (J Clin Oncol 35, 2017 (suppl; abstr e14061)). ', 'references': [{'id': 9092, 'pubMedId': None, 'title': 'Phase Ib pharmacokinetics of non-hormonal SM88 in patients with non-metastatic recurrent prostate cancer.', 'url': 'http://abstracts.asco.org/199/AbstView_199_182430.html'}]}]",SM88,2017-06-19T14:56:06Z
0,2016-03-03T19:52:44Z,3673,"[{'description': 'SMI-4a is a small molecule inhibitor of PIM1, PIM2, and PIM3, which may result in decreased cell growth (PMID: 19965690).', 'references': [{'id': 4771, 'pubMedId': 19965690, 'title': 'A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19965690'}]}]",SMI-4a,2016-03-03T19:52:44Z
0,2015-02-28T19:52:26Z,2227,"[{'description': 'SML-10-70-1 is a prodrug derivative of SML-8-73-1 and a GTP competitive inhibitor of KRAS G12C capable of passing through cell membranes (PMID: 24259466). ', 'references': [{'id': 2046, 'pubMedId': 24259466, 'title': 'Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24259466'}]}]",SML-10-70-1 ,2015-02-28T19:52:26Z
0,2015-02-28T19:46:25Z,2226,"[{'description': 'SML-8-73-1 (SML) is a GTP-competitive inhibitor of KRAS G12C (PMID: 24889603). ', 'references': [{'id': 2045, 'pubMedId': 24889603, 'title': 'In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24889603'}]}]",SML-8-73-1,2015-02-28T19:53:02Z
0,2016-04-21T19:53:29Z,3982,"[{'description': 'SN-38 is a metabolite of the topoisomerase inhibitor, irinotecan, which causes cell cycle arrest and apoptotic induction thereby resulting in possible inhibition of tumor growth (PMID: 21609311). ', 'references': [{'id': 5196, 'pubMedId': 21609311, 'title': 'Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21609311'}]}]",SN-38,2016-04-21T19:55:30Z
0,2016-04-21T20:00:27Z,3986,[],SN-38 + Talazoparib,2017-06-12T15:58:54Z
0,2015-08-14T14:38:13Z,3030,"[{'description': 'SN30000 is a hypoxia-activated prodrug that causes DNA damage within hypoxic regions of tumors, potentially providing antineoplastic activity (PMID: 20732963).', 'references': [{'id': 3471, 'pubMedId': 20732963, 'title': 'Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20732963'}]}]",SN30000,2015-08-14T14:38:13Z
0,2016-02-23T15:03:17Z,3593,"[{'description': 'SNG12, Shionogi compound 12, is a selective inhibitor of TTK (MPS1) that prevents cell proliferation (PMID: 24900510).', 'references': [{'id': 4666, 'pubMedId': 24900510, 'title': 'Diaminopyridine-based potent and selective mps1 kinase inhibitors binding to an unusual flipped-Peptide conformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24900510'}]}]",SNG12,2016-02-23T15:03:17Z
0,2015-05-20T19:46:34Z,2725,"[{'description': 'SNS-032 (BMS-387032) is an inhibitor of CDK2, CDK7, CDK9, and GSK3A, which may promote cell cycle arrest and induction of apoptosis in cancer cells (PMID: 19169685).', 'references': [{'id': 2792, 'pubMedId': 19169685, 'title': 'SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19169685'}]}]",SNS-032,2015-05-22T01:01:13Z
0,2017-02-03T04:00:03Z,5281,"[{'description': 'SNS-062 inhibits BTK, including BTK mutations associated with inhibitor resistance, which potentially results in decreased tumor growth (Mol Cancer Ther December 1 2015 (14) (12 Supplement 2) C186).', 'references': [{'id': 7737, 'pubMedId': None, 'title': 'Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/C186'}]}]",SNS-062,2017-02-03T04:00:49Z
0,2014-03-12T15:53:16Z,918,"[{'description': 'SNS-314 is a pan-Aurora kinase inhibitor, which prevents cell division and proliferation (PMID: 18678489).', 'references': [{'id': 869, 'pubMedId': 18678489, 'title': 'Discovery of a potent and selective aurora kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18678489'}]}]",SNS-314,2017-04-04T11:38:19Z
0,2015-06-03T17:18:59Z,2764,"[{'description': 'SNX-2112 (PF-04928473) inhibits HSP90, resulting in increased apoptosis and decreased tumor cell growth (PMID: 21821931, PMID:  22447251).', 'references': [{'id': 2911, 'pubMedId': 21821931, 'title': 'SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821931'}, {'id': 2912, 'pubMedId': 22447251, 'title': 'The heat shock protein 90 inhibitor SNX-2112 inhibits B16 melanoma cell growth in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22447251'}]}]",SNX-2112,2015-06-03T17:18:59Z
0,2014-03-12T15:53:16Z,866,[],SNX-5422,2014-09-25T19:56:51Z
0,2016-02-22T19:26:20Z,3591,"[{'description': 'SNX-7081 inhibits Hsp90, resulting in increased cell cycle arrest and apoptosis of tumor cells (PMID: 20738310).', 'references': [{'id': 4659, 'pubMedId': 20738310, 'title': 'The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20738310'}]}]",SNX-7081,2016-02-22T19:26:20Z
0,2016-11-09T15:46:24Z,4929,"[{'description': 'ASONEP (sonepcizumab) is a monoclonal antibody against sphingosine 1-phosphate (S1P) that may inhibit tumor growth through inhibition of angiogenesis (PMID: 27727447).', 'references': [{'id': 7002, 'pubMedId': 27727447, 'title': 'A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27727447'}]}]",sonepcizumab,2016-11-09T15:47:27Z
0,2014-09-11T01:33:47Z,1428,"[{'description': 'Odomzo (sonidegib) is a small molecule inhibitor of SMO, which inhibits proliferation (PMID: 23935925). Odomzo (sonidegib) is FDA approved for use in patients with locally advanced basal cell carcinoma (FDA.gov).', 'references': [{'id': 691, 'pubMedId': 23935925, 'title': 'NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23935925'}]}]",Sonidegib,2017-06-19T19:28:10Z
0,2014-03-12T15:53:16Z,919,[],Sophoretin,
0,2014-03-12T15:53:16Z,920,"[{'description': 'Nexavar (sorafenib) is a multikinase inhibitor with activity against several kinases, including RAF kinases, VEGFR2, VEGFR3, PDGFR-beta, KIT, FLT3, RET and CSF1R, potentially resulting in decreased tumor growth (PMID: 18445656, PMID: 15466206, PMID: 21517818). Nexavar (sorafenib) is approved for metastatic differentiated thyroid cancer and hepatocellular and renal carcinoma (FDA.gov). ', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Sorafenib,2017-05-08T18:41:53Z
0,2014-07-27T21:47:56Z,1119,[],Sorafenib + Avastin + Cyclophosphamide,2014-07-27T21:47:56Z
0,2014-10-08T21:37:18Z,1633,[],Sorafenib + Azacitidine,2014-10-08T21:37:18Z
0,2015-02-23T09:14:58Z,2132,[],Sorafenib + Bevacizumab + Oxaliplatin,2015-02-23T09:14:58Z
0,2014-06-06T20:59:02Z,1067,[],Sorafenib + BEZ235,
0,2015-03-19T09:46:21Z,2428,[],Sorafenib + Capecitabine,2015-03-19T09:46:21Z
0,2016-01-21T19:35:34Z,3428,[],Sorafenib + Carboplatin + Paclitaxel,2016-01-21T19:35:34Z
0,2015-03-19T10:10:28Z,2430,[],Sorafenib + CC-122,2015-03-19T10:10:28Z
0,2015-03-19T10:21:10Z,2431,[],Sorafenib + Cisplatin + Docetaxel,2015-03-19T10:21:10Z
0,2014-09-25T15:05:35Z,1534,[],Sorafenib + Cisplatin + Paclitaxel,2014-12-17T14:31:09Z
0,2014-07-15T12:39:11Z,1086,[],Sorafenib + Fluorouracil,2014-07-15T12:39:11Z
0,2014-07-29T16:39:20Z,1208,[],Sorafenib + Hydroxychloroquine,2014-07-29T16:39:43Z
0,2014-07-31T19:29:24Z,1323,[],Sorafenib + Irinotecan,2014-07-31T19:29:24Z
0,2015-03-13T10:29:27Z,2387,[],Sorafenib + KD018,2015-03-13T10:29:27Z
0,2015-03-13T10:34:36Z,2388,[],Sorafenib + Temsirolimus,2015-03-13T10:34:36Z
0,2015-02-27T15:18:55Z,2197,[],Sorafenib + Trametinib,2015-02-27T15:18:55Z
0,2015-03-12T01:43:40Z,2357,[],Sorafenib + Vinorelbine,2015-03-12T01:43:40Z
0,2015-03-12T01:28:46Z,2356,[],Sorafenib + Vorinostat,2015-03-12T01:28:46Z
0,2016-01-06T18:13:45Z,3366,"[{'description': 'SP600125 is an ATP-competitive inhibitor of JNK, with activity against JNK1, JNK2, and JNK3 and also TTK (Mps1), which may lead to cell-cycle inhibition and decreased growth of tumor cells (PMID: 19478553, PMID: 11717429, PMID: 16113653).', 'references': [{'id': 4213, 'pubMedId': 11717429, 'title': 'SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11717429'}, {'id': 4212, 'pubMedId': 19478553, 'title': 'JNK inhibitor SP600125 promotes the formation of polymerized tubulin, leading to G2/M phase arrest, endoreduplication, and delayed apoptosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19478553'}]}]",SP600125,2016-01-21T11:29:50Z
0,2015-04-24T05:28:20Z,2580,"[{'description': 'SPC2996 is an antisense oligonucleotide against BCL-2, which inhibits BCL-2 protein expression, potentially resulting in increased tumor cell death (PMID: 21358717).', 'references': [{'id': 2566, 'pubMedId': 21358717, 'title': 'The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21358717'}]}]",SPC2996,2015-12-10T19:31:11Z
0,2016-03-24T19:20:36Z,3827,"[{'description': 'SPC3042 is an antisense oligonuecliotide that targets Survivin leading to decreased Survivin expression, which may result in increased tumor cell apoptosis and increased sensitivity to chemotherapeutics (PMID: 18790754).', 'references': [{'id': 5012, 'pubMedId': 18790754, 'title': 'SPC3042: a proapoptotic survivin inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18790754'}]}]",SPC3042,2016-03-24T19:20:36Z
0,2016-03-24T19:25:57Z,3828,[],SPC3042 + Taxol,2016-03-24T19:26:39Z
0,2016-02-03T16:32:31Z,3500,"[{'description': 'SPI-001 specifically inhibits Ppm1d, which may result in decreased tumor cell growth (PMID: 25466181).', 'references': [{'id': 4504, 'pubMedId': 25466181, 'title': 'Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25466181'}]}]",SPI-001,2016-02-03T16:32:31Z
0,2016-02-03T16:36:17Z,3501,[],SPI-001 + Doxorubicin,2016-02-03T16:36:17Z
0,2015-07-30T17:52:40Z,2983,"[{'description': 'SPI-112Me is an inhibitor of Shp2, which may result in the inhibition of epidermal growth factor and ERK1/2 activity and potentially lead to suppression of cell survival (PMID: 20510203). ', 'references': [{'id': 3364, 'pubMedId': 20510203, 'title': 'Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20510203'}]}]",SPI-112Me,2015-07-30T17:52:40Z
0,2017-05-24T17:17:04Z,5763,"[{'description': 'Limited information is currently available on SPL-108 (May, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",SPL-108,2017-05-24T17:17:04Z
0,2016-05-11T13:17:18Z,4096,"[{'description': 'Spliceostatin A binds to and inhibits SF3B1, resulting in inhibition of pre-mRNA splicing in cells (PMID: 17643111). ', 'references': [{'id': 5493, 'pubMedId': 17643111, 'title': 'Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17643111'}]}]",Spliceostatin A,2016-05-11T13:17:18Z
0,2015-07-22T20:16:06Z,2949,"[{'description': 'SPP86 is a multi-kinase inhibitor with activity against RET, EPHA1, FGFR1, FGFR2, FLT4, LCK, and YES, which may reduce proliferation and induce apoptosis in cancer cells (PMID: 25409876).', 'references': [{'id': 3306, 'pubMedId': 25409876, 'title': 'Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25409876'}]}]",SPP86,2017-04-03T17:10:22Z
0,2014-03-12T15:53:16Z,928,[],SR13668,
0,2016-12-08T16:10:13Z,5069,"[{'description': 'SRA737 (CCT245737) is an oral CHK1 inhibitor, which has the potential to enhance chemotherapeutics, thereby resulting in antitumor activity (PMID: 27167172). ', 'references': [{'id': 7267, 'pubMedId': 27167172, 'title': 'Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27167172'}]}]",SRA737,2017-06-05T20:09:04Z
0,2016-05-27T01:06:45Z,4154,"[{'description': 'SRT1460 is a SIRT1 activator, which may decrease tumor cell growth and enhance sensitivity to other anti-cancer agents (PMID: 26655844).', 'references': [{'id': 5700, 'pubMedId': 26655844, 'title': 'SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26655844'}]}]",SRT1460,2016-11-11T19:31:00Z
0,2016-05-27T01:46:29Z,4157,[],SRT1460 + Paclitaxel,2016-05-27T01:46:29Z
0,2016-05-27T01:08:46Z,4155,"[{'description': 'SRT1720 is a SIRT1 activator, which potentially results in increased tumor cell death and decreased tumor growth, and may enhance sensitivity to other anti-cancer agents (PMID: 26655844).', 'references': [{'id': 5700, 'pubMedId': 26655844, 'title': 'SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26655844'}]}]",SRT1720,2016-11-11T19:33:22Z
0,2016-05-27T01:52:16Z,4159,[],SRT1720 + Gemcitabine,2016-05-27T01:52:16Z
0,2016-05-27T01:48:10Z,4158,[],SRT1720 + Paclitaxel,2016-05-27T01:48:10Z
0,2016-05-27T01:10:55Z,4156,"[{'description': 'SRT3025 is a SIRT1 activator, which may lead to decreased tumor  growth and increased senstivity to other anti-cancer agents (PMID: 26655844).', 'references': []}]",SRT3025,2016-11-11T19:38:15Z
0,2016-02-12T01:28:49Z,3520,"[{'description': 'SS1P is an anti-mesothelin antibody linked to the cytotoxic fragment of Pseudomonas endotoxin A in clinical development (PMID: 23136186).', 'references': [{'id': 4559, 'pubMedId': 23136186, 'title': 'A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23136186'}]}]",SS1P,2016-02-12T01:28:49Z
0,2015-04-08T14:51:36Z,2508,"[{'description': 'SSR128129E is an allosteric pan-FGFR inhibitor which may inhibit angiogenesis and tumor growth (PMID: 23597562, PMID: 24760775). ', 'references': [{'id': 2413, 'pubMedId': 24760775, 'title': 'Tumor vasculature is regulated by FGF/FGFR signaling-mediated angiogenesis and bone marrow-derived cell recruitment: this mechanism is inhibited by SSR128129E, the first allosteric antagonist of FGFRs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24760775'}]}]",SSR128129E,2015-04-08T15:00:20Z
0,2016-02-24T16:11:08Z,3602,"[{'description': 'SST0116CL1 is a second-generation small molecule inhibitor of Hsp90, which leads to decreased expression of Hsp90 client proteins and reduced tumor cell proliferation and tumor growth (PMID: 25096516).', 'references': [{'id': 4679, 'pubMedId': 25096516, 'title': 'Preclinical antitumor activity of SST0116CL1: a novel heat shock protein 90 inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25096516'}]}]",SST0116CL1,2016-02-24T16:11:08Z
0,2016-09-07T16:21:31Z,4663,"[{'description': 'ST-11 targets tubulin to destabilize microtubules, and is capable of crossing the blood-brain barrier, potentially resulting increased death of tumor cells (PMID: 27325686).', 'references': [{'id': 6571, 'pubMedId': 27325686, 'title': 'ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27325686'}]}]",ST-11,2016-09-07T16:21:31Z
0,2014-09-26T16:47:22Z,1563,"[{'description': 'ST2825 binds to and interferes with homodimerization of MyD88 and subsequent activation of the IL-1 signaling pathway (PMID: 17548806). ', 'references': [{'id': 860, 'pubMedId': 17548806, 'title': 'Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17548806'}]}]",ST2825,2014-10-24T00:22:24Z
0,2016-04-21T20:39:10Z,3989,"[{'description': 'ST7612AA1 is a second-generation pan-HDAC inhibitor, which leads to decreased proliferation and increased apoptosis of tumor cells (PMID: 25671299).', 'references': [{'id': 5200, 'pubMedId': 25671299, 'title': 'Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25671299'}]}]",ST7612AA1,2016-04-21T20:39:10Z
0,2016-10-17T17:14:47Z,4842,"[{'description': 'STA-8666 is a molecule that targets active HSP90 and is linked to the active metabolite of Camptosar (irinotecan), SN38, which may result in antitumor activity including tumor stabilization and regression (PMID: 27267850). ', 'references': [{'id': 6776, 'pubMedId': 27267850, 'title': 'A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27267850'}]}]",STA-8666,2017-07-28T18:33:22Z
0,2016-06-27T14:15:25Z,4381,"[{'description': 'Stattic is a small molecule inhibitor of STAT3, which blocks Stat3 activation, dimerization, and translocation to the nucleus thereby  potentially resulting in antitumor activity (PMID: 17114005, PMID: 23382914). ', 'references': [{'id': 6091, 'pubMedId': 23382914, 'title': 'Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23382914'}, {'id': 6090, 'pubMedId': 17114005, 'title': 'Stattic: a small-molecule inhibitor of STAT3 activation and dimerization.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17114005'}]}]",Stattic,2016-06-27T14:15:25Z
0,2015-08-10T15:06:01Z,3001,"[{'description': 'Staurosporine is an alkaloid pan-protein kinase C (PKC) inhibitor, with activity against several additional protein kinases, which may result in increased apoptosis and decreased tumor cell growth (PMID: 3457562, PMID: 8529658, PMID: 8913270).', 'references': [{'id': 8751, 'pubMedId': 8529658, 'title': 'Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/8529658'}, {'id': 2086, 'pubMedId': 3457562, 'title': 'Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/3457562'}]}]",Staurosporine,2017-05-01T19:31:52Z
0,2015-02-18T01:05:19Z,2085,"[{'description': 'StAx-35 inhibits CTNNB1/TCF4 mediated transcription, thereby decreasing downstream Wnt signaling to prevent cell proliferation (PMID: 23071338).', 'references': [{'id': 1916, 'pubMedId': 23071338, 'title': 'Inhibition of oncogenic Wnt signaling through direct targeting of β-catenin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23071338'}]}]",StAx-35,2015-02-18T01:05:19Z
0,2014-09-26T05:58:26Z,1561,"[{'description': 'STF-62247 shows selective toxicity and growth inhibition to VHL-deficient renal carcinoma cells (PMID: 18769110).', 'references': [{'id': 856, 'pubMedId': 18769110, 'title': 'Targeted therapy for the loss of von Hippel-Lindau in renal cell carcinoma: a novel molecule that induces autophagic cell death.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18769110'}]}]",STF-62247,2014-09-26T05:58:26Z
0,2016-06-17T19:27:01Z,4304,[],Streptozocin,2016-06-17T19:27:01Z
0,2015-05-20T20:05:07Z,2726,"[{'description': 'SU 9516 is an inhibitor of CDK1, CDK2, and CDK4, which inhibits phosphorylation of downstream targets and may promote cell cycle arrest and apoptosis in cancer cells (PMID: 11507069). ', 'references': [{'id': 2793, 'pubMedId': 11507069, 'title': 'A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11507069'}]}]",SU 9516,2015-05-20T20:05:07Z
0,2014-07-16T07:19:57Z,1089,"[{'description': 'SU11274 is an inhibitor of MET and MST1R (RON), which prevents activation of downstream signaling, and decreases tumor cell proliferation and migration (PMID: 14617781, PMID: 21543897).', 'references': [{'id': 968, 'pubMedId': 14617781, 'title': 'Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/14617781'}]}]",SU11274,2015-12-03T17:59:10Z
0,2015-03-02T15:14:41Z,2235,"[{'description': 'SU11652 is an inhibitor of multiple tyrosine kinase receptors including Pdgfr-beta, Kdr (Vegfr2), Fgfr1, and Kit, which blocks pathway activation, promotes cell cycle arrest, and induces apoptosis of tumor cells (PMID: 12091352, PMID: 23216927).', 'references': [{'id': 2062, 'pubMedId': 12091352, 'title': 'Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12091352'}, {'id': 2063, 'pubMedId': 23216927, 'title': 'SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23216927'}]}]",SU11652,2015-03-10T12:24:26Z
0,2016-09-13T16:58:53Z,4703,"[{'description': 'SU14813 is a multi-kinase inhibitor with activity against VEGFR1-3, PDGFRA, PDGFRB, KIT, and FLT3, which potentially results in decreased tumor angiogenesis and growth (PMID: 16891463, PMID: 20605934).  ', 'references': [{'id': 6612, 'pubMedId': 16891463, 'title': 'SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16891463'}, {'id': 6611, 'pubMedId': 20605934, 'title': 'Phase I trial of SU14813 in patients with advanced solid malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20605934'}]}]",SU14813,2016-09-13T16:58:53Z
0,2015-12-18T21:11:06Z,3305,"[{'description': 'SU5402 is an ATP-competitive inhibitor of FGFR1, FGFR2, FGFR3, and VEGFR, which may inhibit cell proliferation and reduce cell migration (PMID: 21119661, PMID: 23420874, PMID: 18852144). ', 'references': [{'id': 4135, 'pubMedId': 18852144, 'title': 'Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18852144'}, {'id': 4133, 'pubMedId': 21119661, 'title': 'Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21119661'}, {'id': 4134, 'pubMedId': 23420874, 'title': 'Grb2 controls phosphorylation of FGFR2 by inhibiting receptor kinase and Shp2 phosphatase activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23420874'}]}]",SU5402,2015-12-18T21:11:06Z
0,2016-03-03T10:00:08Z,3666,"[{'description': 'HMPL-012 (Sulfatinib) is a dual VEGFR/FGFR1 inhibitor, which inhibits tumor growth (AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A1).', 'references': [{'id': 4764, 'pubMedId': None, 'title': 'First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/A1.short'}]}]",Sulfatinib,2016-03-03T10:21:35Z
0,2015-02-20T18:01:43Z,2126,"[{'description': 'Clinoril (sulindac) is a non-selective COX1-2 inhibitor, FDA approved as an anti-inflammatory agent (FDA.gov). Clinoril (sulindac) also reduces intestinal tumor burden (PMID: 19755659).', 'references': [{'id': 1927, 'pubMedId': 19755659, 'title': 'Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19755659'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Sulindac,2015-08-10T15:04:19Z
0,2014-03-12T15:53:16Z,930,"[{'description': 'Sutent (sunitinib) inhibits KDR (VEGFR2), PDGFR, c-KIT, FLT3, RET, and CSF1R, thereby inhibiting angiogenesis and cell proliferation (NCI Drug Dictionary; PMID: 25085632). Sutent (sunitinib) is approved for neuroendocrine tumors of the pancreas, advanced renal cell carcinoma, and GIST (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 590, 'pubMedId': 25085632, 'title': 'Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25085632'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Sunitinib,2017-04-03T17:10:47Z
0,2015-01-19T14:15:44Z,1962,[],Sunitinib + Crizotinib,2015-01-19T14:15:44Z
0,2015-07-15T15:50:18Z,2923,[],Sunitinib + Cytarabine + Daunorubicin,2015-07-15T15:50:18Z
0,2015-01-19T14:12:55Z,1961,[],Sunitinib + Regorafenib,2015-01-19T14:12:55Z
0,2015-01-19T15:27:00Z,1963,[],Sunitinib + Tamoxifen + Cisplatin,2015-01-19T15:27:00Z
0,2016-11-02T01:47:04Z,4905,[],Sunitinib + Temozolomide,2016-11-02T01:47:04Z
0,2016-10-28T16:35:29Z,4874,[],Sunitinib + Trametinib,2016-10-28T16:35:29Z
0,2014-10-23T15:24:12Z,1658,[],Sunitinib + Trastuzumab,2014-10-23T15:24:12Z
0,2015-08-27T01:54:16Z,3057,[],Sunitinib + Varlilumab,2015-08-27T01:54:16Z
0,2016-04-05T03:08:32Z,3894,"[{'description': 'SW044248 inhibits topoisomerase I by a non-canonical mechanism, potentially resulting in increased tumor cell death (PMID: 26668189).', 'references': [{'id': 5101, 'pubMedId': 26668189, 'title': 'A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non-Small Cell Lung Cancer Cell Lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26668189'}]}]",SW044248,2016-04-05T03:08:32Z
0,2015-06-01T18:52:08Z,2758,"[{'description': 'SX-007 is an inhibitor of TGFBR1, which may promote immune response and inhibit tumor growth (PMID: 20001556, PMID: 17522330).', 'references': [{'id': 2881, 'pubMedId': 17522330, 'title': 'Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17522330'}, {'id': 2760, 'pubMedId': 20001556, 'title': 'Targeting the transforming growth factor-beta signaling pathway in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20001556'}]}]",SX-007,2015-06-01T18:52:08Z
0,2017-05-26T17:33:51Z,5786,"[{'description': 'Limited information is available on SX-682, a putative inhibitor of CXCR1/2 (May, 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",SX-682,2017-05-26T17:33:51Z
0,2017-05-19T17:45:45Z,5700,"[{'description': 'SY-1365 is a selective CDK7 inhibitor that induces apoptosis in tumor cells (Proceedings of the AACR, Vol 58, April 2017, Abstract # 1151).', 'references': [{'id': 8945, 'pubMedId': None, 'title': 'SY-1365, a potent and selective CDK7 inhibitor, exhibits promising anti-tumor activity in multiple preclinical models of aggressive solid tumors', 'url': 'https://books.google.com/books?id=4UFUDgAAQBAJ&pg=PT1269&lpg=PT1269&dq=SY-1365+aacr&source=bl&ots=qSIk2T1yGY&sig=KtZ3HYzvtHo8njvplLeHoPoXTFg&hl=en&sa=X&ved=0ahUKEwim2sfivPzTAhUY0GMKHdZ3CxMQ6AEIPjAE#v='}]}]",SY-1365,2017-05-19T17:45:45Z
0,2017-05-19T18:24:08Z,5703,[],SY-1365 + Venetoclax,2017-05-19T18:24:08Z
0,2016-08-08T17:36:14Z,4539,"[{'description': 'SYD985 is an antibody-drug conjugate consisting of the Erbb2 (Her2)-targeting antibody trastuzumab bound to a derivative of the cytotoxic drug duocarmycin, which results in increased death of Erbb2 (Her2)-expressing tumor cells (PMID: 27256376).', 'references': [{'id': 6448, 'pubMedId': 27256376, 'title': 'SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27256376'}]}]",SYD985,2016-08-08T17:36:14Z
0,2014-03-12T15:53:16Z,931,"[{'description': 'Symphogen (Sym004) is comprised of two antibodies that bind EGFR and prevent ligand binding, which may prevent downstream signaling and result in decreased tumor cell proliferation  (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",SYM004,2015-05-13T09:18:12Z
0,2016-06-03T13:40:19Z,4231,[],SYM004 + Radiotherapy,2016-06-03T13:40:19Z
0,2016-06-20T01:05:48Z,4322,"[{'description': 'Sym015 is a mixture of two antibodies that bind to MET, leading to MET degradation and decreased growth of MET-dependent tumor cells (Cancer Res July 15 2016 (76) (14 Supplement) 1219).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}, {'id': 7828, 'pubMedId': None, 'title': 'Abstract 1219: Sym015, a novel antibody mixture targeting non-overlapping epitopes of MET, effectively inhibits growth of MET dependent tumors and overcomes resistance to a single monoclonal antibody', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1219'}]}]",SYM015,2017-02-16T16:40:31Z
0,2017-02-16T04:33:42Z,5330,"[{'description': 'SYN004 is a monoclonal antibody that binds to and inhibits EGFR signaling, leading to potential anti-tumor activity (NCI Drug Dictionary).', 'references': []}]",SYN004,2017-02-24T16:13:00Z
0,2015-01-08T16:08:19Z,1932,"[{'description': 'SZL-P1-41 binds Skp2 and selectively inhibits interaction in the SCF ubiquitin E3 ligase complex without affecting other SCF complexes, triggering Akt mediated glycolysis and p53 independent cellular senescence in tumor cells (PMID: 23911321). ', 'references': [{'id': 1605, 'pubMedId': 23911321, 'title': 'Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23911321'}]}]",SZL-P1-41,2015-06-26T00:49:40Z
0,2016-09-15T13:56:05Z,4715,"[{'description': 'T-3256336 is a small molecule antagonist of inhibitor of apoptosis proteins (IAP) that induces IAP degradation, leading to apoptosis in tumor cells (PMID: 23243058).', 'references': [{'id': 6632, 'pubMedId': 23243058, 'title': 'Antitumor activity and pharmacodynamic biomarkers of a novel and orally available small-molecule antagonist of inhibitor of apoptosis proteins.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23243058'}]}]",T-3256336 ,2016-09-15T13:56:05Z
0,2017-02-08T19:00:30Z,5293,"[{'description': 'T-3775440 is a small molecule inhibitor of KDM1A (LSD1), which may lead to antileukemic activity, including apoptotic activity and inhibition of tumor growth (PMID: 27903753).', 'references': [{'id': 7754, 'pubMedId': 27903753, 'title': 'A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27903753'}]}]",T-3775440,2017-06-16T15:54:06Z
0,2015-01-05T14:34:22Z,1907,[],T-DM1 + Lapatinib + Abraxane,2015-01-05T14:34:22Z
0,2014-09-18T19:52:04Z,1492,[],T-DM1 + Pertuzumab,2014-09-18T19:52:04Z
0,2017-03-15T18:07:00Z,5440,"[{'description': 'Tacedinaline (CI-994) inhibits HDAC activity, which may result in decreased tumor growth  (PMID: 18497959, PMID: 16391874).', 'references': []}]",Tacedinaline,2017-03-15T18:12:04Z
0,2014-12-23T15:26:37Z,1843,"[{'description': 'Tacrolimus binds to FKBP-12 and inhibits calcineurin activity, resulting in immunosuppression (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Tacrolimus,2016-03-24T19:13:15Z
0,2015-12-21T15:20:21Z,3321,[],Tacrolimus + Methotrexate,2015-12-21T15:20:21Z
0,2015-02-18T02:38:33Z,2086,"[{'description': 'TAE226 inhibits FAK and IGF-IR, resulting in decreased signaling pathway activation, decreased tumor cell growth and invasion, and increased cell-cycle arrest (PMID: 17431114).', 'references': [{'id': 1918, 'pubMedId': 17431114, 'title': 'Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17431114'}]}]",TAE226,2015-02-18T02:38:33Z
0,2015-03-13T02:33:39Z,2386,"[{'description': 'TAE684 inhibits Fes, Alk, and Tnk2 (Ack1) kinase activity, which may result in decreased proliferation of tumor cells (PMID: 17185414, PMID: 25699576, PMID: 22520759).', 'references': [{'id': 2188, 'pubMedId': 17185414, 'title': 'Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17185414'}]}]",TAE684,2017-01-17T14:57:52Z
0,2016-10-17T18:42:16Z,4845,"[{'description': 'TAK-264 (MLN0264) is an antibody-drug conjugate comprising an anti-Guanylyl Cyclase C (GCC, also known as GUCY2C) antibody linked to the microtubule disrupting drug MMAE, which delivers the cytotoxic agent to GCC-expressing tumor cells, potentially resulting in decreased growth of GCC-expressing tumors (PMID: 27178743).', 'references': [{'id': 6783, 'pubMedId': 27178743, 'title': 'Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27178743'}]}]",TAK-264,2016-10-17T19:03:31Z
0,2015-02-23T15:50:10Z,2135,"[{'description': 'TAK-285 inhibits EGFR, ERBB2 (HER2), and ERBB4, resulting in decreased tumor cell growth (PMID: 23983820).', 'references': [{'id': 1960, 'pubMedId': 23983820, 'title': 'Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23983820'}]}]",TAK-285,2015-02-23T15:50:10Z
0,2015-03-17T16:41:25Z,2425,"[{'description': 'TAK-441 is a SMO antagonist that inhibits Hedgehog pathway signaling, potentially resulting in decreased tumor growth (PMID: 23564295).', 'references': [{'id': 2250, 'pubMedId': 23564295, 'title': 'TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23564295'}]}]",TAK-441,2015-03-17T16:41:59Z
0,2015-12-18T19:48:31Z,3300,"[{'description': 'TAK-632 is an inhibitor of Raf, which has been shown to suppress the kinase activity of the Raf dimer thereby resulting in diminished paradoxical activation of Raf (PMID: 24121489).', 'references': [{'id': 4126, 'pubMedId': 24121489, 'title': 'Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24121489'}]}]",TAK-632,2015-12-18T19:48:31Z
0,2015-10-21T02:43:27Z,3146,"[{'description': 'TAK-659 is an inhibitor of spleen tyrosine kinase (SYK), which may lead to B-cell inhibition and antitumor activity (http://meetinglibrary.asco.org/content/134551-144).', 'references': [{'id': 3776, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/134551-144'}]}]",TAK-659,2015-10-21T20:38:30Z
0,2015-02-25T17:26:51Z,2160,"[{'description': 'TAK-701 is a monoclonal antibody that targets HGF and prevents its binding to MET, resulting in decreased activation of HGF/MET signaling and potentially resulting in increased tumor cell death (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",TAK-701,2017-07-20T18:13:38Z
0,2015-02-26T19:51:59Z,2179,[],TAK-701 + Gefitinib,2015-02-26T19:51:59Z
0,2014-03-12T15:53:16Z,932,"[{'description': 'TAK-733 inhibits MEK1 and MEK2, preventing the activation of the RAS/RAF/MEK/ERK pathway, possibly inhibiting growth factor-mediated cell signaling and tumor cell proliferation (PMID: 26439693).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 8454, 'pubMedId': 26439693, 'title': 'Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26439693'}]}]",TAK-733,2017-04-06T10:30:21Z
0,2014-09-29T16:12:00Z,1564,"[{'description': 'TAK-901 is a selective inhibitor of Aurora B kinase, Flt3, and Fgfr2, and has demonstrated anti-tumor activity in several cancer models (PMID: 23358665).', 'references': [{'id': 867, 'pubMedId': 23358665, 'title': 'Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23358665'}]}]",TAK-901,2017-04-04T14:19:51Z
0,2016-03-18T17:39:32Z,3780,"[{'description': 'TAK-960 is an inhibitor of PLK1, which may result in cell growth inhibition and a reduction in tumor size (PMID: 22188812). ', 'references': [{'id': 4929, 'pubMedId': 22188812, 'title': 'TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22188812'}]}]",TAK-960,2016-03-18T17:39:32Z
0,2017-05-30T16:58:19Z,5809,"[{'description': 'Talacotuzumab (JNJ-56022473) is a monoclonal antibody directed against CD123 (IL3RA), which may increase antibody-dependent cell-mediated cytoxicity of CD123 (IL3RA)-expressing tumor cells (Blood Dec 2015, 126 (23) 4946).', 'references': []}]",Talacotuzumab,2017-05-30T17:08:07Z
0,2014-10-02T07:41:57Z,1587,"[{'description': 'Taladegib inhibits the Smo, thereby inhibiting Hedgehog signaling and subsequent cell proliferation (PMID: 22007748, Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1: Abstract #2819).', 'references': [{'id': 883, 'pubMedId': None, 'title': '', 'url': 'http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/71/8_MeetingAbstracts/2819?si'}, {'id': 911, 'pubMedId': 22007748, 'title': 'Investigational Notch and Hedgehog inhibitors--therapies for cardiovascular disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22007748'}]}]",Taladegib,2017-06-08T19:05:05Z
0,2014-03-12T15:53:16Z,682,"[{'description': 'Talazoparib (BMN-673) binds to the nuclear enzyme poly(ADP-ribose) polymerase (PARP), preventing DNA repair of single strand DNA breaks, thus causing the accumulation of DNA strand breaks, genomic instability and apoptosis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Talazoparib,2017-06-12T15:55:43Z
0,2014-08-06T01:03:34Z,1377,[],Talazoparib + Temozolomide,2017-06-12T15:56:05Z
0,2015-05-15T12:37:46Z,2695,"[{'description': 'OncoVEX GM-CSF (talimogene laherparepvec) is a GM-CSF expressing herpes simplex type-1 virus (HSV-1) that selectively infects and lyses tumor cells, and potentially induces a cytotoxic immune response against tumor cells (PMID: 25777572).', 'references': [{'id': 2737, 'pubMedId': 25777572, 'title': 'Oncolytic virus immunotherapy for melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25777572'}]}]",talimogene laherparepvec ,2015-05-19T13:48:03Z
0,2017-03-28T03:02:41Z,5481,[],talimogene laherparepvec + Dabrafenib + Trametinib,2017-03-28T03:02:41Z
0,2016-12-12T01:59:26Z,5080,[],Talimogene laherparepvec + Nivolumab,2016-12-13T17:16:15Z
0,2016-04-04T16:41:04Z,3891,"[{'description': 'Talniflumate inhibits the mucin-synthesizing enzyme GCNT3, resulting in decreased mucin expression and potentially leading to enhanced efficacy of other antitumor agents (PMID: 26880801).', 'references': [{'id': 5098, 'pubMedId': 26880801, 'title': 'Small-Molecule Inhibition of GCNT3 Disrupts Mucin Biosynthesis and Malignant Cellular Behaviors in Pancreatic Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26880801'}]}]",Talniflumate,2016-04-04T16:45:22Z
0,2014-09-11T16:16:28Z,1456,"[{'description': 'Nolvadex (tamoxifen) is a selective estrogen receptor modulator (SERM), which decreases DNA synthesis and cell growth (NCI Drug Dictionary). Nolvadex (tamoxifen) is FDA approved for breast cancer (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Tamoxifen,2014-09-11T17:45:41Z
0,2014-09-18T15:43:56Z,1474,[],Tamoxifen + Alisertib,2014-09-18T15:43:56Z
0,2014-03-12T15:53:16Z,933,"[{'description': 'Tandutinib (CT53518) is a tyrosine kinase inhibitor of FLT3, KIT, and PDGFRbeta, which inhibits cell proliferation and induces apoptosis (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Tandutinib,2014-09-18T11:16:01Z
0,2014-03-12T15:53:16Z,934,"[{'description': 'Tanespimycin (17-AAG) is a HSP90 inhibitor, potentially leading to decreased tumor growth (PMID: 19601813).', 'references': [{'id': 1421, 'pubMedId': 19601813, 'title': '17 AAG for HSP90 inhibition in cancer--from bench to bedside.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19601813'}]}]",Tanespimycin,2015-06-03T17:01:16Z
0,2016-09-02T15:39:41Z,4644,[],Tanespimycin + Vorinostat,2016-09-02T15:39:41Z
0,2015-04-09T18:25:51Z,2515,"[{'description': 'Tanibirumab (TTAC-0001) is a monoclonal antibody directed against KDR (VEGFR2), which may inhibit tumor angiogenesis (PMID: 21910042). ', 'references': [{'id': 2430, 'pubMedId': 21910042, 'title': 'Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21910042'}]}]",Tanibirumab,2015-04-09T18:25:51Z
0,2016-12-05T17:19:34Z,5061,"[{'description': 'Tapalumab is a monoclonal antibody that neutralizes BAFF, resulting in decreased development of osteoclasts and thus, potential antitumor activity (PMID: 27287072).', 'references': [{'id': 7246, 'pubMedId': 27287072, 'title': 'Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27287072'}]}]",Tapalumab,2016-12-05T17:19:34Z
0,2015-04-17T18:41:47Z,2547,"[{'description': 'Tarextumab (OMP-59R5) is a monoclonal antibody that binds Notch2 and Notch3 to prevent ligand interaction, which may inhibit angiogenesis and tumor growth (PMID: 25934888).', 'references': [{'id': 2730, 'pubMedId': 25934888, 'title': 'Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25934888'}, {'id': 2507, 'pubMedId': None, 'title': '688P FINAL RESULTS OF A PHASE 1B OF OMP-59R5 (ANTI-NOTCH2/3/STEM CELL ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL AND GEMCITABINE (NAB-P + GEM) IN PATIENTS (PTS) WITH UNTREATED METASTATIC PANCREATIC CANCER (MPC): ALPINE STUDY', 'url': 'http://annonc.oxfordjournals.org/content/25/suppl_4/iv233.3'}]}]",Tarextumab,2016-07-15T14:20:40Z
0,2015-05-15T02:07:39Z,2689,[],Tarextumab + Gemcitabine,2015-05-15T02:07:39Z
0,2016-06-22T01:43:31Z,4334,"[{'description': 'TAS-114 is a dual inhibitor of deoxyuridine triphosphatase (dUTPase) and dihydropyrimidine dehydrogenase (DPD), which may enhance anti-tumor activity of 5-FU through modulating its metabolism (PMID: 24452393).', 'references': [{'id': 5978, 'pubMedId': 24452393, 'title': 'First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24452393'}]}]",TAS-114,2016-06-22T01:43:31Z
0,2016-08-07T16:00:56Z,4527,[],TAS-114 + TS-1,2016-08-07T16:00:56Z
0,2016-04-21T14:11:04Z,3976,"[{'description': 'TAS-115 is a small molecule inhibitor of MET and KDR (VEGFR2), which may lead to angiogenesis blockade and tumor regression (PMID: 24140932). ', 'references': [{'id': 5188, 'pubMedId': 24140932, 'title': 'The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24140932'}]}]",TAS-115,2016-04-21T14:36:35Z
0,2015-06-03T17:47:52Z,2768,"[{'description': 'TAS-116 is a selective inhibitor of HSP90-alpha and HSP90-beta, which may lead to decreased tumor growth (PMID: 25416789).', 'references': [{'id': 2918, 'pubMedId': 25416789, 'title': 'TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25416789'}]}]",TAS-116,2015-06-03T17:47:52Z
0,2017-01-12T16:26:40Z,5189,[],TAS-116 + Radiotherapy,2017-01-12T16:26:40Z
0,2014-08-18T17:35:22Z,1400,"[{'description': 'TAS-119 is a selective inhibitor of the serine/threonine kinase Aurora A, which may cause disruption of mitotic spindle assembly and chromosome segregation, thus inhibiting cell division and inducing apoptosis (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",TAS-119,2017-04-04T13:08:28Z
0,2014-10-28T18:11:02Z,1669,[],TAS-119 + Docetaxel,2014-10-28T18:11:02Z
0,2014-10-28T18:10:14Z,1668,[],TAS-119 + Paclitaxel,2014-10-28T18:10:14Z
0,2014-05-14T14:52:46Z,1053,"[{'description': 'TAS-120 is a pan-FGFR inhibitor, which result in the inhibition of FGFR-mediated signal transduction pathways and tumor cell proliferation (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD).', 'references': [{'id': 9948, 'pubMedId': None, 'title': 'First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",TAS-120,2017-09-19T17:38:17Z
0,2016-06-20T02:41:30Z,4329,"[{'description': 'TAS3681 is an androgen receptor (AR) inhibitor that induces cell death in AR-positive prostate cancer cells (J Clin Oncol 33, 2015 (suppl 7; abstr 266)).', 'references': [{'id': 5968, 'pubMedId': None, 'title': 'TAS3681: New class of androgen receptor antagonist with androgen receptor downregulating activity.', 'url': 'http://meetinglibrary.asco.org/content/140838-159'}]}]",TAS3681,2016-07-05T15:10:44Z
0,2017-06-16T15:30:29Z,5897,"[{'description': 'TAS4464 inhibits NEDD8 activating enzyme (NAE), therefore inhibits tumor cell growth (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C176).', 'references': [{'id': 9151, 'pubMedId': None, 'title': 'TAS4464, a novel, highly potent, and selective inhibitor of NEDD8 activating enzyme demonstrates sustained target inhibition and antitumor activity in a preclinical model', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/C176'}]}]",TAS4464,2017-06-16T15:30:29Z
0,2016-11-01T13:09:32Z,4896,"[{'description': 'TASIN-1 is a small molecule that selectively inhibits growth of cancer cells expressing truncated APC through inhibition of cholesterol biosynthesis (PMID: 27798265).', 'references': [{'id': 6906, 'pubMedId': 27798265, 'title': 'Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27798265'}]}]",TASIN-1,2016-11-01T13:09:32Z
0,2015-05-15T15:21:12Z,2699,"[{'description': 'Tasquinimod is a small molecule that exerts anti-tumor activity through both stimulation of immune response and inhibition of tumor angiogenesis (PMID: 24162378).', 'references': [{'id': 2741, 'pubMedId': 24162378, 'title': 'Mechanisms of action of tasquinimod on the tumour microenvironment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24162378'}]}]",Tasquinimod,2015-06-26T02:57:25Z
0,2015-05-14T18:38:26Z,2683,"[{'description': 'Tazemetostat (EPZ-6438) inhibits EZH2 methylation of H3K27, which may inhibit cell proliferation and tumor growth (PMID: 23620515). ', 'references': [{'id': 2724, 'pubMedId': 23620515, 'title': 'Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23620515'}]}]",Tazemetostat,2016-04-13T18:00:03Z
0,2017-01-31T05:05:00Z,5267,[],Tazemetostat + Fluconazole,2017-01-31T05:05:00Z
0,2016-09-13T17:13:02Z,4704,"[{'description': 'TB-403 (RO5323441) is an antibody directed against Placental Growth Factor (PLGF), which inhibits binding of PLGF to VEGFR1, potentially resulting in decreased tumor growth (PMID: 22333707).', 'references': [{'id': 6613, 'pubMedId': 22333707, 'title': 'A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22333707'}]}]",TB-403,2016-09-13T17:17:08Z
0,2017-04-27T18:33:21Z,5579,"[{'description': 'TC-A2317 specifically inhibits Aurora kinase A, resulting in cell cycle arrest and apoptosis in cancer cells (PMID: 27713168).', 'references': []}]",TC-A2317,2017-04-27T18:33:21Z
0,2015-04-29T19:06:21Z,2615,"[{'description': 'TCS 359 is a FLT3 inhibitor, which may inhibit the proliferation of cancer cells (PMID: 16580199).', 'references': [{'id': 2616, 'pubMedId': 16580199, 'title': 'Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16580199'}]}]",TCS 359,2015-04-29T19:27:16Z
0,2015-07-13T20:24:55Z,2907,"[{'description': 'TdCyd is a DNA demethylating agent shown to diminish the levels of DNA methyltransferase 1, which may result in tumor growth inhibition (PMID: 24908436).', 'references': [{'id': 3233, 'pubMedId': 24908436, 'title': ""Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4'-thio-2'-deoxycytidine and 5-aza-4'-thio-2'-deoxycytidine."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24908436'}]}]",TdCyd,2015-07-13T20:24:55Z
0,2016-09-13T17:33:40Z,4705,"[{'description': 'Tefinostat (CHR-2845) is a monocyte/macrophage targeted HDAC inhibitor, which may result in decreased proliferation of hCE1-expressing hematological tumor cells (PMID: 23647373).', 'references': [{'id': 6615, 'pubMedId': 23647373, 'title': 'A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23647373'}]}]",Tefinostat,2016-09-13T17:33:40Z
0,2015-06-11T18:38:25Z,2820,"[{'description': 'Telapristone is a progesterone receptor modulator (PRM), which has been demonstrated to result in growth inhibition of PR positive tumor cells and induce apoptosis (PMID: 21119048).', 'references': [{'id': 3019, 'pubMedId': 21119048, 'title': 'CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21119048'}]}]",Telapristone,2015-06-19T12:08:11Z
0,2014-03-12T15:53:16Z,935,"[{'description': 'BAY 57-9352 (Telatinib) inhibits VEGFR2, VEGFR3, PDGFR-beta, and KIT, which may result in decreased proliferation and angiogenesis in tumors expressing these factors (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Telatinib,2016-05-26T11:08:09Z
0,2014-07-28T12:53:28Z,1141,"[{'description': 'Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Temozolomide,2015-04-24T05:57:11Z
0,2014-12-18T16:47:53Z,1804,[],Temozolomide + Etoposide,2014-12-18T16:47:53Z
0,2014-10-02T18:42:36Z,1607,[],Temozolomide + Etoposide + Doxil + Dexamethasone + Ibrutinib,2014-10-02T18:45:50Z
0,2014-09-11T20:33:51Z,1462,[],Temozolomide + Irinotecan,2014-09-11T20:33:51Z
0,2014-09-11T20:35:34Z,1463,[],Temozolomide + Irinotecan + Bevacizumab,2014-09-11T20:35:34Z
0,2017-06-04T01:59:05Z,5851,[],Temozolomide + TG02,2017-06-04T01:59:05Z
0,2017-06-26T19:23:33Z,5932,[],Temozolomide + Trastuzumab emtansine,2017-06-26T19:24:00Z
0,2017-05-24T18:55:15Z,5768,[],Temozolomide + TRC102,2017-05-24T18:55:15Z
0,2017-03-10T16:10:47Z,5427,[],Temozolomide + Valproic acid,2017-03-10T16:10:47Z
0,2014-03-12T15:53:16Z,936,"[{'description': 'Torisel (temsirolimus) binds and allosterically inhibits mTOR (NCI Drug Dictionary). Torisel (temsirolimus) is FDA approved for advanced renal cell carcinoma (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Temsirolimus,2015-04-02T23:46:45Z
0,2015-10-16T13:16:07Z,3133,[],Temsirolimus + Bevacizumab,2015-10-16T13:16:07Z
0,2014-07-28T14:33:08Z,1159,[],Temsirolimus + Bevacizumab + Cetuximab,2014-07-28T14:33:08Z
0,2014-08-05T18:14:30Z,1376,[],Temsirolimus + Bevacizumab + Valproic Acid + Cetuximab,2014-08-05T18:14:30Z
0,2014-10-28T19:05:13Z,1671,[],Temsirolimus + Cetuximab,2014-10-28T19:05:13Z
0,2014-08-01T05:32:45Z,1340,[],Temsirolimus + Erlotinib,2014-08-01T05:32:45Z
0,2015-03-04T11:09:00Z,2280,[],Temsirolimus + Lenalidomide,2015-03-04T11:09:00Z
0,2014-07-31T20:56:07Z,1325,[],Temsirolimus + Metformin,2014-07-31T20:56:07Z
0,2014-09-23T21:55:15Z,1527,[],Temsirolimus + Neratinib,2014-09-23T21:55:15Z
0,2016-10-10T18:53:30Z,4808,[],Temsirolimus + Radiotherapy,2016-10-10T18:53:30Z
0,2015-04-03T15:31:24Z,2492,[],Temsirolimus + Vinblastine,2015-04-03T15:31:24Z
0,2015-03-03T02:41:49Z,2263,[],Temsirolimus + vorinostat,2015-03-03T02:41:49Z
0,2014-03-12T15:53:16Z,937,"[{'description': 'TEN-010 binds to the bromodomain of BET proteins preventing their interaction with acetylated histone peptides, thus disrupting chromatin remodeling, gene expression, and cell proliferation (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A49).', 'references': [{'id': 6144, 'pubMedId': None, 'title': 'Clinically efficacy of the BET bromodomain inhibitor TEN-010 in an open-label substudy with patients with documented NUT-midline carcinoma (NMC)', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/A49'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",TEN-010,2017-05-22T17:45:05Z
0,2016-06-17T19:28:13Z,4305,[],Teniposide,2016-06-17T19:28:13Z
0,2015-05-12T14:36:56Z,2656,"[{'description': 'Tenovin-1 inhibits the activity of SIRT1 and SIRT2, resulting in decreased degradation of p53, which potentially results in decreased tumor growth (PMID: 18455128).', 'references': [{'id': 2687, 'pubMedId': 18455128, 'title': 'Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18455128'}]}]",Tenovin-1,2016-11-11T19:39:46Z
0,2015-05-12T14:30:30Z,2655,"[{'description': 'Tenovin-6 inhibits the activity of SIRT1 and SIRT2, resulting in decreased degradation of p53, which potentially results in decreased tumor growth (PMID: 18455128).', 'references': [{'id': 2687, 'pubMedId': 18455128, 'title': 'Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18455128'}]}]",Tenovin-6 ,2016-11-11T19:40:13Z
0,2016-02-19T15:06:54Z,3566,"[{'description': 'Tetrahydrouridine is a synthetic pyrimidine analogue that inhibits deoxycytidine monophosphate (dCMP) deaminase, which in turn inhibits cell proliferation (PMID: 22616006).', 'references': [{'id': 4631, 'pubMedId': 22616006, 'title': 'Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22616006'}]}]",Tetrahydrouridine,2016-02-19T15:06:54Z
0,2015-10-21T03:01:07Z,3147,"[{'description': 'Tetrathiomolybdate depletes systemic copper, thereby inhibiting cuproenzymes and leading to antitumor effects (PMID: 26160923).', 'references': [{'id': 3777, 'pubMedId': 26160923, 'title': 'BIOMEDICINE. Targeting copper to treat breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26160923'}]}]",Tetrathiomolybdate,2015-10-21T15:06:07Z
0,2015-08-12T01:30:50Z,3011,"[{'description': 'TEW 7197 is a small molecule that inhibits ALK5, leading to decreased TGF-beta signaling and potentially resulting in decreased tumor cell metastasis (PMID: 24817629)', 'references': [{'id': 3611, 'pubMedId': 24817629, 'title': 'EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24817629'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",TEW 7197,2017-05-24T16:58:10Z
0,2015-06-18T21:16:57Z,2853,"[{'description': 'TG-0054 binds to CXCR4 and inhibits SDF-1 (CXCL12) binding, potentially resulting in increased mobilization of hematopoietic cells (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",TG-0054,2015-06-25T21:02:03Z
0,2017-06-01T19:43:53Z,5836,"[{'description': 'TG02 is a pyrimidine-based molecule that inhibits Cdk1, Cdk2, Cdk7, Cdk9, Jak2, and Flt3, which results in growth inhibition in tumor cells (PMID: 21860433).', 'references': [{'id': 9049, 'pubMedId': 21860433, 'title': 'TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21860433'}]}]",TG02,2017-06-16T17:35:42Z
0,2015-04-09T19:49:01Z,2516,"[{'description': 'TG100-115 is a selective inhibitor of PIK3CD and PIK3CG, which may inhibit tumor growth and metastasis (PMID: 17172449, PMID: 21665146).', 'references': [{'id': 2434, 'pubMedId': 21665146, 'title': 'Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21665146'}, {'id': 2435, 'pubMedId': 17172449, 'title': 'Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17172449'}]}]",TG100-115,2015-04-09T20:14:37Z
0,2015-03-16T15:42:11Z,2403,"[{'description': 'TG101209 is an ATP-competitive inhibitor of Jak2, Ret, and Flt3 kinases, which may inhibit proliferation and induce apoptosis in cancer cells (PMID: 17541402).', 'references': [{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}]}]",TG101209,2017-04-03T17:24:12Z
0,2015-02-08T11:52:40Z,2022,"[{'description': 'TGR-1202 is a selective inhibitor of PIK3CD, which prevents Akt phosphorylation and induces cytotoxicity (J Clin Oncol 32:5s, 2014 (suppl; abstr 2513)).', 'references': [{'id': 1821, 'pubMedId': None, 'title': 'Activity of TGR-1202, a novel once-daily PI3K? inhibitor, in patients with relapsed or refractory hematologic malignancies.', 'url': 'http://meetinglibrary.asco.org/content/134240-144'}]}]",TGR-1202,2015-02-08T11:52:40Z
0,2015-03-06T16:02:46Z,2319,[],TGR-1202 + Ublituximab,2015-03-06T16:02:46Z
0,2015-07-29T19:00:58Z,2962,"[{'description': 'TGX-115 inhibits PIK3CB and PIK3CD, which may block activation of the PI3K signaling pathway and inhibit tumor cell proliferation (PMID: 16647110).', 'references': [{'id': 3347, 'pubMedId': 16647110, 'title': 'A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16647110'}]}]",TGX-115,2015-07-29T19:00:58Z
0,2016-02-06T12:00:27Z,3503,"[{'description': 'TGX-155 is a small molecule selective inhibitor of the PIK3CB catalytic subunit of PI3K, with 10-fold selectivity for PIK3CB over PIK3CD and little inhibitory activity against PIK3CA and PIK3CG (PMID: 19033389).\r\n', 'references': [{'id': 3346, 'pubMedId': 19033389, 'title': 'Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19033389'}]}]",TGX-155,2016-02-06T12:02:09Z
0,2015-04-09T13:41:54Z,2514,"[{'description': 'TGX-221 is a selective inhibitor of PIK3CB which may inhibit transformation and proliferation of tumor cells (PMID: 15834429, PMID: 25473181).', 'references': [{'id': 2425, 'pubMedId': 15834429, 'title': 'PI 3-kinase p110beta: a new target for antithrombotic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15834429'}, {'id': 2426, 'pubMedId': 25473181, 'title': 'Phosphatidylinositol 3-kinase CB association with preoperative radiotherapy response in rectal adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25473181'}]}]",TGX-221,2015-04-09T13:41:54Z
0,2015-07-14T00:38:13Z,2910,"[{'description': 'TH-4000 is a pan-HER inhibitor prodrug, which is activated within hypoxic tumor conditions, potentially resulting in decreased proliferation of HER-expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",TH-4000,2015-07-14T00:38:13Z
0,2014-09-18T16:01:00Z,1475,[],Thalidomide,2014-09-18T16:01:00Z
0,2016-03-03T10:43:04Z,3668,"[{'description': 'Limited information is currently available on HMPL-309 (Theliatinib), a putative Egfr inhibitor (Mar, 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",Theliatinib,2016-03-03T10:43:04Z
0,2014-05-14T14:52:46Z,1054,"[{'description': 'ThermoDox is liposomal formulation of the anthracyline, doxorubicin (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",ThermoDox,2014-08-27T11:00:56Z
0,2014-10-14T17:27:40Z,1641,[],Thioguanine,2014-10-14T17:27:40Z
0,2015-04-23T01:58:45Z,2563,[],Thiotepa,2015-04-23T01:58:45Z
0,2015-08-06T04:17:49Z,2999,"[{'description': 'Kevetrin (thioureidobutyronitrile) leads to stabilization of wild-type p53 and degradation of mutant p53, resulting in apoptosis and decreased growth of tumors with wild-type and mutant p53 (J Clin Oncol 31, 2013 (suppl; abstr TPS2627)).', 'references': [{'id': 3759, 'pubMedId': None, 'title': 'A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/113150-132'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",thioureidobutyronitrile,2017-05-02T18:31:12Z
0,2016-05-11T16:41:16Z,4101,"[{'description': 'Thymoquinone is a compound derived from the Nigella sativa plant that has anti-tumor activity (PMID: 26023736, PMID: 25847385).', 'references': [{'id': 5503, 'pubMedId': 25847385, 'title': 'Mechanistic perspectives on cancer chemoprevention/chemotherapeutic effects of thymoquinone.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847385'}, {'id': 5502, 'pubMedId': 26023736, 'title': 'Thymoquinone inhibits cancer metastasis by downregulating TWIST1 expression to reduce epithelial to mesenchymal transition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26023736'}]}]",Thymoquinone,2016-05-11T16:42:46Z
0,2016-04-07T17:47:38Z,3908,"[{'description': 'THZ1 is a covalent Cdk7 inhibitor that inhibits tumor cell proliferation (PMID: 25043025).', 'references': [{'id': 5124, 'pubMedId': 25043025, 'title': 'Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25043025'}]}]",THZ1,2016-04-07T17:47:38Z
0,2014-03-12T15:53:16Z,938,"[{'description': 'Zarnestra (tipifarnib) is a farnesyltransferase inhibitor, which alters post-translational modification and activation of Ras proteins, and may result in decreased tumor cell proliferation and reduced tumor growth (PMID: 11196150, PMID: 25323927).', 'references': [{'id': 2048, 'pubMedId': 25323927, 'title': 'Drugging the undruggable RAS: Mission possible?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25323927'}]}]",Tipifarnib,2016-09-13T18:18:27Z
0,2015-08-14T14:15:02Z,3028,"[{'description': 'Tirazone (tirapazamine) is a hypoxia-activated prodrug that induces DNA damage within hypoxic regions of tumors, potentially providing antineoplastic activity (PMID: 18666379).', 'references': [{'id': 3469, 'pubMedId': 18666379, 'title': 'Tirapazamine: from bench to clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18666379'}]}]",tirapazamine,2015-10-13T18:46:03Z
0,2017-07-07T17:44:18Z,5981,"[{'description': 'Kymriah (tisagenlecleucel) is a preparation of autologous T-lymphocytes engineered to express chimeric antigen receptors targeting CD19-positive cells, resulting in anti-tumor immune response (J Clin Oncol 35, 2017 (suppl; abstr 10523)). Kymriah (tisagenlecleucel) is FDA approved for pediatric and young adult patients with B-cell precursor acute lymphoblastic leukemia (FDA.gov). ', 'references': [{'id': 9302, 'pubMedId': None, 'title': 'Patient-reported quality of life (QOL) following CTL019 in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL).', 'url': 'http://abstracts.asco.org/199/AbstView_199_187018.html'}]}]",Tisagenlecleucel,2017-08-30T19:16:42Z
0,2017-08-14T19:20:12Z,6113,"[{'description': 'Tisotumab vedotin is an antibody-drug conjugate consists of anti-tissue factor (TF) antibody and the cytotoxic agent monomethyl auristatin E (MMAE), which induces killing of tumor cells over expressing tissue factor (PMID: 24371232).', 'references': [{'id': 9705, 'pubMedId': 24371232, 'title': 'An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24371232'}]}]",Tisotumab Vedotin,2017-08-14T19:20:12Z
0,2014-03-12T15:53:16Z,636,"[{'description': 'Tivantinib (ARQ197) binds to the c-Met protein and disrupts c-Met signal transduction pathways, which may induce cell death in tumor cells overexpressing c-Met (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Tivantinib,2014-11-13T20:17:28Z
0,2014-07-29T13:17:08Z,1200,[],Tivantinib + Temsirolimus,2014-07-29T13:17:08Z
0,2014-09-18T16:21:08Z,1477,[],Tivantinib + Topotecan + Pegfilgrastim,2014-09-18T16:21:08Z
0,2014-05-14T14:52:46Z,1055,"[{'description': 'Tivozanib (AV-951) inhibits VEGFR1-3, which may result in decreased tumor angiogenesis and proliferation and increased cell death (PMID: 23788831).', 'references': [{'id': 3866, 'pubMedId': 23788831, 'title': 'Tivozanib in the treatment of renal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23788831'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Tivozanib,2016-10-13T15:09:54Z
0,2016-06-17T22:03:29Z,4314,"[{'description': 'TK216 binds to and inhibits Ets-family transcription factor, which may lead to anti-tumor effects (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",TK216,2016-06-17T22:03:29Z
0,2016-03-21T17:44:41Z,3794,"[{'description': 'TKM-080301 is a lipid nanoparticle of a small interfering RNA targeting PLK1, which may lead to antitumor activity (Cancer Res April 15, 2013 73; LB-289). ', 'references': [{'id': 4948, 'pubMedId': None, 'title': 'Abstract LB-289: A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors', 'url': 'http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-289'}]}]",TKM-080301,2016-03-21T17:44:41Z
0,2017-03-13T17:50:09Z,5432,"[{'description': 'TMU-35435 is an HDAC inhibitor, which induces cell-cycle arrest and apoptosis of tumor cells (PMID: 28233309).', 'references': []}]",TMU-35435,2017-03-17T16:44:33Z
0,2015-11-16T14:56:23Z,3209,"[{'description': 'Toca 511 is a retroviral vector encoding yeast cytosine deaminase, which converts the prodrug flucytosine into 5-fluorouracil upon infection of tumor cells, leading to tumor cell death (PMID: 22547150).', 'references': [{'id': 3926, 'pubMedId': 22547150, 'title': 'Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22547150'}]}]",Toca 511,2015-12-01T18:09:15Z
0,2015-11-16T15:08:21Z,3211,[],Toca 511 + Toca FC,2015-11-16T15:08:21Z
0,2015-11-16T15:06:51Z,3210,"[{'description': 'Toca FC is an extended release form of flucytosine, which inhibits DNA synthesis after conversion to 5-fluorouracil (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Toca FC,2015-12-01T18:08:59Z
0,2017-05-08T16:02:27Z,5647,[],Tocilizumab,2017-05-08T16:02:27Z
0,2014-03-12T15:53:16Z,941,"[{'description': 'Xeljanz (tofacitinib) inhibits Janus kinases (JAK1, JAK2, JAK3), thereby preventing activation of the STAT pathway and resulting in reduced inflammation (NCI Drug Dictionary). Xeljanz (tofacitinib) is FDA approved for rheumatoid arthritis (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Tofacitinib,2015-06-08T18:35:50Z
0,2014-03-12T15:53:16Z,942,"[{'description': 'Topotecan binds to topoisomerase I and stablizes complexes with DNA, resulting in decreased repair of DNA single-strand breaks, and potentially leading to cell death (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Topotecan,2015-04-06T20:07:09Z
0,2014-09-18T14:41:35Z,1469,[],Topotecan + Pazopanib,2014-09-18T14:41:35Z
0,2014-07-29T19:58:46Z,1228,[],Topotecan + Sorafenib,2014-07-29T19:58:46Z
0,2016-07-05T14:07:14Z,4419,[],Toremifine,2016-07-05T14:07:14Z
0,2015-03-02T19:18:19Z,2247,"[{'description': 'Torin 1 inhibits mTOR signaling through mTORC1 and mTORC2, thereby preventing cell proliferation (PMID: 19209957).', 'references': [{'id': 2064, 'pubMedId': 19209957, 'title': 'Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19209957'}]}]",Torin 1,2016-04-01T16:40:22Z
0,2017-02-28T17:16:17Z,5384,[],Torin 1 + WEHI-539,2017-02-28T17:16:17Z
0,2015-03-02T20:05:34Z,2249,"[{'description': 'Torin 2 inhibits ATM, ATR and mTOR signaling through mTORC1/2, thereby preventing cell proliferation (PMID: 21322566, PMID: 23436801).', 'references': [{'id': 2070, 'pubMedId': 21322566, 'title': 'Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21322566'}]}]",Torin 2,2016-04-01T16:40:39Z
0,2015-03-02T18:52:32Z,2240,"[{'description': 'Torkinib (PP242) inhibits mTOR signaling through mTORC1/2, thereby preventing cell proliferation (PMID: 19209957).', 'references': [{'id': 2064, 'pubMedId': 19209957, 'title': 'Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19209957'}]}]",Torkinib,2017-07-07T18:47:45Z
0,2017-03-30T20:22:50Z,5500,[],Torkinib + U0126,2017-07-07T18:44:45Z
0,2014-03-12T15:53:16Z,943,"[{'description': 'Tozasertib (VX-680) is a pan-AURK inhibitor with increased potency against Aurora kinase A (AURKA), and has additional activity against BCR-ABL, potentially resulting in decreased tumor growth (PMID: 14981513, PMID: 22772060).', 'references': [{'id': 2115, 'pubMedId': 14981513, 'title': 'VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/14981513'}]}]",Tozasertib,2017-05-05T03:22:01Z
0,2016-03-23T17:27:29Z,3826,"[{'description': 'TP-0903 is a selective Axl inhibitor that inhibits tumor cell survival (PMID: 22247788).', 'references': [{'id': 5003, 'pubMedId': 22247788, 'title': 'Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22247788'}]}]",TP-0903,2017-03-16T16:20:19Z
0,2016-03-03T19:06:21Z,3672,"[{'description': 'TP-3654 is an inhibitor of PIM1, PIM2, PIM3, and moderately inhibits FLT3, which may result in anti-tumor activity (PMID: 24953177).', 'references': [{'id': 4769, 'pubMedId': 24953177, 'title': 'A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24953177'}]}]",TP-3654,2016-03-03T19:06:21Z
0,2015-03-03T15:35:05Z,2274,"[{'description': 'TPI 287 is taxane that binds to tubulin, resulting in microtubule stabilization and cell-cycle arrest (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",TPI 287,2015-03-03T15:35:05Z
0,2016-05-27T19:05:33Z,4179,"[{'description': 'Limited information is currently available on TPIV 200, a putative multi-epitope anti-folate receptor vaccine (May, 2016).', 'references': []}]",TPIV 200,2016-05-27T19:05:33Z
0,2016-04-19T15:21:55Z,3950,"[{'description': 'TPX-0005 is a dual ALK/SRC inhibitor that overcomes acquired resistance to current ALK inhibitors, resulting in tumor cell death (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).', 'references': [{'id': 5176, 'pubMedId': None, 'title': 'The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=055d4461-9793-4f83-b663-f356d9ae0fdb&cKey=ff6f8d25-f06a-4ae4-9dbf-7e390ef45123&mKey={1D10D749-4B6A-4AB3-BCD4-F80FB1922267}'}]}]",TPX-0005,2016-04-25T14:50:16Z
0,2016-01-19T18:04:37Z,3420,"[{'description': 'Yondelis (trabectedin) is a marine-derived alkaloid that binds to DNA and induces DNA strand break, leading to cell cycle arrest and cell death in tumor cells (PMID: 24755886).', 'references': [{'id': 4381, 'pubMedId': 24755886, 'title': 'Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24755886'}]}]",trabectedin,2017-06-19T19:39:12Z
0,2017-05-30T00:06:50Z,5800,[],trabectedin + Ipilimumab + Nivolumab,2017-05-30T00:06:50Z
0,2016-11-11T05:31:24Z,4935,[],Trabectedin + Venetoclax,2016-11-11T05:31:24Z
0,2015-05-19T14:05:23Z,2705,"[{'description': 'Trabedersen (AP 12009) is an antisense oligonucleotide that inhibits TGFB2 translation, which may result in decreased proliferation and migration of cancer cells (PMID: 21366804).', 'references': [{'id': 2756, 'pubMedId': 21366804, 'title': 'Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21366804'}]}]",Trabedersen,2016-03-24T15:23:07Z
0,2014-01-20T22:50:12Z,2,"[{'description': 'Mekinist (trametinib) inhibits MEK 1 and 2, which potentially leads to reduced tumor cell proliferation (PMID: 27956260). Mekinist (trametinib) is FDA approved for melanoma patients harboring BRAF V600E or BRAF V600K mutations, and in combination with Tafinlar (dabrafinib) for BRAF V600E/K-mutant melanoma and BRAF V600E mutant non-small cell lung cancer (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Trametinib,2017-09-18T01:49:34Z
0,2014-06-06T19:24:32Z,1066,[],Trametinib + Dabrafenib,
0,2014-07-31T09:05:55Z,1303,[],Trametinib + Dabrafenib + Navitoclax,2014-07-31T09:05:55Z
0,2014-09-11T14:55:20Z,1446,[],Trametinib + Digoxin,2014-09-11T14:55:20Z
0,2014-07-27T18:33:44Z,1113,[],Trametinib + Fluorouracil,2014-07-27T18:33:44Z
0,2014-07-31T08:04:25Z,1298,[],Trametinib + GSK2141795,2014-07-31T08:04:25Z
0,2014-08-06T02:13:16Z,1386,[],Trametinib + Navitoclax,2014-08-06T02:13:16Z
0,2017-03-29T04:03:00Z,5493,[],Trametinib + Paclitaxel,2017-03-29T04:03:00Z
0,2017-10-10T20:28:01Z,6312,[],Trametinib + Triciribine,2017-10-10T20:28:01Z
0,2016-02-14T18:20:30Z,3532,[],Trametinib + TW-37,2016-02-14T18:20:30Z
0,2016-06-03T17:41:29Z,4234,[],Trametinib + Vemurafenib,2016-06-03T17:41:29Z
0,2016-03-22T17:32:41Z,3805,[],Trametinib + Volasertib,2016-03-22T17:32:41Z
0,2017-08-18T18:57:11Z,6126,[],Tranylcypromine + Tretinoin ,2017-08-18T18:57:11Z
0,2014-03-12T15:53:16Z,947,"[{'description': 'Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cell cytotoxicity (NCI Drug Dictionary). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Trastuzumab,2015-04-30T18:54:14Z
0,2014-10-02T15:17:03Z,1596,[],Trastuzumab + Bevacizumab,2014-10-02T15:17:03Z
0,2015-01-05T02:18:19Z,1905,[],Trastuzumab + Carboplatin,2015-01-05T02:18:19Z
0,2014-09-18T18:41:12Z,1485,[],Trastuzumab + Docetaxel + Carboplatin,2014-09-18T18:41:12Z
0,2015-01-04T00:39:47Z,1893,[],Trastuzumab + Everolimus,2015-01-04T00:39:47Z
0,2014-08-29T11:57:17Z,1411,[],Trastuzumab + Everolimus + Vinorelbine,2014-08-29T12:00:29Z
0,2016-01-22T01:23:03Z,3439,[],Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin,2016-01-22T01:27:04Z
0,2014-08-31T10:14:02Z,1414,[],Trastuzumab + Lapatinib,2014-08-31T10:22:57Z
0,2014-08-29T12:13:59Z,1412,[],Trastuzumab + Oxaliplatin,2014-08-29T12:13:59Z
0,2014-09-25T19:06:32Z,1551,[],Trastuzumab + Paclitaxel,2014-09-25T19:06:32Z
0,2014-08-06T02:40:23Z,1389,[],Trastuzumab + Pertuzumab,2014-08-06T02:40:23Z
0,2015-12-11T20:40:49Z,3290,[],Trastuzumab + Pertuzumab + Fulvestrant,2015-12-11T20:40:54Z
0,2015-01-03T22:03:36Z,1891,[],Trastuzumab + Sargramostim,2015-01-03T22:03:36Z
0,2017-03-23T16:15:38Z,5471,[],Trastuzumab + trastuzumab emtansine,2017-03-23T16:15:38Z
0,2014-08-29T08:57:59Z,1408,[],Trastuzumab + TS-1,2014-08-29T12:14:15Z
0,2015-08-18T18:55:31Z,3034,[],trastuzumab + varlitinib,2015-08-18T18:55:31Z
0,2014-08-31T10:24:28Z,1415,[],Trastuzumab + XL147,2014-08-31T10:24:28Z
0,2014-08-27T01:20:41Z,1402,"[{'description': 'Kadcyla (trastuzumab emtansine) is a combination of the ERBB2 (HER2) monoclonal antibody, trastuzumab, and an anti-tubulin agent (NCI Drug Dictionary). Kadcyla (trastuzumab emtansine) is FDA approved for metastatic ERBB2 (HER2)-positive breast cancer (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",trastuzumab emtansine,2017-09-18T00:47:03Z
0,2015-01-26T13:23:30Z,1976,[],trastuzumab emtansine + Capecitabine,2015-01-26T13:23:30Z
0,2014-09-30T21:03:36Z,1583,[],Trastuzumab emtansine + Lapatinib,2014-09-30T21:03:36Z
0,2016-01-21T20:00:11Z,3429,[],Trastuzumab emtansine + Vinorelbine,2016-01-21T20:00:11Z
0,2017-05-24T18:52:53Z,5767,"[{'description': 'TRC102 inhibits the base excision repair pathway, potentially resulting in increased sensitivity to chemotherapeutic agents and anti-tumor activity (J Clin Oncol 34, 2016 (suppl; abstr 2556)).', 'references': [{'id': 8977, 'pubMedId': None, 'title': 'A phase 1 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with solid tumors and lymphomas.', 'url': 'http://meetinglibrary.asco.org/content/168775-176'}]}]",TRC102,2017-05-24T18:52:53Z
0,2014-08-01T01:58:09Z,1335,[],TRC105 + Axitinib,2014-08-01T01:58:09Z
0,2014-09-11T02:20:49Z,1431,[],TRC105 + Pazopanib,2014-09-11T02:20:49Z
0,2017-05-24T19:16:07Z,5770,"[{'description': 'TRC253 binds androgen receptor (AR), including wild-type AR and some mutant versions, resulting in decreased receptor activation and downstream signaling, and potentially leading to decreased growth of AR-expressing tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",TRC253,2017-05-24T19:16:07Z
0,2017-05-24T20:01:15Z,5772,"[{'description': 'TRC694 inhibits NF-kappaB Inducing Kinase (NIK; MAP3K14), potentially resulting in decreased proliferation of tumor cells with activation of non-canonical NF-kappaB signaling (AACR 2017 Annual Meeting, Abstract nr 4199).', 'references': [{'id': 8981, 'pubMedId': None, 'title': 'Inhibition of NF-kB inducing kinase (NIK) selectively abrogates NIK and TRAF3 mutant multiple myeloma tumor growth', 'url': 'http://www.abstractsonline.com/pp8/#!/4292/presentation/3906'}]}]",TRC694,2017-05-24T20:25:07Z
0,2014-07-29T18:59:00Z,1218,"[{'description': 'Trebananib inhibits angiogenesis through  binding to the angiopoietins Ang1 and Ang2, thereby preventing interaction  with their receptors (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Trebananib,2017-08-08T20:13:39Z
0,2014-07-29T19:00:17Z,1219,[],Trebananib + Bevacizumab,2014-07-29T19:00:17Z
0,2014-07-29T19:01:50Z,1220,[],Trebananib + Pazopanib,2014-07-29T19:01:50Z
0,2014-07-29T19:02:43Z,1221,[],Trebananib + Sorafenib,2014-07-29T19:02:43Z
0,2014-07-29T19:03:36Z,1223,[],Trebananib + Sunitinib,2014-07-29T19:03:36Z
0,2014-09-18T19:54:33Z,1493,[],Trebananib + Trastuzumab,2014-09-18T19:54:33Z
0,2014-10-14T20:57:31Z,1652,"[{'description': 'Tremelimumab binds to and inhibits cytotoxic T-lymphocyte-associated protein 4 (CTLA4), thereby enhancing T-cell activation by blocking CTLA4-mediated inhibition of T-cell activation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Tremelimumab,2017-09-25T18:21:13Z
0,2014-12-31T04:06:25Z,1877,"[{'description': 'Vesanoid (tretinoin) is a form of retinoic acid, which binds to retinoic acid receptors and activates downstream signaling, potentially resulting in increased differentiation and decreased tumor cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Tretinoin  ,2015-04-10T16:46:04Z
0,2016-03-31T17:43:53Z,3888,[],Tretinoin + Trastuzumab,2016-03-31T17:43:53Z
0,2015-06-25T14:51:32Z,2867,"[{'description': 'Trichostatin A (TSA) inhibits histone deacetylase (HDAC) activity, which may lead to decreased tumor cell proliferation and viability and reduced tumor growth (PMID: 11309348, PMID: 22158273). ', 'references': [{'id': 8267, 'pubMedId': 22158273, 'title': 'Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22158273'}, {'id': 3126, 'pubMedId': 11309348, 'title': 'Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11309348'}]}]",Trichostatin A,2017-03-17T17:20:18Z
0,2014-03-12T15:53:16Z,948,"[{'description': 'Triciribine (API-2) is a pan-AKT inhibitor, which may reduce proliferation and promote apoptosis in cancer cells (PMID: 21636709, PMID: 19422047).', 'references': [{'id': 2286, 'pubMedId': 21636709, 'title': 'Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21636709'}]}]",Triciribine,2017-03-17T18:24:16Z
0,2014-08-06T01:50:17Z,1382,[],Trientine,2014-08-06T01:50:17Z
0,2016-08-18T19:49:19Z,4586,[],Trifluridine,2016-08-18T19:49:19Z
0,2015-03-18T13:19:28Z,2426,"[{'description': 'Lonsurf (trifluridine/tipiracil hydrochloride) is an oral combination comprised of TFT and a thymidine phosphorylase inhibitor, which can result in DNA fragmentation thereby preventing angiogenesis and tumor growth (NCI Drug Dictionary). Lonsurf (TAS-102) is FDA approved for colorectal cancer (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",trifluridine/tipiracil hydrochloride,2017-06-19T19:44:49Z
0,2017-07-28T19:58:01Z,6054,"[{'description': 'Limited information is available for Trigriluzole, a putative inhibitor of metabotropic glutamate receptors (PubMed, Jul 2017). ', 'references': [{'id': 285, 'pubMedId': None, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed'}]}]",Trigriluzole,2017-07-28T19:58:01Z
0,2015-09-01T19:46:24Z,3074,"[{'description': 'Trilaciclib (G1T28) is a small molecule that inhibits CDK4/6, resulting in reversible cell-cycle arrest, and potentially reduces myelosuppression induced by chemotherapeutics (PMID: 26826116).', 'references': [{'id': 3584, 'pubMedId': None, 'title': 'Abstract 941: G1T28-1, a novel CDK4/6 inhibitor, protects murine hematopoietic stem and progenitor cells from cytotoxic chemotherapy', 'url': ''}, {'id': 5519, 'pubMedId': 26826116, 'title': 'Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26826116'}]}]",Trilaciclib,2017-05-22T17:26:47Z
0,2016-05-12T16:35:01Z,4109,[],Trilaciclib + Topotecan,2017-05-22T17:27:07Z
0,2016-03-28T18:25:25Z,3855,"[{'description': 'Triolimus is a composed of a micelle containing the drugs rapamycin, 17-AAG, and paclitaxel, which act synergistically to inhibit tumor growth (PMID: 22896668).', 'references': [{'id': 5037, 'pubMedId': 22896668, 'title': 'Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22896668'}]}]",Triolimus,2016-03-28T18:25:25Z
0,2015-02-11T16:36:40Z,2050,"[{'description': 'Triptorelin is an analog of luteinizing-hormone-releasing hormone (LHRH), which suppresses gonadotropin secretion, leading to decreased testosterone production in males (NCI Drug dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Triptorelin,2015-02-11T16:36:40Z
0,2017-06-01T19:31:31Z,5835,"[{'description': 'Limited information is currently available on TRK-950 (Jun 2017).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",TRK-950,2017-06-01T19:31:31Z
0,2016-02-12T02:45:45Z,3521,"[{'description': 'MSI-1436 is a small molecule allosteric inhibitor of PTP1B, which results in reduced tumor growth (PMID: 24845231).', 'references': [{'id': 4563, 'pubMedId': 24845231, 'title': 'Targeting the disordered C terminus of PTP1B with an allosteric inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24845231'}]}]",Trodusquemine,2016-02-18T05:37:06Z
0,2016-05-26T16:36:54Z,4139,"[{'description': 'Limited information is currently available on TRPH 011, a putative human bispecific antibody targeting vascular endothelial growth factor receptor 2 (KDR) and tyrosine kinase receptor 2 (Tie2) (May, 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",TRPH 011 ,2016-05-26T16:36:54Z
0,2016-06-08T19:28:54Z,4259,"[{'description': 'TRX-E-002-1 is a super-benzopyran analogue that demonstrates potent anti-proliferation activity through regulation of c-Jun and Mek signaling (PMID: 27196760).', 'references': [{'id': 5826, 'pubMedId': 27196760, 'title': 'TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196760'}]}]",TRX-E-002-1,2016-06-08T19:41:51Z
0,2016-02-25T19:38:31Z,3613,"[{'description': 'TRX518 is a monoclonal anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody that blocks GITR signaling, leading to activation of immune response (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",TRX518,2016-02-25T19:38:31Z
0,2014-08-29T08:56:03Z,1407,"[{'description': 'TS-1 (tegafur-gimeracil-oteracil potassium) is composed of tegafur, gimestat and otastat potassium, of which the ultimate active ingredient is 5-FU (PMID: 12066214).', 'references': [{'id': 611, 'pubMedId': 12066214, 'title': 'Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12066214'}]}]",TS-1,2016-08-07T16:01:32Z
0,2014-03-12T15:53:16Z,949,"[{'description': 'Belizatinib (TSR-011) binds to ALK and TRK kinases and inhibits downstream signaling, which may result in decreased proliferation of ALK/TRK expressing tumor cells (PMID: 26753004).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 8336, 'pubMedId': 26753004, 'title': 'ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26753004'}]}]",TSR-011,2017-03-24T17:40:30Z
0,2017-10-17T16:17:21Z,6320,"[{'description': 'TSR-042 is a humanized monoclonal antibody against PD-1 that blocks PD-1 binding to PD-L1 and PD-L2, which leads to increased IL-2 production and immune modulation (Eur J Cancer 2016 Dec; 69 (Suppl 1):S102, Abstract # 310).', 'references': [{'id': 10133, 'pubMedId': None, 'title': 'Identification and characterization of TSR-042, a novel anti-human PD-1 therapeutic antibody', 'url': 'http://www.sciencedirect.com/science/article/pii/S0959804916329021?via%3Dihub'}]}]",TSR-042,2017-10-17T16:17:21Z
0,2017-07-03T15:29:47Z,5960,"[{'description': 'TTC-352 is a partial estrogen receptor agonist that inhibits growth of ER-positive cancer cells (PMID: 25205655).', 'references': []}]",TTC-352,2017-07-06T19:28:10Z
0,2017-02-20T16:36:04Z,5338,"[{'description': 'TTI-621 (SIRPalpha-Fc) is a immune checkpoint inhibitor that binds to CD47 and blocks inhibitory signaling to macrophages, resulting in increased phagocytosis of tumor cells and potentially leading to decreased tumor growth (PMID: 27856600).', 'references': [{'id': 7888, 'pubMedId': 27856600, 'title': 'TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27856600'}]}]",TTI-621,2017-02-20T16:37:34Z
0,2016-02-26T17:57:29Z,3635,"[{'description': 'Tubastatin A inhibits HDAC6, which results in decreased tumor cell proliferation (PMID: 25957812).', 'references': [{'id': 4713, 'pubMedId': 25957812, 'title': 'Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25957812'}]}]",Tubastatin A,2016-02-26T17:57:29Z
0,2014-03-12T15:53:16Z,639,"[{'description': 'Tucatinib (ARRY-380) selectivity inhibits ERBB2 (HER2), resulting in decreased proliferation and increased apoptosis in ERBB2 (HER2) expressing tumor cells (PMID: 28053022). ', 'references': [{'id': 7781, 'pubMedId': 28053022, 'title': 'Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2(+)-Advanced Solid Tumors, with an Expansion Cohort in HER2(+) Metastatic Breast Cancer (MBC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28053022'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 2310, 'pubMedId': None, 'title': 'Abstract A143: ARRY-380, a selective HER2 inhibitor: From drug design to clinical evaluation.', 'url': 'http://mct.aacrjournals.org/content/10/11_Supplement/A143.short'}]}]",Tucatinib,2017-07-07T02:39:02Z
0,2016-02-25T17:46:16Z,3611,"[{'description': 'TVB-2640 is a fatty acid synthase (FASN) inhibitor that inhibits lipid metabolism in tumor cells (PMID: 26519059).', 'references': [{'id': 4702, 'pubMedId': 26519059, 'title': 'Molecular Pathways: Fatty Acid Synthase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26519059'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",TVB-2640,2016-05-26T09:42:28Z
0,2015-12-11T17:16:46Z,3285,"[{'description': 'TW-37 is a third-generation BH3 mimetic that inhibits BCL2, MCL1, and with lesser affinity, BCL-XL, which may result in increased tumor cell apoptosis and increased sensitivity to chemotherapeutics (PMID:  17404107).', 'references': [{'id': 4097, 'pubMedId': 17404107, 'title': 'Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17404107'}]}]",TW-37,2015-12-11T17:16:46Z
0,2017-04-27T19:49:53Z,5586,"[{'description': 'TY-011 inhibits Aurora kinase A and B, as well as KDR (VEGFR2), resulting in inhibition growth and angiogenesis in tumors (PMID: 27887633).', 'references': [{'id': 8743, 'pubMedId': 27887633, 'title': 'Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27887633'}]}]",TY-011,2017-04-27T19:49:53Z
0,2015-06-04T09:52:05Z,2783,"[{'description': 'Tyrphostin B42 (AG-490) is an inhibitor of EGFR and JAK2, which inhibits cell proliferation (PMID: 1676428, PMID: 8628398).', 'references': [{'id': 2940, 'pubMedId': 8628398, 'title': 'Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/8628398'}, {'id': 2939, 'pubMedId': 1676428, 'title': 'Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/1676428'}]}]",Tyrphostin B42,2015-06-04T17:18:04Z
0,2015-03-18T15:00:27Z,2427,"[{'description': 'U0126 binds and inhibits Mek1 and Mek2, which may inhibit the activation of downstream signaling targets and reduce tumor cell proliferation (PMID: 9873633). ', 'references': [{'id': 2259, 'pubMedId': 9873633, 'title': 'MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/9873633'}]}]",U0126,2017-04-06T10:42:00Z
0,2016-04-21T19:10:57Z,3980,"[{'description': 'U3-1784 is a human anti-FGFR4 antibody that inhibits FGFR4 signaling, results in growth inhibition in tumor cells (AACR, Cancer Res: April 2016; Volume 57, Abstract #3852).', 'references': [{'id': 5194, 'pubMedId': None, 'title': 'U3-1784, a human anti-FGFR4 antibody for the treatment of cancer', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=800c7dcf-322a-4e97-830b-0887c43f4108&cKey=4b473f86-5e89-431f-b228-b5a1a902ce34&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]}]",U3-1784,2016-04-25T14:59:33Z
0,2016-05-11T13:49:25Z,4098,"[{'description': 'UAB30 is a synthetic analogue of 9-cis-retinoic acid that activates the retinoid X receptor and may lead to a decrease in cell proliferation and tumor growth (PMID: 26873726).', 'references': [{'id': 5496, 'pubMedId': 26873726, 'title': 'Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26873726'}]}]",UAB30,2016-05-11T13:50:22Z
0,2015-03-05T14:03:41Z,2287,"[{'description': 'Ublituximab is a monoclonal antibody that targets CD20 that may induce complement-dependent and antibody-dependent cell-mediated cytotoxicity against B-cells expressing CD20, potentially resulting in increased B-cell death (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Ublituximab,2017-05-24T17:55:30Z
0,2015-06-23T15:47:39Z,2860,"[{'description': 'UC-773587 is a small molecule inhibitor of SOS1, which blocks SOS1- RAS interaction and SOS-1 mediated RAS activation, potentially leading to decreased growth of SOS1 dependent tumor cells (PMID: 25825487).', 'references': [{'id': 3114, 'pubMedId': 25825487, 'title': 'Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25825487'}]}]",UC-773587,2015-06-23T15:47:39Z
0,2015-06-23T15:48:14Z,2861,"[{'description': 'UC-857993 is a small molecule inhibitor of SOS1, which blocks SOS1- RAS interaction and SOS-1 mediated RAS activation, potentially leading to decreased growth of SOS-1 dependent tumor cells (PMID: 25825487).\r\n', 'references': [{'id': 3114, 'pubMedId': 25825487, 'title': 'Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25825487'}]}]",UC-857993,2015-06-23T15:48:14Z
0,2017-07-14T18:59:26Z,5994,"[{'description': 'UCART123 are allogeneic T cells that contain anti-CD123 CAR and an RQR8 depletion ligand, which may result in cytotoxicity of cells expressing CD123 (ASH Meeting, 2016, abstract nr 4039). ', 'references': [{'id': 9431, 'pubMedId': None, 'title': 'Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)', 'url': 'https://ash.confex.com/ash/2016/webprogram/Paper95092.html'}]}]",UCART123,2017-07-14T18:59:26Z
0,2017-07-17T16:02:46Z,5997,"[{'description': 'UCART19 are allogeneic T-cells engineered to knockout TCR alpha and CD52, and co-express a chimeric antigen receptor targeting CD19 and Rqr8, that demonstrated anti-tumor activity (J Clin Oncol 33, 2015 (suppl; abstr 3069)).', 'references': [{'id': 9446, 'pubMedId': None, 'title': 'UCART19, an allogeneic “off-the-shelf” adoptive T-cell immunotherapy against CD19+ B-cell leukemias.', 'url': 'http://meetinglibrary.asco.org/record/110654/abstract'}]}]",UCART19,2017-07-17T16:02:46Z
0,2014-03-12T15:53:16Z,951,"[{'description': 'UCN-01 (sc-3510) is a derivative of staurosporine that inhibits CHK1 and PKC, with higher potency toward PKC-alpha, PKC-beta, and PKC-gamma, and also modulates CDK activity through upregulation of CDK inhibitors, potentially resulting in inhibition of tumor growth (PMID: 8022414, PMID: 15831461, PMID:15150122).', 'references': [{'id': 2166, 'pubMedId': 8022414, 'title': 'Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/8022414'}]}]",UCN-01,2017-05-01T19:30:27Z
0,2017-06-09T16:07:08Z,5869,"[{'description': 'UD-017 is a specific CDK7 inhibitor that induces cell cycle arrest and apoptosis in cancer cells (J Clin Oncol 35, 2017 (suppl; abstr e14085)).', 'references': [{'id': 9099, 'pubMedId': None, 'title': 'Preclinical in vitro and in vivo evaluation of antitumor activity of UD-017, a novel selective and orally available CDK7 inhibitor, in colorectal cancer.', 'url': 'http://abstracts.asco.org/199/AbstView_199_194372.html'}]}]",UD-017,2017-06-09T16:07:39Z
0,2015-06-18T19:53:21Z,2847,"[{'description': 'Ulocuplumab (BMS-936564) is a monoclonal antibody that binds to CXCR4 and prevents binding of SDF-1 (CXCL12), potentially resulting in increased apoptosis and decreased migration of tumor cells (PMID: 23213054).', 'references': [{'id': 3084, 'pubMedId': 23213054, 'title': 'BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23213054'}]}]",Ulocuplumab,2015-06-25T21:06:10Z
0,2016-06-15T17:33:22Z,4287,"[{'description': 'UM-164 is a small molecule that binds to a specific inactive conformation of Src, resulting in inhibition of Src downstream signaling and inhibits p38 MAPKs, resulting in growth inhibition, and apoptosis in tumor cells (PMID: 27154914).', 'references': []}]",UM-164,2016-06-23T17:06:07Z
0,2015-12-11T16:16:04Z,3284,"[{'description': 'UMI-77 is a small molecule that selectively inhibits MCL1, which leads to increased tumor cell apoptosis and decreased tumor cell growth (PMID: 24019208).', 'references': [{'id': 4096, 'pubMedId': 24019208, 'title': 'A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24019208'}]}]",UMI-77,2015-12-11T16:16:04Z
0,2014-11-29T19:40:39Z,1753,"[{'description': 'UNC0638 inhibits the methyltransferase activity of EHMT2 (G9A) and GLP, resulting in a decrease in H3K9me2 levels and de-repression of silenced genes (PMID: 21743462).', 'references': [{'id': 1183, 'pubMedId': 21743462, 'title': 'A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21743462'}]}]",UNC0638,2015-08-10T15:31:14Z
0,2014-12-03T18:38:53Z,1757,"[{'description': 'UNC1999 inhibits EZH1 and EZH2, resulting in decreased H3K27 methylation, increased gene transcription in cell-based assays, and cell death in EZH2 mutant cell lines (PMID: 24183969).', 'references': [{'id': 1237, 'pubMedId': 24183969, 'title': 'Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24183969'}]}]",UNC1999,2015-05-29T03:34:05Z
0,2015-12-11T21:50:12Z,3291,"[{'description': 'UNC2025 inhibits FLT3 and MER, which may result in decreased growth of MER-dependent and FLT3-dependent tumor cells (PMID: 25068800).', 'references': [{'id': 4104, 'pubMedId': 25068800, 'title': 'UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25068800'}]}]",UNC2025,2015-12-11T21:50:12Z
0,2017-03-28T17:51:30Z,5489,[],unspecified CTLA4 antibody,2017-03-28T17:51:30Z
0,2016-08-17T17:12:17Z,4575,[],unspecified EGFR antibody,2016-08-17T17:12:17Z
0,2016-08-17T17:43:58Z,4579,[],unspecified EGFR antibody + unspecified ERBB3 antibody,2016-08-17T17:43:58Z
0,2016-08-17T17:37:09Z,4578,[],unspecified EGFR antibody + unspecified IGF-1R antibody,2016-08-17T17:38:04Z
0,2016-08-17T17:12:30Z,4576,[],unspecified ERBB3 antibody,2016-08-17T17:12:30Z
0,2016-05-03T19:11:27Z,4066,[],unspecified IGF-1R antibody,2016-05-03T19:11:27Z
0,2016-04-04T14:51:33Z,3890,[],unspecified PD-1 antibody,2016-04-04T14:51:33Z
0,2017-01-24T18:43:22Z,5249,[],unspecified PD-1 antibody + Imatinib,2017-01-24T18:43:22Z
0,2016-11-23T20:05:09Z,5014,[],unspecified PD-1 antibody + Sirolimus,2016-11-23T20:05:32Z
0,2017-01-24T18:41:34Z,5248,[],unspecified PD-L1 antibody,2017-01-24T18:41:34Z
0,2017-01-24T18:44:48Z,5250,[],unspecified PD-L1 antibody + Imatinib,2017-01-24T18:44:48Z
0,2016-03-25T17:26:28Z,3842,[],unspecified VEGFR2 antibody,2016-03-25T17:59:11Z
0,2016-02-17T16:03:58Z,3538,"[{'description': 'UPF 1069 selectively inhibits PARP-2, which may result in increased apoptosis (PMID: 19422384).', 'references': [{'id': 4606, 'pubMedId': 19422384, 'title': 'Selective PARP-2 inhibitors increase apoptosis in hippocampal slices but protect cortical cells in models of post-ischaemic brain damage.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19422384'}]}]",UPF 1069,2016-02-17T16:04:24Z
0,2015-02-11T19:14:25Z,2055,"[{'description': 'Urelumab is a monoclonal antibody that targets CD137, resulting in activation of CD137-expressing immune cells, thereby enhancing T-cell mediated response to tumor cells (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Urelumab,2015-02-11T19:14:25Z
0,2016-12-13T18:02:08Z,5086,"[{'description': 'Utomilumab (PF-05082566) is a monoclonal antibody that targets and antagonizes CD137 (4-1BB), potentially resulting in increased immune response against tumor cells (PMID: 27369047).', 'references': [{'id': 7280, 'pubMedId': 27369047, 'title': 'Enhancing PD-1 Blockade in Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27369047'}]}]",Utomilumab,2017-10-10T17:53:25Z
0,2017-08-14T17:19:16Z,6111,[],Utomilumab + Rituximab,2017-10-10T17:43:57Z
0,2017-05-31T15:50:32Z,5824,"[{'description': 'V158411 is a small molecule that inhibits CHK1, which results in increased DNA damage and decreased growth of tumor cells (PMID: 27829224).', 'references': [{'id': 9030, 'pubMedId': 27829224, 'title': 'Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27829224'}]}]",V158411,2017-05-31T15:50:32Z
0,2015-07-14T03:08:39Z,2921,"[{'description': 'VAL-083 is a DNA cross-linking agent which has shown antitumor activities in cell culture (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",VAL-083,2015-07-14T03:08:39Z
0,2017-01-09T19:46:11Z,5171,"[{'description': 'Valacyclovir is the prodrug of acylovir, which is an antiviral agent that functions by inhibiting viral DNA polymerase (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Valacyclovir,2017-01-09T19:46:11Z
0,2014-06-14T11:57:09Z,1076,"[{'description': 'Valproic acid inhibits HDAC activity, potentially resulting in decreased angiogenesis, increased tumor cell differentiation, and reduced tumor growth (PMID: 11742974, PMID: 14978230). Valproic acid is FDA-approved for use in treating seizures (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 8270, 'pubMedId': 14978230, 'title': 'Valproic acid inhibits angiogenesis in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/14978230'}, {'id': 8269, 'pubMedId': 11742974, 'title': 'Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11742974'}]}]",Valproic acid,2017-03-17T17:44:52Z
0,2014-10-28T20:50:08Z,1677,[],Valproic Acid + Ellipticine,2014-10-28T20:50:08Z
0,2014-10-30T04:19:48Z,1686,[],Valproic Acid + Mitomycin C,2014-10-30T04:19:48Z
0,2017-03-10T16:39:43Z,5430,[],Valproic acid + Radiotherapy,2017-03-10T16:39:43Z
0,2014-05-14T14:52:46Z,1056,"[{'description': 'Valstar (valrubicin) is an anthracycline that is metabolized into compounds that inhibit topoisomerase II, resulting in inhibition of DNA synthesis and potentially leading to decreased tumor growth (PMID: 19145271, PMID: 20554745). Valstar (valrubicin) is FDA-approved for treatment of BCG-refractory urinary bladder carcinoma in situ (FDA.gov).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 8726, 'pubMedId': 20554745, 'title': 'Topical application of valrubicin has a beneficial effect on developing skin tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20554745'}, {'id': 8725, 'pubMedId': 19145271, 'title': 'Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19145271'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Valstar,2017-04-26T14:57:32Z
0,2014-03-12T15:53:16Z,953,"[{'description': 'Caprelsa (vandetanib) is a multi-tyrosine kinase inhibitor with activity against VEGFR, EGFR, RET, SRC, and ABL1 kinases, potentially resulting in decreased tumor growth (PMID: 25031937, PMID: 25490448). Caprelsa (vandetanib) is FDA approved for use in medullary thyroid cancer (FDA.gov). ', 'references': [{'id': 301, 'pubMedId': 19002384, 'title': 'Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19002384'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Vandetanib,2017-04-03T17:24:29Z
0,2014-11-06T18:23:07Z,1712,[],Vandetanib + Capecitabine + Oxaliplatin,2014-11-06T18:23:07Z
0,2014-09-09T16:40:02Z,1422,[],Vandetanib + Cyclophosphamide + Methotrexate,2014-09-09T16:40:02Z
0,2014-09-24T17:18:09Z,1529,[],Vandetanib + Dasatinib,2014-09-24T17:18:09Z
0,2014-07-28T16:43:15Z,1163,[],Vandetanib + Everolimus,2014-07-28T16:43:15Z
0,2014-10-31T03:01:55Z,1693,[],Vandetanib + FOLFOX,2014-10-31T03:01:55Z
0,2014-10-31T02:18:45Z,1692,[],Vandetanib + Gemcitabine,2014-10-31T02:18:45Z
0,2015-10-02T14:53:34Z,3094,[],Vandetanib + Temozolomide,2015-10-02T14:53:34Z
0,2016-06-28T15:34:34Z,4397,"[{'description': 'Vantictumab (OMP-18R5) is a monoclonal antibody that targets Frizzled receptors 1, 2, 5, 7, and 8, resulting in decreased Wnt signaling and potentially leading to decreased tumor growth (PMID: 22753465).', 'references': [{'id': 6127, 'pubMedId': 22753465, 'title': 'Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22753465'}]}]",Vantictumab,2016-06-28T15:38:25Z
0,2016-06-28T16:27:48Z,4399,[],Vantictumab + Gemcitabine,2016-06-28T16:27:48Z
0,2016-06-28T16:21:53Z,4398,[],Vantictumab + Paclitaxel,2016-06-28T16:21:53Z
0,2015-04-10T15:23:21Z,2525,"[{'description': 'Varlilumab is a human monoclonal antibody that binds to CD27 and potentially increases antibody-dependent cellular cytotoxicity towards CD-27 positive tumor cells (PMID: 22589397).', 'references': [{'id': 2448, 'pubMedId': 22589397, 'title': 'Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22589397'}]}]",Varlilumab,2015-04-16T03:06:31Z
0,2014-05-14T14:52:46Z,1057,"[{'description': 'Varlitinib is a selective inhibitor of EGFR and ERBB2 (HER2), which inhibits downstream signaling, potentially resulting in decreased tumor cell proliferation and increased cell death (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",varlitinib,2016-02-01T20:28:41Z
0,2015-11-03T17:27:10Z,3171,"[{'description': 'Vatalanib inhibits VEGFR1-3, PDGFRs, and KIT, potentially resulting in decreased tumor angiogenesis and growth (PMID: 23700288, PMID: 12124335).', 'references': [{'id': 3867, 'pubMedId': 23700288, 'title': 'A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23700288'}, {'id': 3868, 'pubMedId': 12124335, 'title': 'PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12124335'}]}]",Vatalanib,2015-11-03T17:27:55Z
0,2015-03-03T16:27:06Z,2276,"[{'description': 'VB-111 is a engineered adenovirus that expresses Fas-c specifically within endothelial cells, resulting in endothelial cell death and decreased tumor blood supply, and potentially leading to tumor cell death (PMID: 22701765)', 'references': [{'id': 2075, 'pubMedId': 22701765, 'title': 'Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22701765'}]}]",VB-111,2015-03-03T16:27:06Z
0,2016-05-02T16:45:17Z,4038,"[{'description': 'VCN-01 is a replication-competent oncolytic adenovirus that may lead to decreased tumor cell viability and reduced tumor growth (PMID: 26603261).', 'references': [{'id': 5296, 'pubMedId': 26603261, 'title': 'The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26603261'}]}]",VCN-01,2016-05-02T16:45:17Z
0,2015-07-02T14:12:10Z,2877,"[{'description': 'VE-821 is a small molecule inhibitor of ATR, which may inhibit cell growth and enhance the sensitivity of chemotherapeutics (PMID: 22825331).', 'references': [{'id': 3169, 'pubMedId': 22825331, 'title': 'The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22825331'}]}]",VE-821,2015-07-10T12:07:59Z
0,2016-06-02T18:40:36Z,4201,"[{'description': 'Entyvio (vedolizumab) is a monoclonal antibody that targets alpha4beta7 integrin and blocks interaction with MAdCAM-1, thereby preventing endothelial binding and extravasation of leukocytes (PMID: 27003961).', 'references': [{'id': 5724, 'pubMedId': 27003961, 'title': 'Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27003961'}]}]",Vedolizumab,2016-06-03T18:34:14Z
0,2015-07-20T17:48:25Z,2937,"[{'description': 'VEGFR2-169 is a KDR (VEGFR2) HLA-A*2402 allele specific peptide vaccine, which may stimulate cytotoxic T cell response against tumor cells expressing VEGFR2 (KDR) (NCI Drug Dictionary). ', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",VEGFR2-169,2015-07-20T18:10:04Z
0,2015-07-20T17:51:45Z,2938,[],VEGFR2-169 + Gemcitabine,2015-07-20T17:51:45Z
0,2014-03-12T15:53:16Z,954,"[{'description': 'Veliparib (ABT-888) is a PARP1 and PARP2 inhibitor, which prevents DNA repair and induces apoptosis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Veliparib,2017-05-11T16:15:38Z
0,2015-05-18T15:51:35Z,2704,[],Veliparib + Carboplatin,2015-05-18T15:51:35Z
0,2016-06-13T15:38:21Z,4283,[],Veliparib + Cyclophosphamide,2016-06-13T15:38:21Z
0,2014-07-30T18:31:06Z,1277,[],Veliparib + Dinaciclib,2014-07-30T18:31:06Z
0,2014-07-30T18:31:44Z,1278,[],Veliparib + Dinaciclib + carboplatin,2014-07-30T18:31:44Z
0,2014-07-28T12:08:26Z,1134,[],Veliparib + Mitomycin C,2014-07-28T12:08:26Z
0,2017-02-26T04:00:12Z,5368,[],Veliparib + Nivolumab,2017-02-26T04:00:12Z
0,2016-04-21T19:57:58Z,3983,[],Veliparib + SN-38,2016-04-21T19:57:58Z
0,2014-07-29T07:03:27Z,1193,[],Veliparib + Temozolomide,2014-07-29T07:03:27Z
0,2014-07-28T11:57:10Z,1132,[],Veliparib + Topotecan,2014-07-28T11:57:10Z
0,2014-01-28T20:53:17Z,342,"[{'description': 'Zelboraf (vemurafenib) inhibits BRAF V600E, wild-type BRAF, ARAF, and CRAF (PMID: 20179705), which may result in an inhibition of MAPK signaling pathway resulting in a reduction of tumor cell proliferation (PMID: 20823850). Zelboraf (vemurafenib) is FDA approved for BRAF V600E-mutant melanoma (FDA.gov).', 'references': [{'id': 327, 'pubMedId': 20823850, 'title': 'Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20823850'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]}]",Vemurafenib,2017-08-07T14:41:42Z
0,2015-01-13T16:47:12Z,1936,[],Vemurafenib + Acitretin,2015-01-13T16:47:12Z
0,2014-07-29T16:42:59Z,1209,[],Vemurafenib + Carboplatin + Paclitaxel ,2014-07-29T16:42:59Z
0,2014-11-06T17:40:27Z,1711,[],Vemurafenib + Cetuximab,2014-11-06T17:40:27Z
0,2014-08-01T00:44:26Z,1331,[],Vemurafenib + Cetuximab + Irinotecan ,2014-08-01T00:44:26Z
0,2014-10-17T09:45:35Z,1657,[],Vemurafenib + Cobimetinib,2014-10-17T09:45:35Z
0,2014-07-30T15:40:14Z,1259,[],Vemurafenib + Decitabine,2014-07-30T15:40:14Z
0,2014-11-06T17:30:15Z,1710,[],Vemurafenib + Erlotinib,2014-11-06T17:30:15Z
0,2014-07-28T17:31:29Z,1174,[],Vemurafenib + Everolimus,2014-07-28T17:31:29Z
0,2014-11-06T17:21:33Z,1709,[],Vemurafenib + Gefitinib,2014-11-06T17:22:14Z
0,2014-07-31T02:58:56Z,1281,[],Vemurafenib + Hydroxychloroquine,2014-07-31T02:58:56Z
0,2014-07-31T08:19:26Z,1300,[],Vemurafenib + Interferon alfa-2b,2014-07-31T08:19:26Z
0,2014-07-29T17:09:43Z,1210,[],Vemurafenib + Metformin ,2014-07-29T17:09:43Z
0,2014-11-09T04:28:09Z,1717,[],Vemurafenib + Panitumumab,2014-11-09T04:28:09Z
0,2015-12-20T10:46:58Z,3310,[],Vemurafenib + SBI-060756,2015-12-20T10:50:01Z
0,2014-07-31T21:01:11Z,1326,[],Vemurafenib + Sorafenib,2014-07-31T21:01:11Z
0,2014-07-28T17:32:20Z,1175,[],Vemurafenib + Temsirolimus,2014-07-28T17:32:20Z
0,2014-07-30T07:09:35Z,1241,[],Vemurafenib + Tizanidine,2014-07-30T07:09:35Z
0,2014-08-06T01:52:12Z,1383,[],Vemurafenib + Trientine,2014-08-06T01:52:12Z
0,2016-02-14T18:19:43Z,3531,[],Vemurafenib + TW-37,2016-02-14T18:19:43Z
0,2014-07-30T06:34:52Z,1238,[],Vemurafenib + Voruciclib,2017-05-15T18:22:48Z
0,2016-03-17T17:15:34Z,3772,[],Vemurafenib + ZSTK474,2016-03-17T17:15:34Z
0,2014-09-26T07:16:45Z,1562,"[{'description': 'Venclexta (venetoclax) is a BH3-mimetic that binds to and inhibits BCL2, resulting in increased tumor cell apoptosis (PMID: 26589495, PMID: 25048785). Venclexta (venetoclax) is FDA approved for use in patients with chronic lymphocytic leukemia (CLL) with 17p deletion (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 5223, 'pubMedId': 26589495, 'title': 'ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26589495'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 5222, 'pubMedId': 25048785, 'title': 'Targeting BCL2 for the treatment of lymphoid malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25048785'}]}]",Venetoclax,2017-06-19T19:45:56Z
0,2017-02-09T03:17:31Z,5294,[],Venetoclax + DA-EPOCH-R,2017-02-09T03:17:31Z
0,2017-03-04T05:12:56Z,5404,[],Venetoclax + Rituximab + Ifosfamide + Carboplatin + Etoposide,2017-03-04T05:14:58Z
0,2017-02-28T15:34:21Z,5375,[],Venetoclax + VX-11e,2017-02-28T15:34:21Z
0,2015-05-20T14:53:19Z,2715,"[{'description': 'Verrucarin A is a small molecule that leads to decreased SRC-3 protein levels and indirectly inhibits the activity of SRC-3, resulting in increased tumor cell death (PMID: 24743578).', 'references': [{'id': 2775, 'pubMedId': 24743578, 'title': 'Identification of verrucarin a as a potent and selective steroid receptor coactivator-3 small molecule inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24743578'}]}]",Verrucarin A,2015-05-20T14:53:19Z
0,2015-05-20T16:56:07Z,2719,[],Verrucarin A + Tamoxifen,2015-05-20T16:56:07Z
0,2015-12-21T02:53:44Z,3319,"[{'description': 'Visudyne (verteporfin) is a small molecule that binds to YAP and inhibits the interaction between YAP and TEAD, potentially resulting in decreased growth of YAP-driven tumor cells (PMID: 22677547). Verteporfin is FDA-approved for treatment of age-related macular degeneration (FDA.gov).\r\n', 'references': []}]",Verteporfin,2017-06-16T15:55:21Z
0,2015-05-08T01:33:28Z,2635,[],Vinblastine,2015-05-08T01:33:28Z
0,2014-10-08T21:18:51Z,1631,"[{'description': 'Oncovin (vincristine) binds microtubules and prevents mitotic spindle formation, resulting in cell-cycle arrest (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Vincristine,2017-06-21T13:48:07Z
0,2014-09-11T03:13:24Z,1436,[],Vincristine + Dactinomycin,2014-09-11T03:13:24Z
0,2014-09-11T03:09:28Z,1435,[],Vincristine + Dactinomycin + Cyclophosphamide,2014-09-11T03:12:03Z
0,2014-12-22T16:08:34Z,1830,[],Vincristine + Dexamethasone + Pegaspargase + Doxorubicin,2014-12-22T16:08:34Z
0,2014-09-11T02:33:05Z,1433,[],Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide,2014-09-11T02:33:05Z
0,2014-09-11T02:39:38Z,1434,[],Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others,2014-09-11T02:39:38Z
0,2015-05-14T01:20:23Z,2670,[],Vincristine + Doxorubicin + Dactinomycin + Ifosfamide + Etoposide,2015-05-14T01:20:23Z
0,2014-12-22T14:57:43Z,1826,[],Vincristine + Irinotecan + Temozolomide ,2014-12-22T14:57:43Z
0,2014-12-22T13:48:38Z,1824,[],Vincristine + Methotrexate + Mercaptopurine,2014-12-22T13:48:38Z
0,2014-12-15T17:08:27Z,1781,[],Vincristine + Pegaspargase + Daunorubicin,2014-12-15T17:08:27Z
0,2016-10-04T15:00:13Z,4781,[],Vincristine + Volasertib,2016-10-04T15:00:13Z
0,2014-10-30T01:48:16Z,1685,"[{'description': 'Navelbine (vinorelbine) is a tubulin binding alkaloid that inhibits tubulin polymerization, thus inhibiting spindle formation, leading to apoptosis (NCI Drug Dictionary). Navelbine (vinorelbine) is approved for use in NSCLC (FDA.gov).', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Vinorelbine,2015-10-13T16:39:39Z
0,2015-01-03T21:57:52Z,1890,[],Vinorelbine + Trastuzumab,2015-01-03T21:57:52Z
0,2015-12-01T21:06:34Z,3231,"[{'description': 'Vintafolide is a derivative of folic acid linked to desacetylvinblastine hydrazide, which binds to the folate receptor, and upon endocytosis interferes with mitotic spindle formation, leading to cell death (PMID: 26136852).', 'references': [{'id': 4008, 'pubMedId': 26136852, 'title': 'Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26136852'}]}]",Vintafolide,2015-12-02T18:10:18Z
0,2014-03-12T15:53:16Z,956,"[{'description': 'Erivedge (vismodegib) binds to and inhibits Smoothened (SMO), resulting in inhibition of downstream signaling and decreased tumor growth (PMID: 24259609, PMID: 19716296). Erivedge (vismodegib) is FDA approved for use in patients with basal cell carcinoma (FDA.gov).', 'references': [{'id': 2234, 'pubMedId': 19716296, 'title': 'GDC-0449-a potent inhibitor of the hedgehog pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19716296'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 2235, 'pubMedId': 24259609, 'title': 'Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24259609'}]}]",Vismodegib,2015-03-20T10:56:00Z
0,2014-12-18T15:39:31Z,1799,[],Vismodegib + Gemcitabine + Abraxane,2014-12-18T15:39:31Z
0,2015-11-05T17:11:38Z,3179,[],Vismodegib + Ribavirin,2015-11-05T17:11:38Z
0,2014-07-25T14:26:08Z,1096,[],Vismodegib + RO4929097,2014-07-25T14:26:08Z
0,2014-05-14T14:52:46Z,991,"[{'description': 'Vistusertib (AZD2014) inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Vistusertib,2017-06-09T14:56:29Z
0,2015-02-27T16:13:21Z,2199,[],Vistusertib + Fulvestrant,2017-06-09T14:57:30Z
0,2015-01-23T18:12:06Z,1973,[],Vistusertib + Paclitaxel,2017-06-09T14:57:10Z
0,2016-10-26T12:26:37Z,4863,[],Vistusertib + Tamoxifen,2017-06-09T15:00:19Z
0,2017-02-28T17:17:20Z,5385,[],Vistusertib + WEHI-539,2017-06-09T15:03:06Z
0,2015-07-30T01:43:56Z,2973,"[{'description': 'Oncophage (vitespen) is a cancer vaccine using gp96 as antigen, which induces immune response against tumor cells expressing gp96 (PMID: 11727524).', 'references': [{'id': 3356, 'pubMedId': 11727524, 'title': 'HSPPC-96: a personalised cancer vaccine.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11727524'}]}]",Vitespen,2017-01-16T17:46:17Z
0,2016-12-01T17:50:27Z,5039,"[{'description': 'VLX1570 is a small-molecule that inhibits USP14 and UCHL5, which may result in increased tumor cell death (PMID: 27813535).', 'references': [{'id': 7224, 'pubMedId': 27813535, 'title': 'Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27813535'}]}]",VLX1570,2016-12-01T17:50:27Z
0,2016-12-14T03:58:04Z,5099,[],VLX1570 + Dexamethasone,2016-12-14T03:58:04Z
0,2014-03-12T15:53:16Z,957,"[{'description': 'BI 6727 (Volasertib) inhibits Polo-like kinase I, resulting in cell cycle arrest and apoptosis in tumor cells (PMID: 27330107).', 'references': [{'id': 6200, 'pubMedId': 27330107, 'title': 'Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27330107'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Volasertib,2016-07-06T09:09:59Z
0,2014-11-28T23:10:23Z,1745,[],Volasertib + Decitabine,2014-11-28T23:10:39Z
0,2014-06-16T10:48:03Z,1077,"[{'description': 'Zolinza (vorinostat) inhibits HDAC activity, resulting in cell-cycle arrest, decreased proliferation, and increased differentiation of tumor cells (PMID: 9501205, PMID: 11731433, PMID: 11016644). Zolinza (vorinostat) is FDA approved for use in cutaneous T-cell lymphoma (FDA.gov). ', 'references': [{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 8273, 'pubMedId': 9501205, 'title': 'A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/9501205'}, {'id': 8272, 'pubMedId': 11016644, 'title': 'Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11016644'}, {'id': 8271, 'pubMedId': 11731433, 'title': 'The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11731433'}]}]",Vorinostat,2017-03-17T18:10:32Z
0,2015-10-16T09:37:36Z,3132,[],Vorinostat + ABT-737,2015-10-16T09:37:36Z
0,2014-07-28T20:15:25Z,1182,[],Vorinostat + Etoposide,2014-07-28T20:15:25Z
0,2014-07-28T12:11:04Z,1135,[],Vorinostat + Hydroxychloroquine,2014-07-28T12:11:04Z
0,2015-01-28T14:22:45Z,1983,[],vorinostat + Paclitaxel,2015-01-28T14:22:45Z
0,2015-04-05T10:56:32Z,2493,[],Vorinostat + Tozasertib,2015-04-05T10:56:32Z
0,2016-03-30T14:32:32Z,3875,[],vorinostat + WP1066,2016-03-30T14:32:32Z
0,2014-03-12T15:53:16Z,842,"[{'description': 'Voruciclib (P1446A-05) is a selective CDK4/6 inhibitor that results in cell cycle arrest and apoptosis in cancer cells (J Clin Oncol 33, 2015 (suppl; abstr 9076)).', 'references': [{'id': 5185, 'pubMedId': None, 'title': 'Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma.', 'url': 'http://meetinglibrary.asco.org/content/153239-156'}]}]",Voruciclib,2017-05-15T18:22:30Z
0,2014-12-05T04:45:11Z,1765,"[{'description': 'Vosaroxin is a naphthyridine analog that intercalates into DNA, resulting in decreased DNA and RNA synthesis, cell cycle arrest, and increased cell death (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Vosaroxin,2014-12-05T04:45:11Z
0,2016-06-23T18:21:09Z,4351,"[{'description': 'VRT11E is an inhibitor of Erk, which may result in decreased cell growth (PMID: 24265153). ', 'references': [{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]}]",VRT11E,2016-06-23T18:21:09Z
0,2015-04-10T17:57:36Z,2534,"[{'description': 'VRX0466617 is an inhibitor of Chk2, which potentially decreases tumor cell proliferation (PMID: 17363488).', 'references': [{'id': 2453, 'pubMedId': 17363488, 'title': 'Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17363488'}]}]",VRX0466617,2015-04-10T17:57:36Z
0,2015-01-12T03:59:53Z,1933,"[{'description': 'VS-4718 is a focal adhesion kinase (FAK) inhibitor, which prevents FAK autophosphorylation and activation of downstream signaling, potentially resulting in decreased tumor cell proliferation, migration, and survival (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",VS-4718,2015-01-12T03:59:53Z
0,2014-03-12T15:53:16Z,960,"[{'description': 'VS-5584 inhibits mTOR kinase and all class I PI3K isoforms, disrupting phosphorylation of substrates downstream of PI3K and mTOR, thereby preventing cell proliferation and inhibiting tumor growth (PMID: 23270925).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 351, 'pubMedId': 23270925, 'title': 'VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23270925'}]}]",VS-5584,2017-05-01T19:10:45Z
0,2015-03-26T13:27:41Z,2464,[],VS-5584 + VS-6063,2015-03-26T13:27:41Z
0,2014-03-12T15:53:16Z,958,"[{'description': 'Defactinib (VS-6063) inhibits FAK, resulting in decreased downstream signaling, and potentially leading to reduced tumor cell proliferation and survival (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",VS-6063,2015-09-02T13:37:38Z
0,2015-03-17T13:25:27Z,2423,"[{'description': 'VSV-IFN-beta is a recombinant vesicular stomatitis virus (VSV) carrying the human interferon-beta (IFN-b) gene, which replicates specifically in tumors and stimulates anti-viral, anti-tumor immune response in surrounding normal cells (PMID: 24115092).', 'references': [{'id': 2244, 'pubMedId': 24115092, 'title': 'Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neck.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24115092'}]}]",VSV-IFN-beta,2015-03-17T13:25:27Z
0,2015-06-11T18:52:17Z,2822,"[{'description': 'VT-464 inhibits CYP17 17,20 lyase activity, resulting in decreased androgen production, which may inhibit growth of androgen-dependent tumors (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",VT-464,2015-06-11T18:52:17Z
0,2014-07-25T10:03:18Z,1094,[],VTX-11e,2014-07-25T10:03:18Z
0,2015-06-05T01:06:14Z,2804,"[{'description': 'VX-11e is an ATP-competitive inhibitor of Mapk1 (Erk2) and Mapk3 (Erk1), which may result in growth inhibition and tumor regression (PMID: 17300186, PMID: 19827834)', 'references': [{'id': 2974, 'pubMedId': 19827834, 'title': 'Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19827834'}]}]",VX-11e,2015-06-05T01:06:14Z
0,2017-02-28T14:54:28Z,5374,[],VX-11e + WEHI-539,2017-02-28T14:54:28Z
0,2015-06-03T20:45:46Z,2777,"[{'description': 'Decernotinib (VX-509) is a selective JAK3 inhibitor, which may modulate the immune response (PMID: 25762693). ', 'references': [{'id': 2930, 'pubMedId': 25762693, 'title': 'VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25762693'}]}]",VX-509,2015-06-03T20:45:46Z
0,2015-07-02T14:37:51Z,2879,"[{'description': 'VX-970 is a small molecule inhibitor of ATR, which may enhance the sensitivity of chemotherapeutic agents resulting in antitumor activity (PMID: 25269479).', 'references': [{'id': 3172, 'pubMedId': 25269479, 'title': 'ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25269479'}]}]",VX-970,2017-09-26T15:40:31Z
0,2015-07-02T19:52:53Z,2883,[],VX-970 + Irinotecan,2015-07-02T19:52:53Z
0,2017-09-12T17:02:43Z,6204,[],VX-970 + Radiotherapy,2017-09-12T17:02:43Z
0,2016-03-15T14:25:59Z,3738,"[{'description': 'VX15/2503 is a monoclonal antibody that binds to semaphorin 4D and blocks plexin-B1 binding, leading to anti-tumor and immune regulatory activity (PMID: 26446947).', 'references': [{'id': 4854, 'pubMedId': 26446947, 'title': 'Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26446947'}]}]",VX15/2503,2016-03-15T14:25:59Z
0,2016-09-01T17:22:02Z,4640,"[{'description': 'WANT3 is a peptide that targets NCKAP1 thereby disrupting the interaction between NCKAP1 and WASF3, and may result in suppression of cell invasion (PMID: 27432794). ', 'references': [{'id': 6553, 'pubMedId': 27432794, 'title': 'The WASF3-NCKAP1-CYFIP1 Complex Is Essential for Breast Cancer Metastasis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432794'}]}]",WANT3,2016-09-01T17:22:02Z
0,2015-04-08T02:06:46Z,2505,[],Warfarin,2015-04-08T02:06:46Z
0,2015-03-02T19:08:47Z,2245,"[{'description': 'WAY-600 inhibits mTOR signaling through mTORC1 and mTORC2, thereby promoting cell cycle arrest and apoptosis (PMID: 19584280).', 'references': [{'id': 2066, 'pubMedId': 19584280, 'title': 'Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19584280'}]}]",WAY-600,2016-04-01T16:40:57Z
0,2017-02-28T14:53:06Z,5373,"[{'description': 'WEHI-539 is a selective inhibitor of BCL-XL that stimulates apoptotic responses in cells, resulting in killing of tumor cells (PMID: 23603658).', 'references': []}]",WEHI-539,2017-02-28T14:53:06Z
0,2016-03-09T18:35:32Z,3697,"[{'description': 'Withacnistin is a natural product that inhibits phosphorylation of STAT3 and STAT5, potentially resulting in decreased tumor growth (PMID: 24983364).', 'references': [{'id': 4802, 'pubMedId': 24983364, 'title': 'Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24983364'}]}]",Withacnistin,2016-03-09T18:35:32Z
0,2015-06-03T17:51:42Z,2769,"[{'description': 'WK88-1 inhibits HSP90, resulting in decreased expression of HSP90 client proteins and potentially leading to decreased tumor cell growth (PMID: 25117641).', 'references': [{'id': 2919, 'pubMedId': 25117641, 'title': 'Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25117641'}]}]",WK88-1,2015-06-03T18:22:44Z
0,2016-03-17T17:48:00Z,3775,"[{'description': 'WNT-C59 is a small molecule inhibitor of PORCN, which subsequently inhibits Wnt/beta-catenin signaling and thus, may result in tumor growth reduction (PMID: 25980501).', 'references': [{'id': 4905, 'pubMedId': 25980501, 'title': 'Wnt-C59 arrests stemness and suppresses growth of nasopharyngeal carcinoma in mice by inhibiting the Wnt pathway in the tumor microenvironment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25980501'}]}]",WNT-C59,2016-03-17T17:48:00Z
0,2015-06-04T09:58:40Z,2784,"[{'description': 'WP1066 is an inhibitor of JAK2, JAK2 V617F, and STAT3, which inhibits cell proliferation (PMID: 18245540, PMID: 21792892).', 'references': [{'id': 2941, 'pubMedId': 18245540, 'title': 'WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18245540'}, {'id': 2942, 'pubMedId': 21792892, 'title': 'The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21792892'}]}]",WP1066,2015-06-04T09:58:40Z
0,2015-07-10T16:14:51Z,2901,"[{'description': ""WT1 sensitized T cells are T cells that have been sensitized to Wilms' Tumor Protein 1 (WT1), which have the potential to bind to WT1 expressing cells and induce cellular lysis (NCI Drug Dictionary)."", 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",WT1 senstized T cells,2016-05-04T14:51:21Z
0,2015-07-10T14:07:51Z,2893,"[{'description': ""Multiple vaccines consisting of a variety of synthetic peptides derived from the human Wilms' Tumor (WT1) Protein used to induce a cytotoxic T-cell lymphocyte response against cells expressing WT1 (PMID: 25699052)."", 'references': [{'id': 3210, 'pubMedId': 25699052, 'title': 'Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25699052'}]}]",WT1 vaccine,2015-07-10T14:07:51Z
0,2014-03-12T15:53:16Z,972,"[{'description': 'WX-037 is a PI3K inhibitor, with highest activity against PIK3CA and PIK3CD, which reduces downstream signaling and potentially results in decreased tumor growth (PMID: 27837257).', 'references': []}]",WX-037,2017-04-11T13:46:43Z
0,2014-05-14T14:52:46Z,1058,"[{'description': 'WX-554 inhibits the activity of MEK1/2, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation (PMID: 27837257).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 8456, 'pubMedId': 27837257, 'title': 'Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27837257'}]}]",WX-554,2017-04-06T10:46:45Z
0,2015-03-02T19:00:57Z,2242,"[{'description': 'WYE-125132 (WYE-132) inhibits mTOR signaling through mTORC1/2, thereby preventing cell proliferation (PMID: 20068177).', 'references': [{'id': 2065, 'pubMedId': 20068177, 'title': 'Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20068177'}]}]",WYE-125132,2016-04-01T16:41:11Z
0,2015-06-09T09:09:07Z,2810,"[{'description': 'WYE-151650 is a selective ATP-competitive inhibitor of JAK3 (PMID: 25217444).', 'references': [{'id': 2991, 'pubMedId': 25217444, 'title': 'Selective inhibitors of the Janus kinase Jak3--Are they effective?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25217444'}]}]",WYE-151650,2015-06-09T09:09:07Z
0,2015-03-02T19:07:01Z,2243,"[{'description': 'WYE-354 inhibits mTOR signaling through mTORC1 and mTORC2, thereby promoting cell cycle arrest and apoptosis (PMID: 19584280).', 'references': [{'id': 2066, 'pubMedId': 19584280, 'title': 'Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19584280'}]}]",WYE-354,2016-04-01T16:41:21Z
0,2015-03-02T19:07:58Z,2244,"[{'description': 'WYE-687 inhibits mTOR signaling through mTORC1 and mTORC2, thereby promoting cell cycle arrest and apoptosis (PMID: 19584280).', 'references': [{'id': 2066, 'pubMedId': 19584280, 'title': 'Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19584280'}]}]",WYE-687,2016-04-01T16:41:35Z
0,2015-09-02T02:57:16Z,3075,"[{'description': 'WZ4002 is a mutant-selective irreversible EGFR inhibitor that inhibits proliferation of tumor cells, including those harboring EGFR T790M (PMID: 20033049).', 'references': [{'id': 3587, 'pubMedId': 20033049, 'title': 'Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20033049'}]}]",WZ4002,2015-10-01T16:38:48Z
0,2015-12-30T20:57:11Z,3350,[],WZ4002 + CI-1040,2015-12-30T20:57:11Z
0,2016-10-27T19:36:35Z,4872,[],WZ4002 + Crizotinib,2016-10-27T19:36:35Z
0,2015-12-30T20:58:01Z,3351,[],WZ4002 + Trametinib,2015-12-30T20:58:01Z
0,2017-02-01T16:11:38Z,5271,"[{'description': 'WZ4003 inhibits NUAK1 and NUAK2, resulting in decreased cell proliferation and migration (PMID: 24171924).', 'references': [{'id': 7717, 'pubMedId': 24171924, 'title': 'Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24171924'}]}]",WZ4003,2017-02-01T16:11:38Z
0,2015-04-10T02:38:07Z,2520,"[{'description': 'X-376 is a small molecule inhibitor of ALK, which may reduce growth of ALK-driven tumor cells (PMID: 21613408).', 'references': [{'id': 2442, 'pubMedId': 21613408, 'title': 'Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21613408'}]}]",X-376,2017-03-24T15:55:51Z
0,2014-03-12T15:53:16Z,961,"[{'description': 'Ensartinib (X-396) is a small molecule inhibitor of ALK, which inhibits downstream signaling and potentially leads to decreased growth of ALK-expressing tumors (PMID: 21613408).', 'references': [{'id': 2442, 'pubMedId': 21613408, 'title': 'Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21613408'}, {'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",X-396,2017-03-24T15:50:44Z
0,2014-03-12T15:53:16Z,962,"[{'description': 'X-82 is a dual VEGFR/PDGFR inhibitor, which inhibits tumor angiogenesis and cell proliferation (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",X-82,2015-07-13T12:43:31Z
0,2014-09-11T03:55:11Z,1442,[],X-82 + Docetaxel,2014-09-11T03:55:11Z
0,2014-07-30T16:55:03Z,1272,[],X-82 + Everolimus,2014-07-30T16:55:03Z
0,2016-03-28T19:06:34Z,3858,"[{'description': 'X480 is a dual PI3K/mTOR inhibitor, which may lead to decreased tumor growth and metastasis (Eur J Cancer, 2012, 48, S5:235).', 'references': [{'id': 5043, 'pubMedId': None, 'title': '976 Effects of Dual PI3K and mTOR Inhibition on Incidence and Local Growth of Prostate Cancer Bone Metastases', 'url': 'http://www.sciencedirect.com/science/article/pii/S0959804912715940'}]}]",X480,2016-03-28T19:06:34Z
0,2016-02-19T15:19:06Z,3570,"[{'description': 'Limited information is currently available on X4P-001, a putative CXCR4 antagonist (Feb, 2016).', 'references': [{'id': 275, 'pubMedId': 10, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10'}]}]",X4P-001,2016-02-25T17:35:17Z
0,2014-11-20T19:27:03Z,1732,"[{'description': 'XAV939 selectively inhibits Wnt/beta-catenin-mediated signaling by inhibiting tankyrase1/2, thus stabilizing axin and stimulating beta-catenin degradation (PMID: 19759537).', 'references': [{'id': 1147, 'pubMedId': 19759537, 'title': 'Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19759537'}]}]",XAV939,2015-09-22T19:19:26Z
0,2016-03-14T17:45:41Z,3734,[],XAV939 + Everolimus,2016-03-14T17:45:41Z
0,2015-07-14T01:18:52Z,2916,"[{'description': 'Xentuzumab (BI 836845) is a monoclonal antibody that binds to IGF-1 and IGF-2 and prevents binding to the IGF receptor (IGF-1R), resulting in decreased IGF-1R signaling (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",Xentuzumab,2017-07-20T17:13:19Z
0,2016-12-13T20:58:20Z,5096,[],Xentuzumab + PHA-665752,2017-04-07T18:50:00Z
0,2015-04-29T17:34:11Z,2612,"[{'description': 'XI-006 is a small molecule that inhibits expression of MDM4 (MDMX), resutling in activation of p53 and increased tumor cell death (PMID: 21075910).', 'references': [{'id': 2606, 'pubMedId': 21075910, 'title': 'A small-molecule inhibitor of MDMX activates p53 and induces apoptosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21075910'}]}]",XI-006,2015-06-03T19:19:34Z
0,2015-04-29T17:09:05Z,2607,"[{'description': 'XI-011 is a small molecule that activates p53 expression through downregulation of MDM4 (MDMX) expression, resulting in increased tumor cell death (PMID: 21750655, PMID: 22957303).', 'references': [{'id': 2605, 'pubMedId': 22957303, 'title': 'High levels of Hdmx promote cell growth in a subset of uveal melanomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22957303'}, {'id': 2604, 'pubMedId': 21750655, 'title': 'A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21750655'}]}]",XI-011,2015-06-03T19:19:53Z
0,2015-02-09T00:45:36Z,2026,"[{'description': 'XL-884 is CHK1 and CHK2 inhibitor, which may enhance radiosensitivity of tumor cells (PMID: 20024691).', 'references': [{'id': 1829, 'pubMedId': 20024691, 'title': 'A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20024691'}]}]",XL-844,2015-02-09T00:45:36Z
0,2015-06-03T21:24:15Z,2778,"[{'description': 'XL019 is an ATP-competitive JAK2 inhibitor, which inhibits STAT signaling to promote apoptosis (PMID: 23127890).', 'references': [{'id': 2933, 'pubMedId': 23127890, 'title': 'SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127890'}]}]",XL019,2015-06-08T17:20:05Z
0,2014-05-14T14:52:46Z,1050,"[{'description': 'Pilaralisib (XL147) is an inhibitor of all class I PI3Ks, thereby blocking activation of the PI3K signaling pathway and potentially resulting in antitumor activity including inhibition of cell proliferation, cell invasion, and tumor growth (PMID: 25637314).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 5522, 'pubMedId': 25637314, 'title': 'The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25637314'}]}]",XL147,2017-05-02T15:15:07Z
0,2016-05-12T20:23:45Z,4116,[],XL147 + Carboplatin,2016-05-12T20:23:45Z
0,2015-10-16T15:18:09Z,3135,[],XL147 + Carboplatin + Paclitaxel,2015-10-16T15:18:09Z
0,2016-05-12T20:23:00Z,4115,[],XL147 + Paclitaxel,2016-05-12T20:23:00Z
0,2014-03-12T15:53:16Z,965,"[{'description': 'XL228 inhibits multiple tyrosine kinases, including the insulin-like growth factor 1 receptor (IGF1R), Src tyrosine kinase, and Bcr-Abl tyrosine kinase, which can prevent cell division, tumor angiogenic activity, and metastasis (NCI Drug Dictionary).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]}]",XL228,2015-04-13T19:46:55Z
0,2014-03-12T15:53:16Z,966,"[{'description': 'XL281 is a pan-RAF kinase inhibitor, which blocks RAS/RAF/MEK/ERK signaling to prevent cell proliferation (PMID: 25476894).', 'references': [{'id': 1822, 'pubMedId': 25476894, 'title': 'Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25476894'}]}]",XL281,2015-02-08T11:57:59Z
0,2016-03-28T17:26:24Z,3849,"[{'description': 'XL388 is a selective ATP-competitive mTOR inhibitor that inhibits mTORC1 and mTORC2, resulting in decreased activation of downstream targets and potentially leading to decreased tumor growth (PMID: 23394126).', 'references': [{'id': 5032, 'pubMedId': 23394126, 'title': 'Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23394126'}]}]",XL388,2016-03-28T17:26:24Z
0,2014-03-12T15:53:16Z,967,"[{'description': 'XL647 is an inhibitor of multiple receptor tyrosine kinases, including ERBB2 (HER2), EGFR, VEGFR2 and VEGFR3, and EphB4, potentially resulting in decreased tumor growth and angiogenesis (PMID: 17575237).', 'references': [{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}, {'id': 1833, 'pubMedId': 17575237, 'title': 'Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17575237'}]}]",XL647,2016-01-14T21:59:22Z
0,2014-12-31T17:03:53Z,1880,[],XL647 + Trastuzumab,2014-12-31T17:03:53Z
0,2014-03-12T15:53:16Z,969,[],XL820,
0,2014-03-12T15:53:16Z,970,"[{'description': 'XL888 inhibits HSP90, resulting in degradation of HSP90 client proteins, and potentially leading to decreased tumor growth (PMID: 23538902, PMID: 22877636).', 'references': [{'id': 2924, 'pubMedId': 23538902, 'title': 'Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23538902'}, {'id': 2925, 'pubMedId': 22877636, 'title': 'Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22877636'}]}]",XL888,2015-06-03T19:00:10Z
0,2014-07-29T18:38:07Z,1217,[],XL888 + Vemurafenib,2014-07-29T18:38:07Z
0,2014-03-12T15:53:16Z,971,"[{'description': 'XL999 inhibits multiple tyrosine kinases including VEGFR2/KDR, FGFR1/3, PDGFR-beta, FLT3, RET, KIT, and SRC which can result in anti-tumor activity (J Clin Oncol, 25:18s, 2007 (suppl;abstr 3591), PMID: 19581523). ', 'references': [{'id': 2476, 'pubMedId': None, 'title': 'Integrated report of the phase 2 experience with XL999 administered IV to patients (pts) with NSCLC, renal cell CA (RCC), metastatic colorectal CA (CRC), recurrent ovarian CA, acute myelogenous leaukemia (AML), and multiple myeloma (MM)', 'url': 'http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/3591'}, {'id': 2475, 'pubMedId': 19581523, 'title': 'The role of Src in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19581523'}]}]",XL999,2017-04-03T17:28:14Z
0,2016-03-16T20:25:53Z,3761,"[{'description': 'XMD15-44 inhibits RET, resulting in decreased downstream signaling and reduced tumor cell proliferation (PMID: 26046350).', 'references': [{'id': 4887, 'pubMedId': 26046350, 'title': 'Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26046350'}]}]",XMD15-44,2017-04-03T17:29:26Z
0,2016-03-22T16:44:25Z,3804,"[{'description': 'XMD16-5 inhibits Tnk2 (Ack1), resulting in decreased proliferation of tumor cells with Tnk2 activation (PMID: 26677978).', 'references': [{'id': 4455, 'pubMedId': 26677978, 'title': 'Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26677978'}]}]",XMD16-5,2016-03-22T16:44:25Z
0,2016-03-22T16:43:50Z,3803,"[{'description': 'XMD8-87 inhibits Tnk2 (Ack1), resulting in decreased proliferation of tumor cells with Tnk2 activation (PMID: 26677978).', 'references': [{'id': 4455, 'pubMedId': 26677978, 'title': 'Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26677978'}]}]",XMD8-87,2016-03-22T16:43:50Z
0,2017-06-01T19:21:33Z,5834,"[{'description': 'XMT-1522 is an antibody-drug conjugate comprising an ERBB2 (HER2)-targeted antibody linked to auristatin, which delivers the cytotoxic agent to Erbb2 (Her2)-expressing tumor cells, potentially resulting in decreased tumor growth (Cancer Res 2016;76(4 Suppl): Abstract nr P4-14-28).', 'references': [{'id': 9048, 'pubMedId': None, 'title': 'XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer', 'url': 'http://cancerres.aacrjournals.org/content/76/4_Supplement/P4-14-28'}]}]",XMT-1522,2017-07-13T04:07:44Z
0,2016-05-10T13:33:34Z,4094,"[{'description': 'XMT-1536 is an anti-type II sodium-dependent potassium transporter (NaPi2b) antibody in conjugation with cytotoxic auristatin molecules, which delivers auristatin to tumor cells over expressing NaPi2b and results in tumor cell death (Proceedings of AACR, Vol 57, Apr 2016, Abstract # 1194).', 'references': [{'id': 5466, 'pubMedId': None, 'title': 'Discovery and preclinical development of a highly potent NaPi2b-targeted antibody-drug conjugate (ADC) with significant activity in patient-derived non-small cell lung cancer (NSCLC) xenograft models', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=43ef76fe-c845-4b4b-8531-601f2b1c2c32&cKey=132d0ba9-cd0a-4831-b61a-3bba3ae06518&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]}]",XMT-1536,2016-05-10T13:33:34Z
0,2017-01-04T15:48:04Z,5154,"[{'description': 'XMU-MP-2 is a small molecule that inhibits PTK6 (BRK), resulting in decreased downstream signaling and reduced proliferation of PTK6 (BRK)-expressing tumor cells (PMID: 27758886).', 'references': [{'id': 7466, 'pubMedId': 27758886, 'title': 'Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27758886'}]}]",XMU-MP-2,2017-01-04T15:48:04Z
0,2016-04-08T02:35:39Z,3912,"[{'description': 'Y078-DM1 is an antibody drug conjugate composed of a RET antibody (Y078) linked to a derivative of the cytotoxic agent maytansine, which may lead to  increased cytotoxicity in RET-expressing tumors (PMID: 26240273).\r\n', 'references': [{'id': 5131, 'pubMedId': 26240273, 'title': 'Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26240273'}]}]",Y078-DM1,2017-04-03T17:30:24Z
0,2016-04-08T02:37:50Z,3913,"[{'description': 'Y078-DM4 is an antibody-drug conjugate composed of a RET antibody (Y078) linked to a derivative of the cytotoxic agent maytansine, which may lead to  increased cytotoxicity in RET-expressing tumors (PMID: 26240273).', 'references': [{'id': 5131, 'pubMedId': 26240273, 'title': 'Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26240273'}]}]",Y078-DM4,2017-04-03T17:31:11Z
0,2015-02-18T03:15:29Z,2088,"[{'description': 'Y15 is a small molecule inhibitor of FAK, which decreases FAK autophosphorylation, leading to decreased tumor growth (PMID: 19571674).', 'references': [{'id': 1920, 'pubMedId': 19571674, 'title': 'A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19571674'}]}]",Y15,2015-02-18T03:15:29Z
0,2015-08-10T03:20:58Z,3000,"[{'description': 'Y90 clivatuzumab tetraxetan consists of an anti-MUC1 antibody conjugated to radioactive yttrium Y 90, which binds and delivers cytotoxic radiation to MUC1-expressing tumor cells (PMID: 26187510).', 'references': [{'id': 3415, 'pubMedId': 26187510, 'title': '(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26187510'}]}]",Y90 clivatuzumab tetraxetan,2015-08-10T14:49:12Z
0,2016-01-18T18:19:08Z,3419,"[{'description': 'YK-4-279 is a small molecule inhibitor of the ETS transcription factors, ERG and ETV1, which may result in inhibition of cell mobility and invasion (PMID: 21559405). ', 'references': [{'id': 4357, 'pubMedId': 21559405, 'title': 'YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21559405'}]}]",YK-4-279,2016-01-18T18:19:08Z
0,2016-07-15T01:07:00Z,4453,"[{'description': 'YLL545 inhibits KDR (VEGFR2), resulting in decreased downstream signaling and potentially leading to decreased angiogenesis and reduced tumor cell proliferation and tumor growth (PMID: 27203384).', 'references': [{'id': 6308, 'pubMedId': 27203384, 'title': 'The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27203384'}]}]",YLL545,2016-07-15T01:07:00Z
0,2015-07-29T19:47:20Z,2967,"[{'description': 'YM-024 inhibits PIK3CA and PIK3CD, which may block activation of the PI3K signaling pathway and inhibit tumor cell proliferation (PMID: 19815551).', 'references': [{'id': 3352, 'pubMedId': 19815551, 'title': 'Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein VI-induced platelet signaling and thrombus formation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19815551'}]}]",YM-024,2015-07-29T19:47:20Z
0,2015-10-22T18:45:18Z,3149,"[{'description': 'YM155 is a small molecule inhibitor of BIRC5 (survivin), which may result in tumor regression and growth inhibition (PMID: 17804712).', 'references': [{'id': 3803, 'pubMedId': 17804712, 'title': 'YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17804712'}]}]",YM155,2015-10-22T18:45:18Z
0,2016-03-24T19:41:50Z,3829,[],YM155 + Cisplatin,2016-03-24T19:41:50Z
0,2015-04-17T19:22:34Z,2550,"[{'description': 'YO-01027 (dibenzazepine) is a dipeptidic gamma secretase inhibitor, which blocks Notch cleavage and activation, and may inhibit angiogenesis and tumor growth (PMID: 20064975).', 'references': [{'id': 2513, 'pubMedId': 20064975, 'title': 'Pharmacological analysis of Drosophila melanogaster gamma-secretase with respect to differential proteolysis of Notch and APP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20064975'}]}]",YO-01027,2015-04-27T17:29:20Z
0,2016-09-26T23:50:18Z,4766,[],Yttrium-90,2016-09-26T23:50:18Z
0,2017-10-17T15:30:57Z,6319,[],Yttrium-90 + Nivolumab,2017-10-17T15:30:57Z
0,2016-09-28T01:53:49Z,4769,[],Yttrium-90 + Nivolumab + Ipilimumab,2016-09-28T01:53:49Z
0,2016-03-30T19:43:05Z,3880,"[{'description': 'YU238259 is a sulfonamide compound that inhibits homology-dependent DSB repair, therefore sensitizing tumor cells to DSB-inducing treatments (PMID: 26116172).', 'references': [{'id': 5087, 'pubMedId': 26116172, 'title': 'YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26116172'}]}]",YU238259,2016-03-30T19:43:05Z
0,2016-04-26T18:50:54Z,4006,"[{'description': 'YW3-56 is a peptidylarginine deiminase (PAD) inhibitor with activity against PAD2 and PAD4, which results in decreased histone citrullination and activation of the endoplasmic reticulum stress response, potentially resulting in decreased tumor cell growth (PMID: 22605338, PMID: 25612620).', 'references': [{'id': 5232, 'pubMedId': 22605338, 'title': 'Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22605338'}, {'id': 5233, 'pubMedId': 25612620, 'title': 'ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25612620'}]}]",YW3-56,2016-04-26T18:50:54Z
0,2015-09-06T21:02:53Z,3076,"[{'description': 'Z-endoxifen HCl is the active metabolite of tamoxifen, which competitively inhibits estradiol binding to estrogen receptors (ER), thereby inhibiting growth of ER-positive tumors (PMID: 26232141).', 'references': [{'id': 3603, 'pubMedId': 26232141, 'title': 'Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26232141'}]}]",Z-endoxifen HCl,2015-09-09T02:34:58Z
0,2016-02-26T17:38:20Z,3634,"[{'description': 'Z-VAD is a pan-Caspase inhibitor, which increases sensitivity of tumor cells to radiation (PMID: 19417149).', 'references': [{'id': 4712, 'pubMedId': 19417149, 'title': 'Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19417149'}]}]",Z-VAD,2016-02-26T17:38:20Z
0,2015-12-02T16:09:26Z,3237,"[{'description': 'Plevitrexed (BGC 9331) is a thymidylate synthase inhibitor that is transported into the cell via Folr1 and the reduced folate carrier system, potentially resulting in increased tumor cell death (PMID: 9815766, PMID: 15094210).', 'references': [{'id': 4016, 'pubMedId': 15094210, 'title': 'Antifolates targeted specifically to the folate receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15094210'}, {'id': 4015, 'pubMedId': 9815766, 'title': 'Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/9815766'}]}]",ZD9331,2017-07-31T18:21:45Z
0,2016-05-05T20:19:24Z,4077,[],Zebularine,2016-05-05T20:19:24Z
0,2016-04-29T19:16:37Z,4032,"[{'description': 'Limited information is currently available on ZEN003694 (Apr, 2016).', 'references': []}]",ZEN003694,2016-04-29T19:16:37Z
0,2016-09-13T18:41:31Z,4706,"[{'description': 'Zibotentan (ZD4054) is an antagonist of the ET(A) endothelin receptor, which results in decreased ET-1/ET(A)-mediated signaling, and may lead to decreased proliferation and increased apoptosis of tumor cells and reduced tumor growth (PMID: 17620430, PMID: 18616419).', 'references': [{'id': 6619, 'pubMedId': 18616419, 'title': 'ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18616419'}, {'id': 6618, 'pubMedId': 17620430, 'title': 'ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17620430'}]}]",Zibotentan,2016-09-13T18:41:31Z
0,2016-06-26T19:31:49Z,4360,[],Zidovudine,2016-06-26T19:31:49Z
0,2014-12-16T05:05:52Z,1788,[],Zileuton,2014-12-16T05:05:52Z
0,2014-12-16T05:07:37Z,1789,[],Zileuton + Dasatinib,2014-12-16T05:07:37Z
0,2015-05-28T19:25:29Z,2735,"[{'description': 'ZK 304709 is a small molecule kinase inhibitor of CDKs 1, 2, 4, 7, and 9, VEGFR-1,2,3, and PDGFR-beta, which may result in inhibition of both the cell cycle and angiogenesis (PMID: 18653327). ', 'references': [{'id': 2842, 'pubMedId': 18653327, 'title': 'Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18653327'}]}]",ZK304709,2015-06-04T14:00:25Z
0,2014-11-13T19:06:02Z,1728,"[{'description': 'ZM336372 is a small molecule RAF1 inhibitor that paradoxically causes RAF1 activation through a putative feedback mechanism, resulting in decreased proliferation and cell cycle inhibition in carcinoid tumor cells (PMID: 15956248).', 'references': [{'id': 1104, 'pubMedId': 15956248, 'title': 'ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15956248'}]}]",ZM336372,2016-11-04T15:24:29Z
0,2015-06-04T17:17:06Z,2795,"[{'description': 'ZM39923 is the prodrug of ZM449829, an inhibitor of JAK1/3, TGM2, and EGFR (PMID: 18804034, PMID: 10741557).', 'references': [{'id': 2960, 'pubMedId': 18804034, 'title': 'Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18804034'}]}]",ZM39923,2015-07-20T02:04:56Z
0,2016-02-12T07:45:42Z,3523,"[{'description': 'ZM447439 inhibits Aurora Kinase A and B, resulting in increased tumor cell death (PMID: 26732741, PMID: 24152827).', 'references': [{'id': 4566, 'pubMedId': 26732741, 'title': ""A Cell Biologist's Field Guide to Aurora Kinase Inhibitors."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732741'}, {'id': 4567, 'pubMedId': 24152827, 'title': 'The dual Aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell growth and tumorigenicity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24152827'}]}]",ZM447439,2017-04-04T13:10:58Z
0,2015-07-30T01:01:22Z,2971,[],Zoledronic acid,2017-06-19T18:22:28Z
0,2015-03-02T10:38:38Z,2229,"[{'description': 'Zotarolimus (ABT-578) is a rapamycin analogue which inhibits FKBP-12 to prevent mTOR signaling (PMID: 19075588).', 'references': [{'id': 2060, 'pubMedId': 19075588, 'title': 'mTOR pathway and mTOR inhibitors as agents for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19075588'}]}]",Zotarolimus,2015-04-03T00:17:43Z
0,2014-03-12T15:53:16Z,973,"[{'description': 'ZSTK474 is a pan-PI3K inhibitor, which blocks PI3K/AKT signaling to prevent cell growth (PMID: 16622124).', 'references': [{'id': 1823, 'pubMedId': 16622124, 'title': 'Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16622124'}]}]",ZSTK474,2015-02-08T12:04:58Z
0,2015-12-03T15:28:50Z,3254,"[{'description': 'Zt/f2 is a monoclonal antibody that targets the maturation-required sequences in the extracellular domain of MST1R (RON), leading to RON endocytosis and decreased downstream signaling, and may result in reduced growth of RON-expressing tumors (PMID: 21749705).', 'references': [{'id': 4027, 'pubMedId': 21749705, 'title': 'The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21749705'}]}]",Zt/f2,2015-12-03T15:28:50Z
0,2015-12-03T15:58:02Z,3258,"[{'description': 'Zt/g4 is a monoclonal antibody that binds to MST1R (RON), leading to endocytosis of MST1R (RON), which may result in decreased downstream signaling, increased sensitivity to cytotoxic agents, and inhibition of growth of RON-expressing tumor cells (PMID: 20596675).', 'references': [{'id': 4029, 'pubMedId': 20596675, 'title': 'Monoclonal antibody (mAb)-induced down-regulation of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20596675'}]}]",Zt/g4,2015-12-03T15:58:02Z
0,2015-12-03T15:44:36Z,3255,"[{'description': 'Zt/g4-DM1 is an antibody-drug conjugate that consists of an anti-MSTR1 (RON) antibody linked to the microtubule-inhibiting drug DM1, which resulting in endocytosis of MSTR1 (RON) and DM1, leading to increased tumor cell death and decreased growth of RON-expressing tumors (PMID: 25294907).', 'references': [{'id': 4028, 'pubMedId': 25294907, 'title': 'Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25294907'}]}]",Zt/g4-DM1,2015-12-03T15:44:36Z
0,2017-09-26T13:42:33Z,6240,"[{'description': 'ZW25 is a bispecific antibody targeting ERBB2 (HER2), which induces anti-tumor immune response against Erbbb2 (Her2)-expressing tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P).', 'references': [{'id': 9992, 'pubMedId': None, 'title': 'Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]}]",ZW25,2017-09-26T13:42:33Z
